data_6yeg_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6yeg _Structure_validation_residue.Date_analyzed 2020-10-16 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo . . . . . 0 N--CA 1.465 -0.158 0 N-CA-C 112.428 0.126 . . . . 13.51 112.428 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 96.8 mt -121.61 119.82 59.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 N-CA-C 108.013 -1.106 . . . . 9.1300000000000008 108.013 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -85.7 169.04 13.83 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.927 0.87 . . . . 42.109999999999999 110.698 -177.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.04 -11.39 66.81 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.394 -0.821 . . . . 17.079999999999998 114.363 175.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -95.14 -15.26 23.47 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 117.644 0.722 . . . . 17.079999999999998 112.175 171.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -77.23 -2.83 36.63 Favored 'General case' 0 CA--C 1.519 -0.24 0 N-CA-C 114.095 1.146 . . . . 27.350000000000001 114.095 -171.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.0 123.19 61.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 119.701 1.137 . . . . 17.079999999999998 108.231 -177.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.506 ' NZ ' ' O ' ' A' ' 149' ' ' GLU . 51.7 mtmt -133.02 163.34 29.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.553 0.692 . . . . 28.68 110.008 175.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 19.2 m-30 -114.03 97.68 6.52 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.095 -0.957 . . . . 17.079999999999998 108.511 -165.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.7 mt -73.14 123.84 24.42 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 109.843 -0.428 . . . . 37.840000000000003 109.843 175.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-30 -107.96 152.97 23.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.148 0.499 . . . . 15.369999999999999 109.917 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -147.1 134.91 21.22 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.152 -0.684 . . . . 19.809999999999999 109.152 174.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.1 t -74.93 155.25 37.64 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.601 0.715 . . . . 17.079999999999998 110.812 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -76.61 -13.28 14.55 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 N-CA-C 113.275 0.842 . . . . 2.0499999999999998 113.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -113.81 -7.16 13.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 112.736 0.643 . . . . 37.159999999999997 112.736 -169.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.34 -46.49 32.88 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 119.703 -0.799 . . . . 27.539999999999999 111.514 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.77 43.28 31.6 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.91 1.284 . . . . 12.24 111.382 -170.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.8 p -119.91 125.13 47.72 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.41 0.684 . . . . 6.8300000000000001 109.243 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.46 75.31 2.32 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 121.44 -0.409 . . . . 16.100000000000001 113.424 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.6 p -131.52 -27.18 1.97 Allowed 'General case' 0 C--O 1.235 0.338 0 C-N-CA 120.595 -0.442 . . . . 44.719999999999999 111.699 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.25 74.39 0.81 Allowed Pre-proline 0 C--O 1.236 0.382 0 C-N-CA 127.029 2.132 . . . . 31.440000000000001 112.434 -173.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -72.26 104.49 1.69 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 CA-C-N 119.637 0.906 . . . . 11.57 112.332 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -78.98 163.98 24.76 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.038 -0.727 . . . . 7.3399999999999999 109.038 167.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -102.55 136.9 19.27 Favored Pre-proline 0 C--N 1.314 -0.966 1 C-N-CA 110.707 -4.397 . . . . 9.9000000000000004 110.11 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -77.36 178.59 7.43 Favored 'Trans proline' 0 C--O 1.234 0.276 0 CA-C-N 118.655 0.555 . . . . 36.590000000000003 112.534 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . 57.16 57.91 4.25 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.472 1.109 . . . . 21.0 112.035 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 1.8 m-30 -73.39 -176.71 2.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 122.901 1.334 . . . . 47.899999999999999 112.348 -179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -148.85 -159.56 1.05 Allowed 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 103.4 -2.815 . . . . 15.199999999999999 103.4 169.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 13.3 t -66.77 164.19 17.68 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 122.604 1.193 . . . . 24.620000000000001 111.673 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -135.11 -170.51 2.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.12 -1.4 . . . . 37.700000000000003 108.296 -170.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.79 132.73 1.69 Allowed Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.482 -0.781 . . . . 3.8300000000000001 111.203 169.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 69.1 m -121.58 84.59 2.27 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 106.154 -1.795 . . . . 7.3600000000000003 106.154 176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.0 m -90.36 110.1 21.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 108.563 -0.902 . . . . 11.35 108.563 -172.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.7 m -98.76 94.77 6.79 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 107.912 -1.144 . . . . 19.640000000000001 107.912 -171.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -96.94 102.64 2.78 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.329 -0.938 . . . . 16.280000000000001 113.645 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -108.67 123.92 49.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.684 -0.858 . . . . 11.619999999999999 108.684 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 88.8 mtm-85 -83.27 -173.29 4.63 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.151 -0.685 . . . . 43.289999999999999 109.151 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -158.62 141.56 14.62 Favored 'General case' 0 C--N 1.329 -0.322 0 O-C-N 121.756 -0.59 . . . . 29.649999999999999 110.179 -170.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.26 113.4 5.84 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 108.772 -0.825 . . . . 9.6099999999999994 108.772 174.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -124.46 106.32 10.1 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.65 -0.5 . . . . 38.630000000000003 109.65 -171.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -132.11 -170.3 2.39 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 123.186 0.594 . . . . 31.640000000000001 110.922 175.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -125.28 -37.69 2.37 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 113.633 0.975 . . . . 8.5899999999999999 113.633 177.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLN . . . . . . . . . . . . . 76.0 mm-40 59.4 32.93 22.15 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.14 1.376 . . . . 39.630000000000003 112.462 172.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.1 p 52.64 38.9 27.25 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.28 1.432 . . . . 17.079999999999998 111.705 -171.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -138.43 -165.15 1.76 Allowed 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.552 -1.277 . . . . 29.239999999999998 107.552 -176.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -67.2 -23.31 65.73 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.267 0.469 . . . . 28.940000000000001 112.267 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 143.38 164.81 10.46 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.308 -0.717 . . . . 30.469999999999999 111.308 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 18.3 tpp85 -125.09 52.07 1.62 Allowed 'General case' 0 C--O 1.235 0.296 0 N-CA-C 105.577 -2.008 . . . . 7.5300000000000002 105.577 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 6.1 tt -73.08 -11.53 14.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-N 114.939 -1.028 . . . . 40.719999999999999 111.805 -169.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 7.7 mp -71.18 -16.12 62.51 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 123.173 0.589 . . . . 41.039999999999999 112.477 -172.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.38 143.12 38.48 Favored Glycine 0 N--CA 1.443 -0.838 0 CA-C-O 121.462 0.479 . . . . 26.699999999999999 114.104 -172.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -77.67 178.91 7.03 Favored 'Trans proline' 0 C--N 1.326 -0.636 0 C-N-CA 121.25 1.3 . . . . 9.1500000000000004 111.787 -176.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -150.68 174.72 29.94 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 109.584 -1.406 . . . . 43.789999999999999 109.584 177.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -75.78 144.77 41.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.668 0.747 . . . . 2.52 110.333 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 2.3 p -101.84 117.55 47.32 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 108.68 -0.859 . . . . 23.559999999999999 108.68 -177.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -116.06 110.9 19.53 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 107.045 -1.465 . . . . 17.079999999999998 107.045 174.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -110.85 120.89 43.89 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.812 -0.81 . . . . 64.909999999999997 108.812 -172.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.6 m -109.4 168.93 9.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 124.767 1.227 . . . . 11.550000000000001 110.411 -176.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -147.33 125.27 2.12 Favored Glycine 0 N--CA 1.443 -0.842 0 CA-C-N 115.142 -0.935 . . . . 17.079999999999998 112.564 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -101.73 99.31 9.55 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.355 -1.35 . . . . 49.670000000000002 107.355 172.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 97.2 t -106.33 120.66 57.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 108.19 -1.041 . . . . 0.32000000000000001 108.19 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 68.5 p -115.88 147.33 41.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.435 -0.58 . . . . 17.079999999999998 109.435 177.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 53.1 p90 -156.41 -174.1 4.79 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 108.585 -0.894 . . . . 2.3500000000000001 108.585 175.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.7 m-30 -116.04 140.48 49.23 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 176.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.21 116.56 4.24 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 116.097 -0.501 . . . . 17.079999999999998 114.318 -175.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.447 ' O ' ' NE2' ' A' ' 76' ' ' GLN . 38.9 ttmt -92.0 148.98 21.79 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.185 -0.672 . . . . 1.74 109.185 175.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 21.0 ptp180 -69.11 -17.21 63.82 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.008 1.114 . . . . 30.370000000000001 114.008 -169.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.85 -143.08 5.75 Favored Glycine 0 N--CA 1.452 -0.284 0 N-CA-C 109.891 -1.284 . . . . 20.890000000000001 109.891 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.1 t0 60.0 74.23 0.45 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 124.915 1.286 . . . . 37.950000000000003 111.123 167.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.04 10.76 0.05 Allowed 'General case' 0 C--O 1.234 0.276 0 N-CA-C 117.227 2.306 . . . . 25.190000000000001 117.227 -161.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.8 -40.25 94.81 Favored Glycine 0 C--N 1.338 0.643 0 C-N-CA 120.407 -0.902 . . . . 30.350000000000001 112.776 170.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.447 ' NE2' ' O ' ' A' ' 70' ' ' LYS . 21.8 pt20 -68.7 -24.56 64.51 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 119.999 -0.68 . . . . 11.83 111.811 172.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.6 mttp -73.79 -23.81 59.74 Favored 'General case' 0 CA--C 1.517 -0.31 0 C-N-CA 119.758 -0.777 . . . . 12.640000000000001 111.301 172.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.12 -31.7 61.2 Favored 'General case' 0 C--O 1.239 0.542 0 C-N-CA 120.617 -0.433 . . . . 17.68 111.157 169.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 51.9 mm -62.97 -42.82 98.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.134 0.493 . . . . 30.140000000000001 110.282 171.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -75.66 -22.74 56.47 Favored 'General case' 0 C--O 1.234 0.263 0 O-C-N 121.875 -0.515 . . . . 17.440000000000001 112.085 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -70.52 -31.68 68.85 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 120.146 -0.621 . . . . 42.539999999999999 111.167 169.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -74.84 -35.55 62.39 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 119.435 -0.906 . . . . 7.5899999999999999 111.572 174.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -83.51 -63.05 1.43 Allowed 'General case' 0 C--O 1.236 0.36 0 C-N-CA 120.256 -0.578 . . . . 17.079999999999998 112.111 -175.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -76.43 -42.61 43.5 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 111.93 0.344 . . . . 23.140000000000001 111.93 -166.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -72.25 -41.45 66.76 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 119.998 -0.681 . . . . 31.739999999999998 111.001 172.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.26 96.68 2.45 Favored Glycine 0 N--CA 1.449 -0.499 0 O-C-N 122.27 -0.269 . . . . 5.8099999999999996 113.224 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -148.14 -161.82 1.42 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 106.887 -1.523 . . . . 17.079999999999998 106.887 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -129.08 176.8 7.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.392 0.615 . . . . 17.079999999999998 109.662 171.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 78.9 mt -129.61 132.41 66.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.117 -0.492 . . . . 29.530000000000001 109.866 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 36.4 mtmm -82.96 120.38 25.63 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 108.424 -0.954 . . . . 22.16 108.424 166.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -117.69 127.58 54.06 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 124.42 1.088 . . . . 16.399999999999999 110.106 -165.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -128.72 128.79 44.74 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 123.838 0.855 . . . . 13.220000000000001 108.929 -178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -110.97 96.02 5.9 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.284 -1.006 . . . . 25.989999999999998 108.284 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.24 161.19 7.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 122.341 1.067 . . . . 35.899999999999999 109.813 -172.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -105.19 165.41 11.12 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 114.71 -1.132 . . . . 16.18 110.951 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 33.2 m -98.79 -29.68 12.85 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.024 -0.989 . . . . 17.0 112.437 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 35.4 m -68.88 154.94 8.03 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 CA-C-O 121.756 0.788 . . . . 17.079999999999998 110.191 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.585 ' NZ ' ' O ' ' A' ' 99' ' ' ASN . 29.2 tptp -91.07 119.28 31.09 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.67 -0.695 . . . . 34.859999999999999 109.761 -176.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.585 ' O ' ' NZ ' ' A' ' 98' ' ' LYS . 35.1 m120 -78.83 168.56 19.54 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-O 121.844 0.83 . . . . 18.719999999999999 109.9 171.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -105.48 -11.37 16.44 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.684 0.994 . . . . 15.359999999999999 113.684 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -93.28 -49.91 5.73 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.221 0.464 . . . . 14.890000000000001 111.532 168.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -109.77 -176.8 3.1 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.642 -0.873 . . . . 22.870000000000001 108.642 173.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.64 -57.09 4.09 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 120.221 -0.592 . . . . 47.869999999999997 110.112 168.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -133.47 -171.46 2.71 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 107.771 -1.196 . . . . 28.57 107.771 -178.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 21.8 p-10 -149.67 169.18 21.61 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.529 0.68 . . . . 38.210000000000001 109.498 176.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -153.1 160.34 42.9 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.258 -0.883 . . . . 2.5299999999999998 111.315 -162.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.44 ' OE1' ' OH ' ' B' ' 118' ' ' TYR . 88.0 mt-30 -119.07 122.43 42.11 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 106.994 -1.484 . . . . 12.91 106.994 159.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -109.47 150.72 27.7 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.132 0.973 . . . . 23.100000000000001 110.286 -164.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -172.84 153.05 17.67 Favored Glycine 0 C--N 1.333 0.379 0 C-N-CA 119.483 -1.342 . . . . 15.91 112.73 174.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -93.41 108.97 20.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 108.967 -0.753 . . . . 2.0899999999999999 108.967 170.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -112.24 162.02 15.95 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 121.52 0.676 . . . . 31.23 111.738 -167.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 69.5 t80 -137.99 140.87 40.4 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.591 -1.186 . . . . 17.940000000000001 107.842 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 78.1 mt -87.15 130.32 37.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.823 -0.436 . . . . 17.079999999999998 109.823 -171.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -73.12 -64.21 1.02 Allowed 'General case' 0 C--O 1.236 0.355 0 C-N-CA 119.816 -0.754 . . . . 25.559999999999999 110.742 164.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 74.7 m -142.05 149.61 40.17 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-O 121.7 0.762 . . . . 4.6500000000000004 110.379 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 8.7 tmm_? -123.61 94.53 4.27 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 104.856 -2.276 . . . . 4.8399999999999999 104.856 176.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -115.52 107.33 15.01 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.637 -1.245 . . . . 25.07 107.637 -175.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.44 ' OH ' ' OE1' ' F' ' 107' ' ' GLN . 19.7 p90 -113.05 144.58 42.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.556 0.693 . . . . 17.079999999999998 112.056 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' SER . . . . . . . . . . . . . 35.2 t -100.25 130.98 46.44 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 114.606 -1.179 . . . . 17.079999999999998 109.885 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -106.63 98.56 8.21 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 106.278 -1.749 . . . . 44.340000000000003 106.278 169.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.56 -157.87 22.91 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 121.685 0.603 . . . . 4.0599999999999996 111.828 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.45 -62.66 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 108.141 -1.059 . . . . 22.239999999999998 108.141 176.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -85.44 -40.08 16.81 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 113.112 0.782 . . . . 64.969999999999999 113.112 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -74.12 149.71 41.32 Favored Glycine 0 N--CA 1.452 -0.261 0 N-CA-C 109.875 -1.29 . . . . 17.059999999999999 109.875 172.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.91 168.37 19.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.752 0.787 . . . . 17.079999999999998 110.163 175.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.5 m -68.93 146.19 12.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-N 115.138 -0.937 . . . . 17.079999999999998 109.878 -176.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -136.22 125.0 23.92 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-N 116.302 -0.408 . . . . 21.27 110.304 -176.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 86.6 mt -95.25 120.89 45.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 109.359 -0.608 . . . . 17.079999999999998 109.359 -177.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 67.4 m -100.84 135.6 42.04 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.422 -0.955 . . . . 31.379999999999999 108.422 170.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 65.2 mt -137.88 129.37 38.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.406 0 N-CA-C 108.958 -0.756 . . . . 17.079999999999998 108.958 -177.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' SER . . . . . . . . . . . . . 58.4 m -95.86 151.7 19.16 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 121.054 0.454 . . . . 31.170000000000002 110.255 175.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 6.9 mp -135.87 139.64 43.52 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.198 -0.456 . . . . 54.409999999999997 111.144 -179.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -120.67 137.22 54.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.546 -0.909 . . . . 17.079999999999998 108.546 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 11.4 p -136.69 148.57 26.81 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 108.508 -0.923 . . . . 9.6600000000000001 108.508 175.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 18.5 mm -59.58 -59.34 4.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 121.304 0.574 . . . . 16.440000000000001 110.848 176.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -165.26 141.74 7.24 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 109.649 -1.38 . . . . 8.5800000000000001 109.649 -177.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -69.61 155.17 40.91 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.618 0.723 . . . . 15.49 110.531 179.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' LEU . . . . . . . . . . . . . 33.2 tp -140.65 125.76 18.5 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.033 -1.469 . . . . 6.3099999999999996 107.033 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -85.08 67.67 10.27 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 122.289 1.042 . . . . 20.25 109.871 -169.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -88.24 74.69 8.69 Favored 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 108.312 -0.996 . . . . 11.24 108.312 175.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.69 112.12 3.71 Favored Glycine 0 C--O 1.237 0.295 0 N-CA-C 110.373 -1.091 . . . . 21.84 110.373 174.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -118.65 -172.46 2.29 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 109.414 -0.587 . . . . 31.329999999999998 109.414 -174.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . . . . . . . . . 1.2 pp -107.02 -63.3 1.88 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 113.418 0.896 . . . . 37.789999999999999 113.418 -169.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ASP . . . . . . . . . . . . . 23.7 p-10 -80.86 129.41 34.51 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 118.928 0.785 . . . . 42.090000000000003 111.052 -168.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 66.9 p -121.65 12.0 10.62 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.345 0.498 . . . . 12.06 112.345 176.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.408 ' O ' ' N ' ' A' ' 148' ' ' GLU . 4.2 mm? 54.24 75.97 0.56 Allowed Pre-proline 0 C--O 1.238 0.458 0 C-N-CA 126.881 2.073 . . . . 21.66 110.184 -177.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -68.51 70.79 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 N-CA-C 115.392 1.266 . . . . 17.079999999999998 115.392 -161.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLU . . . . . 0.525 ' OE1' ' ND2' ' A' ' 152' ' ' ASN . 79.4 mm-40 -104.5 12.95 32.62 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.955 -0.566 . . . . 43.659999999999997 111.281 167.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.506 ' O ' ' NZ ' ' A' ' 12' ' ' LYS . 25.9 pm0 -139.43 4.76 2.21 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.545 0.572 . . . . 22.949999999999999 112.545 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 46.1 mm -113.28 -49.7 5.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 118.738 0.699 . . . . 42.75 111.153 -178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 35.2 t -106.46 -26.88 3.18 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 N-CA-C 107.691 -1.226 . . . . 36.490000000000002 107.691 -177.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.525 ' ND2' ' OE1' ' A' ' 148' ' ' GLU . 36.7 t-20 -67.3 -32.02 72.72 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.227 -0.442 . . . . 23.02 111.642 -178.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -75.51 95.82 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.52 -1.289 . . . . 17.079999999999998 107.52 170.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.9 t -117.26 -61.91 1.64 Allowed 'General case' 0 C--O 1.234 0.278 0 CA-C-N 115.605 -0.725 . . . . 5.0499999999999998 112.688 -172.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 17.7 tppt? -135.67 -28.92 1.08 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 113.751 1.019 . . . . 32.539999999999999 113.751 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.45 -52.39 3.07 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 119.243 0.929 . . . . 26.850000000000001 111.356 -170.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -83.69 143.3 21.49 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-O 122.122 0.845 . . . . 17.079999999999998 112.542 178.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 18.5 m-30 -112.03 -172.5 2.05 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 124.356 1.062 . . . . 21.149999999999999 108.717 177.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -79.33 -75.24 0.25 Allowed 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.642 -1.223 . . . . 47.890000000000001 113.111 -158.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . . . . . . . . . 39.5 p90 176.85 173.01 0.44 Allowed 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 127.699 2.4 . . . . 17.079999999999998 109.528 168.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -156.56 99.68 1.9 Allowed 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 105.347 -2.094 . . . . 23.469999999999999 105.347 155.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 -69.47 -46.26 26.93 Favored Pre-proline 0 C--O 1.244 0.811 0 N-CA-C 113.978 1.103 . . . . 6.79 113.978 -167.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -77.54 -13.7 16.38 Favored 'Trans proline' 0 C--N 1.369 1.648 0 CA-C-N 122.288 1.853 . . . . 31.899999999999999 112.789 174.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -139.5 35.4 1.95 Allowed Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 119.527 2.571 . . . . 35.659999999999997 119.527 -169.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLN . . . . . . . . . . . . . 9.7 tp-100 -68.34 -60.73 2.24 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 119.056 1.428 . . . . 22.710000000000001 111.322 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 34.1 p 53.57 50.11 17.96 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.642 1.577 . . . . 56.030000000000001 111.709 178.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 3.0 m -139.27 147.72 42.05 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 119.872 -0.731 . . . . 6.1799999999999997 109.6 -168.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -86.16 -124.8 1.63 Allowed Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.225 -0.75 . . . . 39.670000000000002 111.225 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 15.6 tm-20 -74.44 -63.32 1.26 Allowed 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.887 0.343 . . . . 24.43 111.364 -175.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.32 105.28 0.83 Allowed Pre-proline 0 C--O 1.235 0.318 0 C-N-CA 123.907 0.883 . . . . 14.119999999999999 109.426 -175.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.64 -176.04 3.06 Favored 'Trans proline' 0 C--N 1.323 -0.774 0 C-N-CA 121.454 1.436 . . . . 13.98 113.115 -156.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.43 69.06 1.46 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 116.799 1.48 . . . . 21.940000000000001 116.799 165.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.6 t -130.23 166.18 20.86 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.946 0.879 . . . . 8.5899999999999999 109.44 169.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.0 m -78.72 159.81 73.28 Favored Pre-proline 0 C--O 1.24 0.596 0 CA-C-N 114.601 -1.181 . . . . 18.25 107.949 177.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -68.32 106.36 1.38 Allowed 'Trans proline' 0 CA--C 1.512 -0.596 0 CA-C-N 119.787 0.96 . . . . 12.65 110.81 173.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.256 0 C-N-CA 125.149 1.38 . . . . 43.579999999999998 112.351 -168.551 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 N--CA 1.465 -0.168 0 CA-C-O 119.981 -0.091 . . . . 11.57 111.986 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . . . . . . . . . 96.7 mt -124.72 118.35 53.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.907 -1.145 . . . . 14.119999999999999 107.907 176.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' MET . . . . . . . . . . . . . 39.0 mmt -85.01 168.7 14.68 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.883 0.849 . . . . 36.259999999999998 110.639 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.73 -14.96 68.25 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.326 -0.852 . . . . 11.49 114.155 172.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -92.68 -14.21 28.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 117.598 0.699 . . . . 14.52 112.376 171.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -76.82 -5.27 47.58 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 114.088 1.144 . . . . 28.940000000000001 114.088 -171.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 60.1 t -127.03 124.33 64.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 119.734 1.152 . . . . 18.920000000000002 108.101 -177.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' LYS . . . . . 0.45 ' NZ ' ' O ' ' B' ' 149' ' ' GLU . 50.9 mtmt -133.56 164.96 26.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.593 0.711 . . . . 17.809999999999999 109.845 174.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' TYR . . . . . . . . . . . . . 19.4 m-30 -114.9 96.14 5.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.024 -0.989 . . . . 5.3700000000000001 108.818 -163.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' LEU . . . . . . . . . . . . . 93.2 mt -73.54 123.24 23.57 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 120.708 -0.397 . . . . 31.940000000000001 109.949 176.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' PHE . . . . . . . . . . . . . 21.4 m-30 -107.45 150.89 26.26 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.763 -0.458 . . . . 20.34 109.763 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLN . . . . . . . . . . . . . 70.0 tp60 -144.99 135.57 24.38 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 109.099 -0.704 . . . . 14.51 109.099 174.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' SER . . . . . . . . . . . . . 36.8 t -74.59 157.48 35.36 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.619 -0.719 . . . . 1.99 111.077 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 41.9 pt -78.04 -15.49 14.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 113.229 0.826 . . . . 4.5499999999999998 113.229 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -113.13 -8.59 13.57 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 112.775 0.657 . . . . 29.629999999999999 112.775 -169.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 119.689 -0.804 . . . . 24.140000000000001 111.488 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.43 41.16 32.14 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.014 1.326 . . . . 4.4800000000000004 111.663 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' THR . . . . . . . . . . . . . 73.3 p -123.02 129.13 51.1 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.387 0.675 . . . . 17.5 109.208 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.73 76.55 2.17 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 116.268 -0.423 . . . . 11.69 114.075 -176.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' SER . . . . . . . . . . . . . 87.8 p -129.17 -29.05 2.3 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 120.59 -0.444 . . . . 26.57 111.711 -178.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.79 74.59 0.77 Allowed Pre-proline 0 C--O 1.237 0.405 0 C-N-CA 126.842 2.057 . . . . 14.279999999999999 112.212 -172.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -71.75 104.22 1.58 Allowed 'Trans proline' 0 CA--C 1.516 -0.408 0 CA-C-N 119.578 0.885 . . . . 9.1400000000000006 111.874 176.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -84.89 163.75 18.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 108.882 -0.784 . . . . 2.0699999999999998 108.882 166.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -100.24 143.2 26.06 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 111.906 -3.918 . . . . 7.1299999999999999 110.0 -174.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -77.49 167.84 23.7 Favored 'Trans proline' 0 CA--C 1.517 -0.347 0 CA-C-N 119.038 0.692 . . . . 14.369999999999999 112.195 177.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . 57.45 61.64 2.42 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.538 1.135 . . . . 17.09 112.04 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-30 -76.02 -176.17 3.36 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.834 1.302 . . . . 12.49 111.298 177.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -144.07 -161.21 1.23 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 103.567 -2.753 . . . . 20.780000000000001 103.567 174.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' THR . . . . . . . . . . . . . 12.9 t -64.39 163.04 13.88 Favored 'General case' 0 C--O 1.244 0.774 0 CA-C-O 122.749 1.261 . . . . 24.370000000000001 111.633 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 82.5 m-20 -135.72 -169.4 2.4 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 113.977 -1.465 . . . . 38.729999999999997 108.194 -168.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 177.41 132.89 1.74 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.386 -0.825 . . . . 14.4 111.113 168.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' SER . . . . . . . . . . . . . 65.2 m -120.9 84.41 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 105.58 -2.008 . . . . 7.8300000000000001 105.58 175.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' VAL . . . . . . . . . . . . . 3.5 m -92.38 109.17 21.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 108.494 -0.928 . . . . 17.010000000000002 108.494 -172.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' SER . . . . . . . . . . . . . 44.2 m -100.13 98.74 9.42 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.719 -1.215 . . . . 18.870000000000001 107.719 -170.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . -101.17 104.29 2.71 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.283 -0.961 . . . . 0.17999999999999999 113.165 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -107.36 121.22 44.15 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.52 -0.918 . . . . 9.2100000000000009 108.52 -178.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -80.49 -176.27 5.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.731 0.776 . . . . 29.739999999999998 109.321 -178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -158.85 147.48 18.44 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.804 -0.56 . . . . 20.010000000000002 109.536 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' LEU . . . . . . . . . . . . . 70.1 mt -68.94 113.19 6.12 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 108.89 -0.782 . . . . 17.43 108.89 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -109.1 104.55 13.76 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 108.916 -0.772 . . . . 25.469999999999999 108.916 -173.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -136.33 179.1 6.56 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.302 -0.408 . . . . 27.640000000000001 111.575 -175.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -128.35 -38.52 1.76 Allowed 'General case' 0 C--O 1.236 0.381 0 N-CA-C 113.67 0.989 . . . . 19.25 113.67 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' GLN . . . . . . . . . . . . . 79.9 mm-40 57.85 33.75 23.57 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.305 1.442 . . . . 23.02 112.448 175.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' THR . . . . . . . . . . . . . 44.3 p 52.53 39.84 28.7 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.305 1.442 . . . . 17.030000000000001 111.702 -172.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -138.12 -164.73 1.67 Allowed 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.497 -1.297 . . . . 4.3099999999999996 107.497 -176.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -65.44 -27.71 68.71 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.252 -0.431 . . . . 23.579999999999998 112.044 173.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 148.06 157.71 7.62 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.928 -0.469 . . . . 11.19 111.928 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' ARG . . . . . . . . . . . . . 17.6 tpp85 -123.1 50.71 1.51 Allowed 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.328 -2.101 . . . . 5.0599999999999996 105.328 176.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' ILE . . . . . . . . . . . . . 8.0 tt -81.3 -5.81 9.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 CA-C-N 115.202 -0.908 . . . . 30.68 111.083 -172.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' LEU . . . . . . . . . . . . . 7.2 mp -66.04 -20.5 66.2 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.767 0.655 . . . . 26.800000000000001 112.767 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.65 145.21 43.38 Favored Glycine 0 N--CA 1.443 -0.836 0 CA-C-O 121.473 0.485 . . . . 12.91 114.08 -172.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -76.37 -179.8 5.64 Favored 'Trans proline' 0 C--N 1.327 -0.56 0 C-N-CA 121.284 1.323 . . . . 12.85 112.028 -175.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' GLY . . . . . . . . . . . . . . . -151.89 172.92 31.22 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 109.679 -1.369 . . . . 19.440000000000001 109.679 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' SER . . . . . . . . . . . . . 46.7 t -75.28 146.55 40.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.604 0.716 . . . . 18.91 110.389 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 5.8 p -100.23 127.55 53.1 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.184 -1.043 . . . . 17.050000000000001 108.184 -178.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -125.49 113.19 17.15 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 106.976 -1.49 . . . . 0.01 106.976 173.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -115.11 120.88 41.3 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.814 -0.81 . . . . 28.32 108.814 -171.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' SER . . . . . 0.458 ' OG ' ' OE1' ' B' ' 133' ' ' GLN . 70.8 m -107.09 164.68 11.95 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.484 1.114 . . . . 20.219999999999999 110.458 -176.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' GLY . . . . . . . . . . . . . . . -139.74 121.66 2.08 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-N 115.173 -0.921 . . . . 6.6299999999999999 112.529 175.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 -101.73 94.14 5.68 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 107.299 -1.371 . . . . 33.789999999999999 107.299 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' VAL . . . . . . . . . . . . . 89.5 t -106.23 120.05 56.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.053 -1.091 . . . . 17.030000000000001 108.053 -177.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 64.7 p -115.24 149.34 37.91 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.457 -0.572 . . . . 17.030000000000001 109.457 177.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -155.53 -174.12 4.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 108.976 -0.749 . . . . 12.32 108.976 174.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' TYR . . . . . . . . . . . . . 15.0 m-30 -114.16 136.26 53.13 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 109.414 -0.587 . . . . 15.039999999999999 109.414 174.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.85 113.15 3.62 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.84 -0.695 . . . . 15.65 113.936 -175.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.425 ' O ' ' NE2' ' B' ' 76' ' ' GLN . 38.5 ttmt -82.62 149.72 27.24 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.768 -0.827 . . . . 28.210000000000001 108.768 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -67.28 -16.68 64.42 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 114.002 1.112 . . . . 11.970000000000001 114.002 -170.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.22 -142.49 5.58 Favored Glycine 0 N--CA 1.451 -0.337 0 N-CA-C 110.153 -1.179 . . . . 24.43 110.153 176.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' ASP . . . . . . . . . . . . . 31.1 t0 59.86 74.86 0.43 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.048 1.339 . . . . 18.350000000000001 111.108 168.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.28 11.02 0.03 OUTLIER 'General case' 0 C--O 1.235 0.29 0 N-CA-C 117.535 2.42 . . . . 30.510000000000002 117.535 -160.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.78 -41.01 95.75 Favored Glycine 0 C--N 1.338 0.686 0 C-N-CA 120.356 -0.926 . . . . 16.260000000000002 112.797 170.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' GLN . . . . . 0.425 ' NE2' ' O ' ' B' ' 70' ' ' LYS . 21.8 pt20 -69.2 -24.36 64.02 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 119.865 -0.734 . . . . 19.690000000000001 111.819 172.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -72.58 -25.13 61.23 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 119.751 -0.78 . . . . 22.73 111.108 171.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.19 -31.42 60.93 Favored 'General case' 0 C--O 1.239 0.501 0 C-N-CA 120.67 -0.412 . . . . 17.07 111.238 170.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' ILE . . . . . . . . . . . . . 51.2 mm -63.16 -43.04 98.64 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.148 0.499 . . . . 4.3499999999999996 110.291 171.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -75.64 -19.32 59.28 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.894 -0.504 . . . . 15.890000000000001 111.999 178.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -71.49 -31.37 67.05 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.972 -0.691 . . . . 26.41 111.027 167.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.71 -29.32 56.19 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 119.668 -0.813 . . . . 15.34 111.775 175.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' TYR . . . . . . . . . . . . . 83.0 t80 -95.71 -60.39 1.66 Allowed 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.776 -0.77 . . . . 12.51 112.26 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -72.0 -42.0 66.96 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 111.701 0.259 . . . . 26.5 111.701 -170.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -75.0 -47.42 29.21 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 119.986 -0.685 . . . . 1.8899999999999999 110.989 170.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.3 97.37 2.49 Favored Glycine 0 N--CA 1.449 -0.479 0 O-C-N 122.231 -0.293 . . . . 18.629999999999999 113.175 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -147.41 -162.88 1.64 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 107.023 -1.473 . . . . 15.85 107.023 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -127.68 173.36 9.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.317 0.579 . . . . 18.670000000000002 109.663 173.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 70.5 mt -128.53 134.44 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.059 0.457 . . . . 27.239999999999998 109.847 -171.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -85.11 119.28 25.32 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.603 -0.888 . . . . 23.039999999999999 108.603 165.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -116.7 126.86 53.78 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 124.463 1.105 . . . . 23.66 110.195 -165.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -127.29 127.43 44.33 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.949 0.9 . . . . 25.699999999999999 109.018 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' ARG . . . . . . . . . . . . . 78.1 ttt-85 -109.3 95.43 5.62 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.261 -1.015 . . . . 8.0 108.261 173.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' VAL . . . . . . . . . . . . . 24.7 m -109.52 162.27 7.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 122.196 0.998 . . . . 9.8499999999999996 109.652 -172.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -109.95 169.16 8.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.94 -1.027 . . . . 17.120000000000001 111.411 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 33.3 m -101.65 -29.85 11.69 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 114.862 -1.063 . . . . 10.699999999999999 112.594 -175.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 35.6 m -68.9 153.17 9.06 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 CA-C-O 121.738 0.78 . . . . 3.8399999999999999 110.16 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' LYS . . . . . 0.582 ' NZ ' ' O ' ' B' ' 99' ' ' ASN . 29.7 tptp -89.45 125.85 35.33 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.619 -0.719 . . . . 16.579999999999998 109.739 -176.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . 0.582 ' O ' ' NZ ' ' B' ' 98' ' ' LYS . 34.4 m120 -85.19 168.41 14.81 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 121.843 0.83 . . . . 17.280000000000001 110.031 172.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 55.9 mp0 -103.28 -14.76 16.19 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 113.593 0.96 . . . . 25.010000000000002 113.593 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -94.48 -47.86 6.37 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.303 0.501 . . . . 7.6500000000000004 111.16 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -108.5 -175.17 2.7 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 108.836 -0.801 . . . . 20.359999999999999 108.836 175.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -80.6 -57.3 3.64 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.216 0.532 . . . . 29.0 110.165 168.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -133.11 -173.34 3.17 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.897 -1.149 . . . . 23.559999999999999 107.897 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 25.8 p-10 -146.99 168.61 21.09 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.575 0.702 . . . . 13.41 109.706 176.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -154.13 158.01 39.77 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.167 -0.924 . . . . 19.829999999999998 111.166 -162.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' GLN . . . . . 0.455 ' OE1' ' OH ' ' C' ' 118' ' ' TYR . 88.9 mt-30 -119.03 123.18 43.89 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.123 -1.436 . . . . 9.0099999999999998 107.123 159.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -111.58 151.1 29.12 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 124.196 0.998 . . . . 7.9699999999999998 110.526 -163.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -170.4 156.01 26.1 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 119.743 -1.218 . . . . 3.3199999999999998 112.591 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -95.21 108.45 20.58 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 109.023 -0.732 . . . . 7.9800000000000004 109.023 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.71 161.7 15.5 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-O 121.513 0.673 . . . . 28.030000000000001 111.769 -166.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -140.24 138.21 34.88 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.659 -1.155 . . . . 19.649999999999999 107.963 -177.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 82.9 mt -85.13 128.75 38.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 109.984 -0.376 . . . . 8.3300000000000001 109.984 -171.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -71.11 -64.08 0.98 Allowed 'General case' 0 C--O 1.234 0.287 0 C-N-CA 119.779 -0.768 . . . . 32.149999999999999 110.668 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' SER . . . . . . . . . . . . . 73.7 m -142.32 149.45 39.49 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.581 0.705 . . . . 15.75 110.375 -169.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -123.13 94.75 4.36 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 105.039 -2.208 . . . . 15.68 105.039 175.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -115.35 108.52 16.65 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.409 -1.33 . . . . 21.710000000000001 107.409 -176.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' TYR . . . . . 0.44 ' OH ' ' OE1' ' A' ' 107' ' ' GLN . 25.2 p90 -112.95 139.22 48.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.616 0.722 . . . . 9.2300000000000004 111.854 177.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' SER . . . . . . . . . . . . . 37.4 t -95.66 131.37 41.97 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 114.6 -1.182 . . . . 17.030000000000001 109.821 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 59.6 t0 -111.15 100.42 9.08 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 106.5 -1.667 . . . . 12.65 106.5 172.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' GLY . . . . . . . . . . . . . . . -83.12 -158.55 25.8 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-O 121.707 0.615 . . . . 12.210000000000001 112.014 177.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.08 -62.36 2.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 107.969 -1.122 . . . . 20.199999999999999 107.969 177.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' GLU . . . . . 0.518 ' OE2' ' NH2' ' G' ' 41' ' ' ARG . 94.9 mt-10 -91.49 -36.38 13.77 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.204 0.816 . . . . 40.229999999999997 113.204 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' GLY . . . . . . . . . . . . . . . -70.85 142.86 35.51 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 109.939 -1.264 . . . . 13.539999999999999 109.939 172.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.09 165.57 23.25 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.774 0.797 . . . . 14.449999999999999 110.339 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . . . . . . . . . 27.5 m -68.78 149.08 11.39 Favored 'Isoleucine or valine' 0 C--O 1.238 0.49 0 CA-C-N 115.111 -0.949 . . . . 17.469999999999999 109.749 -176.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -138.8 126.23 21.73 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.295 -0.411 . . . . 25.050000000000001 109.994 -179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' ILE . . . . . . . . . . . . . 89.5 mt -93.65 118.58 39.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.034 -0.728 . . . . 3.8100000000000001 109.034 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' SER . . . . . . . . . . . . . 69.2 m -98.61 133.66 42.65 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.365 -0.976 . . . . 20.760000000000002 108.365 171.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 68.9 mt -135.57 128.51 47.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.054 -0.721 . . . . 15.91 109.054 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' SER . . . . . . . . . . . . . 50.2 m -96.14 151.66 19.27 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.129 -0.487 . . . . 19.899999999999999 110.005 175.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . . . . . . . . . 7.1 mp -136.07 142.79 44.4 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 29.359999999999999 110.906 -177.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' GLN . . . . . 0.458 ' OE1' ' OG ' ' B' ' 62' ' ' SER . 30.0 mm100 -124.67 137.13 54.38 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.236 -1.024 . . . . 3.2400000000000002 108.236 169.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -136.36 148.88 27.07 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 108.65 -0.871 . . . . 0.37 108.65 175.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 16.0 mm -60.42 -59.11 4.63 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.244 0.545 . . . . 8.0700000000000003 110.826 176.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' GLY . . . . . . . . . . . . . . . -165.04 139.5 5.86 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 109.611 -1.396 . . . . 15.08 109.611 -176.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -67.58 151.17 47.78 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.571 0.701 . . . . 14.210000000000001 110.547 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' LEU . . . . . . . . . . . . . 35.2 tp -140.55 125.25 18.06 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.166 -1.42 . . . . 11.08 107.166 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.98 69.11 10.23 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 122.287 1.041 . . . . 22.239999999999998 109.796 -168.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -87.98 74.82 8.87 Favored 'General case' 0 C--N 1.333 -0.137 0 N-CA-C 108.18 -1.044 . . . . 15.48 108.18 175.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.4 113.86 4.44 Favored Glycine 0 C--O 1.237 0.32 0 N-CA-C 110.546 -1.021 . . . . 18.710000000000001 110.546 176.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -118.45 -172.84 2.35 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.344 -0.613 . . . . 30.93 109.344 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' ILE . . . . . . . . . . . . . 1.3 pp -109.66 -61.93 2.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 N-CA-C 113.191 0.811 . . . . 20.34 113.191 -169.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -80.83 125.22 29.82 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.384 -0.822 . . . . 24.010000000000002 110.964 -169.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' THR . . . . . . . . . . . . . 70.8 p -117.59 13.37 14.3 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 119.024 -0.512 . . . . 16.280000000000001 112.357 178.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' LEU . . . . . 0.4 ' O ' ' N ' ' B' ' 148' ' ' GLU . 4.1 mm? 54.24 75.63 0.6 Allowed Pre-proline 0 C--O 1.237 0.423 0 C-N-CA 126.953 2.101 . . . . 22.379999999999999 110.478 -179.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -68.79 71.05 1.08 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 N-CA-C 115.498 1.307 . . . . 12.25 115.498 -160.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' GLU . . . . . 0.516 ' OE1' ' ND2' ' B' ' 152' ' ' ASN . 79.8 mm-40 -105.08 13.17 31.23 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.221 -0.445 . . . . 18.960000000000001 111.387 167.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' GLU . . . . . 0.45 ' O ' ' NZ ' ' B' ' 12' ' ' LYS . 25.8 pm0 -139.79 3.41 2.05 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 112.776 0.658 . . . . 14.880000000000001 112.776 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' ILE . . . . . . . . . . . . . 50.0 mm -115.03 -52.13 4.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.807 0.73 . . . . 17.32 111.228 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' VAL . . . . . . . . . . . . . 23.8 t -105.5 -24.79 3.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 107.457 -1.312 . . . . 20.57 107.457 -176.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' ASN . . . . . 0.516 ' ND2' ' OE1' ' B' ' 148' ' ' GLU . 39.0 t-20 -66.95 -33.19 75.04 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.238 -0.437 . . . . 20.949999999999999 111.565 179.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.72 96.44 1.23 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.42 1.105 . . . . 19.59 108.046 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' SER . . . . . . . . . . . . . 37.4 t -117.48 -61.1 1.74 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.494 -0.775 . . . . 13.41 112.501 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 155' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -134.93 -29.09 1.15 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 113.794 1.035 . . . . 36.82 113.794 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.71 -59.88 4.26 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 110.581 -1.008 . . . . 21.399999999999999 110.581 -167.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.85 143.84 28.2 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.535 -0.84 . . . . 4.2300000000000004 112.42 177.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 158' ' ' TYR . . . . . . . . . . . . . 16.9 m-30 -113.59 -172.03 2.0 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.861 1.264 . . . . 22.359999999999999 108.997 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 159' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -79.16 -74.94 0.26 Allowed 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 118.771 -1.172 . . . . 26.780000000000001 113.134 -156.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 160' ' ' PHE . . . . . . . . . . . . . 39.0 p90 177.12 172.1 0.5 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 127.413 2.285 . . . . 1.9399999999999999 109.676 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -156.87 99.77 1.86 Allowed 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 105.426 -2.064 . . . . 12.07 105.426 155.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -69.64 -45.26 25.43 Favored Pre-proline 0 C--O 1.243 0.754 0 N-CA-C 114.001 1.112 . . . . 8.3000000000000007 114.001 -166.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -78.01 -13.68 15.61 Favored 'Trans proline' 0 C--N 1.369 1.628 0 CA-C-N 122.22 1.829 . . . . 17.940000000000001 112.62 173.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 164' ' ' GLY . . . . . . . . . . . . . . . -140.13 34.95 1.95 Allowed Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 119.889 2.716 . . . . 22.02 119.889 -170.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 165' ' ' GLN . . . . . . . . . . . . . 9.7 tp-100 -68.45 -57.86 5.21 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 119.257 1.529 . . . . 21.640000000000001 111.09 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 166' ' ' THR . . . . . . . . . . . . . 31.2 p 54.18 49.54 18.47 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.745 1.618 . . . . 29.91 111.728 176.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 167' ' ' THR . . . . . . . . . . . . . 3.2 m -139.47 149.23 43.76 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 119.835 -0.746 . . . . 11.07 109.547 -167.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 168' ' ' GLY . . . . . . . . . . . . . . . -85.7 -124.37 1.46 Allowed Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.87 -0.892 . . . . 22.27 110.87 169.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 169' ' ' GLU . . . . . . . . . . . . . 15.6 tm-20 -74.37 -63.84 1.15 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 120.548 -0.461 . . . . 18.300000000000001 111.304 -176.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.41 104.5 0.66 Allowed Pre-proline 0 C--O 1.235 0.326 0 C-N-CA 124.057 0.943 . . . . 22.280000000000001 109.887 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 171' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -80.04 -172.93 1.66 Allowed 'Trans proline' 0 C--N 1.323 -0.779 0 C-N-CA 121.475 1.45 . . . . 14.9 112.983 -156.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.43 68.65 1.56 Allowed Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 116.481 1.352 . . . . 17.93 116.481 166.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 173' ' ' THR . . . . . . . . . . . . . 11.4 t -133.28 166.14 23.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.909 0.861 . . . . 15.99 109.426 170.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -82.3 158.59 66.35 Favored Pre-proline 0 C--O 1.239 0.547 0 N-CA-C 107.334 -1.358 . . . . 14.16 107.334 174.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 175' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -67.27 108.94 1.65 Allowed 'Trans proline' 0 CA--C 1.514 -0.524 0 CA-C-N 119.769 0.953 . . . . 26.18 111.469 175.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.246 0 C-N-CA 125.295 1.438 . . . . 26.620000000000001 112.443 -174.113 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 5' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo . . . . . 0 N--CA 1.464 -0.213 0 N-CA-C 112.213 0.044 . . . . 5.9199999999999999 112.213 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 6' ' ' ILE . . . . . . . . . . . . . 96.6 mt -124.53 119.32 56.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 N-CA-C 107.896 -1.15 . . . . 20.07 107.896 176.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -79.59 173.17 12.85 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 121.945 0.878 . . . . 39.140000000000001 110.381 178.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 8' ' ' GLY . . . . . . . . . . . . . . . -72.89 -10.88 77.98 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.546 -0.835 . . . . 17.34 113.81 167.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -97.04 -15.82 20.85 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.788 0.835 . . . . 3.5299999999999998 112.215 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -74.93 -5.48 44.04 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 114.192 1.182 . . . . 33.799999999999997 114.192 -171.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' VAL . . . . . . . . . . . . . 83.1 t -128.17 125.51 64.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 N-CA-C 107.983 -1.117 . . . . 6.96 107.983 -177.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' LYS . . . . . 0.515 ' NZ ' ' O ' ' C' ' 149' ' ' GLU . 51.8 mtmt -132.92 161.92 32.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.526 0.679 . . . . 27.149999999999999 110.009 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' TYR . . . . . . . . . . . . . 19.1 m-30 -112.14 96.52 6.08 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 108.046 -1.094 . . . . 17.34 108.046 -165.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' LEU . . . . . . . . . . . . . 89.6 mt -74.68 126.24 30.44 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.961 -0.385 . . . . 45.310000000000002 109.961 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' PHE . . . . . . . . . . . . . 21.5 m-30 -108.69 151.12 26.6 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.138 0.494 . . . . 30.289999999999999 109.921 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' GLN . . . . . . . . . . . . . 70.2 tp60 -145.27 135.68 24.15 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.033 -0.729 . . . . 31.670000000000002 109.033 174.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' SER . . . . . . . . . . . . . 37.8 t -76.23 153.62 35.89 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.616 0.722 . . . . 6.0999999999999996 110.978 178.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -76.41 -13.5 14.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.266 0.839 . . . . 17.34 113.266 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -111.96 -8.42 14.08 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 112.678 0.621 . . . . 49.350000000000001 112.678 -171.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.63 -46.83 35.7 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 119.759 -0.776 . . . . 27.899999999999999 111.536 -176.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . 54.24 39.75 31.09 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.053 1.341 . . . . 16.850000000000001 111.677 -172.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' THR . . . . . . . . . . . . . 69.8 p -123.23 129.07 50.88 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.426 0.69 . . . . 3.25 109.431 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.6 76.01 2.29 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 114.294 0.477 . . . . 6.3700000000000001 114.294 -177.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' SER . . . . . . . . . . . . . 92.1 p -129.69 -26.08 2.51 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 120.487 -0.485 . . . . 40.57 111.654 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.16 73.6 0.95 Allowed Pre-proline 0 C--O 1.237 0.441 0 C-N-CA 126.869 2.067 . . . . 53.810000000000002 112.511 -173.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -72.27 104.36 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 CA-C-N 119.591 0.89 . . . . 15.140000000000001 111.71 176.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -86.36 153.6 21.81 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 108.801 -0.814 . . . . 17.34 108.801 166.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -99.88 130.06 27.23 Favored Pre-proline 0 C--N 1.318 -0.791 1 C-N-CA 110.635 -4.426 . . . . 22.149999999999999 110.207 -178.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -73.91 -172.0 1.01 Allowed 'Trans proline' 0 C--O 1.235 0.344 0 C-N-CA 120.518 0.812 . . . . 29.329999999999998 113.708 -177.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . 55.79 57.66 5.05 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.517 1.127 . . . . 3.8799999999999999 111.339 -175.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' TYR . . . . . . . . . . . . . 1.5 m-30 -69.93 -179.02 1.72 Allowed 'General case' 0 N--CA 1.455 -0.199 0 CA-C-O 123.067 1.413 . . . . 45.020000000000003 112.403 -179.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' GLN . . . . . . . . . . . . . 6.9 tp-100 -148.82 -159.36 1.02 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 103.305 -2.85 . . . . 21.77 103.305 168.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' C' ' 66' ' ' THR . 15.3 t -65.95 164.92 14.13 Favored 'General case' 0 C--O 1.242 0.707 0 CA-C-O 122.67 1.224 . . . . 21.710000000000001 111.616 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -135.4 -168.46 2.19 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 114.04 -1.437 . . . . 44.640000000000001 108.269 -167.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' GLY . . . . . . . . . . . . . . . 172.25 135.11 1.9 Allowed Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.507 -0.769 . . . . 7.5800000000000001 111.464 170.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' SER . . . . . . . . . . . . . 67.7 m -125.74 84.62 2.29 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 106.016 -1.846 . . . . 5.5999999999999996 106.016 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' VAL . . . . . . . . . . . . . 4.2 m -90.62 111.33 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 108.314 -0.995 . . . . 19.140000000000001 108.314 -172.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' SER . . . . . . . . . . . . . 47.6 m -101.28 93.66 5.55 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.935 -1.135 . . . . 36.049999999999997 107.935 -169.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.92 102.64 2.84 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.13 -1.033 . . . . 35.700000000000003 113.475 -177.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -108.61 125.28 51.68 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 108.499 -0.926 . . . . 11.65 108.499 -178.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 87.8 mtm-85 -84.63 -173.04 4.51 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.615 0.722 . . . . 37.369999999999997 109.086 -178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' GLU . . . . . . . . . . . . . 20.8 pt-20 -161.02 148.1 15.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.523 -0.547 . . . . 38.549999999999997 109.523 -170.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' LEU . . . . . . . . . . . . . 72.2 mt -69.73 124.26 23.51 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 108.926 -0.768 . . . . 27.59 108.926 177.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -124.12 101.23 7.1 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.233 -0.654 . . . . 37.439999999999998 109.233 -169.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 45' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -137.23 -177.27 4.7 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 122.733 0.413 . . . . 41.82 111.44 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 46' ' ' GLU . . . . . . . . . . . . . 57.5 mp0 -127.27 -37.67 2.03 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 113.398 0.888 . . . . 16.370000000000001 113.398 175.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 47' ' ' GLN . . . . . . . . . . . . . 85.5 mm-40 60.05 33.77 21.32 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.051 1.341 . . . . 39.229999999999997 112.622 170.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 48' ' ' THR . . . . . . . . . . . . . 49.1 p 52.61 39.32 28.01 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.137 1.375 . . . . 17.34 111.625 -171.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 49' ' ' LYS . . . . . . . . . . . . . 48.5 mmtm -138.09 -165.42 1.79 Allowed 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.534 -1.284 . . . . 17.52 107.534 -177.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -68.42 -25.7 65.16 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.27 -0.423 . . . . 24.920000000000002 112.038 173.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 51' ' ' GLY . . . . . . . . . . . . . . . 144.9 160.12 8.39 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 117.908 0.322 . . . . 24.579999999999998 112.597 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 52' ' ' ARG . . . . . . . . . . . . . 16.4 tpp85 -122.93 49.96 1.58 Allowed 'General case' 0 C--O 1.234 0.289 0 N-CA-C 105.425 -2.065 . . . . 19.34 105.425 176.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 53' ' ' ILE . . . . . . . . . . . . . 7.7 tt -82.31 -5.2 8.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-N 115.319 -0.855 . . . . 43.759999999999998 110.942 -173.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 54' ' ' LEU . . . . . . . . . . . . . 6.8 mp -64.85 -23.64 67.3 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 112.597 0.591 . . . . 34.390000000000001 112.597 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.0 143.37 41.37 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.461 0.478 . . . . 1.6799999999999999 113.997 -170.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.77 177.16 8.86 Favored 'Trans proline' 0 C--N 1.327 -0.584 0 C-N-CA 121.333 1.355 . . . . 14.029999999999999 112.031 -174.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 57' ' ' GLY . . . . . . . . . . . . . . . -148.14 173.31 28.2 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 109.619 -1.392 . . . . 28.690000000000001 109.619 177.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 58' ' ' SER . . . . . . . . . . . . . 42.8 t -75.76 148.36 38.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.582 0.706 . . . . 2.6299999999999999 110.498 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -101.06 131.99 47.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 107.901 -1.148 . . . . 17.34 107.901 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 60' ' ' ALA . . . . . . . . . . . . . . . -128.72 113.23 15.1 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.714 -1.588 . . . . 21.300000000000001 106.714 171.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 61' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -114.13 120.5 40.74 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.7 -0.852 . . . . 35.310000000000002 108.7 -170.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 62' ' ' SER . . . . . 0.459 ' OG ' ' OE1' ' C' ' 133' ' ' GLN . 71.1 m -106.6 163.0 13.25 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.462 1.105 . . . . 5.4199999999999999 110.252 -176.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 63' ' ' GLY . . . . . . . . . . . . . . . -138.47 121.08 2.09 Favored Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 115.049 -0.978 . . . . 17.34 112.217 176.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -99.47 96.45 7.69 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 107.272 -1.381 . . . . 47.509999999999998 107.272 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 65' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.84 117.84 51.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.148 -1.056 . . . . 17.34 108.148 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 66' ' ' THR . . . . . 0.441 ' OG1' ' O ' ' C' ' 33' ' ' THR . 67.2 p -113.77 144.37 43.1 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.134 -0.691 . . . . 9.8399999999999999 109.134 176.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 67' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -155.13 -175.06 5.25 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.814 -0.809 . . . . 20.719999999999999 108.814 176.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 68' ' ' TYR . . . . . . . . . . . . . 14.9 m-30 -114.55 137.32 52.02 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 109.311 -0.626 . . . . 17.34 109.311 174.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 69' ' ' GLY . . . . . . . . . . . . . . . -85.18 111.47 3.53 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.938 -0.649 . . . . 17.34 114.122 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 70' ' ' LYS . . . . . 0.409 ' O ' ' NE2' ' C' ' 76' ' ' GLN . 38.3 ttmt -80.0 153.35 28.92 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 108.645 -0.872 . . . . 17.34 108.645 174.462 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -68.67 -15.61 63.57 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 114.048 1.129 . . . . 24.920000000000002 114.048 -171.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.63 -141.49 5.19 Favored Glycine 0 N--CA 1.451 -0.327 0 N-CA-C 110.217 -1.153 . . . . 51.189999999999998 110.217 177.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 73' ' ' ASP . . . . . . . . . . . . . 30.1 t0 60.06 72.89 0.5 Allowed 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.166 1.386 . . . . 18.34 111.169 168.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.3 10.94 0.05 Allowed 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 117.241 2.312 . . . . 52.710000000000001 117.241 -160.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.51 -40.1 93.97 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 120.172 -1.013 . . . . 16.66 112.513 169.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 76' ' ' GLN . . . . . 0.409 ' NE2' ' O ' ' C' ' 70' ' ' LYS . 22.2 pt20 -69.96 -22.37 63.17 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 119.894 -0.722 . . . . 29.16 111.938 172.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -73.78 -25.36 60.1 Favored 'General case' 0 CA--C 1.517 -0.31 0 C-N-CA 119.359 -0.936 . . . . 18.43 111.411 170.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.98 -31.85 64.81 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 120.236 -0.586 . . . . 44.700000000000003 111.102 169.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 79' ' ' ILE . . . . . . . . . . . . . 51.0 mm -62.94 -45.31 99.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-O 121.066 0.46 . . . . 34.229999999999997 110.455 172.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -75.41 -21.08 58.5 Favored 'General case' 0 C--O 1.235 0.295 0 O-C-N 121.899 -0.5 . . . . 25.41 112.016 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 81' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -69.18 -34.33 74.77 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 120.223 -0.591 . . . . 39.479999999999997 111.178 167.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 82' ' ' ALA . . . . . . . . . . . . . . . -73.3 -36.7 66.32 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 119.661 -0.816 . . . . 17.34 111.667 176.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 83' ' ' TYR . . . . . . . . . . . . . 83.0 t80 -84.08 -62.23 1.62 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 120.284 -0.566 . . . . 7.5599999999999996 112.047 -176.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -73.81 -42.41 60.97 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.919 0.34 . . . . 25.84 111.919 -167.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 85' ' ' ASN . . . . . . . . . . . . . 35.6 m120 -76.2 -44.99 35.24 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 119.885 -0.726 . . . . 7.5099999999999998 111.075 173.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.31 96.73 2.4 Favored Glycine 0 N--CA 1.449 -0.486 0 O-C-N 122.255 -0.278 . . . . 4.2000000000000002 113.374 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 87' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.26 -162.72 1.61 Allowed 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 107.165 -1.42 . . . . 17.34 107.165 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 88' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.39 174.24 9.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.371 0.605 . . . . 17.34 109.718 172.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 89' ' ' ILE . . . . . . . . . . . . . 72.9 mt -128.67 134.99 63.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 116.108 -0.496 . . . . 28.059999999999999 109.698 -173.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 90' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -84.54 117.41 23.69 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.66 -0.867 . . . . 24.09 108.66 165.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 91' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -112.64 127.59 56.15 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.766 1.226 . . . . 25.039999999999999 110.179 -167.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 92' ' ' TRP . . . . . . . . . . . . . 90.1 m95 -126.51 130.94 51.59 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 124.131 0.972 . . . . 7.3899999999999997 108.749 -178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 93' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -113.83 93.73 4.51 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 108.136 -1.061 . . . . 30.73 108.136 172.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 94' ' ' VAL . . . . . . . . . . . . . 21.6 m -107.71 163.07 5.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 122.344 1.069 . . . . 28.649999999999999 109.679 -172.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 95' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -106.21 165.79 10.99 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 114.719 -1.128 . . . . 15.99 111.343 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 96' ' ' THR . . . . . . . . . . . . . 30.1 m -101.33 -29.87 11.81 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 114.89 -1.05 . . . . 20.039999999999999 112.338 -178.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 97' ' ' VAL . . . . . . . . . . . . . 35.0 m -68.92 153.43 8.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.464 0 CA-C-O 121.806 0.813 . . . . 2.8799999999999999 109.968 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 98' ' ' LYS . . . . . 0.56 ' NZ ' ' O ' ' C' ' 99' ' ' ASN . 29.8 tptp -89.58 125.79 35.36 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.67 -0.696 . . . . 21.890000000000001 109.674 -176.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 99' ' ' ASN . . . . . 0.56 ' O ' ' NZ ' ' C' ' 98' ' ' LYS . 35.8 m120 -86.43 168.37 13.84 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.77 0.795 . . . . 6.9699999999999998 109.792 171.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 100' ' ' GLU . . . . . . . . . . . . . 55.1 mp0 -104.31 -13.0 16.3 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 113.824 1.046 . . . . 29.489999999999998 113.824 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 101' ' ' ASN . . . . . . . . . . . . . 16.2 p30 -91.94 -59.59 2.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 118.408 0.549 . . . . 48.439999999999998 111.48 165.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 102' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -98.27 -179.75 4.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 108.631 -0.877 . . . . 25.219999999999999 108.631 174.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 103' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -75.2 -56.95 4.22 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 120.265 -0.574 . . . . 45.030000000000001 110.073 169.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 104' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -133.96 -170.93 2.61 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 108.179 -1.045 . . . . 16.91 108.179 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 105' ' ' ASP . . . . . 0.404 ' N ' ' OD1' ' C' ' 105' ' ' ASP . 20.7 p-10 -151.25 171.03 18.06 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.498 0.665 . . . . 20.23 109.512 176.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 106' ' ' ALA . . . . . . . . . . . . . . . -154.21 153.93 32.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.222 -0.899 . . . . 30.469999999999999 111.104 -164.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 107' ' ' GLN . . . . . 0.461 ' OE1' ' OH ' ' D' ' 118' ' ' TYR . 87.3 mt-30 -110.82 125.66 53.82 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 106.828 -1.545 . . . . 7.3899999999999997 106.828 156.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 108' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -117.03 153.33 32.89 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 123.654 0.782 . . . . 14.880000000000001 110.698 -160.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 109' ' ' GLY . . . . . . . . . . . . . . . -172.78 163.01 34.78 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 119.156 -1.497 . . . . 6.0300000000000002 112.924 172.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 110' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -99.08 109.2 21.96 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 108.874 -0.787 . . . . 17.34 108.874 168.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 111' ' ' ALA . . . . . . . . . . . . . . . -112.3 161.61 16.43 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.522 0.677 . . . . 5.6399999999999997 111.799 -166.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 112' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -138.73 138.43 37.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.575 -1.193 . . . . 14.029999999999999 107.817 -176.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 113' ' ' ILE . . . . . . . . . . . . . 79.6 mt -84.25 130.1 36.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 N-CA-C 109.777 -0.453 . . . . 17.760000000000002 109.777 -172.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 114' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -73.67 -64.32 1.02 Allowed 'General case' 0 C--O 1.235 0.319 0 C-N-CA 119.779 -0.768 . . . . 49.829999999999998 110.654 163.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 115' ' ' SER . . . . . . . . . . . . . 72.8 m -142.08 149.46 39.93 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.65 0.738 . . . . 32.520000000000003 110.355 -167.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 116' ' ' ARG . . . . . . . . . . . . . 8.7 tmm_? -125.66 95.43 4.43 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 105.105 -2.183 . . . . 17.34 105.105 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -117.86 109.09 16.12 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 107.642 -1.244 . . . . 32.82 107.642 -175.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 118' ' ' TYR . . . . . 0.455 ' OH ' ' OE1' ' B' ' 107' ' ' GLN . 19.7 p90 -113.94 143.1 45.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.578 0.704 . . . . 1.27 112.115 177.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 119' ' ' SER . . . . . . . . . . . . . 35.2 t -98.6 133.73 42.54 Favored 'General case' 0 C--O 1.24 0.574 0 CA-C-N 114.605 -1.18 . . . . 7.79 109.981 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 120' ' ' ASP . . . . . . . . . . . . . 58.4 t0 -111.82 98.53 7.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 106.406 -1.701 . . . . 20.309999999999999 106.406 172.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.32 -163.52 32.94 Favored Glycine 0 N--CA 1.449 -0.481 0 CA-C-O 121.731 0.628 . . . . 9.6699999999999999 111.963 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 122' ' ' VAL . . . . . . . . . . . . . 68.8 t -108.72 -61.68 2.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 107.795 -1.187 . . . . 10.529999999999999 107.795 177.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 123' ' ' GLU . . . . . 0.429 ' OE2' ' NH2' ' H' ' 41' ' ' ARG . 96.7 mt-10 -87.09 -38.22 16.7 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.966 0.728 . . . . 56.310000000000002 112.966 176.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.13 149.14 42.14 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 110.194 -1.162 . . . . 24.309999999999999 110.194 174.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.16 167.57 20.88 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.67 0.747 . . . . 5.5499999999999998 110.161 173.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 126' ' ' VAL . . . . . . . . . . . . . 31.2 m -68.82 151.89 9.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.499 0 CA-C-N 115.318 -0.856 . . . . 17.34 109.61 -178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 127' ' ' GLU . . . . . . . . . . . . . 19.3 pt-20 -142.19 124.69 15.74 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 116.423 -0.353 . . . . 31.440000000000001 110.248 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 128' ' ' ILE . . . . . . . . . . . . . 88.5 mt -93.65 120.72 43.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.221 -0.659 . . . . 17.34 109.221 -177.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 129' ' ' SER . . . . . . . . . . . . . 69.9 m -102.6 133.61 47.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.398 -0.964 . . . . 17.280000000000001 108.398 172.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 130' ' ' ILE . . . . . . . . . . . . . 71.2 mt -135.67 128.26 46.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 N-CA-C 109.177 -0.675 . . . . 17.34 109.177 -176.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 131' ' ' SER . . . . . . . . . . . . . 62.7 m -96.18 150.59 20.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.195 -0.457 . . . . 12.56 110.165 175.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 132' ' ' LEU . . . . . . . . . . . . . 7.3 mp -135.32 140.81 45.39 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.081 -0.509 . . . . 44.049999999999997 110.837 -177.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 133' ' ' GLN . . . . . 0.459 ' OE1' ' OG ' ' C' ' 62' ' ' SER . 30.4 mm100 -120.04 135.64 54.86 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 108.391 -0.966 . . . . 10.199999999999999 108.391 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 134' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.02 149.16 30.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 N-CA-C 108.318 -0.993 . . . . 4.3899999999999997 108.318 175.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 135' ' ' ILE . . . . . . . . . . . . . 25.2 mm -62.83 -60.9 2.02 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-O 121.311 0.576 . . . . 28.75 110.849 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.47 138.79 5.62 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 109.32 -1.512 . . . . 19.59 109.32 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 137' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 -68.78 150.41 47.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.633 0.73 . . . . 12.529999999999999 110.459 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 138' ' ' LEU . . . . . . . . . . . . . 36.6 tp -139.23 127.51 22.71 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 106.995 -1.483 . . . . 10.09 106.995 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -89.39 67.16 7.66 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 122.244 1.021 . . . . 9.0099999999999998 109.775 -168.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 140' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -85.56 76.73 9.98 Favored 'General case' 0 C--N 1.332 -0.163 0 N-CA-C 108.165 -1.05 . . . . 17.34 108.165 175.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 141' ' ' GLY . . . . . . . . . . . . . . . -74.29 114.95 4.68 Favored Glycine 0 C--O 1.237 0.289 0 N-CA-C 110.502 -1.039 . . . . 17.559999999999999 110.502 175.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.38 -173.52 2.59 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 109.369 -0.604 . . . . 9.6899999999999995 109.369 -175.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 143' ' ' ILE . . . . . . . . . . . . . 1.2 pp -108.3 -62.51 2.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 113.186 0.81 . . . . 34.840000000000003 113.186 -170.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 144' ' ' ASP . . . . . . . . . . . . . 20.8 p-10 -80.76 125.3 29.89 Favored 'General case' 0 C--N 1.331 -0.217 0 O-C-N 121.43 -0.794 . . . . 26.5 111.144 -168.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -117.92 16.71 14.27 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 112.33 0.492 . . . . 8.2799999999999994 112.33 177.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 146' ' ' LEU . . . . . 0.409 ' O ' ' N ' ' C' ' 148' ' ' GLU . 4.1 mm? 54.49 76.12 0.55 Allowed Pre-proline 0 C--O 1.237 0.436 0 C-N-CA 126.932 2.093 . . . . 28.359999999999999 110.522 179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 147' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -68.19 71.8 0.86 Allowed 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 121.239 1.292 . . . . 17.34 115.346 -160.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 148' ' ' GLU . . . . . 0.509 ' OE1' ' ND2' ' C' ' 152' ' ' ASN . 80.1 mm-40 -113.25 11.43 18.7 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.992 -0.549 . . . . 26.920000000000002 111.598 169.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 149' ' ' GLU . . . . . 0.515 ' O ' ' NZ ' ' C' ' 12' ' ' LYS . 25.7 pm0 -136.94 4.5 2.76 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.331 0.493 . . . . 15.59 112.331 178.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 150' ' ' ILE . . . . . . . . . . . . . 50.3 mm -115.54 -50.76 4.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 118.708 0.685 . . . . 21.559999999999999 111.228 -177.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.65 -25.45 3.67 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.558 -1.275 . . . . 21.989999999999998 107.558 -176.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 152' ' ' ASN . . . . . 0.509 ' ND2' ' OE1' ' C' ' 148' ' ' GLU . 37.8 t-20 -67.19 -32.48 73.59 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.343 -0.39 . . . . 25.48 111.486 179.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -74.42 97.48 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.466 0 N-CA-C 107.744 -1.206 . . . . 11.01 107.744 170.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 154' ' ' SER . . . . . . . . . . . . . 33.9 t -116.62 -61.2 1.76 Allowed 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.598 -0.728 . . . . 36.850000000000001 112.402 -173.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 155' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -135.03 -28.85 1.15 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 113.616 0.969 . . . . 40.390000000000001 113.616 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.07 -54.02 2.89 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 119.269 0.94 . . . . 30.030000000000001 111.158 -168.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 157' ' ' GLY . . . . . . . . . . . . . . . -83.45 143.49 21.79 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.518 -0.849 . . . . 17.34 112.485 178.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 158' ' ' TYR . . . . . . . . . . . . . 18.1 m-30 -112.96 -173.17 2.19 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.414 1.086 . . . . 17.449999999999999 108.791 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 159' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -77.49 -75.0 0.23 Allowed 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 118.969 -1.093 . . . . 41.149999999999999 113.281 -155.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 160' ' ' PHE . . . . . . . . . . . . . 41.1 p90 177.05 173.02 0.47 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 127.8 2.44 . . . . 7.5800000000000001 109.228 167.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 161' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -157.06 100.49 1.87 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 105.466 -2.05 . . . . 21.219999999999999 105.466 154.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 162' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -68.39 -45.47 37.3 Favored Pre-proline 0 C--O 1.243 0.725 0 N-CA-C 113.971 1.101 . . . . 15.32 113.971 -167.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 163' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -77.74 -17.02 14.35 Favored 'Trans proline' 0 C--N 1.369 1.618 0 CA-C-N 122.145 1.802 . . . . 38.409999999999997 112.587 173.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 164' ' ' GLY . . . . . . . . . . . . . . . -139.5 34.69 2.02 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 119.683 2.633 . . . . 33.369999999999997 119.683 -169.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 165' ' ' GLN . . . . . . . . . . . . . 9.8 tp-100 -67.06 -58.09 5.57 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.087 1.443 . . . . 42.189999999999998 111.062 177.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 166' ' ' THR . . . . . . . . . . . . . 34.6 p 55.17 46.4 23.95 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 125.736 1.614 . . . . 59.880000000000003 111.701 175.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 167' ' ' THR . . . . . . . . . . . . . 2.0 m -138.9 151.25 46.79 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 120.036 -0.666 . . . . 16.539999999999999 109.451 -167.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 168' ' ' GLY . . . . . . . . . . . . . . . -87.5 -126.29 2.27 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 115.754 -0.657 . . . . 29.670000000000002 111.935 171.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 169' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -74.22 -62.59 1.46 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.835 0.317 . . . . 45.159999999999997 111.312 -175.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.44 104.66 0.64 Allowed Pre-proline 0 C--O 1.236 0.347 0 N-CA-C 108.698 -0.852 . . . . 8.4399999999999995 108.698 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 171' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.37 -173.99 1.82 Allowed 'Trans proline' 0 C--N 1.324 -0.76 0 C-N-CA 121.294 1.329 . . . . 3.1499999999999999 112.816 -153.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.68 69.92 1.3 Allowed Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 117.496 1.759 . . . . 5.4500000000000002 117.496 163.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 173' ' ' THR . . . . . . . . . . . . . 10.6 t -131.34 164.8 24.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 118.108 0.954 . . . . 8.3599999999999994 109.69 169.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 174' ' ' VAL . . . . . . . . . . . . . 29.3 m -77.73 159.66 76.14 Favored Pre-proline 0 C--O 1.239 0.531 0 N-CA-C 107.631 -1.248 . . . . 22.82 107.631 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 175' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -69.78 105.59 1.51 Allowed 'Trans proline' 0 CA--C 1.513 -0.547 0 CA-C-N 120.05 1.053 . . . . 8.4499999999999993 111.628 178.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.197 0 C-N-CA 125.636 1.575 . . . . 68.609999999999999 112.578 -173.523 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 5' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo . . . . . 0 N--CA 1.465 -0.177 0 N-CA-C 112.49 0.15 . . . . 17.710000000000001 112.49 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 6' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.66 120.78 62.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 N-CA-C 108.057 -1.09 . . . . 10.960000000000001 108.057 179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 7' ' ' MET . . . . . . . . . . . . . 39.0 mmt -86.39 170.92 11.56 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.894 0.854 . . . . 50.409999999999997 110.443 -177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.32 -12.43 69.27 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.43 -0.804 . . . . 5.1399999999999997 114.23 174.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -96.07 -14.73 22.68 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 117.586 0.693 . . . . 19.300000000000001 112.151 172.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -76.37 -3.39 36.65 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 114.04 1.126 . . . . 38.590000000000003 114.04 -171.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -128.48 124.7 62.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.342 0 CA-C-N 119.665 1.12 . . . . 22.800000000000001 107.987 -177.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' LYS . . . . . 0.534 ' NZ ' ' O ' ' D' ' 149' ' ' GLU . 51.9 mtmt -133.13 162.12 32.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.597 0.713 . . . . 21.760000000000002 110.202 175.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' TYR . . . . . . . . . . . . . 19.5 m-30 -112.63 97.77 6.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.008 -0.996 . . . . 3.75 108.338 -166.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' LEU . . . . . . . . . . . . . 91.8 mt -76.69 125.16 28.78 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 110.015 -0.365 . . . . 49.030000000000001 110.015 178.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -109.18 147.94 31.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.068 0.461 . . . . 32.350000000000001 109.768 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -144.61 135.72 25.15 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.164 -0.68 . . . . 14.4 109.164 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' SER . . . . . 0.468 ' O ' ' NZ ' ' D' ' 90' ' ' LYS . 40.3 t -75.0 157.38 35.02 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.625 0.726 . . . . 11.699999999999999 111.13 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' ILE . . . . . . . . . . . . . 43.8 pt -80.49 -7.4 10.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 113.322 0.86 . . . . 7.4400000000000004 113.322 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -119.44 -10.81 9.6 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 112.847 0.684 . . . . 16.129999999999999 112.847 -170.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.18 -44.09 48.51 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 119.906 -0.717 . . . . 21.91 111.701 -175.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.33 41.85 32.1 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.945 1.298 . . . . 19.34 111.537 -170.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' THR . . . . . . . . . . . . . 74.1 p -122.36 125.27 45.56 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.435 0.694 . . . . 11.94 109.242 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.05 76.01 2.21 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 116.297 -0.411 . . . . 17.710000000000001 113.155 -178.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' SER . . . . . . . . . . . . . 89.5 p -127.98 -29.37 2.56 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 120.694 -0.403 . . . . 46.049999999999997 111.592 -178.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.46 73.91 0.89 Allowed Pre-proline 0 C--O 1.236 0.356 0 C-N-CA 127.012 2.125 . . . . 15.66 112.311 -173.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_exo -71.95 104.8 1.7 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 CA-C-N 119.442 0.836 . . . . 19.190000000000001 111.92 176.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -87.46 151.48 23.01 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.958 -0.756 . . . . 17.710000000000001 108.958 167.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -98.22 131.59 26.05 Favored Pre-proline 0 C--N 1.319 -0.725 1 C-N-CA 110.713 -4.395 . . . . 24.370000000000001 110.071 -177.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -72.98 -174.06 1.43 Allowed 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 120.492 0.795 . . . . 36.840000000000003 113.973 -176.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . 54.61 59.76 3.93 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.646 1.178 . . . . 12.130000000000001 111.601 -175.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' TYR . . . . . . . . . . . . . 1.6 m-30 -69.88 179.7 2.15 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 123.06 1.409 . . . . 27.629999999999999 112.212 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -148.48 -159.16 0.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 103.437 -2.801 . . . . 31.27 103.437 170.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' THR . . . . . . . . . . . . . 14.9 t -65.3 162.57 17.19 Favored 'General case' 0 C--O 1.245 0.83 0 CA-C-O 122.723 1.249 . . . . 27.399999999999999 111.578 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -135.46 -169.52 2.41 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.871 -1.513 . . . . 51.240000000000002 107.962 -168.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' GLY . . . . . . . . . . . . . . . 171.51 134.51 1.79 Allowed Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 111.177 -0.769 . . . . 16.370000000000001 111.177 168.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' SER . . . . . . . . . . . . . 69.6 m -121.57 84.84 2.31 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 105.821 -1.918 . . . . 4.0700000000000003 105.821 174.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' VAL . . . . . . . . . . . . . 4.0 m -89.23 108.44 19.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 108.359 -0.978 . . . . 12.880000000000001 108.359 -173.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' SER . . . . . . . . . . . . . 44.9 m -97.89 93.46 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 107.782 -1.192 . . . . 8.1999999999999993 107.782 -170.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' GLY . . . . . . . . . . . . . . . -96.34 102.29 2.76 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.411 -0.9 . . . . 17.710000000000001 113.49 -177.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -108.41 123.95 49.64 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.63 -0.878 . . . . 10.85 108.63 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 41' ' ' ARG . . . . . . . . . . . . . 88.3 mtm-85 -83.77 -172.0 3.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.236 -0.653 . . . . 47.43 109.236 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 42' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -160.61 145.15 14.15 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 121.767 -0.583 . . . . 34.93 110.03 -169.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 43' ' ' LEU . . . . . . . . . . . . . 72.0 mt -68.57 137.47 54.32 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.118 -0.697 . . . . 20.289999999999999 109.118 177.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 44' ' ' PHE . . . . . . . . . . . . . 75.6 t80 -140.68 102.59 4.34 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.106 -0.331 . . . . 18.559999999999999 110.106 -168.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 45' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -133.51 -173.16 3.14 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 122.882 0.473 . . . . 41.43 110.808 168.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 46' ' ' GLU . . . . . . . . . . . . . 54.0 mp0 -127.55 -34.12 2.26 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 113.747 1.018 . . . . 26.440000000000001 113.747 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 47' ' ' GLN . . . . . . . . . . . . . 80.1 mm-40 61.5 29.09 18.22 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.931 1.293 . . . . 19.350000000000001 112.856 169.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 48' ' ' THR . . . . . . . . . . . . . 48.1 p 51.14 41.3 27.49 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.94 1.296 . . . . 38.659999999999997 111.439 -169.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 49' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -137.88 -166.11 1.9 Allowed 'General case' 0 C--O 1.236 0.381 0 N-CA-C 107.467 -1.308 . . . . 17.710000000000001 107.467 -176.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 50' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -67.85 -24.84 65.3 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 112.183 0.438 . . . . 32.969999999999999 112.183 173.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 51' ' ' GLY . . . . . . . . . . . . . . . 141.23 158.6 7.6 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.99 -0.444 . . . . 33.100000000000001 111.99 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 52' ' ' ARG . . . . . . . . . . . . . 17.5 tpp85 -124.08 50.73 1.62 Allowed 'General case' 0 C--O 1.235 0.31 0 N-CA-C 105.83 -1.915 . . . . 6.79 105.83 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 53' ' ' ILE . . . . . . . . . . . . . 8.6 tt -79.08 -5.34 7.94 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 115.365 -0.834 . . . . 9.1899999999999995 111.246 -174.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 54' ' ' LEU . . . . . . . . . . . . . 7.0 mp -65.78 -21.26 66.49 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 112.872 0.693 . . . . 37.270000000000003 112.872 -176.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.07 143.33 41.19 Favored Glycine 0 N--CA 1.444 -0.822 0 CA-C-O 121.417 0.454 . . . . 19.460000000000001 113.961 -171.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 56' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.56 176.89 9.13 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 121.351 1.367 . . . . 17.710000000000001 112.039 -175.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 57' ' ' GLY . . . . . . . . . . . . . . . -148.45 173.35 28.46 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 109.57 -1.412 . . . . 11.140000000000001 109.57 178.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 58' ' ' SER . . . . . . . . . . . . . 46.8 t -75.9 146.58 39.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.685 0.755 . . . . 17.710000000000001 110.354 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 59' ' ' VAL . . . . . . . . . . . . . 2.6 p -103.01 122.08 54.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.43 0 N-CA-C 108.555 -0.906 . . . . 3.48 108.555 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 60' ' ' ALA . . . . . . . . . . . . . . . -119.5 112.17 19.03 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 106.799 -1.556 . . . . 39.460000000000001 106.799 173.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 61' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -111.77 121.66 45.68 Favored 'General case' 0 C--O 1.24 0.585 0 N-CA-C 108.59 -0.893 . . . . 24.09 108.59 -172.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 62' ' ' SER . . . . . 0.422 ' OG ' ' OE1' ' D' ' 133' ' ' GLN . 70.1 m -109.14 166.37 10.9 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.203 1.001 . . . . 24.260000000000002 110.429 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 63' ' ' GLY . . . . . . . . . . . . . . . -141.2 123.01 2.2 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.15 -0.932 . . . . 3.5600000000000001 112.297 177.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 64' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -101.9 99.42 9.62 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 107.292 -1.373 . . . . 25.370000000000001 107.292 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 65' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.26 119.39 57.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.143 -1.058 . . . . 20.879999999999999 108.143 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 66' ' ' THR . . . . . . . . . . . . . 50.6 p -115.59 146.24 41.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.484 -0.562 . . . . 11.07 109.484 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 67' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -155.28 -173.76 4.69 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.72 -0.845 . . . . 11.51 108.72 176.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 68' ' ' TYR . . . . . . . . . . . . . 14.9 m-30 -116.13 139.17 50.59 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.844 -0.428 . . . . 4.2699999999999996 109.844 176.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.69 118.75 4.69 Favored Glycine 0 N--CA 1.449 -0.485 0 N-CA-C 114.447 0.539 . . . . 18.98 114.447 -175.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 70' ' ' LYS . . . . . 0.419 ' O ' ' NE2' ' D' ' 76' ' ' GLN . 39.0 ttmt -93.04 152.15 19.47 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.868 -0.79 . . . . 28.91 108.868 174.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 71' ' ' ARG . . . . . . . . . . . . . 21.0 ptp180 -69.52 -15.58 63.27 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.042 1.127 . . . . 24.140000000000001 114.042 -171.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.85 -141.03 5.2 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.191 -1.164 . . . . 34.32 110.191 176.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 73' ' ' ASP . . . . . . . . . . . . . 32.2 t0 59.93 71.73 0.56 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.185 1.394 . . . . 17.699999999999999 111.221 167.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.62 9.85 0.08 Allowed 'General case' 0 C--O 1.234 0.288 0 N-CA-C 117.167 2.284 . . . . 46.909999999999997 117.167 -159.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.98 -39.66 94.47 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.285 -0.96 . . . . 4.2599999999999998 112.572 170.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 76' ' ' GLN . . . . . 0.419 ' NE2' ' O ' ' D' ' 70' ' ' LYS . 22.3 pt20 -69.33 -24.15 63.88 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 119.859 -0.736 . . . . 12.4 111.856 172.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 77' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -72.98 -25.19 60.91 Favored 'General case' 0 CA--C 1.517 -0.314 0 C-N-CA 119.61 -0.836 . . . . 26.670000000000002 111.306 171.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.73 -32.15 63.72 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 120.41 -0.516 . . . . 19.879999999999999 111.28 169.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 79' ' ' ILE . . . . . . . . . . . . . 51.8 mm -62.99 -42.71 97.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 121.168 0.509 . . . . 17.52 110.324 171.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -74.74 -22.2 58.93 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 121.887 -0.508 . . . . 20.760000000000002 111.948 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 81' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -69.73 -32.49 71.08 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 120.182 -0.607 . . . . 9.8699999999999992 111.183 168.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 82' ' ' ALA . . . . . . . . . . . . . . . -73.63 -37.08 65.47 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 119.547 -0.861 . . . . 0.029999999999999999 111.677 174.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 83' ' ' TYR . . . . . . . . . . . . . 81.6 t80 -84.55 -62.5 1.54 Allowed 'General case' 0 C--O 1.235 0.333 0 C-N-CA 119.979 -0.688 . . . . 12.94 112.195 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -73.91 -39.19 64.01 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 111.86 0.319 . . . . 34.890000000000001 111.86 -167.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -78.32 -45.5 22.49 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 119.942 -0.703 . . . . 17.710000000000001 111.155 173.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.03 96.63 2.4 Favored Glycine 0 N--CA 1.45 -0.403 0 O-C-N 122.23 -0.294 . . . . 4.0199999999999996 113.285 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 87' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.48 -161.97 1.46 Allowed 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.135 -1.431 . . . . 17.710000000000001 107.135 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 88' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -130.19 176.0 8.46 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.428 0.632 . . . . 17.710000000000001 109.802 170.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 89' ' ' ILE . . . . . . . . . . . . . 81.9 mt -129.96 133.04 65.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 116.109 -0.496 . . . . 13.1 109.901 -173.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 90' ' ' LYS . . . . . 0.468 ' NZ ' ' O ' ' D' ' 17' ' ' SER . 36.8 mtmm -82.78 120.14 25.25 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 108.514 -0.921 . . . . 26.030000000000001 108.514 165.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 91' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -116.72 128.13 55.04 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.58 1.152 . . . . 14.57 109.993 -166.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 92' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -127.38 131.84 50.27 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 123.815 0.846 . . . . 30.93 108.928 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 93' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -114.16 97.12 6.16 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.343 -0.984 . . . . 17.710000000000001 108.343 172.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 94' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.06 159.7 8.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 CA-C-O 122.333 1.064 . . . . 15.359999999999999 109.885 -172.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 95' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -103.3 159.15 15.81 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.681 -1.145 . . . . 28.34 110.653 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 96' ' ' THR . . . . . . . . . . . . . 28.5 m -95.67 -29.41 14.31 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.164 -0.925 . . . . 23.09 112.365 -178.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 97' ' ' VAL . . . . . . . . . . . . . 35.0 m -68.67 153.62 8.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-O 121.827 0.822 . . . . 4.3899999999999997 109.993 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 98' ' ' LYS . . . . . 0.598 ' NZ ' ' O ' ' D' ' 99' ' ' ASN . 29.7 tptp -88.43 124.25 33.77 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.609 -0.723 . . . . 27.59 109.739 -175.462 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 99' ' ' ASN . . . . . 0.598 ' O ' ' NZ ' ' D' ' 98' ' ' LYS . 34.7 m120 -84.41 166.98 16.89 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.796 0.808 . . . . 7.4100000000000001 109.818 170.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 100' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -103.93 -13.23 16.43 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 113.732 1.012 . . . . 30.25 113.732 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 101' ' ' ASN . . . . . . . . . . . . . 16.6 p30 -89.7 -58.69 2.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 118.323 0.511 . . . . 8.9600000000000009 111.538 167.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 102' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -100.85 -177.79 3.57 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 108.52 -0.918 . . . . 31.68 108.52 173.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 103' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -73.23 -58.15 3.52 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.037 -0.665 . . . . 36.329999999999998 110.045 168.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 104' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -132.94 -170.95 2.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 107.652 -1.24 . . . . 20.57 107.652 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 105' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -149.57 169.03 21.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.446 0.641 . . . . 18.469999999999999 109.427 175.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 106' ' ' ALA . . . . . . . . . . . . . . . -153.06 158.88 42.6 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.324 -0.853 . . . . 13.65 111.123 -162.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 107' ' ' GLN . . . . . 0.43 ' OE1' ' OH ' ' E' ' 118' ' ' TYR . 88.5 mt-30 -117.69 120.54 38.32 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 107.046 -1.464 . . . . 25.149999999999999 107.046 160.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 108' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -104.15 152.4 22.17 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.669 0.788 . . . . 16.050000000000001 110.274 -168.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 109' ' ' GLY . . . . . . . . . . . . . . . -167.35 156.05 27.52 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 119.928 -1.129 . . . . 22.859999999999999 112.403 168.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 110' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -93.87 110.37 22.03 Favored 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.812 -0.811 . . . . 14.08 108.812 168.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 111' ' ' ALA . . . . . . . . . . . . . . . -114.5 159.85 19.89 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.47 0.652 . . . . 26.73 111.799 -167.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 112' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -135.66 139.02 43.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.62 -1.173 . . . . 21.98 107.941 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 113' ' ' ILE . . . . . . . . . . . . . 78.4 mt -83.78 129.47 37.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 N-CA-C 109.79 -0.448 . . . . 16.609999999999999 109.79 -172.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 114' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -72.91 -64.32 0.99 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 119.694 -0.802 . . . . 29.140000000000001 110.696 164.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -142.27 152.6 43.18 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 121.683 0.754 . . . . 34.359999999999999 110.362 -169.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -127.27 93.65 3.79 Favored 'General case' 0 C--N 1.332 -0.196 0 N-CA-C 104.946 -2.242 . . . . 10.27 104.946 178.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 117' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -115.09 108.91 17.28 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.624 -1.251 . . . . 37.960000000000001 107.624 -175.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 118' ' ' TYR . . . . . 0.461 ' OH ' ' OE1' ' C' ' 107' ' ' GLN . 21.1 p90 -114.61 146.41 40.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.523 0.678 . . . . 17.710000000000001 111.964 177.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 119' ' ' SER . . . . . . . . . . . . . 35.7 t -102.5 134.94 45.02 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 114.717 -1.128 . . . . 17.710000000000001 110.012 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 120' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -115.3 96.38 5.64 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.621 -1.622 . . . . 20.719999999999999 106.621 172.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.09 -158.2 22.28 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-O 121.694 0.608 . . . . 30.48 112.193 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 122' ' ' VAL . . . . . . . . . . . . . 72.9 t -113.04 -63.21 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 107.913 -1.143 . . . . 20.460000000000001 107.913 175.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 123' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -79.12 -44.94 21.01 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 112.725 0.639 . . . . 58.759999999999998 112.725 178.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.08 151.96 46.33 Favored Glycine 0 C--O 1.236 0.278 0 N-CA-C 110.263 -1.135 . . . . 20.52 110.263 174.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.0 171.38 14.21 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.726 0.774 . . . . 17.579999999999998 110.207 173.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 126' ' ' VAL . . . . . . . . . . . . . 33.8 m -69.19 154.48 8.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.558 0 CA-C-N 115.252 -0.885 . . . . 8.7599999999999998 109.578 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 127' ' ' GLU . . . . . . . . . . . . . 19.4 pt-20 -144.81 124.92 13.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.379 -0.373 . . . . 32.619999999999997 110.086 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 128' ' ' ILE . . . . . . . . . . . . . 87.3 mt -95.28 119.96 44.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.335 -0.617 . . . . 17.710000000000001 109.335 -176.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 129' ' ' SER . . . . . . . . . . . . . 69.0 m -100.48 134.42 43.46 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.359 -0.978 . . . . 13.09 108.359 170.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 130' ' ' ILE . . . . . . . . . . . . . 66.1 mt -136.81 128.91 43.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.997 -0.742 . . . . 14.17 108.997 -177.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 131' ' ' SER . . . . . . . . . . . . . 58.7 m -97.36 150.53 20.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.202 -0.453 . . . . 8.7699999999999996 110.142 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 132' ' ' LEU . . . . . . . . . . . . . 7.4 mp -134.7 140.63 46.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.118 -0.492 . . . . 35.369999999999997 110.912 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 133' ' ' GLN . . . . . 0.422 ' OE1' ' OG ' ' D' ' 62' ' ' SER . 29.9 mm100 -119.1 137.01 53.87 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.567 -0.901 . . . . 17.710000000000001 108.567 167.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -135.62 146.9 29.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 N-CA-C 108.546 -0.909 . . . . 21.280000000000001 108.546 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 135' ' ' ILE . . . . . . . . . . . . . 26.5 mm -61.21 -61.14 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.331 0 CA-C-N 115.885 -0.598 . . . . 10.66 110.808 178.033 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.1 139.55 6.11 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 109.858 -1.297 . . . . 38.829999999999998 109.858 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 137' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -68.79 152.6 45.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.606 0.717 . . . . 10.130000000000001 110.291 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 138' ' ' LEU . . . . . . . . . . . . . 33.4 tp -138.38 124.46 20.2 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 107.265 -1.383 . . . . 14.09 107.265 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -82.9 70.04 9.83 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 122.313 1.054 . . . . 16.98 109.758 -169.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 140' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -90.34 76.07 6.79 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.243 -1.021 . . . . 26.199999999999999 108.243 177.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.53 112.07 3.71 Favored Glycine 0 C--O 1.237 0.302 0 N-CA-C 110.433 -1.067 . . . . 10.67 110.433 174.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -119.73 -174.25 2.71 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.375 -0.602 . . . . 8.3399999999999999 109.375 -175.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 143' ' ' ILE . . . . . . . . . . . . . 1.2 pp -105.54 -63.69 1.77 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 113.438 0.903 . . . . 32.75 113.438 -170.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 144' ' ' ASP . . . . . . . . . . . . . 24.5 p-10 -80.9 131.06 35.33 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 121.438 -0.789 . . . . 27.27 111.05 -167.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 145' ' ' THR . . . . . . . . . . . . . 74.8 p -122.18 15.15 10.61 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 112.529 0.566 . . . . 30.289999999999999 112.529 176.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 146' ' ' LEU . . . . . 0.409 ' O ' ' N ' ' D' ' 148' ' ' GLU . 4.2 mm? 54.56 76.16 0.54 Allowed Pre-proline 0 C--O 1.237 0.434 0 C-N-CA 126.702 2.001 . . . . 9.6400000000000006 110.169 -178.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 147' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -68.21 71.24 0.89 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 N-CA-C 115.434 1.282 . . . . 19.870000000000001 115.434 -160.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 148' ' ' GLU . . . . . 0.53 ' OE1' ' ND2' ' D' ' 152' ' ' ASN . 79.3 mm-40 -109.89 9.25 24.55 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 123.186 0.594 . . . . 36.670000000000002 111.438 170.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 149' ' ' GLU . . . . . 0.534 ' O ' ' NZ ' ' D' ' 12' ' ' LYS . 25.8 pm0 -138.15 4.39 2.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.411 0.523 . . . . 10.02 112.411 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 150' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.52 -47.77 6.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 118.717 0.69 . . . . 14.890000000000001 111.101 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 151' ' ' VAL . . . . . . . . . . . . . 45.2 t -106.94 -29.52 2.65 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 107.879 -1.156 . . . . 22.899999999999999 107.879 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 152' ' ' ASN . . . . . 0.53 ' ND2' ' OE1' ' D' ' 148' ' ' GLU . 33.8 t-20 -67.49 -28.08 67.54 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.128 -0.487 . . . . 19.559999999999999 111.709 -176.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -75.26 96.02 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 107.35 -1.352 . . . . 21.600000000000001 107.35 168.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 154' ' ' SER . . . . . . . . . . . . . 39.3 t -117.44 -62.2 1.6 Allowed 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.633 -0.712 . . . . 12.43 112.663 -172.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 155' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -135.51 -28.81 1.1 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 113.819 1.044 . . . . 28.199999999999999 113.819 179.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 156' ' ' GLY . . . . . . . . . . . . . . . 90.37 -61.05 3.27 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 119.368 0.986 . . . . 30.809999999999999 110.881 -169.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.77 141.6 25.63 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.45 -0.881 . . . . 33.960000000000001 112.217 176.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 158' ' ' TYR . . . . . . . . . . . . . 19.8 m-30 -112.15 -171.27 1.82 Allowed 'General case' 0 C--O 1.236 0.343 0 C-N-CA 124.185 0.994 . . . . 7.5 108.677 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 159' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -76.66 -74.16 0.25 Allowed 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.351 -0.94 . . . . 29.41 113.307 -155.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 160' ' ' PHE . . . . . . . . . . . . . 41.1 p90 177.4 173.8 0.49 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 127.782 2.433 . . . . 9.2599999999999998 109.318 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 161' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -156.76 100.81 1.94 Allowed 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 105.446 -2.057 . . . . 8.0299999999999994 105.446 154.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 162' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -68.66 -46.3 34.52 Favored Pre-proline 0 C--O 1.242 0.672 0 N-CA-C 113.997 1.11 . . . . 17.710000000000001 113.997 -167.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 163' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -77.86 -19.17 12.72 Favored 'Trans proline' 0 C--N 1.367 1.532 0 CA-C-N 122.097 1.785 . . . . 29.739999999999998 112.467 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 164' ' ' GLY . . . . . . . . . . . . . . . -138.39 35.43 2.01 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 119.237 2.455 . . . . 33.789999999999999 119.237 -167.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 165' ' ' GLN . . . . . . . . . . . . . 9.8 tp-100 -66.29 -57.59 7.19 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 118.715 1.257 . . . . 31.23 111.032 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 166' ' ' THR . . . . . . . . . . . . . 33.8 p 54.74 46.86 23.73 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.754 1.621 . . . . 34.310000000000002 111.644 176.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 167' ' ' THR . . . . . . . . . . . . . 2.6 m -137.99 150.35 46.91 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 119.744 -0.783 . . . . 3.71 109.431 -168.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 168' ' ' GLY . . . . . . . . . . . . . . . -82.73 -129.45 1.34 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 111.272 -0.731 . . . . 40.109999999999999 111.272 168.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 169' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -73.15 -62.72 1.37 Allowed 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.817 -0.353 . . . . 45.840000000000003 111.413 -176.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.47 104.33 0.59 Allowed Pre-proline 0 C--O 1.235 0.293 0 C-N-CA 123.798 0.839 . . . . 8.1600000000000001 109.098 -176.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 171' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -83.01 -174.62 2.09 Favored 'Trans proline' 0 C--N 1.323 -0.814 0 C-N-CA 121.306 1.338 . . . . 17.710000000000001 112.863 -152.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 172' ' ' GLY . . . . . . . . . . . . . . . 72.06 69.38 1.4 Allowed Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 116.69 1.436 . . . . 15.19 116.69 165.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -130.84 167.17 19.36 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.881 0.848 . . . . 3.3199999999999998 109.346 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 174' ' ' VAL . . . . . . . . . . . . . 23.9 m -82.8 157.72 66.3 Favored Pre-proline 0 C--O 1.239 0.549 0 CA-C-N 114.605 -1.179 . . . . 5.8399999999999999 108.445 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 175' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -66.19 110.98 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.551 0 CA-C-N 119.465 0.844 . . . . 11.609999999999999 111.887 175.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.384 0 C-N-CA 125.508 1.523 . . . . 35.920000000000002 112.762 -172.538 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 5' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo . . . . . 0 N--CA 1.466 -0.112 0 CA-C-O 119.86 -0.142 . . . . 5.4299999999999997 112.451 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 6' ' ' ILE . . . . . . . . . . . . . 96.4 mt -121.94 120.72 62.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 N-CA-C 107.989 -1.115 . . . . 17.43 107.989 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -89.12 170.74 10.36 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.934 0.873 . . . . 47.719999999999999 110.802 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.0 -11.59 66.98 Favored Glycine 0 C--N 1.333 0.397 0 CA-C-N 115.308 -0.86 . . . . 17.059999999999999 114.391 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -96.1 -14.01 23.19 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 117.654 0.727 . . . . 17.43 112.277 171.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -77.02 -5.72 49.85 Favored 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 113.908 1.077 . . . . 28.449999999999999 113.908 -171.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' VAL . . . . . . . . . . . . . 71.9 t -127.03 124.92 65.53 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 119.597 1.089 . . . . 41.68 108.07 -176.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' LYS . . . . . 0.543 ' NZ ' ' O ' ' E' ' 149' ' ' GLU . 51.1 mtmt -134.5 162.61 31.77 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.639 0.733 . . . . 25.52 109.859 175.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' TYR . . . . . . . . . . . . . 19.9 m-30 -113.23 97.09 6.27 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.942 -1.026 . . . . 17.43 108.483 -165.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' LEU . . . . . . . . . . . . . 86.9 mt -74.98 125.67 29.4 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 120.689 -0.404 . . . . 54.210000000000001 110.056 177.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -109.27 147.8 32.04 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.773 -0.454 . . . . 24.77 109.773 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -144.14 135.82 25.99 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 109.173 -0.677 . . . . 30.25 109.173 176.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' SER . . . . . 0.452 ' O ' ' NZ ' ' E' ' 90' ' ' LYS . 36.8 t -74.64 159.42 32.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.636 0.732 . . . . 6.5199999999999996 111.158 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -82.0 -12.65 12.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 115.414 -0.812 . . . . 8.3000000000000007 113.163 178.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -115.32 -9.86 12.13 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 112.769 0.655 . . . . 24.649999999999999 112.769 -169.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.16 -45.12 42.84 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 119.7 -0.8 . . . . 24.920000000000002 111.628 -177.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.3 41.11 32.15 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.024 1.33 . . . . 25.41 111.646 -171.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -123.39 126.01 46.02 Favored 'General case' 0 C--O 1.236 0.344 0 C-N-CA 123.422 0.689 . . . . 17.43 109.2 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.47 77.14 2.08 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 114.33 0.492 . . . . 26.120000000000001 114.33 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' SER . . . . . . . . . . . . . 93.3 p -128.65 -26.63 2.69 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 120.541 -0.463 . . . . 43.189999999999998 111.672 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.16 73.74 0.92 Allowed Pre-proline 0 C--O 1.237 0.4 0 C-N-CA 126.961 2.104 . . . . 21.350000000000001 112.48 -173.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -72.16 104.62 1.7 Allowed 'Trans proline' 0 C--O 1.236 0.386 0 CA-C-N 119.494 0.855 . . . . 23.52 112.067 176.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -86.11 151.73 23.44 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.915 -0.772 . . . . 17.43 108.915 166.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -99.52 132.14 23.68 Favored Pre-proline 0 C--N 1.305 -1.359 1 C-N-CA 111.674 -4.01 . . . . 27.949999999999999 110.151 -178.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.32 -172.74 1.1 Allowed 'Trans proline' 0 C--O 1.234 0.315 0 N-CA-C 114.15 0.788 . . . . 11.880000000000001 114.15 -176.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 56.47 56.93 5.23 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.705 1.202 . . . . 17.010000000000002 111.677 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' TYR . . . . . . . . . . . . . 2.1 m-30 -70.29 178.54 2.81 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-O 123.012 1.387 . . . . 39.340000000000003 112.097 179.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -149.34 -158.57 0.93 Allowed 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 103.473 -2.788 . . . . 48.049999999999997 103.473 172.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' THR . . . . . . . . . . . . . 14.2 t -63.71 161.55 14.85 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 122.736 1.255 . . . . 26.329999999999998 111.719 178.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -136.12 -168.75 2.29 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 113.829 -1.532 . . . . 59.619999999999997 107.856 -167.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' GLY . . . . . . . . . . . . . . . 172.27 135.04 1.89 Allowed Glycine 0 N--CA 1.441 -0.984 0 C-N-CA 120.37 -0.919 . . . . 17.43 111.843 167.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' SER . . . . . . . . . . . . . 66.0 m -123.3 84.98 2.35 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 105.618 -1.993 . . . . 6.96 105.618 174.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' VAL . . . . . . . . . . . . . 3.9 m -92.15 109.35 21.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.41 -0.959 . . . . 4.5199999999999996 108.41 -172.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' SER . . . . . . . . . . . . . 49.9 m -98.83 94.59 6.68 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.923 -1.14 . . . . 24.09 107.923 -168.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.43 102.89 2.9 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.373 -0.918 . . . . 29.57 113.669 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -109.33 118.64 37.19 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.859 . . . . 10.27 108.682 -178.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 41' ' ' ARG . . . . . . . . . . . . . 88.8 mtm-85 -81.69 -174.38 4.97 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.553 0.692 . . . . 46.899999999999999 109.473 -177.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 42' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -161.29 146.43 13.81 Favored 'General case' 0 C--N 1.329 -0.29 0 O-C-N 121.855 -0.528 . . . . 55.700000000000003 110.082 -170.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 43' ' ' LEU . . . . . . . . . . . . . 81.5 mt -77.94 146.77 35.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.638 -0.71 . . . . 17.559999999999999 109.526 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 44' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -147.71 125.68 12.04 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.533 0.206 . . . . 32.68 110.929 172.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 45' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -125.63 -170.96 2.27 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 108.52 -0.918 . . . . 36.520000000000003 108.52 157.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 46' ' ' GLU . . . . . . . . . . . . . 49.0 mp0 -113.67 -34.65 5.44 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 113.679 0.992 . . . . 24.789999999999999 113.679 174.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 47' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 59.17 25.58 14.15 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.355 1.462 . . . . 27.02 112.281 -179.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 48' ' ' THR . . . . . . . . . . . . . 56.2 p 48.07 45.57 19.44 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.006 1.323 . . . . 12.289999999999999 111.406 -165.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 49' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -137.32 -165.33 1.74 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.523 -1.288 . . . . 17.43 107.523 -175.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 50' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -66.84 -25.28 66.35 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.376 0.51 . . . . 30.210000000000001 112.376 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 51' ' ' GLY . . . . . . . . . . . . . . . 138.81 160.08 8.26 Favored Glycine 0 N--CA 1.448 -0.555 0 N-CA-C 111.577 -0.609 . . . . 9.6500000000000004 111.577 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 52' ' ' ARG . . . . . . . . . . . . . 17.0 tpp85 -124.49 51.24 1.62 Allowed 'General case' 0 C--O 1.234 0.285 0 N-CA-C 106.228 -1.767 . . . . 7.8399999999999999 106.228 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 53' ' ' ILE . . . . . . . . . . . . . 6.5 tt -79.06 -4.94 7.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.672 -0.695 . . . . 59.640000000000001 111.4 -173.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 54' ' ' LEU . . . . . . . . . . . . . 7.0 mp -64.66 -21.71 66.8 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 47.32 112.897 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.15 145.02 43.92 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-O 121.481 0.49 . . . . 23.399999999999999 114.209 -170.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 56' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -75.7 -178.97 4.69 Favored 'Trans proline' 0 C--N 1.328 -0.542 0 C-N-CA 121.31 1.34 . . . . 17.43 112.001 -175.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 57' ' ' GLY . . . . . . . . . . . . . . . -153.89 171.18 32.58 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.468 -1.453 . . . . 25.399999999999999 109.468 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 58' ' ' SER . . . . . . . . . . . . . 44.0 t -73.61 146.69 44.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.656 0.741 . . . . 10.01 110.409 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 59' ' ' VAL . . . . . . . . . . . . . 2.7 p -107.57 122.49 61.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 N-CA-C 108.517 -0.92 . . . . 2.8900000000000001 108.517 -177.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.28 118.07 29.46 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.931 -1.507 . . . . 14.699999999999999 106.931 172.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 61' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -113.08 121.11 43.59 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.425 -0.954 . . . . 61.060000000000002 108.425 -172.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 62' ' ' SER . . . . . 0.444 ' OG ' ' OE1' ' E' ' 133' ' ' GLN . 66.8 m -106.33 165.13 11.48 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.727 0.811 . . . . 17.43 110.399 -176.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 63' ' ' GLY . . . . . . . . . . . . . . . -139.76 122.02 2.15 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.191 -0.913 . . . . 17.43 112.419 177.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 64' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -103.32 95.51 6.14 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 107.359 -1.348 . . . . 56.280000000000001 107.359 174.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 65' ' ' VAL . . . . . . . . . . . . . 86.4 t -106.73 119.79 56.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.111 -1.07 . . . . 17.43 108.111 -178.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 66' ' ' THR . . . . . . . . . . . . . 72.9 p -116.68 145.24 43.58 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.522 -0.547 . . . . 24.780000000000001 109.522 177.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 67' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -154.82 -174.92 5.18 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.901 -0.777 . . . . 1.29 108.901 178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 68' ' ' TYR . . . . . . . . . . . . . 15.6 m-30 -114.68 136.57 52.91 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 109.555 -0.535 . . . . 17.43 109.555 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 69' ' ' GLY . . . . . . . . . . . . . . . -85.29 114.3 3.95 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.969 -0.634 . . . . 17.43 113.939 -176.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 70' ' ' LYS . . . . . 0.499 ' O ' ' NE2' ' E' ' 76' ' ' GLN . 38.3 ttmt -82.97 152.75 25.33 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.609 -0.886 . . . . 17.43 108.609 174.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -68.49 -15.6 63.6 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 113.935 1.087 . . . . 40.310000000000002 113.935 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.51 -140.08 5.04 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 110.083 -1.207 . . . . 37.119999999999997 110.083 175.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 59.88 73.01 0.5 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 125.145 1.378 . . . . 16.309999999999999 111.125 168.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.68 11.3 0.07 Allowed 'General case' 0 C--O 1.235 0.291 0 N-CA-C 117.113 2.264 . . . . 26.300000000000001 117.113 -158.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.29 96.75 Favored Glycine 0 C--N 1.338 0.661 0 C-N-CA 120.268 -0.967 . . . . 23.800000000000001 112.555 170.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 76' ' ' GLN . . . . . 0.499 ' NE2' ' O ' ' E' ' 70' ' ' LYS . 22.1 pt20 -70.47 -23.73 62.75 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 119.921 -0.712 . . . . 32.420000000000002 111.859 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 77' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -70.71 -28.08 64.47 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 119.693 -0.803 . . . . 14.130000000000001 111.191 170.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.64 -30.28 62.84 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 120.624 -0.43 . . . . 40.880000000000003 111.443 170.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 79' ' ' ILE . . . . . . . . . . . . . 50.6 mm -64.3 -43.42 97.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 CA-C-O 121.098 0.475 . . . . 17.43 110.301 172.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.55 -22.69 60.01 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.362 -0.535 . . . . 30.960000000000001 112.009 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 81' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -69.32 -32.67 71.93 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 120.314 -0.554 . . . . 22.699999999999999 111.24 168.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.44 -34.95 61.01 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 119.548 -0.861 . . . . 17.43 111.642 175.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 83' ' ' TYR . . . . . . . . . . . . . 83.3 t80 -84.3 -62.1 1.64 Allowed 'General case' 0 C--O 1.235 0.336 0 C-N-CA 120.184 -0.606 . . . . 9.6099999999999994 112.135 -176.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 84' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -73.56 -41.01 63.51 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 111.922 0.342 . . . . 15.779999999999999 111.922 -167.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 85' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -74.18 -43.44 57.28 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 119.836 -0.745 . . . . 19.48 111.008 171.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.86 97.03 2.48 Favored Glycine 0 N--CA 1.448 -0.544 0 O-C-N 122.253 -0.28 . . . . 17.43 112.902 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 87' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -147.88 -162.2 1.5 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.057 -1.46 . . . . 17.43 107.057 -178.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 88' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -129.94 175.21 9.05 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.48 0.657 . . . . 17.43 109.82 170.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 89' ' ' ILE . . . . . . . . . . . . . 70.1 mt -128.88 134.26 64.63 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-N 115.903 -0.59 . . . . 18.82 109.618 -172.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 90' ' ' LYS . . . . . 0.452 ' NZ ' ' O ' ' E' ' 17' ' ' SER . 36.5 mtmm -83.27 120.34 25.71 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.465 -0.939 . . . . 13.359999999999999 108.465 165.055 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 91' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -118.15 129.36 55.48 Favored 'General case' 0 C--O 1.237 0.422 0 C-N-CA 124.319 1.047 . . . . 5.2699999999999996 110.032 -165.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 92' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -129.11 130.87 47.02 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.87 0.868 . . . . 17.43 108.898 -177.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 93' ' ' ARG . . . . . . . . . . . . . 78.1 ttt-85 -112.19 94.31 4.87 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.187 -1.042 . . . . 15.550000000000001 108.187 172.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 94' ' ' VAL . . . . . . . . . . . . . 25.4 m -107.36 162.22 5.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.197 0.998 . . . . 46.020000000000003 109.636 -172.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 95' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -109.47 167.96 9.74 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.842 -1.072 . . . . 15.359999999999999 111.291 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 96' ' ' THR . . . . . . . . . . . . . 28.3 m -101.51 -29.68 11.84 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 114.941 -1.027 . . . . 29.59 112.527 -175.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 97' ' ' VAL . . . . . . . . . . . . . 35.1 m -69.28 152.97 9.08 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 CA-C-O 121.702 0.763 . . . . 11.140000000000001 110.153 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 98' ' ' LYS . . . . . 0.589 ' NZ ' ' O ' ' E' ' 99' ' ' ASN . 29.7 tptp -89.31 123.53 33.58 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.699 -0.682 . . . . 30.449999999999999 109.822 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 99' ' ' ASN . . . . . 0.589 ' O ' ' NZ ' ' E' ' 98' ' ' LYS . 34.7 m120 -84.06 168.25 16.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.779 0.799 . . . . 6.7000000000000002 109.949 171.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 100' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 -105.83 -12.46 15.86 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 113.64 0.978 . . . . 18.170000000000002 113.64 178.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 101' ' ' ASN . . . . . . . . . . . . . 15.8 p30 -94.55 -56.25 2.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 118.296 0.498 . . . . 32.030000000000001 111.088 170.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 102' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -99.12 -174.28 2.71 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 107.965 -1.124 . . . . 20.710000000000001 107.965 168.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 103' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.07 -54.88 4.94 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 120.18 -0.608 . . . . 50.009999999999998 110.144 169.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 104' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -131.4 -171.37 2.58 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 107.723 -1.214 . . . . 17.43 107.723 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 105' ' ' ASP . . . . . . . . . . . . . 22.6 p-10 -150.5 167.08 28.23 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.604 0.716 . . . . 27.129999999999999 109.543 176.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 106' ' ' ALA . . . . . . . . . . . . . . . -154.78 159.79 40.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.087 -0.961 . . . . 10.17 110.991 -162.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 107' ' ' GLN . . . . . 0.467 ' OE1' ' OH ' ' F' ' 118' ' ' TYR . 88.7 mt-30 -121.41 121.31 37.31 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 107.187 -1.412 . . . . 8.0399999999999991 107.187 161.593 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 108' ' ' PHE . . . . . . . . . . . . . 92.8 t80 -105.88 152.88 22.71 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.265 1.026 . . . . 14.65 110.282 -165.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 109' ' ' GLY . . . . . . . . . . . . . . . -169.47 155.09 24.94 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.753 -1.213 . . . . 7.8399999999999999 112.491 171.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 110' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -94.32 107.55 19.5 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 108.924 -0.769 . . . . 16.850000000000001 108.924 168.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.24 160.17 16.75 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-O 121.537 0.685 . . . . 32.200000000000003 111.621 -166.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 112' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -138.31 136.45 36.44 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.615 -1.175 . . . . 13.210000000000001 108.073 -178.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 113' ' ' ILE . . . . . . . . . . . . . 79.8 mt -83.27 129.4 37.53 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.871 -0.418 . . . . 19.960000000000001 109.871 -171.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 114' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.67 -64.25 1.0 Allowed 'General case' 0 C--O 1.236 0.343 0 C-N-CA 119.77 -0.772 . . . . 38.93 110.645 164.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 115' ' ' SER . . . . . . . . . . . . . 73.3 m -141.67 149.25 40.35 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-O 121.634 0.731 . . . . 34.039999999999999 110.333 -169.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -123.43 94.91 4.39 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 105.119 -2.178 . . . . 13.74 105.119 176.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 117' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -115.54 108.47 16.49 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.387 -1.338 . . . . 44.539999999999999 107.387 -175.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 118' ' ' TYR . . . . . 0.43 ' OH ' ' OE1' ' D' ' 107' ' ' GLN . 23.7 p90 -112.97 140.89 47.39 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.594 0.711 . . . . 4.4199999999999999 111.896 177.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 119' ' ' SER . . . . . . . . . . . . . 36.5 t -97.64 132.86 42.9 Favored 'General case' 0 C--O 1.239 0.545 0 CA-C-N 114.641 -1.163 . . . . 17.93 109.815 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 120' ' ' ASP . . . . . . . . . . . . . 58.9 t0 -114.09 98.63 7.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 106.61 -1.626 . . . . 14.02 106.61 173.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 121' ' ' GLY . . . . . . . . . . . . . . . -83.6 -157.42 24.68 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-O 121.727 0.626 . . . . 5.3600000000000003 112.176 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 122' ' ' VAL . . . . . . . . . . . . . 59.5 t -111.85 -62.8 2.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 107.618 -1.253 . . . . 14.68 107.618 176.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 123' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -82.78 -45.15 14.71 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.891 0.7 . . . . 69.269999999999996 112.891 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 124' ' ' GLY . . . . . . . . . . . . . . . -71.06 144.78 38.48 Favored Glycine 0 C--O 1.236 0.279 0 N-CA-C 110.28 -1.128 . . . . 22.710000000000001 110.28 175.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.23 168.01 18.19 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-O 121.754 0.788 . . . . 2.6499999999999999 110.296 174.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 126' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.16 151.01 10.3 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 CA-C-N 115.131 -0.94 . . . . 20.579999999999998 109.738 -176.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 127' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -140.67 126.72 19.54 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.312 -0.403 . . . . 33.409999999999997 109.958 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 128' ' ' ILE . . . . . . . . . . . . . 95.2 mt -93.88 118.77 40.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 108.991 -0.744 . . . . 17.43 108.991 -178.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 129' ' ' SER . . . . . . . . . . . . . 70.1 m -98.87 133.41 43.2 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.344 -0.984 . . . . 7.3300000000000001 108.344 171.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 130' ' ' ILE . . . . . . . . . . . . . 62.2 mt -135.83 128.38 46.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 109.275 -0.639 . . . . 17.43 109.275 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 131' ' ' SER . . . . . . . . . . . . . 49.5 m -95.81 152.98 17.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.123 -0.49 . . . . 12.69 109.964 175.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 132' ' ' LEU . . . . . . . . . . . . . 7.2 mp -137.98 140.83 40.4 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.149 -0.478 . . . . 51.130000000000003 110.711 -177.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 133' ' ' GLN . . . . . 0.444 ' OE1' ' OG ' ' E' ' 62' ' ' SER . 30.3 mm100 -120.51 137.27 54.46 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 108.45 -0.945 . . . . 17.43 108.45 167.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 134' ' ' VAL . . . . . . . . . . . . . 8.6 p -137.25 148.39 26.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.44 0 N-CA-C 108.455 -0.942 . . . . 13.1 108.455 175.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 135' ' ' ILE . . . . . . . . . . . . . 27.0 mm -62.17 -60.7 2.31 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.333 0.587 . . . . 8.8599999999999994 110.928 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.71 141.77 7.53 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.161 -1.575 . . . . 35.109999999999999 109.161 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 137' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -68.73 153.58 43.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 121.555 0.693 . . . . 32.630000000000003 110.306 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 138' ' ' LEU . . . . . . . . . . . . . 36.0 tp -138.55 122.83 18.19 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.203 -1.406 . . . . 4.9000000000000004 107.203 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -84.3 70.12 10.56 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 122.323 1.059 . . . . 18.690000000000001 109.698 -169.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 140' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -85.98 76.45 9.83 Favored 'General case' 0 C--N 1.334 -0.093 0 N-CA-C 108.148 -1.056 . . . . 18.620000000000001 108.148 176.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 141' ' ' GLY . . . . . . . . . . . . . . . -71.74 111.0 3.43 Favored Glycine 0 C--O 1.237 0.307 0 N-CA-C 110.51 -1.036 . . . . 22.52 110.51 175.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -119.96 -172.24 2.3 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.353 0.597 . . . . 30.98 109.398 -173.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 143' ' ' ILE . . . . . . . . . . . . . 1.4 pp -112.28 -59.27 3.28 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 113.152 0.797 . . . . 11.98 113.152 -169.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 144' ' ' ASP . . . . . . . . . . . . . 18.9 p-10 -84.44 126.36 33.18 Favored 'General case' 0 C--N 1.33 -0.239 0 O-C-N 121.453 -0.78 . . . . 36.159999999999997 111.141 -169.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 145' ' ' THR . . . . . . . . . . . . . 73.2 p -117.0 12.07 14.49 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 112.527 0.566 . . . . 39.490000000000002 112.527 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 146' ' ' LEU . . . . . 0.407 ' O ' ' N ' ' E' ' 148' ' ' GLU . 4.2 mm? 54.29 75.75 0.59 Allowed Pre-proline 0 C--O 1.237 0.4 0 C-N-CA 126.782 2.033 . . . . 8.7899999999999991 110.261 -178.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 147' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -68.54 71.02 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 N-CA-C 115.393 1.266 . . . . 10.23 115.393 -160.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 148' ' ' GLU . . . . . 0.513 ' OE1' ' ND2' ' E' ' 152' ' ' ASN . 80.0 mm-40 -103.49 11.68 36.08 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.036 -0.529 . . . . 7.7800000000000002 111.48 167.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 149' ' ' GLU . . . . . 0.543 ' O ' ' NZ ' ' E' ' 12' ' ' LYS . 26.0 pm0 -141.13 4.67 1.86 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 113.111 0.782 . . . . 11.91 113.111 -178.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 150' ' ' ILE . . . . . . . . . . . . . 47.4 mm -113.89 -53.91 4.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 118.997 0.817 . . . . 10.56 111.28 -176.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 151' ' ' VAL . . . . . . . . . . . . . 23.8 t -106.2 -23.59 4.39 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.781 -1.563 . . . . 16.0 106.781 -177.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 152' ' ' ASN . . . . . 0.513 ' ND2' ' OE1' ' E' ' 148' ' ' GLU . 44.1 t-20 -64.68 -38.01 89.54 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.761 -0.654 . . . . 35.340000000000003 111.797 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -73.78 99.08 1.16 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.444 0 N-CA-C 108.111 -1.07 . . . . 0.22 108.111 173.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 154' ' ' SER . . . . . . . . . . . . . 36.6 t -116.31 -61.46 1.73 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.533 -0.758 . . . . 14.699999999999999 112.477 -171.18 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 155' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -134.47 -28.74 1.26 Allowed 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 113.659 0.985 . . . . 41.950000000000003 113.659 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.97 -59.18 2.81 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 110.655 -0.978 . . . . 49.119999999999997 110.655 -168.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 157' ' ' GLY . . . . . . . . . . . . . . . -81.98 143.59 23.27 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.466 -0.873 . . . . 17.43 112.156 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 158' ' ' TYR . . . . . . . . . . . . . 14.6 m-30 -110.47 -172.57 2.06 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.373 0.669 . . . . 3.9399999999999999 109.555 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 159' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -77.07 -72.37 0.35 Allowed 'General case' 0 C--O 1.235 0.291 0 N-CA-C 113.202 0.816 . . . . 58.890000000000001 113.202 -149.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 160' ' ' PHE . . . . . . . . . . . . . 33.3 p90 177.6 173.27 0.55 Allowed 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 127.952 2.501 . . . . 7.4299999999999997 108.984 161.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -158.99 108.8 1.96 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 105.379 -2.082 . . . . 28.57 105.379 156.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 162' ' ' GLN . . . . . . . . . . . . . 89.4 mt-30 -73.51 -49.27 6.64 Favored Pre-proline 0 C--O 1.242 0.674 0 C-N-CA 119.006 -1.077 . . . . 24.870000000000001 113.722 -170.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 163' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -76.72 -23.71 10.83 Favored 'Trans proline' 0 C--N 1.371 1.716 0 CA-C-N 122.096 1.784 . . . . 34.810000000000002 112.814 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 164' ' ' GLY . . . . . . . . . . . . . . . -134.93 38.88 1.76 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 119.22 2.448 . . . . 45.409999999999997 119.22 -169.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 165' ' ' GLN . . . . . . . . . . . . . 9.8 tp-100 -67.46 -55.87 11.86 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 119.005 1.402 . . . . 11.869999999999999 111.008 178.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 166' ' ' THR . . . . . . . . . . . . . 33.3 p 53.57 53.44 11.54 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.808 1.643 . . . . 30.440000000000001 111.671 176.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 167' ' ' THR . . . . . . . . . . . . . 6.4 m -142.41 146.62 35.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.484 -0.562 . . . . 15.31 109.484 -166.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 168' ' ' GLY . . . . . . . . . . . . . . . -81.69 -129.06 1.06 Allowed Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.908 -0.877 . . . . 48.490000000000002 110.908 165.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 169' ' ' GLU . . . . . . . . . . . . . 15.1 tm-20 -73.31 -61.17 1.92 Allowed 'General case' 0 C--O 1.235 0.302 0 O-C-N 122.514 -0.403 . . . . 42.170000000000002 111.467 -176.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.01 103.32 0.44 Allowed Pre-proline 0 C--N 1.344 0.35 0 C-N-CA 124.077 0.951 . . . . 17.43 109.707 -172.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 171' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -81.94 -179.0 4.46 Favored 'Trans proline' 0 C--N 1.323 -0.807 0 C-N-CA 121.373 1.382 . . . . 8.8200000000000003 112.96 -151.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.2 68.93 1.5 Allowed Glycine 0 N--CA 1.449 -0.468 0 N-CA-C 117.008 1.563 . . . . 21.559999999999999 117.008 164.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 173' ' ' THR . . . . . . . . . . . . . 11.1 t -130.0 165.24 22.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 117.971 0.886 . . . . 19.48 109.533 171.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 174' ' ' VAL . . . . . . . . . . . . . 30.6 m -76.75 158.62 80.48 Favored Pre-proline 0 C--O 1.24 0.563 0 CA-C-N 114.666 -1.152 . . . . 21.079999999999998 107.949 176.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 175' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -63.71 112.37 1.78 Allowed 'Trans proline' 0 C--N 1.353 0.784 0 CA-C-N 119.633 0.905 . . . . 13.550000000000001 112.14 175.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.413 0 C-N-CA 125.771 1.629 . . . . 42.060000000000002 113.442 -172.846 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 5' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo . . . . . 0 N--CA 1.466 -0.146 0 N-CA-C 112.424 0.125 . . . . 2.5899999999999999 112.424 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 6' ' ' ILE . . . . . . . . . . . . . 96.4 mt -121.48 120.73 62.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.416 0 N-CA-C 107.895 -1.15 . . . . 30.140000000000001 107.895 177.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 7' ' ' MET . . . . . . . . . . . . . 39.1 mmt -90.16 172.91 8.47 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.903 0.858 . . . . 49.380000000000003 110.908 -176.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.3 -11.29 67.5 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.291 -0.868 . . . . 8.8300000000000001 114.414 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -96.6 -15.58 21.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 117.692 0.746 . . . . 16.649999999999999 112.176 172.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -76.57 -4.75 44.53 Favored 'General case' 0 CA--C 1.519 -0.223 0 N-CA-C 113.885 1.068 . . . . 26.530000000000001 113.885 -171.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' VAL . . . . . . . . . . . . . 95.1 t -126.72 123.76 63.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 N-CA-C 108.117 -1.068 . . . . 12.140000000000001 108.117 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' LYS . . . . . 0.51 ' NZ ' ' O ' ' F' ' 149' ' ' GLU . 51.3 mtmt -133.55 161.73 33.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.526 0.679 . . . . 21.969999999999999 110.084 175.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' TYR . . . . . . . . . . . . . 18.8 m-30 -112.16 96.11 5.84 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 108.319 -0.993 . . . . 17.609999999999999 108.319 -166.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' LEU . . . . . . . . . . . . . 80.9 mt -73.04 125.28 27.28 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.445 -0.343 . . . . 59.119999999999997 110.161 176.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -108.14 153.39 23.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.176 0.512 . . . . 11.289999999999999 109.89 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' GLN . . . . . . . . . . . . . 69.9 tp60 -147.71 135.51 21.05 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.967 -0.753 . . . . 11.640000000000001 108.967 174.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' SER . . . . . . . . . . . . . 38.1 t -76.59 153.57 35.22 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 121.613 0.721 . . . . 14.99 110.957 178.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' ILE . . . . . . . . . . . . . 41.7 pt -76.19 -15.33 15.15 Favored 'Isoleucine or valine' 0 C--O 1.237 0.416 0 N-CA-C 113.205 0.817 . . . . 17.609999999999999 113.205 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -108.98 -8.47 15.21 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 112.661 0.615 . . . . 18.469999999999999 112.661 -171.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.96 -46.9 32.36 Favored 'General case' 0 C--O 1.236 0.388 0 C-N-CA 119.726 -0.789 . . . . 23.239999999999998 111.555 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.36 41.03 32.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.061 1.344 . . . . 27.48 111.639 -171.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' THR . . . . . . . . . . . . . 69.5 p -123.0 127.62 49.06 Favored 'General case' 0 C--O 1.236 0.344 0 C-N-CA 123.394 0.678 . . . . 13.15 109.365 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.34 76.08 2.26 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 114.269 0.467 . . . . 19.120000000000001 114.269 -177.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' SER . . . . . . . . . . . . . 92.9 p -129.82 -26.01 2.49 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 120.503 -0.479 . . . . 33.960000000000001 111.59 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' ALA . . . . . . . . . . . . . . . 50.98 73.36 0.99 Allowed Pre-proline 0 C--O 1.237 0.399 0 C-N-CA 126.912 2.085 . . . . 41.469999999999999 112.568 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_exo -72.94 104.65 1.8 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 CA-C-N 119.552 0.876 . . . . 5.8700000000000001 111.998 176.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -82.56 153.43 25.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 108.795 -0.817 . . . . 17.609999999999999 108.795 166.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -97.56 127.33 38.14 Favored Pre-proline 0 C--N 1.321 -0.635 1 C-N-CA 110.516 -4.474 . . . . 35.640000000000001 110.187 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.44 -173.0 1.17 Allowed 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 120.595 0.863 . . . . 28.079999999999998 113.56 -176.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 55.15 61.61 2.85 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.498 1.119 . . . . 17.609999999999999 111.231 -174.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' TYR . . . . . . . . . . . . . 1.3 m-30 -72.96 -177.08 2.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 123.072 1.415 . . . . 15.25 112.424 -178.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -149.27 -158.77 0.95 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 103.389 -2.819 . . . . 20.789999999999999 103.389 166.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' THR . . . . . . . . . . . . . 15.2 t -67.51 167.14 13.39 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 122.646 1.212 . . . . 7.4699999999999998 111.682 -179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -135.7 -169.0 2.31 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.076 -1.42 . . . . 37.960000000000001 108.355 -168.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' GLY . . . . . . . . . . . . . . . 177.07 133.63 1.85 Allowed Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.478 -0.783 . . . . 28.649999999999999 111.341 170.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' SER . . . . . . . . . . . . . 69.0 m -127.56 84.98 2.3 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.246 -1.761 . . . . 17.609999999999999 106.246 175.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' VAL . . . . . . . . . . . . . 4.9 m -93.22 113.19 27.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.438 -0.949 . . . . 6.9699999999999998 108.438 -172.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' SER . . . . . . . . . . . . . 48.6 m -103.72 90.09 3.54 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.207 -1.034 . . . . 14.300000000000001 108.207 -168.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.49 103.9 3.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.488 -0.863 . . . . 1.8899999999999999 113.76 -176.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -109.9 119.21 38.63 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.651 -0.87 . . . . 17.609999999999999 108.651 -178.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 41' ' ' ARG . . . . . 0.471 ' O ' ' CA ' ' F' ' 57' ' ' GLY . 87.2 mtm-85 -83.65 -173.9 4.98 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.479 0.657 . . . . 37.990000000000002 109.367 -177.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 42' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -161.34 137.32 8.05 Favored 'General case' 0 C--N 1.33 -0.26 0 O-C-N 121.982 -0.449 . . . . 26.25 110.233 -169.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 43' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.68 127.27 32.09 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 109.05 -0.722 . . . . 16.059999999999999 109.05 175.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 44' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -132.84 119.04 19.71 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 110.091 -0.337 . . . . 24.52 110.091 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 45' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -125.72 -169.02 1.93 Allowed 'General case' 0 C--O 1.235 0.339 0 N-CA-C 109.245 -0.65 . . . . 48.289999999999999 109.245 164.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 46' ' ' GLU . . . . . . . . . . . . . 56.4 mp0 -121.28 -33.79 3.61 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 113.529 0.937 . . . . 12.4 113.529 176.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 47' ' ' GLN . . . . . . . . . . . . . 87.6 mm-40 60.1 28.38 17.92 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.347 1.459 . . . . 47.490000000000002 112.402 174.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 48' ' ' THR . . . . . . . . . . . . . 50.7 p 50.32 43.31 26.58 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.069 1.348 . . . . 5.1399999999999997 111.43 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 49' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -137.69 -165.34 1.76 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.445 -1.317 . . . . 14.640000000000001 107.445 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 50' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -67.19 -25.12 65.98 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 112.335 0.494 . . . . 32.609999999999999 112.335 174.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 51' ' ' GLY . . . . . . . . . . . . . . . 143.19 166.81 11.32 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 111.228 -0.749 . . . . 33.780000000000001 111.228 -178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 52' ' ' ARG . . . . . . . . . . . . . 17.5 tpp85 -128.71 52.32 1.94 Allowed 'General case' 0 C--O 1.234 0.28 0 N-CA-C 106.606 -1.627 . . . . 15.470000000000001 106.606 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 53' ' ' ILE . . . . . . . . . . . . . 5.9 tt -75.98 -8.76 12.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.739 -0.664 . . . . 51.770000000000003 111.664 -171.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 54' ' ' LEU . . . . . . . . . . . . . 7.5 mp -67.1 -21.33 65.87 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.277 0.631 . . . . 45.170000000000002 112.687 -176.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.45 141.99 38.09 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-O 121.437 0.465 . . . . 49.640000000000001 114.001 -170.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 56' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -76.73 -179.37 5.3 Favored 'Trans proline' 0 C--N 1.327 -0.572 0 C-N-CA 121.177 1.252 . . . . 15.4 111.803 -175.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 57' ' ' GLY . . . . . 0.471 ' CA ' ' O ' ' F' ' 41' ' ' ARG . . . -153.03 173.24 31.96 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 110.091 -1.203 . . . . 46.630000000000003 110.091 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 58' ' ' SER . . . . . . . . . . . . . 40.4 t -76.13 144.65 40.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.663 0.744 . . . . 5.3600000000000003 110.611 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 59' ' ' VAL . . . . . . . . . . . . . 3.1 p -104.04 124.13 58.24 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 N-CA-C 108.562 -0.903 . . . . 8.3200000000000003 108.562 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 60' ' ' ALA . . . . . . . . . . . . . . . -123.04 117.75 26.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.039 -1.467 . . . . 17.609999999999999 107.039 173.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 61' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -117.12 120.91 39.77 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.817 -0.808 . . . . 70.099999999999994 108.817 -168.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 62' ' ' SER . . . . . 0.457 ' OG ' ' OE1' ' F' ' 133' ' ' GLN . 69.0 m -108.58 164.1 12.65 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 124.211 1.005 . . . . 17.609999999999999 110.585 -175.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 63' ' ' GLY . . . . . . . . . . . . . . . -140.07 122.54 2.23 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.108 -0.951 . . . . 3.8700000000000001 112.733 177.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 64' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -101.18 95.41 6.52 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 107.499 -1.297 . . . . 61.560000000000002 107.499 173.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 65' ' ' VAL . . . . . . . . . . . . . 92.6 t -102.57 119.46 50.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.2 -1.037 . . . . 17.609999999999999 108.2 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 66' ' ' THR . . . . . . . . . . . . . 79.6 p -115.24 144.31 43.91 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.195 -0.669 . . . . 9.0399999999999991 109.195 176.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 67' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -155.09 -173.63 4.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.922 -0.77 . . . . 17.609999999999999 108.922 175.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 68' ' ' TYR . . . . . . . . . . . . . 16.8 m-30 -115.37 136.89 52.63 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 109.232 -0.655 . . . . 17.609999999999999 109.232 175.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.86 113.51 3.74 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.944 -0.646 . . . . 17.609999999999999 114.403 -175.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 70' ' ' LYS . . . . . 0.473 ' O ' ' NE2' ' F' ' 76' ' ' GLN . 38.4 ttmt -83.44 152.08 25.16 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 108.766 -0.827 . . . . 16.420000000000002 108.766 175.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -68.2 -17.21 64.26 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 113.997 1.11 . . . . 17.59 113.997 -171.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.62 -140.39 5.09 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.114 -1.194 . . . . 24.640000000000001 110.114 176.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 73' ' ' ASP . . . . . . . . . . . . . 31.2 t0 59.75 72.71 0.51 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.18 1.392 . . . . 10.75 111.082 168.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.42 10.92 0.05 Allowed 'General case' 0 C--O 1.235 0.29 0 N-CA-C 117.309 2.337 . . . . 31.350000000000001 117.309 -159.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.47 -40.75 94.78 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 120.227 -0.987 . . . . 22.48 112.598 170.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 76' ' ' GLN . . . . . 0.473 ' NE2' ' O ' ' F' ' 70' ' ' LYS . 22.1 pt20 -70.66 -22.35 62.5 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 119.972 -0.691 . . . . 12.029999999999999 111.873 172.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 77' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -72.36 -26.65 61.99 Favored 'General case' 0 CA--C 1.517 -0.293 0 C-N-CA 119.345 -0.942 . . . . 23.73 111.389 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.16 -30.72 63.78 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.222 -0.591 . . . . 9.8499999999999996 111.169 169.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 79' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.61 -45.64 97.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 CA-C-O 121.05 0.453 . . . . 17.609999999999999 110.491 172.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -75.02 -22.79 58.25 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 121.827 -0.546 . . . . 22.420000000000002 111.992 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 81' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -70.07 -33.6 72.13 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.212 -0.595 . . . . 37.799999999999997 111.301 168.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 82' ' ' ALA . . . . . . . . . . . . . . . -74.2 -33.16 63.32 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.388 -0.925 . . . . 8.4600000000000009 111.537 175.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 83' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -83.23 -62.63 1.54 Allowed 'General case' 0 C--O 1.235 0.341 0 C-N-CA 120.421 -0.512 . . . . 20.559999999999999 111.966 -176.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -76.24 -41.71 48.28 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 111.92 0.341 . . . . 10.83 111.92 -166.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 85' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -72.9 -41.5 64.55 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 119.812 -0.755 . . . . 28.109999999999999 110.905 171.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.33 96.93 2.46 Favored Glycine 0 N--CA 1.449 -0.469 0 O-C-N 122.266 -0.271 . . . . 4.5899999999999999 113.205 178.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 87' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -147.94 -163.11 1.69 Allowed 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 107.139 -1.43 . . . . 17.329999999999998 107.139 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 88' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 -128.72 173.48 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.408 0.623 . . . . 17.52 109.705 171.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 89' ' ' ILE . . . . . . . . . . . . . 72.9 mt -128.33 133.67 66.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 116.059 -0.519 . . . . 11.07 109.722 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -81.64 118.14 22.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 108.585 -0.894 . . . . 20.469999999999999 108.585 166.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 91' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -114.31 129.84 56.65 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 124.685 1.194 . . . . 12.460000000000001 109.939 -166.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 92' ' ' TRP . . . . . . . . . . . . . 89.6 m95 -130.15 129.11 43.06 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 123.967 0.907 . . . . 21.109999999999999 108.838 -177.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 93' ' ' ARG . . . . . . . . . . . . . 78.6 ttt-85 -111.57 92.33 3.99 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 108.101 -1.074 . . . . 11.99 108.101 173.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 94' ' ' VAL . . . . . . . . . . . . . 22.2 m -105.68 162.82 4.78 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 CA-C-O 122.3 1.048 . . . . 14.23 109.646 -172.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 95' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -108.05 167.65 9.84 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 114.789 -1.096 . . . . 18.32 111.305 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 96' ' ' THR . . . . . . . . . . . . . 27.7 m -101.78 -29.94 11.58 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 114.87 -1.059 . . . . 25.620000000000001 112.447 -176.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 97' ' ' VAL . . . . . . . . . . . . . 35.4 m -69.0 154.13 8.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.771 0.796 . . . . 17.609999999999999 110.144 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 98' ' ' LYS . . . . . 0.564 ' NZ ' ' O ' ' F' ' 99' ' ' ASN . 29.7 tptp -91.3 122.61 34.06 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.67 -0.695 . . . . 17.609999999999999 109.803 -175.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 99' ' ' ASN . . . . . 0.564 ' O ' ' NZ ' ' F' ' 98' ' ' LYS . 34.6 m120 -81.78 169.11 17.29 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.825 0.821 . . . . 21.02 109.903 171.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 100' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -107.55 -12.12 15.34 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 113.983 1.105 . . . . 6.7300000000000004 113.983 -179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 101' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -96.15 -54.45 3.29 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 118.492 0.587 . . . . 6.2400000000000002 111.438 167.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 102' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -98.65 -173.36 2.52 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.249 -1.019 . . . . 23.719999999999999 108.249 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 103' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.52 -54.86 4.3 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.208 0.528 . . . . 59.25 110.306 172.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 104' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -132.01 -171.11 2.55 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 107.985 -1.117 . . . . 26.329999999999998 107.985 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 105' ' ' ASP . . . . . 0.401 ' N ' ' OD1' ' F' ' 105' ' ' ASP . 20.8 p-10 -151.24 169.11 22.73 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 121.515 0.674 . . . . 16.879999999999999 109.362 175.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 106' ' ' ALA . . . . . . . . . . . . . . . -155.02 159.24 40.17 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.186 -0.916 . . . . 17.609999999999999 110.926 -163.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 107' ' ' GLN . . . . . 0.44 ' OE1' ' OH ' ' A' ' 118' ' ' TYR . 88.2 mt-30 -117.27 121.26 40.67 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.1 -1.444 . . . . 15.050000000000001 107.1 159.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 108' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -108.83 152.9 24.26 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.383 1.073 . . . . 25.920000000000002 110.249 -164.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 109' ' ' GLY . . . . . . . . . . . . . . . -174.39 155.48 21.37 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 119.367 -1.396 . . . . 17.609999999999999 112.533 172.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 110' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -92.27 108.85 20.25 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 108.867 -0.79 . . . . 12.6 108.867 169.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 111' ' ' ALA . . . . . . . . . . . . . . . -111.59 161.79 15.83 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-O 121.493 0.663 . . . . 46.93 111.606 -168.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 112' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -138.78 136.6 35.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 114.704 -1.134 . . . . 25.940000000000001 107.955 -176.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 113' ' ' ILE . . . . . . . . . . . . . 72.9 mt -82.74 131.33 34.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 109.665 -0.494 . . . . 17.609999999999999 109.665 -172.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 114' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -75.33 -64.47 1.06 Allowed 'General case' 0 C--O 1.235 0.301 0 C-N-CA 119.74 -0.784 . . . . 24.43 110.752 164.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 115' ' ' SER . . . . . . . . . . . . . 70.1 m -141.13 149.49 41.61 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.647 0.737 . . . . 37.799999999999997 110.186 -168.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -125.44 93.74 3.95 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 105.028 -2.212 . . . . 0.93000000000000005 105.028 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 117' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -115.84 109.36 17.53 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 107.522 -1.288 . . . . 33.979999999999997 107.522 -175.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 118' ' ' TYR . . . . . 0.467 ' OH ' ' OE1' ' E' ' 107' ' ' GLN . 20.6 p90 -115.33 142.38 46.76 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.558 0.694 . . . . 25.469999999999999 112.122 178.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 119' ' ' SER . . . . . . . . . . . . . 35.1 t -98.24 131.13 44.83 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 114.611 -1.177 . . . . 17.609999999999999 109.949 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 120' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -107.11 98.71 8.32 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.361 -1.718 . . . . 28.190000000000001 106.361 170.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.73 -158.15 24.01 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-O 121.717 0.621 . . . . 25.420000000000002 112.013 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 122' ' ' VAL . . . . . . . . . . . . . 59.8 t -114.53 -62.82 2.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.13 -1.063 . . . . 14.279999999999999 108.13 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 123' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -83.3 -43.07 16.42 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.941 0.719 . . . . 57.93 112.941 179.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 124' ' ' GLY . . . . . . . . . . . . . . . -74.41 150.02 41.28 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.083 -1.207 . . . . 23.460000000000001 110.083 173.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.78 170.33 15.52 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.697 0.761 . . . . 21.780000000000001 110.192 174.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 126' ' ' VAL . . . . . . . . . . . . . 26.8 m -69.14 149.9 10.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.522 0 CA-C-N 115.203 -0.908 . . . . 17.609999999999999 109.885 -175.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 127' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -138.28 125.92 22.17 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.34 -0.391 . . . . 53.509999999999998 110.222 -179.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 128' ' ' ILE . . . . . . . . . . . . . 87.6 mt -95.36 121.4 45.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.324 -0.621 . . . . 17.609999999999999 109.324 -177.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 129' ' ' SER . . . . . . . . . . . . . 70.9 m -102.98 134.23 46.76 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.476 -0.935 . . . . 46.920000000000002 108.476 172.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 130' ' ' ILE . . . . . . . . . . . . . 71.5 mt -136.77 128.41 43.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 N-CA-C 109.157 -0.682 . . . . 10.99 109.157 -175.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 131' ' ' SER . . . . . . . . . . . . . 62.3 m -96.23 151.85 19.12 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-O 120.975 0.417 . . . . 40.729999999999997 110.19 175.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 132' ' ' LEU . . . . . . . . . . . . . 7.2 mp -136.26 141.21 43.87 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 116.141 -0.482 . . . . 37.609999999999999 110.873 -178.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 133' ' ' GLN . . . . . 0.457 ' OE1' ' OG ' ' F' ' 62' ' ' SER . 30.5 mm100 -120.64 136.95 54.68 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 108.448 -0.945 . . . . 17.609999999999999 108.448 168.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.87 148.04 25.66 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 N-CA-C 108.328 -0.99 . . . . 32.789999999999999 108.328 175.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 135' ' ' ILE . . . . . . . . . . . . . 27.3 mm -62.56 -61.21 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-O 121.319 0.581 . . . . 18.82 110.915 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.51 139.3 6.0 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 109.243 -1.543 . . . . 54.560000000000002 109.243 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 137' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -69.08 153.65 43.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.611 0.72 . . . . 15.77 110.288 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 138' ' ' LEU . . . . . . . . . . . . . 35.7 tp -138.49 124.49 20.08 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.119 -1.437 . . . . 9.0199999999999996 107.119 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.08 68.84 10.42 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 122.35 1.071 . . . . 6.8399999999999999 109.816 -168.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 140' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -87.32 77.08 9.02 Favored 'General case' 0 C--N 1.334 -0.101 0 N-CA-C 108.22 -1.03 . . . . 16.59 108.22 176.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.14 111.31 3.45 Favored Glycine 0 C--O 1.237 0.333 0 N-CA-C 110.493 -1.043 . . . . 22.309999999999999 110.493 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.5 -172.08 2.3 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 109.278 -0.638 . . . . 25.190000000000001 109.278 -174.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 143' ' ' ILE . . . . . . . . . . . . . 1.3 pp -109.82 -60.95 2.67 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 N-CA-C 113.558 0.948 . . . . 12.99 113.558 -167.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 144' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -82.26 132.9 35.23 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.34 -0.85 . . . . 27.649999999999999 110.949 -170.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 145' ' ' THR . . . . . . . . . . . . . 66.2 p -122.53 13.09 10.11 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 119.042 -0.504 . . . . 7.5599999999999996 112.219 176.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 146' ' ' LEU . . . . . 0.41 ' O ' ' N ' ' F' ' 148' ' ' GLU . 4.1 mm? 54.26 76.48 0.51 Allowed Pre-proline 0 C--O 1.238 0.456 0 C-N-CA 126.827 2.051 . . . . 14.48 110.083 -178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 147' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -67.8 73.04 0.69 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 121.31 1.34 . . . . 10.58 115.38 -159.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 148' ' ' GLU . . . . . 0.535 ' OE1' ' ND2' ' F' ' 152' ' ' ASN . 79.6 mm-40 -108.54 9.37 27.4 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.716 -0.675 . . . . 20.190000000000001 111.65 169.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 149' ' ' GLU . . . . . 0.51 ' O ' ' NZ ' ' F' ' 12' ' ' LYS . 26.0 pm0 -139.49 5.21 2.22 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 112.709 0.633 . . . . 31.940000000000001 112.709 -178.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 150' ' ' ILE . . . . . . . . . . . . . 47.5 mm -113.89 -54.86 4.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 118.8 0.727 . . . . 24.34 111.308 -176.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 151' ' ' VAL . . . . . . . . . . . . . 26.3 t -104.44 -24.57 3.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.062 -1.458 . . . . 27.280000000000001 107.062 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 152' ' ' ASN . . . . . 0.535 ' ND2' ' OE1' ' F' ' 148' ' ' GLU . 41.1 t-20 -66.66 -36.07 81.67 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.96 -0.564 . . . . 33.960000000000001 111.722 -178.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -73.99 98.2 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.427 0 N-CA-C 107.856 -1.164 . . . . 10.33 107.856 172.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 154' ' ' SER . . . . . . . . . . . . . 30.1 t -116.82 -62.29 1.6 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.471 -0.786 . . . . 12.960000000000001 112.525 -172.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 155' ' ' LYS . . . . . . . . . . . . . 16.9 tppt? -132.74 -31.78 1.31 Allowed 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 113.721 1.008 . . . . 56.670000000000002 113.721 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.34 -55.77 2.79 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 119.359 0.982 . . . . 18.649999999999999 110.794 -169.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 157' ' ' GLY . . . . . . . . . . . . . . . -80.09 142.54 24.32 Favored Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.475 -0.869 . . . . 4.6100000000000003 112.343 176.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 158' ' ' TYR . . . . . . . . . . . . . 14.4 m-30 -111.44 -173.28 2.21 Favored 'General case' 0 C--O 1.236 0.388 0 C-N-CA 123.727 0.811 . . . . 20.34 109.417 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 159' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -77.55 -73.84 0.28 Allowed 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.451 -0.9 . . . . 66.329999999999998 113.007 -153.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 160' ' ' PHE . . . . . . . . . . . . . 38.5 p90 177.02 173.47 0.45 Allowed 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 128.262 2.625 . . . . 17.609999999999999 109.009 162.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 161' ' ' GLN . . . . . . . . . . . . . 65.5 tt0 -157.6 104.74 2.0 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 105.589 -2.004 . . . . 17.359999999999999 105.589 155.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 162' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -71.3 -48.33 13.02 Favored Pre-proline 0 C--O 1.243 0.756 0 N-CA-C 113.806 1.039 . . . . 14.19 113.806 -169.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 163' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -77.05 -19.64 13.6 Favored 'Trans proline' 0 C--N 1.372 1.795 0 CA-C-N 122.237 1.835 . . . . 31.800000000000001 112.496 176.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 164' ' ' GLY . . . . . . . . . . . . . . . -134.4 37.52 1.95 Allowed Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 119.752 2.661 . . . . 38.740000000000002 119.752 -170.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -67.99 -59.25 3.41 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 119.06 1.43 . . . . 22.780000000000001 111.152 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 166' ' ' THR . . . . . . . . . . . . . 33.7 p 54.57 49.53 17.99 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.765 1.626 . . . . 30.57 111.582 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 167' ' ' THR . . . . . . . . . . . . . 3.4 m -140.69 149.79 42.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.369 -0.604 . . . . 10.119999999999999 109.369 -167.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 168' ' ' GLY . . . . . . . . . . . . . . . -86.44 -125.06 1.74 Allowed Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.098 -0.801 . . . . 18.699999999999999 111.098 168.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 169' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -74.21 -63.47 1.22 Allowed 'General case' 0 C--O 1.236 0.344 0 C-N-CA 120.865 -0.334 . . . . 31.859999999999999 111.374 -176.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.6 104.59 0.63 Allowed Pre-proline 0 C--O 1.235 0.336 0 C-N-CA 123.982 0.913 . . . . 23.960000000000001 109.457 -174.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 171' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.17 -177.23 3.66 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.461 1.441 . . . . 17.609999999999999 112.964 -153.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.67 69.35 1.41 Allowed Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 116.952 1.541 . . . . 22.969999999999999 116.952 164.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 173' ' ' THR . . . . . . . . . . . . . 9.3 t -130.03 165.72 21.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.868 0.842 . . . . 17.609999999999999 109.264 168.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 174' ' ' VAL . . . . . . . . . . . . . 28.7 m -80.55 158.85 70.7 Favored Pre-proline 0 C--O 1.24 0.576 0 N-CA-C 107.816 -1.179 . . . . 10.57 107.816 176.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 175' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -64.28 110.42 1.37 Allowed 'Trans proline' 0 CA--C 1.512 -0.582 0 CA-C-N 119.609 0.896 . . . . 16.460000000000001 110.14 170.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.192 0 C-N-CA 125.077 1.351 . . . . 45.890000000000001 111.255 -161.482 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 5' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 N--CA 1.465 -0.161 0 CA-C-O 119.643 -0.232 . . . . 15.58 112.396 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 6' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.24 120.5 62.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 108.052 -1.092 . . . . 19.16 108.052 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.58 169.39 11.37 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 121.846 0.832 . . . . 39.270000000000003 110.616 -177.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.23 -12.86 63.91 Favored Glycine 0 C--N 1.334 0.437 0 CA-C-N 115.441 -0.799 . . . . 17.559999999999999 114.626 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -92.52 -14.67 28.04 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 117.76 0.78 . . . . 17.559999999999999 112.378 173.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -77.73 -5.03 49.22 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 113.812 1.041 . . . . 30.530000000000001 113.812 -170.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' VAL . . . . . . . . . . . . . 74.7 t -128.84 125.25 62.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.808 -1.182 . . . . 21.850000000000001 107.808 -177.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' LYS . . . . . 0.515 ' NZ ' ' O ' ' G' ' 149' ' ' GLU . 53.4 mtmt -134.12 160.6 37.31 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.544 0.687 . . . . 18.16 110.009 175.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' TYR . . . . . . . . . . . . . 16.7 m-30 -110.84 96.77 6.37 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.053 -1.091 . . . . 17.559999999999999 108.053 -167.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' LEU . . . . . . . . . . . . . 99.0 mt -74.76 133.61 41.96 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.337 -0.616 . . . . 65.620000000000005 109.337 176.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' PHE . . . . . . . . . . . . . 20.8 m-30 -115.32 150.78 35.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.037 0.446 . . . . 34.210000000000001 109.829 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' GLN . . . . . . . . . . . . . 71.0 tp60 -145.64 137.25 25.15 Favored 'General case' 0 C--O 1.237 0.418 0 N-CA-C 109.058 -0.719 . . . . 16.199999999999999 109.058 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' SER . . . . . 0.481 ' O ' ' NZ ' ' G' ' 90' ' ' LYS . 39.0 t -75.54 155.69 35.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.623 0.725 . . . . 16.469999999999999 111.115 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' ILE . . . . . . . . . . . . . 44.1 pt -77.44 -10.59 13.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 CA-C-N 115.468 -0.787 . . . . 17.559999999999999 112.966 176.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -113.33 -9.19 13.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.764 0.653 . . . . 27.16 112.764 -169.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' ALA . . . . . . . . . . . . . . . -79.46 -47.79 15.05 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 119.622 -0.831 . . . . 27.760000000000002 112.026 -170.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.55 47.09 25.45 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.711 1.204 . . . . 12.42 111.278 -166.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -123.62 121.13 34.78 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 123.537 0.735 . . . . 37.770000000000003 109.017 179.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.17 74.56 2.31 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.075 -0.583 . . . . 17.559999999999999 113.053 -178.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' SER . . . . . . . . . . . . . 90.6 p -129.12 -29.81 2.24 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 120.607 -0.437 . . . . 28.469999999999999 111.585 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.33 74.36 0.81 Allowed Pre-proline 0 C--O 1.236 0.381 0 C-N-CA 126.932 2.093 . . . . 17.260000000000002 112.229 -173.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -71.29 105.94 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 CA-C-N 119.488 0.853 . . . . 17.559999999999999 112.524 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -82.22 158.06 23.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.951 -0.759 . . . . 17.559999999999999 108.951 165.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -103.86 129.51 25.14 Favored Pre-proline 0 N--CA 1.447 -0.6 1 C-N-CA 109.793 -4.763 . . . . 19.129999999999999 110.247 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -73.6 -172.3 1.04 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 120.56 0.84 . . . . 4.2699999999999996 114.083 -175.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 52.23 57.49 6.4 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.553 1.141 . . . . 2.0600000000000001 110.843 -171.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -68.8 163.34 24.36 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 122.975 1.369 . . . . 34.590000000000003 112.015 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -136.19 -163.27 1.38 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 103.07 -2.937 . . . . 19.100000000000001 103.07 169.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' THR . . . . . . . . . . . . . 15.3 t -67.72 166.08 15.95 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.546 1.165 . . . . 10.869999999999999 112.027 -173.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -132.13 -170.7 2.47 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.163 -1.38 . . . . 46.859999999999999 108.408 -170.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' GLY . . . . . . . . . . . . . . . 177.93 132.65 1.73 Allowed Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.98 -0.848 . . . . 31.699999999999999 110.98 169.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' SER . . . . . . . . . . . . . 67.4 m -125.52 84.56 2.29 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.035 -1.839 . . . . 17.559999999999999 106.035 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' VAL . . . . . . . . . . . . . 4.5 m -93.58 113.44 28.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 108.448 -0.945 . . . . 14.44 108.448 -171.033 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' SER . . . . . 0.446 ' O ' ' OH ' ' H' ' 83' ' ' TYR . 51.1 m -102.02 88.76 3.43 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 108.411 -0.959 . . . . 15.27 108.411 -167.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' GLY . . . . . . . . . . . . . . . -90.99 98.89 2.51 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.201 -0.999 . . . . 49.310000000000002 113.231 -178.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -102.42 117.96 35.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 17.550000000000001 108.169 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 41' ' ' ARG . . . . . 0.518 ' NH2' ' OE2' ' B' ' 123' ' ' GLU . 91.0 mtm-85 -76.63 177.75 7.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.558 0.694 . . . . 31.579999999999998 109.511 -176.495 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 42' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -157.76 159.45 36.81 Favored 'General case' 0 C--N 1.329 -0.304 0 O-C-N 121.622 -0.674 . . . . 33.509999999999998 109.671 -174.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 43' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.6 106.92 19.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.721 -0.672 . . . . 10.66 109.393 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 44' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -106.89 119.11 38.47 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.307 -1.368 . . . . 30.359999999999999 107.307 173.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 45' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -130.77 174.24 10.14 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 108.468 -0.938 . . . . 29.010000000000002 108.468 -173.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 46' ' ' GLU . . . . . . . . . . . . . 59.9 mp0 -126.72 -41.14 1.86 Allowed 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.858 1.058 . . . . 19.890000000000001 113.858 -170.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 47' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 67.43 23.26 9.15 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 114.005 1.113 . . . . 37.149999999999999 114.005 154.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 48' ' ' THR . . . . . . . . . . . . . 53.3 p 51.23 37.74 19.33 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.618 1.167 . . . . 28.329999999999998 111.121 -167.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm -139.72 -165.91 1.97 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 106.846 -1.539 . . . . 18.5 106.846 -175.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 50' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -69.95 -31.2 68.82 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 120.538 -0.465 . . . . 32.530000000000001 112.019 171.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.34 166.18 14.73 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 121.323 -0.465 . . . . 5.3899999999999997 113.747 -178.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 52' ' ' ARG . . . . . . . . . . . . . 19.4 tpp85 -133.58 57.95 1.79 Allowed 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.831 -1.174 . . . . 14.66 107.831 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 53' ' ' ILE . . . . . . . . . . . . . 7.6 tt -66.08 -5.02 2.64 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 C-N-CA 125.19 1.396 . . . . 50.619999999999997 113.67 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 54' ' ' LEU . . . . . . . . . . . . . 8.9 mp -61.95 -23.41 66.36 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 124.251 1.02 . . . . 74.620000000000005 113.711 -170.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.15 120.01 12.81 Favored Glycine 0 N--CA 1.44 -1.099 0 CA-C-O 121.626 0.57 . . . . 7.3200000000000003 114.179 -169.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 56' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.37 169.29 22.64 Favored 'Trans proline' 0 C--N 1.326 -0.621 0 C-N-CA 120.873 1.049 . . . . 7.4800000000000004 109.873 171.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 57' ' ' GLY . . . . . . . . . . . . . . . -137.2 170.38 23.58 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.577 -1.409 . . . . 23.59 109.577 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 58' ' ' SER . . . . . . . . . . . . . 45.9 t -72.81 147.11 45.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.618 -0.833 . . . . 17.34 109.595 172.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 59' ' ' VAL . . . . . . . . . . . . . 2.2 p -103.13 112.94 38.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 108.388 -0.967 . . . . 1.78 108.388 -177.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 60' ' ' ALA . . . . . . . . . . . . . . . -108.19 110.6 22.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 106.681 -1.6 . . . . 13.09 106.681 174.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 61' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -115.07 118.3 32.99 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.33 -0.989 . . . . 46.859999999999999 108.33 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 62' ' ' SER . . . . . 0.474 ' OG ' ' OE1' ' G' ' 133' ' ' GLN . 56.9 m -107.07 165.89 11.02 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 124.102 0.961 . . . . 11.699999999999999 110.418 -173.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 63' ' ' GLY . . . . . . . . . . . . . . . -139.45 121.12 2.0 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 119.992 -1.099 . . . . 17.559999999999999 113.183 174.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 64' ' ' GLU . . . . . . . . . . . . . 67.2 mm-40 -97.79 95.51 7.59 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.253 -1.388 . . . . 37.600000000000001 107.253 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 65' ' ' VAL . . . . . . . . . . . . . 86.1 t -105.36 116.58 49.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 108.404 -0.961 . . . . 5.8200000000000003 108.404 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 66' ' ' THR . . . . . . . . . . . . . 64.8 p -115.1 143.08 45.76 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.978 -0.749 . . . . 17.559999999999999 108.978 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 67' ' ' TYR . . . . . . . . . . . . . 55.6 p90 -154.3 -170.64 3.6 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.408 0.623 . . . . 15.390000000000001 109.433 176.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 68' ' ' TYR . . . . . . . . . . . . . 14.3 m-30 -116.99 134.74 54.35 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 123.868 0.867 . . . . 3.8300000000000001 109.488 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.4 116.55 4.25 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.995 -0.621 . . . . 7.04 114.315 -175.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 70' ' ' LYS . . . . . 0.493 ' O ' ' NE2' ' G' ' 76' ' ' GLN . 38.8 ttmt -91.05 150.46 21.42 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 3.0099999999999998 108.83 175.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 71' ' ' ARG . . . . . . . . . . . . . 20.6 ptp180 -69.0 -16.67 63.78 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 113.925 1.083 . . . . 16.93 113.925 -170.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.97 -138.15 4.7 Favored Glycine 0 N--CA 1.451 -0.301 0 N-CA-C 109.902 -1.279 . . . . 35.850000000000001 109.902 175.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 73' ' ' ASP . . . . . . . . . . . . . 31.4 t0 59.95 73.18 0.49 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 125.045 1.338 . . . . 12.83 111.135 167.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.69 10.39 0.05 OUTLIER 'General case' 0 C--O 1.233 0.228 0 N-CA-C 117.438 2.385 . . . . 58.079999999999998 117.438 -157.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.3 -42.07 97.16 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 120.31 -0.948 . . . . 6.6399999999999997 112.845 171.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 76' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' G' ' 70' ' ' LYS . 22.0 pt20 -70.89 -23.38 62.28 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 119.546 -0.862 . . . . 30.280000000000001 111.714 174.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 77' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -70.27 -28.01 64.88 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 119.919 -0.712 . . . . 1.1000000000000001 111.352 170.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.93 -30.89 62.8 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 120.716 -0.394 . . . . 14.890000000000001 111.352 171.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 79' ' ' ILE . . . . . . . . . . . . . 51.0 mm -64.45 -44.99 97.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-O 121.076 0.465 . . . . 17.559999999999999 110.347 172.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.16 -24.01 60.52 Favored 'General case' 0 C--O 1.234 0.289 0 O-C-N 121.895 -0.503 . . . . 21.16 112.007 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 81' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -70.3 -35.07 73.45 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.307 -0.557 . . . . 27.620000000000001 111.533 170.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 82' ' ' ALA . . . . . . . . . . . . . . . -74.62 -32.36 62.29 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 119.178 -1.009 . . . . 5.9699999999999998 111.561 175.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 83' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' L' ' 38' ' ' SER . 86.1 t80 -83.29 -62.47 1.58 Allowed 'General case' 0 C--O 1.234 0.281 0 C-N-CA 120.504 -0.478 . . . . 17.559999999999999 112.049 -176.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 84' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -76.28 -39.17 54.98 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.577 -0.283 . . . . 18.170000000000002 111.735 -165.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 85' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -75.6 -40.69 56.1 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.929 -0.709 . . . . 19.489999999999998 111.011 172.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.42 96.33 2.44 Favored Glycine 0 N--CA 1.45 -0.403 0 O-C-N 122.234 -0.291 . . . . 17.559999999999999 113.544 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 87' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -148.69 -162.03 1.47 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 106.882 -1.525 . . . . 17.25 106.882 -178.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 88' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -129.13 178.78 6.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.724 0.773 . . . . 13.52 111.035 167.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 89' ' ' ILE . . . . . . . . . . . . . 68.0 mt -128.73 135.1 63.13 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 115.209 -0.905 . . . . 19.690000000000001 109.618 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 90' ' ' LYS . . . . . 0.481 ' NZ ' ' O ' ' G' ' 17' ' ' SER . 36.4 mtmm -84.9 116.66 23.46 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.559 -0.904 . . . . 24.48 108.559 165.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 91' ' ' PHE . . . . . . . . . . . . . 61.5 t80 -111.71 134.38 53.32 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 124.692 1.197 . . . . 31.77 110.577 -166.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 92' ' ' TRP . . . . . . . . . . . . . 92.5 m95 -133.49 125.56 29.23 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 123.905 0.882 . . . . 14.67 110.168 -173.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 93' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -111.87 90.85 3.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 108.196 -1.039 . . . . 14.24 108.196 171.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 m -105.65 163.38 4.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 122.139 0.971 . . . . 17.91 109.391 -174.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 95' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -109.8 164.71 12.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.013 -0.994 . . . . 33.229999999999997 111.136 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 96' ' ' THR . . . . . . . . . . . . . 28.4 m -98.82 -30.85 12.17 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 114.973 -1.012 . . . . 22.239999999999998 112.645 -175.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -68.69 155.17 7.86 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 CA-C-O 121.76 0.79 . . . . 25.399999999999999 110.137 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 98' ' ' LYS . . . . . 0.587 ' NZ ' ' O ' ' G' ' 99' ' ' ASN . 29.6 tptp -90.46 122.0 32.92 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.72 -0.673 . . . . 9.5600000000000005 109.821 -176.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 99' ' ' ASN . . . . . 0.587 ' O ' ' NZ ' ' G' ' 98' ' ' LYS . 34.9 m120 -83.81 171.44 13.12 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.828 0.823 . . . . 16.050000000000001 109.99 171.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 100' ' ' GLU . . . . . . . . . . . . . 58.4 mp0 -108.45 -17.2 14.04 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 113.463 0.912 . . . . 31.57 113.463 178.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 101' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -86.47 -49.69 7.41 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 118.175 0.443 . . . . 14.91 111.04 170.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 102' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -112.58 -174.74 2.52 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.321 -0.992 . . . . 23.649999999999999 108.321 172.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 103' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -77.06 -55.01 5.82 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.015 -0.674 . . . . 33.920000000000002 110.076 168.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 104' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -133.25 -171.0 2.58 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.548 -0.908 . . . . 7.1200000000000001 108.548 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 105' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -151.68 166.52 31.02 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.163 -0.68 . . . . 53.270000000000003 109.163 177.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 106' ' ' ALA . . . . . . . . . . . . . . . -156.85 156.54 33.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.419 -0.81 . . . . 17.559999999999999 111.404 -162.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 107' ' ' GLN . . . . . 0.457 ' OE1' ' OH ' ' H' ' 118' ' ' TYR . 87.4 mt-30 -114.8 123.62 49.67 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.805 -1.554 . . . . 9.6899999999999995 106.805 158.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 108' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -110.61 153.81 24.66 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 123.735 0.814 . . . . 7.7000000000000002 110.262 -165.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 109' ' ' GLY . . . . . . . . . . . . . . . -164.75 167.41 38.51 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 119.553 -1.308 . . . . 37.560000000000002 112.79 173.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 110' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -108.18 108.81 20.01 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 114.667 -0.767 . . . . 18.989999999999998 109.276 168.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 111' ' ' ALA . . . . . . . . . . . . . . . -107.03 157.04 18.12 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.618 0.723 . . . . 47.07 111.71 -166.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 112' ' ' TYR . . . . . . . . . . . . . 55.1 t80 -137.87 136.65 37.32 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.168 -1.419 . . . . 0.60999999999999999 107.168 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 113' ' ' ILE . . . . . . . . . . . . . 83.5 mt -86.53 128.16 39.75 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 109.95 -0.389 . . . . 3.73 109.95 -169.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 114' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -70.93 -64.63 0.87 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 119.904 -0.718 . . . . 20.300000000000001 110.479 164.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 115' ' ' SER . . . . . . . . . . . . . 67.7 m -140.93 147.8 39.39 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-O 121.562 0.696 . . . . 11.26 110.391 -170.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 116' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -120.17 89.87 3.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 104.782 -2.303 . . . . 8.25 104.782 175.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 117' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -112.85 108.38 17.33 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.494 -1.298 . . . . 27.879999999999999 107.494 -175.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 118' ' ' TYR . . . . . 0.449 ' OH ' ' OE1' ' L' ' 107' ' ' GLN . 19.1 p90 -114.55 142.53 46.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.536 0.684 . . . . 28.760000000000002 111.917 177.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 119' ' ' SER . . . . . . . . . . . . . 37.2 t -96.4 128.37 43.26 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 114.673 -1.149 . . . . 17.559999999999999 109.938 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 120' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -106.22 97.9 7.65 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 106.039 -1.838 . . . . 34.729999999999997 106.039 170.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.3 -155.07 15.64 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-O 121.814 0.674 . . . . 5.1500000000000004 112.086 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 122' ' ' VAL . . . . . . . . . . . . . 79.4 t -112.72 -60.61 2.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 108.329 -0.989 . . . . 16.969999999999999 108.329 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 123' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -103.24 -30.67 10.51 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.074 0.768 . . . . 56.789999999999999 113.074 -174.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.05 148.51 41.29 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 109.287 -1.525 . . . . 28.649999999999999 109.287 165.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.13 165.31 24.59 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-O 121.686 0.755 . . . . 12.09 110.265 176.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 126' ' ' VAL . . . . . . . . . . . . . 28.0 m -68.96 145.91 13.08 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-N 115.303 -0.862 . . . . 17.559999999999999 109.75 -176.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 127' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -135.41 132.06 37.03 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 109.521 -0.548 . . . . 47.399999999999999 109.521 -176.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 128' ' ' ILE . . . . . . . . . . . . . 84.2 mt -101.82 121.3 52.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.393 -0.595 . . . . 17.559999999999999 109.393 -176.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 129' ' ' SER . . . . . . . . . . . . . 68.6 m -100.29 132.67 45.53 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.44 -0.948 . . . . 23.09 108.44 170.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 130' ' ' ILE . . . . . . . . . . . . . 81.6 mt -135.23 128.07 48.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 N-CA-C 108.652 -0.869 . . . . 17.559999999999999 108.652 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 131' ' ' SER . . . . . . . . . . . . . 57.1 m -93.28 146.65 23.55 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-O 121.158 0.504 . . . . 17.559999999999999 109.797 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 132' ' ' LEU . . . . . . . . . . . . . 7.4 mp -129.5 149.89 51.07 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.967 -0.561 . . . . 41.5 110.275 -177.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 133' ' ' GLN . . . . . 0.474 ' OE1' ' OG ' ' G' ' 62' ' ' SER . 21.2 mm100 -137.64 127.69 25.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.373 -0.831 . . . . 2.8300000000000001 109.382 177.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 134' ' ' VAL . . . . . . . . . . . . . 10.7 p -136.04 148.91 27.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 108.962 -0.755 . . . . 7.7300000000000004 108.962 -178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 135' ' ' ILE . . . . . . . . . . . . . 25.8 mm -64.28 -60.13 3.2 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.224 0.535 . . . . 12.81 110.878 177.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.54 136.91 4.72 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 111.008 -0.837 . . . . 0.26000000000000001 111.008 -179.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 137' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.27 153.92 42.53 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.435 0.636 . . . . 27.0 110.347 177.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 138' ' ' LEU . . . . . . . . . . . . . 31.7 tp -136.06 128.82 30.94 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 107.71 -1.219 . . . . 17.559999999999999 107.71 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -81.47 76.5 8.39 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 122.46 1.124 . . . . 17.559999999999999 109.268 -171.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 140' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -97.8 79.46 2.67 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.12 -0.946 . . . . 16.670000000000002 108.829 -177.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.78 112.27 3.88 Favored Glycine 0 C--O 1.237 0.304 0 C-N-CA 120.0 -1.095 . . . . 39.450000000000003 110.398 173.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -123.99 -172.16 2.48 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.06 -0.718 . . . . 40.109999999999999 109.06 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 143' ' ' ILE . . . . . . . . . . . . . 1.3 pp -112.13 -62.84 2.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 113.383 0.883 . . . . 35.390000000000001 113.383 -170.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 144' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -81.54 127.08 32.46 Favored 'General case' 0 C--N 1.331 -0.217 0 O-C-N 121.356 -0.84 . . . . 46.880000000000003 111.13 -169.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 145' ' ' THR . . . . . . . . . . . . . 77.2 p -121.2 14.56 11.35 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 112.454 0.539 . . . . 11.02 112.454 177.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 146' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 54.48 75.86 0.57 Allowed Pre-proline 0 C--O 1.237 0.416 0 C-N-CA 126.697 1.999 . . . . 14.06 110.596 -177.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 147' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -68.75 71.03 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 N-CA-C 115.434 1.282 . . . . 11.529999999999999 115.434 -162.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 148' ' ' GLU . . . . . 0.514 ' OE1' ' ND2' ' G' ' 152' ' ' ASN . 79.6 mm-40 -104.14 8.09 36.32 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.982 0.513 . . . . 33.719999999999999 111.334 167.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 149' ' ' GLU . . . . . 0.515 ' O ' ' NZ ' ' G' ' 12' ' ' LYS . 25.9 pm0 -139.61 8.34 2.38 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.604 0.594 . . . . 21.890000000000001 112.604 -177.254 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 150' ' ' ILE . . . . . . . . . . . . . 43.9 mm -113.31 -46.59 5.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.71 0.687 . . . . 13.890000000000001 111.0 178.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 151' ' ' VAL . . . . . . . . . . . . . 48.9 t -108.47 -32.0 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.256 -1.016 . . . . 41.229999999999997 108.256 -178.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 152' ' ' ASN . . . . . 0.514 ' ND2' ' OE1' ' G' ' 148' ' ' GLU . 37.3 t-20 -66.62 -32.21 73.38 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.264 -0.425 . . . . 21.899999999999999 111.736 -176.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -74.17 99.3 1.29 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 107.503 -1.295 . . . . 17.559999999999999 107.503 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 154' ' ' SER . . . . . . . . . . . . . 35.2 t -117.08 -58.64 2.04 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.379 -0.828 . . . . 13.23 111.872 -171.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 155' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -127.52 -34.65 2.22 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 113.274 0.842 . . . . 8.0500000000000007 113.274 177.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.22 -60.51 1.33 Allowed Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 110.135 -1.186 . . . . 33.329999999999998 110.135 -157.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.42 168.52 26.86 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-O 122.128 0.849 . . . . 17.559999999999999 112.774 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 158' ' ' TYR . . . . . . . . . . . . . 15.8 m-30 -116.25 -173.91 2.45 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.866 1.267 . . . . 24.579999999999998 109.559 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 159' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -79.35 -68.89 0.62 Allowed 'General case' 0 C--O 1.235 0.331 0 C-N-CA 119.227 -0.989 . . . . 39.939999999999998 112.165 -170.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 160' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -176.33 161.72 2.3 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.835 -0.802 . . . . 38.049999999999997 108.835 -175.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 161' ' ' GLN . . . . . . . . . . . . . 65.8 tt0 -150.88 96.4 2.33 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 105.204 -2.147 . . . . 20.84 105.204 154.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 162' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -71.89 -43.59 11.01 Favored Pre-proline 0 C--O 1.243 0.726 0 N-CA-C 113.976 1.102 . . . . 11.58 113.976 -165.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 163' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -73.89 -48.57 0.23 Allowed 'Trans proline' 0 C--N 1.37 1.696 0 CA-C-N 122.144 1.801 . . . . 64.260000000000005 114.146 172.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.37 40.78 1.9 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 116.886 1.515 . . . . 42.509999999999998 116.886 -162.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 165' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -63.75 -65.88 0.62 Allowed 'General case' 0 C--O 1.237 0.424 0 CA-C-N 117.477 0.638 . . . . 17.579999999999998 110.815 173.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 166' ' ' THR . . . . . . . . . . . . . 37.3 p 52.61 50.35 18.36 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.893 1.677 . . . . 52.200000000000003 111.777 176.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 167' ' ' THR . . . . . . . . . . . . . 2.0 m -132.09 168.08 18.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.581 -1.266 . . . . 10.869999999999999 107.581 -169.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.13 -125.38 1.0 Allowed Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.743 -1.343 . . . . 3.2400000000000002 109.743 173.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 169' ' ' GLU . . . . . . . . . . . . . 14.0 tm-20 -79.16 -60.38 2.39 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 119.008 -1.077 . . . . 41.609999999999999 110.668 -178.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.18 105.91 0.95 Allowed Pre-proline 0 C--O 1.235 0.327 0 C-N-CA 123.729 0.812 . . . . 11.199999999999999 109.8 -176.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 171' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -83.44 -173.78 1.75 Allowed 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 121.367 1.378 . . . . 10.85 111.868 -158.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 172' ' ' GLY . . . . . . . . . . . . . . . 80.17 65.8 1.71 Allowed Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 114.665 -1.152 . . . . 35.560000000000002 114.982 167.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 173' ' ' THR . . . . . . . . . . . . . 10.5 t -138.38 164.45 29.3 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.95 0.881 . . . . 33.609999999999999 109.529 170.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 174' ' ' VAL . . . . . . . . . . . . . 18.7 m -74.35 154.11 88.04 Favored Pre-proline 0 C--O 1.24 0.568 0 N-CA-C 107.883 -1.155 . . . . 27.77 107.883 174.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 175' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -67.58 107.36 1.42 Allowed 'Trans proline' 0 CA--C 1.515 -0.452 0 CA-C-N 119.43 0.832 . . . . 7.8399999999999999 111.569 176.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.261 0 C-N-CA 125.728 1.611 . . . . 40.399999999999999 112.996 -171.857 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 5' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 N--CA 1.466 -0.137 0 CA-C-O 119.748 -0.188 . . . . 16.199999999999999 112.181 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 6' ' ' ILE . . . . . . . . . . . . . 88.5 mt -122.9 122.72 66.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 N-CA-C 108.003 -1.11 . . . . 23.77 108.003 178.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.44 168.81 11.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 121.934 0.874 . . . . 38.670000000000002 110.647 -178.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.67 -12.8 64.91 Favored Glycine 0 C--N 1.333 0.396 0 CA-C-N 115.39 -0.823 . . . . 32.630000000000003 114.599 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -92.34 -13.73 29.79 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 117.906 0.853 . . . . 10.359999999999999 112.333 173.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -78.67 -5.71 53.78 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 113.708 1.003 . . . . 43.640000000000001 113.708 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -127.07 123.05 61.54 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.971 -1.122 . . . . 8.4199999999999999 107.971 -176.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' LYS . . . . . 0.48 ' NZ ' ' O ' ' H' ' 149' ' ' GLU . 53.7 mtmt -133.07 162.07 32.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 34.189999999999998 109.773 177.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' TYR . . . . . . . . . . . . . 16.6 m-30 -112.42 96.88 6.25 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.527 -0.916 . . . . 16.859999999999999 108.527 -166.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' LEU . . . . . . . . . . . . . 98.7 mt -75.6 130.6 39.05 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.005 -0.678 . . . . 65.400000000000006 109.252 175.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' PHE . . . . . . . . . . . . . 21.9 m-30 -112.06 156.45 22.19 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.433 -0.58 . . . . 25.18 109.433 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -151.13 136.03 17.35 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 109.065 -0.717 . . . . 26.989999999999998 109.065 175.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' SER . . . . . 0.467 ' O ' ' NZ ' ' H' ' 90' ' ' LYS . 41.1 t -75.57 155.76 35.67 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.588 0.709 . . . . 16.859999999999999 111.02 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 pt -77.24 -12.64 14.08 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 115.491 -0.777 . . . . 16.859999999999999 113.052 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.8 -6.73 12.09 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 112.581 0.585 . . . . 65.379999999999995 112.581 -170.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.59 -47.66 25.71 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 119.907 -0.717 . . . . 14.619999999999999 111.787 -172.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.46 44.76 29.49 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.82 1.248 . . . . 8.3100000000000005 111.45 -169.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' THR . . . . . . . . . . . . . 68.7 p -126.03 123.47 38.5 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.927 -0.768 . . . . 28.629999999999999 108.927 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.44 75.99 2.14 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.322 -0.466 . . . . 12.1 113.052 -178.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' SER . . . . . . . . . . . . . 91.7 p -127.55 -30.72 2.55 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 120.68 -0.408 . . . . 14.99 111.473 -177.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.52 74.95 0.71 Allowed Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 126.679 1.991 . . . . 35.289999999999999 112.292 -174.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -70.41 105.47 1.6 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 CA-C-N 119.624 0.901 . . . . 16.859999999999999 112.83 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -85.21 168.03 15.14 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.852 -0.795 . . . . 16.859999999999999 108.852 163.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -111.11 141.57 24.55 Favored Pre-proline 0 N--CA 1.448 -0.532 1 C-N-CA 110.815 -4.354 . . . . 16.809999999999999 110.46 -171.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -73.71 166.72 29.04 Favored 'Trans proline' 0 C--O 1.234 0.289 0 CA-C-N 118.79 0.604 . . . . 18.690000000000001 113.418 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . 54.45 54.5 9.28 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.708 1.203 . . . . 18.73 111.609 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' TYR . . . . . . . . . . . . . 1.8 m-30 -69.49 164.1 23.88 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 122.777 1.275 . . . . 38.689999999999998 111.562 176.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' GLN . . . . . . . . . . . . . 8.4 tp-100 -132.3 -165.02 1.53 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 103.566 -2.753 . . . . 16.640000000000001 103.566 175.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' THR . . . . . . . . . . . . . 13.2 t -67.25 167.33 12.48 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-O 122.595 1.188 . . . . 38.600000000000001 112.161 -172.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -132.59 -170.88 2.52 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.101 -1.409 . . . . 36.950000000000003 108.521 -169.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' GLY . . . . . . . . . . . . . . . 178.06 132.16 1.66 Allowed Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 111.05 -0.82 . . . . 21.66 111.05 168.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' SER . . . . . . . . . . . . . 66.1 m -123.44 84.69 2.31 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 105.912 -1.884 . . . . 16.859999999999999 105.912 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' VAL . . . . . . . . . . . . . 3.5 m -91.88 109.3 21.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.372 -0.974 . . . . 16.859999999999999 108.372 -172.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' SER . . . . . . . . . . . . . 49.1 m -98.85 92.21 5.44 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.084 -1.08 . . . . 16.859999999999999 108.084 -167.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' GLY . . . . . . . . . . . . . . . -94.36 98.95 2.39 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.053 -1.07 . . . . 40.710000000000001 113.511 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -101.45 119.08 38.22 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.095 -1.076 . . . . 13.09 108.095 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 41' ' ' ARG . . . . . 0.429 ' NH2' ' OE2' ' C' ' 123' ' ' GLU . 93.8 mtm-85 -76.82 178.17 7.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.51 0.671 . . . . 56.060000000000002 109.429 -175.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 42' ' ' GLU . . . . . . . . . . . . . 24.4 pt-20 -156.86 155.45 31.48 Favored 'General case' 0 C--N 1.33 -0.26 0 O-C-N 121.519 -0.738 . . . . 4.9299999999999997 109.836 -176.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 43' ' ' LEU . . . . . . . . . . . . . 55.0 mt -91.55 112.43 24.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.55 -0.75 . . . . 18.100000000000001 109.155 170.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 44' ' ' PHE . . . . . . . . . . . . . 67.4 t80 -117.19 116.66 27.71 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 107.43 -1.322 . . . . 29.989999999999998 107.43 174.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 45' ' ' ASP . . . . . . . . . . . . . 75.2 m-20 -132.02 177.59 7.44 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 108.138 -1.06 . . . . 16.879999999999999 108.138 -172.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 46' ' ' GLU . . . . . . . . . . . . . 57.5 mp0 -126.08 -39.34 2.09 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 114.381 1.252 . . . . 18.239999999999998 114.381 -169.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 47' ' ' GLN . . . . . . . . . . . . . 90.3 mm-40 66.05 23.54 11.09 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.613 1.165 . . . . 42.469999999999999 113.967 156.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 48' ' ' THR . . . . . . . . . . . . . 54.9 p 50.66 38.85 20.2 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 124.637 1.175 . . . . 17.050000000000001 111.142 -166.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 49' ' ' LYS . . . . . . . . . . . . . 47.7 mmtm -139.19 -165.38 1.84 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 106.728 -1.582 . . . . 11.44 106.728 -176.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 50' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -75.53 -28.47 59.09 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 120.022 -0.671 . . . . 19.039999999999999 112.075 172.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 51' ' ' GLY . . . . . . . . . . . . . . . 159.64 162.92 12.63 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 115.962 1.145 . . . . 5.6799999999999997 115.962 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 52' ' ' ARG . . . . . . . . . . . . . 19.8 tpp85 -126.93 56.82 1.48 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.096 -1.446 . . . . 16.859999999999999 107.096 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 53' ' ' ILE . . . . . . . . . . . . . 6.7 tt -68.84 -6.71 6.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.467 0 C-N-CA 124.147 0.979 . . . . 63.969999999999999 112.894 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 54' ' ' LEU . . . . . . . . . . . . . 7.6 mp -60.28 -27.13 67.02 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.664 1.186 . . . . 49.310000000000002 113.425 -171.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.09 119.38 11.68 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-O 121.753 0.641 . . . . 20.289999999999999 114.47 -168.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 56' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.95 166.91 28.14 Favored 'Trans proline' 0 C--N 1.326 -0.647 0 C-N-CA 120.763 0.975 . . . . 10.69 109.892 170.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 57' ' ' GLY . . . . . . . . . . . . . . . -134.52 171.44 22.28 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 108.849 -1.7 . . . . 37.890000000000001 108.849 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 58' ' ' SER . . . . . . . . . . . . . 45.7 t -72.43 146.84 46.67 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 119.474 -0.89 . . . . 16.859999999999999 109.55 173.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 59' ' ' VAL . . . . . . . . . . . . . 2.8 p -102.38 121.17 53.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.461 0 N-CA-C 108.22 -1.03 . . . . 6.4299999999999997 108.22 -178.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 60' ' ' ALA . . . . . . . . . . . . . . . -118.96 109.2 15.69 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.855 -1.535 . . . . 6.0199999999999996 106.855 175.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 61' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -108.2 119.98 41.03 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.301 -1.0 . . . . 62.57 108.301 -174.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 62' ' ' SER . . . . . 0.501 ' OG ' ' OE1' ' H' ' 133' ' ' GLN . 62.4 m -102.97 164.58 11.52 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.121 0.969 . . . . 24.25 110.043 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 63' ' ' GLY . . . . . . . . . . . . . . . -137.12 123.0 2.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 120.125 -1.036 . . . . 16.859999999999999 112.781 175.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 64' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -99.44 94.83 6.63 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.16 -1.422 . . . . 44.189999999999998 107.16 171.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 65' ' ' VAL . . . . . . . . . . . . . 95.4 t -106.05 116.33 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 108.095 -1.076 . . . . 9.0099999999999998 108.095 -177.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 66' ' ' THR . . . . . . . . . . . . . 67.6 p -115.52 143.42 45.35 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.262 -0.644 . . . . 16.859999999999999 109.262 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 67' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -153.4 -170.81 3.71 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 109.336 -0.616 . . . . 15.68 109.336 174.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 68' ' ' TYR . . . . . . . . . . . . . 15.5 m-30 -116.17 134.1 55.3 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.823 0.849 . . . . 8.8100000000000005 109.625 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.36 115.62 4.22 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.786 -0.721 . . . . 16.84 113.758 -176.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 70' ' ' LYS . . . . . 0.435 ' O ' ' NE2' ' H' ' 76' ' ' GLN . 38.6 ttmt -92.63 149.53 21.28 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.679 -0.86 . . . . 11.94 108.679 173.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 71' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -68.1 -16.4 64.0 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 114.128 1.158 . . . . 26.48 114.128 -168.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.24 -139.48 4.81 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.286 -1.126 . . . . 8.1099999999999994 110.286 176.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 73' ' ' ASP . . . . . . . . . . . . . 30.2 t0 59.9 74.38 0.45 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 125.17 1.388 . . . . 18.640000000000001 111.148 168.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.17 10.74 0.04 OUTLIER 'General case' 0 C--O 1.234 0.287 0 N-CA-C 117.48 2.4 . . . . 50.460000000000001 117.48 -159.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.16 94.26 Favored Glycine 0 C--N 1.338 0.678 0 C-N-CA 120.318 -0.944 . . . . 12.0 112.647 170.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 76' ' ' GLN . . . . . 0.435 ' NE2' ' O ' ' H' ' 70' ' ' LYS . 21.8 pt20 -68.81 -24.3 64.37 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 120.033 -0.667 . . . . 41.689999999999998 111.774 172.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -74.44 -23.82 58.98 Favored 'General case' 0 CA--C 1.517 -0.327 0 C-N-CA 119.807 -0.757 . . . . 19.670000000000002 111.279 171.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 78' ' ' ALA . . . . . . . . . . . . . . . -74.03 -32.59 63.41 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 120.47 -0.492 . . . . 8.9199999999999999 111.059 169.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 79' ' ' ILE . . . . . . . . . . . . . 51.1 mm -63.21 -45.71 97.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 CA-C-O 121.116 0.484 . . . . 15.390000000000001 110.483 172.015 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -76.48 -20.18 57.26 Favored 'General case' 0 C--O 1.234 0.276 0 O-C-N 121.908 -0.495 . . . . 33.450000000000003 111.963 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 81' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -72.73 -31.58 65.07 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 120.078 -0.649 . . . . 12.140000000000001 111.27 167.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.44 -29.59 59.74 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 119.357 -0.937 . . . . 14.369999999999999 111.63 175.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 83' ' ' TYR . . . . . 0.446 ' OH ' ' O ' ' G' ' 38' ' ' SER . 82.2 t80 -95.48 -59.81 1.8 Allowed 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.222 -0.591 . . . . 16.859999999999999 112.186 -173.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 84' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -73.45 -34.15 65.26 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 122.314 -0.241 . . . . 30.859999999999999 111.509 -170.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 85' ' ' ASN . . . . . . . . . . . . . 34.2 m120 -83.32 -47.69 11.22 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.027 -0.669 . . . . 11.16 111.17 171.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.57 96.9 2.3 Favored Glycine 0 N--CA 1.45 -0.374 0 O-C-N 122.141 -0.349 . . . . 14.58 113.688 178.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 87' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -148.85 -162.04 1.47 Allowed 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.071 -1.455 . . . . 15.51 107.071 -178.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 88' ' ' GLN . . . . . . . . . . . . . 62.7 mt-30 -127.7 -178.98 4.7 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.738 0.78 . . . . 26.23 110.871 166.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 89' ' ' ILE . . . . . . . . . . . . . 60.1 mt -129.08 135.23 62.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 115.19 -0.914 . . . . 11.220000000000001 109.457 -172.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 90' ' ' LYS . . . . . 0.467 ' NZ ' ' O ' ' H' ' 17' ' ' SER . 36.6 mtmm -84.48 116.89 23.34 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.352 -0.981 . . . . 18.75 108.352 163.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 91' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -114.37 133.02 56.0 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.424 1.09 . . . . 12.74 110.79 -164.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 92' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -132.44 124.26 28.27 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.136 0.974 . . . . 29.059999999999999 110.317 -172.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 93' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -109.39 92.49 4.07 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 108.107 -1.071 . . . . 16.859999999999999 108.107 170.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 94' ' ' VAL . . . . . . . . . . . . . 21.4 m -107.66 163.96 5.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 122.122 0.963 . . . . 29.43 109.445 -174.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 95' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -111.73 167.9 9.99 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.985 -1.007 . . . . 16.859999999999999 111.255 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 96' ' ' THR . . . . . . . . . . . . . 26.9 m -101.49 -29.44 11.99 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.008 -0.996 . . . . 15.460000000000001 112.647 -174.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -70.01 155.83 7.45 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 CA-C-O 121.71 0.767 . . . . 16.859999999999999 110.249 -177.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 98' ' ' LYS . . . . . 0.585 ' NZ ' ' O ' ' H' ' 99' ' ' ASN . 29.5 tptp -90.76 125.06 35.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.683 -0.69 . . . . 8.25 109.749 -177.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 99' ' ' ASN . . . . . 0.585 ' O ' ' NZ ' ' H' ' 98' ' ' LYS . 34.6 m120 -85.53 171.12 11.99 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.874 0.845 . . . . 11.539999999999999 110.074 172.247 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 100' ' ' GLU . . . . . . . . . . . . . 57.4 mp0 -105.28 -14.96 15.19 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 113.572 0.953 . . . . 3.2200000000000002 113.572 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 101' ' ' ASN . . . . . . . . . . . . . 20.2 p30 -93.29 -47.04 7.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 118.143 0.429 . . . . 23.879999999999999 111.545 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 102' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -112.28 -175.08 2.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.954 -0.758 . . . . 55.170000000000002 108.954 174.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 103' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -79.92 -55.21 5.13 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 120.426 -0.509 . . . . 35.899999999999999 110.18 169.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 104' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -133.07 -172.88 3.04 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 108.22 -1.03 . . . . 23.109999999999999 108.22 -178.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 105' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -149.9 164.64 34.87 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.474 0.654 . . . . 48.439999999999998 109.266 177.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 106' ' ' ALA . . . . . . . . . . . . . . . -155.82 158.54 38.27 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.256 -0.884 . . . . 28.359999999999999 111.309 -162.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 107' ' ' GLN . . . . . 0.479 ' OE1' ' OH ' ' I' ' 118' ' ' TYR . 87.5 mt-30 -119.23 126.26 51.11 Favored 'General case' 0 C--O 1.236 0.379 0 N-CA-C 107.015 -1.476 . . . . 21.32 107.015 159.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 108' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -112.25 155.07 24.64 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 123.585 0.754 . . . . 12.32 110.202 -164.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 109' ' ' GLY . . . . . . . . . . . . . . . -168.29 162.57 36.35 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 119.507 -1.33 . . . . 7.1299999999999999 112.639 172.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 110' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -101.91 109.05 20.69 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 114.885 -0.658 . . . . 20.079999999999998 109.496 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 111' ' ' ALA . . . . . . . . . . . . . . . -107.23 156.54 18.73 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.528 0.68 . . . . 59.579999999999998 111.77 -166.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 112' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -136.9 138.28 40.51 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 107.349 -1.352 . . . . 17.890000000000001 107.349 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 113' ' ' ILE . . . . . . . . . . . . . 80.4 mt -88.77 128.22 41.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 109.953 -0.388 . . . . 5.2699999999999996 109.953 -169.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 114' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -71.28 -64.57 0.89 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 119.881 -0.728 . . . . 20.329999999999998 110.533 163.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 115' ' ' SER . . . . . . . . . . . . . 74.5 m -140.38 152.12 45.51 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-O 121.639 0.733 . . . . 2.9199999999999999 110.627 -170.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 116' ' ' ARG . . . . . . . . . . . . . 8.6 tmm_? -125.49 94.51 4.16 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 104.807 -2.294 . . . . 16.859999999999999 104.807 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 117' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -117.52 107.36 14.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.689 -1.226 . . . . 34.770000000000003 107.689 -173.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 118' ' ' TYR . . . . . 0.457 ' OH ' ' OE1' ' G' ' 107' ' ' GLN . 13.6 p90 -111.53 144.0 41.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.599 0.714 . . . . 4.9100000000000001 111.829 177.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 119' ' ' SER . . . . . . . . . . . . . 39.5 t -97.03 126.97 42.55 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-N 114.616 -1.175 . . . . 6.3700000000000001 109.591 176.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 120' ' ' ASP . . . . . . . . . . . . . 59.3 t0 -104.99 98.13 7.89 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 106.063 -1.829 . . . . 27.989999999999998 106.063 170.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.5 -153.88 13.55 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-O 121.864 0.702 . . . . 32.420000000000002 112.155 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -116.19 -59.45 3.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 107.955 -1.128 . . . . 22.960000000000001 107.955 177.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 123' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -102.97 -32.33 9.79 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 113.005 0.743 . . . . 64.75 113.005 -175.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 124' ' ' GLY . . . . . . . . . . . . . . . -75.04 145.82 34.08 Favored Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 109.228 -1.549 . . . . 58.969999999999999 109.228 165.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.96 165.99 23.91 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 119.806 -0.758 . . . . 16.859999999999999 110.26 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 126' ' ' VAL . . . . . . . . . . . . . 27.9 m -68.78 149.1 11.38 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 CA-C-N 115.234 -0.894 . . . . 16.859999999999999 109.908 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 127' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -138.19 129.71 27.83 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.841 -0.429 . . . . 30.969999999999999 109.841 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 128' ' ' ILE . . . . . . . . . . . . . 93.5 mt -98.63 122.55 50.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.146 -0.687 . . . . 16.859999999999999 109.146 -177.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 129' ' ' SER . . . . . . . . . . . . . 69.2 m -100.67 132.79 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.309 -0.997 . . . . 6.4100000000000001 108.309 170.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 130' ' ' ILE . . . . . . . . . . . . . 96.0 mt -132.82 127.94 56.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 108.678 -0.86 . . . . 16.859999999999999 108.678 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 131' ' ' SER . . . . . . . . . . . . . 57.0 m -92.59 145.46 24.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 116.089 -0.505 . . . . 24.390000000000001 109.729 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 132' ' ' LEU . . . . . . . . . . . . . 7.2 mp -129.86 151.41 50.45 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 116.03 -0.532 . . . . 22.57 110.212 -178.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 133' ' ' GLN . . . . . 0.501 ' OE1' ' OG ' ' H' ' 62' ' ' SER . 18.7 mm100 -142.05 123.7 15.07 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 123.89 0.876 . . . . 3.25 109.106 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 134' ' ' VAL . . . . . . . . . . . . . 12.4 p -132.57 148.67 31.72 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 109.032 -0.729 . . . . 14.470000000000001 109.032 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -62.64 -59.17 4.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 CA-C-O 121.212 0.53 . . . . 16.859999999999999 110.923 176.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.58 137.09 4.8 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.581 -0.819 . . . . 16.859999999999999 111.53 -178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 137' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -67.07 149.33 50.73 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.44 0.638 . . . . 21.989999999999998 110.35 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 138' ' ' LEU . . . . . . . . . . . . . 31.9 tp -133.58 127.75 33.75 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.546 -1.279 . . . . 16.859999999999999 107.546 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -81.55 76.89 8.46 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 122.345 1.069 . . . . 10.83 109.402 -170.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 140' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -98.51 77.02 2.29 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.209 -0.905 . . . . 30.300000000000001 108.779 -177.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.53 106.85 2.04 Favored Glycine 0 C--O 1.237 0.311 0 N-CA-C 110.419 -1.072 . . . . 20.899999999999999 110.419 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -117.29 -173.15 2.35 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 109.112 -0.699 . . . . 16.579999999999998 109.112 -176.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 143' ' ' ILE . . . . . . . . . . . . . 1.3 pp -111.79 -62.29 2.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 N-CA-C 113.217 0.821 . . . . 29.280000000000001 113.217 -169.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 144' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -81.52 125.46 30.52 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 121.355 -0.841 . . . . 19.390000000000001 111.106 -169.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 145' ' ' THR . . . . . . . . . . . . . 68.0 p -120.76 17.1 11.91 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 112.685 0.624 . . . . 30.43 112.685 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 146' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 54.48 76.2 0.54 Allowed Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 126.572 1.949 . . . . 8.9399999999999995 110.891 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 147' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -68.46 72.98 0.88 Allowed 'Trans proline' 0 C--N 1.347 0.486 0 N-CA-C 115.411 1.274 . . . . 9.5600000000000005 115.411 -162.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 148' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.97 10.67 28.32 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.022 -0.536 . . . . 26.899999999999999 111.548 167.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 149' ' ' GLU . . . . . 0.48 ' O ' ' NZ ' ' H' ' 12' ' ' LYS . 26.1 pm0 -139.74 7.64 2.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 112.829 0.678 . . . . 12.56 112.829 -177.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 150' ' ' ILE . . . . . . . . . . . . . 43.1 mm -111.36 -47.39 6.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.816 0.734 . . . . 11.42 111.129 -178.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 151' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.84 -29.04 2.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.488 0 N-CA-C 108.228 -1.027 . . . . 29.260000000000002 108.228 -176.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 152' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -66.22 -32.48 73.93 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.252 -0.431 . . . . 16.93 111.635 -177.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -74.91 98.74 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-O 122.211 1.005 . . . . 16.859999999999999 108.448 171.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 154' ' ' SER . . . . . . . . . . . . . 41.5 t -118.98 -61.75 1.61 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.723 -0.672 . . . . 22.09 112.32 -178.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 155' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -128.72 -37.7 1.74 Allowed 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 113.738 1.014 . . . . 33.479999999999997 113.738 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 156' ' ' GLY . . . . . . . . . . . . . . . 93.09 -53.91 2.52 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.583 -1.407 . . . . 16.859999999999999 109.583 -160.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.2 155.5 24.41 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-O 122.095 0.831 . . . . 16.859999999999999 112.584 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 158' ' ' TYR . . . . . . . . . . . . . 20.4 m-30 -118.79 -171.2 2.05 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.948 1.699 . . . . 20.890000000000001 108.481 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 159' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -78.8 -71.4 0.44 Allowed 'General case' 0 C--O 1.236 0.368 0 C-N-CA 118.54 -1.264 . . . . 23.050000000000001 112.459 -169.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 160' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -178.09 163.65 1.74 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.643 0.777 . . . . 25.309999999999999 109.165 -175.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 161' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -149.63 94.46 2.19 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 105.306 -2.109 . . . . 17.710000000000001 105.306 153.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 162' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -66.21 -42.93 53.04 Favored Pre-proline 0 C--O 1.244 0.796 0 N-CA-C 114.318 1.229 . . . . 33.509999999999998 114.318 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 163' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -73.79 -42.51 0.8 Allowed 'Trans proline' 0 C--N 1.364 1.38 0 CA-C-N 122.206 1.824 . . . . 29.170000000000002 113.261 172.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 164' ' ' GLY . . . . . . . . . . . . . . . -129.8 40.51 1.67 Allowed Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 117.941 1.936 . . . . 30.18 117.941 -165.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -62.99 -63.48 1.19 Allowed 'General case' 0 C--O 1.238 0.471 0 CA-C-N 118.324 1.062 . . . . 16.859999999999999 110.574 171.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 166' ' ' THR . . . . . . . . . . . . . 41.3 p 53.82 51.03 15.63 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.86 1.664 . . . . 55.520000000000003 111.711 173.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 167' ' ' THR . . . . . . . . . . . . . 1.8 m -134.27 166.27 23.2 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 107.818 -1.179 . . . . 18.579999999999998 107.818 -168.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.78 -125.49 1.15 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.634 -1.387 . . . . 33.57 109.634 170.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 169' ' ' GLU . . . . . . . . . . . . . 16.6 tm-20 -77.65 -60.81 2.21 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 119.362 -0.935 . . . . 30.670000000000002 110.975 -179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.65 105.0 0.65 Allowed Pre-proline 0 C--O 1.236 0.348 0 C-N-CA 124.051 0.94 . . . . 5.6500000000000004 109.654 -172.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 171' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -83.7 -174.26 1.87 Allowed 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 121.392 1.395 . . . . 18.190000000000001 111.912 -155.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 172' ' ' GLY . . . . . . . . . . . . . . . 73.9 66.74 1.92 Allowed Glycine 0 N--CA 1.446 -0.661 0 CA-C-N 114.49 -1.232 . . . . 29.359999999999999 114.863 167.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 173' ' ' THR . . . . . . . . . . . . . 11.3 t -133.35 166.85 21.55 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.776 0.798 . . . . 8.7899999999999991 109.259 170.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 m -72.1 153.58 92.55 Favored Pre-proline 0 C--O 1.24 0.573 0 CA-C-N 114.89 -1.05 . . . . 22.5 108.231 176.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 175' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_exo -63.89 111.92 1.69 Allowed 'Trans proline' 0 C--N 1.35 0.649 0 CA-C-N 119.347 0.802 . . . . 44.920000000000002 111.264 175.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.195 0 C-N-CA 125.609 1.564 . . . . 44.530000000000001 111.821 -171.217 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 5' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo . . . . . 0 N--CA 1.466 -0.092 0 CA-C-O 119.583 -0.257 . . . . 23.329999999999998 112.409 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 6' ' ' ILE . . . . . . . . . . . . . 96.7 mt -125.27 122.0 61.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.464 0 N-CA-C 108.088 -1.078 . . . . 7.1200000000000001 108.088 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 7' ' ' MET . . . . . 0.436 ' N ' ' OD2' ' I' ' 10' ' ' ASP . 39.3 mmt -93.0 170.83 9.36 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 121.817 0.817 . . . . 40.909999999999997 110.604 -177.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.97 -14.0 67.43 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.476 -0.784 . . . . 7.6900000000000004 114.581 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -90.76 -13.96 32.98 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 117.819 0.81 . . . . 7.6799999999999997 112.382 172.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' ASP . . . . . 0.436 ' OD2' ' N ' ' I' ' 7' ' ' MET . 82.8 m-20 -77.88 -7.17 56.34 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 113.751 1.019 . . . . 33.109999999999999 113.751 -170.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' VAL . . . . . . . . . . . . . 80.9 t -128.22 124.64 62.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.908 -1.145 . . . . 11.83 107.908 -176.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' LYS . . . . . 0.524 ' NZ ' ' O ' ' I' ' 149' ' ' GLU . 52.7 mtmt -133.24 162.12 32.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.599 0.714 . . . . 4.3399999999999999 110.221 176.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' TYR . . . . . . . . . . . . . 19.0 m-30 -112.69 94.76 5.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.008 -0.996 . . . . 17.0 108.458 -165.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' LEU . . . . . 0.429 ' O ' ' CB ' ' I' ' 92' ' ' TRP . 97.6 mt -77.1 131.58 38.43 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.083 -0.647 . . . . 58.600000000000001 109.5 177.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' PHE . . . . . . . . . . . . . 22.0 m-30 -112.83 155.37 24.75 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.395 -0.595 . . . . 13.06 109.395 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' GLN . . . . . . . . . . . . . 71.0 tp60 -148.6 137.5 21.57 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 109.21 -0.663 . . . . 35.810000000000002 109.21 174.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' SER . . . . . 0.502 ' O ' ' NZ ' ' I' ' 90' ' ' LYS . 40.0 t -77.0 155.19 32.78 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.646 0.736 . . . . 12.949999999999999 111.194 -178.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 pt -78.77 -13.13 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.457 -0.792 . . . . 17.0 113.031 178.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -113.42 -6.72 13.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.454 0.538 . . . . 57.909999999999997 112.454 -172.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.84 -47.97 23.42 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 119.964 -0.694 . . . . 27.52 111.853 -171.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.09 45.32 28.96 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.811 1.245 . . . . 18.719999999999999 111.428 -168.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' THR . . . . . . . . . . . . . 72.8 p -127.59 123.96 36.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 108.985 -0.746 . . . . 10.9 108.985 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.32 76.58 2.15 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 121.528 -0.367 . . . . 9.7400000000000002 113.377 -178.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' SER . . . . . . . . . . . . . 95.4 p -128.39 -30.61 2.36 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 120.562 -0.455 . . . . 23.98 112.181 -176.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.86 74.97 0.7 Allowed Pre-proline 0 C--O 1.236 0.394 0 C-N-CA 126.812 2.045 . . . . 33.079999999999998 112.485 -173.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -70.5 106.14 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 CA-C-N 119.473 0.848 . . . . 3.4900000000000002 113.032 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -87.85 169.72 11.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.101 -0.703 . . . . 11.210000000000001 109.101 164.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -112.78 143.76 29.68 Favored Pre-proline 0 N--CA 1.449 -0.497 1 C-N-CA 111.426 -4.109 . . . . 33.390000000000001 110.475 -172.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.34 161.83 41.76 Favored 'Trans proline' 0 CA--C 1.518 -0.315 0 CA-C-N 118.946 0.659 . . . . 53.299999999999997 113.679 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . 55.61 59.83 3.65 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.781 1.232 . . . . 7.0700000000000003 111.708 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -71.34 167.34 19.73 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 122.624 1.202 . . . . 40.619999999999997 111.085 173.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -136.79 -162.67 1.31 Allowed 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 103.636 -2.727 . . . . 29.07 103.636 177.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' THR . . . . . . . . . . . . . 15.3 t -64.66 162.56 15.51 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-O 122.631 1.205 . . . . 36.869999999999997 112.033 -172.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -134.79 -172.46 3.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.018 -1.446 . . . . 37.640000000000001 108.182 -162.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' GLY . . . . . . . . . . . . . . . 171.02 134.46 1.77 Allowed Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.399 -0.905 . . . . 17.370000000000001 112.283 166.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' SER . . . . . . . . . . . . . 64.9 m -121.87 84.64 2.28 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 105.77 -1.937 . . . . 17.0 105.77 173.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' VAL . . . . . . . . . . . . . 3.2 m -89.7 108.24 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 108.395 -0.965 . . . . 17.0 108.395 -173.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' SER . . . . . . . . . . . . . 48.3 m -98.01 95.99 7.85 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.923 -1.14 . . . . 17.0 107.923 -170.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' GLY . . . . . . . . . . . . . . . -99.18 102.63 2.6 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.153 -1.022 . . . . 29.57 112.964 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -102.43 126.25 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.159 -1.052 . . . . 16.350000000000001 108.159 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 41' ' ' ARG . . . . . . . . . . . . . 93.2 mtm-85 -80.76 -176.67 5.95 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.488 0.661 . . . . 62.130000000000003 109.368 -177.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 42' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -161.59 160.48 28.93 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.493 -0.558 . . . . 60.399999999999999 109.493 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 43' ' ' LEU . . . . . . . . . . . . . 47.2 mt -88.23 128.09 35.46 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.848 -0.615 . . . . 4.9400000000000004 109.417 175.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 44' ' ' PHE . . . . . . . . . . . . . 67.3 t80 -120.84 107.52 12.82 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 108.307 -0.998 . . . . 75.540000000000006 108.307 -173.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 45' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -134.76 162.19 33.07 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 116.264 -0.426 . . . . 17.0 110.596 -169.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 46' ' ' GLU . . . . . . . . . . . . . 59.8 mp0 -125.91 -42.73 1.88 Allowed 'General case' 0 C--O 1.236 0.348 0 N-CA-C 113.721 1.008 . . . . 15.68 113.721 -175.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 47' ' ' GLN . . . . . . . . . . . . . 91.1 mm-40 67.45 24.69 8.73 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 124.401 1.08 . . . . 41.359999999999999 113.871 153.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 48' ' ' THR . . . . . . . . . . . . . 65.3 p 51.29 37.35 18.48 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 124.818 1.247 . . . . 43.18 111.35 -169.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 49' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -139.44 -164.75 1.73 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 106.936 -1.505 . . . . 8.4100000000000001 106.936 -176.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 50' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -73.87 -23.55 59.61 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 120.41 -0.516 . . . . 14.0 111.807 171.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 51' ' ' GLY . . . . . . . . . . . . . . . 145.23 155.81 6.61 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 121.389 -0.434 . . . . 12.970000000000001 113.398 179.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 52' ' ' ARG . . . . . . . . . . . . . 21.7 tpp85 -124.7 54.22 1.41 Allowed 'General case' 0 C--O 1.235 0.294 0 N-CA-C 105.349 -2.093 . . . . 5.1699999999999999 105.349 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 53' ' ' ILE . . . . . . . . . . . . . 7.4 tt -73.58 -5.07 6.08 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.127 -0.942 . . . . 26.870000000000001 111.474 -177.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 54' ' ' LEU . . . . . . . . . . . . . 8.2 mp -51.78 -29.32 18.5 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 127.619 2.368 . . . . 61.280000000000001 114.451 -175.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 55' ' ' GLY . . . . . . . . . . . . . . . -64.27 123.01 26.82 Favored Glycine 0 N--CA 1.44 -1.095 0 CA-C-O 121.567 0.537 . . . . 17.239999999999998 113.98 -166.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.18 156.31 65.44 Favored 'Trans proline' 0 C--N 1.326 -0.656 0 C-N-CA 121.063 1.176 . . . . 13.15 110.376 171.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 57' ' ' GLY . . . . . . . . . . . . . . . -126.23 172.27 17.99 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 108.477 -1.849 . . . . 17.02 108.477 178.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 58' ' ' SER . . . . . . . . . . . . . 42.1 t -74.88 144.32 43.42 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 119.817 -0.753 . . . . 17.620000000000001 110.063 176.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 59' ' ' VAL . . . . . . . . . . . . . 2.6 p -95.65 121.25 46.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 108.357 -0.979 . . . . 17.0 108.357 -178.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.2 114.72 22.34 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 106.905 -1.517 . . . . 10.789999999999999 106.905 175.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 61' ' ' ASP . . . . . . . . . . . . . 51.5 t0 -117.93 120.48 37.98 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.863 -0.792 . . . . 53.380000000000003 108.863 -169.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 62' ' ' SER . . . . . 0.505 ' OG ' ' OE1' ' I' ' 133' ' ' GLN . 67.9 m -105.16 166.74 10.19 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.068 0.947 . . . . 7.5499999999999998 110.532 -176.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 63' ' ' GLY . . . . . . . . . . . . . . . -139.32 123.27 2.48 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.05 -0.977 . . . . 9.1099999999999994 113.058 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 64' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -101.73 97.24 7.66 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 107.552 -1.277 . . . . 63.469999999999999 107.552 173.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 65' ' ' VAL . . . . . . . . . . . . . 93.7 t -107.24 116.29 50.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 108.282 -1.007 . . . . 17.0 108.282 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 66' ' ' THR . . . . . . . . . . . . . 70.1 p -115.62 143.11 45.82 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.247 -0.649 . . . . 22.760000000000002 109.247 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 67' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -153.52 -170.32 3.56 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.364 0.602 . . . . 12.710000000000001 109.405 175.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -116.01 134.15 55.26 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.676 0.79 . . . . 17.940000000000001 109.367 179.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.03 107.74 2.73 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.953 -0.641 . . . . 38.990000000000002 113.911 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -83.73 147.25 27.74 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 108.812 -0.81 . . . . 5.0199999999999996 108.812 173.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -67.01 -16.7 64.53 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.126 1.158 . . . . 21.0 114.126 -168.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.78 -141.53 5.45 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.108 -1.197 . . . . 17.670000000000002 110.108 176.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 73' ' ' ASP . . . . . . . . . . . . . 31.4 t0 59.49 72.65 0.52 Allowed 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.157 1.383 . . . . 17.0 111.106 169.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.75 11.25 0.04 OUTLIER 'General case' 0 C--O 1.235 0.313 0 N-CA-C 117.285 2.328 . . . . 31.59 117.285 -159.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.21 -38.7 90.79 Favored Glycine 0 C--N 1.338 0.647 0 C-N-CA 120.355 -0.926 . . . . 22.739999999999998 112.727 169.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 76' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -69.4 -24.71 63.89 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.69 -0.804 . . . . 8.2799999999999994 111.325 173.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 77' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -73.51 -24.98 60.22 Favored 'General case' 0 CA--C 1.516 -0.347 0 C-N-CA 119.597 -0.841 . . . . 25.75 111.356 171.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.71 -33.37 66.4 Favored 'General case' 0 C--O 1.239 0.551 0 C-N-CA 120.274 -0.57 . . . . 15.109999999999999 111.041 169.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 79' ' ' ILE . . . . . . . . . . . . . 51.1 mm -63.76 -43.84 98.09 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.087 0.47 . . . . 4.6200000000000001 110.435 172.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 80' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -75.05 -20.78 59.4 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 121.88 -0.512 . . . . 37.770000000000003 112.01 179.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 81' ' ' ASP . . . . . . . . . . . . . 55.3 m-20 -71.35 -33.45 69.61 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 120.165 -0.614 . . . . 27.129999999999999 111.224 168.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 82' ' ' ALA . . . . . . . . . . . . . . . -73.6 -36.42 65.52 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 119.416 -0.913 . . . . 4.6600000000000001 111.634 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 83' ' ' TYR . . . . . . . . . . . . . 84.2 t80 -83.79 -61.9 1.71 Allowed 'General case' 0 C--O 1.235 0.317 0 C-N-CA 120.486 -0.486 . . . . 17.0 112.139 -176.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 84' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -74.65 -40.01 61.73 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 111.763 0.283 . . . . 18.960000000000001 111.763 -166.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 85' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -76.66 -47.11 23.13 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.952 -0.699 . . . . 34.93 111.015 172.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.19 96.3 2.28 Favored Glycine 0 N--CA 1.45 -0.421 0 O-C-N 122.261 -0.275 . . . . 21.670000000000002 113.34 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 87' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.87 -161.8 1.42 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 107.052 -1.462 . . . . 19.940000000000001 107.052 -177.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 88' ' ' GLN . . . . . . . . . . . . . 63.5 mt-30 -129.64 177.64 7.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.777 0.798 . . . . 25.100000000000001 111.045 167.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -127.35 136.93 59.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 115.215 -0.902 . . . . 18.469999999999999 109.446 -173.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 90' ' ' LYS . . . . . 0.502 ' NZ ' ' O ' ' I' ' 17' ' ' SER . 36.9 mtmm -85.26 118.7 24.97 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.436 -0.95 . . . . 12.1 108.436 164.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 91' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -111.94 133.56 54.05 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.342 1.057 . . . . 9.8900000000000006 110.671 -166.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 92' ' ' TRP . . . . . 0.429 ' CB ' ' O ' ' I' ' 14' ' ' LEU . 91.7 m95 -132.48 125.67 31.2 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 124.183 0.993 . . . . 25.760000000000002 109.894 -173.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 93' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -112.65 90.63 3.4 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 108.142 -1.059 . . . . 17.0 108.142 171.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 94' ' ' VAL . . . . . . . . . . . . . 20.3 m -105.11 165.24 3.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 122.061 0.934 . . . . 22.420000000000002 109.385 -174.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 95' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -110.72 165.14 12.07 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.07 -0.968 . . . . 21.140000000000001 111.583 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 96' ' ' THR . . . . . . . . . . . . . 31.9 m -98.22 -33.07 11.25 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 114.901 -1.045 . . . . 18.199999999999999 112.751 -176.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 97' ' ' VAL . . . . . . . . . . . . . 34.1 m -70.3 155.6 7.55 Favored 'Isoleucine or valine' 0 C--O 1.237 0.431 0 CA-C-O 121.81 0.814 . . . . 2.0099999999999998 110.197 -177.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 98' ' ' LYS . . . . . 0.592 ' NZ ' ' O ' ' I' ' 99' ' ' ASN . 29.6 tptp -88.28 129.39 35.38 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.626 -0.715 . . . . 17.920000000000002 109.633 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 99' ' ' ASN . . . . . 0.592 ' O ' ' NZ ' ' I' ' 98' ' ' LYS . 35.4 m120 -91.37 173.16 8.06 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.76 0.79 . . . . 24.739999999999998 110.022 172.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 100' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -108.59 -16.39 14.21 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 113.667 0.988 . . . . 25.489999999999998 113.667 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 101' ' ' ASN . . . . . . . . . . . . . 21.3 p30 -86.73 -47.2 9.32 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 118.188 0.449 . . . . 14.220000000000001 111.054 170.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 102' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -119.44 -174.77 2.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.588 -0.893 . . . . 56.619999999999997 108.588 174.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 103' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -74.3 -57.63 3.82 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 120.184 -0.606 . . . . 34.07 110.318 169.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 104' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -132.62 -170.77 2.5 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 108.863 -0.791 . . . . 6.6200000000000001 108.863 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 105' ' ' ASP . . . . . 0.419 ' N ' ' OD1' ' I' ' 105' ' ' ASP . 17.4 p-10 -151.73 166.53 31.03 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 121.471 0.653 . . . . 44.490000000000002 109.241 177.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 106' ' ' ALA . . . . . . . . . . . . . . . -157.96 154.75 28.29 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 115.337 -0.847 . . . . 17.0 111.159 -163.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 107' ' ' GLN . . . . . 0.466 ' OE1' ' OH ' ' J' ' 118' ' ' TYR . 88.4 mt-30 -112.86 124.82 53.49 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.915 -1.513 . . . . 17.34 106.915 159.484 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 108' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -111.41 154.44 24.64 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 123.543 0.737 . . . . 8.8900000000000006 110.268 -165.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 109' ' ' GLY . . . . . . . . . . . . . . . -164.79 168.78 39.2 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 119.537 -1.315 . . . . 18.719999999999999 112.714 172.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 110' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.14 110.86 22.2 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.626 -0.787 . . . . 23.190000000000001 109.058 168.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 111' ' ' ALA . . . . . . . . . . . . . . . -109.93 155.94 21.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 121.607 0.718 . . . . 38.299999999999997 111.826 -165.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 112' ' ' TYR . . . . . . . . . . . . . 51.7 t80 -136.02 137.75 41.5 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 107.267 -1.383 . . . . 3.8500000000000001 107.267 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 113' ' ' ILE . . . . . . . . . . . . . 84.2 mt -86.72 128.03 39.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.881 -0.414 . . . . 5.6100000000000003 109.881 -170.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 114' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -71.15 -64.36 0.93 Allowed 'General case' 0 C--O 1.235 0.29 0 C-N-CA 119.832 -0.747 . . . . 26.68 110.555 164.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 115' ' ' SER . . . . . . . . . . . . . 74.3 m -141.94 153.46 44.36 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.612 0.72 . . . . 25.879999999999999 110.375 -170.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 116' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -127.05 89.95 3.07 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 104.725 -2.324 . . . . 12.69 104.725 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 117' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -112.63 106.85 15.36 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.733 -1.21 . . . . 24.530000000000001 107.733 -174.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 118' ' ' TYR . . . . . 0.479 ' OH ' ' OE1' ' H' ' 107' ' ' GLN . 11.9 p90 -111.88 143.59 42.59 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.621 0.724 . . . . 17.0 111.939 176.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 119' ' ' SER . . . . . . . . . . . . . 35.7 t -99.3 128.79 45.46 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-N 114.633 -1.167 . . . . 5.54 109.869 178.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 120' ' ' ASP . . . . . . . . . . . . . 59.3 t0 -103.56 96.33 6.66 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.217 -1.771 . . . . 25.940000000000001 106.217 170.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 121' ' ' GLY . . . . . . . . . . . . . . . -80.09 -159.94 20.29 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-O 121.842 0.69 . . . . 22.530000000000001 112.252 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 122' ' ' VAL . . . . . . . . . . . . . 88.8 t -116.45 -63.0 2.06 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 108.614 -0.884 . . . . 21.859999999999999 108.614 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 123' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -96.37 -22.37 17.21 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 112.718 0.636 . . . . 41.280000000000001 112.718 -176.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 124' ' ' GLY . . . . . . . . . . . . . . . -86.55 155.18 27.87 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 109.526 -1.43 . . . . 17.0 109.526 165.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.04 167.97 20.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.683 0.754 . . . . 14.91 110.213 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 126' ' ' VAL . . . . . . . . . . . . . 35.9 m -69.21 153.17 9.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.492 0 CA-C-N 115.287 -0.87 . . . . 17.18 109.585 -177.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 127' ' ' GLU . . . . . . . . . . . . . 21.9 pt-20 -143.79 133.45 23.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 109.859 -0.423 . . . . 47.07 109.859 -178.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 128' ' ' ILE . . . . . . . . . . . . . 90.1 mt -102.05 123.23 55.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.371 -0.603 . . . . 17.0 109.371 -176.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 129' ' ' SER . . . . . . . . . . . . . 66.3 m -102.3 132.71 48.1 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.55 -0.907 . . . . 31.149999999999999 108.55 170.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 130' ' ' ILE . . . . . . . . . . . . . 91.4 mt -133.89 128.12 53.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.793 -0.817 . . . . 17.0 108.793 -179.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 131' ' ' SER . . . . . . . . . . . . . 62.1 m -94.26 147.6 23.03 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.087 -0.506 . . . . 20.210000000000001 109.84 175.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 132' ' ' LEU . . . . . . . . . . . . . 7.1 mp -132.57 152.02 51.75 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 115.999 -0.546 . . . . 30.199999999999999 110.142 -176.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 133' ' ' GLN . . . . . 0.505 ' OE1' ' OG ' ' I' ' 62' ' ' SER . 18.9 mm100 -141.24 126.83 18.93 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.794 0.837 . . . . 17.0 109.105 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 134' ' ' VAL . . . . . . . . . . . . . 13.1 p -133.06 147.54 31.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.406 0 N-CA-C 109.185 -0.672 . . . . 17.0 109.185 -177.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 135' ' ' ILE . . . . . . . . . . . . . 22.1 mm -63.45 -60.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.038 -0.528 . . . . 29.199999999999999 110.877 176.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 136' ' ' GLY . . . . . . . . . . . . . . . -158.33 134.43 3.85 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.56 -0.829 . . . . 17.0 111.59 -177.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 137' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -67.09 146.61 54.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.442 0.639 . . . . 17.0 110.278 175.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 138' ' ' LEU . . . . . . . . . . . . . 34.7 tp -133.12 127.91 34.96 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.74 -1.207 . . . . 17.0 107.74 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -82.13 78.42 8.81 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 122.434 1.112 . . . . 8.5700000000000003 109.376 -171.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 140' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -97.2 81.08 2.99 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.125 -0.943 . . . . 12.82 108.594 -178.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.33 110.81 3.26 Favored Glycine 0 C--O 1.236 0.273 0 C-N-CA 120.053 -1.07 . . . . 45.729999999999997 110.478 175.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 142' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -122.79 -174.11 2.85 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.14 -0.689 . . . . 13.18 109.14 -176.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 143' ' ' ILE . . . . . . . . . . . . . 1.3 pp -112.11 -62.1 2.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.342 0 N-CA-C 113.468 0.914 . . . . 1.9099999999999999 113.468 -169.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 144' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -82.18 129.17 34.76 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 121.373 -0.829 . . . . 32.890000000000001 111.217 -169.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 145' ' ' THR . . . . . . . . . . . . . 77.8 p -122.24 16.51 10.66 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.678 0.622 . . . . 26.609999999999999 112.678 177.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 146' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 54.49 75.79 0.58 Allowed Pre-proline 0 C--O 1.238 0.457 0 C-N-CA 126.638 1.975 . . . . 20.07 110.505 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 147' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -68.53 73.63 0.87 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 N-CA-C 115.543 1.324 . . . . 17.0 115.543 -161.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 148' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -111.46 12.0 21.44 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 116.077 -0.511 . . . . 27.600000000000001 111.653 168.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 149' ' ' GLU . . . . . 0.524 ' O ' ' NZ ' ' I' ' 12' ' ' LYS . 25.8 pm0 -139.59 4.28 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 112.789 0.663 . . . . 17.0 112.789 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 150' ' ' ILE . . . . . . . . . . . . . 44.3 mm -112.36 -44.67 5.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 118.708 0.685 . . . . 41.170000000000002 111.027 -178.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 151' ' ' VAL . . . . . . . . . . . . . 47.1 t -108.17 -32.98 2.5 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 N-CA-C 108.68 -0.859 . . . . 8.8300000000000001 108.68 -174.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 152' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -67.54 -31.43 71.52 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 116.324 -0.398 . . . . 31.5 111.801 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -75.35 98.69 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-O 122.11 0.957 . . . . 18.399999999999999 109.156 176.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 154' ' ' SER . . . . . . . . . . . . . 39.5 t -118.89 -60.86 1.71 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.784 -0.644 . . . . 17.0 112.522 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 155' ' ' LYS . . . . . . . . . . . . . 5.8 tppp? -129.12 -38.95 1.58 Allowed 'General case' 0 C--O 1.236 0.379 0 N-CA-C 113.652 0.982 . . . . 15.31 113.652 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.97 -54.16 2.93 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.97 -1.252 . . . . 47.270000000000003 109.97 -161.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.81 155.5 29.14 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-O 122.075 0.819 . . . . 3.3100000000000001 112.727 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 158' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -120.59 -172.99 2.48 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 126.018 1.727 . . . . 1.98 108.949 -176.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 159' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -79.24 -70.84 0.48 Allowed 'General case' 0 C--O 1.236 0.359 0 C-N-CA 118.734 -1.187 . . . . 19.199999999999999 112.534 -169.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 160' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -176.17 160.36 2.2 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 108.893 -0.78 . . . . 12.289999999999999 108.893 -175.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -151.64 95.65 2.15 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 105.111 -2.181 . . . . 22.710000000000001 105.111 156.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 162' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -71.12 -44.51 13.97 Favored Pre-proline 0 C--O 1.244 0.771 0 N-CA-C 114.258 1.207 . . . . 39.710000000000001 114.258 -162.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 163' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -72.72 -48.27 0.31 Allowed 'Trans proline' 0 C--N 1.366 1.48 0 CA-C-N 122.269 1.846 . . . . 41.219999999999999 112.675 171.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.08 41.32 1.81 Allowed Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 117.719 1.847 . . . . 24.719999999999999 117.719 -163.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 165' ' ' GLN . . . . . . . . . . . . . 9.8 tp-100 -63.54 -58.92 5.45 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 117.981 0.891 . . . . 26.670000000000002 110.572 171.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 166' ' ' THR . . . . . . . . . . . . . 35.9 p 54.88 43.78 29.42 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.867 1.667 . . . . 46.93 111.66 173.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -128.47 160.36 32.54 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 107.792 -1.188 . . . . 17.0 107.792 -168.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 168' ' ' GLY . . . . . . . . . . . . . . . -80.32 -129.88 0.86 Allowed Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 111.015 -0.834 . . . . 38.890000000000001 111.015 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -75.07 -62.67 1.47 Allowed 'General case' 0 C--O 1.235 0.302 0 C-N-CA 119.815 -0.754 . . . . 25.129999999999999 110.978 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.3 106.14 1.11 Allowed Pre-proline 0 C--O 1.236 0.344 0 C-N-CA 123.35 0.66 . . . . 26.940000000000001 109.507 -177.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 171' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -81.89 -171.56 1.23 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.466 1.444 . . . . 8.7200000000000006 112.269 -158.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 172' ' ' GLY . . . . . . . . . . . . . . . 81.26 65.34 1.69 Allowed Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.566 -1.197 . . . . 18.010000000000002 116.028 168.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -137.7 167.14 22.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.869 0.842 . . . . 22.620000000000001 109.351 167.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 174' ' ' VAL . . . . . . . . . . . . . 27.3 m -73.82 159.44 84.3 Favored Pre-proline 0 C--O 1.24 0.585 0 CA-C-N 114.772 -1.103 . . . . 11.699999999999999 108.626 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 175' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -61.66 125.22 16.19 Favored 'Trans proline' 0 C--N 1.353 0.789 0 CA-C-N 119.591 0.89 . . . . 32.140000000000001 110.708 169.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.3 0 C-N-CA 125.355 1.462 . . . . 57.590000000000003 111.159 -166.129 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 5' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo . . . . . 0 N--CA 1.466 -0.133 0 CA-C-O 119.576 -0.26 . . . . 30.719999999999999 112.43 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 6' ' ' ILE . . . . . . . . . . . . . 96.8 mt -122.67 119.62 58.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.103 -1.073 . . . . 15.06 108.103 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 7' ' ' MET . . . . . 0.451 ' N ' ' OD2' ' J' ' 10' ' ' ASP . 39.3 mmt -89.75 170.62 10.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.769 0.795 . . . . 47.850000000000001 110.496 -178.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.63 -13.5 65.87 Favored Glycine 0 C--N 1.333 0.402 0 CA-C-N 115.492 -0.776 . . . . 5.0099999999999998 114.548 178.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 9' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -91.96 -13.82 30.49 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 117.729 0.764 . . . . 8.7200000000000006 112.25 172.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 10' ' ' ASP . . . . . 0.451 ' OD2' ' N ' ' J' ' 7' ' ' MET . 84.1 m-20 -78.16 -3.93 45.0 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.792 1.034 . . . . 25.010000000000002 113.792 -171.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 11' ' ' VAL . . . . . . . . . . . . . 91.9 t -131.3 125.88 57.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 107.722 -1.214 . . . . 36.759999999999998 107.722 -177.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 12' ' ' LYS . . . . . 0.492 ' NZ ' ' O ' ' J' ' 149' ' ' GLU . 53.2 mtmt -133.89 160.58 37.24 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.682 0.753 . . . . 25.210000000000001 110.318 175.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 13' ' ' TYR . . . . . . . . . . . . . 17.7 m-30 -110.49 97.37 6.83 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.03 -1.1 . . . . 16.57 108.03 -166.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 14' ' ' LEU . . . . . . . . . . . . . 97.6 mt -78.66 132.08 36.9 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.034 -0.666 . . . . 38.68 109.457 178.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 15' ' ' PHE . . . . . . . . . . . . . 21.2 m-30 -112.07 151.56 29.23 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.781 -0.451 . . . . 22.489999999999998 109.781 -178.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 16' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -147.13 137.05 23.17 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.086 -0.709 . . . . 16.710000000000001 109.086 175.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 17' ' ' SER . . . . . 0.522 ' O ' ' NZ ' ' J' ' 90' ' ' LYS . 38.5 t -75.25 153.75 37.86 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-O 121.639 0.733 . . . . 16.57 111.153 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 18' ' ' ILE . . . . . . . . . . . . . 46.5 pt -80.04 -6.53 9.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.409 -0.814 . . . . 16.57 112.917 176.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 19' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -116.05 -9.56 11.7 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 112.667 0.617 . . . . 45.68 112.667 -173.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.01 15.89 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 119.834 -0.746 . . . . 19.739999999999998 112.01 -170.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.52 49.19 20.96 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.667 1.187 . . . . 7.7300000000000004 111.235 -166.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 22' ' ' THR . . . . . . . . . . . . . 67.7 p -127.94 120.86 28.52 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.853 -0.795 . . . . 3.3799999999999999 108.853 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.4 75.45 2.21 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.262 -0.494 . . . . 16.57 112.629 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 24' ' ' SER . . . . . . . . . . . . . 88.6 p -127.84 -29.8 2.56 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 120.892 -0.323 . . . . 42.469999999999999 111.6 -176.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.43 74.37 0.81 Allowed Pre-proline 0 C--O 1.236 0.388 0 C-N-CA 126.868 2.067 . . . . 14.69 112.388 -173.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 26' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -70.79 106.06 1.77 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 CA-C-N 119.54 0.871 . . . . 16.57 112.682 177.033 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 27' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -83.52 162.52 20.87 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.044 -0.725 . . . . 13.06 109.044 166.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 28' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -108.21 132.23 21.22 Favored Pre-proline 0 C--N 1.349 0.557 1 C-N-CA 108.786 -5.166 . . . . 18.039999999999999 110.256 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 177.51 6.0 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 120.713 0.942 . . . . 19.91 114.207 -175.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 52.86 62.12 2.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 124.552 1.141 . . . . 3.7799999999999998 111.211 -172.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 31' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -68.56 163.98 22.35 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.894 1.331 . . . . 22.350000000000001 111.693 176.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 32' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -136.59 -162.9 1.33 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 103.329 -2.841 . . . . 26.390000000000001 103.329 170.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 33' ' ' THR . . . . . . . . . . . . . 15.0 t -65.71 163.51 16.38 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-O 122.611 1.196 . . . . 30.789999999999999 111.998 -173.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 34' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -133.35 -170.62 2.51 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.033 -1.439 . . . . 37.560000000000002 108.103 -165.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 35' ' ' GLY . . . . . . . . . . . . . . . 171.8 134.85 1.85 Allowed Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.85 -0.69 . . . . 16.469999999999999 111.741 168.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 36' ' ' SER . . . . . . . . . . . . . 67.0 m -125.89 84.43 2.27 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 105.93 -1.878 . . . . 16.57 105.93 174.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 37' ' ' VAL . . . . . . . . . . . . . 4.2 m -91.24 112.92 26.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 108.404 -0.961 . . . . 16.57 108.404 -171.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 38' ' ' SER . . . . . . . . . . . . . 47.1 m -101.25 93.41 5.42 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 108.169 -1.049 . . . . 12.93 108.169 -167.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.33 100.03 2.49 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 119.693 -1.241 . . . . 26.600000000000001 113.12 -177.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 40' ' ' GLU . . . . . . . . . . . . . 78.3 tt0 -104.08 117.5 34.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.116 -1.068 . . . . 6.7300000000000004 108.116 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 41' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -77.34 -179.72 5.89 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.705 0.764 . . . . 44.799999999999997 109.426 -176.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 42' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -158.9 160.82 36.54 Favored 'General case' 0 N--CA 1.451 -0.376 0 O-C-N 121.716 -0.615 . . . . 22.91 109.433 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 43' ' ' LEU . . . . . . . . . . . . . 41.6 mt -89.33 124.35 34.35 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 115.862 -0.608 . . . . 0.97999999999999998 109.476 175.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 44' ' ' PHE . . . . . . . . . . . . . 78.0 t80 -120.72 107.89 13.32 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.037 -1.098 . . . . 66.870000000000005 108.037 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 45' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -135.74 164.47 27.81 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.147 -0.479 . . . . 22.300000000000001 109.834 -170.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 46' ' ' GLU . . . . . . . . . . . . . 59.6 mp0 -125.71 -41.95 1.96 Allowed 'General case' 0 C--O 1.235 0.323 0 N-CA-C 113.747 1.018 . . . . 34.25 113.747 -172.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 47' ' ' GLN . . . . . . . . . . . . . 93.0 mm-40 68.18 25.87 7.2 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.431 1.092 . . . . 40.68 113.703 154.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 48' ' ' THR . . . . . . . . . . . . . 66.2 p 50.91 38.05 19.04 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.718 1.207 . . . . 36.909999999999997 111.225 -168.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm -139.66 -165.06 1.8 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.777 -1.564 . . . . 12.44 106.777 -175.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 50' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -74.42 -20.96 59.85 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 120.39 -0.524 . . . . 12.93 111.946 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 51' ' ' GLY . . . . . . . . . . . . . . . 145.78 158.25 7.63 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 121.158 -0.544 . . . . 7.6699999999999999 113.651 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 52' ' ' ARG . . . . . . . . . . . . . 20.5 tpp85 -128.36 55.67 1.67 Allowed 'General case' 0 C--O 1.234 0.275 0 N-CA-C 106.695 -1.595 . . . . 20.539999999999999 106.695 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 53' ' ' ILE . . . . . . . . . . . . . 5.3 tt -70.95 -6.95 8.05 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 CA-C-N 115.333 -0.849 . . . . 31.890000000000001 112.019 -176.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 54' ' ' LEU . . . . . . . . . . . . . 8.7 mp -55.68 -28.55 56.16 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 127.215 2.206 . . . . 57.079999999999998 114.328 -170.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 55' ' ' GLY . . . . . . . . . . . . . . . -64.81 125.37 30.46 Favored Glycine 0 N--CA 1.441 -0.976 0 CA-C-O 121.552 0.529 . . . . 16.57 114.206 -165.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 56' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.53 159.74 52.42 Favored 'Trans proline' 0 C--N 1.325 -0.675 0 C-N-CA 120.998 1.132 . . . . 16.57 110.225 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 57' ' ' GLY . . . . . . . . . . . . . . . -131.45 170.86 21.35 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 109.209 -1.556 . . . . 32.979999999999997 109.209 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 58' ' ' SER . . . . . . . . . . . . . 44.7 t -73.36 149.68 42.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 119.76 -0.776 . . . . 13.43 109.903 175.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 59' ' ' VAL . . . . . . . . . . . . . 3.0 p -104.42 121.69 56.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 108.254 -1.017 . . . . 16.57 108.254 -177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 60' ' ' ALA . . . . . . . . . . . . . . . -117.8 112.23 20.12 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.299 -1.741 . . . . 48.82 106.299 172.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 61' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -115.16 123.49 49.05 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.164 -1.05 . . . . 42.039999999999999 108.164 -171.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 62' ' ' SER . . . . . 0.451 ' OG ' ' OE1' ' J' ' 133' ' ' GLN . 68.3 m -111.13 162.29 15.07 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 10.82 110.509 -171.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.17 118.52 2.04 Favored Glycine 0 N--CA 1.443 -0.891 0 CA-C-N 115.109 -0.95 . . . . 16.57 112.296 177.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 64' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -99.14 96.72 7.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.096 -1.446 . . . . 39.719999999999999 107.096 172.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 65' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.0 116.89 52.44 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 108.333 -0.988 . . . . 16.57 108.333 -177.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 66' ' ' THR . . . . . . . . . . . . . 52.7 p -115.07 142.32 46.8 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.871 -0.788 . . . . 17.359999999999999 108.871 176.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 67' ' ' TYR . . . . . . . . . . . . . 55.0 p90 -153.66 -171.43 3.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.398 0.618 . . . . 23.219999999999999 109.418 176.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 68' ' ' TYR . . . . . . . . . . . . . 16.3 m-30 -115.99 131.48 56.93 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 123.776 0.83 . . . . 11.199999999999999 109.271 178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.67 113.73 3.76 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.909 -0.662 . . . . 10.640000000000001 114.5 -174.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 70' ' ' LYS . . . . . 0.476 ' O ' ' NE2' ' J' ' 76' ' ' GLN . 38.5 ttmt -85.92 151.07 24.05 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.803 -0.814 . . . . 23.57 108.803 175.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -68.75 -15.85 63.63 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 114.02 1.119 . . . . 34.460000000000001 114.02 -169.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.79 -138.26 4.75 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 110.132 -1.187 . . . . 16.57 110.132 175.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 t0 60.31 73.47 0.48 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.056 1.342 . . . . 5.1200000000000001 111.319 167.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.18 9.95 0.04 OUTLIER 'General case' 0 C--O 1.235 0.322 0 N-CA-C 117.574 2.435 . . . . 22.960000000000001 117.574 -158.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.97 -42.93 97.1 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 120.31 -0.948 . . . . 14.789999999999999 112.711 170.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 76' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' J' ' 70' ' ' LYS . 21.4 pt20 -69.79 -23.54 63.36 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 119.791 -0.764 . . . . 46.189999999999998 111.785 173.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -70.39 -28.9 65.45 Favored 'General case' 0 CA--C 1.518 -0.271 0 C-N-CA 119.88 -0.728 . . . . 31.440000000000001 111.323 170.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.62 -32.2 65.75 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 120.461 -0.495 . . . . 22.59 111.354 171.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 79' ' ' ILE . . . . . . . . . . . . . 51.8 mm -64.21 -43.53 97.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 121.14 0.495 . . . . 8.3100000000000005 110.426 173.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 80' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -73.05 -22.48 60.61 Favored 'General case' 0 C--O 1.235 0.29 0 O-C-N 121.89 -0.506 . . . . 26.079999999999998 112.0 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 81' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 -69.94 -33.3 71.96 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 120.315 -0.554 . . . . 33.880000000000003 111.298 168.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 82' ' ' ALA . . . . . . . . . . . . . . . -74.01 -36.5 64.49 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 119.466 -0.894 . . . . 8.7400000000000002 111.64 175.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 83' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -83.92 -61.17 1.89 Allowed 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.146 -0.622 . . . . 10.35 112.004 -175.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -74.95 -40.6 60.69 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 111.794 0.294 . . . . 20.52 111.794 -167.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 85' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -77.84 -43.57 29.97 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 119.932 -0.707 . . . . 10.720000000000001 111.189 173.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 86' ' ' GLY . . . . . . . . . . . . . . . 107.94 96.48 2.45 Favored Glycine 0 N--CA 1.45 -0.397 0 O-C-N 122.302 -0.249 . . . . 8.3800000000000008 113.344 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 87' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -149.22 -161.41 1.34 Allowed 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 107.05 -1.463 . . . . 7.0599999999999996 107.05 -178.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 88' ' ' GLN . . . . . . . . . . . . . 68.9 mt-30 -131.73 179.32 6.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.827 0.822 . . . . 13.19 111.146 167.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 89' ' ' ILE . . . . . . . . . . . . . 69.9 mt -129.25 134.82 63.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 115.089 -0.96 . . . . 13.029999999999999 109.682 -171.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 90' ' ' LYS . . . . . 0.522 ' NZ ' ' O ' ' J' ' 17' ' ' SER . 36.7 mtmm -84.59 116.27 23.07 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 108.402 -0.962 . . . . 12.630000000000001 108.402 164.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 91' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -110.95 134.47 52.55 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 124.374 1.07 . . . . 15.58 110.719 -166.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 92' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -131.94 128.99 39.66 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.093 0.957 . . . . 16.780000000000001 110.033 -174.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 93' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -115.59 93.42 4.27 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 108.453 -0.943 . . . . 16.57 108.453 170.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 94' ' ' VAL . . . . . . . . . . . . . 20.1 m -107.26 163.1 5.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 122.208 1.004 . . . . 23.829999999999998 109.559 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 95' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -107.36 156.9 18.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.869 -1.059 . . . . 13.800000000000001 110.966 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 96' ' ' THR . . . . . . . . . . . . . 27.9 m -93.59 -31.19 14.61 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.15 -0.932 . . . . 32.659999999999997 112.616 -177.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -70.07 153.01 8.8 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.817 0.817 . . . . 0.84999999999999998 109.936 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 98' ' ' LYS . . . . . 0.565 ' NZ ' ' O ' ' J' ' 99' ' ' ASN . 29.6 tptp -87.37 129.39 35.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.593 -0.731 . . . . 16.280000000000001 109.758 -173.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 99' ' ' ASN . . . . . 0.565 ' O ' ' NZ ' ' J' ' 98' ' ' LYS . 35.0 m120 -92.3 173.47 7.79 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.766 0.793 . . . . 20.329999999999998 109.995 171.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 100' ' ' GLU . . . . . . . . . . . . . 58.1 mp0 -110.09 -15.09 14.1 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.633 0.975 . . . . 20.280000000000001 113.633 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 101' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -86.38 -58.85 2.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 118.245 0.475 . . . . 31.02 110.979 168.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 102' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -102.55 -176.69 3.18 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.806 -1.183 . . . . 34.340000000000003 107.806 170.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 103' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -71.84 -60.5 2.2 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 118.982 -1.087 . . . . 34.399999999999999 110.356 163.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 104' ' ' TYR . . . . . . . . . . . . . 35.3 m-85 -128.58 -172.02 2.61 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.386 -0.968 . . . . 28.219999999999999 108.386 -175.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 105' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' J' ' 105' ' ' ASP . 16.1 p-10 -151.08 168.87 23.29 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.016 -0.735 . . . . 19.84 109.016 177.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 106' ' ' ALA . . . . . . . . . . . . . . . -154.6 155.71 35.22 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.81 0.814 . . . . 0.01 111.259 -163.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 107' ' ' GLN . . . . . 0.451 ' OE1' ' OH ' ' K' ' 118' ' ' TYR . 88.0 mt-30 -113.01 122.68 48.34 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.619 -1.623 . . . . 27.879999999999999 106.619 158.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 108' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -111.38 153.21 26.37 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 123.825 0.85 . . . . 6.21 110.113 -165.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 109' ' ' GLY . . . . . . . . . . . . . . . -163.87 167.83 38.13 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.591 -1.29 . . . . 16.57 112.822 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 110' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -109.23 109.47 20.42 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.646 -0.777 . . . . 16.140000000000001 108.971 168.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.63 155.77 21.91 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.572 0.701 . . . . 46.109999999999999 111.778 -165.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 112' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -134.26 137.93 44.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 114.326 -1.306 . . . . 15.970000000000001 107.552 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 113' ' ' ILE . . . . . . . . . . . . . 81.0 mt -84.66 128.37 39.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 N-CA-C 109.96 -0.385 . . . . 16.57 109.96 -169.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.1 -64.72 0.85 Allowed 'General case' 0 C--O 1.234 0.276 0 C-N-CA 119.871 -0.732 . . . . 18.82 110.601 164.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 115' ' ' SER . . . . . . . . . . . . . 72.2 m -142.38 151.16 41.59 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.567 0.698 . . . . 29.440000000000001 110.385 -168.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 116' ' ' ARG . . . . . . . . . . . . . 9.1 tmm_? -126.45 88.53 2.85 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 104.951 -2.24 . . . . 1.6799999999999999 104.951 178.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 117' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -111.88 110.14 20.32 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 107.353 -1.351 . . . . 28.530000000000001 107.353 -175.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 118' ' ' TYR . . . . . 0.466 ' OH ' ' OE1' ' I' ' 107' ' ' GLN . 18.5 p90 -116.72 143.5 45.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.491 0.662 . . . . 16.57 111.841 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 119' ' ' SER . . . . . . . . . . . . . 37.9 t -99.06 131.34 45.18 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.719 -1.128 . . . . 2.3599999999999999 110.122 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 120' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -109.13 97.77 7.33 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 106.376 -1.713 . . . . 34.5 106.376 172.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 121' ' ' GLY . . . . . . . . . . . . . . . -81.05 -161.15 25.91 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-O 121.82 0.678 . . . . 23.550000000000001 112.164 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 122' ' ' VAL . . . . . . . . . . . . . 92.0 t -115.1 -63.19 2.02 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 N-CA-C 108.701 -0.851 . . . . 1.5800000000000001 108.701 178.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 123' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -96.23 -18.13 20.27 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.976 -0.556 . . . . 51.149999999999999 112.471 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 124' ' ' GLY . . . . . . . . . . . . . . . -92.0 157.59 24.35 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 109.587 -1.405 . . . . 24.719999999999999 109.587 163.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 125' ' ' ALA . . . . . . . . . . . . . . . -77.0 171.12 15.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.755 0.788 . . . . 25.969999999999999 110.35 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 126' ' ' VAL . . . . . . . . . . . . . 33.9 m -71.06 157.97 6.43 Favored 'Isoleucine or valine' 0 C--O 1.239 0.536 0 CA-C-N 115.37 -0.832 . . . . 18.77 109.713 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 127' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -147.19 135.46 21.64 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.596 -0.52 . . . . 51.189999999999998 109.596 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 128' ' ' ILE . . . . . . . . . . . . . 87.8 mt -104.54 124.43 59.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 109.641 -0.503 . . . . 16.57 109.641 -176.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 129' ' ' SER . . . . . . . . . . . . . 68.2 m -103.54 132.97 49.33 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.729 -0.841 . . . . 32.380000000000003 108.729 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 130' ' ' ILE . . . . . . . . . . . . . 82.1 mt -135.58 130.17 49.76 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 N-CA-C 108.681 -0.859 . . . . 16.57 108.681 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 131' ' ' SER . . . . . . . . . . . . . 55.2 m -98.05 149.43 22.48 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-O 121.026 0.441 . . . . 22.329999999999998 110.087 175.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 132' ' ' LEU . . . . . . . . . . . . . 7.8 mp -133.84 144.27 48.85 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.03 -0.532 . . . . 15.49 110.544 -177.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 133' ' ' GLN . . . . . 0.451 ' OE1' ' OG ' ' J' ' 62' ' ' SER . 29.8 mm100 -125.28 139.08 54.03 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.622 -0.881 . . . . 16.57 108.622 170.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 134' ' ' VAL . . . . . . . . . . . . . 8.8 p -135.95 149.37 27.76 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 108.91 -0.774 . . . . 18.73 108.91 177.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 135' ' ' ILE . . . . . . . . . . . . . 23.5 mm -62.46 -61.38 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.326 0 CA-C-O 121.299 0.571 . . . . 25.649999999999999 110.587 176.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.88 133.44 3.21 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.33 -0.708 . . . . 11.800000000000001 111.33 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 137' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -66.49 147.3 53.49 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 121.44 0.638 . . . . 27.02 110.675 177.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 138' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.9 130.95 38.52 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.099 -1.074 . . . . 11.710000000000001 108.099 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -83.03 81.02 8.86 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-O 122.398 1.094 . . . . 10.869999999999999 109.359 -171.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 140' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -102.74 83.02 2.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.195 -0.912 . . . . 9.0600000000000005 108.984 -177.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.96 122.6 6.65 Favored Glycine 0 C--O 1.237 0.289 0 C-N-CA 119.984 -1.103 . . . . 23.969999999999999 110.439 173.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 142' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -132.1 -171.71 2.7 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 109.342 -0.614 . . . . 14.99 109.342 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 143' ' ' ILE . . . . . . . . . . . . . 1.5 pp -112.78 -56.86 4.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.307 0 N-CA-C 113.575 0.954 . . . . 10.0 113.575 -167.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -87.48 124.97 34.01 Favored 'General case' 0 C--O 1.234 0.237 0 O-C-N 121.285 -0.884 . . . . 3.21 111.19 -172.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 145' ' ' THR . . . . . . . . . . . . . 70.6 p -119.91 18.5 12.51 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 112.553 0.575 . . . . 34.619999999999997 112.553 176.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 146' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 54.94 75.92 0.56 Allowed Pre-proline 0 C--O 1.237 0.411 0 C-N-CA 126.669 1.987 . . . . 11.85 110.782 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 147' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -68.81 69.69 1.15 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 N-CA-C 115.586 1.341 . . . . 7.2599999999999998 115.586 -163.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 148' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -107.79 7.03 28.07 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 122.952 0.501 . . . . 8.3000000000000007 111.614 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 149' ' ' GLU . . . . . 0.492 ' O ' ' NZ ' ' J' ' 12' ' ' LYS . 26.0 pm0 -138.19 7.19 2.63 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.515 0.561 . . . . 11.789999999999999 112.515 -178.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 150' ' ' ILE . . . . . . . . . . . . . 44.8 mm -113.87 -44.79 4.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 118.693 0.679 . . . . 9.6199999999999992 111.061 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 151' ' ' VAL . . . . . . . . . . . . . 48.1 t -108.16 -32.19 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 108.275 -1.009 . . . . 13.449999999999999 108.275 -176.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 152' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -67.72 -30.63 70.17 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.35 -0.386 . . . . 18.539999999999999 111.821 -176.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -73.82 100.25 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.403 0 CA-C-O 122.165 0.983 . . . . 30.18 108.464 173.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 154' ' ' SER . . . . . . . . . . . . . 38.8 t -117.51 -59.13 1.97 Allowed 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.603 -0.726 . . . . 15.74 112.176 -174.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 155' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -128.37 -36.93 1.86 Allowed 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 113.675 0.991 . . . . 22.030000000000001 113.675 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.57 -58.09 1.61 Allowed Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 110.118 -1.193 . . . . 33.789999999999999 110.118 -156.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 157' ' ' GLY . . . . . . . . . . . . . . . -92.7 162.32 26.49 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.615 -0.802 . . . . 16.57 112.666 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 158' ' ' TYR . . . . . . . . . . . . . 20.2 m-30 -117.6 -172.84 2.31 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.085 1.354 . . . . 25.68 108.807 -178.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 159' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -79.2 -70.74 0.48 Allowed 'General case' 0 C--O 1.236 0.365 0 C-N-CA 118.827 -1.149 . . . . 14.210000000000001 112.436 -167.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 160' ' ' PHE . . . . . . . . . . . . . 30.2 p90 -176.72 160.49 1.94 Allowed 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.699 0.761 . . . . 11.17 109.0 -175.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 161' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.51 100.44 2.26 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 104.747 -2.316 . . . . 26.640000000000001 104.747 155.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 162' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -72.82 -46.95 8.95 Favored Pre-proline 0 C--O 1.243 0.746 0 N-CA-C 113.985 1.105 . . . . 38.060000000000002 113.985 -161.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 163' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -75.72 -47.01 0.18 Allowed 'Trans proline' 0 C--N 1.365 1.396 0 CA-C-N 122.262 1.843 . . . . 18.109999999999999 112.936 174.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 164' ' ' GLY . . . . . . . . . . . . . . . -119.18 41.14 2.06 Favored Glycine 0 N--CA 1.448 -0.529 0 N-CA-C 116.323 1.289 . . . . 27.039999999999999 116.323 -161.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -64.62 -59.63 4.05 Favored 'General case' 0 C--O 1.238 0.481 0 C-N-CA 120.059 -0.656 . . . . 16.57 110.593 172.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 166' ' ' THR . . . . . . . . . . . . . 42.9 p 54.01 48.56 20.84 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.916 1.687 . . . . 35.560000000000002 111.697 174.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 167' ' ' THR . . . . . . . . . . . . . 2.5 m -133.85 160.53 37.37 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.069 -1.086 . . . . 11.289999999999999 108.069 -168.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 168' ' ' GLY . . . . . . . . . . . . . . . -80.66 -130.07 0.93 Allowed Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.165 -0.774 . . . . 24.379999999999999 111.165 172.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 169' ' ' GLU . . . . . . . . . . . . . 15.5 tm-20 -73.29 -62.25 1.54 Allowed 'General case' 0 C--O 1.235 0.313 0 C-N-CA 119.939 -0.705 . . . . 44.07 111.037 -178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.97 105.67 1.12 Allowed Pre-proline 0 C--O 1.235 0.333 0 C-N-CA 123.271 0.629 . . . . 6.9400000000000004 109.592 -176.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 171' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.4 -172.39 1.48 Allowed 'Trans proline' 0 C--N 1.325 -0.694 0 C-N-CA 121.484 1.456 . . . . 20.440000000000001 112.04 -159.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 172' ' ' GLY . . . . . . . . . . . . . . . 81.83 64.82 1.7 Allowed Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 114.636 -1.165 . . . . 34.549999999999997 115.84 167.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 173' ' ' THR . . . . . . . . . . . . . 11.4 t -134.89 170.19 16.25 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.712 0.768 . . . . 6.5199999999999996 109.192 168.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 174' ' ' VAL . . . . . . . . . . . . . 34.0 m -73.32 158.78 86.24 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-N 115.024 -0.989 . . . . 16.57 108.76 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 175' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -59.84 124.54 15.57 Favored 'Trans proline' 0 CA--C 1.516 -0.416 0 N-CA-C 109.754 -0.902 . . . . 11.960000000000001 109.754 164.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.312 0 C-N-CA 125.231 1.413 . . . . 26.469999999999999 110.506 -161.281 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 5' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo . . . . . 0 N--CA 1.466 -0.145 0 CA-C-O 119.791 -0.17 . . . . 1.8600000000000001 112.304 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 6' ' ' ILE . . . . . . . . . . . . . 93.9 mt -121.53 122.15 66.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 N-CA-C 107.99 -1.115 . . . . 6.3600000000000003 107.99 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 7' ' ' MET . . . . . 0.413 ' N ' ' OD2' ' K' ' 10' ' ' ASP . 39.2 mmt -90.57 170.17 10.41 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 121.866 0.841 . . . . 36.210000000000001 110.636 -177.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.15 -11.44 63.94 Favored Glycine 0 C--N 1.333 0.412 0 CA-C-N 115.375 -0.829 . . . . 17.789999999999999 114.688 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 9' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -94.62 -14.16 25.21 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 117.833 0.817 . . . . 18.920000000000002 112.256 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 10' ' ' ASP . . . . . 0.413 ' OD2' ' N ' ' K' ' 7' ' ' MET . 85.7 m-20 -77.18 -4.71 46.0 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 113.711 1.004 . . . . 27.43 113.711 -171.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 11' ' ' VAL . . . . . . . . . . . . . 69.9 t -129.04 125.32 62.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 N-CA-C 107.829 -1.174 . . . . 27.140000000000001 107.829 -176.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 12' ' ' LYS . . . . . 0.541 ' NZ ' ' O ' ' K' ' 149' ' ' GLU . 53.6 mtmt -134.1 160.66 37.1 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.487 0.661 . . . . 4.7300000000000004 110.077 176.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 13' ' ' TYR . . . . . . . . . . . . . 18.8 m-30 -110.71 98.79 7.86 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.21 -1.033 . . . . 17.789999999999999 108.21 -167.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 14' ' ' LEU . . . . . . . . . . . . . 95.7 mt -79.08 129.27 34.27 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 120.002 -0.679 . . . . 40.780000000000001 109.652 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 15' ' ' PHE . . . . . . . . . . . . . 21.9 m-30 -109.89 150.05 29.0 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.602 -0.518 . . . . 38.490000000000002 109.602 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 16' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -145.34 135.53 23.92 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 109.148 -0.686 . . . . 15.720000000000001 109.148 175.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 17' ' ' SER . . . . . 0.405 ' O ' ' NZ ' ' K' ' 90' ' ' LYS . 40.8 t -75.44 153.55 37.57 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.644 0.735 . . . . 10.6 111.013 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 18' ' ' ILE . . . . . . . . . . . . . 45.0 pt -78.63 -11.58 13.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.466 -0.788 . . . . 17.84 113.03 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 19' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -113.67 -12.22 12.85 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 112.638 0.607 . . . . 18.77 112.638 -173.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.15 -49.54 27.66 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 120.269 -0.573 . . . . 22.23 111.754 -172.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.63 48.03 22.52 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.91 1.284 . . . . 2.3999999999999999 111.557 -171.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 22' ' ' THR . . . . . . . . . . . . . 69.7 p -127.19 123.83 37.57 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 108.656 -0.868 . . . . 29.530000000000001 108.656 177.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.37 75.42 2.21 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 121.25 -0.5 . . . . 0.35999999999999999 113.254 -176.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 24' ' ' SER . . . . . . . . . . . . . 89.4 p -126.58 -29.13 2.94 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 120.868 -0.333 . . . . 21.789999999999999 111.332 -178.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.21 73.83 0.91 Allowed Pre-proline 0 C--O 1.237 0.411 0 C-N-CA 126.952 2.101 . . . . 16.710000000000001 112.281 -173.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 26' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -71.68 106.07 1.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 CA-C-N 119.498 0.856 . . . . 12.73 112.823 177.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 27' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -79.98 161.45 25.46 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 119.731 -0.788 . . . . 8.0 108.987 163.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 28' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -107.58 132.0 21.31 Favored Pre-proline 0 N--CA 1.447 -0.617 1 C-N-CA 109.352 -4.939 . . . . 9.4900000000000002 110.28 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.7 -174.64 1.55 Allowed 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 120.627 0.885 . . . . 18.539999999999999 114.309 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 51.56 60.71 3.66 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.591 1.156 . . . . 22.449999999999999 111.091 -169.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 31' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -69.24 160.83 30.46 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 122.846 1.307 . . . . 25.48 111.884 178.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 32' ' ' GLN . . . . . . . . . . . . . 7.7 tp-100 -136.94 -162.69 1.31 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 103.193 -2.891 . . . . 3.7999999999999998 103.193 170.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 33' ' ' THR . . . . . . . . . . . . . 15.3 t -65.25 162.05 18.12 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.68 1.228 . . . . 31.239999999999998 111.939 -172.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 34' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -132.18 -170.88 2.5 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.129 -1.396 . . . . 35.109999999999999 107.871 -166.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 35' ' ' GLY . . . . . . . . . . . . . . . 171.59 134.79 1.83 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.141 -1.028 . . . . 16.59 112.512 170.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 36' ' ' SER . . . . . . . . . . . . . 66.6 m -128.03 84.71 2.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.107 -1.812 . . . . 15.91 106.107 175.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 37' ' ' VAL . . . . . . . . . . . . . 3.5 m -91.79 110.52 22.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 108.46 -0.941 . . . . 12.48 108.46 -172.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 38' ' ' SER . . . . . . . . . . . . . 50.3 m -99.3 92.75 5.58 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.278 -1.008 . . . . 2.5800000000000001 108.278 -166.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 39' ' ' GLY . . . . . . . . . . . . . . . -93.28 100.31 2.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.128 -1.034 . . . . 12.960000000000001 113.757 -176.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 40' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -106.26 117.99 35.47 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.233 -1.025 . . . . 17.789999999999999 108.233 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 41' ' ' ARG . . . . . . . . . . . . . 92.4 mtm-85 -77.37 -178.65 5.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.551 0.691 . . . . 43.350000000000001 109.746 -174.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 42' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -160.27 164.13 32.9 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 121.631 -0.668 . . . . 43.490000000000002 109.623 -174.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 43' ' ' LEU . . . . . . . . . . . . . 81.6 mt -106.81 111.93 24.67 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.161 -0.681 . . . . 10.890000000000001 109.161 172.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 44' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.89 113.4 25.94 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.104 -1.443 . . . . 14.630000000000001 107.104 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 45' ' ' ASP . . . . . . . . . . . . . 78.1 m-20 -127.0 175.91 7.74 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.299 -1.0 . . . . 12.5 108.299 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 46' ' ' GLU . . . . . . . . . . . . . 58.7 mp0 -126.1 -40.29 2.01 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 114.323 1.231 . . . . 5.8099999999999996 114.323 -166.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 47' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 66.65 20.17 10.76 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.532 1.133 . . . . 45.079999999999998 113.987 155.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 48' ' ' THR . . . . . . . . . . . . . 49.8 p 50.13 41.02 23.12 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.466 1.106 . . . . 37.359999999999999 110.945 -165.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 49' ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -139.46 -166.3 2.03 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.165 -1.42 . . . . 21.75 107.165 -175.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 50' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -72.91 -27.43 61.87 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 120.605 -0.438 . . . . 26.899999999999999 111.989 172.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.29 163.19 11.56 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 121.301 -0.476 . . . . 28.579999999999998 114.068 -177.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 52' ' ' ARG . . . . . . . . . . . . . 19.0 tpp85 -133.33 57.26 1.81 Allowed 'General case' 0 C--O 1.233 0.236 0 N-CA-C 107.928 -1.138 . . . . 16.539999999999999 107.928 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 53' ' ' ILE . . . . . . . . . . . . . 6.5 tt -66.44 -5.47 3.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 C-N-CA 124.937 1.295 . . . . 32.670000000000002 113.304 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 54' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.33 -23.21 65.58 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 124.973 1.309 . . . . 55.759999999999998 113.604 -170.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.07 119.69 12.32 Favored Glycine 0 N--CA 1.44 -1.037 0 CA-C-O 121.645 0.581 . . . . 15.390000000000001 114.097 -170.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 56' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.0 164.98 34.06 Favored 'Trans proline' 0 C--N 1.325 -0.67 0 C-N-CA 120.872 1.048 . . . . 17.789999999999999 109.753 171.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 57' ' ' GLY . . . . . . . . . . . . . . . -132.04 168.14 22.59 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.11 -1.596 . . . . 41.740000000000002 109.11 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 58' ' ' SER . . . . . . . . . . . . . 44.0 t -72.8 148.34 44.64 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 119.672 -0.811 . . . . 25.75 109.591 173.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 59' ' ' VAL . . . . . . . . . . . . . 2.9 p -105.46 122.5 58.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 N-CA-C 108.228 -1.027 . . . . 20.059999999999999 108.228 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.41 110.58 15.8 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 106.745 -1.576 . . . . 6.8499999999999996 106.745 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 61' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -106.11 124.94 50.36 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.202 -1.036 . . . . 32.68 108.202 -175.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 62' ' ' SER . . . . . 0.44 ' OG ' ' OE1' ' K' ' 133' ' ' GLN . 69.8 m -107.08 163.19 13.2 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 124.19 0.996 . . . . 8.4800000000000004 110.223 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.43 123.27 3.34 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 115.029 -0.987 . . . . 24.449999999999999 112.261 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 64' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -102.84 94.55 5.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.127 -1.434 . . . . 33.439999999999998 107.127 171.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 65' ' ' VAL . . . . . . . . . . . . . 91.1 t -107.39 115.63 49.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.123 -1.066 . . . . 17.789999999999999 108.123 -177.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 66' ' ' THR . . . . . . . . . . . . . 72.5 p -116.81 142.31 47.09 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.589 -0.523 . . . . 20.120000000000001 109.589 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 67' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -152.98 -170.81 3.74 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.16 -0.616 . . . . 16.829999999999998 109.469 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 68' ' ' TYR . . . . . . . . . . . . . 17.7 m-30 -115.59 131.99 56.76 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 123.787 0.835 . . . . 13.279999999999999 109.219 177.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.16 113.26 3.61 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.552 -0.833 . . . . 10.35 113.733 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 70' ' ' LYS . . . . . 0.497 ' O ' ' NE2' ' K' ' 76' ' ' GLN . 38.5 ttmt -86.9 151.5 23.26 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.683 -0.858 . . . . 10.83 108.683 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 71' ' ' ARG . . . . . . . . . . . . . 20.6 ptp180 -68.45 -14.93 63.34 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 114.141 1.163 . . . . 20.780000000000001 114.141 -169.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 72' ' ' GLY . . . . . . . . . . . . . . . -129.11 -136.79 4.18 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 110.062 -1.215 . . . . 35.329999999999998 110.062 176.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 73' ' ' ASP . . . . . . . . . . . . . 33.5 t0 60.0 72.93 0.5 Allowed 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 125.103 1.361 . . . . 2.8500000000000001 111.12 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.64 9.63 0.06 Allowed 'General case' 0 C--O 1.234 0.275 0 N-CA-C 117.433 2.383 . . . . 36.880000000000003 117.433 -158.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.47 -41.09 96.95 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.303 -0.951 . . . . 23.98 112.62 170.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 76' ' ' GLN . . . . . 0.497 ' NE2' ' O ' ' K' ' 70' ' ' LYS . 22.0 pt20 -70.74 -23.21 62.39 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 119.81 -0.756 . . . . 17.800000000000001 111.847 173.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 77' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -70.95 -28.01 64.16 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 119.742 -0.783 . . . . 3.0499999999999998 111.237 170.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.01 -30.93 64.14 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 120.571 -0.452 . . . . 14.34 111.346 170.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 79' ' ' ILE . . . . . . . . . . . . . 49.7 mm -64.52 -45.55 95.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-O 121.057 0.456 . . . . 9.0399999999999991 110.425 172.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 80' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -73.93 -21.25 60.11 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 120.551 -0.459 . . . . 20.010000000000002 111.991 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 81' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -71.53 -31.54 67.15 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 120.088 -0.645 . . . . 22.010000000000002 111.331 168.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.0 -32.56 61.68 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 119.554 -0.858 . . . . 11.58 111.565 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 83' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -91.39 -59.54 2.12 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 120.207 -0.597 . . . . 9.9000000000000004 112.171 -174.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 84' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -74.28 -35.79 63.76 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.641 0.237 . . . . 19.129999999999999 111.641 -169.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 85' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -80.95 -44.29 18.45 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 119.984 -0.686 . . . . 18.789999999999999 111.207 171.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.12 97.07 2.48 Favored Glycine 0 N--CA 1.45 -0.413 0 O-C-N 122.266 -0.271 . . . . 8.25 113.414 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 87' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -149.13 -161.57 1.37 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 107.122 -1.436 . . . . 5.9800000000000004 107.122 -178.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 88' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -129.11 -179.04 4.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.78 0.8 . . . . 23.34 110.98 167.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 89' ' ' ILE . . . . . . . . . . . . . 58.3 mt -129.51 136.18 59.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-N 115.104 -0.953 . . . . 9.3699999999999992 109.379 -173.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 90' ' ' LYS . . . . . 0.405 ' NZ ' ' O ' ' K' ' 17' ' ' SER . 37.0 mtmm -84.8 117.77 24.05 Favored 'General case' 0 C--O 1.237 0.408 0 N-CA-C 108.213 -1.032 . . . . 22.170000000000002 108.213 163.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 91' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -112.98 134.96 54.26 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.934 0.894 . . . . 13.710000000000001 110.706 -165.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 92' ' ' TRP . . . . . . . . . . . . . 91.7 m95 -132.54 130.39 40.31 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 124.06 0.944 . . . . 17.789999999999999 110.111 -174.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 93' ' ' ARG . . . . . . . . . . . . . 78.5 ttt-85 -116.64 94.13 4.49 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 108.121 -1.066 . . . . 12.039999999999999 108.121 170.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 94' ' ' VAL . . . . . . . . . . . . . 22.5 m -106.94 163.48 5.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 122.183 0.992 . . . . 19.98 109.411 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 95' ' ' ASP . . . . . . . . . . . . . 82.7 m-20 -107.99 162.85 13.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.961 -1.018 . . . . 20.829999999999998 110.92 177.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 96' ' ' THR . . . . . . . . . . . . . 28.9 m -97.72 -31.43 12.26 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 115.007 -0.997 . . . . 24.079999999999998 112.709 -175.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 97' ' ' VAL . . . . . . . . . . . . . 34.0 m -70.66 155.2 7.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-O 121.732 0.777 . . . . 21.68 110.15 -177.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 98' ' ' LYS . . . . . 0.574 ' NZ ' ' O ' ' K' ' 99' ' ' ASN . 29.5 tptp -87.16 127.21 35.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.696 -0.683 . . . . 25.879999999999999 109.551 -177.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 99' ' ' ASN . . . . . 0.574 ' O ' ' NZ ' ' K' ' 98' ' ' LYS . 34.6 m120 -89.95 171.79 9.33 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.795 0.807 . . . . 21.309999999999999 110.048 172.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 100' ' ' GLU . . . . . . . . . . . . . 57.3 mp0 -108.91 -17.57 13.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 113.681 0.993 . . . . 48.420000000000002 113.681 178.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 101' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -84.94 -51.31 6.8 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 122.991 0.517 . . . . 25.09 111.59 170.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 102' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -113.03 -173.51 2.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.298 -1.001 . . . . 38.340000000000003 108.298 169.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 103' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -75.81 -56.49 4.63 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.085 -0.646 . . . . 31.210000000000001 110.348 168.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 104' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -131.77 -171.15 2.54 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.403 -0.962 . . . . 26.809999999999999 108.403 -178.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 105' ' ' ASP . . . . . 0.407 ' N ' ' OD1' ' K' ' 105' ' ' ASP . 18.3 p-10 -151.9 163.85 38.35 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.497 0.665 . . . . 41.969999999999999 109.268 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 106' ' ' ALA . . . . . . . . . . . . . . . -155.66 157.41 36.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.315 -0.857 . . . . 2.0899999999999999 111.142 -162.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 107' ' ' GLN . . . . . 0.475 ' OE1' ' OH ' ' L' ' 118' ' ' TYR . 86.7 mt-30 -117.49 125.97 51.8 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.085 -1.45 . . . . 12.69 107.085 160.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 108' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -113.83 153.76 28.59 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.766 0.826 . . . . 17.09 110.319 -163.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 109' ' ' GLY . . . . . . . . . . . . . . . -164.01 168.79 38.65 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 119.615 -1.279 . . . . 5.6799999999999997 112.685 174.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 110' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -110.79 110.71 21.46 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 108.807 -0.812 . . . . 13.369999999999999 108.807 168.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.75 157.58 19.62 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 121.625 0.726 . . . . 30.609999999999999 111.906 -165.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 112' ' ' TYR . . . . . . . . . . . . . 63.6 t80 -138.17 134.75 34.93 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.363 -1.289 . . . . 16.170000000000002 107.603 -179.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 113' ' ' ILE . . . . . . . . . . . . . 77.9 mt -84.96 129.03 38.41 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.99 -0.374 . . . . 11.93 109.99 -169.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -72.39 -64.22 0.99 Allowed 'General case' 0 C--O 1.235 0.328 0 C-N-CA 120.029 -0.669 . . . . 49.869999999999997 110.598 164.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 115' ' ' SER . . . . . . . . . . . . . 75.6 m -141.2 151.35 43.72 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.72 0.772 . . . . 25.920000000000002 110.435 -169.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 116' ' ' ARG . . . . . . . . . . . . . 8.6 tmm_? -126.52 92.96 3.66 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 104.653 -2.351 . . . . 27.800000000000001 104.653 177.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 117' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -116.8 110.23 18.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.61 -1.255 . . . . 39.689999999999998 107.61 -173.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 118' ' ' TYR . . . . . 0.451 ' OH ' ' OE1' ' J' ' 107' ' ' GLN . 13.9 p90 -115.29 145.09 42.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.634 0.731 . . . . 11.08 111.992 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 119' ' ' SER . . . . . . . . . . . . . 39.3 t -98.99 129.68 45.3 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 114.565 -1.198 . . . . 17.789999999999999 109.706 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 120' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -108.6 97.21 6.9 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 106.234 -1.765 . . . . 41.369999999999997 106.234 172.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 121' ' ' GLY . . . . . . . . . . . . . . . -81.71 -156.88 17.8 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-O 121.823 0.679 . . . . 19.829999999999998 112.281 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 122' ' ' VAL . . . . . . . . . . . . . 96.8 t -118.22 -63.2 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.365 0 N-CA-C 108.177 -1.046 . . . . 11.449999999999999 108.177 176.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 123' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -95.54 -17.03 21.74 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 112.677 0.621 . . . . 37.479999999999997 112.677 -174.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.58 154.69 21.06 Favored Glycine 0 N--CA 1.452 -0.276 0 N-CA-C 109.532 -1.427 . . . . 3.5 109.532 164.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.35 169.33 18.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.721 0.772 . . . . 7.9000000000000004 110.325 176.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 126' ' ' VAL . . . . . . . . . . . . . 34.7 m -70.44 155.08 7.78 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 CA-C-N 115.338 -0.846 . . . . 14.300000000000001 109.678 -175.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 127' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -144.03 132.07 21.66 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 109.677 -0.49 . . . . 26.879999999999999 109.677 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 128' ' ' ILE . . . . . . . . . . . . . 88.4 mt -102.13 123.7 55.54 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 N-CA-C 109.291 -0.633 . . . . 17.789999999999999 109.291 -176.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 129' ' ' SER . . . . . . . . . . . . . 69.8 m -102.03 133.57 46.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.496 -0.927 . . . . 24.52 108.496 170.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 130' ' ' ILE . . . . . . . . . . . . . 87.7 mt -134.68 128.54 50.92 Favored 'Isoleucine or valine' 0 C--O 1.237 0.443 0 N-CA-C 108.888 -0.782 . . . . 3.46 108.888 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 131' ' ' SER . . . . . . . . . . . . . 56.5 m -94.03 149.06 21.57 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.085 0.469 . . . . 23.199999999999999 109.974 175.015 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 132' ' ' LEU . . . . . . . . . . . . . 7.4 mp -133.96 147.07 50.99 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.162 -0.472 . . . . 11.15 110.352 -178.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 133' ' ' GLN . . . . . 0.44 ' OE1' ' OG ' ' K' ' 62' ' ' SER . 30.4 mm100 -131.04 133.11 45.41 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.882 -0.784 . . . . 17.789999999999999 108.882 174.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 134' ' ' VAL . . . . . . . . . . . . . 14.2 p -134.16 145.0 33.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 N-CA-C 109.039 -0.726 . . . . 3.9300000000000002 109.039 177.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 135' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.65 -58.16 8.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.91 -0.586 . . . . 34.350000000000001 110.763 175.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 136' ' ' GLY . . . . . . . . . . . . . . . -156.05 132.45 3.35 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.014 -1.088 . . . . 0.12 112.314 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 137' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -66.64 150.13 49.49 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.435 0.636 . . . . 30.039999999999999 110.337 173.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 138' ' ' LEU . . . . . . . . . . . . . 31.4 tp -138.39 130.24 28.14 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.057 -1.09 . . . . 8.1899999999999995 108.057 -178.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -83.42 80.24 9.16 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-O 122.357 1.075 . . . . 11.43 109.353 -171.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 140' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 -99.95 81.14 2.39 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 122.009 0.909 . . . . 20.280000000000001 108.673 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.22 112.69 3.99 Favored Glycine 0 C--O 1.237 0.333 0 N-CA-C 110.329 -1.108 . . . . 21.449999999999999 110.329 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 142' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -123.42 -171.64 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.224 -0.658 . . . . 26.870000000000001 109.224 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 143' ' ' ILE . . . . . . . . . . . . . 1.4 pp -116.99 -60.08 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 113.345 0.868 . . . . 19.359999999999999 113.345 -169.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 144' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -82.95 125.6 31.57 Favored 'General case' 0 C--O 1.233 0.22 0 O-C-N 121.411 -0.806 . . . . 14.69 111.159 -171.033 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 145' ' ' THR . . . . . . . . . . . . . 75.5 p -120.53 15.49 12.01 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 112.642 0.608 . . . . 27.109999999999999 112.642 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 146' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 54.55 76.42 0.52 Allowed Pre-proline 0 C--N 1.345 0.406 0 C-N-CA 126.54 1.936 . . . . 26.219999999999999 110.88 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 147' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_exo -68.38 72.72 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 N-CA-C 115.435 1.283 . . . . 17.789999999999999 115.435 -162.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 148' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -107.09 5.32 27.83 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 123.092 0.557 . . . . 32.619999999999997 111.569 167.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 149' ' ' GLU . . . . . 0.541 ' O ' ' NZ ' ' K' ' 12' ' ' LYS . 25.9 pm0 -139.98 5.8 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 112.885 0.698 . . . . 8.2899999999999991 112.885 -176.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 150' ' ' ILE . . . . . . . . . . . . . 44.1 mm -111.56 -48.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.857 0.753 . . . . 15.81 111.093 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 151' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.93 -28.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 107.483 -1.303 . . . . 6.4100000000000001 107.483 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 152' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -67.82 -30.07 69.39 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 116.08 -0.509 . . . . 28.390000000000001 111.72 -177.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -73.59 100.4 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.378 0 N-CA-C 108.107 -1.072 . . . . 17.789999999999999 108.107 172.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 154' ' ' SER . . . . . . . . . . . . . 39.0 t -117.9 -58.38 2.02 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.395 -0.82 . . . . 20.41 111.88 -173.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 155' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -127.85 -34.68 2.15 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 124.047 0.939 . . . . 23.960000000000001 113.408 178.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.25 -57.99 1.43 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 109.9 -1.28 . . . . 33.75 109.9 -157.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 157' ' ' GLY . . . . . . . . . . . . . . . -97.31 177.46 32.29 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-O 122.037 0.798 . . . . 17.789999999999999 112.475 177.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 158' ' ' TYR . . . . . . . . . . . . . 20.2 m-30 -115.8 -172.22 2.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.336 1.055 . . . . 8.0600000000000005 109.463 -178.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 159' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -79.19 -68.45 0.66 Allowed 'General case' 0 C--O 1.236 0.355 0 C-N-CA 119.55 -0.86 . . . . 22.640000000000001 111.85 -172.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 160' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -175.85 159.31 2.22 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 108.72 -0.845 . . . . 15.75 108.72 -176.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 161' ' ' GLN . . . . . . . . . . . . . 65.9 tt0 -153.32 100.14 2.42 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 105.29 -2.115 . . . . 32.700000000000003 105.29 154.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 162' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -74.33 -45.4 6.03 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 117.927 -1.035 . . . . 25.370000000000001 113.705 -163.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 163' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -76.18 -46.09 0.19 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 CA-C-N 122.204 1.823 . . . . 28.41 113.704 173.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 164' ' ' GLY . . . . . . . . . . . . . . . -120.35 39.41 2.45 Favored Glycine 0 N--CA 1.449 -0.451 0 N-CA-C 116.666 1.426 . . . . 17.559999999999999 116.666 -160.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 165' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -66.47 -62.31 1.53 Allowed 'General case' 0 C--O 1.238 0.468 0 C-N-CA 120.025 -0.67 . . . . 25.100000000000001 110.799 173.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 166' ' ' THR . . . . . . . . . . . . . 42.0 p 53.1 50.46 17.78 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 125.901 1.68 . . . . 29.050000000000001 111.7 177.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 167' ' ' THR . . . . . . . . . . . . . 1.7 m -138.0 164.54 28.8 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.046 -1.094 . . . . 1.8899999999999999 108.046 -169.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.98 -126.53 1.32 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.1 -0.8 . . . . 15.93 111.1 173.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -72.69 -61.91 1.64 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 120.404 -0.519 . . . . 40.509999999999998 111.036 -178.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.68 105.21 0.76 Allowed Pre-proline 0 C--O 1.235 0.335 0 C-N-CA 124.026 0.93 . . . . 19.75 109.605 -175.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 171' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -84.52 -173.85 1.63 Allowed 'Trans proline' 0 C--N 1.322 -0.834 0 C-N-CA 121.262 1.308 . . . . 0.27000000000000002 111.791 -159.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 172' ' ' GLY . . . . . . . . . . . . . . . 76.55 66.71 1.79 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 114.544 -1.207 . . . . 37.090000000000003 115.429 166.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 173' ' ' THR . . . . . . . . . . . . . 7.2 t -139.36 166.77 23.67 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.74 0.781 . . . . 40.25 109.363 169.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 174' ' ' VAL . . . . . . . . . . . . . 28.5 m -71.64 156.67 91.01 Favored Pre-proline 0 C--O 1.241 0.617 0 CA-C-N 114.964 -1.017 . . . . 0.0 109.103 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 175' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -62.21 122.04 10.32 Favored 'Trans proline' 0 C--N 1.349 0.597 0 CA-C-N 119.245 0.766 . . . . 25.620000000000001 110.692 169.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.303 0 C-N-CA 125.514 1.526 . . . . 20.350000000000001 110.384 -165.253 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 5' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo . . . . . 0 N--CA 1.465 -0.157 0 CA-C-O 119.607 -0.247 . . . . 20.920000000000002 112.408 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 6' ' ' ILE . . . . . . . . . . . . . 96.5 mt -123.55 121.82 63.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.99 -1.115 . . . . 41.640000000000001 107.99 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 7' ' ' MET . . . . . 0.424 ' N ' ' OD2' ' L' ' 10' ' ' ASP . 39.3 mmt -91.47 170.55 9.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.935 0.874 . . . . 39.840000000000003 110.799 -176.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.19 -9.88 64.63 Favored Glycine 0 C--N 1.334 0.42 0 CA-C-N 115.403 -0.817 . . . . 17.300000000000001 114.719 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -94.87 -14.95 24.09 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 117.883 0.842 . . . . 17.300000000000001 112.291 172.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' ASP . . . . . 0.424 ' OD2' ' N ' ' L' ' 7' ' ' MET . 82.8 m-20 -76.12 -7.03 53.84 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 113.739 1.014 . . . . 23.449999999999999 113.739 -170.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' VAL . . . . . . . . . . . . . 66.3 t -127.11 125.33 66.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 N-CA-C 107.917 -1.142 . . . . 11.789999999999999 107.917 -176.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' L' ' 149' ' ' GLU . 53.6 mtmt -134.93 161.19 35.96 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.502 0.668 . . . . 14.380000000000001 110.011 176.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' TYR . . . . . . . . . . . . . 18.6 m-30 -112.15 95.47 5.48 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.215 -1.031 . . . . 17.300000000000001 108.215 -166.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' LEU . . . . . 0.421 ' O ' ' CB ' ' L' ' 92' ' ' TRP . 98.0 mt -74.78 131.2 40.61 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 120.246 -0.582 . . . . 57.329999999999998 109.56 176.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' PHE . . . . . . . . . . . . . 22.0 m-30 -112.41 151.61 29.63 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.64 -0.504 . . . . 23.699999999999999 109.64 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' GLN . . . . . . . . . . . . . 71.6 tp60 -145.14 136.24 24.85 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 109.291 -0.633 . . . . 17.640000000000001 109.291 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' SER . . . . . 0.421 ' O ' ' NZ ' ' L' ' 90' ' ' LYS . 40.1 t -75.61 155.53 35.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 121.614 0.721 . . . . 7.0800000000000001 111.175 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' ILE . . . . . . . . . . . . . 44.5 pt -79.27 -11.9 13.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.4 0 CA-C-N 115.425 -0.807 . . . . 16.920000000000002 113.102 178.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -112.33 -11.75 13.65 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 112.661 0.615 . . . . 23.23 112.661 -170.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.45 -47.0 24.5 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 119.965 -0.694 . . . . 21.18 111.87 -170.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.18 45.12 29.28 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.887 1.275 . . . . 17.300000000000001 111.399 -168.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' THR . . . . . . . . . . . . . 69.3 p -123.95 121.3 34.93 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 108.979 -0.748 . . . . 38.780000000000001 108.979 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.16 76.59 2.14 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 116.264 -0.425 . . . . 17.300000000000001 113.758 -176.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' SER . . . . . . . . . . . . . 92.4 p -128.84 -26.64 2.64 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 120.373 -0.531 . . . . 14.69 111.469 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.31 74.38 0.81 Allowed Pre-proline 0 C--O 1.237 0.395 0 C-N-CA 127.01 2.124 . . . . 61.950000000000003 112.099 -172.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -71.68 105.74 1.84 Allowed 'Trans proline' 0 C--N 1.345 0.381 0 CA-C-N 119.4 0.821 . . . . 17.300000000000001 112.633 177.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -81.55 155.86 25.52 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.13 -0.693 . . . . 5.96 109.13 165.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.1 t80 -101.61 130.06 25.43 Favored Pre-proline 0 N--CA 1.446 -0.64 1 C-N-CA 109.56 -4.856 . . . . 6.2400000000000002 110.173 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.9 -173.58 1.27 Allowed 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 120.638 0.892 . . . . 11.84 114.248 -175.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . 53.42 60.23 3.85 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.769 1.228 . . . . 9.1500000000000004 111.048 -172.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -70.44 163.22 27.19 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 122.934 1.349 . . . . 22.48 111.948 179.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -136.43 -161.85 1.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 103.146 -2.909 . . . . 4.9800000000000004 103.146 169.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' THR . . . . . . . . . . . . . 15.1 t -65.9 164.73 14.39 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 122.557 1.17 . . . . 29.350000000000001 112.066 -174.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -135.28 -169.24 2.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.061 -1.427 . . . . 48.329999999999998 108.26 -167.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' GLY . . . . . . . . . . . . . . . 171.25 135.35 1.91 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.896 -0.669 . . . . 4.7599999999999998 111.745 170.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' SER . . . . . . . . . . . . . 66.1 m -127.32 84.63 2.28 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.015 -1.846 . . . . 17.300000000000001 106.015 175.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' VAL . . . . . . . . . . . . . 3.6 m -91.9 110.73 23.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.513 -0.921 . . . . 4.1699999999999999 108.513 -171.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' G' ' 83' ' ' TYR . 51.0 m -100.47 84.09 2.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.335 -0.987 . . . . 22.199999999999999 108.335 -167.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' GLY . . . . . . . . . . . . . . . -88.09 99.63 2.53 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.769 -0.729 . . . . 32.579999999999998 113.177 -177.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.95 124.65 47.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.067 -1.086 . . . . 2.6600000000000001 108.067 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 41' ' ' ARG . . . . . 0.437 ' O ' ' CA ' ' L' ' 57' ' ' GLY . 93.0 mtm-85 -79.01 -178.49 6.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.449 0.642 . . . . 27.559999999999999 109.581 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 42' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -162.52 163.85 27.23 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.425 -0.583 . . . . 24.149999999999999 109.425 -175.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 43' ' ' LEU . . . . . . . . . . . . . 77.8 mt -106.99 112.53 25.53 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.069 -0.715 . . . . 11.23 109.069 171.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 44' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -117.07 112.09 20.43 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 107.569 -1.271 . . . . 17.120000000000001 107.569 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 45' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -127.51 -173.83 3.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.971 -0.751 . . . . 23.32 108.971 -172.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 46' ' ' GLU . . . . . . . . . . . . . 58.5 mp0 -127.3 -40.95 1.78 Allowed 'General case' 0 C--O 1.233 0.233 0 N-CA-C 114.68 1.363 . . . . 7.0 114.68 -169.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 47' ' ' GLN . . . . . . . . . . . . . 92.0 mm-40 65.29 21.69 12.03 Favored 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 124.788 1.235 . . . . 50.57 114.046 161.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 50.6 p 50.8 39.58 22.52 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.487 1.115 . . . . 9.0299999999999994 110.941 -165.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 49' ' ' LYS . . . . . . . . . . . . . 45.4 mmtm -139.83 -165.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 106.957 -1.497 . . . . 16.789999999999999 106.957 -174.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 50' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -72.38 -30.38 64.63 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 120.594 -0.442 . . . . 44.689999999999998 112.066 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 157.03 166.68 16.99 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 121.058 -0.591 . . . . 16.23 114.553 -178.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 52' ' ' ARG . . . . . . . . . . . . . 17.7 tpp85 -133.74 57.06 1.82 Allowed 'General case' 0 C--O 1.234 0.24 0 N-CA-C 108.243 -1.021 . . . . 17.300000000000001 108.243 -178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 53' ' ' ILE . . . . . . . . . . . . . 7.8 tt -69.4 -3.9 3.32 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 C-N-CA 124.442 1.097 . . . . 32.259999999999998 113.084 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 54' ' ' LEU . . . . . . . . . . . . . 7.9 mp -59.43 -24.91 63.9 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.295 1.038 . . . . 60.18 113.339 -176.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 55' ' ' GLY . . . . . . . . . . . . . . . -66.7 118.74 11.03 Favored Glycine 0 N--CA 1.44 -1.094 0 CA-C-O 121.64 0.578 . . . . 17.300000000000001 113.905 -172.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 56' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.36 173.8 13.61 Favored 'Trans proline' 0 C--N 1.326 -0.624 0 C-N-CA 120.773 0.982 . . . . 17.300000000000001 109.844 172.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 57' ' ' GLY . . . . . 0.437 ' CA ' ' O ' ' L' ' 41' ' ' ARG . . . -136.18 166.14 24.76 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 109.466 -1.454 . . . . 34.450000000000003 109.466 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 58' ' ' SER . . . . . . . . . . . . . 42.5 t -74.76 143.67 43.97 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 119.711 -0.796 . . . . 12.73 109.658 172.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 59' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.29 111.55 26.71 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.482 -0.932 . . . . 33.100000000000001 108.482 -177.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 60' ' ' ALA . . . . . . . . . . . . . . . -109.34 112.74 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.82 -1.548 . . . . 49.859999999999999 106.82 174.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 61' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -118.1 120.64 38.38 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.692 -0.855 . . . . 40.560000000000002 108.692 -169.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 62' ' ' SER . . . . . 0.487 ' OG ' ' OE1' ' L' ' 133' ' ' GLN . 65.3 m -108.8 168.47 9.32 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 124.025 0.93 . . . . 17.300000000000001 110.604 -174.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -140.07 128.29 3.83 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 114.983 -1.008 . . . . 17.300000000000001 113.041 177.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 64' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -106.04 97.06 6.92 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.524 -1.287 . . . . 31.629999999999999 107.524 172.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.18 115.93 49.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 N-CA-C 108.303 -0.999 . . . . 17.300000000000001 108.303 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 66' ' ' THR . . . . . . . . . . . . . 63.6 p -116.91 142.47 46.89 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.354 -0.61 . . . . 3.1400000000000001 109.354 178.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 67' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -152.92 -170.47 3.64 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.41 0.624 . . . . 12.33 109.392 177.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 68' ' ' TYR . . . . . . . . . . . . . 15.5 m-30 -115.7 134.29 55.18 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.734 0.814 . . . . 20.66 109.518 178.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.73 113.51 3.65 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.788 -0.72 . . . . 17.300000000000001 113.771 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 70' ' ' LYS . . . . . 0.494 ' O ' ' NE2' ' L' ' 76' ' ' GLN . 38.4 ttmt -89.29 147.76 23.93 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.824 -0.806 . . . . 19.57 108.824 174.195 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -66.92 -16.38 64.29 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.099 1.148 . . . . 38.0 114.099 -169.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.33 -138.52 4.86 Favored Glycine 0 N--CA 1.451 -0.327 0 N-CA-C 109.927 -1.269 . . . . 17.300000000000001 109.927 175.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 73' ' ' ASP . . . . . . . . . . . . . 32.8 t0 59.74 72.83 0.51 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 125.089 1.356 . . . . 18.16 111.16 168.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.97 9.58 0.07 Allowed 'General case' 0 C--O 1.235 0.31 0 N-CA-C 117.28 2.326 . . . . 58.549999999999997 117.28 -158.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.36 97.04 Favored Glycine 0 C--N 1.337 0.612 0 C-N-CA 120.302 -0.951 . . . . 17.300000000000001 112.663 170.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 76' ' ' GLN . . . . . 0.494 ' NE2' ' O ' ' L' ' 70' ' ' LYS . 21.9 pt20 -71.15 -23.53 62.09 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 119.578 -0.849 . . . . 44.869999999999997 111.291 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 77' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -70.38 -28.7 65.3 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 119.865 -0.734 . . . . 17.300000000000001 111.299 170.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.91 -31.11 64.43 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 120.417 -0.513 . . . . 31.280000000000001 111.34 171.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 79' ' ' ILE . . . . . . . . . . . . . 49.5 mm -64.78 -44.77 96.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-O 121.052 0.453 . . . . 34.0 110.421 173.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -72.76 -22.65 60.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 121.915 -0.491 . . . . 27.039999999999999 111.947 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 81' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -69.34 -34.96 75.41 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.258 -0.577 . . . . 21.239999999999998 111.415 168.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 82' ' ' ALA . . . . . . . . . . . . . . . -74.07 -33.68 63.76 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 119.417 -0.913 . . . . 15.07 111.629 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 83' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -83.25 -62.21 1.65 Allowed 'General case' 0 C--O 1.235 0.318 0 C-N-CA 120.404 -0.518 . . . . 7.6399999999999997 112.053 -176.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 84' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -75.39 -38.03 60.19 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 111.722 0.268 . . . . 25.280000000000001 111.722 -165.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 85' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -77.18 -43.11 35.02 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 119.886 -0.726 . . . . 7.2999999999999998 111.045 171.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 86' ' ' GLY . . . . . . . . . . . . . . . 107.8 96.33 2.44 Favored Glycine 0 N--CA 1.45 -0.404 0 O-C-N 122.256 -0.277 . . . . 23.559999999999999 113.361 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 87' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -148.88 -162.26 1.52 Allowed 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.067 -1.457 . . . . 6.04 107.067 -177.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 88' ' ' GLN . . . . . . . . . . . . . 65.4 mt-30 -128.64 178.0 6.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.721 0.772 . . . . 10.539999999999999 110.875 167.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 89' ' ' ILE . . . . . . . . . . . . . 57.4 mt -128.46 137.05 58.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.244 -0.889 . . . . 17.300000000000001 109.282 -173.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 90' ' ' LYS . . . . . 0.421 ' NZ ' ' O ' ' L' ' 17' ' ' SER . 36.6 mtmm -84.99 118.34 24.51 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.498 -0.927 . . . . 18.93 108.498 164.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 91' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -111.96 133.76 53.94 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 124.434 1.094 . . . . 28.149999999999999 110.718 -166.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 92' ' ' TRP . . . . . 0.421 ' CB ' ' O ' ' L' ' 14' ' ' LEU . 89.8 m95 -132.63 125.5 30.52 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 10.58 109.971 -173.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 93' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -111.91 90.35 3.31 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.067 -1.086 . . . . 11.859999999999999 108.067 171.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 20.2 m -104.89 165.03 3.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 CA-C-O 122.07 0.938 . . . . 14.710000000000001 109.295 -174.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 95' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -110.5 168.97 9.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.132 -0.94 . . . . 25.489999999999998 111.501 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 96' ' ' THR . . . . . . . . . . . . . 29.8 m -102.03 -32.58 10.09 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.877 -1.056 . . . . 34.219999999999999 112.803 -175.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 97' ' ' VAL . . . . . . . . . . . . . 34.4 m -70.42 155.69 7.5 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.767 0.794 . . . . 17.329999999999998 110.244 -177.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 98' ' ' LYS . . . . . 0.583 ' NZ ' ' O ' ' L' ' 99' ' ' ASN . 29.6 tptp -89.19 125.43 35.06 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.696 -0.684 . . . . 14.09 109.683 -178.002 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 99' ' ' ASN . . . . . 0.583 ' O ' ' NZ ' ' L' ' 98' ' ' LYS . 35.3 m120 -86.52 171.22 11.23 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.749 0.785 . . . . 22.140000000000001 109.994 171.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 100' ' ' GLU . . . . . . . . . . . . . 57.1 mp0 -107.3 -14.38 14.9 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 113.762 1.023 . . . . 21.129999999999999 113.762 178.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 101' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -89.84 -52.18 5.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 118.186 0.448 . . . . 14.65 111.488 170.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 102' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -110.79 -173.55 2.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.355 -0.98 . . . . 44.119999999999997 108.355 170.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 103' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -79.04 -54.8 5.65 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 120.095 -0.642 . . . . 39.880000000000003 110.395 170.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 104' ' ' TYR . . . . . . . . . . . . . 71.2 m-85 -132.0 -170.35 2.39 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 108.774 -0.824 . . . . 27.289999999999999 108.774 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 105' ' ' ASP . . . . . 0.422 ' N ' ' OD1' ' L' ' 105' ' ' ASP . 15.8 p-10 -152.95 165.22 36.19 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 109.139 -0.689 . . . . 43.340000000000003 109.139 177.26 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 106' ' ' ALA . . . . . . . . . . . . . . . -157.69 154.81 28.89 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.274 -0.875 . . . . 5.3200000000000003 111.095 -163.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 107' ' ' GLN . . . . . 0.449 ' OE1' ' OH ' ' G' ' 118' ' ' TYR . 87.9 mt-30 -114.08 125.07 53.57 Favored 'General case' 0 C--O 1.235 0.33 0 N-CA-C 106.896 -1.52 . . . . 20.109999999999999 106.896 159.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 108' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -112.68 154.66 25.76 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 123.657 0.783 . . . . 17.300000000000001 110.197 -164.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 109' ' ' GLY . . . . . . . . . . . . . . . -166.17 167.64 39.43 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 119.405 -1.378 . . . . 17.300000000000001 112.684 174.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 110' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -108.53 110.82 22.4 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.626 -0.787 . . . . 40.159999999999997 108.957 168.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 111' ' ' ALA . . . . . . . . . . . . . . . -109.06 156.56 19.64 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 121.598 0.713 . . . . 33.530000000000001 111.76 -165.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 112' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -137.6 136.92 37.98 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.135 -1.432 . . . . 14.99 107.135 -179.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 113' ' ' ILE . . . . . . . . . . . . . 75.6 mt -87.18 129.46 38.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 109.869 -0.419 . . . . 7.4400000000000004 109.869 -169.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 114' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -73.1 -64.77 0.9 Allowed 'General case' 0 C--O 1.235 0.328 0 C-N-CA 119.906 -0.718 . . . . 49.450000000000003 110.584 164.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 115' ' ' SER . . . . . . . . . . . . . 74.4 m -140.56 149.33 42.26 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.676 0.751 . . . . 8.0800000000000001 110.365 -170.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -122.59 89.71 3.16 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 104.425 -2.435 . . . . 16.25 104.425 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -112.75 108.38 17.36 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 107.639 -1.245 . . . . 30.170000000000002 107.639 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 118' ' ' TYR . . . . . 0.475 ' OH ' ' OE1' ' K' ' 107' ' ' GLN . 12.4 p90 -113.74 144.56 42.75 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.534 0.683 . . . . 22.449999999999999 112.056 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 36.9 t -99.8 126.94 45.96 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.67 -1.15 . . . . 17.300000000000001 109.877 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 120' ' ' ASP . . . . . . . . . . . . . 59.7 t0 -100.4 97.93 8.62 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 106.115 -1.809 . . . . 15.869999999999999 106.115 168.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 121' ' ' GLY . . . . . . . . . . . . . . . -79.19 -158.2 13.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-O 121.92 0.733 . . . . 12.550000000000001 112.483 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 122' ' ' VAL . . . . . . . . . . . . . 66.4 t -116.37 -62.91 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 N-CA-C 108.314 -0.995 . . . . 29.859999999999999 108.314 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 123' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.11 -18.22 14.62 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.64 0.607 . . . . 47.609999999999999 112.64 -174.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 124' ' ' GLY . . . . . . . . . . . . . . . -86.8 154.83 27.21 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 109.221 -1.552 . . . . 24.420000000000002 109.221 161.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.97 168.85 19.16 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 119.709 -0.797 . . . . 6.8399999999999999 110.335 176.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 126' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.41 153.56 8.73 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 CA-C-N 115.347 -0.842 . . . . 17.300000000000001 109.556 -177.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 127' ' ' GLU . . . . . . . . . . . . . 21.9 pt-20 -143.88 133.26 23.29 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.723 -0.473 . . . . 35.390000000000001 109.723 -178.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 128' ' ' ILE . . . . . . . . . . . . . 86.5 mt -102.61 123.32 55.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 109.376 -0.602 . . . . 17.300000000000001 109.376 -176.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 129' ' ' SER . . . . . . . . . . . . . 68.8 m -102.54 132.78 48.38 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.55 -0.907 . . . . 24.949999999999999 108.55 171.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 130' ' ' ILE . . . . . . . . . . . . . 85.0 mt -134.96 128.31 49.64 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 108.873 -0.788 . . . . 17.300000000000001 108.873 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 131' ' ' SER . . . . . . . . . . . . . 60.1 m -93.83 147.27 23.23 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.109 -0.496 . . . . 17.300000000000001 110.011 175.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 132' ' ' LEU . . . . . . . . . . . . . 7.0 mp -131.39 152.4 50.67 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 116.057 -0.519 . . . . 34.950000000000003 110.236 -176.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 133' ' ' GLN . . . . . 0.487 ' OE1' ' OG ' ' L' ' 62' ' ' SER . 20.6 mm100 -141.78 125.99 17.48 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.791 0.836 . . . . 17.300000000000001 109.454 -177.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 134' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.83 147.06 28.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 109.322 -0.622 . . . . 8.4299999999999997 109.322 -177.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 135' ' ' ILE . . . . . . . . . . . . . 24.3 mm -62.46 -60.34 2.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 116.004 -0.544 . . . . 6.8499999999999996 110.796 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 136' ' ' GLY . . . . . . . . . . . . . . . -158.64 137.36 5.18 Favored Glycine 0 N--CA 1.443 -0.854 0 N-CA-C 111.343 -0.703 . . . . 17.300000000000001 111.343 -178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 137' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -67.35 155.69 38.31 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 121.387 0.613 . . . . 29.670000000000002 110.22 175.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 138' ' ' LEU . . . . . . . . . . . . . 30.8 tp -140.59 128.61 22.06 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.87 -1.159 . . . . 12.51 107.87 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -83.72 76.64 9.97 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 122.391 1.091 . . . . 17.300000000000001 109.344 -170.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 140' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -94.07 83.14 4.25 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.105 -0.952 . . . . 37.969999999999999 108.558 -178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.18 108.16 2.41 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.093 -1.051 . . . . 30.129999999999999 110.479 175.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.65 -172.66 2.42 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.23 -0.655 . . . . 18.300000000000001 109.23 -174.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 143' ' ' ILE . . . . . . . . . . . . . 1.5 pp -117.82 -59.12 3.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 113.344 0.868 . . . . 28.550000000000001 113.344 -170.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -86.34 129.5 34.83 Favored 'General case' 0 C--N 1.33 -0.254 0 O-C-N 121.326 -0.859 . . . . 17.670000000000002 111.385 -169.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 145' ' ' THR . . . . . . . . . . . . . 71.7 p -121.91 11.94 10.41 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 112.691 0.626 . . . . 21.73 112.691 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 146' ' ' LEU . . . . . . . . . . . . . 4.1 mm? 54.29 75.77 0.58 Allowed Pre-proline 0 C--O 1.237 0.413 0 C-N-CA 126.753 2.021 . . . . 17.300000000000001 110.135 -176.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 147' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -68.76 74.56 0.88 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 N-CA-C 115.585 1.34 . . . . 5.5499999999999998 115.585 -160.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 148' ' ' GLU . . . . . 0.461 ' OE1' ' ND2' ' L' ' 152' ' ' ASN . 80.2 mm-40 -105.3 8.69 33.91 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 116.032 -0.531 . . . . 32.810000000000002 111.632 166.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 149' ' ' GLU . . . . . 0.537 ' O ' ' NZ ' ' L' ' 12' ' ' LYS . 25.9 pm0 -140.07 4.81 2.08 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 112.883 0.697 . . . . 23.489999999999998 112.883 -176.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 150' ' ' ILE . . . . . . . . . . . . . 43.9 mm -111.98 -47.65 5.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.88 0.763 . . . . 28.280000000000001 111.061 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 151' ' ' VAL . . . . . . . . . . . . . 45.0 t -105.87 -29.32 2.74 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.538 -1.282 . . . . 19.43 107.538 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 152' ' ' ASN . . . . . 0.461 ' ND2' ' OE1' ' L' ' 148' ' ' GLU . 37.8 t-20 -68.5 -31.5 70.8 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 116.046 -0.524 . . . . 17.300000000000001 111.719 -176.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -73.88 99.65 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.775 -1.194 . . . . 9.4199999999999999 107.775 172.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 154' ' ' SER . . . . . . . . . . . . . 37.1 t -117.56 -58.73 2.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.232 -0.895 . . . . 37.020000000000003 111.747 -172.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 155' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -128.66 -29.94 2.34 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 123.887 0.875 . . . . 26.059999999999999 113.057 176.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.64 -60.72 1.48 Allowed Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.236 -1.146 . . . . 41.560000000000002 110.236 -160.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 157' ' ' GLY . . . . . . . . . . . . . . . -96.52 172.8 29.18 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-O 121.985 0.769 . . . . 17.300000000000001 112.237 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 158' ' ' TYR . . . . . . . . . . . . . 13.6 m-30 -113.92 -173.4 2.27 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.401 0.68 . . . . 14.35 110.311 -177.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -79.08 -67.7 0.73 Allowed 'General case' 0 C--O 1.236 0.37 0 C-N-CA 119.849 -0.741 . . . . 46.380000000000003 111.921 -167.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 160' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -175.85 157.83 2.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 108.618 -0.882 . . . . 18.940000000000001 108.618 -175.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 161' ' ' GLN . . . . . . . . . . . . . 65.9 tt0 -153.08 98.85 2.34 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 104.802 -2.296 . . . . 27.82 104.802 154.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 162' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -74.51 -46.18 5.68 Favored Pre-proline 0 C--O 1.241 0.624 0 CA-C-O 117.981 -1.009 . . . . 23.739999999999998 113.7 -159.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 163' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -77.55 -46.14 0.14 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 CA-C-N 122.092 1.783 . . . . 7.4699999999999998 113.759 171.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 164' ' ' GLY . . . . . . . . . . . . . . . -113.76 39.51 2.8 Favored Glycine 0 N--CA 1.449 -0.441 0 N-CA-C 116.278 1.271 . . . . 48.82 116.278 -160.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -68.02 -63.13 1.12 Allowed 'General case' 0 C--O 1.238 0.473 0 C-N-CA 120.335 -0.546 . . . . 15.69 110.8 176.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 166' ' ' THR . . . . . . . . . . . . . 33.7 p 53.12 51.52 15.52 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.88 1.672 . . . . 15.26 111.765 176.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 1.6 m -136.22 168.45 19.39 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 107.721 -1.214 . . . . 5.6399999999999997 107.721 -169.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.94 -125.49 1.19 Allowed Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.256 -1.137 . . . . 4.5999999999999996 110.256 172.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -76.81 -62.11 1.75 Allowed 'General case' 0 C--O 1.235 0.317 0 C-N-CA 119.789 -0.765 . . . . 30.030000000000001 110.979 -178.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.81 106.07 1.04 Allowed Pre-proline 0 C--O 1.236 0.376 0 C-N-CA 123.834 0.854 . . . . 3.7999999999999998 109.685 -176.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 171' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -83.56 -172.96 1.47 Allowed 'Trans proline' 0 C--N 1.324 -0.738 0 C-N-CA 121.392 1.395 . . . . 32.060000000000002 111.782 -159.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 172' ' ' GLY . . . . . . . . . . . . . . . 80.52 64.63 1.81 Allowed Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 114.596 -1.184 . . . . 46.270000000000003 114.905 167.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 173' ' ' THR . . . . . . . . . . . . . 9.5 t -135.67 168.84 18.53 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.707 0.765 . . . . 45.850000000000001 109.227 170.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 174' ' ' VAL . . . . . . . . . . . . . 28.8 m -70.97 154.4 94.23 Favored Pre-proline 0 C--O 1.242 0.665 0 CA-C-N 114.994 -1.003 . . . . 1.04 108.654 178.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 175' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -63.03 111.01 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 CA-C-N 119.31 0.789 . . . . 17.34 111.007 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.2 0 C-N-CA 125.483 1.513 . . . . 20.789999999999999 110.993 -163.491 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.491 ' HB2' ' H ' ' A' ' 6' ' ' ILE . 43.9 Cg_endo . . . . . 0 N--CA 1.465 -0.158 0 N-CA-C 112.428 0.126 . . . . 13.51 112.428 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.491 ' H ' ' HB2' ' A' ' 5' ' ' PRO . 96.8 mt -121.61 119.82 59.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 N-CA-C 108.013 -1.106 . . . . 9.13 108.013 178.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -85.7 169.04 13.83 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.927 0.87 . . . . 42.11 110.698 -177.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.04 -11.39 66.81 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.394 -0.821 . . . . 17.08 114.363 175.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -95.14 -15.26 23.47 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 117.644 0.722 . . . . 17.08 112.175 171.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -77.23 -2.83 36.63 Favored 'General case' 0 CA--C 1.519 -0.24 0 N-CA-C 114.095 1.146 . . . . 27.35 114.095 -171.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.0 123.19 61.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 119.701 1.137 . . . . 17.08 108.231 -177.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.02 163.34 29.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.553 0.692 . . . . 28.68 110.008 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.405 ' CE1' ' HG3' ' A' ' 93' ' ' ARG . 19.2 m-30 -114.03 97.68 6.52 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.095 -0.957 . . . . 17.08 108.511 -165.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.812 HD23 ' HB3' ' A' ' 27' ' ' LEU . 96.7 mt -73.14 123.84 24.42 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 109.843 -0.428 . . . . 37.84 109.843 175.614 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-30 -107.96 152.97 23.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.148 0.499 . . . . 15.37 109.917 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -147.1 134.91 21.22 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.152 -0.684 . . . . 19.81 109.152 174.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.1 t -74.93 155.25 37.64 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.601 0.715 . . . . 17.08 110.812 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -76.61 -13.28 14.55 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 N-CA-C 113.275 0.842 . . . . 2.05 113.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -113.81 -7.16 13.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 112.736 0.643 . . . . 37.16 112.736 -169.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.34 -46.49 32.88 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 119.703 -0.799 . . . . 27.54 111.514 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.77 43.28 31.6 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.91 1.284 . . . . 12.24 111.382 -170.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.8 p -119.91 125.13 47.72 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.41 0.684 . . . . 6.83 109.243 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.46 75.31 2.32 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 121.44 -0.409 . . . . 16.1 113.424 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.6 p -131.52 -27.18 1.97 Allowed 'General case' 0 C--O 1.235 0.338 0 C-N-CA 120.595 -0.442 . . . . 44.72 111.699 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.25 74.39 0.81 Allowed Pre-proline 0 C--O 1.236 0.382 0 C-N-CA 127.029 2.132 . . . . 31.44 112.434 -173.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -72.26 104.49 1.69 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 CA-C-N 119.637 0.906 . . . . 11.57 112.332 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.812 ' HB3' HD23 ' A' ' 14' ' ' LEU . 2.1 pt? -78.98 163.98 24.76 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.038 -0.727 . . . . 7.34 109.038 167.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -102.55 136.9 19.27 Favored Pre-proline 0 C--N 1.314 -0.966 1 C-N-CA 110.707 -4.397 . . . . 9.9 110.11 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -77.36 178.59 7.43 Favored 'Trans proline' 0 C--O 1.234 0.276 0 CA-C-N 118.655 0.555 . . . . 36.59 112.534 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.74 ' HA ' ' HB3' ' L' ' 47' ' ' GLN . . . 57.16 57.91 4.25 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.472 1.109 . . . . 21.0 112.035 178.293 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 1.8 m-30 -73.39 -176.71 2.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 122.901 1.334 . . . . 47.9 112.348 -179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.46 ' HG3' ' H ' ' A' ' 33' ' ' THR . 7.6 tp-100 -148.85 -159.56 1.05 Allowed 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 103.4 -2.815 . . . . 15.2 103.4 169.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.46 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 13.3 t -66.77 164.19 17.68 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 122.604 1.193 . . . . 24.62 111.673 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.485 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 84.1 m-20 -135.11 -170.51 2.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.12 -1.4 . . . . 37.7 108.296 -170.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.697 ' O ' ' HA2' ' A' ' 63' ' ' GLY . . . 176.79 132.73 1.69 Allowed Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.482 -0.781 . . . . 3.83 111.203 169.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 69.1 m -121.58 84.59 2.27 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 106.154 -1.795 . . . . 7.36 106.154 176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.56 HG23 ' HB2' ' A' ' 62' ' ' SER . 4.0 m -90.36 110.1 21.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 108.563 -0.902 . . . . 11.35 108.563 -172.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.7 m -98.76 94.77 6.79 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 107.912 -1.144 . . . . 19.64 107.912 -171.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -96.94 102.64 2.78 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.329 -0.938 . . . . 16.28 113.645 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -108.67 123.92 49.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.684 -0.858 . . . . 11.62 108.684 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.597 ' O ' ' HA3' ' A' ' 57' ' ' GLY . 88.8 mtm-85 -83.27 -173.29 4.63 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.151 -0.685 . . . . 43.29 109.151 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -158.62 141.56 14.62 Favored 'General case' 0 C--N 1.329 -0.322 0 O-C-N 121.756 -0.59 . . . . 29.65 110.179 -170.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.26 113.4 5.84 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 108.772 -0.825 . . . . 9.61 108.772 174.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.448 ' HD1' HG13 ' A' ' 53' ' ' ILE . 83.6 t80 -124.46 106.32 10.1 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.65 -0.5 . . . . 38.63 109.65 -171.009 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -132.11 -170.3 2.39 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 123.186 0.594 . . . . 31.64 110.922 175.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.662 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . 56.4 mp0 -125.28 -37.69 2.37 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 113.633 0.975 . . . . 8.59 113.633 177.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLN . . . . . . . . . . . . . 76.0 mm-40 59.4 32.93 22.15 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.14 1.376 . . . . 39.63 112.462 172.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.1 p 52.64 38.9 27.25 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.28 1.432 . . . . 17.08 111.705 -171.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -138.43 -165.15 1.76 Allowed 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.552 -1.277 . . . . 29.24 107.552 -176.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -67.2 -23.31 65.73 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.267 0.469 . . . . 28.94 112.267 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.662 ' HA2' ' HA ' ' A' ' 46' ' ' GLU . . . 143.38 164.81 10.46 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.308 -0.717 . . . . 30.47 111.308 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 18.3 tpp85 -125.09 52.07 1.62 Allowed 'General case' 0 C--O 1.235 0.296 0 N-CA-C 105.577 -2.008 . . . . 7.53 105.577 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.448 HG13 ' HD1' ' A' ' 44' ' ' PHE . 6.1 tt -73.08 -11.53 14.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-N 114.939 -1.028 . . . . 40.72 111.805 -169.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 7.7 mp -71.18 -16.12 62.51 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 123.173 0.589 . . . . 41.04 112.477 -172.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.38 143.12 38.48 Favored Glycine 0 N--CA 1.443 -0.838 0 CA-C-O 121.462 0.479 . . . . 26.7 114.104 -172.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -77.67 178.91 7.03 Favored 'Trans proline' 0 C--N 1.326 -0.636 0 C-N-CA 121.25 1.3 . . . . 9.15 111.787 -176.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.597 ' HA3' ' O ' ' A' ' 41' ' ' ARG . . . -150.68 174.72 29.94 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 109.584 -1.406 . . . . 43.79 109.584 177.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -75.78 144.77 41.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.668 0.747 . . . . 2.52 110.333 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 2.3 p -101.84 117.55 47.32 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 108.68 -0.859 . . . . 23.56 108.68 -177.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -116.06 110.9 19.53 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 107.045 -1.465 . . . . 17.08 107.045 174.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -110.85 120.89 43.89 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.812 -0.81 . . . . 64.91 108.812 -172.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.718 ' HA ' ' O ' ' A' ' 132' ' ' LEU . 69.6 m -109.4 168.93 9.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 124.767 1.227 . . . . 11.55 110.411 -176.14 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.697 ' HA2' ' O ' ' A' ' 35' ' ' GLY . . . -147.33 125.27 2.12 Favored Glycine 0 N--CA 1.443 -0.842 0 CA-C-N 115.142 -0.935 . . . . 17.08 112.564 177.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -101.73 99.31 9.55 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.355 -1.35 . . . . 49.67 107.355 172.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 97.2 t -106.33 120.66 57.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 108.19 -1.041 . . . . 0.32 108.19 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 68.5 p -115.88 147.33 41.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.435 -0.58 . . . . 17.08 109.435 177.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' TYR . . . . . 0.445 ' HE1' HD12 ' A' ' 130' ' ' ILE . 53.1 p90 -156.41 -174.1 4.79 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 108.585 -0.894 . . . . 2.35 108.585 175.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.7 m-30 -116.04 140.48 49.23 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 176.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.21 116.56 4.24 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 116.097 -0.501 . . . . 17.08 114.318 -175.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.447 ' O ' ' NE2' ' A' ' 76' ' ' GLN . 38.9 ttmt -92.0 148.98 21.79 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.185 -0.672 . . . . 1.74 109.185 175.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 21.0 ptp180 -69.11 -17.21 63.82 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.008 1.114 . . . . 30.37 114.008 -169.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.85 -143.08 5.75 Favored Glycine 0 N--CA 1.452 -0.284 0 N-CA-C 109.891 -1.284 . . . . 20.89 109.891 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.1 t0 60.0 74.23 0.45 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 124.915 1.286 . . . . 37.95 111.123 167.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.04 10.76 0.05 Allowed 'General case' 0 C--O 1.234 0.276 0 N-CA-C 117.227 2.306 . . . . 25.19 117.227 -161.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.8 -40.25 94.81 Favored Glycine 0 C--N 1.338 0.643 0 C-N-CA 120.407 -0.902 . . . . 30.35 112.776 170.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.447 ' NE2' ' O ' ' A' ' 70' ' ' LYS . 21.8 pt20 -68.7 -24.56 64.51 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 119.999 -0.68 . . . . 11.83 111.811 172.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.6 mttp -73.79 -23.81 59.74 Favored 'General case' 0 CA--C 1.517 -0.31 0 C-N-CA 119.758 -0.777 . . . . 12.64 111.301 172.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.12 -31.7 61.2 Favored 'General case' 0 C--O 1.239 0.542 0 C-N-CA 120.617 -0.433 . . . . 17.68 111.157 169.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 51.9 mm -62.97 -42.82 98.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.134 0.493 . . . . 30.14 110.282 171.159 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -75.66 -22.74 56.47 Favored 'General case' 0 C--O 1.234 0.263 0 O-C-N 121.875 -0.515 . . . . 17.44 112.085 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -70.52 -31.68 68.85 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 120.146 -0.621 . . . . 42.54 111.167 169.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.775 ' HA ' ' HB2' ' A' ' 87' ' ' LYS . . . -74.84 -35.55 62.39 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 119.435 -0.906 . . . . 7.59 111.572 174.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -83.51 -63.05 1.43 Allowed 'General case' 0 C--O 1.236 0.36 0 C-N-CA 120.256 -0.578 . . . . 17.08 112.111 -175.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -76.43 -42.61 43.5 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 111.93 0.344 . . . . 23.14 111.93 -166.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -72.25 -41.45 66.76 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 119.998 -0.681 . . . . 31.74 111.001 172.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.26 96.68 2.45 Favored Glycine 0 N--CA 1.449 -0.499 0 O-C-N 122.27 -0.269 . . . . 5.81 113.224 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.775 ' HB2' ' HA ' ' A' ' 82' ' ' ALA . 98.5 mttt -148.14 -161.82 1.42 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 106.887 -1.523 . . . . 17.08 106.887 -179.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -129.08 176.8 7.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.392 0.615 . . . . 17.08 109.662 171.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 113' ' ' ILE . 78.9 mt -129.61 132.41 66.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.117 -0.492 . . . . 29.53 109.866 -173.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 36.4 mtmm -82.96 120.38 25.63 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 108.424 -0.954 . . . . 22.16 108.424 166.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.521 ' HB3' ' O ' ' A' ' 109' ' ' GLY . 88.7 t80 -117.69 127.58 54.06 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 124.42 1.088 . . . . 16.4 110.106 -165.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' TRP . . . . . 0.536 ' HB2' ' HB2' ' A' ' 14' ' ' LEU . 91.3 m95 -128.72 128.79 44.74 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 123.838 0.855 . . . . 13.22 108.929 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.806 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 78.4 ttt-85 -110.97 96.02 5.9 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.284 -1.006 . . . . 25.99 108.284 173.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 106' ' ' ALA . 27.0 m -109.24 161.19 7.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 122.341 1.067 . . . . 35.9 109.813 -172.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -105.19 165.41 11.12 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 114.71 -1.132 . . . . 16.18 110.951 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.484 HG23 HG23 ' A' ' 150' ' ' ILE . 33.2 m -98.79 -29.68 12.85 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.024 -0.989 . . . . 17.0 112.437 -177.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 35.4 m -68.88 154.94 8.03 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 CA-C-O 121.756 0.788 . . . . 17.08 110.191 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.435 ' NZ ' ' O ' ' A' ' 99' ' ' ASN . 29.2 tptp -91.07 119.28 31.09 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.67 -0.695 . . . . 34.86 109.761 -176.061 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.435 ' O ' ' NZ ' ' A' ' 98' ' ' LYS . 35.1 m120 -78.83 168.56 19.54 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-O 121.844 0.83 . . . . 18.72 109.9 171.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -105.48 -11.37 16.44 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.684 0.994 . . . . 15.36 113.684 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -93.28 -49.91 5.73 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.221 0.464 . . . . 14.89 111.532 168.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -109.77 -176.8 3.1 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.642 -0.873 . . . . 22.87 108.642 173.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.67 ' H ' HG22 ' A' ' 143' ' ' ILE . 97.0 mttt -75.64 -57.09 4.09 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 120.221 -0.592 . . . . 47.87 110.112 168.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -133.47 -171.46 2.71 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 107.771 -1.196 . . . . 28.57 107.771 -178.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.519 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 21.8 p-10 -149.67 169.18 21.61 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.529 0.68 . . . . 38.21 109.498 176.131 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.806 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . -153.1 160.34 42.9 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.258 -0.883 . . . . 2.53 111.315 -162.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.433 ' OE1' ' OH ' ' B' ' 118' ' ' TYR . 88.0 mt-30 -119.07 122.43 42.11 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 106.994 -1.484 . . . . 12.91 106.994 159.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.418 ' HB3' ' O ' ' A' ' 138' ' ' LEU . 85.7 t80 -109.47 150.72 27.7 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.132 0.973 . . . . 23.1 110.286 -164.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLY . . . . . 0.521 ' O ' ' HB3' ' A' ' 91' ' ' PHE . . . -172.84 153.05 17.67 Favored Glycine 0 C--N 1.333 0.379 0 C-N-CA 119.483 -1.342 . . . . 15.91 112.73 174.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -93.41 108.97 20.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 108.967 -0.753 . . . . 2.09 108.967 170.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -112.24 162.02 15.95 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 121.52 0.676 . . . . 31.23 111.738 -167.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 69.5 t80 -137.99 140.87 40.4 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.591 -1.186 . . . . 17.94 107.842 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 89' ' ' ILE . 78.1 mt -87.15 130.32 37.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.823 -0.436 . . . . 17.08 109.823 -171.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.536 ' HB2' ' HB2' ' A' ' 131' ' ' SER . 98.0 mt-10 -73.12 -64.21 1.02 Allowed 'General case' 0 C--O 1.236 0.355 0 C-N-CA 119.816 -0.754 . . . . 25.56 110.742 164.605 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 74.7 m -142.05 149.61 40.17 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-O 121.7 0.762 . . . . 4.65 110.379 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 8.7 tmm_? -123.61 94.53 4.27 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 104.856 -2.276 . . . . 4.84 104.856 176.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.524 ' HB3' HG12 ' F' ' 37' ' ' VAL . 97.6 mt-10 -115.52 107.33 15.01 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.637 -1.245 . . . . 25.07 107.637 -175.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.538 ' HB3' ' HA ' ' A' ' 128' ' ' ILE . 19.7 p90 -113.05 144.58 42.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.556 0.693 . . . . 17.08 112.056 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' SER . . . . . . . . . . . . . 35.2 t -100.25 130.98 46.44 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 114.606 -1.179 . . . . 17.08 109.885 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.642 ' HB3' ' HB2' ' F' ' 34' ' ' ASP . 59.5 t0 -106.63 98.56 8.21 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 106.278 -1.749 . . . . 44.34 106.278 169.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.56 -157.87 22.91 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 121.685 0.603 . . . . 4.06 111.828 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.45 -62.66 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 108.141 -1.059 . . . . 22.24 108.141 176.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -85.44 -40.08 16.81 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 113.112 0.782 . . . . 64.97 113.112 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.549 ' HA2' HD21 ' L' ' 43' ' ' LEU . . . -74.12 149.71 41.32 Favored Glycine 0 N--CA 1.452 -0.261 0 N-CA-C 109.875 -1.29 . . . . 17.06 109.875 172.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.91 168.37 19.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.752 0.787 . . . . 17.08 110.163 175.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.637 HG12 ' HA ' ' A' ' 120' ' ' ASP . 30.5 m -68.93 146.19 12.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-N 115.138 -0.937 . . . . 17.08 109.878 -176.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -136.22 125.0 23.92 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-N 116.302 -0.408 . . . . 21.27 110.304 -176.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.538 ' HA ' ' HB3' ' A' ' 118' ' ' TYR . 86.6 mt -95.25 120.89 45.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 109.359 -0.608 . . . . 17.08 109.359 -177.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' SER . . . . . 0.488 ' HB2' ' O ' ' A' ' 117' ' ' GLU . 67.4 m -100.84 135.6 42.04 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.422 -0.955 . . . . 31.38 108.422 170.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.445 HD12 ' HE1' ' A' ' 67' ' ' TYR . 65.2 mt -137.88 129.37 38.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.406 0 N-CA-C 108.958 -0.756 . . . . 17.08 108.958 -177.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' SER . . . . . 0.536 ' HB2' ' HB2' ' A' ' 114' ' ' GLU . 58.4 m -95.86 151.7 19.16 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 121.054 0.454 . . . . 31.17 110.255 175.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.718 ' O ' ' HA ' ' A' ' 62' ' ' SER . 6.9 mp -135.87 139.64 43.52 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.198 -0.456 . . . . 54.41 111.144 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.441 ' HG2' ' HG3' ' A' ' 114' ' ' GLU . 91.1 mm-40 -120.67 137.22 54.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.546 -0.909 . . . . 17.08 108.546 170.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 11.4 p -136.69 148.57 26.81 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 108.508 -0.923 . . . . 9.66 108.508 175.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 18.5 mm -59.58 -59.34 4.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 121.304 0.574 . . . . 16.44 110.848 176.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -165.26 141.74 7.24 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 109.649 -1.38 . . . . 8.58 109.649 -177.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -69.61 155.17 40.91 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.618 0.723 . . . . 15.49 110.531 179.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 108' ' ' PHE . 33.2 tp -140.65 125.76 18.5 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.033 -1.469 . . . . 6.31 107.033 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -85.08 67.67 10.27 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 122.289 1.042 . . . . 20.25 109.871 -169.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -88.24 74.69 8.69 Favored 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 108.312 -0.996 . . . . 11.24 108.312 175.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.69 112.12 3.71 Favored Glycine 0 C--O 1.237 0.295 0 N-CA-C 110.373 -1.091 . . . . 21.84 110.373 174.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -118.65 -172.46 2.29 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 109.414 -0.587 . . . . 31.33 109.414 -174.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.67 HG22 ' H ' ' A' ' 103' ' ' LYS . 1.2 pp -107.02 -63.3 1.88 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 113.418 0.896 . . . . 37.79 113.418 -169.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ASP . . . . . . . . . . . . . 23.7 p-10 -80.86 129.41 34.51 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 118.928 0.785 . . . . 42.09 111.052 -168.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 66.9 p -121.65 12.0 10.62 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.345 0.498 . . . . 12.06 112.345 176.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.402 ' O ' ' N ' ' A' ' 148' ' ' GLU . 4.2 mm? 54.24 75.97 0.56 Allowed Pre-proline 0 C--O 1.238 0.458 0 C-N-CA 126.881 2.073 . . . . 21.66 110.184 -177.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -68.51 70.79 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 N-CA-C 115.392 1.266 . . . . 17.08 115.392 -161.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLU . . . . . 0.525 ' OE1' ' ND2' ' A' ' 152' ' ' ASN . 79.4 mm-40 -104.5 12.95 32.62 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.955 -0.566 . . . . 43.66 111.281 167.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 25.9 pm0 -139.43 4.76 2.21 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.545 0.572 . . . . 22.95 112.545 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.484 HG23 HG23 ' A' ' 96' ' ' THR . 46.1 mm -113.28 -49.7 5.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 118.738 0.699 . . . . 42.75 111.153 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 35.2 t -106.46 -26.88 3.18 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 N-CA-C 107.691 -1.226 . . . . 36.49 107.691 -177.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.525 ' ND2' ' OE1' ' A' ' 148' ' ' GLU . 36.7 t-20 -67.3 -32.02 72.72 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.227 -0.442 . . . . 23.02 111.642 -178.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -75.51 95.82 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.52 -1.289 . . . . 17.08 107.52 170.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.9 t -117.26 -61.91 1.64 Allowed 'General case' 0 C--O 1.234 0.278 0 CA-C-N 115.605 -0.725 . . . . 5.05 112.688 -172.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 17.7 tppt? -135.67 -28.92 1.08 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 113.751 1.019 . . . . 32.54 113.751 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.45 -52.39 3.07 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 119.243 0.929 . . . . 26.85 111.356 -170.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -83.69 143.3 21.49 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-O 122.122 0.845 . . . . 17.08 112.542 178.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.446 ' CD2' ' HG2' ' A' ' 171' ' ' PRO . 18.5 m-30 -112.03 -172.5 2.05 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 124.356 1.062 . . . . 21.15 108.717 177.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -79.33 -75.24 0.25 Allowed 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.642 -1.223 . . . . 47.89 113.111 -158.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.427 ' CD2' ' HG3' ' A' ' 162' ' ' GLN . 39.5 p90 176.85 173.01 0.44 Allowed 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 127.699 2.4 . . . . 17.08 109.528 168.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -156.56 99.68 1.9 Allowed 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 105.347 -2.094 . . . . 23.47 105.347 155.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLN . . . . . 0.427 ' HG3' ' CD2' ' A' ' 160' ' ' PHE . 89.2 mt-30 -69.47 -46.26 26.93 Favored Pre-proline 0 C--O 1.244 0.811 0 N-CA-C 113.978 1.103 . . . . 6.79 113.978 -167.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -77.54 -13.7 16.38 Favored 'Trans proline' 0 C--N 1.369 1.648 0 CA-C-N 122.288 1.853 . . . . 31.9 112.789 174.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -139.5 35.4 1.95 Allowed Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 119.527 2.571 . . . . 35.66 119.527 -169.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLN . . . . . 0.45 ' HG2' ' HD3' ' G' ' 90' ' ' LYS . 9.7 tp-100 -68.34 -60.73 2.24 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 119.056 1.428 . . . . 22.71 111.322 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 34.1 p 53.57 50.11 17.96 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.642 1.577 . . . . 56.03 111.709 178.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 3.0 m -139.27 147.72 42.05 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 119.872 -0.731 . . . . 6.18 109.6 -168.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -86.16 -124.8 1.63 Allowed Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.225 -0.75 . . . . 39.67 111.225 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 15.6 tm-20 -74.44 -63.32 1.26 Allowed 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.887 0.343 . . . . 24.43 111.364 -175.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.32 105.28 0.83 Allowed Pre-proline 0 C--O 1.235 0.318 0 C-N-CA 123.907 0.883 . . . . 14.12 109.426 -175.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.446 ' HG2' ' CD2' ' A' ' 158' ' ' TYR . 72.0 Cg_endo -78.64 -176.04 3.06 Favored 'Trans proline' 0 C--N 1.323 -0.774 0 C-N-CA 121.454 1.436 . . . . 13.98 113.115 -156.195 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.43 69.06 1.46 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 116.799 1.48 . . . . 21.94 116.799 165.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.6 t -130.23 166.18 20.86 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.946 0.879 . . . . 8.59 109.44 169.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.0 m -78.72 159.81 73.28 Favored Pre-proline 0 C--O 1.24 0.596 0 CA-C-N 114.601 -1.181 . . . . 18.25 107.949 177.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -68.32 106.36 1.38 Allowed 'Trans proline' 0 CA--C 1.512 -0.596 0 CA-C-N 119.787 0.96 . . . . 12.65 110.81 173.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.256 0 C-N-CA 125.149 1.38 . . . . 43.58 112.351 -168.551 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.576 ' HG3' HH11 ' H' ' 52' ' ' ARG . 52.3 Cg_endo . . . . . 0 N--CA 1.465 -0.168 0 CA-C-O 119.981 -0.091 . . . . 11.57 111.986 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.443 ' H ' ' HB2' ' B' ' 5' ' ' PRO . 96.7 mt -124.72 118.35 53.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.907 -1.145 . . . . 14.12 107.907 176.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' MET . . . . . . . . . . . . . 39.0 mmt -85.01 168.7 14.68 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.883 0.849 . . . . 36.26 110.639 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.73 -14.96 68.25 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.326 -0.852 . . . . 11.49 114.155 172.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -92.68 -14.21 28.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 117.598 0.699 . . . . 14.52 112.376 171.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -76.82 -5.27 47.58 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 114.088 1.144 . . . . 28.94 114.088 -171.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 60.1 t -127.03 124.33 64.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 119.734 1.152 . . . . 18.92 108.101 -177.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -133.56 164.96 26.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.593 0.711 . . . . 17.81 109.845 174.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' TYR . . . . . 0.414 ' CE1' ' HG3' ' B' ' 93' ' ' ARG . 19.4 m-30 -114.9 96.14 5.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.024 -0.989 . . . . 5.37 108.818 -163.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' LEU . . . . . 0.788 HD23 ' HB3' ' B' ' 27' ' ' LEU . 93.2 mt -73.54 123.24 23.57 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 120.708 -0.397 . . . . 31.94 109.949 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' PHE . . . . . . . . . . . . . 21.4 m-30 -107.45 150.89 26.26 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.763 -0.458 . . . . 20.34 109.763 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLN . . . . . . . . . . . . . 70.0 tp60 -144.99 135.57 24.38 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 109.099 -0.704 . . . . 14.51 109.099 174.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' SER . . . . . . . . . . . . . 36.8 t -74.59 157.48 35.36 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.619 -0.719 . . . . 1.99 111.077 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 41.9 pt -78.04 -15.49 14.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 113.229 0.826 . . . . 4.55 113.229 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -113.13 -8.59 13.57 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 112.775 0.657 . . . . 29.63 112.775 -169.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 119.689 -0.804 . . . . 24.14 111.488 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.43 41.16 32.14 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.014 1.326 . . . . 4.48 111.663 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' THR . . . . . . . . . . . . . 73.3 p -123.02 129.13 51.1 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.387 0.675 . . . . 17.5 109.208 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.73 76.55 2.17 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 116.268 -0.423 . . . . 11.69 114.075 -176.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' SER . . . . . . . . . . . . . 87.8 p -129.17 -29.05 2.3 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 120.59 -0.444 . . . . 26.57 111.711 -178.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' ALA . . . . . 0.444 ' HB1' ' HB3' ' B' ' 14' ' ' LEU . . . 51.79 74.59 0.77 Allowed Pre-proline 0 C--O 1.237 0.405 0 C-N-CA 126.842 2.057 . . . . 14.28 112.212 -172.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -71.75 104.22 1.58 Allowed 'Trans proline' 0 CA--C 1.516 -0.408 0 CA-C-N 119.578 0.885 . . . . 9.14 111.874 176.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' LEU . . . . . 0.788 ' HB3' HD23 ' B' ' 14' ' ' LEU . 2.1 pt? -84.89 163.75 18.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 108.882 -0.784 . . . . 2.07 108.882 166.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -100.24 143.2 26.06 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 111.906 -3.918 . . . . 7.13 110.0 -174.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -77.49 167.84 23.7 Favored 'Trans proline' 0 CA--C 1.517 -0.347 0 CA-C-N 119.038 0.692 . . . . 14.37 112.195 177.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.676 ' HA ' ' HB3' ' G' ' 47' ' ' GLN . . . 57.45 61.64 2.42 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.538 1.135 . . . . 17.09 112.04 177.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-30 -76.02 -176.17 3.36 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.834 1.302 . . . . 12.49 111.298 177.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' GLN . . . . . 0.482 ' HG3' ' H ' ' B' ' 33' ' ' THR . 7.2 tp-100 -144.07 -161.21 1.23 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 103.567 -2.753 . . . . 20.78 103.567 174.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' THR . . . . . 0.482 ' H ' ' HG3' ' B' ' 32' ' ' GLN . 12.9 t -64.39 163.04 13.88 Favored 'General case' 0 C--O 1.244 0.774 0 CA-C-O 122.749 1.261 . . . . 24.37 111.633 177.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' ASP . . . . . 0.493 ' HB2' ' HB3' ' C' ' 120' ' ' ASP . 82.5 m-20 -135.72 -169.4 2.4 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 113.977 -1.465 . . . . 38.73 108.194 -168.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' GLY . . . . . 0.673 ' O ' ' HA2' ' B' ' 63' ' ' GLY . . . 177.41 132.89 1.74 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.386 -0.825 . . . . 14.4 111.113 168.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' SER . . . . . . . . . . . . . 65.2 m -120.9 84.41 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 105.58 -2.008 . . . . 7.83 105.58 175.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' VAL . . . . . 0.58 HG23 ' HB2' ' B' ' 62' ' ' SER . 3.5 m -92.38 109.17 21.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 108.494 -0.928 . . . . 17.01 108.494 -172.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' SER . . . . . . . . . . . . . 44.2 m -100.13 98.74 9.42 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.719 -1.215 . . . . 18.87 107.719 -170.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . -101.17 104.29 2.71 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.283 -0.961 . . . . 0.18 113.165 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -107.36 121.22 44.15 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.52 -0.918 . . . . 9.21 108.52 -178.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.632 ' O ' ' HA3' ' B' ' 57' ' ' GLY . 89.3 mtm-85 -80.49 -176.27 5.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.731 0.776 . . . . 29.74 109.321 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -158.85 147.48 18.44 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.804 -0.56 . . . . 20.01 109.536 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' LEU . . . . . . . . . . . . . 70.1 mt -68.94 113.19 6.12 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 108.89 -0.782 . . . . 17.43 108.89 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -109.1 104.55 13.76 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 108.916 -0.772 . . . . 25.47 108.916 -173.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ASP . . . . . 0.526 ' HB2' ' HB3' ' B' ' 52' ' ' ARG . 77.1 m-20 -136.33 179.1 6.56 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.302 -0.408 . . . . 27.64 111.575 -175.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' GLU . . . . . 0.706 ' HA ' ' HA2' ' B' ' 51' ' ' GLY . 56.4 mp0 -128.35 -38.52 1.76 Allowed 'General case' 0 C--O 1.236 0.381 0 N-CA-C 113.67 0.989 . . . . 19.25 113.67 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' GLN . . . . . . . . . . . . . 79.9 mm-40 57.85 33.75 23.57 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.305 1.442 . . . . 23.02 112.448 175.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' THR . . . . . . . . . . . . . 44.3 p 52.53 39.84 28.7 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.305 1.442 . . . . 17.03 111.702 -172.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -138.12 -164.73 1.67 Allowed 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.497 -1.297 . . . . 4.31 107.497 -176.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -65.44 -27.71 68.71 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.252 -0.431 . . . . 23.58 112.044 173.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.706 ' HA2' ' HA ' ' B' ' 46' ' ' GLU . . . 148.06 157.71 7.62 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.928 -0.469 . . . . 11.19 111.928 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' ARG . . . . . 0.526 ' HB3' ' HB2' ' B' ' 45' ' ' ASP . 17.6 tpp85 -123.1 50.71 1.51 Allowed 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.328 -2.101 . . . . 5.06 105.328 176.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' ILE . . . . . . . . . . . . . 8.0 tt -81.3 -5.81 9.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 CA-C-N 115.202 -0.908 . . . . 30.68 111.083 -172.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' LEU . . . . . . . . . . . . . 7.2 mp -66.04 -20.5 66.2 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.767 0.655 . . . . 26.8 112.767 -177.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.65 145.21 43.38 Favored Glycine 0 N--CA 1.443 -0.836 0 CA-C-O 121.473 0.485 . . . . 12.91 114.08 -172.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -76.37 -179.8 5.64 Favored 'Trans proline' 0 C--N 1.327 -0.56 0 C-N-CA 121.284 1.323 . . . . 12.85 112.028 -175.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' GLY . . . . . 0.632 ' HA3' ' O ' ' B' ' 41' ' ' ARG . . . -151.89 172.92 31.22 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 109.679 -1.369 . . . . 19.44 109.679 178.499 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 58' ' ' SER . . . . . . . . . . . . . 46.7 t -75.28 146.55 40.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.604 0.716 . . . . 18.91 110.389 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 5.8 p -100.23 127.55 53.1 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.184 -1.043 . . . . 17.05 108.184 -178.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -125.49 113.19 17.15 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 106.976 -1.49 . . . . 0.01 106.976 173.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -115.11 120.88 41.3 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.814 -0.81 . . . . 28.32 108.814 -171.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 62' ' ' SER . . . . . 0.711 ' HA ' ' O ' ' B' ' 132' ' ' LEU . 70.8 m -107.09 164.68 11.95 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.484 1.114 . . . . 20.22 110.458 -176.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' GLY . . . . . 0.673 ' HA2' ' O ' ' B' ' 35' ' ' GLY . . . -139.74 121.66 2.08 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-N 115.173 -0.921 . . . . 6.63 112.529 175.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 64' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 -101.73 94.14 5.68 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 107.299 -1.371 . . . . 33.79 107.299 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 65' ' ' VAL . . . . . . . . . . . . . 89.5 t -106.23 120.05 56.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.053 -1.091 . . . . 17.03 108.053 -177.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 64.7 p -115.24 149.34 37.91 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.457 -0.572 . . . . 17.03 109.457 177.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -155.53 -174.12 4.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 108.976 -0.749 . . . . 12.32 108.976 174.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' TYR . . . . . . . . . . . . . 15.0 m-30 -114.16 136.26 53.13 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 109.414 -0.587 . . . . 15.04 109.414 174.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.85 113.15 3.62 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.84 -0.695 . . . . 15.65 113.936 -175.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.425 ' O ' ' NE2' ' B' ' 76' ' ' GLN . 38.5 ttmt -82.62 149.72 27.24 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.768 -0.827 . . . . 28.21 108.768 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -67.28 -16.68 64.42 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 114.002 1.112 . . . . 11.97 114.002 -170.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.22 -142.49 5.58 Favored Glycine 0 N--CA 1.451 -0.337 0 N-CA-C 110.153 -1.179 . . . . 24.43 110.153 176.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' ASP . . . . . . . . . . . . . 31.1 t0 59.86 74.86 0.43 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.048 1.339 . . . . 18.35 111.108 168.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.28 11.02 0.03 OUTLIER 'General case' 0 C--O 1.235 0.29 0 N-CA-C 117.535 2.42 . . . . 30.51 117.535 -160.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.78 -41.01 95.75 Favored Glycine 0 C--N 1.338 0.686 0 C-N-CA 120.356 -0.926 . . . . 16.26 112.797 170.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' GLN . . . . . 0.425 ' NE2' ' O ' ' B' ' 70' ' ' LYS . 21.8 pt20 -69.2 -24.36 64.02 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 119.865 -0.734 . . . . 19.69 111.819 172.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -72.58 -25.13 61.23 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 119.751 -0.78 . . . . 22.73 111.108 171.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.19 -31.42 60.93 Favored 'General case' 0 C--O 1.239 0.501 0 C-N-CA 120.67 -0.412 . . . . 17.07 111.238 170.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' ILE . . . . . . . . . . . . . 51.2 mm -63.16 -43.04 98.64 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.148 0.499 . . . . 4.35 110.291 171.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -75.64 -19.32 59.28 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.894 -0.504 . . . . 15.89 111.999 178.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -71.49 -31.37 67.05 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.972 -0.691 . . . . 26.41 111.027 167.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 82' ' ' ALA . . . . . 0.724 ' HA ' ' HB2' ' B' ' 87' ' ' LYS . . . -76.71 -29.32 56.19 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 119.668 -0.813 . . . . 15.34 111.775 175.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 83' ' ' TYR . . . . . . . . . . . . . 83.0 t80 -95.71 -60.39 1.66 Allowed 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.776 -0.77 . . . . 12.51 112.26 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -72.0 -42.0 66.96 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 111.701 0.259 . . . . 26.5 111.701 -170.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -75.0 -47.42 29.21 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 119.986 -0.685 . . . . 1.89 110.989 170.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.3 97.37 2.49 Favored Glycine 0 N--CA 1.449 -0.479 0 O-C-N 122.231 -0.293 . . . . 18.63 113.175 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' LYS . . . . . 0.724 ' HB2' ' HA ' ' B' ' 82' ' ' ALA . 98.3 mttt -147.41 -162.88 1.64 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 107.023 -1.473 . . . . 15.85 107.023 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' GLN . . . . . 0.526 ' HG2' ' HD1' ' B' ' 112' ' ' TYR . 25.7 mt-30 -127.68 173.36 9.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.317 0.579 . . . . 18.67 109.663 173.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 70.5 mt -128.53 134.44 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.059 0.457 . . . . 27.24 109.847 -171.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -85.11 119.28 25.32 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.603 -0.888 . . . . 23.04 108.603 165.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' PHE . . . . . 0.42 ' HB3' ' O ' ' B' ' 109' ' ' GLY . 79.8 t80 -116.7 126.86 53.78 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 124.463 1.105 . . . . 23.66 110.195 -165.605 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 92' ' ' TRP . . . . . 0.485 ' HB2' ' HB2' ' B' ' 14' ' ' LEU . 90.0 m95 -127.29 127.43 44.33 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.949 0.9 . . . . 25.7 109.018 -177.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 93' ' ' ARG . . . . . 0.763 ' O ' ' HA ' ' B' ' 106' ' ' ALA . 78.1 ttt-85 -109.3 95.43 5.62 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.261 -1.015 . . . . 8.0 108.261 173.016 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' VAL . . . . . 0.531 HG12 ' HB2' ' B' ' 106' ' ' ALA . 24.7 m -109.52 162.27 7.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 122.196 0.998 . . . . 9.85 109.652 -172.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -109.95 169.16 8.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.94 -1.027 . . . . 17.12 111.411 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.549 HG23 HG23 ' B' ' 150' ' ' ILE . 33.3 m -101.65 -29.85 11.69 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 114.862 -1.063 . . . . 10.7 112.594 -175.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 35.6 m -68.9 153.17 9.06 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 CA-C-O 121.738 0.78 . . . . 3.84 110.16 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' LYS . . . . . 0.486 ' NZ ' ' O ' ' B' ' 99' ' ' ASN . 29.7 tptp -89.45 125.85 35.33 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.619 -0.719 . . . . 16.58 109.739 -176.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 99' ' ' ASN . . . . . 0.486 ' O ' ' NZ ' ' B' ' 98' ' ' LYS . 34.4 m120 -85.19 168.41 14.81 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 121.843 0.83 . . . . 17.28 110.031 172.141 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 55.9 mp0 -103.28 -14.76 16.19 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 113.593 0.96 . . . . 25.01 113.593 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 101' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -94.48 -47.86 6.37 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.303 0.501 . . . . 7.65 111.16 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -108.5 -175.17 2.7 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 108.836 -0.801 . . . . 20.36 108.836 175.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' LYS . . . . . 0.675 ' H ' HG22 ' B' ' 143' ' ' ILE . 97.6 mttt -80.6 -57.3 3.64 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.216 0.532 . . . . 29.0 110.165 168.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 104' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -133.11 -173.34 3.17 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.897 -1.149 . . . . 23.56 107.897 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' B' ' 94' ' ' VAL . 25.8 p-10 -146.99 168.61 21.09 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.575 0.702 . . . . 13.41 109.706 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.763 ' HA ' ' O ' ' B' ' 93' ' ' ARG . . . -154.13 158.01 39.77 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.167 -0.924 . . . . 19.83 111.166 -162.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 107' ' ' GLN . . . . . 0.455 ' OE1' ' OH ' ' C' ' 118' ' ' TYR . 88.9 mt-30 -119.03 123.18 43.89 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.123 -1.436 . . . . 9.01 107.123 159.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 108' ' ' PHE . . . . . 0.441 ' HB3' ' O ' ' B' ' 138' ' ' LEU . 87.7 t80 -111.58 151.1 29.12 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 124.196 0.998 . . . . 7.97 110.526 -163.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 109' ' ' GLY . . . . . 0.42 ' O ' ' HB3' ' B' ' 91' ' ' PHE . . . -170.4 156.01 26.1 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 119.743 -1.218 . . . . 3.32 112.591 174.517 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 110' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -95.21 108.45 20.58 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 109.023 -0.732 . . . . 7.98 109.023 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.71 161.7 15.5 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-O 121.513 0.673 . . . . 28.03 111.769 -166.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' TYR . . . . . 0.526 ' HD1' ' HG2' ' B' ' 88' ' ' GLN . 52.8 t80 -140.24 138.21 34.88 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.659 -1.155 . . . . 19.65 107.963 -177.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 82.9 mt -85.13 128.75 38.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 109.984 -0.376 . . . . 8.33 109.984 -171.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 114' ' ' GLU . . . . . 0.512 ' HB2' ' HB2' ' B' ' 131' ' ' SER . 98.1 mt-10 -71.11 -64.08 0.98 Allowed 'General case' 0 C--O 1.234 0.287 0 C-N-CA 119.779 -0.768 . . . . 32.15 110.668 163.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 115' ' ' SER . . . . . . . . . . . . . 73.7 m -142.32 149.45 39.49 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.581 0.705 . . . . 15.75 110.375 -169.163 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -123.13 94.75 4.36 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 105.039 -2.208 . . . . 15.68 105.039 175.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 117' ' ' GLU . . . . . 0.539 ' HB3' HG12 ' A' ' 37' ' ' VAL . 98.3 mt-10 -115.35 108.52 16.65 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.409 -1.33 . . . . 21.71 107.409 -176.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 118' ' ' TYR . . . . . 0.511 ' HB3' ' HA ' ' B' ' 128' ' ' ILE . 25.2 p90 -112.95 139.22 48.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.616 0.722 . . . . 9.23 111.854 177.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 119' ' ' SER . . . . . . . . . . . . . 37.4 t -95.66 131.37 41.97 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 114.6 -1.182 . . . . 17.03 109.821 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.562 ' HA ' HG12 ' B' ' 126' ' ' VAL . 59.6 t0 -111.15 100.42 9.08 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 106.5 -1.667 . . . . 12.65 106.5 172.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 121' ' ' GLY . . . . . . . . . . . . . . . -83.12 -158.55 25.8 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-O 121.707 0.615 . . . . 12.21 112.014 177.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 122' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.08 -62.36 2.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 107.969 -1.122 . . . . 20.2 107.969 177.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 123' ' ' GLU . . . . . 0.489 ' OE2' ' NH2' ' G' ' 41' ' ' ARG . 94.9 mt-10 -91.49 -36.38 13.77 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.204 0.816 . . . . 40.23 113.204 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 124' ' ' GLY . . . . . 0.566 ' HA2' HD21 ' G' ' 43' ' ' LEU . . . -70.85 142.86 35.51 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 109.939 -1.264 . . . . 13.54 109.939 172.218 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.09 165.57 23.25 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.774 0.797 . . . . 14.45 110.339 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.562 HG12 ' HA ' ' B' ' 120' ' ' ASP . 27.5 m -68.78 149.08 11.39 Favored 'Isoleucine or valine' 0 C--O 1.238 0.49 0 CA-C-N 115.111 -0.949 . . . . 17.47 109.749 -176.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 127' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -138.8 126.23 21.73 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.295 -0.411 . . . . 25.05 109.994 -179.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 128' ' ' ILE . . . . . 0.511 ' HA ' ' HB3' ' B' ' 118' ' ' TYR . 89.5 mt -93.65 118.58 39.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.034 -0.728 . . . . 3.81 109.034 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 129' ' ' SER . . . . . 0.513 ' HB2' ' O ' ' B' ' 117' ' ' GLU . 69.2 m -98.61 133.66 42.65 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.365 -0.976 . . . . 20.76 108.365 171.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 68.9 mt -135.57 128.51 47.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.054 -0.721 . . . . 15.91 109.054 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 131' ' ' SER . . . . . 0.512 ' HB2' ' HB2' ' B' ' 114' ' ' GLU . 50.2 m -96.14 151.66 19.27 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.129 -0.487 . . . . 19.9 110.005 175.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.711 ' O ' ' HA ' ' B' ' 62' ' ' SER . 7.1 mp -136.07 142.79 44.4 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 29.36 110.906 -177.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 133' ' ' GLN . . . . . 0.549 ' NE2' ' OG ' ' B' ' 62' ' ' SER . 89.7 mm-40 -124.67 137.13 54.38 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.236 -1.024 . . . . 3.24 108.236 169.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -136.36 148.88 27.07 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 108.65 -0.871 . . . . 0.37 108.65 175.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 16.0 mm -60.42 -59.11 4.63 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.244 0.545 . . . . 8.07 110.826 176.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 136' ' ' GLY . . . . . . . . . . . . . . . -165.04 139.5 5.86 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 109.611 -1.396 . . . . 15.08 109.611 -176.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -67.58 151.17 47.78 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.571 0.701 . . . . 14.21 110.547 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 138' ' ' LEU . . . . . 0.441 ' O ' ' HB3' ' B' ' 108' ' ' PHE . 35.2 tp -140.55 125.25 18.06 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.166 -1.42 . . . . 11.08 107.166 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.98 69.11 10.23 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 122.287 1.041 . . . . 22.24 109.796 -168.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -87.98 74.82 8.87 Favored 'General case' 0 C--N 1.333 -0.137 0 N-CA-C 108.18 -1.044 . . . . 15.48 108.18 175.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.4 113.86 4.44 Favored Glycine 0 C--O 1.237 0.32 0 N-CA-C 110.546 -1.021 . . . . 18.71 110.546 176.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -118.45 -172.84 2.35 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.344 -0.613 . . . . 30.93 109.344 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 143' ' ' ILE . . . . . 0.675 HG22 ' H ' ' B' ' 103' ' ' LYS . 1.3 pp -109.66 -61.93 2.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 N-CA-C 113.191 0.811 . . . . 20.34 113.191 -169.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -80.83 125.22 29.82 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.384 -0.822 . . . . 24.01 110.964 -169.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 145' ' ' THR . . . . . . . . . . . . . 70.8 p -117.59 13.37 14.3 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 119.024 -0.512 . . . . 16.28 112.357 178.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 146' ' ' LEU . . . . . . . . . . . . . 4.1 mm? 54.24 75.63 0.6 Allowed Pre-proline 0 C--O 1.237 0.423 0 C-N-CA 126.953 2.101 . . . . 22.38 110.478 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -68.79 71.05 1.08 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 N-CA-C 115.498 1.307 . . . . 12.25 115.498 -160.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 148' ' ' GLU . . . . . 0.516 ' OE1' ' ND2' ' B' ' 152' ' ' ASN . 79.8 mm-40 -105.08 13.17 31.23 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.221 -0.445 . . . . 18.96 111.387 167.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 149' ' ' GLU . . . . . . . . . . . . . 25.8 pm0 -139.79 3.41 2.05 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 112.776 0.658 . . . . 14.88 112.776 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 150' ' ' ILE . . . . . 0.549 HG23 HG23 ' B' ' 96' ' ' THR . 50.0 mm -115.03 -52.13 4.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.807 0.73 . . . . 17.32 111.228 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 151' ' ' VAL . . . . . . . . . . . . . 23.8 t -105.5 -24.79 3.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 107.457 -1.312 . . . . 20.57 107.457 -176.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 152' ' ' ASN . . . . . 0.516 ' ND2' ' OE1' ' B' ' 148' ' ' GLU . 39.0 t-20 -66.95 -33.19 75.04 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.238 -0.437 . . . . 20.95 111.565 179.382 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.72 96.44 1.23 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.42 1.105 . . . . 19.59 108.046 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 154' ' ' SER . . . . . . . . . . . . . 37.4 t -117.48 -61.1 1.74 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.494 -0.775 . . . . 13.41 112.501 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 155' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -134.93 -29.09 1.15 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 113.794 1.035 . . . . 36.82 113.794 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.71 -59.88 4.26 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 110.581 -1.008 . . . . 21.4 110.581 -167.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.85 143.84 28.2 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.535 -0.84 . . . . 4.23 112.42 177.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 158' ' ' TYR . . . . . 0.423 ' CD2' ' HG2' ' B' ' 171' ' ' PRO . 16.9 m-30 -113.59 -172.03 2.0 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.861 1.264 . . . . 22.36 108.997 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 159' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -79.16 -74.94 0.26 Allowed 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 118.771 -1.172 . . . . 26.78 113.134 -156.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 160' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' B' ' 162' ' ' GLN . 39.0 p90 177.12 172.1 0.5 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 127.413 2.285 . . . . 1.94 109.676 168.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -156.87 99.77 1.86 Allowed 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 105.426 -2.064 . . . . 12.07 105.426 155.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.412 ' HG3' ' CD2' ' B' ' 160' ' ' PHE . 90.2 mt-30 -69.64 -45.26 25.43 Favored Pre-proline 0 C--O 1.243 0.754 0 N-CA-C 114.001 1.112 . . . . 8.3 114.001 -166.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -78.01 -13.68 15.61 Favored 'Trans proline' 0 C--N 1.369 1.628 0 CA-C-N 122.22 1.829 . . . . 17.94 112.62 173.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 164' ' ' GLY . . . . . . . . . . . . . . . -140.13 34.95 1.95 Allowed Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 119.889 2.716 . . . . 22.02 119.889 -170.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 165' ' ' GLN . . . . . 0.433 ' HG2' ' HD3' ' H' ' 90' ' ' LYS . 9.7 tp-100 -68.45 -57.86 5.21 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 119.257 1.529 . . . . 21.64 111.09 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 166' ' ' THR . . . . . . . . . . . . . 31.2 p 54.18 49.54 18.47 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.745 1.618 . . . . 29.91 111.728 176.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 167' ' ' THR . . . . . 0.463 HG21 ' HA ' ' B' ' 171' ' ' PRO . 3.2 m -139.47 149.23 43.76 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 119.835 -0.746 . . . . 11.07 109.547 -167.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 168' ' ' GLY . . . . . . . . . . . . . . . -85.7 -124.37 1.46 Allowed Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.87 -0.892 . . . . 22.27 110.87 169.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 169' ' ' GLU . . . . . . . . . . . . . 15.6 tm-20 -74.37 -63.84 1.15 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 120.548 -0.461 . . . . 18.3 111.304 -176.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.41 104.5 0.66 Allowed Pre-proline 0 C--O 1.235 0.326 0 C-N-CA 124.057 0.943 . . . . 22.28 109.887 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 171' ' ' PRO . . . . . 0.463 ' HA ' HG21 ' B' ' 167' ' ' THR . 90.2 Cg_endo -80.04 -172.93 1.66 Allowed 'Trans proline' 0 C--N 1.323 -0.779 0 C-N-CA 121.475 1.45 . . . . 14.9 112.983 -156.238 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.43 68.65 1.56 Allowed Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 116.481 1.352 . . . . 17.93 116.481 166.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 173' ' ' THR . . . . . . . . . . . . . 11.4 t -133.28 166.14 23.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.909 0.861 . . . . 15.99 109.426 170.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -82.3 158.59 66.35 Favored Pre-proline 0 C--O 1.239 0.547 0 N-CA-C 107.334 -1.358 . . . . 14.16 107.334 174.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 175' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -67.27 108.94 1.65 Allowed 'Trans proline' 0 CA--C 1.514 -0.524 0 CA-C-N 119.769 0.953 . . . . 26.18 111.469 175.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.246 0 C-N-CA 125.295 1.438 . . . . 26.62 112.443 -174.113 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 5' ' ' PRO . . . . . 0.538 ' HG3' HH11 ' I' ' 52' ' ' ARG . 56.1 Cg_endo . . . . . 0 N--CA 1.464 -0.213 0 N-CA-C 112.213 0.044 . . . . 5.92 112.213 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 6' ' ' ILE . . . . . 0.466 ' H ' ' HB2' ' C' ' 5' ' ' PRO . 96.6 mt -124.53 119.32 56.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 N-CA-C 107.896 -1.15 . . . . 20.07 107.896 176.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -79.59 173.17 12.85 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 121.945 0.878 . . . . 39.14 110.381 178.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 8' ' ' GLY . . . . . . . . . . . . . . . -72.89 -10.88 77.98 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.546 -0.835 . . . . 17.34 113.81 167.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 9' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -97.04 -15.82 20.85 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.788 0.835 . . . . 3.53 112.215 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 10' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -74.93 -5.48 44.04 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 114.192 1.182 . . . . 33.8 114.192 -171.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' VAL . . . . . . . . . . . . . 83.1 t -128.17 125.51 64.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 N-CA-C 107.983 -1.117 . . . . 6.96 107.983 -177.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 12' ' ' LYS . . . . . 0.431 ' NZ ' ' O ' ' C' ' 149' ' ' GLU . 51.8 mtmt -132.92 161.92 32.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.526 0.679 . . . . 27.15 110.009 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 13' ' ' TYR . . . . . 0.417 ' CE1' ' HG3' ' C' ' 93' ' ' ARG . 19.1 m-30 -112.14 96.52 6.08 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 108.046 -1.094 . . . . 17.34 108.046 -165.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 14' ' ' LEU . . . . . 0.716 HD23 ' HB3' ' C' ' 27' ' ' LEU . 89.6 mt -74.68 126.24 30.44 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.961 -0.385 . . . . 45.31 109.961 177.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 15' ' ' PHE . . . . . . . . . . . . . 21.5 m-30 -108.69 151.12 26.6 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.138 0.494 . . . . 30.29 109.921 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 16' ' ' GLN . . . . . . . . . . . . . 70.2 tp60 -145.27 135.68 24.15 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.033 -0.729 . . . . 31.67 109.033 174.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' SER . . . . . . . . . . . . . 37.8 t -76.23 153.62 35.89 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.616 0.722 . . . . 6.1 110.978 178.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -76.41 -13.5 14.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.266 0.839 . . . . 17.34 113.266 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -111.96 -8.42 14.08 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 112.678 0.621 . . . . 49.35 112.678 -171.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.63 -46.83 35.7 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 119.759 -0.776 . . . . 27.9 111.536 -176.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . 54.24 39.75 31.09 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.053 1.341 . . . . 16.85 111.677 -172.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' THR . . . . . . . . . . . . . 69.8 p -123.23 129.07 50.88 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.426 0.69 . . . . 3.25 109.431 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.6 76.01 2.29 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 114.294 0.477 . . . . 6.37 114.294 -177.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 24' ' ' SER . . . . . . . . . . . . . 92.1 p -129.69 -26.08 2.51 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 120.487 -0.485 . . . . 40.57 111.654 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.16 73.6 0.95 Allowed Pre-proline 0 C--O 1.237 0.441 0 C-N-CA 126.869 2.067 . . . . 53.81 112.511 -173.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -72.27 104.36 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 CA-C-N 119.591 0.89 . . . . 15.14 111.71 176.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.716 ' HB3' HD23 ' C' ' 14' ' ' LEU . 2.1 pt? -86.36 153.6 21.81 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 108.801 -0.814 . . . . 17.34 108.801 166.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 28' ' ' PHE . . . . . 0.479 ' HE1' ' HB3' ' C' ' 73' ' ' ASP . 69.7 t80 -99.88 130.06 27.23 Favored Pre-proline 0 C--N 1.318 -0.791 1 C-N-CA 110.635 -4.426 . . . . 22.15 110.207 -178.118 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 29' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -73.91 -172.0 1.01 Allowed 'Trans proline' 0 C--O 1.235 0.344 0 C-N-CA 120.518 0.812 . . . . 29.33 113.708 -177.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.654 ' HA ' ' HB3' ' H' ' 47' ' ' GLN . . . 55.79 57.66 5.05 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.517 1.127 . . . . 3.88 111.339 -175.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 31' ' ' TYR . . . . . . . . . . . . . 1.5 m-30 -69.93 -179.02 1.72 Allowed 'General case' 0 N--CA 1.455 -0.199 0 CA-C-O 123.067 1.413 . . . . 45.02 112.403 -179.195 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' GLN . . . . . 0.474 ' HG3' ' H ' ' C' ' 33' ' ' THR . 6.9 tp-100 -148.82 -159.36 1.02 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 103.305 -2.85 . . . . 21.77 103.305 168.175 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' THR . . . . . 0.474 ' H ' ' HG3' ' C' ' 32' ' ' GLN . 15.3 t -65.95 164.92 14.13 Favored 'General case' 0 C--O 1.242 0.707 0 CA-C-O 122.67 1.224 . . . . 21.71 111.616 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 34' ' ' ASP . . . . . 0.582 ' HB2' ' HB3' ' D' ' 120' ' ' ASP . 84.6 m-20 -135.4 -168.46 2.19 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 114.04 -1.437 . . . . 44.64 108.269 -167.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' GLY . . . . . 0.593 ' O ' ' HA2' ' C' ' 63' ' ' GLY . . . 172.25 135.11 1.9 Allowed Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.507 -0.769 . . . . 7.58 111.464 170.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 36' ' ' SER . . . . . . . . . . . . . 67.7 m -125.74 84.62 2.29 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 106.016 -1.846 . . . . 5.6 106.016 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 37' ' ' VAL . . . . . 0.584 HG23 ' HB2' ' C' ' 62' ' ' SER . 4.2 m -90.62 111.33 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 108.314 -0.995 . . . . 19.14 108.314 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 38' ' ' SER . . . . . . . . . . . . . 47.6 m -101.28 93.66 5.55 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.935 -1.135 . . . . 36.05 107.935 -169.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.92 102.64 2.84 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.13 -1.033 . . . . 35.7 113.475 -177.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -108.61 125.28 51.68 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 108.499 -0.926 . . . . 11.65 108.499 -178.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 41' ' ' ARG . . . . . 0.567 ' O ' ' HA3' ' C' ' 57' ' ' GLY . 87.8 mtm-85 -84.63 -173.04 4.51 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.615 0.722 . . . . 37.37 109.086 -178.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 42' ' ' GLU . . . . . . . . . . . . . 20.8 pt-20 -161.02 148.1 15.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.523 -0.547 . . . . 38.55 109.523 -170.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 43' ' ' LEU . . . . . . . . . . . . . 72.2 mt -69.73 124.26 23.51 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 108.926 -0.768 . . . . 27.59 108.926 177.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -124.12 101.23 7.1 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.233 -0.654 . . . . 37.44 109.233 -169.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 45' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -137.23 -177.27 4.7 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 122.733 0.413 . . . . 41.82 111.44 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 46' ' ' GLU . . . . . 0.706 ' HA ' ' HA2' ' C' ' 51' ' ' GLY . 57.5 mp0 -127.27 -37.67 2.03 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 113.398 0.888 . . . . 16.37 113.398 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 47' ' ' GLN . . . . . . . . . . . . . 85.5 mm-40 60.05 33.77 21.32 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.051 1.341 . . . . 39.23 112.622 170.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 48' ' ' THR . . . . . . . . . . . . . 49.1 p 52.61 39.32 28.01 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.137 1.375 . . . . 17.34 111.625 -171.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 49' ' ' LYS . . . . . . . . . . . . . 48.5 mmtm -138.09 -165.42 1.79 Allowed 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.534 -1.284 . . . . 17.52 107.534 -177.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -68.42 -25.7 65.16 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.27 -0.423 . . . . 24.92 112.038 173.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 51' ' ' GLY . . . . . 0.706 ' HA2' ' HA ' ' C' ' 46' ' ' GLU . . . 144.9 160.12 8.39 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 117.908 0.322 . . . . 24.58 112.597 179.006 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 52' ' ' ARG . . . . . . . . . . . . . 16.4 tpp85 -122.93 49.96 1.58 Allowed 'General case' 0 C--O 1.234 0.289 0 N-CA-C 105.425 -2.065 . . . . 19.34 105.425 176.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 53' ' ' ILE . . . . . . . . . . . . . 7.7 tt -82.31 -5.2 8.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-N 115.319 -0.855 . . . . 43.76 110.942 -173.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 54' ' ' LEU . . . . . . . . . . . . . 6.8 mp -64.85 -23.64 67.3 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 112.597 0.591 . . . . 34.39 112.597 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.0 143.37 41.37 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.461 0.478 . . . . 1.68 113.997 -170.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.77 177.16 8.86 Favored 'Trans proline' 0 C--N 1.327 -0.584 0 C-N-CA 121.333 1.355 . . . . 14.03 112.031 -174.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 57' ' ' GLY . . . . . 0.567 ' HA3' ' O ' ' C' ' 41' ' ' ARG . . . -148.14 173.31 28.2 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 109.619 -1.392 . . . . 28.69 109.619 177.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 58' ' ' SER . . . . . . . . . . . . . 42.8 t -75.76 148.36 38.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.582 0.706 . . . . 2.63 110.498 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -101.06 131.99 47.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 107.901 -1.148 . . . . 17.34 107.901 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 60' ' ' ALA . . . . . . . . . . . . . . . -128.72 113.23 15.1 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.714 -1.588 . . . . 21.3 106.714 171.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 61' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -114.13 120.5 40.74 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.7 -0.852 . . . . 35.31 108.7 -170.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 62' ' ' SER . . . . . 0.733 ' HA ' ' O ' ' C' ' 132' ' ' LEU . 71.1 m -106.6 163.0 13.25 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.462 1.105 . . . . 5.42 110.252 -176.261 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 63' ' ' GLY . . . . . 0.593 ' HA2' ' O ' ' C' ' 35' ' ' GLY . . . -138.47 121.08 2.09 Favored Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 115.049 -0.978 . . . . 17.34 112.217 176.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 64' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -99.47 96.45 7.69 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 107.272 -1.381 . . . . 47.51 107.272 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 65' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.84 117.84 51.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.148 -1.056 . . . . 17.34 108.148 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 66' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' C' ' 33' ' ' THR . 67.2 p -113.77 144.37 43.1 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.134 -0.691 . . . . 9.84 109.134 176.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 67' ' ' TYR . . . . . 0.44 ' HE1' HD12 ' C' ' 130' ' ' ILE . 52.7 p90 -155.13 -175.06 5.25 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.814 -0.809 . . . . 20.72 108.814 176.056 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 68' ' ' TYR . . . . . . . . . . . . . 14.9 m-30 -114.55 137.32 52.02 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 109.311 -0.626 . . . . 17.34 109.311 174.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 69' ' ' GLY . . . . . . . . . . . . . . . -85.18 111.47 3.53 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.938 -0.649 . . . . 17.34 114.122 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 70' ' ' LYS . . . . . 0.409 ' O ' ' NE2' ' C' ' 76' ' ' GLN . 38.3 ttmt -80.0 153.35 28.92 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 108.645 -0.872 . . . . 17.34 108.645 174.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -68.67 -15.61 63.57 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 114.048 1.129 . . . . 24.92 114.048 -171.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.63 -141.49 5.19 Favored Glycine 0 N--CA 1.451 -0.327 0 N-CA-C 110.217 -1.153 . . . . 51.19 110.217 177.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 73' ' ' ASP . . . . . 0.479 ' HB3' ' HE1' ' C' ' 28' ' ' PHE . 30.1 t0 60.06 72.89 0.5 Allowed 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.166 1.386 . . . . 18.34 111.169 168.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.3 10.94 0.05 Allowed 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 117.241 2.312 . . . . 52.71 117.241 -160.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.51 -40.1 93.97 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 120.172 -1.013 . . . . 16.66 112.513 169.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 76' ' ' GLN . . . . . 0.409 ' NE2' ' O ' ' C' ' 70' ' ' LYS . 22.2 pt20 -69.96 -22.37 63.17 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 119.894 -0.722 . . . . 29.16 111.938 172.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -73.78 -25.36 60.1 Favored 'General case' 0 CA--C 1.517 -0.31 0 C-N-CA 119.359 -0.936 . . . . 18.43 111.411 170.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.98 -31.85 64.81 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 120.236 -0.586 . . . . 44.7 111.102 169.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 79' ' ' ILE . . . . . . . . . . . . . 51.0 mm -62.94 -45.31 99.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-O 121.066 0.46 . . . . 34.23 110.455 172.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -75.41 -21.08 58.5 Favored 'General case' 0 C--O 1.235 0.295 0 O-C-N 121.899 -0.5 . . . . 25.41 112.016 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 81' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -69.18 -34.33 74.77 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 120.223 -0.591 . . . . 39.48 111.178 167.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 82' ' ' ALA . . . . . 0.696 ' HA ' ' HB2' ' C' ' 87' ' ' LYS . . . -73.3 -36.7 66.32 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 119.661 -0.816 . . . . 17.34 111.667 176.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 83' ' ' TYR . . . . . . . . . . . . . 83.0 t80 -84.08 -62.23 1.62 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 120.284 -0.566 . . . . 7.56 112.047 -176.159 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -73.81 -42.41 60.97 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.919 0.34 . . . . 25.84 111.919 -167.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 85' ' ' ASN . . . . . . . . . . . . . 35.6 m120 -76.2 -44.99 35.24 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 119.885 -0.726 . . . . 7.51 111.075 173.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.31 96.73 2.4 Favored Glycine 0 N--CA 1.449 -0.486 0 O-C-N 122.255 -0.278 . . . . 4.2 113.374 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 87' ' ' LYS . . . . . 0.696 ' HB2' ' HA ' ' C' ' 82' ' ' ALA . 98.0 mttt -148.26 -162.72 1.61 Allowed 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 107.165 -1.42 . . . . 17.34 107.165 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 88' ' ' GLN . . . . . 0.567 ' HG2' ' HD1' ' C' ' 112' ' ' TYR . 27.2 mt-30 -129.39 174.24 9.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.371 0.605 . . . . 17.34 109.718 172.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 89' ' ' ILE . . . . . 0.403 HD11 HD11 ' C' ' 113' ' ' ILE . 72.9 mt -128.67 134.99 63.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 116.108 -0.496 . . . . 28.06 109.698 -173.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 90' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -84.54 117.41 23.69 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.66 -0.867 . . . . 24.09 108.66 165.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 91' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -112.64 127.59 56.15 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.766 1.226 . . . . 25.04 110.179 -167.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 92' ' ' TRP . . . . . 0.478 ' HB2' ' HB2' ' C' ' 14' ' ' LEU . 90.1 m95 -126.51 130.94 51.59 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 124.131 0.972 . . . . 7.39 108.749 -178.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 93' ' ' ARG . . . . . 0.774 ' O ' ' HA ' ' C' ' 106' ' ' ALA . 78.4 ttt-85 -113.83 93.73 4.51 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 108.136 -1.061 . . . . 30.73 108.136 172.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 94' ' ' VAL . . . . . 0.565 HG12 ' HB2' ' C' ' 106' ' ' ALA . 21.6 m -107.71 163.07 5.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 122.344 1.069 . . . . 28.65 109.679 -172.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 95' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -106.21 165.79 10.99 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 114.719 -1.128 . . . . 15.99 111.343 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 96' ' ' THR . . . . . 0.562 HG23 HD12 ' C' ' 150' ' ' ILE . 30.1 m -101.33 -29.87 11.81 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 114.89 -1.05 . . . . 20.04 112.338 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 97' ' ' VAL . . . . . . . . . . . . . 35.0 m -68.92 153.43 8.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.464 0 CA-C-O 121.806 0.813 . . . . 2.88 109.968 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 98' ' ' LYS . . . . . 0.517 ' NZ ' ' O ' ' C' ' 99' ' ' ASN . 29.8 tptp -89.58 125.79 35.36 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.67 -0.696 . . . . 21.89 109.674 -176.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 99' ' ' ASN . . . . . 0.517 ' O ' ' NZ ' ' C' ' 98' ' ' LYS . 35.8 m120 -86.43 168.37 13.84 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.77 0.795 . . . . 6.97 109.792 171.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 100' ' ' GLU . . . . . . . . . . . . . 55.1 mp0 -104.31 -13.0 16.3 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 113.824 1.046 . . . . 29.49 113.824 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 101' ' ' ASN . . . . . . . . . . . . . 16.2 p30 -91.94 -59.59 2.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 118.408 0.549 . . . . 48.44 111.48 165.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 102' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -98.27 -179.75 4.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 108.631 -0.877 . . . . 25.22 108.631 174.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 103' ' ' LYS . . . . . 0.724 ' H ' HG22 ' C' ' 143' ' ' ILE . 96.9 mttt -75.2 -56.95 4.22 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 120.265 -0.574 . . . . 45.03 110.073 169.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 104' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -133.96 -170.93 2.61 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 108.179 -1.045 . . . . 16.91 108.179 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 105' ' ' ASP . . . . . 0.51 ' O ' ' HA ' ' C' ' 94' ' ' VAL . 20.7 p-10 -151.25 171.03 18.06 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.498 0.665 . . . . 20.23 109.512 176.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 106' ' ' ALA . . . . . 0.774 ' HA ' ' O ' ' C' ' 93' ' ' ARG . . . -154.21 153.93 32.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.222 -0.899 . . . . 30.47 111.104 -164.192 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 107' ' ' GLN . . . . . 0.461 ' OE1' ' OH ' ' D' ' 118' ' ' TYR . 87.3 mt-30 -110.82 125.66 53.82 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 106.828 -1.545 . . . . 7.39 106.828 156.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 108' ' ' PHE . . . . . 0.637 ' HB3' ' O ' ' C' ' 138' ' ' LEU . 88.0 t80 -117.03 153.33 32.89 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 123.654 0.782 . . . . 14.88 110.698 -160.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 109' ' ' GLY . . . . . . . . . . . . . . . -172.78 163.01 34.78 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 119.156 -1.497 . . . . 6.03 112.924 172.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 110' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -99.08 109.2 21.96 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 108.874 -0.787 . . . . 17.34 108.874 168.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 111' ' ' ALA . . . . . . . . . . . . . . . -112.3 161.61 16.43 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.522 0.677 . . . . 5.64 111.799 -166.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 112' ' ' TYR . . . . . 0.567 ' HD1' ' HG2' ' C' ' 88' ' ' GLN . 58.3 t80 -138.73 138.43 37.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.575 -1.193 . . . . 14.03 107.817 -176.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 113' ' ' ILE . . . . . 0.403 HD11 HD11 ' C' ' 89' ' ' ILE . 79.6 mt -84.25 130.1 36.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 N-CA-C 109.777 -0.453 . . . . 17.76 109.777 -172.248 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 114' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' C' ' 131' ' ' SER . 98.5 mt-10 -73.67 -64.32 1.02 Allowed 'General case' 0 C--O 1.235 0.319 0 C-N-CA 119.779 -0.768 . . . . 49.83 110.654 163.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 115' ' ' SER . . . . . . . . . . . . . 72.8 m -142.08 149.46 39.93 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.65 0.738 . . . . 32.52 110.355 -167.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 116' ' ' ARG . . . . . . . . . . . . . 8.7 tmm_? -125.66 95.43 4.43 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 105.105 -2.183 . . . . 17.34 105.105 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 117' ' ' GLU . . . . . 0.526 ' HB3' HG12 ' B' ' 37' ' ' VAL . 98.6 mt-10 -117.86 109.09 16.12 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 107.642 -1.244 . . . . 32.82 107.642 -175.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 118' ' ' TYR . . . . . 0.567 ' HB3' ' HA ' ' C' ' 128' ' ' ILE . 19.7 p90 -113.94 143.1 45.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.578 0.704 . . . . 1.27 112.115 177.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 119' ' ' SER . . . . . . . . . . . . . 35.2 t -98.6 133.73 42.54 Favored 'General case' 0 C--O 1.24 0.574 0 CA-C-N 114.605 -1.18 . . . . 7.79 109.981 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 120' ' ' ASP . . . . . 0.574 ' HA ' HG12 ' C' ' 126' ' ' VAL . 58.4 t0 -111.82 98.53 7.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 106.406 -1.701 . . . . 20.31 106.406 172.489 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.32 -163.52 32.94 Favored Glycine 0 N--CA 1.449 -0.481 0 CA-C-O 121.731 0.628 . . . . 9.67 111.963 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 122' ' ' VAL . . . . . . . . . . . . . 68.8 t -108.72 -61.68 2.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 107.795 -1.187 . . . . 10.53 107.795 177.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 123' ' ' GLU . . . . . 0.429 ' OE2' ' NH2' ' H' ' 41' ' ' ARG . 96.7 mt-10 -87.09 -38.22 16.7 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.966 0.728 . . . . 56.31 112.966 176.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 124' ' ' GLY . . . . . 0.596 ' HA2' HD21 ' H' ' 43' ' ' LEU . . . -73.13 149.14 42.14 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 110.194 -1.162 . . . . 24.31 110.194 174.021 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 125' ' ' ALA . . . . . 0.475 ' HB2' HD13 ' H' ' 43' ' ' LEU . . . -73.16 167.57 20.88 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.67 0.747 . . . . 5.55 110.161 173.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 126' ' ' VAL . . . . . 0.574 HG12 ' HA ' ' C' ' 120' ' ' ASP . 31.2 m -68.82 151.89 9.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.499 0 CA-C-N 115.318 -0.856 . . . . 17.34 109.61 -178.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 127' ' ' GLU . . . . . . . . . . . . . 19.3 pt-20 -142.19 124.69 15.74 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 116.423 -0.353 . . . . 31.44 110.248 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 128' ' ' ILE . . . . . 0.567 ' HA ' ' HB3' ' C' ' 118' ' ' TYR . 88.5 mt -93.65 120.72 43.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.221 -0.659 . . . . 17.34 109.221 -177.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 129' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' C' ' 117' ' ' GLU . 69.9 m -102.6 133.61 47.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.398 -0.964 . . . . 17.28 108.398 172.031 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 130' ' ' ILE . . . . . 0.44 HD12 ' HE1' ' C' ' 67' ' ' TYR . 71.2 mt -135.67 128.26 46.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 N-CA-C 109.177 -0.675 . . . . 17.34 109.177 -176.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 131' ' ' SER . . . . . 0.521 ' HB2' ' HB2' ' C' ' 114' ' ' GLU . 62.7 m -96.18 150.59 20.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.195 -0.457 . . . . 12.56 110.165 175.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 132' ' ' LEU . . . . . 0.733 ' O ' ' HA ' ' C' ' 62' ' ' SER . 7.3 mp -135.32 140.81 45.39 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.081 -0.509 . . . . 44.05 110.837 -177.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 133' ' ' GLN . . . . . 0.403 ' HG2' ' HG3' ' C' ' 114' ' ' GLU . 30.4 mm100 -120.04 135.64 54.86 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 108.391 -0.966 . . . . 10.2 108.391 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 134' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.02 149.16 30.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 N-CA-C 108.318 -0.993 . . . . 4.39 108.318 175.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 135' ' ' ILE . . . . . . . . . . . . . 25.2 mm -62.83 -60.9 2.02 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-O 121.311 0.576 . . . . 28.75 110.849 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.47 138.79 5.62 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 109.32 -1.512 . . . . 19.59 109.32 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 137' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 -68.78 150.41 47.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.633 0.73 . . . . 12.53 110.459 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 138' ' ' LEU . . . . . 0.637 ' O ' ' HB3' ' C' ' 108' ' ' PHE . 36.6 tp -139.23 127.51 22.71 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 106.995 -1.483 . . . . 10.09 106.995 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -89.39 67.16 7.66 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 122.244 1.021 . . . . 9.01 109.775 -168.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 140' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -85.56 76.73 9.98 Favored 'General case' 0 C--N 1.332 -0.163 0 N-CA-C 108.165 -1.05 . . . . 17.34 108.165 175.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 141' ' ' GLY . . . . . . . . . . . . . . . -74.29 114.95 4.68 Favored Glycine 0 C--O 1.237 0.289 0 N-CA-C 110.502 -1.039 . . . . 17.56 110.502 175.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.38 -173.52 2.59 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 109.369 -0.604 . . . . 9.69 109.369 -175.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 143' ' ' ILE . . . . . 0.724 HG22 ' H ' ' C' ' 103' ' ' LYS . 1.2 pp -108.3 -62.51 2.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 113.186 0.81 . . . . 34.84 113.186 -170.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 144' ' ' ASP . . . . . . . . . . . . . 20.8 p-10 -80.76 125.3 29.89 Favored 'General case' 0 C--N 1.331 -0.217 0 O-C-N 121.43 -0.794 . . . . 26.5 111.144 -168.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -117.92 16.71 14.27 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 112.33 0.492 . . . . 8.28 112.33 177.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 146' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' C' ' 146' ' ' LEU . 4.1 mm? 54.49 76.12 0.55 Allowed Pre-proline 0 C--O 1.237 0.436 0 C-N-CA 126.932 2.093 . . . . 28.36 110.522 179.672 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 147' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -68.19 71.8 0.86 Allowed 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 121.239 1.292 . . . . 17.34 115.346 -160.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 148' ' ' GLU . . . . . 0.509 ' OE1' ' ND2' ' C' ' 152' ' ' ASN . 80.1 mm-40 -113.25 11.43 18.7 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.992 -0.549 . . . . 26.92 111.598 169.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 149' ' ' GLU . . . . . 0.431 ' O ' ' NZ ' ' C' ' 12' ' ' LYS . 25.7 pm0 -136.94 4.5 2.76 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.331 0.493 . . . . 15.59 112.331 178.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 150' ' ' ILE . . . . . 0.562 HD12 HG23 ' C' ' 96' ' ' THR . 50.3 mm -115.54 -50.76 4.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 118.708 0.685 . . . . 21.56 111.228 -177.323 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.65 -25.45 3.67 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.558 -1.275 . . . . 21.99 107.558 -176.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 152' ' ' ASN . . . . . 0.509 ' ND2' ' OE1' ' C' ' 148' ' ' GLU . 37.8 t-20 -67.19 -32.48 73.59 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.343 -0.39 . . . . 25.48 111.486 179.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -74.42 97.48 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.466 0 N-CA-C 107.744 -1.206 . . . . 11.01 107.744 170.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 154' ' ' SER . . . . . . . . . . . . . 33.9 t -116.62 -61.2 1.76 Allowed 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.598 -0.728 . . . . 36.85 112.402 -173.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 155' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -135.03 -28.85 1.15 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 113.616 0.969 . . . . 40.39 113.616 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.07 -54.02 2.89 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 119.269 0.94 . . . . 30.03 111.158 -168.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 157' ' ' GLY . . . . . . . . . . . . . . . -83.45 143.49 21.79 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.518 -0.849 . . . . 17.34 112.485 178.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 158' ' ' TYR . . . . . 0.454 ' CD2' ' HG2' ' C' ' 171' ' ' PRO . 18.1 m-30 -112.96 -173.17 2.19 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.414 1.086 . . . . 17.45 108.791 178.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 159' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -77.49 -75.0 0.23 Allowed 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 118.969 -1.093 . . . . 41.15 113.281 -155.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 160' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' C' ' 162' ' ' GLN . 41.1 p90 177.05 173.02 0.47 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 127.8 2.44 . . . . 7.58 109.228 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 161' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -157.06 100.49 1.87 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 105.466 -2.05 . . . . 21.22 105.466 154.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 162' ' ' GLN . . . . . 0.412 ' HG3' ' CD2' ' C' ' 160' ' ' PHE . 90.5 mt-30 -68.39 -45.47 37.3 Favored Pre-proline 0 C--O 1.243 0.725 0 N-CA-C 113.971 1.101 . . . . 15.32 113.971 -167.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 163' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -77.74 -17.02 14.35 Favored 'Trans proline' 0 C--N 1.369 1.618 0 CA-C-N 122.145 1.802 . . . . 38.41 112.587 173.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 164' ' ' GLY . . . . . . . . . . . . . . . -139.5 34.69 2.02 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 119.683 2.633 . . . . 33.37 119.683 -169.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 165' ' ' GLN . . . . . 0.415 ' HG2' ' HD3' ' I' ' 90' ' ' LYS . 9.8 tp-100 -67.06 -58.09 5.57 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.087 1.443 . . . . 42.19 111.062 177.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 166' ' ' THR . . . . . 0.411 HG22 ' HB2' ' I' ' 21' ' ' ALA . 34.6 p 55.17 46.4 23.95 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 125.736 1.614 . . . . 59.88 111.701 175.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 167' ' ' THR . . . . . . . . . . . . . 2.0 m -138.9 151.25 46.79 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 120.036 -0.666 . . . . 16.54 109.451 -167.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 168' ' ' GLY . . . . . . . . . . . . . . . -87.5 -126.29 2.27 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 115.754 -0.657 . . . . 29.67 111.935 171.195 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 169' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -74.22 -62.59 1.46 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.835 0.317 . . . . 45.16 111.312 -175.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.44 104.66 0.64 Allowed Pre-proline 0 C--O 1.236 0.347 0 N-CA-C 108.698 -0.852 . . . . 8.44 108.698 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 171' ' ' PRO . . . . . 0.454 ' HG2' ' CD2' ' C' ' 158' ' ' TYR . 85.2 Cg_endo -83.37 -173.99 1.82 Allowed 'Trans proline' 0 C--N 1.324 -0.76 0 C-N-CA 121.294 1.329 . . . . 3.15 112.816 -153.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.68 69.92 1.3 Allowed Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 117.496 1.759 . . . . 5.45 117.496 163.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 173' ' ' THR . . . . . . . . . . . . . 10.6 t -131.34 164.8 24.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 118.108 0.954 . . . . 8.36 109.69 169.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 174' ' ' VAL . . . . . . . . . . . . . 29.3 m -77.73 159.66 76.14 Favored Pre-proline 0 C--O 1.239 0.531 0 N-CA-C 107.631 -1.248 . . . . 22.82 107.631 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 175' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -69.78 105.59 1.51 Allowed 'Trans proline' 0 CA--C 1.513 -0.547 0 CA-C-N 120.05 1.053 . . . . 8.45 111.628 178.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.197 0 C-N-CA 125.636 1.575 . . . . 68.61 112.578 -173.523 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 5' ' ' PRO . . . . . 0.494 ' HB2' ' H ' ' D' ' 6' ' ' ILE . 41.5 Cg_endo . . . . . 0 N--CA 1.465 -0.177 0 N-CA-C 112.49 0.15 . . . . 17.71 112.49 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 6' ' ' ILE . . . . . 0.494 ' H ' ' HB2' ' D' ' 5' ' ' PRO . 96.6 mt -121.66 120.78 62.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 N-CA-C 108.057 -1.09 . . . . 10.96 108.057 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 7' ' ' MET . . . . . . . . . . . . . 39.0 mmt -86.39 170.92 11.56 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.894 0.854 . . . . 50.41 110.443 -177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.32 -12.43 69.27 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.43 -0.804 . . . . 5.14 114.23 174.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 9' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -96.07 -14.73 22.68 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 117.586 0.693 . . . . 19.3 112.151 172.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 10' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -76.37 -3.39 36.65 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 114.04 1.126 . . . . 38.59 114.04 -171.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -128.48 124.7 62.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.342 0 CA-C-N 119.665 1.12 . . . . 22.8 107.987 -177.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' LYS . . . . . 0.455 ' NZ ' ' O ' ' D' ' 149' ' ' GLU . 51.9 mtmt -133.13 162.12 32.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.597 0.713 . . . . 21.76 110.202 175.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 13' ' ' TYR . . . . . . . . . . . . . 19.5 m-30 -112.63 97.77 6.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.008 -0.996 . . . . 3.75 108.338 -166.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 14' ' ' LEU . . . . . 0.696 HD23 ' HB3' ' D' ' 27' ' ' LEU . 91.8 mt -76.69 125.16 28.78 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 110.015 -0.365 . . . . 49.03 110.015 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -109.18 147.94 31.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.068 0.461 . . . . 32.35 109.768 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 16' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -144.61 135.72 25.15 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.164 -0.68 . . . . 14.4 109.164 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -75.0 157.38 35.02 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.625 0.726 . . . . 11.7 111.13 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 18' ' ' ILE . . . . . . . . . . . . . 43.8 pt -80.49 -7.4 10.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 113.322 0.86 . . . . 7.44 113.322 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -119.44 -10.81 9.6 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 112.847 0.684 . . . . 16.13 112.847 -170.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.18 -44.09 48.51 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 119.906 -0.717 . . . . 21.91 111.701 -175.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.33 41.85 32.1 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.945 1.298 . . . . 19.34 111.537 -170.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' THR . . . . . . . . . . . . . 74.1 p -122.36 125.27 45.56 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.435 0.694 . . . . 11.94 109.242 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.05 76.01 2.21 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 116.297 -0.411 . . . . 17.71 113.155 -178.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 24' ' ' SER . . . . . 0.416 ' HA ' ' HG ' ' D' ' 146' ' ' LEU . 89.5 p -127.98 -29.37 2.56 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 120.694 -0.403 . . . . 46.05 111.592 -178.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 25' ' ' ALA . . . . . 0.455 ' HB1' ' HB3' ' D' ' 14' ' ' LEU . . . 51.46 73.91 0.89 Allowed Pre-proline 0 C--O 1.236 0.356 0 C-N-CA 127.012 2.125 . . . . 15.66 112.311 -173.086 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 26' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_exo -71.95 104.8 1.7 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 CA-C-N 119.442 0.836 . . . . 19.19 111.92 176.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 27' ' ' LEU . . . . . 0.696 ' HB3' HD23 ' D' ' 14' ' ' LEU . 2.2 pt? -87.46 151.48 23.01 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.958 -0.756 . . . . 17.71 108.958 167.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 28' ' ' PHE . . . . . 0.469 ' HE1' ' HB3' ' D' ' 73' ' ' ASP . 65.8 t80 -98.22 131.59 26.05 Favored Pre-proline 0 C--N 1.319 -0.725 1 C-N-CA 110.713 -4.395 . . . . 24.37 110.071 -177.818 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -72.98 -174.06 1.43 Allowed 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 120.492 0.795 . . . . 36.84 113.973 -176.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.65 ' HA ' ' HB3' ' I' ' 47' ' ' GLN . . . 54.61 59.76 3.93 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.646 1.178 . . . . 12.13 111.601 -175.017 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 31' ' ' TYR . . . . . . . . . . . . . 1.6 m-30 -69.88 179.7 2.15 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 123.06 1.409 . . . . 27.63 112.212 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' GLN . . . . . 0.485 ' HG3' ' H ' ' D' ' 33' ' ' THR . 28.5 tp60 -148.48 -159.16 0.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 103.437 -2.801 . . . . 31.27 103.437 170.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 33' ' ' THR . . . . . 0.485 ' H ' ' HG3' ' D' ' 32' ' ' GLN . 14.9 t -65.3 162.57 17.19 Favored 'General case' 0 C--O 1.245 0.83 0 CA-C-O 122.723 1.249 . . . . 27.4 111.578 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 34' ' ' ASP . . . . . 0.581 ' HB2' ' HB3' ' E' ' 120' ' ' ASP . 84.4 m-20 -135.46 -169.52 2.41 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.871 -1.513 . . . . 51.24 107.962 -168.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 35' ' ' GLY . . . . . 0.662 ' O ' ' HA2' ' D' ' 63' ' ' GLY . . . 171.51 134.51 1.79 Allowed Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 111.177 -0.769 . . . . 16.37 111.177 168.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 36' ' ' SER . . . . . . . . . . . . . 69.6 m -121.57 84.84 2.31 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 105.821 -1.918 . . . . 4.07 105.821 174.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 37' ' ' VAL . . . . . 0.562 HG23 ' HB2' ' D' ' 62' ' ' SER . 4.0 m -89.23 108.44 19.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 108.359 -0.978 . . . . 12.88 108.359 -173.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 38' ' ' SER . . . . . . . . . . . . . 44.9 m -97.89 93.46 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 107.782 -1.192 . . . . 8.2 107.782 -170.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 39' ' ' GLY . . . . . . . . . . . . . . . -96.34 102.29 2.76 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.411 -0.9 . . . . 17.71 113.49 -177.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' GLU . . . . . 0.408 ' HA ' ' HA ' ' D' ' 59' ' ' VAL . 85.1 tt0 -108.41 123.95 49.64 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.63 -0.878 . . . . 10.85 108.63 -177.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 41' ' ' ARG . . . . . 0.523 ' O ' ' HA3' ' D' ' 57' ' ' GLY . 88.3 mtm-85 -83.77 -172.0 3.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.236 -0.653 . . . . 47.43 109.236 -178.128 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 42' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -160.61 145.15 14.15 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 121.767 -0.583 . . . . 34.93 110.03 -169.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 43' ' ' LEU . . . . . . . . . . . . . 72.0 mt -68.57 137.47 54.32 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.118 -0.697 . . . . 20.29 109.118 177.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 44' ' ' PHE . . . . . 0.45 ' HD1' HG13 ' D' ' 53' ' ' ILE . 75.6 t80 -140.68 102.59 4.34 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.106 -0.331 . . . . 18.56 110.106 -168.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 45' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -133.51 -173.16 3.14 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 122.882 0.473 . . . . 41.43 110.808 168.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 46' ' ' GLU . . . . . 0.576 ' HA ' ' HA2' ' D' ' 51' ' ' GLY . 54.0 mp0 -127.55 -34.12 2.26 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 113.747 1.018 . . . . 26.44 113.747 177.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 47' ' ' GLN . . . . . . . . . . . . . 80.1 mm-40 61.5 29.09 18.22 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.931 1.293 . . . . 19.35 112.856 169.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 48' ' ' THR . . . . . . . . . . . . . 48.1 p 51.14 41.3 27.49 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.94 1.296 . . . . 38.66 111.439 -169.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 49' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -137.88 -166.11 1.9 Allowed 'General case' 0 C--O 1.236 0.381 0 N-CA-C 107.467 -1.308 . . . . 17.71 107.467 -176.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 50' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -67.85 -24.84 65.3 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 112.183 0.438 . . . . 32.97 112.183 173.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 51' ' ' GLY . . . . . 0.576 ' HA2' ' HA ' ' D' ' 46' ' ' GLU . . . 141.23 158.6 7.6 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.99 -0.444 . . . . 33.1 111.99 178.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 52' ' ' ARG . . . . . . . . . . . . . 17.5 tpp85 -124.08 50.73 1.62 Allowed 'General case' 0 C--O 1.235 0.31 0 N-CA-C 105.83 -1.915 . . . . 6.79 105.83 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 53' ' ' ILE . . . . . 0.45 HG13 ' HD1' ' D' ' 44' ' ' PHE . 8.6 tt -79.08 -5.34 7.94 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 115.365 -0.834 . . . . 9.19 111.246 -174.23 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 54' ' ' LEU . . . . . . . . . . . . . 7.0 mp -65.78 -21.26 66.49 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 112.872 0.693 . . . . 37.27 112.872 -176.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.07 143.33 41.19 Favored Glycine 0 N--CA 1.444 -0.822 0 CA-C-O 121.417 0.454 . . . . 19.46 113.961 -171.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 56' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.56 176.89 9.13 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 121.351 1.367 . . . . 17.71 112.039 -175.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 57' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' D' ' 41' ' ' ARG . . . -148.45 173.35 28.46 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 109.57 -1.412 . . . . 11.14 109.57 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 58' ' ' SER . . . . . . . . . . . . . 46.8 t -75.9 146.58 39.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.685 0.755 . . . . 17.71 110.354 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 59' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' D' ' 40' ' ' GLU . 2.6 p -103.01 122.08 54.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.43 0 N-CA-C 108.555 -0.906 . . . . 3.48 108.555 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 60' ' ' ALA . . . . . . . . . . . . . . . -119.5 112.17 19.03 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 106.799 -1.556 . . . . 39.46 106.799 173.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 61' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -111.77 121.66 45.68 Favored 'General case' 0 C--O 1.24 0.585 0 N-CA-C 108.59 -0.893 . . . . 24.09 108.59 -172.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 62' ' ' SER . . . . . 0.65 ' HA ' ' O ' ' D' ' 132' ' ' LEU . 70.1 m -109.14 166.37 10.9 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.203 1.001 . . . . 24.26 110.429 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 63' ' ' GLY . . . . . 0.662 ' HA2' ' O ' ' D' ' 35' ' ' GLY . . . -141.2 123.01 2.2 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.15 -0.932 . . . . 3.56 112.297 177.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 64' ' ' GLU . . . . . 0.406 ' O ' ' HA ' ' D' ' 34' ' ' ASP . 65.3 mm-40 -101.9 99.42 9.62 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 107.292 -1.373 . . . . 25.37 107.292 172.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 65' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.26 119.39 57.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.143 -1.058 . . . . 20.88 108.143 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 66' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' D' ' 128' ' ' ILE . 50.6 p -115.59 146.24 41.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.484 -0.562 . . . . 11.07 109.484 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 67' ' ' TYR . . . . . 0.446 ' HE1' HD12 ' D' ' 130' ' ' ILE . 52.2 p90 -155.28 -173.76 4.69 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.72 -0.845 . . . . 11.51 108.72 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 68' ' ' TYR . . . . . . . . . . . . . 14.9 m-30 -116.13 139.17 50.59 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.844 -0.428 . . . . 4.27 109.844 176.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.69 118.75 4.69 Favored Glycine 0 N--CA 1.449 -0.485 0 N-CA-C 114.447 0.539 . . . . 18.98 114.447 -175.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 70' ' ' LYS . . . . . 0.417 ' O ' ' NE2' ' D' ' 76' ' ' GLN . 39.0 ttmt -93.04 152.15 19.47 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.868 -0.79 . . . . 28.91 108.868 174.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 71' ' ' ARG . . . . . . . . . . . . . 21.0 ptp180 -69.52 -15.58 63.27 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.042 1.127 . . . . 24.14 114.042 -171.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.85 -141.03 5.2 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.191 -1.164 . . . . 34.32 110.191 176.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 73' ' ' ASP . . . . . 0.469 ' HB3' ' HE1' ' D' ' 28' ' ' PHE . 32.2 t0 59.93 71.73 0.56 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.185 1.394 . . . . 17.7 111.221 167.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.62 9.85 0.08 Allowed 'General case' 0 C--O 1.234 0.288 0 N-CA-C 117.167 2.284 . . . . 46.91 117.167 -159.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.98 -39.66 94.47 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.285 -0.96 . . . . 4.26 112.572 170.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 76' ' ' GLN . . . . . 0.417 ' NE2' ' O ' ' D' ' 70' ' ' LYS . 22.3 pt20 -69.33 -24.15 63.88 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 119.859 -0.736 . . . . 12.4 111.856 172.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 77' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -72.98 -25.19 60.91 Favored 'General case' 0 CA--C 1.517 -0.314 0 C-N-CA 119.61 -0.836 . . . . 26.67 111.306 171.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.73 -32.15 63.72 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 120.41 -0.516 . . . . 19.88 111.28 169.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 79' ' ' ILE . . . . . . . . . . . . . 51.8 mm -62.99 -42.71 97.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 121.168 0.509 . . . . 17.52 110.324 171.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -74.74 -22.2 58.93 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 121.887 -0.508 . . . . 20.76 111.948 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 81' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -69.73 -32.49 71.08 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 120.182 -0.607 . . . . 9.87 111.183 168.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 82' ' ' ALA . . . . . 0.741 ' HA ' ' HB2' ' D' ' 87' ' ' LYS . . . -73.63 -37.08 65.47 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 119.547 -0.861 . . . . 0.03 111.677 174.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 83' ' ' TYR . . . . . . . . . . . . . 81.6 t80 -84.55 -62.5 1.54 Allowed 'General case' 0 C--O 1.235 0.333 0 C-N-CA 119.979 -0.688 . . . . 12.94 112.195 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -73.91 -39.19 64.01 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 111.86 0.319 . . . . 34.89 111.86 -167.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -78.32 -45.5 22.49 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 119.942 -0.703 . . . . 17.71 111.155 173.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.03 96.63 2.4 Favored Glycine 0 N--CA 1.45 -0.403 0 O-C-N 122.23 -0.294 . . . . 4.02 113.285 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 87' ' ' LYS . . . . . 0.741 ' HB2' ' HA ' ' D' ' 82' ' ' ALA . 98.0 mttt -148.48 -161.97 1.46 Allowed 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.135 -1.431 . . . . 17.71 107.135 -178.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 88' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -130.19 176.0 8.46 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.428 0.632 . . . . 17.71 109.802 170.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 89' ' ' ILE . . . . . 0.417 HD11 HD11 ' D' ' 113' ' ' ILE . 81.9 mt -129.96 133.04 65.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 116.109 -0.496 . . . . 13.1 109.901 -173.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 90' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -82.78 120.14 25.25 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 108.514 -0.921 . . . . 26.03 108.514 165.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 91' ' ' PHE . . . . . 0.423 ' HB3' ' O ' ' D' ' 109' ' ' GLY . 85.6 t80 -116.72 128.13 55.04 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.58 1.152 . . . . 14.57 109.993 -166.138 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 92' ' ' TRP . . . . . 0.525 ' HB2' ' HB2' ' D' ' 14' ' ' LEU . 91.8 m95 -127.38 131.84 50.27 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 123.815 0.846 . . . . 30.93 108.928 -178.482 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 93' ' ' ARG . . . . . 0.796 ' O ' ' HA ' ' D' ' 106' ' ' ALA . 78.0 ttt-85 -114.16 97.12 6.16 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.343 -0.984 . . . . 17.71 108.343 172.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 94' ' ' VAL . . . . . 0.527 HG12 ' HB2' ' D' ' 106' ' ' ALA . 27.0 m -109.06 159.7 8.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 CA-C-O 122.333 1.064 . . . . 15.36 109.885 -172.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 95' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -103.3 159.15 15.81 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.681 -1.145 . . . . 28.34 110.653 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 96' ' ' THR . . . . . 0.478 HG23 HG23 ' D' ' 150' ' ' ILE . 28.5 m -95.67 -29.41 14.31 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.164 -0.925 . . . . 23.09 112.365 -178.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 97' ' ' VAL . . . . . . . . . . . . . 35.0 m -68.67 153.62 8.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-O 121.827 0.822 . . . . 4.39 109.993 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 98' ' ' LYS . . . . . 0.51 ' NZ ' ' O ' ' D' ' 99' ' ' ASN . 29.7 tptp -88.43 124.25 33.77 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.609 -0.723 . . . . 27.59 109.739 -175.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 99' ' ' ASN . . . . . 0.51 ' O ' ' NZ ' ' D' ' 98' ' ' LYS . 34.7 m120 -84.41 166.98 16.89 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.796 0.808 . . . . 7.41 109.818 170.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 100' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -103.93 -13.23 16.43 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 113.732 1.012 . . . . 30.25 113.732 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 101' ' ' ASN . . . . . . . . . . . . . 16.6 p30 -89.7 -58.69 2.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 118.323 0.511 . . . . 8.96 111.538 167.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 102' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -100.85 -177.79 3.57 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 108.52 -0.918 . . . . 31.68 108.52 173.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 103' ' ' LYS . . . . . 0.661 ' H ' HG22 ' D' ' 143' ' ' ILE . 97.2 mttt -73.23 -58.15 3.52 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.037 -0.665 . . . . 36.33 110.045 168.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 104' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -132.94 -170.95 2.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 107.652 -1.24 . . . . 20.57 107.652 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 105' ' ' ASP . . . . . 0.473 ' O ' ' HA ' ' D' ' 94' ' ' VAL . 20.2 p-10 -149.57 169.03 21.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.446 0.641 . . . . 18.47 109.427 175.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 106' ' ' ALA . . . . . 0.796 ' HA ' ' O ' ' D' ' 93' ' ' ARG . . . -153.06 158.88 42.6 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.324 -0.853 . . . . 13.65 111.123 -162.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 107' ' ' GLN . . . . . 0.43 ' OE1' ' OH ' ' E' ' 118' ' ' TYR . 88.5 mt-30 -117.69 120.54 38.32 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 107.046 -1.464 . . . . 25.15 107.046 160.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 108' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -104.15 152.4 22.17 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.669 0.788 . . . . 16.05 110.274 -168.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 109' ' ' GLY . . . . . 0.448 ' HA3' HG21 ' D' ' 134' ' ' VAL . . . -167.35 156.05 27.52 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 119.928 -1.129 . . . . 22.86 112.403 168.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 110' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -93.87 110.37 22.03 Favored 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.812 -0.811 . . . . 14.08 108.812 168.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 111' ' ' ALA . . . . . . . . . . . . . . . -114.5 159.85 19.89 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.47 0.652 . . . . 26.73 111.799 -167.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 112' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -135.66 139.02 43.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.62 -1.173 . . . . 21.98 107.941 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 113' ' ' ILE . . . . . 0.417 HD11 HD11 ' D' ' 89' ' ' ILE . 78.4 mt -83.78 129.47 37.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 N-CA-C 109.79 -0.448 . . . . 16.61 109.79 -172.382 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 114' ' ' GLU . . . . . 0.512 ' HB2' ' HB2' ' D' ' 131' ' ' SER . 98.3 mt-10 -72.91 -64.32 0.99 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 119.694 -0.802 . . . . 29.14 110.696 164.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -142.27 152.6 43.18 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 121.683 0.754 . . . . 34.36 110.362 -169.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -127.27 93.65 3.79 Favored 'General case' 0 C--N 1.332 -0.196 0 N-CA-C 104.946 -2.242 . . . . 10.27 104.946 178.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 117' ' ' GLU . . . . . 0.522 ' HB3' HG12 ' C' ' 37' ' ' VAL . 98.3 mt-10 -115.09 108.91 17.28 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.624 -1.251 . . . . 37.96 107.624 -175.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 118' ' ' TYR . . . . . 0.54 ' HB3' ' HA ' ' D' ' 128' ' ' ILE . 21.1 p90 -114.61 146.41 40.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.523 0.678 . . . . 17.71 111.964 177.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 119' ' ' SER . . . . . . . . . . . . . 35.7 t -102.5 134.94 45.02 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 114.717 -1.128 . . . . 17.71 110.012 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 120' ' ' ASP . . . . . 0.582 ' HB3' ' HB2' ' C' ' 34' ' ' ASP . 58.0 t0 -115.3 96.38 5.64 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.621 -1.622 . . . . 20.72 106.621 172.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.09 -158.2 22.28 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-O 121.694 0.608 . . . . 30.48 112.193 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 122' ' ' VAL . . . . . . . . . . . . . 72.9 t -113.04 -63.21 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 107.913 -1.143 . . . . 20.46 107.913 175.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 123' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -79.12 -44.94 21.01 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 112.725 0.639 . . . . 58.76 112.725 178.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.08 151.96 46.33 Favored Glycine 0 C--O 1.236 0.278 0 N-CA-C 110.263 -1.135 . . . . 20.52 110.263 174.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 125' ' ' ALA . . . . . 0.474 ' HB2' HD13 ' I' ' 43' ' ' LEU . . . -75.0 171.38 14.21 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.726 0.774 . . . . 17.58 110.207 173.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 126' ' ' VAL . . . . . 0.491 HG12 ' HA ' ' D' ' 120' ' ' ASP . 33.8 m -69.19 154.48 8.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.558 0 CA-C-N 115.252 -0.885 . . . . 8.76 109.578 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 127' ' ' GLU . . . . . . . . . . . . . 19.4 pt-20 -144.81 124.92 13.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.379 -0.373 . . . . 32.62 110.086 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 128' ' ' ILE . . . . . 0.54 ' HA ' ' HB3' ' D' ' 118' ' ' TYR . 87.3 mt -95.28 119.96 44.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.335 -0.617 . . . . 17.71 109.335 -176.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 129' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' D' ' 117' ' ' GLU . 69.0 m -100.48 134.42 43.46 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.359 -0.978 . . . . 13.09 108.359 170.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 130' ' ' ILE . . . . . 0.446 HD12 ' HE1' ' D' ' 67' ' ' TYR . 66.1 mt -136.81 128.91 43.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.997 -0.742 . . . . 14.17 108.997 -177.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 131' ' ' SER . . . . . 0.512 ' HB2' ' HB2' ' D' ' 114' ' ' GLU . 58.7 m -97.36 150.53 20.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.202 -0.453 . . . . 8.77 110.142 176.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 132' ' ' LEU . . . . . 0.65 ' O ' ' HA ' ' D' ' 62' ' ' SER . 7.4 mp -134.7 140.63 46.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.118 -0.492 . . . . 35.37 110.912 -178.086 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 133' ' ' GLN . . . . . 0.434 ' HG2' ' HG3' ' D' ' 114' ' ' GLU . 29.9 mm100 -119.1 137.01 53.87 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.567 -0.901 . . . . 17.71 108.567 167.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 134' ' ' VAL . . . . . 0.448 HG21 ' HA3' ' D' ' 109' ' ' GLY . 11.0 p -135.62 146.9 29.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 N-CA-C 108.546 -0.909 . . . . 21.28 108.546 175.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 135' ' ' ILE . . . . . . . . . . . . . 26.5 mm -61.21 -61.14 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.331 0 CA-C-N 115.885 -0.598 . . . . 10.66 110.808 178.033 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.1 139.55 6.11 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 109.858 -1.297 . . . . 38.83 109.858 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 137' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -68.79 152.6 45.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.606 0.717 . . . . 10.13 110.291 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 138' ' ' LEU . . . . . . . . . . . . . 33.4 tp -138.38 124.46 20.2 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 107.265 -1.383 . . . . 14.09 107.265 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -82.9 70.04 9.83 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 122.313 1.054 . . . . 16.98 109.758 -169.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 140' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -90.34 76.07 6.79 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.243 -1.021 . . . . 26.2 108.243 177.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.53 112.07 3.71 Favored Glycine 0 C--O 1.237 0.302 0 N-CA-C 110.433 -1.067 . . . . 10.67 110.433 174.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -119.73 -174.25 2.71 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.375 -0.602 . . . . 8.34 109.375 -175.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 143' ' ' ILE . . . . . 0.661 HG22 ' H ' ' D' ' 103' ' ' LYS . 1.2 pp -105.54 -63.69 1.77 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 113.438 0.903 . . . . 32.75 113.438 -170.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 144' ' ' ASP . . . . . . . . . . . . . 24.5 p-10 -80.9 131.06 35.33 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 121.438 -0.789 . . . . 27.27 111.05 -167.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 145' ' ' THR . . . . . . . . . . . . . 74.8 p -122.18 15.15 10.61 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 112.529 0.566 . . . . 30.29 112.529 176.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 146' ' ' LEU . . . . . 0.416 ' HG ' ' HA ' ' D' ' 24' ' ' SER . 4.2 mm? 54.56 76.16 0.54 Allowed Pre-proline 0 C--O 1.237 0.434 0 C-N-CA 126.702 2.001 . . . . 9.64 110.169 -178.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 147' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -68.21 71.24 0.89 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 N-CA-C 115.434 1.282 . . . . 19.87 115.434 -160.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 148' ' ' GLU . . . . . 0.53 ' OE1' ' ND2' ' D' ' 152' ' ' ASN . 79.3 mm-40 -109.89 9.25 24.55 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 123.186 0.594 . . . . 36.67 111.438 170.092 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 149' ' ' GLU . . . . . 0.455 ' O ' ' NZ ' ' D' ' 12' ' ' LYS . 25.8 pm0 -138.15 4.39 2.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.411 0.523 . . . . 10.02 112.411 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 150' ' ' ILE . . . . . 0.478 HG23 HG23 ' D' ' 96' ' ' THR . 45.7 mm -111.52 -47.77 6.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 118.717 0.69 . . . . 14.89 111.101 -178.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 151' ' ' VAL . . . . . . . . . . . . . 45.2 t -106.94 -29.52 2.65 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 107.879 -1.156 . . . . 22.9 107.879 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 152' ' ' ASN . . . . . 0.53 ' ND2' ' OE1' ' D' ' 148' ' ' GLU . 33.8 t-20 -67.49 -28.08 67.54 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.128 -0.487 . . . . 19.56 111.709 -176.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -75.26 96.02 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 107.35 -1.352 . . . . 21.6 107.35 168.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 154' ' ' SER . . . . . . . . . . . . . 39.3 t -117.44 -62.2 1.6 Allowed 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.633 -0.712 . . . . 12.43 112.663 -172.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 155' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -135.51 -28.81 1.1 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 113.819 1.044 . . . . 28.2 113.819 179.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 156' ' ' GLY . . . . . . . . . . . . . . . 90.37 -61.05 3.27 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 119.368 0.986 . . . . 30.81 110.881 -169.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.77 141.6 25.63 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.45 -0.881 . . . . 33.96 112.217 176.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 158' ' ' TYR . . . . . 0.463 ' CD2' ' HG2' ' D' ' 171' ' ' PRO . 19.8 m-30 -112.15 -171.27 1.82 Allowed 'General case' 0 C--O 1.236 0.343 0 C-N-CA 124.185 0.994 . . . . 7.5 108.677 179.448 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 159' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -76.66 -74.16 0.25 Allowed 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.351 -0.94 . . . . 29.41 113.307 -155.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 160' ' ' PHE . . . . . 0.436 ' CD2' ' HG3' ' D' ' 162' ' ' GLN . 41.1 p90 177.4 173.8 0.49 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 127.782 2.433 . . . . 9.26 109.318 165.192 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 161' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -156.76 100.81 1.94 Allowed 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 105.446 -2.057 . . . . 8.03 105.446 154.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 162' ' ' GLN . . . . . 0.436 ' HG3' ' CD2' ' D' ' 160' ' ' PHE . 88.7 mt-30 -68.66 -46.3 34.52 Favored Pre-proline 0 C--O 1.242 0.672 0 N-CA-C 113.997 1.11 . . . . 17.71 113.997 -167.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 163' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -77.86 -19.17 12.72 Favored 'Trans proline' 0 C--N 1.367 1.532 0 CA-C-N 122.097 1.785 . . . . 29.74 112.467 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 164' ' ' GLY . . . . . . . . . . . . . . . -138.39 35.43 2.01 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 119.237 2.455 . . . . 33.79 119.237 -167.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 165' ' ' GLN . . . . . 0.45 ' HG2' ' HD3' ' J' ' 90' ' ' LYS . 9.8 tp-100 -66.29 -57.59 7.19 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 118.715 1.257 . . . . 31.23 111.032 178.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 166' ' ' THR . . . . . 0.412 HG22 ' HB2' ' J' ' 21' ' ' ALA . 33.8 p 54.74 46.86 23.73 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.754 1.621 . . . . 34.31 111.644 176.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 167' ' ' THR . . . . . . . . . . . . . 2.6 m -137.99 150.35 46.91 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 119.744 -0.783 . . . . 3.71 109.431 -168.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 168' ' ' GLY . . . . . . . . . . . . . . . -82.73 -129.45 1.34 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 111.272 -0.731 . . . . 40.11 111.272 168.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 169' ' ' GLU . . . . . 0.427 ' HG3' ' HG ' ' I' ' 54' ' ' LEU . 15.2 tm-20 -73.15 -62.72 1.37 Allowed 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.817 -0.353 . . . . 45.84 111.413 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.47 104.33 0.59 Allowed Pre-proline 0 C--O 1.235 0.293 0 C-N-CA 123.798 0.839 . . . . 8.16 109.098 -176.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 171' ' ' PRO . . . . . 0.463 ' HG2' ' CD2' ' D' ' 158' ' ' TYR . 98.3 Cg_endo -83.01 -174.62 2.09 Favored 'Trans proline' 0 C--N 1.323 -0.814 0 C-N-CA 121.306 1.338 . . . . 17.71 112.863 -152.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 172' ' ' GLY . . . . . . . . . . . . . . . 72.06 69.38 1.4 Allowed Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 116.69 1.436 . . . . 15.19 116.69 165.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -130.84 167.17 19.36 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.881 0.848 . . . . 3.32 109.346 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 174' ' ' VAL . . . . . . . . . . . . . 23.9 m -82.8 157.72 66.3 Favored Pre-proline 0 C--O 1.239 0.549 0 CA-C-N 114.605 -1.179 . . . . 5.84 108.445 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 175' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -66.19 110.98 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.551 0 CA-C-N 119.465 0.844 . . . . 11.61 111.887 175.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.384 0 C-N-CA 125.508 1.523 . . . . 35.92 112.762 -172.538 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 5' ' ' PRO . . . . . 0.47 ' HB2' ' H ' ' E' ' 6' ' ' ILE . 39.9 Cg_endo . . . . . 0 N--CA 1.466 -0.112 0 CA-C-O 119.86 -0.142 . . . . 5.43 112.451 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 6' ' ' ILE . . . . . 0.47 ' H ' ' HB2' ' E' ' 5' ' ' PRO . 96.4 mt -121.94 120.72 62.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 N-CA-C 107.989 -1.115 . . . . 17.43 107.989 177.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -89.12 170.74 10.36 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.934 0.873 . . . . 47.72 110.802 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.0 -11.59 66.98 Favored Glycine 0 C--N 1.333 0.397 0 CA-C-N 115.308 -0.86 . . . . 17.06 114.391 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 9' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -96.1 -14.01 23.19 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 117.654 0.727 . . . . 17.43 112.277 171.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 10' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -77.02 -5.72 49.85 Favored 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 113.908 1.077 . . . . 28.45 113.908 -171.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 11' ' ' VAL . . . . . . . . . . . . . 71.9 t -127.03 124.92 65.53 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 119.597 1.089 . . . . 41.68 108.07 -176.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' LYS . . . . . 0.46 ' NZ ' ' O ' ' E' ' 149' ' ' GLU . 51.1 mtmt -134.5 162.61 31.77 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.639 0.733 . . . . 25.52 109.859 175.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 13' ' ' TYR . . . . . 0.409 ' CE1' ' HG3' ' E' ' 93' ' ' ARG . 19.9 m-30 -113.23 97.09 6.27 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.942 -1.026 . . . . 17.43 108.483 -165.004 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 14' ' ' LEU . . . . . 0.754 HD23 ' HB3' ' E' ' 27' ' ' LEU . 86.9 mt -74.98 125.67 29.4 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 120.689 -0.404 . . . . 54.21 110.056 177.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -109.27 147.8 32.04 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.773 -0.454 . . . . 24.77 109.773 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 16' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -144.14 135.82 25.99 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 109.173 -0.677 . . . . 30.25 109.173 176.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' SER . . . . . . . . . . . . . 36.8 t -74.64 159.42 32.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.636 0.732 . . . . 6.52 111.158 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -82.0 -12.65 12.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 115.414 -0.812 . . . . 8.3 113.163 178.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -115.32 -9.86 12.13 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 112.769 0.655 . . . . 24.65 112.769 -169.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.16 -45.12 42.84 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 119.7 -0.8 . . . . 24.92 111.628 -177.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.3 41.11 32.15 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.024 1.33 . . . . 25.41 111.646 -171.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -123.39 126.01 46.02 Favored 'General case' 0 C--O 1.236 0.344 0 C-N-CA 123.422 0.689 . . . . 17.43 109.2 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.47 77.14 2.08 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 114.33 0.492 . . . . 26.12 114.33 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 24' ' ' SER . . . . . 0.418 ' HA ' ' HG ' ' E' ' 146' ' ' LEU . 93.3 p -128.65 -26.63 2.69 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 120.541 -0.463 . . . . 43.19 111.672 -178.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 25' ' ' ALA . . . . . 0.417 ' HB1' ' HB3' ' E' ' 14' ' ' LEU . . . 51.16 73.74 0.92 Allowed Pre-proline 0 C--O 1.237 0.4 0 C-N-CA 126.961 2.104 . . . . 21.35 112.48 -173.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -72.16 104.62 1.7 Allowed 'Trans proline' 0 C--O 1.236 0.386 0 CA-C-N 119.494 0.855 . . . . 23.52 112.067 176.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 27' ' ' LEU . . . . . 0.754 ' HB3' HD23 ' E' ' 14' ' ' LEU . 2.1 pt? -86.11 151.73 23.44 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.915 -0.772 . . . . 17.43 108.915 166.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 28' ' ' PHE . . . . . 0.496 ' HE1' ' HB3' ' E' ' 73' ' ' ASP . 70.5 t80 -99.52 132.14 23.68 Favored Pre-proline 0 C--N 1.305 -1.359 1 C-N-CA 111.674 -4.01 . . . . 27.95 110.151 -178.595 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' E' E ' 29' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.32 -172.74 1.1 Allowed 'Trans proline' 0 C--O 1.234 0.315 0 N-CA-C 114.15 0.788 . . . . 11.88 114.15 -176.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.68 ' HA ' ' HB3' ' J' ' 47' ' ' GLN . . . 56.47 56.93 5.23 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.705 1.202 . . . . 17.01 111.677 -175.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 31' ' ' TYR . . . . . 0.411 ' HD1' ' HA ' ' E' ' 31' ' ' TYR . 2.1 m-30 -70.29 178.54 2.81 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-O 123.012 1.387 . . . . 39.34 112.097 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 32' ' ' GLN . . . . . 0.478 ' HG3' ' H ' ' E' ' 33' ' ' THR . 27.7 tp60 -149.34 -158.57 0.93 Allowed 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 103.473 -2.788 . . . . 48.05 103.473 172.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 33' ' ' THR . . . . . 0.478 ' H ' ' HG3' ' E' ' 32' ' ' GLN . 14.2 t -63.71 161.55 14.85 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 122.736 1.255 . . . . 26.33 111.719 178.058 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 34' ' ' ASP . . . . . 0.59 ' HB2' ' HB3' ' F' ' 120' ' ' ASP . 83.3 m-20 -136.12 -168.75 2.29 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 113.829 -1.532 . . . . 59.62 107.856 -167.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 35' ' ' GLY . . . . . 0.705 ' O ' ' HA2' ' E' ' 63' ' ' GLY . . . 172.27 135.04 1.89 Allowed Glycine 0 N--CA 1.441 -0.984 0 C-N-CA 120.37 -0.919 . . . . 17.43 111.843 167.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 36' ' ' SER . . . . . . . . . . . . . 66.0 m -123.3 84.98 2.35 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 105.618 -1.993 . . . . 6.96 105.618 174.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 37' ' ' VAL . . . . . 0.563 HG23 ' HB2' ' E' ' 62' ' ' SER . 3.9 m -92.15 109.35 21.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.41 -0.959 . . . . 4.52 108.41 -172.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 38' ' ' SER . . . . . . . . . . . . . 49.9 m -98.83 94.59 6.68 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.923 -1.14 . . . . 24.09 107.923 -168.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.43 102.89 2.9 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.373 -0.918 . . . . 29.57 113.669 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 40' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' E' ' 59' ' ' VAL . 84.6 tt0 -109.33 118.64 37.19 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.859 . . . . 10.27 108.682 -178.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 41' ' ' ARG . . . . . 0.608 ' O ' ' HA3' ' E' ' 57' ' ' GLY . 88.8 mtm-85 -81.69 -174.38 4.97 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.553 0.692 . . . . 46.9 109.473 -177.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 42' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -161.29 146.43 13.81 Favored 'General case' 0 C--N 1.329 -0.29 0 O-C-N 121.855 -0.528 . . . . 55.7 110.082 -170.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 43' ' ' LEU . . . . . . . . . . . . . 81.5 mt -77.94 146.77 35.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.638 -0.71 . . . . 17.56 109.526 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 44' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -147.71 125.68 12.04 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.533 0.206 . . . . 32.68 110.929 172.006 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 45' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -125.63 -170.96 2.27 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 108.52 -0.918 . . . . 36.52 108.52 157.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 46' ' ' GLU . . . . . . . . . . . . . 49.0 mp0 -113.67 -34.65 5.44 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 113.679 0.992 . . . . 24.79 113.679 174.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 47' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 59.17 25.58 14.15 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.355 1.462 . . . . 27.02 112.281 -179.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 48' ' ' THR . . . . . . . . . . . . . 56.2 p 48.07 45.57 19.44 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.006 1.323 . . . . 12.29 111.406 -165.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 49' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -137.32 -165.33 1.74 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.523 -1.288 . . . . 17.43 107.523 -175.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 50' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -66.84 -25.28 66.35 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.376 0.51 . . . . 30.21 112.376 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 51' ' ' GLY . . . . . . . . . . . . . . . 138.81 160.08 8.26 Favored Glycine 0 N--CA 1.448 -0.555 0 N-CA-C 111.577 -0.609 . . . . 9.65 111.577 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 52' ' ' ARG . . . . . . . . . . . . . 17.0 tpp85 -124.49 51.24 1.62 Allowed 'General case' 0 C--O 1.234 0.285 0 N-CA-C 106.228 -1.767 . . . . 7.84 106.228 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 53' ' ' ILE . . . . . . . . . . . . . 6.5 tt -79.06 -4.94 7.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.672 -0.695 . . . . 59.64 111.4 -173.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 54' ' ' LEU . . . . . . . . . . . . . 7.0 mp -64.66 -21.71 66.8 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 47.32 112.897 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.15 145.02 43.92 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-O 121.481 0.49 . . . . 23.4 114.209 -170.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 56' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -75.7 -178.97 4.69 Favored 'Trans proline' 0 C--N 1.328 -0.542 0 C-N-CA 121.31 1.34 . . . . 17.43 112.001 -175.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 57' ' ' GLY . . . . . 0.608 ' HA3' ' O ' ' E' ' 41' ' ' ARG . . . -153.89 171.18 32.58 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.468 -1.453 . . . . 25.4 109.468 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 58' ' ' SER . . . . . . . . . . . . . 44.0 t -73.61 146.69 44.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.656 0.741 . . . . 10.01 110.409 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 59' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' E' ' 40' ' ' GLU . 2.7 p -107.57 122.49 61.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 N-CA-C 108.517 -0.92 . . . . 2.89 108.517 -177.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.28 118.07 29.46 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.931 -1.507 . . . . 14.7 106.931 172.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 61' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -113.08 121.11 43.59 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.425 -0.954 . . . . 61.06 108.425 -172.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 62' ' ' SER . . . . . 0.646 ' HA ' ' O ' ' E' ' 132' ' ' LEU . 66.8 m -106.33 165.13 11.48 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.727 0.811 . . . . 17.43 110.399 -176.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 63' ' ' GLY . . . . . 0.705 ' HA2' ' O ' ' E' ' 35' ' ' GLY . . . -139.76 122.02 2.15 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.191 -0.913 . . . . 17.43 112.419 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 64' ' ' GLU . . . . . 0.418 ' O ' ' HA ' ' E' ' 34' ' ' ASP . 66.8 mm-40 -103.32 95.51 6.14 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 107.359 -1.348 . . . . 56.28 107.359 174.427 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 65' ' ' VAL . . . . . . . . . . . . . 86.4 t -106.73 119.79 56.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.111 -1.07 . . . . 17.43 108.111 -178.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 66' ' ' THR . . . . . . . . . . . . . 72.9 p -116.68 145.24 43.58 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.522 -0.547 . . . . 24.78 109.522 177.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 67' ' ' TYR . . . . . 0.457 ' HE1' HD12 ' E' ' 130' ' ' ILE . 51.4 p90 -154.82 -174.92 5.18 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.901 -0.777 . . . . 1.29 108.901 178.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 68' ' ' TYR . . . . . . . . . . . . . 15.6 m-30 -114.68 136.57 52.91 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 109.555 -0.535 . . . . 17.43 109.555 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 69' ' ' GLY . . . . . . . . . . . . . . . -85.29 114.3 3.95 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.969 -0.634 . . . . 17.43 113.939 -176.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 70' ' ' LYS . . . . . 0.499 ' O ' ' NE2' ' E' ' 76' ' ' GLN . 38.3 ttmt -82.97 152.75 25.33 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.609 -0.886 . . . . 17.43 108.609 174.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -68.49 -15.6 63.6 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 113.935 1.087 . . . . 40.31 113.935 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.51 -140.08 5.04 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 110.083 -1.207 . . . . 37.12 110.083 175.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 73' ' ' ASP . . . . . 0.496 ' HB3' ' HE1' ' E' ' 28' ' ' PHE . 32.9 t0 59.88 73.01 0.5 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 125.145 1.378 . . . . 16.31 111.125 168.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.68 11.3 0.07 Allowed 'General case' 0 C--O 1.235 0.291 0 N-CA-C 117.113 2.264 . . . . 26.3 117.113 -158.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.29 96.75 Favored Glycine 0 C--N 1.338 0.661 0 C-N-CA 120.268 -0.967 . . . . 23.8 112.555 170.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 76' ' ' GLN . . . . . 0.499 ' NE2' ' O ' ' E' ' 70' ' ' LYS . 22.1 pt20 -70.47 -23.73 62.75 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 119.921 -0.712 . . . . 32.42 111.859 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 77' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -70.71 -28.08 64.47 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 119.693 -0.803 . . . . 14.13 111.191 170.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.64 -30.28 62.84 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 120.624 -0.43 . . . . 40.88 111.443 170.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 79' ' ' ILE . . . . . . . . . . . . . 50.6 mm -64.3 -43.42 97.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 CA-C-O 121.098 0.475 . . . . 17.43 110.301 172.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.55 -22.69 60.01 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.362 -0.535 . . . . 30.96 112.009 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 81' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -69.32 -32.67 71.93 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 120.314 -0.554 . . . . 22.7 111.24 168.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 82' ' ' ALA . . . . . 0.746 ' HA ' ' HB2' ' E' ' 87' ' ' LYS . . . -75.44 -34.95 61.01 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 119.548 -0.861 . . . . 17.43 111.642 175.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 83' ' ' TYR . . . . . . . . . . . . . 83.3 t80 -84.3 -62.1 1.64 Allowed 'General case' 0 C--O 1.235 0.336 0 C-N-CA 120.184 -0.606 . . . . 9.61 112.135 -176.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 84' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -73.56 -41.01 63.51 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 111.922 0.342 . . . . 15.78 111.922 -167.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 85' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -74.18 -43.44 57.28 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 119.836 -0.745 . . . . 19.48 111.008 171.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.86 97.03 2.48 Favored Glycine 0 N--CA 1.448 -0.544 0 O-C-N 122.253 -0.28 . . . . 17.43 112.902 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 87' ' ' LYS . . . . . 0.746 ' HB2' ' HA ' ' E' ' 82' ' ' ALA . 98.0 mttt -147.88 -162.2 1.5 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.057 -1.46 . . . . 17.43 107.057 -178.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 88' ' ' GLN . . . . . 0.494 ' HG2' ' HD1' ' E' ' 112' ' ' TYR . 27.7 mt-30 -129.94 175.21 9.05 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.48 0.657 . . . . 17.43 109.82 170.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 89' ' ' ILE . . . . . . . . . . . . . 70.1 mt -128.88 134.26 64.63 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-N 115.903 -0.59 . . . . 18.82 109.618 -172.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -83.27 120.34 25.71 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.465 -0.939 . . . . 13.36 108.465 165.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 91' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' E' ' 109' ' ' GLY . 78.9 t80 -118.15 129.36 55.48 Favored 'General case' 0 C--O 1.237 0.422 0 C-N-CA 124.319 1.047 . . . . 5.27 110.032 -165.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 92' ' ' TRP . . . . . 0.534 ' HB2' ' HB2' ' E' ' 14' ' ' LEU . 89.9 m95 -129.11 130.87 47.02 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.87 0.868 . . . . 17.43 108.898 -177.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 93' ' ' ARG . . . . . 0.794 ' O ' ' HA ' ' E' ' 106' ' ' ALA . 78.1 ttt-85 -112.19 94.31 4.87 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.187 -1.042 . . . . 15.55 108.187 172.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 94' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' E' ' 106' ' ' ALA . 25.4 m -107.36 162.22 5.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.197 0.998 . . . . 46.02 109.636 -172.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 95' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -109.47 167.96 9.74 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.842 -1.072 . . . . 15.36 111.291 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 96' ' ' THR . . . . . 0.5 HG23 HG23 ' E' ' 150' ' ' ILE . 28.3 m -101.51 -29.68 11.84 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 114.941 -1.027 . . . . 29.59 112.527 -175.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 97' ' ' VAL . . . . . . . . . . . . . 35.1 m -69.28 152.97 9.08 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 CA-C-O 121.702 0.763 . . . . 11.14 110.153 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 98' ' ' LYS . . . . . 0.453 ' NZ ' ' O ' ' E' ' 99' ' ' ASN . 29.7 tptp -89.31 123.53 33.58 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.699 -0.682 . . . . 30.45 109.822 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 99' ' ' ASN . . . . . 0.453 ' O ' ' NZ ' ' E' ' 98' ' ' LYS . 34.7 m120 -84.06 168.25 16.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.779 0.799 . . . . 6.7 109.949 171.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 100' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 -105.83 -12.46 15.86 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 113.64 0.978 . . . . 18.17 113.64 178.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 101' ' ' ASN . . . . . . . . . . . . . 15.8 p30 -94.55 -56.25 2.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 118.296 0.498 . . . . 32.03 111.088 170.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 102' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -99.12 -174.28 2.71 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 107.965 -1.124 . . . . 20.71 107.965 168.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 103' ' ' LYS . . . . . 0.644 ' H ' HG22 ' E' ' 143' ' ' ILE . 97.2 mttt -82.07 -54.88 4.94 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 120.18 -0.608 . . . . 50.01 110.144 169.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 104' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -131.4 -171.37 2.58 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 107.723 -1.214 . . . . 17.43 107.723 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 105' ' ' ASP . . . . . 0.412 ' O ' ' HA ' ' E' ' 94' ' ' VAL . 22.6 p-10 -150.5 167.08 28.23 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.604 0.716 . . . . 27.13 109.543 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 106' ' ' ALA . . . . . 0.794 ' HA ' ' O ' ' E' ' 93' ' ' ARG . . . -154.78 159.79 40.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.087 -0.961 . . . . 10.17 110.991 -162.193 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 107' ' ' GLN . . . . . 0.467 ' OE1' ' OH ' ' F' ' 118' ' ' TYR . 88.7 mt-30 -121.41 121.31 37.31 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 107.187 -1.412 . . . . 8.04 107.187 161.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 108' ' ' PHE . . . . . . . . . . . . . 92.8 t80 -105.88 152.88 22.71 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.265 1.026 . . . . 14.65 110.282 -165.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 109' ' ' GLY . . . . . 0.428 ' O ' ' HB3' ' E' ' 91' ' ' PHE . . . -169.47 155.09 24.94 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.753 -1.213 . . . . 7.84 112.491 171.289 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 110' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -94.32 107.55 19.5 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 108.924 -0.769 . . . . 16.85 108.924 168.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.24 160.17 16.75 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-O 121.537 0.685 . . . . 32.2 111.621 -166.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 112' ' ' TYR . . . . . 0.494 ' HD1' ' HG2' ' E' ' 88' ' ' GLN . 64.4 t80 -138.31 136.45 36.44 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.615 -1.175 . . . . 13.21 108.073 -178.253 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 113' ' ' ILE . . . . . . . . . . . . . 79.8 mt -83.27 129.4 37.53 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.871 -0.418 . . . . 19.96 109.871 -171.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 114' ' ' GLU . . . . . 0.532 ' HB2' ' HB2' ' E' ' 131' ' ' SER . 98.1 mt-10 -72.67 -64.25 1.0 Allowed 'General case' 0 C--O 1.236 0.343 0 C-N-CA 119.77 -0.772 . . . . 38.93 110.645 164.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 115' ' ' SER . . . . . . . . . . . . . 73.3 m -141.67 149.25 40.35 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-O 121.634 0.731 . . . . 34.04 110.333 -169.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -123.43 94.91 4.39 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 105.119 -2.178 . . . . 13.74 105.119 176.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 117' ' ' GLU . . . . . 0.543 ' HB3' HG12 ' D' ' 37' ' ' VAL . 98.1 mt-10 -115.54 108.47 16.49 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.387 -1.338 . . . . 44.54 107.387 -175.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 118' ' ' TYR . . . . . 0.523 ' HB3' ' HA ' ' E' ' 128' ' ' ILE . 23.7 p90 -112.97 140.89 47.39 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.594 0.711 . . . . 4.42 111.896 177.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 119' ' ' SER . . . . . . . . . . . . . 36.5 t -97.64 132.86 42.9 Favored 'General case' 0 C--O 1.239 0.545 0 CA-C-N 114.641 -1.163 . . . . 17.93 109.815 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 120' ' ' ASP . . . . . 0.581 ' HB3' ' HB2' ' D' ' 34' ' ' ASP . 58.9 t0 -114.09 98.63 7.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 106.61 -1.626 . . . . 14.02 106.61 173.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 121' ' ' GLY . . . . . . . . . . . . . . . -83.6 -157.42 24.68 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-O 121.727 0.626 . . . . 5.36 112.176 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 122' ' ' VAL . . . . . 0.45 HG13 ' H ' ' I' ' 48' ' ' THR . 59.5 t -111.85 -62.8 2.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 107.618 -1.253 . . . . 14.68 107.618 176.202 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 123' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -82.78 -45.15 14.71 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.891 0.7 . . . . 69.27 112.891 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 124' ' ' GLY . . . . . 0.56 ' HA2' HD21 ' J' ' 43' ' ' LEU . . . -71.06 144.78 38.48 Favored Glycine 0 C--O 1.236 0.279 0 N-CA-C 110.28 -1.128 . . . . 22.71 110.28 175.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 125' ' ' ALA . . . . . 0.424 ' HB2' HD13 ' J' ' 43' ' ' LEU . . . -71.23 168.01 18.19 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-O 121.754 0.788 . . . . 2.65 110.296 174.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 126' ' ' VAL . . . . . 0.534 HG12 ' HA ' ' E' ' 120' ' ' ASP . 35.6 m -69.16 151.01 10.3 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 CA-C-N 115.131 -0.94 . . . . 20.58 109.738 -176.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 127' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -140.67 126.72 19.54 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.312 -0.403 . . . . 33.41 109.958 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 128' ' ' ILE . . . . . 0.523 ' HA ' ' HB3' ' E' ' 118' ' ' TYR . 95.2 mt -93.88 118.77 40.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 108.991 -0.744 . . . . 17.43 108.991 -178.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 129' ' ' SER . . . . . 0.48 ' HB2' ' O ' ' E' ' 117' ' ' GLU . 70.1 m -98.87 133.41 43.2 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.344 -0.984 . . . . 7.33 108.344 171.231 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 130' ' ' ILE . . . . . 0.457 HD12 ' HE1' ' E' ' 67' ' ' TYR . 62.2 mt -135.83 128.38 46.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 109.275 -0.639 . . . . 17.43 109.275 -176.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 131' ' ' SER . . . . . 0.532 ' HB2' ' HB2' ' E' ' 114' ' ' GLU . 49.5 m -95.81 152.98 17.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.123 -0.49 . . . . 12.69 109.964 175.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 132' ' ' LEU . . . . . 0.646 ' O ' ' HA ' ' E' ' 62' ' ' SER . 7.2 mp -137.98 140.83 40.4 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.149 -0.478 . . . . 51.13 110.711 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 133' ' ' GLN . . . . . 0.413 ' HG2' ' HG3' ' E' ' 114' ' ' GLU . 30.3 mm100 -120.51 137.27 54.46 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 108.45 -0.945 . . . . 17.43 108.45 167.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 134' ' ' VAL . . . . . 0.404 HG21 ' HA3' ' E' ' 109' ' ' GLY . 8.6 p -137.25 148.39 26.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.44 0 N-CA-C 108.455 -0.942 . . . . 13.1 108.455 175.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 135' ' ' ILE . . . . . . . . . . . . . 27.0 mm -62.17 -60.7 2.31 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.333 0.587 . . . . 8.86 110.928 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.71 141.77 7.53 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.161 -1.575 . . . . 35.11 109.161 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 137' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -68.73 153.58 43.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 121.555 0.693 . . . . 32.63 110.306 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 138' ' ' LEU . . . . . . . . . . . . . 36.0 tp -138.55 122.83 18.19 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.203 -1.406 . . . . 4.9 107.203 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -84.3 70.12 10.56 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 122.323 1.059 . . . . 18.69 109.698 -169.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 140' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -85.98 76.45 9.83 Favored 'General case' 0 C--N 1.334 -0.093 0 N-CA-C 108.148 -1.056 . . . . 18.62 108.148 176.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 141' ' ' GLY . . . . . . . . . . . . . . . -71.74 111.0 3.43 Favored Glycine 0 C--O 1.237 0.307 0 N-CA-C 110.51 -1.036 . . . . 22.52 110.51 175.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -119.96 -172.24 2.3 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.353 0.597 . . . . 30.98 109.398 -173.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 143' ' ' ILE . . . . . 0.644 HG22 ' H ' ' E' ' 103' ' ' LYS . 1.4 pp -112.28 -59.27 3.28 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 113.152 0.797 . . . . 11.98 113.152 -169.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 144' ' ' ASP . . . . . . . . . . . . . 18.9 p-10 -84.44 126.36 33.18 Favored 'General case' 0 C--N 1.33 -0.239 0 O-C-N 121.453 -0.78 . . . . 36.16 111.141 -169.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 145' ' ' THR . . . . . . . . . . . . . 73.2 p -117.0 12.07 14.49 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 112.527 0.566 . . . . 39.49 112.527 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 146' ' ' LEU . . . . . 0.418 ' HG ' ' HA ' ' E' ' 24' ' ' SER . 4.2 mm? 54.29 75.75 0.59 Allowed Pre-proline 0 C--O 1.237 0.4 0 C-N-CA 126.782 2.033 . . . . 8.79 110.261 -178.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 147' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -68.54 71.02 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 N-CA-C 115.393 1.266 . . . . 10.23 115.393 -160.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 148' ' ' GLU . . . . . 0.513 ' OE1' ' ND2' ' E' ' 152' ' ' ASN . 80.0 mm-40 -103.49 11.68 36.08 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.036 -0.529 . . . . 7.78 111.48 167.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 149' ' ' GLU . . . . . 0.46 ' O ' ' NZ ' ' E' ' 12' ' ' LYS . 26.0 pm0 -141.13 4.67 1.86 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 113.111 0.782 . . . . 11.91 113.111 -178.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 150' ' ' ILE . . . . . 0.5 HG23 HG23 ' E' ' 96' ' ' THR . 47.4 mm -113.89 -53.91 4.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 118.997 0.817 . . . . 10.56 111.28 -176.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 151' ' ' VAL . . . . . . . . . . . . . 23.8 t -106.2 -23.59 4.39 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.781 -1.563 . . . . 16.0 106.781 -177.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 152' ' ' ASN . . . . . 0.513 ' ND2' ' OE1' ' E' ' 148' ' ' GLU . 44.1 t-20 -64.68 -38.01 89.54 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.761 -0.654 . . . . 35.34 111.797 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -73.78 99.08 1.16 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.444 0 N-CA-C 108.111 -1.07 . . . . 0.22 108.111 173.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 154' ' ' SER . . . . . . . . . . . . . 36.6 t -116.31 -61.46 1.73 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.533 -0.758 . . . . 14.7 112.477 -171.18 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 155' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -134.47 -28.74 1.26 Allowed 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 113.659 0.985 . . . . 41.95 113.659 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.97 -59.18 2.81 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 110.655 -0.978 . . . . 49.12 110.655 -168.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 157' ' ' GLY . . . . . . . . . . . . . . . -81.98 143.59 23.27 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.466 -0.873 . . . . 17.43 112.156 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 158' ' ' TYR . . . . . 0.423 ' CD2' ' HG2' ' E' ' 171' ' ' PRO . 14.6 m-30 -110.47 -172.57 2.06 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.373 0.669 . . . . 3.94 109.555 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 159' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -77.07 -72.37 0.35 Allowed 'General case' 0 C--O 1.235 0.291 0 N-CA-C 113.202 0.816 . . . . 58.89 113.202 -149.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 160' ' ' PHE . . . . . 0.403 ' CD2' ' HG3' ' E' ' 162' ' ' GLN . 33.3 p90 177.6 173.27 0.55 Allowed 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 127.952 2.501 . . . . 7.43 108.984 161.002 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -158.99 108.8 1.96 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 105.379 -2.082 . . . . 28.57 105.379 156.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 162' ' ' GLN . . . . . 0.403 ' HG3' ' CD2' ' E' ' 160' ' ' PHE . 89.4 mt-30 -73.51 -49.27 6.64 Favored Pre-proline 0 C--O 1.242 0.674 0 C-N-CA 119.006 -1.077 . . . . 24.87 113.722 -170.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 163' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -76.72 -23.71 10.83 Favored 'Trans proline' 0 C--N 1.371 1.716 0 CA-C-N 122.096 1.784 . . . . 34.81 112.814 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 164' ' ' GLY . . . . . . . . . . . . . . . -134.93 38.88 1.76 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 119.22 2.448 . . . . 45.41 119.22 -169.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 165' ' ' GLN . . . . . 0.467 ' HG2' ' HD3' ' K' ' 90' ' ' LYS . 9.8 tp-100 -67.46 -55.87 11.86 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 119.005 1.402 . . . . 11.87 111.008 178.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 166' ' ' THR . . . . . . . . . . . . . 33.3 p 53.57 53.44 11.54 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.808 1.643 . . . . 30.44 111.671 176.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 167' ' ' THR . . . . . 0.467 HG21 ' HA ' ' E' ' 171' ' ' PRO . 6.4 m -142.41 146.62 35.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.484 -0.562 . . . . 15.31 109.484 -166.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 168' ' ' GLY . . . . . . . . . . . . . . . -81.69 -129.06 1.06 Allowed Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.908 -0.877 . . . . 48.49 110.908 165.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 169' ' ' GLU . . . . . 0.42 ' HG3' ' HG ' ' J' ' 54' ' ' LEU . 15.1 tm-20 -73.31 -61.17 1.92 Allowed 'General case' 0 C--O 1.235 0.302 0 O-C-N 122.514 -0.403 . . . . 42.17 111.467 -176.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.01 103.32 0.44 Allowed Pre-proline 0 C--N 1.344 0.35 0 C-N-CA 124.077 0.951 . . . . 17.43 109.707 -172.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 171' ' ' PRO . . . . . 0.467 ' HA ' HG21 ' E' ' 167' ' ' THR . 98.4 Cg_endo -81.94 -179.0 4.46 Favored 'Trans proline' 0 C--N 1.323 -0.807 0 C-N-CA 121.373 1.382 . . . . 8.82 112.96 -151.053 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.2 68.93 1.5 Allowed Glycine 0 N--CA 1.449 -0.468 0 N-CA-C 117.008 1.563 . . . . 21.56 117.008 164.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 173' ' ' THR . . . . . . . . . . . . . 11.1 t -130.0 165.24 22.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 117.971 0.886 . . . . 19.48 109.533 171.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 174' ' ' VAL . . . . . . . . . . . . . 30.6 m -76.75 158.62 80.48 Favored Pre-proline 0 C--O 1.24 0.563 0 CA-C-N 114.666 -1.152 . . . . 21.08 107.949 176.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 175' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -63.71 112.37 1.78 Allowed 'Trans proline' 0 C--N 1.353 0.784 0 CA-C-N 119.633 0.905 . . . . 13.55 112.14 175.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.413 0 C-N-CA 125.771 1.629 . . . . 42.06 113.442 -172.846 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 5' ' ' PRO . . . . . 0.578 ' HG3' HH11 ' L' ' 52' ' ' ARG . 39.0 Cg_endo . . . . . 0 N--CA 1.466 -0.146 0 N-CA-C 112.424 0.125 . . . . 2.59 112.424 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 6' ' ' ILE . . . . . 0.467 ' H ' ' HB2' ' F' ' 5' ' ' PRO . 96.4 mt -121.48 120.73 62.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.416 0 N-CA-C 107.895 -1.15 . . . . 30.14 107.895 177.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 7' ' ' MET . . . . . . . . . . . . . 39.1 mmt -90.16 172.91 8.47 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.903 0.858 . . . . 49.38 110.908 -176.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.3 -11.29 67.5 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.291 -0.868 . . . . 8.83 114.414 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 9' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -96.6 -15.58 21.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 117.692 0.746 . . . . 16.65 112.176 172.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 10' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -76.57 -4.75 44.53 Favored 'General case' 0 CA--C 1.519 -0.223 0 N-CA-C 113.885 1.068 . . . . 26.53 113.885 -171.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 11' ' ' VAL . . . . . . . . . . . . . 95.1 t -126.72 123.76 63.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 N-CA-C 108.117 -1.068 . . . . 12.14 108.117 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 12' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -133.55 161.73 33.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.526 0.679 . . . . 21.97 110.084 175.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 13' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' F' ' 93' ' ' ARG . 18.8 m-30 -112.16 96.11 5.84 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 108.319 -0.993 . . . . 17.61 108.319 -166.068 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 14' ' ' LEU . . . . . 0.782 HD23 ' HB3' ' F' ' 27' ' ' LEU . 80.9 mt -73.04 125.28 27.28 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.445 -0.343 . . . . 59.12 110.161 176.48 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -108.14 153.39 23.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.176 0.512 . . . . 11.29 109.89 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 16' ' ' GLN . . . . . . . . . . . . . 69.9 tp60 -147.71 135.51 21.05 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.967 -0.753 . . . . 11.64 108.967 174.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' SER . . . . . . . . . . . . . 38.1 t -76.59 153.57 35.22 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 121.613 0.721 . . . . 14.99 110.957 178.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 18' ' ' ILE . . . . . . . . . . . . . 41.7 pt -76.19 -15.33 15.15 Favored 'Isoleucine or valine' 0 C--O 1.237 0.416 0 N-CA-C 113.205 0.817 . . . . 17.61 113.205 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -108.98 -8.47 15.21 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 112.661 0.615 . . . . 18.47 112.661 -171.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.96 -46.9 32.36 Favored 'General case' 0 C--O 1.236 0.388 0 C-N-CA 119.726 -0.789 . . . . 23.24 111.555 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.36 41.03 32.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.061 1.344 . . . . 27.48 111.639 -171.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 22' ' ' THR . . . . . . . . . . . . . 69.5 p -123.0 127.62 49.06 Favored 'General case' 0 C--O 1.236 0.344 0 C-N-CA 123.394 0.678 . . . . 13.15 109.365 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.34 76.08 2.26 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 114.269 0.467 . . . . 19.12 114.269 -177.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 24' ' ' SER . . . . . . . . . . . . . 92.9 p -129.82 -26.01 2.49 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 120.503 -0.479 . . . . 33.96 111.59 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 25' ' ' ALA . . . . . . . . . . . . . . . 50.98 73.36 0.99 Allowed Pre-proline 0 C--O 1.237 0.399 0 C-N-CA 126.912 2.085 . . . . 41.47 112.568 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 26' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_exo -72.94 104.65 1.8 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 CA-C-N 119.552 0.876 . . . . 5.87 111.998 176.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 27' ' ' LEU . . . . . 0.782 ' HB3' HD23 ' F' ' 14' ' ' LEU . 2.1 pt? -82.56 153.43 25.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 108.795 -0.817 . . . . 17.61 108.795 166.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 28' ' ' PHE . . . . . 0.462 ' HE1' ' HB3' ' F' ' 73' ' ' ASP . 71.0 t80 -97.56 127.33 38.14 Favored Pre-proline 0 C--N 1.321 -0.635 1 C-N-CA 110.516 -4.474 . . . . 35.64 110.187 179.274 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' F' F ' 29' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.44 -173.0 1.17 Allowed 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 120.595 0.863 . . . . 28.08 113.56 -176.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.639 ' HA ' ' HB3' ' K' ' 47' ' ' GLN . . . 55.15 61.61 2.85 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.498 1.119 . . . . 17.61 111.231 -174.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 31' ' ' TYR . . . . . 0.429 ' HD1' ' HA ' ' F' ' 31' ' ' TYR . 1.3 m-30 -72.96 -177.08 2.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 123.072 1.415 . . . . 15.25 112.424 -178.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 32' ' ' GLN . . . . . 0.473 ' HG3' ' H ' ' F' ' 33' ' ' THR . 7.0 tp-100 -149.27 -158.77 0.95 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 103.389 -2.819 . . . . 20.79 103.389 166.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 33' ' ' THR . . . . . 0.473 ' H ' ' HG3' ' F' ' 32' ' ' GLN . 15.2 t -67.51 167.14 13.39 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 122.646 1.212 . . . . 7.47 111.682 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 34' ' ' ASP . . . . . 0.642 ' HB2' ' HB3' ' A' ' 120' ' ' ASP . 85.2 m-20 -135.7 -169.0 2.31 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.076 -1.42 . . . . 37.96 108.355 -168.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 35' ' ' GLY . . . . . 0.669 ' O ' ' HA2' ' F' ' 63' ' ' GLY . . . 177.07 133.63 1.85 Allowed Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.478 -0.783 . . . . 28.65 111.341 170.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 36' ' ' SER . . . . . . . . . . . . . 69.0 m -127.56 84.98 2.3 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.246 -1.761 . . . . 17.61 106.246 175.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 37' ' ' VAL . . . . . 0.553 HG23 ' HB2' ' F' ' 62' ' ' SER . 4.9 m -93.22 113.19 27.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.438 -0.949 . . . . 6.97 108.438 -172.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 38' ' ' SER . . . . . . . . . . . . . 48.6 m -103.72 90.09 3.54 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.207 -1.034 . . . . 14.3 108.207 -168.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.49 103.9 3.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.488 -0.863 . . . . 1.89 113.76 -176.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 40' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -109.9 119.21 38.63 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.651 -0.87 . . . . 17.61 108.651 -178.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 41' ' ' ARG . . . . . 0.779 ' O ' ' HA3' ' F' ' 57' ' ' GLY . 87.2 mtm-85 -83.65 -173.9 4.98 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.479 0.657 . . . . 37.99 109.367 -177.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 42' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -161.34 137.32 8.05 Favored 'General case' 0 C--N 1.33 -0.26 0 O-C-N 121.982 -0.449 . . . . 26.25 110.233 -169.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 43' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.68 127.27 32.09 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 109.05 -0.722 . . . . 16.06 109.05 175.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 44' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -132.84 119.04 19.71 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 110.091 -0.337 . . . . 24.52 110.091 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 45' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -125.72 -169.02 1.93 Allowed 'General case' 0 C--O 1.235 0.339 0 N-CA-C 109.245 -0.65 . . . . 48.29 109.245 164.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 46' ' ' GLU . . . . . 0.414 ' HA ' ' HA2' ' F' ' 51' ' ' GLY . 56.4 mp0 -121.28 -33.79 3.61 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 113.529 0.937 . . . . 12.4 113.529 176.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 47' ' ' GLN . . . . . . . . . . . . . 87.6 mm-40 60.1 28.38 17.92 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.347 1.459 . . . . 47.49 112.402 174.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 48' ' ' THR . . . . . . . . . . . . . 50.7 p 50.32 43.31 26.58 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.069 1.348 . . . . 5.14 111.43 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 49' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -137.69 -165.34 1.76 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.445 -1.317 . . . . 14.64 107.445 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 50' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -67.19 -25.12 65.98 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 112.335 0.494 . . . . 32.61 112.335 174.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 51' ' ' GLY . . . . . 0.414 ' HA2' ' HA ' ' F' ' 46' ' ' GLU . . . 143.19 166.81 11.32 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 111.228 -0.749 . . . . 33.78 111.228 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 52' ' ' ARG . . . . . . . . . . . . . 17.5 tpp85 -128.71 52.32 1.94 Allowed 'General case' 0 C--O 1.234 0.28 0 N-CA-C 106.606 -1.627 . . . . 15.47 106.606 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 53' ' ' ILE . . . . . . . . . . . . . 5.9 tt -75.98 -8.76 12.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.739 -0.664 . . . . 51.77 111.664 -171.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 54' ' ' LEU . . . . . . . . . . . . . 7.5 mp -67.1 -21.33 65.87 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.277 0.631 . . . . 45.17 112.687 -176.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.45 141.99 38.09 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-O 121.437 0.465 . . . . 49.64 114.001 -170.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 56' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -76.73 -179.37 5.3 Favored 'Trans proline' 0 C--N 1.327 -0.572 0 C-N-CA 121.177 1.252 . . . . 15.4 111.803 -175.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 57' ' ' GLY . . . . . 0.779 ' HA3' ' O ' ' F' ' 41' ' ' ARG . . . -153.03 173.24 31.96 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 110.091 -1.203 . . . . 46.63 110.091 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 58' ' ' SER . . . . . . . . . . . . . 40.4 t -76.13 144.65 40.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.663 0.744 . . . . 5.36 110.611 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 59' ' ' VAL . . . . . . . . . . . . . 3.1 p -104.04 124.13 58.24 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 N-CA-C 108.562 -0.903 . . . . 8.32 108.562 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 60' ' ' ALA . . . . . . . . . . . . . . . -123.04 117.75 26.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.039 -1.467 . . . . 17.61 107.039 173.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 61' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -117.12 120.91 39.77 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.817 -0.808 . . . . 70.1 108.817 -168.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 62' ' ' SER . . . . . 0.719 ' HA ' ' O ' ' F' ' 132' ' ' LEU . 69.0 m -108.58 164.1 12.65 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 124.211 1.005 . . . . 17.61 110.585 -175.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 63' ' ' GLY . . . . . 0.669 ' HA2' ' O ' ' F' ' 35' ' ' GLY . . . -140.07 122.54 2.23 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.108 -0.951 . . . . 3.87 112.733 177.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 64' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -101.18 95.41 6.52 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 107.499 -1.297 . . . . 61.56 107.499 173.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 65' ' ' VAL . . . . . . . . . . . . . 92.6 t -102.57 119.46 50.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.2 -1.037 . . . . 17.61 108.2 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 66' ' ' THR . . . . . . . . . . . . . 79.6 p -115.24 144.31 43.91 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.195 -0.669 . . . . 9.04 109.195 176.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 67' ' ' TYR . . . . . 0.413 ' HE1' HD12 ' F' ' 130' ' ' ILE . 53.9 p90 -155.09 -173.63 4.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.922 -0.77 . . . . 17.61 108.922 175.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 68' ' ' TYR . . . . . . . . . . . . . 16.8 m-30 -115.37 136.89 52.63 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 109.232 -0.655 . . . . 17.61 109.232 175.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.86 113.51 3.74 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.944 -0.646 . . . . 17.61 114.403 -175.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 70' ' ' LYS . . . . . 0.473 ' O ' ' NE2' ' F' ' 76' ' ' GLN . 38.4 ttmt -83.44 152.08 25.16 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 108.766 -0.827 . . . . 16.42 108.766 175.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -68.2 -17.21 64.26 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 113.997 1.11 . . . . 17.59 113.997 -171.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.62 -140.39 5.09 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.114 -1.194 . . . . 24.64 110.114 176.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 73' ' ' ASP . . . . . 0.462 ' HB3' ' HE1' ' F' ' 28' ' ' PHE . 31.2 t0 59.75 72.71 0.51 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.18 1.392 . . . . 10.75 111.082 168.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.42 10.92 0.05 Allowed 'General case' 0 C--O 1.235 0.29 0 N-CA-C 117.309 2.337 . . . . 31.35 117.309 -159.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.47 -40.75 94.78 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 120.227 -0.987 . . . . 22.48 112.598 170.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 76' ' ' GLN . . . . . 0.473 ' NE2' ' O ' ' F' ' 70' ' ' LYS . 22.1 pt20 -70.66 -22.35 62.5 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 119.972 -0.691 . . . . 12.03 111.873 172.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 77' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -72.36 -26.65 61.99 Favored 'General case' 0 CA--C 1.517 -0.293 0 C-N-CA 119.345 -0.942 . . . . 23.73 111.389 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.16 -30.72 63.78 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.222 -0.591 . . . . 9.85 111.169 169.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 79' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.61 -45.64 97.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 CA-C-O 121.05 0.453 . . . . 17.61 110.491 172.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -75.02 -22.79 58.25 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 121.827 -0.546 . . . . 22.42 111.992 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 81' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -70.07 -33.6 72.13 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.212 -0.595 . . . . 37.8 111.301 168.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 82' ' ' ALA . . . . . 0.737 ' HA ' ' HB2' ' F' ' 87' ' ' LYS . . . -74.2 -33.16 63.32 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.388 -0.925 . . . . 8.46 111.537 175.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 83' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -83.23 -62.63 1.54 Allowed 'General case' 0 C--O 1.235 0.341 0 C-N-CA 120.421 -0.512 . . . . 20.56 111.966 -176.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -76.24 -41.71 48.28 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 111.92 0.341 . . . . 10.83 111.92 -166.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 85' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -72.9 -41.5 64.55 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 119.812 -0.755 . . . . 28.11 110.905 171.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.33 96.93 2.46 Favored Glycine 0 N--CA 1.449 -0.469 0 O-C-N 122.266 -0.271 . . . . 4.59 113.205 178.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 87' ' ' LYS . . . . . 0.737 ' HB2' ' HA ' ' F' ' 82' ' ' ALA . 98.4 mttt -147.94 -163.11 1.69 Allowed 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 107.139 -1.43 . . . . 17.33 107.139 -179.306 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 88' ' ' GLN . . . . . 0.534 ' HG2' ' HD1' ' F' ' 112' ' ' TYR . 27.6 mt-30 -128.72 173.48 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.408 0.623 . . . . 17.52 109.705 171.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 89' ' ' ILE . . . . . 0.414 HD11 HD11 ' F' ' 113' ' ' ILE . 72.9 mt -128.33 133.67 66.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 116.059 -0.519 . . . . 11.07 109.722 -173.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -81.64 118.14 22.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 108.585 -0.894 . . . . 20.47 108.585 166.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 91' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -114.31 129.84 56.65 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 124.685 1.194 . . . . 12.46 109.939 -166.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 92' ' ' TRP . . . . . 0.502 ' HB2' ' O ' ' F' ' 14' ' ' LEU . 89.6 m95 -130.15 129.11 43.06 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 123.967 0.907 . . . . 21.11 108.838 -177.357 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 93' ' ' ARG . . . . . 0.804 ' O ' ' HA ' ' F' ' 106' ' ' ALA . 78.6 ttt-85 -111.57 92.33 3.99 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 108.101 -1.074 . . . . 11.99 108.101 173.391 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 94' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' F' ' 106' ' ' ALA . 22.2 m -105.68 162.82 4.78 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 CA-C-O 122.3 1.048 . . . . 14.23 109.646 -172.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 95' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -108.05 167.65 9.84 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 114.789 -1.096 . . . . 18.32 111.305 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 96' ' ' THR . . . . . 0.5 HG23 HG23 ' F' ' 150' ' ' ILE . 27.7 m -101.78 -29.94 11.58 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 114.87 -1.059 . . . . 25.62 112.447 -176.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 97' ' ' VAL . . . . . . . . . . . . . 35.4 m -69.0 154.13 8.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.771 0.796 . . . . 17.61 110.144 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 98' ' ' LYS . . . . . 0.512 ' NZ ' ' O ' ' F' ' 99' ' ' ASN . 29.7 tptp -91.3 122.61 34.06 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.67 -0.695 . . . . 17.61 109.803 -175.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 99' ' ' ASN . . . . . 0.512 ' O ' ' NZ ' ' F' ' 98' ' ' LYS . 34.6 m120 -81.78 169.11 17.29 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.825 0.821 . . . . 21.02 109.903 171.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 100' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -107.55 -12.12 15.34 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 113.983 1.105 . . . . 6.73 113.983 -179.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 101' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -96.15 -54.45 3.29 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 118.492 0.587 . . . . 6.24 111.438 167.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 102' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -98.65 -173.36 2.52 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.249 -1.019 . . . . 23.72 108.249 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 103' ' ' LYS . . . . . 0.591 ' H ' HG22 ' F' ' 143' ' ' ILE . 97.0 mttt -85.52 -54.86 4.3 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.208 0.528 . . . . 59.25 110.306 172.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 104' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -132.01 -171.11 2.55 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 107.985 -1.117 . . . . 26.33 107.985 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 105' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' F' ' 94' ' ' VAL . 20.8 p-10 -151.24 169.11 22.73 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 121.515 0.674 . . . . 16.88 109.362 175.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 106' ' ' ALA . . . . . 0.804 ' HA ' ' O ' ' F' ' 93' ' ' ARG . . . -155.02 159.24 40.17 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.186 -0.916 . . . . 17.61 110.926 -163.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 107' ' ' GLN . . . . . 0.436 ' OE1' ' OH ' ' A' ' 118' ' ' TYR . 88.2 mt-30 -117.27 121.26 40.67 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.1 -1.444 . . . . 15.05 107.1 159.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 108' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' F' ' 138' ' ' LEU . 85.2 t80 -108.83 152.9 24.26 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.383 1.073 . . . . 25.92 110.249 -164.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 109' ' ' GLY . . . . . . . . . . . . . . . -174.39 155.48 21.37 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 119.367 -1.396 . . . . 17.61 112.533 172.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 110' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -92.27 108.85 20.25 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 108.867 -0.79 . . . . 12.6 108.867 169.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 111' ' ' ALA . . . . . . . . . . . . . . . -111.59 161.79 15.83 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-O 121.493 0.663 . . . . 46.93 111.606 -168.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 112' ' ' TYR . . . . . 0.534 ' HD1' ' HG2' ' F' ' 88' ' ' GLN . 61.1 t80 -138.78 136.6 35.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 114.704 -1.134 . . . . 25.94 107.955 -176.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 113' ' ' ILE . . . . . 0.414 HD11 HD11 ' F' ' 89' ' ' ILE . 72.9 mt -82.74 131.33 34.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 109.665 -0.494 . . . . 17.61 109.665 -172.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 114' ' ' GLU . . . . . 0.544 ' HB2' ' HB2' ' F' ' 131' ' ' SER . 98.8 mt-10 -75.33 -64.47 1.06 Allowed 'General case' 0 C--O 1.235 0.301 0 C-N-CA 119.74 -0.784 . . . . 24.43 110.752 164.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 115' ' ' SER . . . . . . . . . . . . . 70.1 m -141.13 149.49 41.61 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.647 0.737 . . . . 37.8 110.186 -168.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -125.44 93.74 3.95 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 105.028 -2.212 . . . . 0.93 105.028 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 117' ' ' GLU . . . . . 0.533 ' HB3' HG12 ' E' ' 37' ' ' VAL . 97.4 mt-10 -115.84 109.36 17.53 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 107.522 -1.288 . . . . 33.98 107.522 -175.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 118' ' ' TYR . . . . . 0.553 ' HB3' ' HA ' ' F' ' 128' ' ' ILE . 20.6 p90 -115.33 142.38 46.76 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.558 0.694 . . . . 25.47 112.122 178.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 119' ' ' SER . . . . . . . . . . . . . 35.1 t -98.24 131.13 44.83 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 114.611 -1.177 . . . . 17.61 109.949 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 120' ' ' ASP . . . . . 0.59 ' HB3' ' HB2' ' E' ' 34' ' ' ASP . 58.5 t0 -107.11 98.71 8.32 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.361 -1.718 . . . . 28.19 106.361 170.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.73 -158.15 24.01 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-O 121.717 0.621 . . . . 25.42 112.013 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 122' ' ' VAL . . . . . . . . . . . . . 59.8 t -114.53 -62.82 2.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.13 -1.063 . . . . 14.28 108.13 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 123' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -83.3 -43.07 16.42 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.941 0.719 . . . . 57.93 112.941 179.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 124' ' ' GLY . . . . . 0.562 ' HA2' HD21 ' K' ' 43' ' ' LEU . . . -74.41 150.02 41.28 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.083 -1.207 . . . . 23.46 110.083 173.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.78 170.33 15.52 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.697 0.761 . . . . 21.78 110.192 174.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 126' ' ' VAL . . . . . 0.589 HG12 ' HA ' ' F' ' 120' ' ' ASP . 26.8 m -69.14 149.9 10.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.522 0 CA-C-N 115.203 -0.908 . . . . 17.61 109.885 -175.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 127' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -138.28 125.92 22.17 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.34 -0.391 . . . . 53.51 110.222 -179.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 128' ' ' ILE . . . . . 0.553 ' HA ' ' HB3' ' F' ' 118' ' ' TYR . 87.6 mt -95.36 121.4 45.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.324 -0.621 . . . . 17.61 109.324 -177.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 129' ' ' SER . . . . . 0.438 ' HB2' ' O ' ' F' ' 117' ' ' GLU . 70.9 m -102.98 134.23 46.76 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.476 -0.935 . . . . 46.92 108.476 172.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 130' ' ' ILE . . . . . 0.413 HD12 ' HE1' ' F' ' 67' ' ' TYR . 71.5 mt -136.77 128.41 43.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 N-CA-C 109.157 -0.682 . . . . 10.99 109.157 -175.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 131' ' ' SER . . . . . 0.544 ' HB2' ' HB2' ' F' ' 114' ' ' GLU . 62.3 m -96.23 151.85 19.12 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-O 120.975 0.417 . . . . 40.73 110.19 175.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 132' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' F' ' 62' ' ' SER . 7.2 mp -136.26 141.21 43.87 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 116.141 -0.482 . . . . 37.61 110.873 -178.191 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 133' ' ' GLN . . . . . . . . . . . . . 30.5 mm100 -120.64 136.95 54.68 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 108.448 -0.945 . . . . 17.61 108.448 168.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.87 148.04 25.66 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 N-CA-C 108.328 -0.99 . . . . 32.79 108.328 175.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 135' ' ' ILE . . . . . . . . . . . . . 27.3 mm -62.56 -61.21 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-O 121.319 0.581 . . . . 18.82 110.915 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.51 139.3 6.0 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 109.243 -1.543 . . . . 54.56 109.243 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 137' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -69.08 153.65 43.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.611 0.72 . . . . 15.77 110.288 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 138' ' ' LEU . . . . . 0.428 ' O ' ' HB3' ' F' ' 108' ' ' PHE . 35.7 tp -138.49 124.49 20.08 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.119 -1.437 . . . . 9.02 107.119 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.08 68.84 10.42 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 122.35 1.071 . . . . 6.84 109.816 -168.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 140' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -87.32 77.08 9.02 Favored 'General case' 0 C--N 1.334 -0.101 0 N-CA-C 108.22 -1.03 . . . . 16.59 108.22 176.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.14 111.31 3.45 Favored Glycine 0 C--O 1.237 0.333 0 N-CA-C 110.493 -1.043 . . . . 22.31 110.493 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.5 -172.08 2.3 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 109.278 -0.638 . . . . 25.19 109.278 -174.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 143' ' ' ILE . . . . . 0.591 HG22 ' H ' ' F' ' 103' ' ' LYS . 1.3 pp -109.82 -60.95 2.67 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 N-CA-C 113.558 0.948 . . . . 12.99 113.558 -167.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 144' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -82.26 132.9 35.23 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.34 -0.85 . . . . 27.65 110.949 -170.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 145' ' ' THR . . . . . . . . . . . . . 66.2 p -122.53 13.09 10.11 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 119.042 -0.504 . . . . 7.56 112.219 176.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 146' ' ' LEU . . . . . . . . . . . . . 4.1 mm? 54.26 76.48 0.51 Allowed Pre-proline 0 C--O 1.238 0.456 0 C-N-CA 126.827 2.051 . . . . 14.48 110.083 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 147' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -67.8 73.04 0.69 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 121.31 1.34 . . . . 10.58 115.38 -159.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 148' ' ' GLU . . . . . 0.535 ' OE1' ' ND2' ' F' ' 152' ' ' ASN . 79.6 mm-40 -108.54 9.37 27.4 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.716 -0.675 . . . . 20.19 111.65 169.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 149' ' ' GLU . . . . . . . . . . . . . 26.0 pm0 -139.49 5.21 2.22 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 112.709 0.633 . . . . 31.94 112.709 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 150' ' ' ILE . . . . . 0.5 HG23 HG23 ' F' ' 96' ' ' THR . 47.5 mm -113.89 -54.86 4.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 118.8 0.727 . . . . 24.34 111.308 -176.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 151' ' ' VAL . . . . . . . . . . . . . 26.3 t -104.44 -24.57 3.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.062 -1.458 . . . . 27.28 107.062 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 152' ' ' ASN . . . . . 0.535 ' ND2' ' OE1' ' F' ' 148' ' ' GLU . 41.1 t-20 -66.66 -36.07 81.67 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.96 -0.564 . . . . 33.96 111.722 -178.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -73.99 98.2 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.427 0 N-CA-C 107.856 -1.164 . . . . 10.33 107.856 172.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 154' ' ' SER . . . . . . . . . . . . . 30.1 t -116.82 -62.29 1.6 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.471 -0.786 . . . . 12.96 112.525 -172.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 155' ' ' LYS . . . . . . . . . . . . . 16.9 tppt? -132.74 -31.78 1.31 Allowed 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 113.721 1.008 . . . . 56.67 113.721 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.34 -55.77 2.79 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 119.359 0.982 . . . . 18.65 110.794 -169.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 157' ' ' GLY . . . . . . . . . . . . . . . -80.09 142.54 24.32 Favored Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.475 -0.869 . . . . 4.61 112.343 176.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 158' ' ' TYR . . . . . 0.416 ' CD2' ' HG2' ' F' ' 171' ' ' PRO . 14.4 m-30 -111.44 -173.28 2.21 Favored 'General case' 0 C--O 1.236 0.388 0 C-N-CA 123.727 0.811 . . . . 20.34 109.417 178.172 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 159' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -77.55 -73.84 0.28 Allowed 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.451 -0.9 . . . . 66.33 113.007 -153.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 160' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' F' ' 162' ' ' GLN . 38.5 p90 177.02 173.47 0.45 Allowed 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 128.262 2.625 . . . . 17.61 109.009 162.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 161' ' ' GLN . . . . . . . . . . . . . 65.5 tt0 -157.6 104.74 2.0 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 105.589 -2.004 . . . . 17.36 105.589 155.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 162' ' ' GLN . . . . . 0.421 ' HG3' ' CD2' ' F' ' 160' ' ' PHE . 89.7 mt-30 -71.3 -48.33 13.02 Favored Pre-proline 0 C--O 1.243 0.756 0 N-CA-C 113.806 1.039 . . . . 14.19 113.806 -169.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 163' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -77.05 -19.64 13.6 Favored 'Trans proline' 0 C--N 1.372 1.795 0 CA-C-N 122.237 1.835 . . . . 31.8 112.496 176.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 164' ' ' GLY . . . . . . . . . . . . . . . -134.4 37.52 1.95 Allowed Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 119.752 2.661 . . . . 38.74 119.752 -170.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 165' ' ' GLN . . . . . 0.497 ' HG2' ' HD3' ' L' ' 90' ' ' LYS . 9.9 tp-100 -67.99 -59.25 3.41 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 119.06 1.43 . . . . 22.78 111.152 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 166' ' ' THR . . . . . . . . . . . . . 33.7 p 54.57 49.53 17.99 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.765 1.626 . . . . 30.57 111.582 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 167' ' ' THR . . . . . . . . . . . . . 3.4 m -140.69 149.79 42.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.369 -0.604 . . . . 10.12 109.369 -167.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 168' ' ' GLY . . . . . . . . . . . . . . . -86.44 -125.06 1.74 Allowed Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.098 -0.801 . . . . 18.7 111.098 168.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 169' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -74.21 -63.47 1.22 Allowed 'General case' 0 C--O 1.236 0.344 0 C-N-CA 120.865 -0.334 . . . . 31.86 111.374 -176.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.6 104.59 0.63 Allowed Pre-proline 0 C--O 1.235 0.336 0 C-N-CA 123.982 0.913 . . . . 23.96 109.457 -174.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 171' ' ' PRO . . . . . 0.416 ' HG2' ' CD2' ' F' ' 158' ' ' TYR . 83.2 Cg_endo -80.17 -177.23 3.66 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.461 1.441 . . . . 17.61 112.964 -153.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.67 69.35 1.41 Allowed Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 116.952 1.541 . . . . 22.97 116.952 164.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 173' ' ' THR . . . . . . . . . . . . . 9.3 t -130.03 165.72 21.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.868 0.842 . . . . 17.61 109.264 168.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 174' ' ' VAL . . . . . . . . . . . . . 28.7 m -80.55 158.85 70.7 Favored Pre-proline 0 C--O 1.24 0.576 0 N-CA-C 107.816 -1.179 . . . . 10.57 107.816 176.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 175' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -64.28 110.42 1.37 Allowed 'Trans proline' 0 CA--C 1.512 -0.582 0 CA-C-N 119.609 0.896 . . . . 16.46 110.14 170.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.192 0 C-N-CA 125.077 1.351 . . . . 45.89 111.255 -161.482 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 5' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' G' ' 6' ' ' ILE . 39.3 Cg_endo . . . . . 0 N--CA 1.465 -0.161 0 CA-C-O 119.643 -0.232 . . . . 15.58 112.396 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 6' ' ' ILE . . . . . 0.405 ' H ' ' HB2' ' G' ' 5' ' ' PRO . 96.6 mt -121.24 120.5 62.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 108.052 -1.092 . . . . 19.16 108.052 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.58 169.39 11.37 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 121.846 0.832 . . . . 39.27 110.616 -177.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.23 -12.86 63.91 Favored Glycine 0 C--N 1.334 0.437 0 CA-C-N 115.441 -0.799 . . . . 17.56 114.626 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 9' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -92.52 -14.67 28.04 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 117.76 0.78 . . . . 17.56 112.378 173.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 10' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -77.73 -5.03 49.22 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 113.812 1.041 . . . . 30.53 113.812 -170.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' VAL . . . . . . . . . . . . . 74.7 t -128.84 125.25 62.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.808 -1.182 . . . . 21.85 107.808 -177.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' LYS . . . . . 0.466 ' NZ ' ' O ' ' G' ' 149' ' ' GLU . 53.4 mtmt -134.12 160.6 37.31 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.544 0.687 . . . . 18.16 110.009 175.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 13' ' ' TYR . . . . . 0.541 ' HA ' ' O ' ' G' ' 92' ' ' TRP . 16.7 m-30 -110.84 96.77 6.37 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.053 -1.091 . . . . 17.56 108.053 -167.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 14' ' ' LEU . . . . . 0.811 ' O ' ' HB2' ' G' ' 92' ' ' TRP . 99.0 mt -74.76 133.61 41.96 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.337 -0.616 . . . . 65.62 109.337 176.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 15' ' ' PHE . . . . . . . . . . . . . 20.8 m-30 -115.32 150.78 35.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.037 0.446 . . . . 34.21 109.829 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 16' ' ' GLN . . . . . . . . . . . . . 71.0 tp60 -145.64 137.25 25.15 Favored 'General case' 0 C--O 1.237 0.418 0 N-CA-C 109.058 -0.719 . . . . 16.2 109.058 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 17' ' ' SER . . . . . 0.451 ' O ' ' NZ ' ' G' ' 90' ' ' LYS . 39.0 t -75.54 155.69 35.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.623 0.725 . . . . 16.47 111.115 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 18' ' ' ILE . . . . . . . . . . . . . 44.1 pt -77.44 -10.59 13.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 CA-C-N 115.468 -0.787 . . . . 17.56 112.966 176.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -113.33 -9.19 13.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.764 0.653 . . . . 27.16 112.764 -169.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 20' ' ' ALA . . . . . . . . . . . . . . . -79.46 -47.79 15.05 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 119.622 -0.831 . . . . 27.76 112.026 -170.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.55 47.09 25.45 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.711 1.204 . . . . 12.42 111.278 -166.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -123.62 121.13 34.78 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 123.537 0.735 . . . . 37.77 109.017 179.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.17 74.56 2.31 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.075 -0.583 . . . . 17.56 113.053 -178.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 24' ' ' SER . . . . . 0.462 ' HA ' ' HG ' ' G' ' 146' ' ' LEU . 90.6 p -129.12 -29.81 2.24 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 120.607 -0.437 . . . . 28.47 111.585 -178.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 25' ' ' ALA . . . . . 0.465 ' HB1' ' HB3' ' G' ' 14' ' ' LEU . . . 51.33 74.36 0.81 Allowed Pre-proline 0 C--O 1.236 0.381 0 C-N-CA 126.932 2.093 . . . . 17.26 112.229 -173.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 26' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -71.29 105.94 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 CA-C-N 119.488 0.853 . . . . 17.56 112.524 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 27' ' ' LEU . . . . . 0.778 ' HB3' HD23 ' G' ' 14' ' ' LEU . 2.1 pt? -82.22 158.06 23.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.951 -0.759 . . . . 17.56 108.951 165.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 28' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -103.86 129.51 25.14 Favored Pre-proline 0 N--CA 1.447 -0.6 1 C-N-CA 109.793 -4.763 . . . . 19.13 110.247 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 29' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -73.6 -172.3 1.04 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 120.56 0.84 . . . . 4.27 114.083 -175.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 52.23 57.49 6.4 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.553 1.141 . . . . 2.06 110.843 -171.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' TYR . . . . . 0.444 ' HD1' ' HA ' ' G' ' 31' ' ' TYR . 0.6 OUTLIER -68.8 163.34 24.36 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 122.975 1.369 . . . . 34.59 112.015 179.788 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' G' G ' 32' ' ' GLN . . . . . 0.442 ' HG3' ' H ' ' G' ' 33' ' ' THR . 8.3 tp-100 -136.19 -163.27 1.38 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 103.07 -2.937 . . . . 19.1 103.07 169.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 33' ' ' THR . . . . . 0.442 ' H ' ' HG3' ' G' ' 32' ' ' GLN . 15.3 t -67.72 166.08 15.95 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.546 1.165 . . . . 10.87 112.027 -173.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 34' ' ' ASP . . . . . 0.589 ' HB2' ' HB3' ' H' ' 120' ' ' ASP . 89.6 m-20 -132.13 -170.7 2.47 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.163 -1.38 . . . . 46.86 108.408 -170.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 35' ' ' GLY . . . . . 0.724 ' O ' ' HA2' ' G' ' 63' ' ' GLY . . . 177.93 132.65 1.73 Allowed Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.98 -0.848 . . . . 31.7 110.98 169.459 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 36' ' ' SER . . . . . . . . . . . . . 67.4 m -125.52 84.56 2.29 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.035 -1.839 . . . . 17.56 106.035 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 37' ' ' VAL . . . . . 0.536 HG12 ' HB3' ' H' ' 117' ' ' GLU . 4.5 m -93.58 113.44 28.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 108.448 -0.945 . . . . 14.44 108.448 -171.033 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 38' ' ' SER . . . . . . . . . . . . . 51.1 m -102.02 88.76 3.43 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 108.411 -0.959 . . . . 15.27 108.411 -167.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 39' ' ' GLY . . . . . . . . . . . . . . . -90.99 98.89 2.51 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.201 -0.999 . . . . 49.31 113.231 -178.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 40' ' ' GLU . . . . . 0.44 ' HA ' ' HA ' ' G' ' 59' ' ' VAL . 79.4 tt0 -102.42 117.96 35.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 17.55 108.169 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 41' ' ' ARG . . . . . 0.696 ' O ' ' HA3' ' G' ' 57' ' ' GLY . 91.0 mtm-85 -76.63 177.75 7.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.558 0.694 . . . . 31.58 109.511 -176.495 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 42' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -157.76 159.45 36.81 Favored 'General case' 0 C--N 1.329 -0.304 0 O-C-N 121.622 -0.674 . . . . 33.51 109.671 -174.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 43' ' ' LEU . . . . . 0.785 ' HB2' ' HA3' ' G' ' 55' ' ' GLY . 70.6 mt -96.6 106.92 19.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.721 -0.672 . . . . 10.66 109.393 173.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 44' ' ' PHE . . . . . 0.462 ' HD1' HG13 ' G' ' 53' ' ' ILE . 67.6 t80 -106.89 119.11 38.47 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.307 -1.368 . . . . 30.36 107.307 173.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 45' ' ' ASP . . . . . 0.727 ' HB2' ' HB3' ' G' ' 52' ' ' ARG . 77.2 m-20 -130.77 174.24 10.14 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 108.468 -0.938 . . . . 29.01 108.468 -173.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 46' ' ' GLU . . . . . . . . . . . . . 59.9 mp0 -126.72 -41.14 1.86 Allowed 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.858 1.058 . . . . 19.89 113.858 -170.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 47' ' ' GLN . . . . . 0.676 ' HB3' ' HA ' ' B' ' 30' ' ' ALA . 29.0 mm100 67.43 23.26 9.15 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 114.005 1.113 . . . . 37.15 114.005 154.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 48' ' ' THR . . . . . . . . . . . . . 53.3 p 51.23 37.74 19.33 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.618 1.167 . . . . 28.33 111.121 -167.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm -139.72 -165.91 1.97 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 106.846 -1.539 . . . . 18.5 106.846 -175.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 50' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -69.95 -31.2 68.82 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 120.538 -0.465 . . . . 32.53 112.019 171.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.34 166.18 14.73 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 121.323 -0.465 . . . . 5.39 113.747 -178.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 52' ' ' ARG . . . . . 0.727 ' HB3' ' HB2' ' G' ' 45' ' ' ASP . 19.4 tpp85 -133.58 57.95 1.79 Allowed 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.831 -1.174 . . . . 14.66 107.831 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 53' ' ' ILE . . . . . 0.786 HD11 ' HB3' ' H' ' 133' ' ' GLN . 7.6 tt -66.08 -5.02 2.64 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 C-N-CA 125.19 1.396 . . . . 50.62 113.67 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 54' ' ' LEU . . . . . 0.656 HD13 ' HD3' ' G' ' 52' ' ' ARG . 8.9 mp -61.95 -23.41 66.36 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 124.251 1.02 . . . . 74.62 113.711 -170.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 55' ' ' GLY . . . . . 0.785 ' HA3' ' HB2' ' G' ' 43' ' ' LEU . . . -67.15 120.01 12.81 Favored Glycine 0 N--CA 1.44 -1.099 0 CA-C-O 121.626 0.57 . . . . 7.32 114.179 -169.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 56' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.37 169.29 22.64 Favored 'Trans proline' 0 C--N 1.326 -0.621 0 C-N-CA 120.873 1.049 . . . . 7.48 109.873 171.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 57' ' ' GLY . . . . . 0.696 ' HA3' ' O ' ' G' ' 41' ' ' ARG . . . -137.2 170.38 23.58 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.577 -1.409 . . . . 23.59 109.577 -178.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 58' ' ' SER . . . . . 0.421 ' HB3' ' NH2' ' G' ' 41' ' ' ARG . 45.9 t -72.81 147.11 45.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.618 -0.833 . . . . 17.34 109.595 172.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 59' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' G' ' 40' ' ' GLU . 2.2 p -103.13 112.94 38.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 108.388 -0.967 . . . . 1.78 108.388 -177.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 60' ' ' ALA . . . . . . . . . . . . . . . -108.19 110.6 22.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 106.681 -1.6 . . . . 13.09 106.681 174.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 61' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -115.07 118.3 32.99 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.33 -0.989 . . . . 46.86 108.33 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' G' ' 132' ' ' LEU . 56.9 m -107.07 165.89 11.02 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 124.102 0.961 . . . . 11.7 110.418 -173.583 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 63' ' ' GLY . . . . . 0.724 ' HA2' ' O ' ' G' ' 35' ' ' GLY . . . -139.45 121.12 2.0 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 119.992 -1.099 . . . . 17.56 113.183 174.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 64' ' ' GLU . . . . . . . . . . . . . 67.2 mm-40 -97.79 95.51 7.59 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.253 -1.388 . . . . 37.6 107.253 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 65' ' ' VAL . . . . . . . . . . . . . 86.1 t -105.36 116.58 49.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 108.404 -0.961 . . . . 5.82 108.404 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 66' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' G' ' 128' ' ' ILE . 64.8 p -115.1 143.08 45.76 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.978 -0.749 . . . . 17.56 108.978 177.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 67' ' ' TYR . . . . . 0.415 ' HE1' HD12 ' G' ' 130' ' ' ILE . 55.6 p90 -154.3 -170.64 3.6 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.408 0.623 . . . . 15.39 109.433 176.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 68' ' ' TYR . . . . . . . . . . . . . 14.3 m-30 -116.99 134.74 54.35 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 123.868 0.867 . . . . 3.83 109.488 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.4 116.55 4.25 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.995 -0.621 . . . . 7.04 114.315 -175.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 70' ' ' LYS . . . . . 0.493 ' O ' ' NE2' ' G' ' 76' ' ' GLN . 38.8 ttmt -91.05 150.46 21.42 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 3.01 108.83 175.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 71' ' ' ARG . . . . . . . . . . . . . 20.6 ptp180 -69.0 -16.67 63.78 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 113.925 1.083 . . . . 16.93 113.925 -170.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.97 -138.15 4.7 Favored Glycine 0 N--CA 1.451 -0.301 0 N-CA-C 109.902 -1.279 . . . . 35.85 109.902 175.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 73' ' ' ASP . . . . . . . . . . . . . 31.4 t0 59.95 73.18 0.49 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 125.045 1.338 . . . . 12.83 111.135 167.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.69 10.39 0.05 OUTLIER 'General case' 0 C--O 1.233 0.228 0 N-CA-C 117.438 2.385 . . . . 58.08 117.438 -157.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.3 -42.07 97.16 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 120.31 -0.948 . . . . 6.64 112.845 171.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 76' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' G' ' 70' ' ' LYS . 22.0 pt20 -70.89 -23.38 62.28 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 119.546 -0.862 . . . . 30.28 111.714 174.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 77' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -70.27 -28.01 64.88 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 119.919 -0.712 . . . . 1.1 111.352 170.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.93 -30.89 62.8 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 120.716 -0.394 . . . . 14.89 111.352 171.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 79' ' ' ILE . . . . . . . . . . . . . 51.0 mm -64.45 -44.99 97.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-O 121.076 0.465 . . . . 17.56 110.347 172.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.16 -24.01 60.52 Favored 'General case' 0 C--O 1.234 0.289 0 O-C-N 121.895 -0.503 . . . . 21.16 112.007 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 81' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -70.3 -35.07 73.45 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.307 -0.557 . . . . 27.62 111.533 170.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 82' ' ' ALA . . . . . 0.707 ' HA ' ' HB2' ' G' ' 87' ' ' LYS . . . -74.62 -32.36 62.29 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 119.178 -1.009 . . . . 5.97 111.561 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 83' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' L' ' 38' ' ' SER . 86.1 t80 -83.29 -62.47 1.58 Allowed 'General case' 0 C--O 1.234 0.281 0 C-N-CA 120.504 -0.478 . . . . 17.56 112.049 -176.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 84' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -76.28 -39.17 54.98 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.577 -0.283 . . . . 18.17 111.735 -165.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 85' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -75.6 -40.69 56.1 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.929 -0.709 . . . . 19.49 111.011 172.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.42 96.33 2.44 Favored Glycine 0 N--CA 1.45 -0.403 0 O-C-N 122.234 -0.291 . . . . 17.56 113.544 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 87' ' ' LYS . . . . . 0.707 ' HB2' ' HA ' ' G' ' 82' ' ' ALA . 98.3 mttt -148.69 -162.03 1.47 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 106.882 -1.525 . . . . 17.25 106.882 -178.191 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 88' ' ' GLN . . . . . 0.653 ' HG2' ' HD1' ' G' ' 112' ' ' TYR . 64.7 mt-30 -129.13 178.78 6.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.724 0.773 . . . . 13.52 111.035 167.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 89' ' ' ILE . . . . . . . . . . . . . 68.0 mt -128.73 135.1 63.13 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 115.209 -0.905 . . . . 19.69 109.618 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 90' ' ' LYS . . . . . 0.451 ' NZ ' ' O ' ' G' ' 17' ' ' SER . 36.4 mtmm -84.9 116.66 23.46 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.559 -0.904 . . . . 24.48 108.559 165.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 91' ' ' PHE . . . . . . . . . . . . . 61.5 t80 -111.71 134.38 53.32 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 124.692 1.197 . . . . 31.77 110.577 -166.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 92' ' ' TRP . . . . . 0.811 ' HB2' ' O ' ' G' ' 14' ' ' LEU . 92.5 m95 -133.49 125.56 29.23 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 123.905 0.882 . . . . 14.67 110.168 -173.175 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 93' ' ' ARG . . . . . 0.612 ' O ' ' HA ' ' G' ' 106' ' ' ALA . 78.8 ttt-85 -111.87 90.85 3.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 108.196 -1.039 . . . . 14.24 108.196 171.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 94' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' G' ' 106' ' ' ALA . 21.4 m -105.65 163.38 4.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 122.139 0.971 . . . . 17.91 109.391 -174.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 95' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -109.8 164.71 12.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.013 -0.994 . . . . 33.23 111.136 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 96' ' ' THR . . . . . 0.418 HG23 HD12 ' G' ' 150' ' ' ILE . 28.4 m -98.82 -30.85 12.17 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 114.973 -1.012 . . . . 22.24 112.645 -175.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -68.69 155.17 7.86 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 CA-C-O 121.76 0.79 . . . . 25.4 110.137 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 98' ' ' LYS . . . . . 0.512 ' NZ ' ' O ' ' G' ' 99' ' ' ASN . 29.6 tptp -90.46 122.0 32.92 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.72 -0.673 . . . . 9.56 109.821 -176.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 99' ' ' ASN . . . . . 0.512 ' O ' ' NZ ' ' G' ' 98' ' ' LYS . 34.9 m120 -83.81 171.44 13.12 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.828 0.823 . . . . 16.05 109.99 171.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 100' ' ' GLU . . . . . . . . . . . . . 58.4 mp0 -108.45 -17.2 14.04 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 113.463 0.912 . . . . 31.57 113.463 178.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 101' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -86.47 -49.69 7.41 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 118.175 0.443 . . . . 14.91 111.04 170.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 102' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -112.58 -174.74 2.52 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.321 -0.992 . . . . 23.65 108.321 172.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 103' ' ' LYS . . . . . 0.66 ' H ' HG22 ' G' ' 143' ' ' ILE . 96.3 mttt -77.06 -55.01 5.82 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.015 -0.674 . . . . 33.92 110.076 168.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 104' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -133.25 -171.0 2.58 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.548 -0.908 . . . . 7.12 108.548 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 105' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -151.68 166.52 31.02 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.163 -0.68 . . . . 53.27 109.163 177.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 106' ' ' ALA . . . . . 0.612 ' HA ' ' O ' ' G' ' 93' ' ' ARG . . . -156.85 156.54 33.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.419 -0.81 . . . . 17.56 111.404 -162.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 107' ' ' GLN . . . . . 0.445 ' OE1' ' OH ' ' H' ' 118' ' ' TYR . 87.4 mt-30 -114.8 123.62 49.67 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.805 -1.554 . . . . 9.69 106.805 158.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 108' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -110.61 153.81 24.66 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 123.735 0.814 . . . . 7.7 110.262 -165.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 109' ' ' GLY . . . . . 0.4 ' HA3' HG21 ' G' ' 134' ' ' VAL . . . -164.75 167.41 38.51 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 119.553 -1.308 . . . . 37.56 112.79 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 110' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -108.18 108.81 20.01 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 114.667 -0.767 . . . . 18.99 109.276 168.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 111' ' ' ALA . . . . . . . . . . . . . . . -107.03 157.04 18.12 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.618 0.723 . . . . 47.07 111.71 -166.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 112' ' ' TYR . . . . . 0.653 ' HD1' ' HG2' ' G' ' 88' ' ' GLN . 55.1 t80 -137.87 136.65 37.32 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.168 -1.419 . . . . 0.61 107.168 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 113' ' ' ILE . . . . . . . . . . . . . 83.5 mt -86.53 128.16 39.75 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 109.95 -0.389 . . . . 3.73 109.95 -169.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 114' ' ' GLU . . . . . 0.552 ' HB2' ' HB2' ' G' ' 131' ' ' SER . 99.4 mt-10 -70.93 -64.63 0.87 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 119.904 -0.718 . . . . 20.3 110.479 164.248 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 115' ' ' SER . . . . . . . . . . . . . 67.7 m -140.93 147.8 39.39 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-O 121.562 0.696 . . . . 11.26 110.391 -170.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 116' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -120.17 89.87 3.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 104.782 -2.303 . . . . 8.25 104.782 175.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 117' ' ' GLU . . . . . 0.529 ' HB3' HG12 ' L' ' 37' ' ' VAL . 98.3 mt-10 -112.85 108.38 17.33 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.494 -1.298 . . . . 27.88 107.494 -175.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 118' ' ' TYR . . . . . 0.469 ' HB3' ' HA ' ' G' ' 128' ' ' ILE . 19.1 p90 -114.55 142.53 46.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.536 0.684 . . . . 28.76 111.917 177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 119' ' ' SER . . . . . . . . . . . . . 37.2 t -96.4 128.37 43.26 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 114.673 -1.149 . . . . 17.56 109.938 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 120' ' ' ASP . . . . . 0.611 ' HA ' HG12 ' G' ' 126' ' ' VAL . 60.3 t0 -106.22 97.9 7.65 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 106.039 -1.838 . . . . 34.73 106.039 170.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.3 -155.07 15.64 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-O 121.814 0.674 . . . . 5.15 112.086 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 122' ' ' VAL . . . . . . . . . . . . . 79.4 t -112.72 -60.61 2.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 108.329 -0.989 . . . . 16.97 108.329 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 123' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -103.24 -30.67 10.51 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.074 0.768 . . . . 56.79 113.074 -174.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.05 148.51 41.29 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 109.287 -1.525 . . . . 28.65 109.287 165.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.13 165.31 24.59 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-O 121.686 0.755 . . . . 12.09 110.265 176.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 126' ' ' VAL . . . . . 0.611 HG12 ' HA ' ' G' ' 120' ' ' ASP . 28.0 m -68.96 145.91 13.08 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-N 115.303 -0.862 . . . . 17.56 109.75 -176.001 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 127' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -135.41 132.06 37.03 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 109.521 -0.548 . . . . 47.4 109.521 -176.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 128' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' G' ' 66' ' ' THR . 84.2 mt -101.82 121.3 52.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.393 -0.595 . . . . 17.56 109.393 -176.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 129' ' ' SER . . . . . 0.519 ' HB2' ' O ' ' G' ' 117' ' ' GLU . 68.6 m -100.29 132.67 45.53 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.44 -0.948 . . . . 23.09 108.44 170.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 130' ' ' ILE . . . . . 0.415 HD12 ' HE1' ' G' ' 67' ' ' TYR . 81.6 mt -135.23 128.07 48.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 N-CA-C 108.652 -0.869 . . . . 17.56 108.652 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 131' ' ' SER . . . . . 0.552 ' HB2' ' HB2' ' G' ' 114' ' ' GLU . 57.1 m -93.28 146.65 23.55 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-O 121.158 0.504 . . . . 17.56 109.797 174.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 132' ' ' LEU . . . . . 0.613 ' O ' ' HA ' ' G' ' 62' ' ' SER . 7.4 mp -129.5 149.89 51.07 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.967 -0.561 . . . . 41.5 110.275 -177.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 133' ' ' GLN . . . . . 0.767 ' HB3' HD11 ' L' ' 53' ' ' ILE . 21.2 mm100 -137.64 127.69 25.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.373 -0.831 . . . . 2.83 109.382 177.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 134' ' ' VAL . . . . . 0.4 HG21 ' HA3' ' G' ' 109' ' ' GLY . 10.7 p -136.04 148.91 27.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 108.962 -0.755 . . . . 7.73 108.962 -178.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 135' ' ' ILE . . . . . 0.408 HD13 ' HA ' ' G' ' 135' ' ' ILE . 25.8 mm -64.28 -60.13 3.2 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.224 0.535 . . . . 12.81 110.878 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.54 136.91 4.72 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 111.008 -0.837 . . . . 0.26 111.008 -179.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 137' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.27 153.92 42.53 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.435 0.636 . . . . 27.0 110.347 177.069 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 138' ' ' LEU . . . . . . . . . . . . . 31.7 tp -136.06 128.82 30.94 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 107.71 -1.219 . . . . 17.56 107.71 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -81.47 76.5 8.39 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 122.46 1.124 . . . . 17.56 109.268 -171.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 140' ' ' ASN . . . . . . . . . . . . . 21.7 m120 -97.8 79.46 2.67 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.12 -0.946 . . . . 16.67 108.829 -177.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.78 112.27 3.88 Favored Glycine 0 C--O 1.237 0.304 0 C-N-CA 120.0 -1.095 . . . . 39.45 110.398 173.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -123.99 -172.16 2.48 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.06 -0.718 . . . . 40.11 109.06 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 143' ' ' ILE . . . . . 0.66 HG22 ' H ' ' G' ' 103' ' ' LYS . 1.3 pp -112.13 -62.84 2.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 113.383 0.883 . . . . 35.39 113.383 -170.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 144' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -81.54 127.08 32.46 Favored 'General case' 0 C--N 1.331 -0.217 0 O-C-N 121.356 -0.84 . . . . 46.88 111.13 -169.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 145' ' ' THR . . . . . . . . . . . . . 77.2 p -121.2 14.56 11.35 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 112.454 0.539 . . . . 11.02 112.454 177.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 146' ' ' LEU . . . . . 0.462 ' HG ' ' HA ' ' G' ' 24' ' ' SER . 4.2 mm? 54.48 75.86 0.57 Allowed Pre-proline 0 C--O 1.237 0.416 0 C-N-CA 126.697 1.999 . . . . 14.06 110.596 -177.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 147' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -68.75 71.03 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 N-CA-C 115.434 1.282 . . . . 11.53 115.434 -162.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 148' ' ' GLU . . . . . 0.514 ' OE1' ' ND2' ' G' ' 152' ' ' ASN . 79.6 mm-40 -104.14 8.09 36.32 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.982 0.513 . . . . 33.72 111.334 167.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 149' ' ' GLU . . . . . 0.466 ' O ' ' NZ ' ' G' ' 12' ' ' LYS . 25.9 pm0 -139.61 8.34 2.38 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.604 0.594 . . . . 21.89 112.604 -177.254 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 150' ' ' ILE . . . . . 0.418 HD12 HG23 ' G' ' 96' ' ' THR . 43.9 mm -113.31 -46.59 5.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.71 0.687 . . . . 13.89 111.0 178.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 151' ' ' VAL . . . . . . . . . . . . . 48.9 t -108.47 -32.0 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.256 -1.016 . . . . 41.23 108.256 -178.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 152' ' ' ASN . . . . . 0.514 ' ND2' ' OE1' ' G' ' 148' ' ' GLU . 37.3 t-20 -66.62 -32.21 73.38 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.264 -0.425 . . . . 21.9 111.736 -176.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -74.17 99.3 1.29 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 107.503 -1.295 . . . . 17.56 107.503 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 154' ' ' SER . . . . . . . . . . . . . 35.2 t -117.08 -58.64 2.04 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.379 -0.828 . . . . 13.23 111.872 -171.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 155' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -127.52 -34.65 2.22 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 113.274 0.842 . . . . 8.05 113.274 177.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.22 -60.51 1.33 Allowed Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 110.135 -1.186 . . . . 33.33 110.135 -157.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.42 168.52 26.86 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-O 122.128 0.849 . . . . 17.56 112.774 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 158' ' ' TYR . . . . . . . . . . . . . 15.8 m-30 -116.25 -173.91 2.45 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.866 1.267 . . . . 24.58 109.559 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 159' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -79.35 -68.89 0.62 Allowed 'General case' 0 C--O 1.235 0.331 0 C-N-CA 119.227 -0.989 . . . . 39.94 112.165 -170.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 160' ' ' PHE . . . . . 0.428 ' HD2' ' HG3' ' G' ' 162' ' ' GLN . 36.3 p90 -176.33 161.72 2.3 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.835 -0.802 . . . . 38.05 108.835 -175.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 161' ' ' GLN . . . . . . . . . . . . . 65.8 tt0 -150.88 96.4 2.33 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 105.204 -2.147 . . . . 20.84 105.204 154.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 162' ' ' GLN . . . . . 0.428 ' HG3' ' HD2' ' G' ' 160' ' ' PHE . 86.5 mt-30 -71.89 -43.59 11.01 Favored Pre-proline 0 C--O 1.243 0.726 0 N-CA-C 113.976 1.102 . . . . 11.58 113.976 -165.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 163' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -73.89 -48.57 0.23 Allowed 'Trans proline' 0 C--N 1.37 1.696 0 CA-C-N 122.144 1.801 . . . . 64.26 114.146 172.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.37 40.78 1.9 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 116.886 1.515 . . . . 42.51 116.886 -162.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 165' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -63.75 -65.88 0.62 Allowed 'General case' 0 C--O 1.237 0.424 0 CA-C-N 117.477 0.638 . . . . 17.58 110.815 173.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 166' ' ' THR . . . . . . . . . . . . . 37.3 p 52.61 50.35 18.36 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.893 1.677 . . . . 52.2 111.777 176.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 167' ' ' THR . . . . . . . . . . . . . 2.0 m -132.09 168.08 18.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.581 -1.266 . . . . 10.87 107.581 -169.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.13 -125.38 1.0 Allowed Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.743 -1.343 . . . . 3.24 109.743 173.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 169' ' ' GLU . . . . . . . . . . . . . 14.0 tm-20 -79.16 -60.38 2.39 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 119.008 -1.077 . . . . 41.61 110.668 -178.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.18 105.91 0.95 Allowed Pre-proline 0 C--O 1.235 0.327 0 C-N-CA 123.729 0.812 . . . . 11.2 109.8 -176.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 171' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -83.44 -173.78 1.75 Allowed 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 121.367 1.378 . . . . 10.85 111.868 -158.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 172' ' ' GLY . . . . . . . . . . . . . . . 80.17 65.8 1.71 Allowed Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 114.665 -1.152 . . . . 35.56 114.982 167.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 173' ' ' THR . . . . . . . . . . . . . 10.5 t -138.38 164.45 29.3 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.95 0.881 . . . . 33.61 109.529 170.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 174' ' ' VAL . . . . . 0.409 ' H ' HG22 ' G' ' 174' ' ' VAL . 18.7 m -74.35 154.11 88.04 Favored Pre-proline 0 C--O 1.24 0.568 0 N-CA-C 107.883 -1.155 . . . . 27.77 107.883 174.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 175' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -67.58 107.36 1.42 Allowed 'Trans proline' 0 CA--C 1.515 -0.452 0 CA-C-N 119.43 0.832 . . . . 7.84 111.569 176.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.261 0 C-N-CA 125.728 1.611 . . . . 40.4 112.996 -171.857 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 5' ' ' PRO . . . . . 0.42 ' HB2' ' H ' ' H' ' 6' ' ' ILE . 40.0 Cg_endo . . . . . 0 N--CA 1.466 -0.137 0 CA-C-O 119.748 -0.188 . . . . 16.2 112.181 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 6' ' ' ILE . . . . . 0.42 ' H ' ' HB2' ' H' ' 5' ' ' PRO . 88.5 mt -122.9 122.72 66.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 N-CA-C 108.003 -1.11 . . . . 23.77 108.003 178.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.44 168.81 11.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 121.934 0.874 . . . . 38.67 110.647 -178.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.67 -12.8 64.91 Favored Glycine 0 C--N 1.333 0.396 0 CA-C-N 115.39 -0.823 . . . . 32.63 114.599 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 9' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -92.34 -13.73 29.79 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 117.906 0.853 . . . . 10.36 112.333 173.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 10' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -78.67 -5.71 53.78 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 113.708 1.003 . . . . 43.64 113.708 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -127.07 123.05 61.54 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.971 -1.122 . . . . 8.42 107.971 -176.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -133.07 162.07 32.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 34.19 109.773 177.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 13' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' H' ' 92' ' ' TRP . 16.6 m-30 -112.42 96.88 6.25 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.527 -0.916 . . . . 16.86 108.527 -166.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 14' ' ' LEU . . . . . 0.793 ' O ' ' HB2' ' H' ' 92' ' ' TRP . 98.7 mt -75.6 130.6 39.05 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.005 -0.678 . . . . 65.4 109.252 175.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 15' ' ' PHE . . . . . . . . . . . . . 21.9 m-30 -112.06 156.45 22.19 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.433 -0.58 . . . . 25.18 109.433 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 16' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -151.13 136.03 17.35 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 109.065 -0.717 . . . . 26.99 109.065 175.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' SER . . . . . . . . . . . . . 41.1 t -75.57 155.76 35.67 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.588 0.709 . . . . 16.86 111.02 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 pt -77.24 -12.64 14.08 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 115.491 -0.777 . . . . 16.86 113.052 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 19' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.8 -6.73 12.09 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 112.581 0.585 . . . . 65.38 112.581 -170.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.59 -47.66 25.71 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 119.907 -0.717 . . . . 14.62 111.787 -172.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.46 44.76 29.49 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.82 1.248 . . . . 8.31 111.45 -169.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' THR . . . . . . . . . . . . . 68.7 p -126.03 123.47 38.5 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.927 -0.768 . . . . 28.63 108.927 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.44 75.99 2.14 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.322 -0.466 . . . . 12.1 113.052 -178.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 24' ' ' SER . . . . . 0.482 ' HA ' ' HG ' ' H' ' 146' ' ' LEU . 91.7 p -127.55 -30.72 2.55 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 120.68 -0.408 . . . . 14.99 111.473 -177.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 25' ' ' ALA . . . . . 0.528 ' HB1' ' HB3' ' H' ' 14' ' ' LEU . . . 51.52 74.95 0.71 Allowed Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 126.679 1.991 . . . . 35.29 112.292 -174.202 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 26' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -70.41 105.47 1.6 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 CA-C-N 119.624 0.901 . . . . 16.86 112.83 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 27' ' ' LEU . . . . . 0.788 ' HB3' HD23 ' H' ' 14' ' ' LEU . 2.2 pt? -85.21 168.03 15.14 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.852 -0.795 . . . . 16.86 108.852 163.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 28' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -111.11 141.57 24.55 Favored Pre-proline 0 N--CA 1.448 -0.532 1 C-N-CA 110.815 -4.354 . . . . 16.81 110.46 -171.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 29' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -73.71 166.72 29.04 Favored 'Trans proline' 0 C--O 1.234 0.289 0 CA-C-N 118.79 0.604 . . . . 18.69 113.418 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . 54.45 54.5 9.28 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.708 1.203 . . . . 18.73 111.609 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' TYR . . . . . 0.443 ' HD1' ' HA ' ' H' ' 31' ' ' TYR . 1.8 m-30 -69.49 164.1 23.88 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 122.777 1.275 . . . . 38.69 111.562 176.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 32' ' ' GLN . . . . . 0.469 ' HG3' ' H ' ' H' ' 33' ' ' THR . 8.4 tp-100 -132.3 -165.02 1.53 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 103.566 -2.753 . . . . 16.64 103.566 175.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 33' ' ' THR . . . . . 0.469 ' H ' ' HG3' ' H' ' 32' ' ' GLN . 13.2 t -67.25 167.33 12.48 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-O 122.595 1.188 . . . . 38.6 112.161 -172.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 34' ' ' ASP . . . . . 0.64 ' HB2' ' HB3' ' I' ' 120' ' ' ASP . 89.8 m-20 -132.59 -170.88 2.52 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.101 -1.409 . . . . 36.95 108.521 -169.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 35' ' ' GLY . . . . . 0.708 ' O ' ' HA2' ' H' ' 63' ' ' GLY . . . 178.06 132.16 1.66 Allowed Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 111.05 -0.82 . . . . 21.66 111.05 168.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 36' ' ' SER . . . . . . . . . . . . . 66.1 m -123.44 84.69 2.31 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 105.912 -1.884 . . . . 16.86 105.912 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 37' ' ' VAL . . . . . 0.556 HG23 ' HB2' ' H' ' 62' ' ' SER . 3.5 m -91.88 109.3 21.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.372 -0.974 . . . . 16.86 108.372 -172.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 38' ' ' SER . . . . . . . . . . . . . 49.1 m -98.85 92.21 5.44 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.084 -1.08 . . . . 16.86 108.084 -167.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 39' ' ' GLY . . . . . . . . . . . . . . . -94.36 98.95 2.39 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.053 -1.07 . . . . 40.71 113.511 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 40' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' H' ' 59' ' ' VAL . 80.6 tt0 -101.45 119.08 38.22 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.095 -1.076 . . . . 13.09 108.095 178.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 41' ' ' ARG . . . . . 0.58 ' O ' ' HA3' ' H' ' 57' ' ' GLY . 93.8 mtm-85 -76.82 178.17 7.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.51 0.671 . . . . 56.06 109.429 -175.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 42' ' ' GLU . . . . . . . . . . . . . 24.4 pt-20 -156.86 155.45 31.48 Favored 'General case' 0 C--N 1.33 -0.26 0 O-C-N 121.519 -0.738 . . . . 4.93 109.836 -176.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 43' ' ' LEU . . . . . 0.751 ' HB2' ' HA3' ' H' ' 55' ' ' GLY . 55.0 mt -91.55 112.43 24.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.55 -0.75 . . . . 18.1 109.155 170.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 44' ' ' PHE . . . . . . . . . . . . . 67.4 t80 -117.19 116.66 27.71 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 107.43 -1.322 . . . . 29.99 107.43 174.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 45' ' ' ASP . . . . . 0.746 ' HB2' ' HB3' ' H' ' 52' ' ' ARG . 75.2 m-20 -132.02 177.59 7.44 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 108.138 -1.06 . . . . 16.88 108.138 -172.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 46' ' ' GLU . . . . . . . . . . . . . 57.5 mp0 -126.08 -39.34 2.09 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 114.381 1.252 . . . . 18.24 114.381 -169.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 47' ' ' GLN . . . . . 0.654 ' HB3' ' HA ' ' C' ' 30' ' ' ALA . 90.3 mm-40 66.05 23.54 11.09 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.613 1.165 . . . . 42.47 113.967 156.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 48' ' ' THR . . . . . . . . . . . . . 54.9 p 50.66 38.85 20.2 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 124.637 1.175 . . . . 17.05 111.142 -166.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 49' ' ' LYS . . . . . . . . . . . . . 47.7 mmtm -139.19 -165.38 1.84 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 106.728 -1.582 . . . . 11.44 106.728 -176.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 50' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -75.53 -28.47 59.09 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 120.022 -0.671 . . . . 19.04 112.075 172.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 51' ' ' GLY . . . . . . . . . . . . . . . 159.64 162.92 12.63 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 115.962 1.145 . . . . 5.68 115.962 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 52' ' ' ARG . . . . . 0.746 ' HB3' ' HB2' ' H' ' 45' ' ' ASP . 19.8 tpp85 -126.93 56.82 1.48 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.096 -1.446 . . . . 16.86 107.096 179.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 53' ' ' ILE . . . . . 0.795 HD11 ' HB3' ' I' ' 133' ' ' GLN . 6.7 tt -68.84 -6.71 6.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.467 0 C-N-CA 124.147 0.979 . . . . 63.97 112.894 -176.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 54' ' ' LEU . . . . . 0.571 HD13 ' HD3' ' H' ' 52' ' ' ARG . 7.6 mp -60.28 -27.13 67.02 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.664 1.186 . . . . 49.31 113.425 -171.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 55' ' ' GLY . . . . . 0.751 ' HA3' ' HB2' ' H' ' 43' ' ' LEU . . . -67.09 119.38 11.68 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-O 121.753 0.641 . . . . 20.29 114.47 -168.009 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 56' ' ' PRO . . . . . 0.424 ' HD2' ' HA2' ' H' ' 55' ' ' GLY . 60.1 Cg_endo -71.95 166.91 28.14 Favored 'Trans proline' 0 C--N 1.326 -0.647 0 C-N-CA 120.763 0.975 . . . . 10.69 109.892 170.151 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 57' ' ' GLY . . . . . 0.58 ' HA3' ' O ' ' H' ' 41' ' ' ARG . . . -134.52 171.44 22.28 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 108.849 -1.7 . . . . 37.89 108.849 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 58' ' ' SER . . . . . 0.446 ' HB3' ' NH2' ' H' ' 41' ' ' ARG . 45.7 t -72.43 146.84 46.67 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 119.474 -0.89 . . . . 16.86 109.55 173.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 59' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' H' ' 40' ' ' GLU . 2.8 p -102.38 121.17 53.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.461 0 N-CA-C 108.22 -1.03 . . . . 6.43 108.22 -178.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 60' ' ' ALA . . . . . . . . . . . . . . . -118.96 109.2 15.69 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.855 -1.535 . . . . 6.02 106.855 175.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 61' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -108.2 119.98 41.03 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.301 -1.0 . . . . 62.57 108.301 -174.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 62' ' ' SER . . . . . 0.622 ' HA ' ' O ' ' H' ' 132' ' ' LEU . 62.4 m -102.97 164.58 11.52 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.121 0.969 . . . . 24.25 110.043 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 63' ' ' GLY . . . . . 0.708 ' HA2' ' O ' ' H' ' 35' ' ' GLY . . . -137.12 123.0 2.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 120.125 -1.036 . . . . 16.86 112.781 175.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 64' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -99.44 94.83 6.63 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.16 -1.422 . . . . 44.19 107.16 171.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 65' ' ' VAL . . . . . . . . . . . . . 95.4 t -106.05 116.33 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 108.095 -1.076 . . . . 9.01 108.095 -177.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 66' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' H' ' 128' ' ' ILE . 67.6 p -115.52 143.42 45.35 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.262 -0.644 . . . . 16.86 109.262 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 67' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -153.4 -170.81 3.71 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 109.336 -0.616 . . . . 15.68 109.336 174.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 68' ' ' TYR . . . . . . . . . . . . . 15.5 m-30 -116.17 134.1 55.3 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.823 0.849 . . . . 8.81 109.625 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.36 115.62 4.22 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.786 -0.721 . . . . 16.84 113.758 -176.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 70' ' ' LYS . . . . . 0.435 ' O ' ' NE2' ' H' ' 76' ' ' GLN . 38.6 ttmt -92.63 149.53 21.28 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.679 -0.86 . . . . 11.94 108.679 173.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 71' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -68.1 -16.4 64.0 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 114.128 1.158 . . . . 26.48 114.128 -168.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.24 -139.48 4.81 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.286 -1.126 . . . . 8.11 110.286 176.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 73' ' ' ASP . . . . . . . . . . . . . 30.2 t0 59.9 74.38 0.45 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 125.17 1.388 . . . . 18.64 111.148 168.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.17 10.74 0.04 OUTLIER 'General case' 0 C--O 1.234 0.287 0 N-CA-C 117.48 2.4 . . . . 50.46 117.48 -159.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.16 94.26 Favored Glycine 0 C--N 1.338 0.678 0 C-N-CA 120.318 -0.944 . . . . 12.0 112.647 170.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 76' ' ' GLN . . . . . 0.435 ' NE2' ' O ' ' H' ' 70' ' ' LYS . 21.8 pt20 -68.81 -24.3 64.37 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 120.033 -0.667 . . . . 41.69 111.774 172.113 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -74.44 -23.82 58.98 Favored 'General case' 0 CA--C 1.517 -0.327 0 C-N-CA 119.807 -0.757 . . . . 19.67 111.279 171.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 78' ' ' ALA . . . . . . . . . . . . . . . -74.03 -32.59 63.41 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 120.47 -0.492 . . . . 8.92 111.059 169.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 79' ' ' ILE . . . . . . . . . . . . . 51.1 mm -63.21 -45.71 97.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 CA-C-O 121.116 0.484 . . . . 15.39 110.483 172.015 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -76.48 -20.18 57.26 Favored 'General case' 0 C--O 1.234 0.276 0 O-C-N 121.908 -0.495 . . . . 33.45 111.963 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 81' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -72.73 -31.58 65.07 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 120.078 -0.649 . . . . 12.14 111.27 167.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 82' ' ' ALA . . . . . 0.741 ' HA ' ' HB2' ' H' ' 87' ' ' LYS . . . -75.44 -29.59 59.74 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 119.357 -0.937 . . . . 14.37 111.63 175.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 83' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -95.48 -59.81 1.8 Allowed 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.222 -0.591 . . . . 16.86 112.186 -173.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 84' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -73.45 -34.15 65.26 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 122.314 -0.241 . . . . 30.86 111.509 -170.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 85' ' ' ASN . . . . . . . . . . . . . 34.2 m120 -83.32 -47.69 11.22 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.027 -0.669 . . . . 11.16 111.17 171.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.57 96.9 2.3 Favored Glycine 0 N--CA 1.45 -0.374 0 O-C-N 122.141 -0.349 . . . . 14.58 113.688 178.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 87' ' ' LYS . . . . . 0.741 ' HB2' ' HA ' ' H' ' 82' ' ' ALA . 97.9 mttt -148.85 -162.04 1.47 Allowed 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.071 -1.455 . . . . 15.51 107.071 -178.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 88' ' ' GLN . . . . . 0.678 ' HG2' ' HD1' ' H' ' 112' ' ' TYR . 62.7 mt-30 -127.7 -178.98 4.7 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.738 0.78 . . . . 26.23 110.871 166.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 89' ' ' ILE . . . . . 0.472 HD11 HD11 ' H' ' 113' ' ' ILE . 60.1 mt -129.08 135.23 62.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 115.19 -0.914 . . . . 11.22 109.457 -172.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 90' ' ' LYS . . . . . 0.433 ' HD3' ' HG2' ' B' ' 165' ' ' GLN . 36.6 mtmm -84.48 116.89 23.34 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.352 -0.981 . . . . 18.75 108.352 163.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 91' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -114.37 133.02 56.0 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.424 1.09 . . . . 12.74 110.79 -164.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 92' ' ' TRP . . . . . 0.793 ' HB2' ' O ' ' H' ' 14' ' ' LEU . 93.2 m95 -132.44 124.26 28.27 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.136 0.974 . . . . 29.06 110.317 -172.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 93' ' ' ARG . . . . . 0.569 ' O ' ' HA ' ' H' ' 106' ' ' ALA . 78.7 ttt-85 -109.39 92.49 4.07 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 108.107 -1.071 . . . . 16.86 108.107 170.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 94' ' ' VAL . . . . . 0.479 HG12 ' HB2' ' H' ' 106' ' ' ALA . 21.4 m -107.66 163.96 5.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 122.122 0.963 . . . . 29.43 109.445 -174.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 95' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -111.73 167.9 9.99 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.985 -1.007 . . . . 16.86 111.255 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 96' ' ' THR . . . . . 0.418 HG23 HD12 ' H' ' 150' ' ' ILE . 26.9 m -101.49 -29.44 11.99 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.008 -0.996 . . . . 15.46 112.647 -174.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -70.01 155.83 7.45 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 CA-C-O 121.71 0.767 . . . . 16.86 110.249 -177.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 98' ' ' LYS . . . . . 0.503 ' NZ ' ' O ' ' H' ' 99' ' ' ASN . 29.5 tptp -90.76 125.06 35.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.683 -0.69 . . . . 8.25 109.749 -177.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 99' ' ' ASN . . . . . 0.503 ' O ' ' NZ ' ' H' ' 98' ' ' LYS . 34.6 m120 -85.53 171.12 11.99 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.874 0.845 . . . . 11.54 110.074 172.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 100' ' ' GLU . . . . . . . . . . . . . 57.4 mp0 -105.28 -14.96 15.19 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 113.572 0.953 . . . . 3.22 113.572 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 101' ' ' ASN . . . . . . . . . . . . . 20.2 p30 -93.29 -47.04 7.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 118.143 0.429 . . . . 23.88 111.545 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 102' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -112.28 -175.08 2.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.954 -0.758 . . . . 55.17 108.954 174.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 103' ' ' LYS . . . . . 0.69 ' H ' HG22 ' H' ' 143' ' ' ILE . 97.3 mttt -79.92 -55.21 5.13 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 120.426 -0.509 . . . . 35.9 110.18 169.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 104' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -133.07 -172.88 3.04 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 108.22 -1.03 . . . . 23.11 108.22 -178.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 105' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -149.9 164.64 34.87 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.474 0.654 . . . . 48.44 109.266 177.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 106' ' ' ALA . . . . . 0.569 ' HA ' ' O ' ' H' ' 93' ' ' ARG . . . -155.82 158.54 38.27 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.256 -0.884 . . . . 28.36 111.309 -162.094 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 107' ' ' GLN . . . . . 0.479 ' OE1' ' OH ' ' I' ' 118' ' ' TYR . 87.5 mt-30 -119.23 126.26 51.11 Favored 'General case' 0 C--O 1.236 0.379 0 N-CA-C 107.015 -1.476 . . . . 21.32 107.015 159.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 108' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -112.25 155.07 24.64 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 123.585 0.754 . . . . 12.32 110.202 -164.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 109' ' ' GLY . . . . . 0.425 ' HA3' HG21 ' H' ' 134' ' ' VAL . . . -168.29 162.57 36.35 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 119.507 -1.33 . . . . 7.13 112.639 172.295 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 110' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -101.91 109.05 20.69 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 114.885 -0.658 . . . . 20.08 109.496 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 111' ' ' ALA . . . . . . . . . . . . . . . -107.23 156.54 18.73 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.528 0.68 . . . . 59.58 111.77 -166.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 112' ' ' TYR . . . . . 0.678 ' HD1' ' HG2' ' H' ' 88' ' ' GLN . 55.3 t80 -136.9 138.28 40.51 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 107.349 -1.352 . . . . 17.89 107.349 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 113' ' ' ILE . . . . . 0.472 HD11 HD11 ' H' ' 89' ' ' ILE . 80.4 mt -88.77 128.22 41.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 109.953 -0.388 . . . . 5.27 109.953 -169.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 114' ' ' GLU . . . . . 0.499 ' HB2' ' HB2' ' H' ' 131' ' ' SER . 99.2 mt-10 -71.28 -64.57 0.89 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 119.881 -0.728 . . . . 20.33 110.533 163.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 115' ' ' SER . . . . . . . . . . . . . 74.5 m -140.38 152.12 45.51 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-O 121.639 0.733 . . . . 2.92 110.627 -170.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 116' ' ' ARG . . . . . . . . . . . . . 8.6 tmm_? -125.49 94.51 4.16 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 104.807 -2.294 . . . . 16.86 104.807 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 117' ' ' GLU . . . . . 0.536 ' HB3' HG12 ' G' ' 37' ' ' VAL . 98.1 mt-10 -117.52 107.36 14.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.689 -1.226 . . . . 34.77 107.689 -173.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 118' ' ' TYR . . . . . 0.483 ' HB3' ' HA ' ' H' ' 128' ' ' ILE . 13.6 p90 -111.53 144.0 41.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.599 0.714 . . . . 4.91 111.829 177.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 119' ' ' SER . . . . . . . . . . . . . 39.5 t -97.03 126.97 42.55 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-N 114.616 -1.175 . . . . 6.37 109.591 176.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 120' ' ' ASP . . . . . 0.673 ' HA ' HG12 ' H' ' 126' ' ' VAL . 59.3 t0 -104.99 98.13 7.89 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 106.063 -1.829 . . . . 27.99 106.063 170.345 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.5 -153.88 13.55 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-O 121.864 0.702 . . . . 32.42 112.155 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -116.19 -59.45 3.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 107.955 -1.128 . . . . 22.96 107.955 177.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 123' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -102.97 -32.33 9.79 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 113.005 0.743 . . . . 64.75 113.005 -175.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 124' ' ' GLY . . . . . . . . . . . . . . . -75.04 145.82 34.08 Favored Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 109.228 -1.549 . . . . 58.97 109.228 165.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.96 165.99 23.91 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 119.806 -0.758 . . . . 16.86 110.26 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 126' ' ' VAL . . . . . 0.673 HG12 ' HA ' ' H' ' 120' ' ' ASP . 27.9 m -68.78 149.1 11.38 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 CA-C-N 115.234 -0.894 . . . . 16.86 109.908 -173.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 127' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -138.19 129.71 27.83 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.841 -0.429 . . . . 30.97 109.841 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 128' ' ' ILE . . . . . 0.483 ' HA ' ' HB3' ' H' ' 118' ' ' TYR . 93.5 mt -98.63 122.55 50.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.146 -0.687 . . . . 16.86 109.146 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 129' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' H' ' 117' ' ' GLU . 69.2 m -100.67 132.79 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.309 -0.997 . . . . 6.41 108.309 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 130' ' ' ILE . . . . . . . . . . . . . 96.0 mt -132.82 127.94 56.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 108.678 -0.86 . . . . 16.86 108.678 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 131' ' ' SER . . . . . 0.499 ' HB2' ' HB2' ' H' ' 114' ' ' GLU . 57.0 m -92.59 145.46 24.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 116.089 -0.505 . . . . 24.39 109.729 174.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 132' ' ' LEU . . . . . 0.622 ' O ' ' HA ' ' H' ' 62' ' ' SER . 7.2 mp -129.86 151.41 50.45 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 116.03 -0.532 . . . . 22.57 110.212 -178.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 133' ' ' GLN . . . . . 0.786 ' HB3' HD11 ' G' ' 53' ' ' ILE . 18.7 mm100 -142.05 123.7 15.07 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 123.89 0.876 . . . . 3.25 109.106 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 134' ' ' VAL . . . . . 0.425 HG21 ' HA3' ' H' ' 109' ' ' GLY . 12.4 p -132.57 148.67 31.72 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 109.032 -0.729 . . . . 14.47 109.032 -178.19 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -62.64 -59.17 4.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 CA-C-O 121.212 0.53 . . . . 16.86 110.923 176.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.58 137.09 4.8 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.581 -0.819 . . . . 16.86 111.53 -178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 137' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -67.07 149.33 50.73 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.44 0.638 . . . . 21.99 110.35 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 138' ' ' LEU . . . . . . . . . . . . . 31.9 tp -133.58 127.75 33.75 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.546 -1.279 . . . . 16.86 107.546 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -81.55 76.89 8.46 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 122.345 1.069 . . . . 10.83 109.402 -170.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 140' ' ' ASN . . . . . . . . . . . . . 23.3 m120 -98.51 77.02 2.29 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.209 -0.905 . . . . 30.3 108.779 -177.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.53 106.85 2.04 Favored Glycine 0 C--O 1.237 0.311 0 N-CA-C 110.419 -1.072 . . . . 20.9 110.419 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -117.29 -173.15 2.35 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 109.112 -0.699 . . . . 16.58 109.112 -176.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 143' ' ' ILE . . . . . 0.69 HG22 ' H ' ' H' ' 103' ' ' LYS . 1.3 pp -111.79 -62.29 2.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 N-CA-C 113.217 0.821 . . . . 29.28 113.217 -169.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 144' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -81.52 125.46 30.52 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 121.355 -0.841 . . . . 19.39 111.106 -169.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 145' ' ' THR . . . . . . . . . . . . . 68.0 p -120.76 17.1 11.91 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 112.685 0.624 . . . . 30.43 112.685 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 146' ' ' LEU . . . . . 0.482 ' HG ' ' HA ' ' H' ' 24' ' ' SER . 4.2 mm? 54.48 76.2 0.54 Allowed Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 126.572 1.949 . . . . 8.94 110.891 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 147' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -68.46 72.98 0.88 Allowed 'Trans proline' 0 C--N 1.347 0.486 0 N-CA-C 115.411 1.274 . . . . 9.56 115.411 -162.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 148' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.97 10.67 28.32 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.022 -0.536 . . . . 26.9 111.548 167.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 149' ' ' GLU . . . . . . . . . . . . . 26.1 pm0 -139.74 7.64 2.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 112.829 0.678 . . . . 12.56 112.829 -177.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 150' ' ' ILE . . . . . 0.418 HD12 HG23 ' H' ' 96' ' ' THR . 43.1 mm -111.36 -47.39 6.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.816 0.734 . . . . 11.42 111.129 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 151' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.84 -29.04 2.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.488 0 N-CA-C 108.228 -1.027 . . . . 29.26 108.228 -176.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 152' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -66.22 -32.48 73.93 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.252 -0.431 . . . . 16.93 111.635 -177.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -74.91 98.74 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-O 122.211 1.005 . . . . 16.86 108.448 171.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 154' ' ' SER . . . . . . . . . . . . . 41.5 t -118.98 -61.75 1.61 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.723 -0.672 . . . . 22.09 112.32 -178.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 155' ' ' LYS . . . . . 0.545 ' HG3' ' H ' ' H' ' 157' ' ' GLY . 5.4 tppp? -128.72 -37.7 1.74 Allowed 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 113.738 1.014 . . . . 33.48 113.738 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 156' ' ' GLY . . . . . . . . . . . . . . . 93.09 -53.91 2.52 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.583 -1.407 . . . . 16.86 109.583 -160.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 157' ' ' GLY . . . . . 0.545 ' H ' ' HG3' ' H' ' 155' ' ' LYS . . . -90.2 155.5 24.41 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-O 122.095 0.831 . . . . 16.86 112.584 179.19 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 158' ' ' TYR . . . . . . . . . . . . . 20.4 m-30 -118.79 -171.2 2.05 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.948 1.699 . . . . 20.89 108.481 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 159' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -78.8 -71.4 0.44 Allowed 'General case' 0 C--O 1.236 0.368 0 C-N-CA 118.54 -1.264 . . . . 23.05 112.459 -169.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 160' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -178.09 163.65 1.74 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.643 0.777 . . . . 25.31 109.165 -175.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 161' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -149.63 94.46 2.19 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 105.306 -2.109 . . . . 17.71 105.306 153.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 162' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -66.21 -42.93 53.04 Favored Pre-proline 0 C--O 1.244 0.796 0 N-CA-C 114.318 1.229 . . . . 33.51 114.318 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 163' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -73.79 -42.51 0.8 Allowed 'Trans proline' 0 C--N 1.364 1.38 0 CA-C-N 122.206 1.824 . . . . 29.17 113.261 172.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 164' ' ' GLY . . . . . 0.489 ' HA3' ' HG3' ' H' ' 175' ' ' PRO . . . -129.8 40.51 1.67 Allowed Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 117.941 1.936 . . . . 30.18 117.941 -165.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -62.99 -63.48 1.19 Allowed 'General case' 0 C--O 1.238 0.471 0 CA-C-N 118.324 1.062 . . . . 16.86 110.574 171.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 166' ' ' THR . . . . . . . . . . . . . 41.3 p 53.82 51.03 15.63 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.86 1.664 . . . . 55.52 111.711 173.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 167' ' ' THR . . . . . . . . . . . . . 1.8 m -134.27 166.27 23.2 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 107.818 -1.179 . . . . 18.58 107.818 -168.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.78 -125.49 1.15 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.634 -1.387 . . . . 33.57 109.634 170.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 169' ' ' GLU . . . . . . . . . . . . . 16.6 tm-20 -77.65 -60.81 2.21 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 119.362 -0.935 . . . . 30.67 110.975 -179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.65 105.0 0.65 Allowed Pre-proline 0 C--O 1.236 0.348 0 C-N-CA 124.051 0.94 . . . . 5.65 109.654 -172.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 171' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -83.7 -174.26 1.87 Allowed 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 121.392 1.395 . . . . 18.19 111.912 -155.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 172' ' ' GLY . . . . . . . . . . . . . . . 73.9 66.74 1.92 Allowed Glycine 0 N--CA 1.446 -0.661 0 CA-C-N 114.49 -1.232 . . . . 29.36 114.863 167.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 173' ' ' THR . . . . . . . . . . . . . 11.3 t -133.35 166.85 21.55 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.776 0.798 . . . . 8.79 109.259 170.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 m -72.1 153.58 92.55 Favored Pre-proline 0 C--O 1.24 0.573 0 CA-C-N 114.89 -1.05 . . . . 22.5 108.231 176.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 175' ' ' PRO . . . . . 0.489 ' HG3' ' HA3' ' H' ' 164' ' ' GLY . 42.2 Cg_exo -63.89 111.92 1.69 Allowed 'Trans proline' 0 C--N 1.35 0.649 0 CA-C-N 119.347 0.802 . . . . 44.92 111.264 175.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.195 0 C-N-CA 125.609 1.564 . . . . 44.53 111.821 -171.217 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 5' ' ' PRO . . . . . 0.468 ' HB2' ' H ' ' I' ' 6' ' ' ILE . 36.6 Cg_endo . . . . . 0 N--CA 1.466 -0.092 0 CA-C-O 119.583 -0.257 . . . . 23.33 112.409 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 6' ' ' ILE . . . . . 0.468 ' H ' ' HB2' ' I' ' 5' ' ' PRO . 96.7 mt -125.27 122.0 61.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.464 0 N-CA-C 108.088 -1.078 . . . . 7.12 108.088 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -93.0 170.83 9.36 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 121.817 0.817 . . . . 40.91 110.604 -177.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.97 -14.0 67.43 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.476 -0.784 . . . . 7.69 114.581 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 9' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -90.76 -13.96 32.98 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 117.819 0.81 . . . . 7.68 112.382 172.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 10' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -77.88 -7.17 56.34 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 113.751 1.019 . . . . 33.11 113.751 -170.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 11' ' ' VAL . . . . . . . . . . . . . 80.9 t -128.22 124.64 62.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.908 -1.145 . . . . 11.83 107.908 -176.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 12' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -133.24 162.12 32.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.599 0.714 . . . . 4.34 110.221 176.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 13' ' ' TYR . . . . . 0.442 ' HA ' ' O ' ' I' ' 92' ' ' TRP . 19.0 m-30 -112.69 94.76 5.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.008 -0.996 . . . . 17.0 108.458 -165.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 14' ' ' LEU . . . . . 0.848 ' O ' ' HB2' ' I' ' 92' ' ' TRP . 97.6 mt -77.1 131.58 38.43 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.083 -0.647 . . . . 58.6 109.5 177.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 15' ' ' PHE . . . . . . . . . . . . . 22.0 m-30 -112.83 155.37 24.75 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.395 -0.595 . . . . 13.06 109.395 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 16' ' ' GLN . . . . . . . . . . . . . 71.0 tp60 -148.6 137.5 21.57 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 109.21 -0.663 . . . . 35.81 109.21 174.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' SER . . . . . 0.435 ' O ' ' NZ ' ' I' ' 90' ' ' LYS . 40.0 t -77.0 155.19 32.78 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.646 0.736 . . . . 12.95 111.194 -178.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 pt -78.77 -13.13 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.457 -0.792 . . . . 17.0 113.031 178.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -113.42 -6.72 13.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.454 0.538 . . . . 57.91 112.454 -172.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.84 -47.97 23.42 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 119.964 -0.694 . . . . 27.52 111.853 -171.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.411 ' HB2' HG22 ' C' ' 166' ' ' THR . . . 53.09 45.32 28.96 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.811 1.245 . . . . 18.72 111.428 -168.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 22' ' ' THR . . . . . . . . . . . . . 72.8 p -127.59 123.96 36.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 108.985 -0.746 . . . . 10.9 108.985 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.32 76.58 2.15 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 121.528 -0.367 . . . . 9.74 113.377 -178.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 24' ' ' SER . . . . . 0.46 ' HA ' ' HG ' ' I' ' 146' ' ' LEU . 95.4 p -128.39 -30.61 2.36 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 120.562 -0.455 . . . . 23.98 112.181 -176.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 25' ' ' ALA . . . . . 0.542 ' HB1' ' HB3' ' I' ' 14' ' ' LEU . . . 51.86 74.97 0.7 Allowed Pre-proline 0 C--O 1.236 0.394 0 C-N-CA 126.812 2.045 . . . . 33.08 112.485 -173.358 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 26' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -70.5 106.14 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 CA-C-N 119.473 0.848 . . . . 3.49 113.032 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 27' ' ' LEU . . . . . 0.739 ' HB3' HD23 ' I' ' 14' ' ' LEU . 2.2 pt? -87.85 169.72 11.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.101 -0.703 . . . . 11.21 109.101 164.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 28' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -112.78 143.76 29.68 Favored Pre-proline 0 N--CA 1.449 -0.497 1 C-N-CA 111.426 -4.109 . . . . 33.39 110.475 -172.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.34 161.83 41.76 Favored 'Trans proline' 0 CA--C 1.518 -0.315 0 CA-C-N 118.946 0.659 . . . . 53.3 113.679 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . 55.61 59.83 3.65 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.781 1.232 . . . . 7.07 111.708 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' TYR . . . . . 0.435 ' HD1' ' HA ' ' I' ' 31' ' ' TYR . 3.4 m-30 -71.34 167.34 19.73 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 122.624 1.202 . . . . 40.62 111.085 173.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 32' ' ' GLN . . . . . 0.472 ' HG3' ' H ' ' I' ' 33' ' ' THR . 7.8 tp-100 -136.79 -162.67 1.31 Allowed 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 103.636 -2.727 . . . . 29.07 103.636 177.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 33' ' ' THR . . . . . 0.472 ' H ' ' HG3' ' I' ' 32' ' ' GLN . 15.3 t -64.66 162.56 15.51 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-O 122.631 1.205 . . . . 36.87 112.033 -172.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 34' ' ' ASP . . . . . 0.644 ' HB2' ' HB3' ' J' ' 120' ' ' ASP . 79.4 m-20 -134.79 -172.46 3.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.018 -1.446 . . . . 37.64 108.182 -162.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 35' ' ' GLY . . . . . 0.615 ' O ' ' HA2' ' I' ' 63' ' ' GLY . . . 171.02 134.46 1.77 Allowed Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.399 -0.905 . . . . 17.37 112.283 166.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 36' ' ' SER . . . . . . . . . . . . . 64.9 m -121.87 84.64 2.28 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 105.77 -1.937 . . . . 17.0 105.77 173.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 37' ' ' VAL . . . . . 0.565 HG23 ' HB2' ' I' ' 62' ' ' SER . 3.2 m -89.7 108.24 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 108.395 -0.965 . . . . 17.0 108.395 -173.058 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 38' ' ' SER . . . . . . . . . . . . . 48.3 m -98.01 95.99 7.85 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.923 -1.14 . . . . 17.0 107.923 -170.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 39' ' ' GLY . . . . . . . . . . . . . . . -99.18 102.63 2.6 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.153 -1.022 . . . . 29.57 112.964 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 40' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' I' ' 59' ' ' VAL . 81.9 tt0 -102.43 126.25 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.159 -1.052 . . . . 16.35 108.159 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 41' ' ' ARG . . . . . 0.478 ' C ' ' HA3' ' I' ' 57' ' ' GLY . 93.2 mtm-85 -80.76 -176.67 5.95 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.488 0.661 . . . . 62.13 109.368 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 42' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -161.59 160.48 28.93 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.493 -0.558 . . . . 60.4 109.493 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 43' ' ' LEU . . . . . 0.722 ' HB2' ' HA3' ' I' ' 55' ' ' GLY . 47.2 mt -88.23 128.09 35.46 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.848 -0.615 . . . . 4.94 109.417 175.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 44' ' ' PHE . . . . . . . . . . . . . 67.3 t80 -120.84 107.52 12.82 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 108.307 -0.998 . . . . 75.54 108.307 -173.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 45' ' ' ASP . . . . . 0.686 ' HB2' ' HB3' ' I' ' 52' ' ' ARG . 76.3 m-20 -134.76 162.19 33.07 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 116.264 -0.426 . . . . 17.0 110.596 -169.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 46' ' ' GLU . . . . . . . . . . . . . 59.8 mp0 -125.91 -42.73 1.88 Allowed 'General case' 0 C--O 1.236 0.348 0 N-CA-C 113.721 1.008 . . . . 15.68 113.721 -175.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 47' ' ' GLN . . . . . 0.65 ' HB3' ' HA ' ' D' ' 30' ' ' ALA . 91.1 mm-40 67.45 24.69 8.73 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 124.401 1.08 . . . . 41.36 113.871 153.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 48' ' ' THR . . . . . 0.45 ' H ' HG13 ' E' ' 122' ' ' VAL . 65.3 p 51.29 37.35 18.48 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 124.818 1.247 . . . . 43.18 111.35 -169.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 49' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -139.44 -164.75 1.73 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 106.936 -1.505 . . . . 8.41 106.936 -176.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 50' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -73.87 -23.55 59.61 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 120.41 -0.516 . . . . 14.0 111.807 171.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 51' ' ' GLY . . . . . . . . . . . . . . . 145.23 155.81 6.61 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 121.389 -0.434 . . . . 12.97 113.398 179.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 52' ' ' ARG . . . . . 0.737 ' HD3' HD13 ' I' ' 54' ' ' LEU . 21.7 tpp85 -124.7 54.22 1.41 Allowed 'General case' 0 C--O 1.235 0.294 0 N-CA-C 105.349 -2.093 . . . . 5.17 105.349 176.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 53' ' ' ILE . . . . . 0.555 HD11 HE21 ' J' ' 133' ' ' GLN . 7.4 tt -73.58 -5.07 6.08 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.127 -0.942 . . . . 26.87 111.474 -177.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 54' ' ' LEU . . . . . 0.737 HD13 ' HD3' ' I' ' 52' ' ' ARG . 8.2 mp -51.78 -29.32 18.5 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 127.619 2.368 . . . . 61.28 114.451 -175.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 55' ' ' GLY . . . . . 0.722 ' HA3' ' HB2' ' I' ' 43' ' ' LEU . . . -64.27 123.01 26.82 Favored Glycine 0 N--CA 1.44 -1.095 0 CA-C-O 121.567 0.537 . . . . 17.24 113.98 -166.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.18 156.31 65.44 Favored 'Trans proline' 0 C--N 1.326 -0.656 0 C-N-CA 121.063 1.176 . . . . 13.15 110.376 171.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 57' ' ' GLY . . . . . 0.478 ' HA3' ' C ' ' I' ' 41' ' ' ARG . . . -126.23 172.27 17.99 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 108.477 -1.849 . . . . 17.02 108.477 178.342 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 58' ' ' SER . . . . . 0.43 ' HB3' ' NH2' ' I' ' 41' ' ' ARG . 42.1 t -74.88 144.32 43.42 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 119.817 -0.753 . . . . 17.62 110.063 176.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 59' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' I' ' 40' ' ' GLU . 2.6 p -95.65 121.25 46.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 108.357 -0.979 . . . . 17.0 108.357 -178.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.2 114.72 22.34 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 106.905 -1.517 . . . . 10.79 106.905 175.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 61' ' ' ASP . . . . . . . . . . . . . 51.5 t0 -117.93 120.48 37.98 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.863 -0.792 . . . . 53.38 108.863 -169.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' I' ' 132' ' ' LEU . 67.9 m -105.16 166.74 10.19 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.068 0.947 . . . . 7.55 110.532 -176.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 63' ' ' GLY . . . . . 0.615 ' HA2' ' O ' ' I' ' 35' ' ' GLY . . . -139.32 123.27 2.48 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.05 -0.977 . . . . 9.11 113.058 175.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 64' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -101.73 97.24 7.66 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 107.552 -1.277 . . . . 63.47 107.552 173.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 65' ' ' VAL . . . . . . . . . . . . . 93.7 t -107.24 116.29 50.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 108.282 -1.007 . . . . 17.0 108.282 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 66' ' ' THR . . . . . 0.467 ' HA ' ' O ' ' I' ' 128' ' ' ILE . 70.1 p -115.62 143.11 45.82 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.247 -0.649 . . . . 22.76 109.247 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 67' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -153.52 -170.32 3.56 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.364 0.602 . . . . 12.71 109.405 175.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -116.01 134.15 55.26 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.676 0.79 . . . . 17.94 109.367 179.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.03 107.74 2.73 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.953 -0.641 . . . . 38.99 113.911 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -83.73 147.25 27.74 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 108.812 -0.81 . . . . 5.02 108.812 173.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -67.01 -16.7 64.53 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.126 1.158 . . . . 21.0 114.126 -168.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.78 -141.53 5.45 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.108 -1.197 . . . . 17.67 110.108 176.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 73' ' ' ASP . . . . . . . . . . . . . 31.4 t0 59.49 72.65 0.52 Allowed 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.157 1.383 . . . . 17.0 111.106 169.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.75 11.25 0.04 OUTLIER 'General case' 0 C--O 1.235 0.313 0 N-CA-C 117.285 2.328 . . . . 31.59 117.285 -159.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.21 -38.7 90.79 Favored Glycine 0 C--N 1.338 0.647 0 C-N-CA 120.355 -0.926 . . . . 22.74 112.727 169.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 76' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -69.4 -24.71 63.89 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.69 -0.804 . . . . 8.28 111.325 173.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 77' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -73.51 -24.98 60.22 Favored 'General case' 0 CA--C 1.516 -0.347 0 C-N-CA 119.597 -0.841 . . . . 25.75 111.356 171.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.71 -33.37 66.4 Favored 'General case' 0 C--O 1.239 0.551 0 C-N-CA 120.274 -0.57 . . . . 15.11 111.041 169.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 79' ' ' ILE . . . . . . . . . . . . . 51.1 mm -63.76 -43.84 98.09 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.087 0.47 . . . . 4.62 110.435 172.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 80' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -75.05 -20.78 59.4 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 121.88 -0.512 . . . . 37.77 112.01 179.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 81' ' ' ASP . . . . . . . . . . . . . 55.3 m-20 -71.35 -33.45 69.61 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 120.165 -0.614 . . . . 27.13 111.224 168.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 82' ' ' ALA . . . . . 0.742 ' HA ' ' HB2' ' I' ' 87' ' ' LYS . . . -73.6 -36.42 65.52 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 119.416 -0.913 . . . . 4.66 111.634 175.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 83' ' ' TYR . . . . . . . . . . . . . 84.2 t80 -83.79 -61.9 1.71 Allowed 'General case' 0 C--O 1.235 0.317 0 C-N-CA 120.486 -0.486 . . . . 17.0 112.139 -176.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 84' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -74.65 -40.01 61.73 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 111.763 0.283 . . . . 18.96 111.763 -166.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 85' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -76.66 -47.11 23.13 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.952 -0.699 . . . . 34.93 111.015 172.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.19 96.3 2.28 Favored Glycine 0 N--CA 1.45 -0.421 0 O-C-N 122.261 -0.275 . . . . 21.67 113.34 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 87' ' ' LYS . . . . . 0.742 ' HB2' ' HA ' ' I' ' 82' ' ' ALA . 98.0 mttt -148.87 -161.8 1.42 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 107.052 -1.462 . . . . 19.94 107.052 -177.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 88' ' ' GLN . . . . . 0.7 ' HG2' ' HD1' ' I' ' 112' ' ' TYR . 63.5 mt-30 -129.64 177.64 7.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.777 0.798 . . . . 25.1 111.045 167.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 89' ' ' ILE . . . . . 0.461 HD11 HD11 ' I' ' 113' ' ' ILE . 55.8 mt -127.35 136.93 59.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 115.215 -0.902 . . . . 18.47 109.446 -173.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 90' ' ' LYS . . . . . 0.435 ' NZ ' ' O ' ' I' ' 17' ' ' SER . 36.9 mtmm -85.26 118.7 24.97 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.436 -0.95 . . . . 12.1 108.436 164.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 91' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -111.94 133.56 54.05 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.342 1.057 . . . . 9.89 110.671 -166.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 92' ' ' TRP . . . . . 0.848 ' HB2' ' O ' ' I' ' 14' ' ' LEU . 91.7 m95 -132.48 125.67 31.2 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 124.183 0.993 . . . . 25.76 109.894 -173.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 93' ' ' ARG . . . . . 0.593 ' O ' ' HA ' ' I' ' 106' ' ' ALA . 78.8 ttt-85 -112.65 90.63 3.4 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 108.142 -1.059 . . . . 17.0 108.142 171.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 94' ' ' VAL . . . . . 0.472 HG12 ' HB2' ' I' ' 106' ' ' ALA . 20.3 m -105.11 165.24 3.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 122.061 0.934 . . . . 22.42 109.385 -174.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 95' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -110.72 165.14 12.07 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.07 -0.968 . . . . 21.14 111.583 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 96' ' ' THR . . . . . 0.448 HG23 HG23 ' I' ' 150' ' ' ILE . 31.9 m -98.22 -33.07 11.25 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 114.901 -1.045 . . . . 18.2 112.751 -176.035 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 97' ' ' VAL . . . . . . . . . . . . . 34.1 m -70.3 155.6 7.55 Favored 'Isoleucine or valine' 0 C--O 1.237 0.431 0 CA-C-O 121.81 0.814 . . . . 2.01 110.197 -177.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 98' ' ' LYS . . . . . 0.554 ' NZ ' ' O ' ' I' ' 99' ' ' ASN . 29.6 tptp -88.28 129.39 35.38 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.626 -0.715 . . . . 17.92 109.633 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 99' ' ' ASN . . . . . 0.554 ' O ' ' NZ ' ' I' ' 98' ' ' LYS . 35.4 m120 -91.37 173.16 8.06 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.76 0.79 . . . . 24.74 110.022 172.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 100' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -108.59 -16.39 14.21 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 113.667 0.988 . . . . 25.49 113.667 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 101' ' ' ASN . . . . . . . . . . . . . 21.3 p30 -86.73 -47.2 9.32 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 118.188 0.449 . . . . 14.22 111.054 170.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 102' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -119.44 -174.77 2.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.588 -0.893 . . . . 56.62 108.588 174.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 103' ' ' LYS . . . . . 0.725 ' H ' HG22 ' I' ' 143' ' ' ILE . 96.9 mttt -74.3 -57.63 3.82 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 120.184 -0.606 . . . . 34.07 110.318 169.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 104' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -132.62 -170.77 2.5 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 108.863 -0.791 . . . . 6.62 108.863 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 105' ' ' ASP . . . . . 0.419 ' N ' ' OD1' ' I' ' 105' ' ' ASP . 17.4 p-10 -151.73 166.53 31.03 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 121.471 0.653 . . . . 44.49 109.241 177.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' I' ' 93' ' ' ARG . . . -157.96 154.75 28.29 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 115.337 -0.847 . . . . 17.0 111.159 -163.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 107' ' ' GLN . . . . . 0.464 ' OE1' ' OH ' ' J' ' 118' ' ' TYR . 88.4 mt-30 -112.86 124.82 53.49 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.915 -1.513 . . . . 17.34 106.915 159.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 108' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -111.41 154.44 24.64 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 123.543 0.737 . . . . 8.89 110.268 -165.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 109' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' I' ' 134' ' ' VAL . . . -164.79 168.78 39.2 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 119.537 -1.315 . . . . 18.72 112.714 172.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 110' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.14 110.86 22.2 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.626 -0.787 . . . . 23.19 109.058 168.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 111' ' ' ALA . . . . . . . . . . . . . . . -109.93 155.94 21.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 121.607 0.718 . . . . 38.3 111.826 -165.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 112' ' ' TYR . . . . . 0.7 ' HD1' ' HG2' ' I' ' 88' ' ' GLN . 51.7 t80 -136.02 137.75 41.5 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 107.267 -1.383 . . . . 3.85 107.267 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 113' ' ' ILE . . . . . 0.461 HD11 HD11 ' I' ' 89' ' ' ILE . 84.2 mt -86.72 128.03 39.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.881 -0.414 . . . . 5.61 109.881 -170.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 114' ' ' GLU . . . . . 0.493 ' HB2' ' HB2' ' I' ' 131' ' ' SER . 98.7 mt-10 -71.15 -64.36 0.93 Allowed 'General case' 0 C--O 1.235 0.29 0 C-N-CA 119.832 -0.747 . . . . 26.68 110.555 164.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 115' ' ' SER . . . . . . . . . . . . . 74.3 m -141.94 153.46 44.36 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.612 0.72 . . . . 25.88 110.375 -170.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 116' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -127.05 89.95 3.07 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 104.725 -2.324 . . . . 12.69 104.725 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 117' ' ' GLU . . . . . 0.532 ' HB3' HG12 ' H' ' 37' ' ' VAL . 98.3 mt-10 -112.63 106.85 15.36 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.733 -1.21 . . . . 24.53 107.733 -174.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 118' ' ' TYR . . . . . 0.504 ' HB3' ' HA ' ' I' ' 128' ' ' ILE . 11.9 p90 -111.88 143.59 42.59 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.621 0.724 . . . . 17.0 111.939 176.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 119' ' ' SER . . . . . . . . . . . . . 35.7 t -99.3 128.79 45.46 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-N 114.633 -1.167 . . . . 5.54 109.869 178.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 120' ' ' ASP . . . . . 0.64 ' HB3' ' HB2' ' H' ' 34' ' ' ASP . 59.3 t0 -103.56 96.33 6.66 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.217 -1.771 . . . . 25.94 106.217 170.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 121' ' ' GLY . . . . . . . . . . . . . . . -80.09 -159.94 20.29 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-O 121.842 0.69 . . . . 22.53 112.252 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 122' ' ' VAL . . . . . . . . . . . . . 88.8 t -116.45 -63.0 2.06 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 108.614 -0.884 . . . . 21.86 108.614 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 123' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -96.37 -22.37 17.21 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 112.718 0.636 . . . . 41.28 112.718 -176.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 124' ' ' GLY . . . . . . . . . . . . . . . -86.55 155.18 27.87 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 109.526 -1.43 . . . . 17.0 109.526 165.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.04 167.97 20.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.683 0.754 . . . . 14.91 110.213 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 126' ' ' VAL . . . . . 0.597 HG12 ' HA ' ' I' ' 120' ' ' ASP . 35.9 m -69.21 153.17 9.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.492 0 CA-C-N 115.287 -0.87 . . . . 17.18 109.585 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 127' ' ' GLU . . . . . . . . . . . . . 21.9 pt-20 -143.79 133.45 23.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 109.859 -0.423 . . . . 47.07 109.859 -178.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 128' ' ' ILE . . . . . 0.504 ' HA ' ' HB3' ' I' ' 118' ' ' TYR . 90.1 mt -102.05 123.23 55.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.371 -0.603 . . . . 17.0 109.371 -176.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 129' ' ' SER . . . . . 0.506 ' HB2' ' O ' ' I' ' 117' ' ' GLU . 66.3 m -102.3 132.71 48.1 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.55 -0.907 . . . . 31.15 108.55 170.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 130' ' ' ILE . . . . . . . . . . . . . 91.4 mt -133.89 128.12 53.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.793 -0.817 . . . . 17.0 108.793 -179.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 131' ' ' SER . . . . . 0.493 ' HB2' ' HB2' ' I' ' 114' ' ' GLU . 62.1 m -94.26 147.6 23.03 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.087 -0.506 . . . . 20.21 109.84 175.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 132' ' ' LEU . . . . . 0.589 ' O ' ' HA ' ' I' ' 62' ' ' SER . 7.1 mp -132.57 152.02 51.75 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 115.999 -0.546 . . . . 30.2 110.142 -176.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 133' ' ' GLN . . . . . 0.795 ' HB3' HD11 ' H' ' 53' ' ' ILE . 18.9 mm100 -141.24 126.83 18.93 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.794 0.837 . . . . 17.0 109.105 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 134' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' I' ' 109' ' ' GLY . 13.1 p -133.06 147.54 31.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.406 0 N-CA-C 109.185 -0.672 . . . . 17.0 109.185 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 135' ' ' ILE . . . . . . . . . . . . . 22.1 mm -63.45 -60.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.038 -0.528 . . . . 29.2 110.877 176.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 136' ' ' GLY . . . . . . . . . . . . . . . -158.33 134.43 3.85 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.56 -0.829 . . . . 17.0 111.59 -177.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 137' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -67.09 146.61 54.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.442 0.639 . . . . 17.0 110.278 175.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 138' ' ' LEU . . . . . . . . . . . . . 34.7 tp -133.12 127.91 34.96 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.74 -1.207 . . . . 17.0 107.74 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -82.13 78.42 8.81 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 122.434 1.112 . . . . 8.57 109.376 -171.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 140' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -97.2 81.08 2.99 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.125 -0.943 . . . . 12.82 108.594 -178.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.33 110.81 3.26 Favored Glycine 0 C--O 1.236 0.273 0 C-N-CA 120.053 -1.07 . . . . 45.73 110.478 175.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 142' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -122.79 -174.11 2.85 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.14 -0.689 . . . . 13.18 109.14 -176.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 143' ' ' ILE . . . . . 0.725 HG22 ' H ' ' I' ' 103' ' ' LYS . 1.3 pp -112.11 -62.1 2.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.342 0 N-CA-C 113.468 0.914 . . . . 1.91 113.468 -169.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 144' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -82.18 129.17 34.76 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 121.373 -0.829 . . . . 32.89 111.217 -169.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 145' ' ' THR . . . . . . . . . . . . . 77.8 p -122.24 16.51 10.66 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.678 0.622 . . . . 26.61 112.678 177.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 146' ' ' LEU . . . . . 0.46 ' HG ' ' HA ' ' I' ' 24' ' ' SER . 4.2 mm? 54.49 75.79 0.58 Allowed Pre-proline 0 C--O 1.238 0.457 0 C-N-CA 126.638 1.975 . . . . 20.07 110.505 -178.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 147' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -68.53 73.63 0.87 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 N-CA-C 115.543 1.324 . . . . 17.0 115.543 -161.163 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 148' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -111.46 12.0 21.44 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 116.077 -0.511 . . . . 27.6 111.653 168.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 149' ' ' GLU . . . . . . . . . . . . . 25.8 pm0 -139.59 4.28 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 112.789 0.663 . . . . 17.0 112.789 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 150' ' ' ILE . . . . . 0.448 HG23 HG23 ' I' ' 96' ' ' THR . 44.3 mm -112.36 -44.67 5.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 118.708 0.685 . . . . 41.17 111.027 -178.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 151' ' ' VAL . . . . . . . . . . . . . 47.1 t -108.17 -32.98 2.5 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 N-CA-C 108.68 -0.859 . . . . 8.83 108.68 -174.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 152' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -67.54 -31.43 71.52 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 116.324 -0.398 . . . . 31.5 111.801 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -75.35 98.69 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-O 122.11 0.957 . . . . 18.4 109.156 176.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 154' ' ' SER . . . . . . . . . . . . . 39.5 t -118.89 -60.86 1.71 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.784 -0.644 . . . . 17.0 112.522 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 155' ' ' LYS . . . . . 0.57 ' HG3' ' H ' ' I' ' 157' ' ' GLY . 5.8 tppp? -129.12 -38.95 1.58 Allowed 'General case' 0 C--O 1.236 0.379 0 N-CA-C 113.652 0.982 . . . . 15.31 113.652 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.97 -54.16 2.93 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.97 -1.252 . . . . 47.27 109.97 -161.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 157' ' ' GLY . . . . . 0.57 ' H ' ' HG3' ' I' ' 155' ' ' LYS . . . -85.81 155.5 29.14 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-O 122.075 0.819 . . . . 3.31 112.727 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 158' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -120.59 -172.99 2.48 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 126.018 1.727 . . . . 1.98 108.949 -176.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 159' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -79.24 -70.84 0.48 Allowed 'General case' 0 C--O 1.236 0.359 0 C-N-CA 118.734 -1.187 . . . . 19.2 112.534 -169.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 160' ' ' PHE . . . . . 0.498 ' HD2' ' HG3' ' I' ' 162' ' ' GLN . 31.6 p90 -176.17 160.36 2.2 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 108.893 -0.78 . . . . 12.29 108.893 -175.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -151.64 95.65 2.15 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 105.111 -2.181 . . . . 22.71 105.111 156.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 162' ' ' GLN . . . . . 0.498 ' HG3' ' HD2' ' I' ' 160' ' ' PHE . 89.8 mt-30 -71.12 -44.51 13.97 Favored Pre-proline 0 C--O 1.244 0.771 0 N-CA-C 114.258 1.207 . . . . 39.71 114.258 -162.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 163' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -72.72 -48.27 0.31 Allowed 'Trans proline' 0 C--N 1.366 1.48 0 CA-C-N 122.269 1.846 . . . . 41.22 112.675 171.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 164' ' ' GLY . . . . . 0.478 ' HA3' ' HG3' ' I' ' 175' ' ' PRO . . . -123.08 41.32 1.81 Allowed Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 117.719 1.847 . . . . 24.72 117.719 -163.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 165' ' ' GLN . . . . . . . . . . . . . 9.8 tp-100 -63.54 -58.92 5.45 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 117.981 0.891 . . . . 26.67 110.572 171.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 166' ' ' THR . . . . . . . . . . . . . 35.9 p 54.88 43.78 29.42 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.867 1.667 . . . . 46.93 111.66 173.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -128.47 160.36 32.54 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 107.792 -1.188 . . . . 17.0 107.792 -168.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 168' ' ' GLY . . . . . . . . . . . . . . . -80.32 -129.88 0.86 Allowed Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 111.015 -0.834 . . . . 38.89 111.015 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -75.07 -62.67 1.47 Allowed 'General case' 0 C--O 1.235 0.302 0 C-N-CA 119.815 -0.754 . . . . 25.13 110.978 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.3 106.14 1.11 Allowed Pre-proline 0 C--O 1.236 0.344 0 C-N-CA 123.35 0.66 . . . . 26.94 109.507 -177.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 171' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -81.89 -171.56 1.23 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.466 1.444 . . . . 8.72 112.269 -158.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 172' ' ' GLY . . . . . . . . . . . . . . . 81.26 65.34 1.69 Allowed Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.566 -1.197 . . . . 18.01 116.028 168.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -137.7 167.14 22.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.869 0.842 . . . . 22.62 109.351 167.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 174' ' ' VAL . . . . . . . . . . . . . 27.3 m -73.82 159.44 84.3 Favored Pre-proline 0 C--O 1.24 0.585 0 CA-C-N 114.772 -1.103 . . . . 11.7 108.626 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 175' ' ' PRO . . . . . 0.478 ' HG3' ' HA3' ' I' ' 164' ' ' GLY . 51.6 Cg_exo -61.66 125.22 16.19 Favored 'Trans proline' 0 C--N 1.353 0.789 0 CA-C-N 119.591 0.89 . . . . 32.14 110.708 169.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.3 0 C-N-CA 125.355 1.462 . . . . 57.59 111.159 -166.129 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' J' J ' 5' ' ' PRO . . . . . 0.47 ' HB2' ' H ' ' J' ' 6' ' ' ILE . 38.1 Cg_endo . . . . . 0 N--CA 1.466 -0.133 0 CA-C-O 119.576 -0.26 . . . . 30.72 112.43 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 6' ' ' ILE . . . . . 0.47 ' H ' ' HB2' ' J' ' 5' ' ' PRO . 96.8 mt -122.67 119.62 58.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.103 -1.073 . . . . 15.06 108.103 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.75 170.62 10.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.769 0.795 . . . . 47.85 110.496 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.63 -13.5 65.87 Favored Glycine 0 C--N 1.333 0.402 0 CA-C-N 115.492 -0.776 . . . . 5.01 114.548 178.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 9' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -91.96 -13.82 30.49 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 117.729 0.764 . . . . 8.72 112.25 172.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 10' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -78.16 -3.93 45.0 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.792 1.034 . . . . 25.01 113.792 -171.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 11' ' ' VAL . . . . . . . . . . . . . 91.9 t -131.3 125.88 57.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 107.722 -1.214 . . . . 36.76 107.722 -177.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 12' ' ' LYS . . . . . . . . . . . . . 53.2 mtmt -133.89 160.58 37.24 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.682 0.753 . . . . 25.21 110.318 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 13' ' ' TYR . . . . . 0.457 ' HA ' ' O ' ' J' ' 92' ' ' TRP . 17.7 m-30 -110.49 97.37 6.83 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.03 -1.1 . . . . 16.57 108.03 -166.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 14' ' ' LEU . . . . . 0.755 ' O ' ' HB2' ' J' ' 92' ' ' TRP . 97.6 mt -78.66 132.08 36.9 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.034 -0.666 . . . . 38.68 109.457 178.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 15' ' ' PHE . . . . . . . . . . . . . 21.2 m-30 -112.07 151.56 29.23 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.781 -0.451 . . . . 22.49 109.781 -178.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 16' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -147.13 137.05 23.17 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.086 -0.709 . . . . 16.71 109.086 175.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 17' ' ' SER . . . . . 0.476 ' O ' ' NZ ' ' J' ' 90' ' ' LYS . 38.5 t -75.25 153.75 37.86 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-O 121.639 0.733 . . . . 16.57 111.153 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 18' ' ' ILE . . . . . . . . . . . . . 46.5 pt -80.04 -6.53 9.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.409 -0.814 . . . . 16.57 112.917 176.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 19' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -116.05 -9.56 11.7 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 112.667 0.617 . . . . 45.68 112.667 -173.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.01 15.89 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 119.834 -0.746 . . . . 19.74 112.01 -170.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 21' ' ' ALA . . . . . 0.412 ' HB2' HG22 ' D' ' 166' ' ' THR . . . 52.52 49.19 20.96 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.667 1.187 . . . . 7.73 111.235 -166.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 22' ' ' THR . . . . . . . . . . . . . 67.7 p -127.94 120.86 28.52 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.853 -0.795 . . . . 3.38 108.853 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.4 75.45 2.21 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.262 -0.494 . . . . 16.57 112.629 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 24' ' ' SER . . . . . 0.457 ' HA ' ' HG ' ' J' ' 146' ' ' LEU . 88.6 p -127.84 -29.8 2.56 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 120.892 -0.323 . . . . 42.47 111.6 -176.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 25' ' ' ALA . . . . . 0.487 ' HB1' ' HB3' ' J' ' 14' ' ' LEU . . . 51.43 74.37 0.81 Allowed Pre-proline 0 C--O 1.236 0.388 0 C-N-CA 126.868 2.067 . . . . 14.69 112.388 -173.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 26' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -70.79 106.06 1.77 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 CA-C-N 119.54 0.871 . . . . 16.57 112.682 177.033 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 27' ' ' LEU . . . . . 0.652 ' HB3' HD23 ' J' ' 14' ' ' LEU . 2.1 pt? -83.52 162.52 20.87 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.044 -0.725 . . . . 13.06 109.044 166.207 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 28' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -108.21 132.23 21.22 Favored Pre-proline 0 C--N 1.349 0.557 1 C-N-CA 108.786 -5.166 . . . . 18.04 110.256 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 177.51 6.0 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 120.713 0.942 . . . . 19.91 114.207 -175.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 52.86 62.12 2.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 124.552 1.141 . . . . 3.78 111.211 -172.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 31' ' ' TYR . . . . . 0.454 ' HD1' ' HA ' ' J' ' 31' ' ' TYR . 1.0 OUTLIER -68.56 163.98 22.35 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.894 1.331 . . . . 22.35 111.693 176.397 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 32' ' ' GLN . . . . . 0.44 ' HG3' ' H ' ' J' ' 33' ' ' THR . 7.4 tp-100 -136.59 -162.9 1.33 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 103.329 -2.841 . . . . 26.39 103.329 170.003 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 33' ' ' THR . . . . . 0.44 ' H ' ' HG3' ' J' ' 32' ' ' GLN . 15.0 t -65.71 163.51 16.38 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-O 122.611 1.196 . . . . 30.79 111.998 -173.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 34' ' ' ASP . . . . . 0.665 ' HB2' ' HB3' ' K' ' 120' ' ' ASP . 79.9 m-20 -133.35 -170.62 2.51 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.033 -1.439 . . . . 37.56 108.103 -165.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 35' ' ' GLY . . . . . 0.628 ' O ' ' HA2' ' J' ' 63' ' ' GLY . . . 171.8 134.85 1.85 Allowed Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.85 -0.69 . . . . 16.47 111.741 168.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 36' ' ' SER . . . . . . . . . . . . . 67.0 m -125.89 84.43 2.27 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 105.93 -1.878 . . . . 16.57 105.93 174.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 37' ' ' VAL . . . . . 0.555 HG12 ' HB3' ' K' ' 117' ' ' GLU . 4.2 m -91.24 112.92 26.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 108.404 -0.961 . . . . 16.57 108.404 -171.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 38' ' ' SER . . . . . . . . . . . . . 47.1 m -101.25 93.41 5.42 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 108.169 -1.049 . . . . 12.93 108.169 -167.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.33 100.03 2.49 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 119.693 -1.241 . . . . 26.6 113.12 -177.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 40' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' J' ' 59' ' ' VAL . 78.3 tt0 -104.08 117.5 34.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.116 -1.068 . . . . 6.73 108.116 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 41' ' ' ARG . . . . . 0.57 ' O ' ' HA3' ' J' ' 57' ' ' GLY . 91.0 mtm-85 -77.34 -179.72 5.89 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.705 0.764 . . . . 44.8 109.426 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 42' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -158.9 160.82 36.54 Favored 'General case' 0 N--CA 1.451 -0.376 0 O-C-N 121.716 -0.615 . . . . 22.91 109.433 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 43' ' ' LEU . . . . . 0.739 ' HB2' ' HA3' ' J' ' 55' ' ' GLY . 41.6 mt -89.33 124.35 34.35 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 115.862 -0.608 . . . . 0.98 109.476 175.294 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 44' ' ' PHE . . . . . 0.478 ' HD1' HG13 ' J' ' 53' ' ' ILE . 78.0 t80 -120.72 107.89 13.32 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.037 -1.098 . . . . 66.87 108.037 -174.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 45' ' ' ASP . . . . . 0.727 ' HB2' ' HB3' ' J' ' 52' ' ' ARG . 76.7 m-20 -135.74 164.47 27.81 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.147 -0.479 . . . . 22.3 109.834 -170.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 46' ' ' GLU . . . . . 0.474 ' HA ' ' HA2' ' J' ' 51' ' ' GLY . 59.6 mp0 -125.71 -41.95 1.96 Allowed 'General case' 0 C--O 1.235 0.323 0 N-CA-C 113.747 1.018 . . . . 34.25 113.747 -172.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 47' ' ' GLN . . . . . 0.68 ' HB3' ' HA ' ' E' ' 30' ' ' ALA . 93.0 mm-40 68.18 25.87 7.2 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.431 1.092 . . . . 40.68 113.703 154.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 48' ' ' THR . . . . . . . . . . . . . 66.2 p 50.91 38.05 19.04 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.718 1.207 . . . . 36.91 111.225 -168.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm -139.66 -165.06 1.8 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.777 -1.564 . . . . 12.44 106.777 -175.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 50' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -74.42 -20.96 59.85 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 120.39 -0.524 . . . . 12.93 111.946 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 51' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' J' ' 46' ' ' GLU . . . 145.78 158.25 7.63 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 121.158 -0.544 . . . . 7.67 113.651 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 52' ' ' ARG . . . . . 0.727 ' HB3' ' HB2' ' J' ' 45' ' ' ASP . 20.5 tpp85 -128.36 55.67 1.67 Allowed 'General case' 0 C--O 1.234 0.275 0 N-CA-C 106.695 -1.595 . . . . 20.54 106.695 175.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 53' ' ' ILE . . . . . 0.478 HG13 ' HD1' ' J' ' 44' ' ' PHE . 5.3 tt -70.95 -6.95 8.05 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 CA-C-N 115.333 -0.849 . . . . 31.89 112.019 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 54' ' ' LEU . . . . . 0.707 HD13 ' HD3' ' J' ' 52' ' ' ARG . 8.7 mp -55.68 -28.55 56.16 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 127.215 2.206 . . . . 57.08 114.328 -170.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 55' ' ' GLY . . . . . 0.739 ' HA3' ' HB2' ' J' ' 43' ' ' LEU . . . -64.81 125.37 30.46 Favored Glycine 0 N--CA 1.441 -0.976 0 CA-C-O 121.552 0.529 . . . . 16.57 114.206 -165.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 56' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.53 159.74 52.42 Favored 'Trans proline' 0 C--N 1.325 -0.675 0 C-N-CA 120.998 1.132 . . . . 16.57 110.225 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 57' ' ' GLY . . . . . 0.57 ' HA3' ' O ' ' J' ' 41' ' ' ARG . . . -131.45 170.86 21.35 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 109.209 -1.556 . . . . 32.98 109.209 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 58' ' ' SER . . . . . 0.424 ' HB3' ' NH2' ' J' ' 41' ' ' ARG . 44.7 t -73.36 149.68 42.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 119.76 -0.776 . . . . 13.43 109.903 175.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 59' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' J' ' 40' ' ' GLU . 3.0 p -104.42 121.69 56.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 108.254 -1.017 . . . . 16.57 108.254 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 60' ' ' ALA . . . . . . . . . . . . . . . -117.8 112.23 20.12 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.299 -1.741 . . . . 48.82 106.299 172.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 61' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -115.16 123.49 49.05 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.164 -1.05 . . . . 42.04 108.164 -171.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 62' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' J' ' 132' ' ' LEU . 68.3 m -111.13 162.29 15.07 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 10.82 110.509 -171.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 63' ' ' GLY . . . . . 0.628 ' HA2' ' O ' ' J' ' 35' ' ' GLY . . . -134.17 118.52 2.04 Favored Glycine 0 N--CA 1.443 -0.891 0 CA-C-N 115.109 -0.95 . . . . 16.57 112.296 177.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 64' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -99.14 96.72 7.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.096 -1.446 . . . . 39.72 107.096 172.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 65' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.0 116.89 52.44 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 108.333 -0.988 . . . . 16.57 108.333 -177.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 66' ' ' THR . . . . . 0.517 ' HA ' ' O ' ' J' ' 128' ' ' ILE . 52.7 p -115.07 142.32 46.8 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.871 -0.788 . . . . 17.36 108.871 176.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 67' ' ' TYR . . . . . 0.413 ' HE1' HD12 ' J' ' 130' ' ' ILE . 55.0 p90 -153.66 -171.43 3.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.398 0.618 . . . . 23.22 109.418 176.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 68' ' ' TYR . . . . . . . . . . . . . 16.3 m-30 -115.99 131.48 56.93 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 123.776 0.83 . . . . 11.2 109.271 178.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.67 113.73 3.76 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.909 -0.662 . . . . 10.64 114.5 -174.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 70' ' ' LYS . . . . . 0.476 ' O ' ' NE2' ' J' ' 76' ' ' GLN . 38.5 ttmt -85.92 151.07 24.05 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.803 -0.814 . . . . 23.57 108.803 175.366 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -68.75 -15.85 63.63 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 114.02 1.119 . . . . 34.46 114.02 -169.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.79 -138.26 4.75 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 110.132 -1.187 . . . . 16.57 110.132 175.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 t0 60.31 73.47 0.48 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.056 1.342 . . . . 5.12 111.319 167.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.18 9.95 0.04 OUTLIER 'General case' 0 C--O 1.235 0.322 0 N-CA-C 117.574 2.435 . . . . 22.96 117.574 -158.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.97 -42.93 97.1 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 120.31 -0.948 . . . . 14.79 112.711 170.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 76' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' J' ' 70' ' ' LYS . 21.4 pt20 -69.79 -23.54 63.36 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 119.791 -0.764 . . . . 46.19 111.785 173.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -70.39 -28.9 65.45 Favored 'General case' 0 CA--C 1.518 -0.271 0 C-N-CA 119.88 -0.728 . . . . 31.44 111.323 170.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.62 -32.2 65.75 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 120.461 -0.495 . . . . 22.59 111.354 171.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 79' ' ' ILE . . . . . . . . . . . . . 51.8 mm -64.21 -43.53 97.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 121.14 0.495 . . . . 8.31 110.426 173.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 80' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -73.05 -22.48 60.61 Favored 'General case' 0 C--O 1.235 0.29 0 O-C-N 121.89 -0.506 . . . . 26.08 112.0 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 81' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 -69.94 -33.3 71.96 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 120.315 -0.554 . . . . 33.88 111.298 168.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 82' ' ' ALA . . . . . 0.71 ' HA ' ' HB2' ' J' ' 87' ' ' LYS . . . -74.01 -36.5 64.49 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 119.466 -0.894 . . . . 8.74 111.64 175.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 83' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -83.92 -61.17 1.89 Allowed 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.146 -0.622 . . . . 10.35 112.004 -175.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -74.95 -40.6 60.69 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 111.794 0.294 . . . . 20.52 111.794 -167.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 85' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -77.84 -43.57 29.97 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 119.932 -0.707 . . . . 10.72 111.189 173.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 86' ' ' GLY . . . . . . . . . . . . . . . 107.94 96.48 2.45 Favored Glycine 0 N--CA 1.45 -0.397 0 O-C-N 122.302 -0.249 . . . . 8.38 113.344 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 87' ' ' LYS . . . . . 0.71 ' HB2' ' HA ' ' J' ' 82' ' ' ALA . 97.5 mttt -149.22 -161.41 1.34 Allowed 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 107.05 -1.463 . . . . 7.06 107.05 -178.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 88' ' ' GLN . . . . . 0.626 ' HG2' ' HD1' ' J' ' 112' ' ' TYR . 68.9 mt-30 -131.73 179.32 6.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.827 0.822 . . . . 13.19 111.146 167.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 89' ' ' ILE . . . . . 0.462 HD11 HD11 ' J' ' 113' ' ' ILE . 69.9 mt -129.25 134.82 63.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 115.089 -0.96 . . . . 13.03 109.682 -171.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 90' ' ' LYS . . . . . 0.476 ' NZ ' ' O ' ' J' ' 17' ' ' SER . 36.7 mtmm -84.59 116.27 23.07 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 108.402 -0.962 . . . . 12.63 108.402 164.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 91' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -110.95 134.47 52.55 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 124.374 1.07 . . . . 15.58 110.719 -166.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 92' ' ' TRP . . . . . 0.755 ' HB2' ' O ' ' J' ' 14' ' ' LEU . 92.9 m95 -131.94 128.99 39.66 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.093 0.957 . . . . 16.78 110.033 -174.049 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 93' ' ' ARG . . . . . 0.626 ' O ' ' HA ' ' J' ' 106' ' ' ALA . 78.7 ttt-85 -115.59 93.42 4.27 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 108.453 -0.943 . . . . 16.57 108.453 170.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 94' ' ' VAL . . . . . 0.524 HG12 ' HB2' ' J' ' 106' ' ' ALA . 20.1 m -107.26 163.1 5.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 122.208 1.004 . . . . 23.83 109.559 -174.318 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 95' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -107.36 156.9 18.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.869 -1.059 . . . . 13.8 110.966 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 96' ' ' THR . . . . . 0.48 HG23 HG23 ' J' ' 150' ' ' ILE . 27.9 m -93.59 -31.19 14.61 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.15 -0.932 . . . . 32.66 112.616 -177.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -70.07 153.01 8.8 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.817 0.817 . . . . 0.85 109.936 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 98' ' ' LYS . . . . . 0.457 ' NZ ' ' O ' ' J' ' 99' ' ' ASN . 29.6 tptp -87.37 129.39 35.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.593 -0.731 . . . . 16.28 109.758 -173.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 99' ' ' ASN . . . . . 0.457 ' O ' ' NZ ' ' J' ' 98' ' ' LYS . 35.0 m120 -92.3 173.47 7.79 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.766 0.793 . . . . 20.33 109.995 171.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 100' ' ' GLU . . . . . . . . . . . . . 58.1 mp0 -110.09 -15.09 14.1 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.633 0.975 . . . . 20.28 113.633 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 101' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -86.38 -58.85 2.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 118.245 0.475 . . . . 31.02 110.979 168.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 102' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -102.55 -176.69 3.18 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.806 -1.183 . . . . 34.34 107.806 170.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 103' ' ' LYS . . . . . 0.4 ' HG2' ' HE2' ' J' ' 98' ' ' LYS . 94.7 mttt -71.84 -60.5 2.2 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 118.982 -1.087 . . . . 34.4 110.356 163.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 104' ' ' TYR . . . . . . . . . . . . . 35.3 m-85 -128.58 -172.02 2.61 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.386 -0.968 . . . . 28.22 108.386 -175.045 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 105' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' J' ' 105' ' ' ASP . 16.1 p-10 -151.08 168.87 23.29 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.016 -0.735 . . . . 19.84 109.016 177.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 106' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' J' ' 93' ' ' ARG . . . -154.6 155.71 35.22 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.81 0.814 . . . . 0.01 111.259 -163.028 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 107' ' ' GLN . . . . . 0.451 ' OE1' ' OH ' ' K' ' 118' ' ' TYR . 88.0 mt-30 -113.01 122.68 48.34 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.619 -1.623 . . . . 27.88 106.619 158.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 108' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -111.38 153.21 26.37 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 123.825 0.85 . . . . 6.21 110.113 -165.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 109' ' ' GLY . . . . . . . . . . . . . . . -163.87 167.83 38.13 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.591 -1.29 . . . . 16.57 112.822 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 110' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -109.23 109.47 20.42 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.646 -0.777 . . . . 16.14 108.971 168.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.63 155.77 21.91 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.572 0.701 . . . . 46.11 111.778 -165.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 112' ' ' TYR . . . . . 0.626 ' HD1' ' HG2' ' J' ' 88' ' ' GLN . 71.7 t80 -134.26 137.93 44.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 114.326 -1.306 . . . . 15.97 107.552 178.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 113' ' ' ILE . . . . . 0.462 HD11 HD11 ' J' ' 89' ' ' ILE . 81.0 mt -84.66 128.37 39.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 N-CA-C 109.96 -0.385 . . . . 16.57 109.96 -169.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 114' ' ' GLU . . . . . 0.508 ' HB2' ' HB2' ' J' ' 131' ' ' SER . 98.2 mt-10 -71.1 -64.72 0.85 Allowed 'General case' 0 C--O 1.234 0.276 0 C-N-CA 119.871 -0.732 . . . . 18.82 110.601 164.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 115' ' ' SER . . . . . . . . . . . . . 72.2 m -142.38 151.16 41.59 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.567 0.698 . . . . 29.44 110.385 -168.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 116' ' ' ARG . . . . . . . . . . . . . 9.1 tmm_? -126.45 88.53 2.85 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 104.951 -2.24 . . . . 1.68 104.951 178.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 117' ' ' GLU . . . . . 0.528 ' O ' ' HB2' ' J' ' 129' ' ' SER . 98.6 mt-10 -111.88 110.14 20.32 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 107.353 -1.351 . . . . 28.53 107.353 -175.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 118' ' ' TYR . . . . . 0.464 ' OH ' ' OE1' ' I' ' 107' ' ' GLN . 18.5 p90 -116.72 143.5 45.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.491 0.662 . . . . 16.57 111.841 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 119' ' ' SER . . . . . . . . . . . . . 37.9 t -99.06 131.34 45.18 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.719 -1.128 . . . . 2.36 110.122 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 120' ' ' ASP . . . . . 0.644 ' HB3' ' HB2' ' I' ' 34' ' ' ASP . 59.2 t0 -109.13 97.77 7.33 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 106.376 -1.713 . . . . 34.5 106.376 172.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 121' ' ' GLY . . . . . . . . . . . . . . . -81.05 -161.15 25.91 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-O 121.82 0.678 . . . . 23.55 112.164 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 122' ' ' VAL . . . . . . . . . . . . . 92.0 t -115.1 -63.19 2.02 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 N-CA-C 108.701 -0.851 . . . . 1.58 108.701 178.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 123' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -96.23 -18.13 20.27 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.976 -0.556 . . . . 51.15 112.471 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 124' ' ' GLY . . . . . . . . . . . . . . . -92.0 157.59 24.35 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 109.587 -1.405 . . . . 24.72 109.587 163.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 125' ' ' ALA . . . . . . . . . . . . . . . -77.0 171.12 15.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.755 0.788 . . . . 25.97 110.35 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 126' ' ' VAL . . . . . 0.488 HG12 ' HA ' ' J' ' 120' ' ' ASP . 33.9 m -71.06 157.97 6.43 Favored 'Isoleucine or valine' 0 C--O 1.239 0.536 0 CA-C-N 115.37 -0.832 . . . . 18.77 109.713 -176.519 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 127' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -147.19 135.46 21.64 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.596 -0.52 . . . . 51.19 109.596 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 128' ' ' ILE . . . . . 0.517 ' O ' ' HA ' ' J' ' 66' ' ' THR . 87.8 mt -104.54 124.43 59.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 109.641 -0.503 . . . . 16.57 109.641 -176.187 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 129' ' ' SER . . . . . 0.528 ' HB2' ' O ' ' J' ' 117' ' ' GLU . 68.2 m -103.54 132.97 49.33 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.729 -0.841 . . . . 32.38 108.729 170.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 130' ' ' ILE . . . . . 0.413 HD12 ' HE1' ' J' ' 67' ' ' TYR . 82.1 mt -135.58 130.17 49.76 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 N-CA-C 108.681 -0.859 . . . . 16.57 108.681 -178.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 131' ' ' SER . . . . . 0.508 ' HB2' ' HB2' ' J' ' 114' ' ' GLU . 55.2 m -98.05 149.43 22.48 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-O 121.026 0.441 . . . . 22.33 110.087 175.697 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 132' ' ' LEU . . . . . 0.669 ' O ' ' HA ' ' J' ' 62' ' ' SER . 7.8 mp -133.84 144.27 48.85 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.03 -0.532 . . . . 15.49 110.544 -177.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 133' ' ' GLN . . . . . 0.555 HE21 HD11 ' I' ' 53' ' ' ILE . 29.8 mm100 -125.28 139.08 54.03 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.622 -0.881 . . . . 16.57 108.622 170.368 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 134' ' ' VAL . . . . . . . . . . . . . 8.8 p -135.95 149.37 27.76 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 108.91 -0.774 . . . . 18.73 108.91 177.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 135' ' ' ILE . . . . . . . . . . . . . 23.5 mm -62.46 -61.38 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.326 0 CA-C-O 121.299 0.571 . . . . 25.65 110.587 176.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.88 133.44 3.21 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.33 -0.708 . . . . 11.8 111.33 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 137' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -66.49 147.3 53.49 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 121.44 0.638 . . . . 27.02 110.675 177.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 138' ' ' LEU . . . . . . . . . . . . . 35.1 tp -133.9 130.95 38.52 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.099 -1.074 . . . . 11.71 108.099 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -83.03 81.02 8.86 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-O 122.398 1.094 . . . . 10.87 109.359 -171.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 140' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -102.74 83.02 2.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.195 -0.912 . . . . 9.06 108.984 -177.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.96 122.6 6.65 Favored Glycine 0 C--O 1.237 0.289 0 C-N-CA 119.984 -1.103 . . . . 23.97 110.439 173.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 142' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -132.1 -171.71 2.7 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 109.342 -0.614 . . . . 14.99 109.342 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 143' ' ' ILE . . . . . 0.432 ' H ' HG13 ' J' ' 143' ' ' ILE . 1.5 pp -112.78 -56.86 4.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.307 0 N-CA-C 113.575 0.954 . . . . 10.0 113.575 -167.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -87.48 124.97 34.01 Favored 'General case' 0 C--O 1.234 0.237 0 O-C-N 121.285 -0.884 . . . . 3.21 111.19 -172.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 145' ' ' THR . . . . . . . . . . . . . 70.6 p -119.91 18.5 12.51 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 112.553 0.575 . . . . 34.62 112.553 176.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 146' ' ' LEU . . . . . 0.457 ' HG ' ' HA ' ' J' ' 24' ' ' SER . 4.3 mm? 54.94 75.92 0.56 Allowed Pre-proline 0 C--O 1.237 0.411 0 C-N-CA 126.669 1.987 . . . . 11.85 110.782 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 147' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -68.81 69.69 1.15 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 N-CA-C 115.586 1.341 . . . . 7.26 115.586 -163.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 148' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -107.79 7.03 28.07 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 122.952 0.501 . . . . 8.3 111.614 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 149' ' ' GLU . . . . . . . . . . . . . 26.0 pm0 -138.19 7.19 2.63 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.515 0.561 . . . . 11.79 112.515 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 150' ' ' ILE . . . . . 0.48 HG23 HG23 ' J' ' 96' ' ' THR . 44.8 mm -113.87 -44.79 4.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 118.693 0.679 . . . . 9.62 111.061 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 151' ' ' VAL . . . . . . . . . . . . . 48.1 t -108.16 -32.19 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 108.275 -1.009 . . . . 13.45 108.275 -176.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 152' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -67.72 -30.63 70.17 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.35 -0.386 . . . . 18.54 111.821 -176.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -73.82 100.25 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.403 0 CA-C-O 122.165 0.983 . . . . 30.18 108.464 173.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 154' ' ' SER . . . . . . . . . . . . . 38.8 t -117.51 -59.13 1.97 Allowed 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.603 -0.726 . . . . 15.74 112.176 -174.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 155' ' ' LYS . . . . . 0.473 ' HG3' ' H ' ' J' ' 157' ' ' GLY . 5.5 tppp? -128.37 -36.93 1.86 Allowed 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 113.675 0.991 . . . . 22.03 113.675 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.57 -58.09 1.61 Allowed Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 110.118 -1.193 . . . . 33.79 110.118 -156.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 157' ' ' GLY . . . . . 0.473 ' H ' ' HG3' ' J' ' 155' ' ' LYS . . . -92.7 162.32 26.49 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.615 -0.802 . . . . 16.57 112.666 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 158' ' ' TYR . . . . . . . . . . . . . 20.2 m-30 -117.6 -172.84 2.31 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.085 1.354 . . . . 25.68 108.807 -178.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 159' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -79.2 -70.74 0.48 Allowed 'General case' 0 C--O 1.236 0.365 0 C-N-CA 118.827 -1.149 . . . . 14.21 112.436 -167.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 160' ' ' PHE . . . . . 0.535 ' HD2' ' HG3' ' J' ' 162' ' ' GLN . 30.2 p90 -176.72 160.49 1.94 Allowed 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.699 0.761 . . . . 11.17 109.0 -175.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 161' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.51 100.44 2.26 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 104.747 -2.316 . . . . 26.64 104.747 155.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 162' ' ' GLN . . . . . 0.535 ' HG3' ' HD2' ' J' ' 160' ' ' PHE . 88.6 mt-30 -72.82 -46.95 8.95 Favored Pre-proline 0 C--O 1.243 0.746 0 N-CA-C 113.985 1.105 . . . . 38.06 113.985 -161.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 163' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -75.72 -47.01 0.18 Allowed 'Trans proline' 0 C--N 1.365 1.396 0 CA-C-N 122.262 1.843 . . . . 18.11 112.936 174.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 164' ' ' GLY . . . . . 0.404 ' HA3' ' HG3' ' J' ' 175' ' ' PRO . . . -119.18 41.14 2.06 Favored Glycine 0 N--CA 1.448 -0.529 0 N-CA-C 116.323 1.289 . . . . 27.04 116.323 -161.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -64.62 -59.63 4.05 Favored 'General case' 0 C--O 1.238 0.481 0 C-N-CA 120.059 -0.656 . . . . 16.57 110.593 172.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 166' ' ' THR . . . . . . . . . . . . . 42.9 p 54.01 48.56 20.84 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.916 1.687 . . . . 35.56 111.697 174.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 167' ' ' THR . . . . . . . . . . . . . 2.5 m -133.85 160.53 37.37 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.069 -1.086 . . . . 11.29 108.069 -168.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 168' ' ' GLY . . . . . . . . . . . . . . . -80.66 -130.07 0.93 Allowed Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.165 -0.774 . . . . 24.38 111.165 172.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 169' ' ' GLU . . . . . . . . . . . . . 15.5 tm-20 -73.29 -62.25 1.54 Allowed 'General case' 0 C--O 1.235 0.313 0 C-N-CA 119.939 -0.705 . . . . 44.07 111.037 -178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.97 105.67 1.12 Allowed Pre-proline 0 C--O 1.235 0.333 0 C-N-CA 123.271 0.629 . . . . 6.94 109.592 -176.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 171' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.4 -172.39 1.48 Allowed 'Trans proline' 0 C--N 1.325 -0.694 0 C-N-CA 121.484 1.456 . . . . 20.44 112.04 -159.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 172' ' ' GLY . . . . . . . . . . . . . . . 81.83 64.82 1.7 Allowed Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 114.636 -1.165 . . . . 34.55 115.84 167.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 173' ' ' THR . . . . . . . . . . . . . 11.4 t -134.89 170.19 16.25 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.712 0.768 . . . . 6.52 109.192 168.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 174' ' ' VAL . . . . . . . . . . . . . 34.0 m -73.32 158.78 86.24 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-N 115.024 -0.989 . . . . 16.57 108.76 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 175' ' ' PRO . . . . . 0.404 ' HG3' ' HA3' ' J' ' 164' ' ' GLY . 56.9 Cg_exo -59.84 124.54 15.57 Favored 'Trans proline' 0 CA--C 1.516 -0.416 0 N-CA-C 109.754 -0.902 . . . . 11.96 109.754 164.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.312 0 C-N-CA 125.231 1.413 . . . . 26.47 110.506 -161.281 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 5' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' K' ' 6' ' ' ILE . 38.2 Cg_endo . . . . . 0 N--CA 1.466 -0.145 0 CA-C-O 119.791 -0.17 . . . . 1.86 112.304 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 6' ' ' ILE . . . . . 0.405 ' H ' ' HB2' ' K' ' 5' ' ' PRO . 93.9 mt -121.53 122.15 66.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 N-CA-C 107.99 -1.115 . . . . 6.36 107.99 178.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -90.57 170.17 10.41 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 121.866 0.841 . . . . 36.21 110.636 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.15 -11.44 63.94 Favored Glycine 0 C--N 1.333 0.412 0 CA-C-N 115.375 -0.829 . . . . 17.79 114.688 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 9' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -94.62 -14.16 25.21 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 117.833 0.817 . . . . 18.92 112.256 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 10' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -77.18 -4.71 46.0 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 113.711 1.004 . . . . 27.43 113.711 -171.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 11' ' ' VAL . . . . . . . . . . . . . 69.9 t -129.04 125.32 62.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 N-CA-C 107.829 -1.174 . . . . 27.14 107.829 -176.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 12' ' ' LYS . . . . . 0.466 ' NZ ' ' O ' ' K' ' 149' ' ' GLU . 53.6 mtmt -134.1 160.66 37.1 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.487 0.661 . . . . 4.73 110.077 176.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 13' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' K' ' 92' ' ' TRP . 18.8 m-30 -110.71 98.79 7.86 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.21 -1.033 . . . . 17.79 108.21 -167.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 14' ' ' LEU . . . . . 0.8 ' O ' ' HB2' ' K' ' 92' ' ' TRP . 95.7 mt -79.08 129.27 34.27 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 120.002 -0.679 . . . . 40.78 109.652 178.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 15' ' ' PHE . . . . . . . . . . . . . 21.9 m-30 -109.89 150.05 29.0 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.602 -0.518 . . . . 38.49 109.602 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 16' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -145.34 135.53 23.92 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 109.148 -0.686 . . . . 15.72 109.148 175.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 17' ' ' SER . . . . . . . . . . . . . 40.8 t -75.44 153.55 37.57 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.644 0.735 . . . . 10.6 111.013 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 18' ' ' ILE . . . . . . . . . . . . . 45.0 pt -78.63 -11.58 13.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.466 -0.788 . . . . 17.84 113.03 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 19' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -113.67 -12.22 12.85 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 112.638 0.607 . . . . 18.77 112.638 -173.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.15 -49.54 27.66 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 120.269 -0.573 . . . . 22.23 111.754 -172.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.63 48.03 22.52 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.91 1.284 . . . . 2.4 111.557 -171.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 22' ' ' THR . . . . . . . . . . . . . 69.7 p -127.19 123.83 37.57 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 108.656 -0.868 . . . . 29.53 108.656 177.159 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.37 75.42 2.21 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 121.25 -0.5 . . . . 0.36 113.254 -176.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 24' ' ' SER . . . . . 0.517 ' HA ' ' HG ' ' K' ' 146' ' ' LEU . 89.4 p -126.58 -29.13 2.94 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 120.868 -0.333 . . . . 21.79 111.332 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 25' ' ' ALA . . . . . 0.427 ' HB1' ' HB3' ' K' ' 14' ' ' LEU . . . 51.21 73.83 0.91 Allowed Pre-proline 0 C--O 1.237 0.411 0 C-N-CA 126.952 2.101 . . . . 16.71 112.281 -173.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 26' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -71.68 106.07 1.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 CA-C-N 119.498 0.856 . . . . 12.73 112.823 177.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 27' ' ' LEU . . . . . 0.765 ' HB3' HD23 ' K' ' 14' ' ' LEU . 2.0 pt? -79.98 161.45 25.46 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 119.731 -0.788 . . . . 8.0 108.987 163.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 28' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -107.58 132.0 21.31 Favored Pre-proline 0 N--CA 1.447 -0.617 1 C-N-CA 109.352 -4.939 . . . . 9.49 110.28 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.7 -174.64 1.55 Allowed 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 120.627 0.885 . . . . 18.54 114.309 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 51.56 60.71 3.66 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.591 1.156 . . . . 22.45 111.091 -169.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 31' ' ' TYR . . . . . 0.479 ' HD1' ' HA ' ' K' ' 31' ' ' TYR . 0.7 OUTLIER -69.24 160.83 30.46 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 122.846 1.307 . . . . 25.48 111.884 178.228 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' K' K ' 32' ' ' GLN . . . . . 0.459 ' HG3' ' H ' ' K' ' 33' ' ' THR . 7.7 tp-100 -136.94 -162.69 1.31 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 103.193 -2.891 . . . . 3.8 103.193 170.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 33' ' ' THR . . . . . 0.459 ' H ' ' HG3' ' K' ' 32' ' ' GLN . 15.3 t -65.25 162.05 18.12 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.68 1.228 . . . . 31.24 111.939 -172.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 34' ' ' ASP . . . . . 0.674 ' HB2' ' HB3' ' L' ' 120' ' ' ASP . 76.4 m-20 -132.18 -170.88 2.5 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.129 -1.396 . . . . 35.11 107.871 -166.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 35' ' ' GLY . . . . . 0.639 ' O ' ' HA2' ' K' ' 63' ' ' GLY . . . 171.59 134.79 1.83 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.141 -1.028 . . . . 16.59 112.512 170.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 36' ' ' SER . . . . . . . . . . . . . 66.6 m -128.03 84.71 2.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.107 -1.812 . . . . 15.91 106.107 175.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 37' ' ' VAL . . . . . 0.556 HG23 ' HB2' ' K' ' 62' ' ' SER . 3.5 m -91.79 110.52 22.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 108.46 -0.941 . . . . 12.48 108.46 -172.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 38' ' ' SER . . . . . . . . . . . . . 50.3 m -99.3 92.75 5.58 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.278 -1.008 . . . . 2.58 108.278 -166.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 39' ' ' GLY . . . . . . . . . . . . . . . -93.28 100.31 2.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.128 -1.034 . . . . 12.96 113.757 -176.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 40' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' K' ' 59' ' ' VAL . 80.9 tt0 -106.26 117.99 35.47 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.233 -1.025 . . . . 17.79 108.233 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 41' ' ' ARG . . . . . 0.628 ' O ' ' HA3' ' K' ' 57' ' ' GLY . 92.4 mtm-85 -77.37 -178.65 5.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.551 0.691 . . . . 43.35 109.746 -174.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 42' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -160.27 164.13 32.9 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 121.631 -0.668 . . . . 43.49 109.623 -174.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 43' ' ' LEU . . . . . 0.753 ' HB2' ' HA3' ' K' ' 55' ' ' GLY . 81.6 mt -106.81 111.93 24.67 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.161 -0.681 . . . . 10.89 109.161 172.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 44' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.89 113.4 25.94 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.104 -1.443 . . . . 14.63 107.104 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 45' ' ' ASP . . . . . 0.705 ' HB2' ' HB3' ' K' ' 52' ' ' ARG . 78.1 m-20 -127.0 175.91 7.74 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.299 -1.0 . . . . 12.5 108.299 -173.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 46' ' ' GLU . . . . . . . . . . . . . 58.7 mp0 -126.1 -40.29 2.01 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 114.323 1.231 . . . . 5.81 114.323 -166.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 47' ' ' GLN . . . . . 0.639 ' HB3' ' HA ' ' F' ' 30' ' ' ALA . 89.8 mm-40 66.65 20.17 10.76 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.532 1.133 . . . . 45.08 113.987 155.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 48' ' ' THR . . . . . . . . . . . . . 49.8 p 50.13 41.02 23.12 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.466 1.106 . . . . 37.36 110.945 -165.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 49' ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -139.46 -166.3 2.03 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.165 -1.42 . . . . 21.75 107.165 -175.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 50' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -72.91 -27.43 61.87 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 120.605 -0.438 . . . . 26.9 111.989 172.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.29 163.19 11.56 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 121.301 -0.476 . . . . 28.58 114.068 -177.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 52' ' ' ARG . . . . . 0.705 ' HB3' ' HB2' ' K' ' 45' ' ' ASP . 19.0 tpp85 -133.33 57.26 1.81 Allowed 'General case' 0 C--O 1.233 0.236 0 N-CA-C 107.928 -1.138 . . . . 16.54 107.928 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 53' ' ' ILE . . . . . 0.806 HD11 ' HB3' ' L' ' 133' ' ' GLN . 6.5 tt -66.44 -5.47 3.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 C-N-CA 124.937 1.295 . . . . 32.67 113.304 -177.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 54' ' ' LEU . . . . . 0.7 HD13 ' HD3' ' K' ' 52' ' ' ARG . 9.1 mp -61.33 -23.21 65.58 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 124.973 1.309 . . . . 55.76 113.604 -170.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 55' ' ' GLY . . . . . 0.753 ' HA3' ' HB2' ' K' ' 43' ' ' LEU . . . -67.07 119.69 12.32 Favored Glycine 0 N--CA 1.44 -1.037 0 CA-C-O 121.645 0.581 . . . . 15.39 114.097 -170.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 56' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.0 164.98 34.06 Favored 'Trans proline' 0 C--N 1.325 -0.67 0 C-N-CA 120.872 1.048 . . . . 17.79 109.753 171.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 57' ' ' GLY . . . . . 0.628 ' HA3' ' O ' ' K' ' 41' ' ' ARG . . . -132.04 168.14 22.59 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.11 -1.596 . . . . 41.74 109.11 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 58' ' ' SER . . . . . 0.437 ' HB3' ' NH2' ' K' ' 41' ' ' ARG . 44.0 t -72.8 148.34 44.64 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 119.672 -0.811 . . . . 25.75 109.591 173.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 59' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' K' ' 40' ' ' GLU . 2.9 p -105.46 122.5 58.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 N-CA-C 108.228 -1.027 . . . . 20.06 108.228 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.41 110.58 15.8 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 106.745 -1.576 . . . . 6.85 106.745 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 61' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -106.11 124.94 50.36 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.202 -1.036 . . . . 32.68 108.202 -175.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' K' ' 132' ' ' LEU . 69.8 m -107.08 163.19 13.2 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 124.19 0.996 . . . . 8.48 110.223 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 63' ' ' GLY . . . . . 0.639 ' HA2' ' O ' ' K' ' 35' ' ' GLY . . . -133.43 123.27 3.34 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 115.029 -0.987 . . . . 24.45 112.261 178.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 64' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -102.84 94.55 5.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.127 -1.434 . . . . 33.44 107.127 171.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 65' ' ' VAL . . . . . . . . . . . . . 91.1 t -107.39 115.63 49.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.123 -1.066 . . . . 17.79 108.123 -177.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 66' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' K' ' 128' ' ' ILE . 72.5 p -116.81 142.31 47.09 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.589 -0.523 . . . . 20.12 109.589 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 67' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -152.98 -170.81 3.74 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.16 -0.616 . . . . 16.83 109.469 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 68' ' ' TYR . . . . . . . . . . . . . 17.7 m-30 -115.59 131.99 56.76 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 123.787 0.835 . . . . 13.28 109.219 177.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.16 113.26 3.61 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.552 -0.833 . . . . 10.35 113.733 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 70' ' ' LYS . . . . . 0.497 ' O ' ' NE2' ' K' ' 76' ' ' GLN . 38.5 ttmt -86.9 151.5 23.26 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.683 -0.858 . . . . 10.83 108.683 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 71' ' ' ARG . . . . . . . . . . . . . 20.6 ptp180 -68.45 -14.93 63.34 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 114.141 1.163 . . . . 20.78 114.141 -169.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 72' ' ' GLY . . . . . . . . . . . . . . . -129.11 -136.79 4.18 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 110.062 -1.215 . . . . 35.33 110.062 176.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 73' ' ' ASP . . . . . . . . . . . . . 33.5 t0 60.0 72.93 0.5 Allowed 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 125.103 1.361 . . . . 2.85 111.12 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.64 9.63 0.06 Allowed 'General case' 0 C--O 1.234 0.275 0 N-CA-C 117.433 2.383 . . . . 36.88 117.433 -158.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.47 -41.09 96.95 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.303 -0.951 . . . . 23.98 112.62 170.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 76' ' ' GLN . . . . . 0.497 ' NE2' ' O ' ' K' ' 70' ' ' LYS . 22.0 pt20 -70.74 -23.21 62.39 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 119.81 -0.756 . . . . 17.8 111.847 173.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 77' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -70.95 -28.01 64.16 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 119.742 -0.783 . . . . 3.05 111.237 170.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.01 -30.93 64.14 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 120.571 -0.452 . . . . 14.34 111.346 170.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 79' ' ' ILE . . . . . . . . . . . . . 49.7 mm -64.52 -45.55 95.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-O 121.057 0.456 . . . . 9.04 110.425 172.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 80' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -73.93 -21.25 60.11 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 120.551 -0.459 . . . . 20.01 111.991 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 81' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -71.53 -31.54 67.15 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 120.088 -0.645 . . . . 22.01 111.331 168.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 82' ' ' ALA . . . . . 0.741 ' HA ' ' HB2' ' K' ' 87' ' ' LYS . . . -75.0 -32.56 61.68 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 119.554 -0.858 . . . . 11.58 111.565 175.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 83' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -91.39 -59.54 2.12 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 120.207 -0.597 . . . . 9.9 112.171 -174.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 84' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -74.28 -35.79 63.76 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.641 0.237 . . . . 19.13 111.641 -169.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 85' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -80.95 -44.29 18.45 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 119.984 -0.686 . . . . 18.79 111.207 171.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.12 97.07 2.48 Favored Glycine 0 N--CA 1.45 -0.413 0 O-C-N 122.266 -0.271 . . . . 8.25 113.414 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 87' ' ' LYS . . . . . 0.741 ' HB2' ' HA ' ' K' ' 82' ' ' ALA . 97.5 mttt -149.13 -161.57 1.37 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 107.122 -1.436 . . . . 5.98 107.122 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 88' ' ' GLN . . . . . 0.695 ' HG2' ' HD1' ' K' ' 112' ' ' TYR . 65.0 mt-30 -129.11 -179.04 4.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.78 0.8 . . . . 23.34 110.98 167.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 89' ' ' ILE . . . . . 0.48 HD11 HD11 ' K' ' 113' ' ' ILE . 58.3 mt -129.51 136.18 59.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-N 115.104 -0.953 . . . . 9.37 109.379 -173.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 90' ' ' LYS . . . . . 0.467 ' HD3' ' HG2' ' E' ' 165' ' ' GLN . 37.0 mtmm -84.8 117.77 24.05 Favored 'General case' 0 C--O 1.237 0.408 0 N-CA-C 108.213 -1.032 . . . . 22.17 108.213 163.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 91' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -112.98 134.96 54.26 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.934 0.894 . . . . 13.71 110.706 -165.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 92' ' ' TRP . . . . . 0.8 ' HB2' ' O ' ' K' ' 14' ' ' LEU . 91.7 m95 -132.54 130.39 40.31 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 124.06 0.944 . . . . 17.79 110.111 -174.087 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 93' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' K' ' 106' ' ' ALA . 78.5 ttt-85 -116.64 94.13 4.49 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 108.121 -1.066 . . . . 12.04 108.121 170.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 94' ' ' VAL . . . . . 0.484 HG12 ' HB2' ' K' ' 106' ' ' ALA . 22.5 m -106.94 163.48 5.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 122.183 0.992 . . . . 19.98 109.411 -174.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 95' ' ' ASP . . . . . . . . . . . . . 82.7 m-20 -107.99 162.85 13.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.961 -1.018 . . . . 20.83 110.92 177.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 96' ' ' THR . . . . . . . . . . . . . 28.9 m -97.72 -31.43 12.26 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 115.007 -0.997 . . . . 24.08 112.709 -175.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 97' ' ' VAL . . . . . . . . . . . . . 34.0 m -70.66 155.2 7.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-O 121.732 0.777 . . . . 21.68 110.15 -177.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 98' ' ' LYS . . . . . 0.566 ' NZ ' ' O ' ' K' ' 99' ' ' ASN . 29.5 tptp -87.16 127.21 35.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.696 -0.683 . . . . 25.88 109.551 -177.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 99' ' ' ASN . . . . . 0.566 ' O ' ' NZ ' ' K' ' 98' ' ' LYS . 34.6 m120 -89.95 171.79 9.33 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.795 0.807 . . . . 21.31 110.048 172.155 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 100' ' ' GLU . . . . . . . . . . . . . 57.3 mp0 -108.91 -17.57 13.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 113.681 0.993 . . . . 48.42 113.681 178.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 101' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -84.94 -51.31 6.8 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 122.991 0.517 . . . . 25.09 111.59 170.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 102' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -113.03 -173.51 2.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.298 -1.001 . . . . 38.34 108.298 169.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 103' ' ' LYS . . . . . 0.722 ' H ' HG22 ' K' ' 143' ' ' ILE . 97.6 mttt -75.81 -56.49 4.63 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.085 -0.646 . . . . 31.21 110.348 168.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 104' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -131.77 -171.15 2.54 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.403 -0.962 . . . . 26.81 108.403 -178.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 105' ' ' ASP . . . . . 0.407 ' N ' ' OD1' ' K' ' 105' ' ' ASP . 18.3 p-10 -151.9 163.85 38.35 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.497 0.665 . . . . 41.97 109.268 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 106' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' K' ' 93' ' ' ARG . . . -155.66 157.41 36.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.315 -0.857 . . . . 2.09 111.142 -162.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 107' ' ' GLN . . . . . 0.475 ' OE1' ' OH ' ' L' ' 118' ' ' TYR . 86.7 mt-30 -117.49 125.97 51.8 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.085 -1.45 . . . . 12.69 107.085 160.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 108' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -113.83 153.76 28.59 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.766 0.826 . . . . 17.09 110.319 -163.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 109' ' ' GLY . . . . . . . . . . . . . . . -164.01 168.79 38.65 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 119.615 -1.279 . . . . 5.68 112.685 174.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 110' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -110.79 110.71 21.46 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 108.807 -0.812 . . . . 13.37 108.807 168.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.75 157.58 19.62 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 121.625 0.726 . . . . 30.61 111.906 -165.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 112' ' ' TYR . . . . . 0.695 ' HD1' ' HG2' ' K' ' 88' ' ' GLN . 63.6 t80 -138.17 134.75 34.93 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.363 -1.289 . . . . 16.17 107.603 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 113' ' ' ILE . . . . . 0.48 HD11 HD11 ' K' ' 89' ' ' ILE . 77.9 mt -84.96 129.03 38.41 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.99 -0.374 . . . . 11.93 109.99 -169.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 114' ' ' GLU . . . . . 0.512 ' HB2' ' HB2' ' K' ' 131' ' ' SER . 98.2 mt-10 -72.39 -64.22 0.99 Allowed 'General case' 0 C--O 1.235 0.328 0 C-N-CA 120.029 -0.669 . . . . 49.87 110.598 164.54 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 115' ' ' SER . . . . . . . . . . . . . 75.6 m -141.2 151.35 43.72 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.72 0.772 . . . . 25.92 110.435 -169.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 116' ' ' ARG . . . . . . . . . . . . . 8.6 tmm_? -126.52 92.96 3.66 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 104.653 -2.351 . . . . 27.8 104.653 177.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 117' ' ' GLU . . . . . 0.555 ' HB3' HG12 ' J' ' 37' ' ' VAL . 98.1 mt-10 -116.8 110.23 18.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.61 -1.255 . . . . 39.69 107.61 -173.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 118' ' ' TYR . . . . . 0.47 ' HB3' ' HA ' ' K' ' 128' ' ' ILE . 13.9 p90 -115.29 145.09 42.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.634 0.731 . . . . 11.08 111.992 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 119' ' ' SER . . . . . . . . . . . . . 39.3 t -98.99 129.68 45.3 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 114.565 -1.198 . . . . 17.79 109.706 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 120' ' ' ASP . . . . . 0.665 ' HB3' ' HB2' ' J' ' 34' ' ' ASP . 59.1 t0 -108.6 97.21 6.9 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 106.234 -1.765 . . . . 41.37 106.234 172.21 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 121' ' ' GLY . . . . . . . . . . . . . . . -81.71 -156.88 17.8 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-O 121.823 0.679 . . . . 19.83 112.281 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 122' ' ' VAL . . . . . . . . . . . . . 96.8 t -118.22 -63.2 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.365 0 N-CA-C 108.177 -1.046 . . . . 11.45 108.177 176.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 123' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -95.54 -17.03 21.74 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 112.677 0.621 . . . . 37.48 112.677 -174.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.58 154.69 21.06 Favored Glycine 0 N--CA 1.452 -0.276 0 N-CA-C 109.532 -1.427 . . . . 3.5 109.532 164.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.35 169.33 18.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.721 0.772 . . . . 7.9 110.325 176.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 126' ' ' VAL . . . . . 0.591 HG12 ' HA ' ' K' ' 120' ' ' ASP . 34.7 m -70.44 155.08 7.78 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 CA-C-N 115.338 -0.846 . . . . 14.3 109.678 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 127' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -144.03 132.07 21.66 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 109.677 -0.49 . . . . 26.88 109.677 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 128' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' K' ' 66' ' ' THR . 88.4 mt -102.13 123.7 55.54 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 N-CA-C 109.291 -0.633 . . . . 17.79 109.291 -176.306 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 129' ' ' SER . . . . . 0.417 ' HB2' ' O ' ' K' ' 117' ' ' GLU . 69.8 m -102.03 133.57 46.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.496 -0.927 . . . . 24.52 108.496 170.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 130' ' ' ILE . . . . . . . . . . . . . 87.7 mt -134.68 128.54 50.92 Favored 'Isoleucine or valine' 0 C--O 1.237 0.443 0 N-CA-C 108.888 -0.782 . . . . 3.46 108.888 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 131' ' ' SER . . . . . 0.512 ' HB2' ' HB2' ' K' ' 114' ' ' GLU . 56.5 m -94.03 149.06 21.57 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.085 0.469 . . . . 23.2 109.974 175.015 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 132' ' ' LEU . . . . . 0.62 ' O ' ' HA ' ' K' ' 62' ' ' SER . 7.4 mp -133.96 147.07 50.99 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.162 -0.472 . . . . 11.15 110.352 -178.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 133' ' ' GLN . . . . . 0.578 ' NE2' ' OG ' ' K' ' 62' ' ' SER . 90.9 mm-40 -131.04 133.11 45.41 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.882 -0.784 . . . . 17.79 108.882 174.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 134' ' ' VAL . . . . . . . . . . . . . 14.2 p -134.16 145.0 33.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 N-CA-C 109.039 -0.726 . . . . 3.93 109.039 177.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 135' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.65 -58.16 8.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.91 -0.586 . . . . 34.35 110.763 175.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 136' ' ' GLY . . . . . . . . . . . . . . . -156.05 132.45 3.35 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.014 -1.088 . . . . 0.12 112.314 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 137' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -66.64 150.13 49.49 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.435 0.636 . . . . 30.04 110.337 173.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 138' ' ' LEU . . . . . . . . . . . . . 31.4 tp -138.39 130.24 28.14 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.057 -1.09 . . . . 8.19 108.057 -178.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -83.42 80.24 9.16 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-O 122.357 1.075 . . . . 11.43 109.353 -171.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 140' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -99.95 81.14 2.39 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 122.009 0.909 . . . . 20.28 108.673 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.22 112.69 3.99 Favored Glycine 0 C--O 1.237 0.333 0 N-CA-C 110.329 -1.108 . . . . 21.45 110.329 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 142' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -123.42 -171.64 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.224 -0.658 . . . . 26.87 109.224 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 143' ' ' ILE . . . . . 0.722 HG22 ' H ' ' K' ' 103' ' ' LYS . 1.4 pp -116.99 -60.08 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 113.345 0.868 . . . . 19.36 113.345 -169.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 144' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -82.95 125.6 31.57 Favored 'General case' 0 C--O 1.233 0.22 0 O-C-N 121.411 -0.806 . . . . 14.69 111.159 -171.033 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 145' ' ' THR . . . . . . . . . . . . . 75.5 p -120.53 15.49 12.01 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 112.642 0.608 . . . . 27.11 112.642 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 146' ' ' LEU . . . . . 0.517 ' HG ' ' HA ' ' K' ' 24' ' ' SER . 4.2 mm? 54.55 76.42 0.52 Allowed Pre-proline 0 C--N 1.345 0.406 0 C-N-CA 126.54 1.936 . . . . 26.22 110.88 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 147' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_exo -68.38 72.72 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 N-CA-C 115.435 1.283 . . . . 17.79 115.435 -162.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 148' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -107.09 5.32 27.83 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 123.092 0.557 . . . . 32.62 111.569 167.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 149' ' ' GLU . . . . . 0.466 ' O ' ' NZ ' ' K' ' 12' ' ' LYS . 25.9 pm0 -139.98 5.8 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 112.885 0.698 . . . . 8.29 112.885 -176.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 150' ' ' ILE . . . . . . . . . . . . . 44.1 mm -111.56 -48.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.857 0.753 . . . . 15.81 111.093 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 151' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.93 -28.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 107.483 -1.303 . . . . 6.41 107.483 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 152' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -67.82 -30.07 69.39 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 116.08 -0.509 . . . . 28.39 111.72 -177.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -73.59 100.4 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.378 0 N-CA-C 108.107 -1.072 . . . . 17.79 108.107 172.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 154' ' ' SER . . . . . . . . . . . . . 39.0 t -117.9 -58.38 2.02 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.395 -0.82 . . . . 20.41 111.88 -173.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 155' ' ' LYS . . . . . 0.404 ' HG3' ' H ' ' K' ' 157' ' ' GLY . 16.4 tppt? -127.85 -34.68 2.15 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 124.047 0.939 . . . . 23.96 113.408 178.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.25 -57.99 1.43 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 109.9 -1.28 . . . . 33.75 109.9 -157.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 157' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' K' ' 155' ' ' LYS . . . -97.31 177.46 32.29 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-O 122.037 0.798 . . . . 17.79 112.475 177.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 158' ' ' TYR . . . . . . . . . . . . . 20.2 m-30 -115.8 -172.22 2.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.336 1.055 . . . . 8.06 109.463 -178.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 159' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -79.19 -68.45 0.66 Allowed 'General case' 0 C--O 1.236 0.355 0 C-N-CA 119.55 -0.86 . . . . 22.64 111.85 -172.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 160' ' ' PHE . . . . . 0.476 ' HD2' ' HG3' ' K' ' 162' ' ' GLN . 34.5 p90 -175.85 159.31 2.22 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 108.72 -0.845 . . . . 15.75 108.72 -176.147 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 161' ' ' GLN . . . . . . . . . . . . . 65.9 tt0 -153.32 100.14 2.42 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 105.29 -2.115 . . . . 32.7 105.29 154.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 162' ' ' GLN . . . . . 0.476 ' HG3' ' HD2' ' K' ' 160' ' ' PHE . 85.6 mt-30 -74.33 -45.4 6.03 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 117.927 -1.035 . . . . 25.37 113.705 -163.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 163' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -76.18 -46.09 0.19 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 CA-C-N 122.204 1.823 . . . . 28.41 113.704 173.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 164' ' ' GLY . . . . . . . . . . . . . . . -120.35 39.41 2.45 Favored Glycine 0 N--CA 1.449 -0.451 0 N-CA-C 116.666 1.426 . . . . 17.56 116.666 -160.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 165' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -66.47 -62.31 1.53 Allowed 'General case' 0 C--O 1.238 0.468 0 C-N-CA 120.025 -0.67 . . . . 25.1 110.799 173.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 166' ' ' THR . . . . . . . . . . . . . 42.0 p 53.1 50.46 17.78 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 125.901 1.68 . . . . 29.05 111.7 177.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 167' ' ' THR . . . . . . . . . . . . . 1.7 m -138.0 164.54 28.8 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.046 -1.094 . . . . 1.89 108.046 -169.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.98 -126.53 1.32 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.1 -0.8 . . . . 15.93 111.1 173.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -72.69 -61.91 1.64 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 120.404 -0.519 . . . . 40.51 111.036 -178.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.68 105.21 0.76 Allowed Pre-proline 0 C--O 1.235 0.335 0 C-N-CA 124.026 0.93 . . . . 19.75 109.605 -175.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 171' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -84.52 -173.85 1.63 Allowed 'Trans proline' 0 C--N 1.322 -0.834 0 C-N-CA 121.262 1.308 . . . . 0.27 111.791 -159.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 172' ' ' GLY . . . . . . . . . . . . . . . 76.55 66.71 1.79 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 114.544 -1.207 . . . . 37.09 115.429 166.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 173' ' ' THR . . . . . . . . . . . . . 7.2 t -139.36 166.77 23.67 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.74 0.781 . . . . 40.25 109.363 169.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 174' ' ' VAL . . . . . . . . . . . . . 28.5 m -71.64 156.67 91.01 Favored Pre-proline 0 C--O 1.241 0.617 0 CA-C-N 114.964 -1.017 . . . . 0.0 109.103 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 175' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -62.21 122.04 10.32 Favored 'Trans proline' 0 C--N 1.349 0.597 0 CA-C-N 119.245 0.766 . . . . 25.62 110.692 169.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.303 0 C-N-CA 125.514 1.526 . . . . 20.35 110.384 -165.253 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 5' ' ' PRO . . . . . 0.415 ' HB2' ' H ' ' L' ' 6' ' ' ILE . 37.3 Cg_endo . . . . . 0 N--CA 1.465 -0.157 0 CA-C-O 119.607 -0.247 . . . . 20.92 112.408 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 6' ' ' ILE . . . . . 0.415 ' H ' ' HB2' ' L' ' 5' ' ' PRO . 96.5 mt -123.55 121.82 63.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.99 -1.115 . . . . 41.64 107.99 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -91.47 170.55 9.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.935 0.874 . . . . 39.84 110.799 -176.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.19 -9.88 64.63 Favored Glycine 0 C--N 1.334 0.42 0 CA-C-N 115.403 -0.817 . . . . 17.3 114.719 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 9' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -94.87 -14.95 24.09 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 117.883 0.842 . . . . 17.3 112.291 172.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 10' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -76.12 -7.03 53.84 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 113.739 1.014 . . . . 23.45 113.739 -170.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 11' ' ' VAL . . . . . . . . . . . . . 66.3 t -127.11 125.33 66.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 N-CA-C 107.917 -1.142 . . . . 11.79 107.917 -176.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 12' ' ' LYS . . . . . 0.412 ' NZ ' ' O ' ' L' ' 149' ' ' GLU . 53.6 mtmt -134.93 161.19 35.96 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.502 0.668 . . . . 14.38 110.011 176.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 13' ' ' TYR . . . . . 0.522 ' HA ' ' O ' ' L' ' 92' ' ' TRP . 18.6 m-30 -112.15 95.47 5.48 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.215 -1.031 . . . . 17.3 108.215 -166.59 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 14' ' ' LEU . . . . . 0.86 ' O ' ' HB2' ' L' ' 92' ' ' TRP . 98.0 mt -74.78 131.2 40.61 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 120.246 -0.582 . . . . 57.33 109.56 176.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 15' ' ' PHE . . . . . . . . . . . . . 22.0 m-30 -112.41 151.61 29.63 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.64 -0.504 . . . . 23.7 109.64 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 16' ' ' GLN . . . . . . . . . . . . . 71.6 tp60 -145.14 136.24 24.85 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 109.291 -0.633 . . . . 17.64 109.291 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 40.1 t -75.61 155.53 35.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 121.614 0.721 . . . . 7.08 111.175 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 18' ' ' ILE . . . . . . . . . . . . . 44.5 pt -79.27 -11.9 13.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.4 0 CA-C-N 115.425 -0.807 . . . . 16.92 113.102 178.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -112.33 -11.75 13.65 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 112.661 0.615 . . . . 23.23 112.661 -170.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.45 -47.0 24.5 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 119.965 -0.694 . . . . 21.18 111.87 -170.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.18 45.12 29.28 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.887 1.275 . . . . 17.3 111.399 -168.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 22' ' ' THR . . . . . . . . . . . . . 69.3 p -123.95 121.3 34.93 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 108.979 -0.748 . . . . 38.78 108.979 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.16 76.59 2.14 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 116.264 -0.425 . . . . 17.3 113.758 -176.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 24' ' ' SER . . . . . 0.481 ' HA ' ' HG ' ' L' ' 146' ' ' LEU . 92.4 p -128.84 -26.64 2.64 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 120.373 -0.531 . . . . 14.69 111.469 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 25' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' L' ' 14' ' ' LEU . . . 51.31 74.38 0.81 Allowed Pre-proline 0 C--O 1.237 0.395 0 C-N-CA 127.01 2.124 . . . . 61.95 112.099 -172.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 26' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -71.68 105.74 1.84 Allowed 'Trans proline' 0 C--N 1.345 0.381 0 CA-C-N 119.4 0.821 . . . . 17.3 112.633 177.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 27' ' ' LEU . . . . . 0.792 ' HB3' HD23 ' L' ' 14' ' ' LEU . 2.2 pt? -81.55 155.86 25.52 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.13 -0.693 . . . . 5.96 109.13 165.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.1 t80 -101.61 130.06 25.43 Favored Pre-proline 0 N--CA 1.446 -0.64 1 C-N-CA 109.56 -4.856 . . . . 6.24 110.173 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 29' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.9 -173.58 1.27 Allowed 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 120.638 0.892 . . . . 11.84 114.248 -175.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . 53.42 60.23 3.85 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.769 1.228 . . . . 9.15 111.048 -172.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 31' ' ' TYR . . . . . 0.423 ' HD1' ' HA ' ' L' ' 31' ' ' TYR . 1.0 OUTLIER -70.44 163.22 27.19 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 122.934 1.349 . . . . 22.48 111.948 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 32' ' ' GLN . . . . . 0.461 ' HG3' ' H ' ' L' ' 33' ' ' THR . 7.8 tp-100 -136.43 -161.85 1.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 103.146 -2.909 . . . . 4.98 103.146 169.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 33' ' ' THR . . . . . 0.461 ' H ' ' HG3' ' L' ' 32' ' ' GLN . 15.1 t -65.9 164.73 14.39 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 122.557 1.17 . . . . 29.35 112.066 -174.12 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 34' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' G' ' 120' ' ' ASP . 84.0 m-20 -135.28 -169.24 2.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.061 -1.427 . . . . 48.33 108.26 -167.218 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 35' ' ' GLY . . . . . 0.628 ' O ' ' HA2' ' L' ' 63' ' ' GLY . . . 171.25 135.35 1.91 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.896 -0.669 . . . . 4.76 111.745 170.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 36' ' ' SER . . . . . . . . . . . . . 66.1 m -127.32 84.63 2.28 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.015 -1.846 . . . . 17.3 106.015 175.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 37' ' ' VAL . . . . . 0.54 HG23 ' HB2' ' L' ' 62' ' ' SER . 3.6 m -91.9 110.73 23.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.513 -0.921 . . . . 4.17 108.513 -171.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 38' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' G' ' 83' ' ' TYR . 51.0 m -100.47 84.09 2.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.335 -0.987 . . . . 22.2 108.335 -167.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 39' ' ' GLY . . . . . . . . . . . . . . . -88.09 99.63 2.53 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.769 -0.729 . . . . 32.58 113.177 -177.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 40' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' L' ' 59' ' ' VAL . 80.8 tt0 -101.95 124.65 47.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.067 -1.086 . . . . 2.66 108.067 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 41' ' ' ARG . . . . . 0.801 ' O ' ' HA3' ' L' ' 57' ' ' GLY . 93.0 mtm-85 -79.01 -178.49 6.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.449 0.642 . . . . 27.56 109.581 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 42' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -162.52 163.85 27.23 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.425 -0.583 . . . . 24.15 109.425 -175.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 43' ' ' LEU . . . . . 0.768 ' HB2' ' HA3' ' L' ' 55' ' ' GLY . 77.8 mt -106.99 112.53 25.53 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.069 -0.715 . . . . 11.23 109.069 171.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 44' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -117.07 112.09 20.43 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 107.569 -1.271 . . . . 17.12 107.569 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 45' ' ' ASP . . . . . 0.53 ' HB2' ' HB3' ' L' ' 52' ' ' ARG . 79.0 m-20 -127.51 -173.83 3.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.971 -0.751 . . . . 23.32 108.971 -172.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 46' ' ' GLU . . . . . . . . . . . . . 58.5 mp0 -127.3 -40.95 1.78 Allowed 'General case' 0 C--O 1.233 0.233 0 N-CA-C 114.68 1.363 . . . . 7.0 114.68 -169.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 47' ' ' GLN . . . . . 0.74 ' HB3' ' HA ' ' A' ' 30' ' ' ALA . 92.0 mm-40 65.29 21.69 12.03 Favored 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 124.788 1.235 . . . . 50.57 114.046 161.016 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 50.6 p 50.8 39.58 22.52 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.487 1.115 . . . . 9.03 110.941 -165.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 49' ' ' LYS . . . . . . . . . . . . . 45.4 mmtm -139.83 -165.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 106.957 -1.497 . . . . 16.79 106.957 -174.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 50' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -72.38 -30.38 64.63 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 120.594 -0.442 . . . . 44.69 112.066 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 157.03 166.68 16.99 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 121.058 -0.591 . . . . 16.23 114.553 -178.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 52' ' ' ARG . . . . . 0.598 ' HD3' HD13 ' L' ' 54' ' ' LEU . 17.7 tpp85 -133.74 57.06 1.82 Allowed 'General case' 0 C--O 1.234 0.24 0 N-CA-C 108.243 -1.021 . . . . 17.3 108.243 -178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 53' ' ' ILE . . . . . 0.767 HD11 ' HB3' ' G' ' 133' ' ' GLN . 7.8 tt -69.4 -3.9 3.32 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 C-N-CA 124.442 1.097 . . . . 32.26 113.084 -177.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 54' ' ' LEU . . . . . 0.598 HD13 ' HD3' ' L' ' 52' ' ' ARG . 7.9 mp -59.43 -24.91 63.9 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.295 1.038 . . . . 60.18 113.339 -176.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 55' ' ' GLY . . . . . 0.768 ' HA3' ' HB2' ' L' ' 43' ' ' LEU . . . -66.7 118.74 11.03 Favored Glycine 0 N--CA 1.44 -1.094 0 CA-C-O 121.64 0.578 . . . . 17.3 113.905 -172.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 56' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.36 173.8 13.61 Favored 'Trans proline' 0 C--N 1.326 -0.624 0 C-N-CA 120.773 0.982 . . . . 17.3 109.844 172.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 57' ' ' GLY . . . . . 0.801 ' HA3' ' O ' ' L' ' 41' ' ' ARG . . . -136.18 166.14 24.76 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 109.466 -1.454 . . . . 34.45 109.466 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 58' ' ' SER . . . . . 0.419 ' HB3' ' NH2' ' L' ' 41' ' ' ARG . 42.5 t -74.76 143.67 43.97 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 119.711 -0.796 . . . . 12.73 109.658 172.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 59' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' L' ' 40' ' ' GLU . 2.2 p -96.29 111.55 26.71 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.482 -0.932 . . . . 33.1 108.482 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 60' ' ' ALA . . . . . . . . . . . . . . . -109.34 112.74 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.82 -1.548 . . . . 49.86 106.82 174.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 61' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -118.1 120.64 38.38 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.692 -0.855 . . . . 40.56 108.692 -169.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 62' ' ' SER . . . . . 0.54 ' HB2' HG23 ' L' ' 37' ' ' VAL . 65.3 m -108.8 168.47 9.32 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 124.025 0.93 . . . . 17.3 110.604 -174.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 63' ' ' GLY . . . . . 0.628 ' HA2' ' O ' ' L' ' 35' ' ' GLY . . . -140.07 128.29 3.83 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 114.983 -1.008 . . . . 17.3 113.041 177.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 64' ' ' GLU . . . . . 0.467 ' O ' ' HA ' ' L' ' 34' ' ' ASP . 66.0 mm-40 -106.04 97.06 6.92 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.524 -1.287 . . . . 31.63 107.524 172.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.18 115.93 49.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 N-CA-C 108.303 -0.999 . . . . 17.3 108.303 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 66' ' ' THR . . . . . 0.46 ' HA ' ' O ' ' L' ' 128' ' ' ILE . 63.6 p -116.91 142.47 46.89 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.354 -0.61 . . . . 3.14 109.354 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 67' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -152.92 -170.47 3.64 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.41 0.624 . . . . 12.33 109.392 177.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 68' ' ' TYR . . . . . . . . . . . . . 15.5 m-30 -115.7 134.29 55.18 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.734 0.814 . . . . 20.66 109.518 178.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.73 113.51 3.65 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.788 -0.72 . . . . 17.3 113.771 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 70' ' ' LYS . . . . . 0.494 ' O ' ' NE2' ' L' ' 76' ' ' GLN . 38.4 ttmt -89.29 147.76 23.93 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.824 -0.806 . . . . 19.57 108.824 174.195 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -66.92 -16.38 64.29 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.099 1.148 . . . . 38.0 114.099 -169.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.33 -138.52 4.86 Favored Glycine 0 N--CA 1.451 -0.327 0 N-CA-C 109.927 -1.269 . . . . 17.3 109.927 175.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 73' ' ' ASP . . . . . . . . . . . . . 32.8 t0 59.74 72.83 0.51 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 125.089 1.356 . . . . 18.16 111.16 168.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.97 9.58 0.07 Allowed 'General case' 0 C--O 1.235 0.31 0 N-CA-C 117.28 2.326 . . . . 58.55 117.28 -158.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.36 97.04 Favored Glycine 0 C--N 1.337 0.612 0 C-N-CA 120.302 -0.951 . . . . 17.3 112.663 170.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 76' ' ' GLN . . . . . 0.494 ' NE2' ' O ' ' L' ' 70' ' ' LYS . 21.9 pt20 -71.15 -23.53 62.09 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 119.578 -0.849 . . . . 44.87 111.291 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 77' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -70.38 -28.7 65.3 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 119.865 -0.734 . . . . 17.3 111.299 170.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.91 -31.11 64.43 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 120.417 -0.513 . . . . 31.28 111.34 171.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 79' ' ' ILE . . . . . . . . . . . . . 49.5 mm -64.78 -44.77 96.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-O 121.052 0.453 . . . . 34.0 110.421 173.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -72.76 -22.65 60.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 121.915 -0.491 . . . . 27.04 111.947 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 81' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -69.34 -34.96 75.41 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.258 -0.577 . . . . 21.24 111.415 168.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 82' ' ' ALA . . . . . 0.705 ' HA ' ' HB2' ' L' ' 87' ' ' LYS . . . -74.07 -33.68 63.76 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 119.417 -0.913 . . . . 15.07 111.629 176.318 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 83' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -83.25 -62.21 1.65 Allowed 'General case' 0 C--O 1.235 0.318 0 C-N-CA 120.404 -0.518 . . . . 7.64 112.053 -176.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 84' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -75.39 -38.03 60.19 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 111.722 0.268 . . . . 25.28 111.722 -165.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 85' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -77.18 -43.11 35.02 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 119.886 -0.726 . . . . 7.3 111.045 171.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 86' ' ' GLY . . . . . . . . . . . . . . . 107.8 96.33 2.44 Favored Glycine 0 N--CA 1.45 -0.404 0 O-C-N 122.256 -0.277 . . . . 23.56 113.361 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 87' ' ' LYS . . . . . 0.705 ' HB2' ' HA ' ' L' ' 82' ' ' ALA . 98.0 mttt -148.88 -162.26 1.52 Allowed 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.067 -1.457 . . . . 6.04 107.067 -177.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 88' ' ' GLN . . . . . 0.719 ' HG2' ' HD1' ' L' ' 112' ' ' TYR . 65.4 mt-30 -128.64 178.0 6.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.721 0.772 . . . . 10.54 110.875 167.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 89' ' ' ILE . . . . . 0.484 HD11 HD11 ' L' ' 113' ' ' ILE . 57.4 mt -128.46 137.05 58.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.244 -0.889 . . . . 17.3 109.282 -173.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 90' ' ' LYS . . . . . 0.497 ' HD3' ' HG2' ' F' ' 165' ' ' GLN . 36.6 mtmm -84.99 118.34 24.51 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.498 -0.927 . . . . 18.93 108.498 164.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 91' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -111.96 133.76 53.94 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 124.434 1.094 . . . . 28.15 110.718 -166.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 92' ' ' TRP . . . . . 0.86 ' HB2' ' O ' ' L' ' 14' ' ' LEU . 89.8 m95 -132.63 125.5 30.52 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 10.58 109.971 -173.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 93' ' ' ARG . . . . . 0.61 ' O ' ' HA ' ' L' ' 106' ' ' ALA . 78.7 ttt-85 -111.91 90.35 3.31 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.067 -1.086 . . . . 11.86 108.067 171.175 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 94' ' ' VAL . . . . . 0.473 HG12 ' HB2' ' L' ' 106' ' ' ALA . 20.2 m -104.89 165.03 3.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 CA-C-O 122.07 0.938 . . . . 14.71 109.295 -174.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 95' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -110.5 168.97 9.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.132 -0.94 . . . . 25.49 111.501 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 96' ' ' THR . . . . . 0.409 HG23 HG23 ' L' ' 150' ' ' ILE . 29.8 m -102.03 -32.58 10.09 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.877 -1.056 . . . . 34.22 112.803 -175.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 97' ' ' VAL . . . . . . . . . . . . . 34.4 m -70.42 155.69 7.5 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.767 0.794 . . . . 17.33 110.244 -177.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 98' ' ' LYS . . . . . 0.524 ' NZ ' ' O ' ' L' ' 99' ' ' ASN . 29.6 tptp -89.19 125.43 35.06 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.696 -0.684 . . . . 14.09 109.683 -178.002 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 99' ' ' ASN . . . . . 0.524 ' O ' ' NZ ' ' L' ' 98' ' ' LYS . 35.3 m120 -86.52 171.22 11.23 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.749 0.785 . . . . 22.14 109.994 171.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 100' ' ' GLU . . . . . . . . . . . . . 57.1 mp0 -107.3 -14.38 14.9 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 113.762 1.023 . . . . 21.13 113.762 178.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 101' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -89.84 -52.18 5.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 118.186 0.448 . . . . 14.65 111.488 170.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 102' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -110.79 -173.55 2.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.355 -0.98 . . . . 44.12 108.355 170.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 103' ' ' LYS . . . . . 0.674 ' H ' HG22 ' L' ' 143' ' ' ILE . 96.7 mttt -79.04 -54.8 5.65 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 120.095 -0.642 . . . . 39.88 110.395 170.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 104' ' ' TYR . . . . . . . . . . . . . 71.2 m-85 -132.0 -170.35 2.39 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 108.774 -0.824 . . . . 27.29 108.774 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 105' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' L' ' 105' ' ' ASP . 15.8 p-10 -152.95 165.22 36.19 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 109.139 -0.689 . . . . 43.34 109.139 177.26 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 106' ' ' ALA . . . . . 0.61 ' HA ' ' O ' ' L' ' 93' ' ' ARG . . . -157.69 154.81 28.89 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.274 -0.875 . . . . 5.32 111.095 -163.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 107' ' ' GLN . . . . . 0.441 ' OE1' ' OH ' ' G' ' 118' ' ' TYR . 87.9 mt-30 -114.08 125.07 53.57 Favored 'General case' 0 C--O 1.235 0.33 0 N-CA-C 106.896 -1.52 . . . . 20.11 106.896 159.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 108' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -112.68 154.66 25.76 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 123.657 0.783 . . . . 17.3 110.197 -164.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 109' ' ' GLY . . . . . . . . . . . . . . . -166.17 167.64 39.43 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 119.405 -1.378 . . . . 17.3 112.684 174.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 110' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -108.53 110.82 22.4 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.626 -0.787 . . . . 40.16 108.957 168.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 111' ' ' ALA . . . . . . . . . . . . . . . -109.06 156.56 19.64 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 121.598 0.713 . . . . 33.53 111.76 -165.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 112' ' ' TYR . . . . . 0.719 ' HD1' ' HG2' ' L' ' 88' ' ' GLN . 52.8 t80 -137.6 136.92 37.98 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.135 -1.432 . . . . 14.99 107.135 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 113' ' ' ILE . . . . . 0.484 HD11 HD11 ' L' ' 89' ' ' ILE . 75.6 mt -87.18 129.46 38.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 109.869 -0.419 . . . . 7.44 109.869 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 114' ' ' GLU . . . . . 0.53 ' HB2' ' HB2' ' L' ' 131' ' ' SER . 98.7 mt-10 -73.1 -64.77 0.9 Allowed 'General case' 0 C--O 1.235 0.328 0 C-N-CA 119.906 -0.718 . . . . 49.45 110.584 164.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 115' ' ' SER . . . . . . . . . . . . . 74.4 m -140.56 149.33 42.26 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.676 0.751 . . . . 8.08 110.365 -170.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -122.59 89.71 3.16 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 104.425 -2.435 . . . . 16.25 104.425 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 117' ' ' GLU . . . . . 0.539 ' HB3' HG12 ' K' ' 37' ' ' VAL . 98.3 mt-10 -112.75 108.38 17.36 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 107.639 -1.245 . . . . 30.17 107.639 -174.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 118' ' ' TYR . . . . . 0.508 ' HB3' ' HA ' ' L' ' 128' ' ' ILE . 12.4 p90 -113.74 144.56 42.75 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.534 0.683 . . . . 22.45 112.056 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 36.9 t -99.8 126.94 45.96 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.67 -1.15 . . . . 17.3 109.877 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 120' ' ' ASP . . . . . 0.674 ' HB3' ' HB2' ' K' ' 34' ' ' ASP . 59.7 t0 -100.4 97.93 8.62 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 106.115 -1.809 . . . . 15.87 106.115 168.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 121' ' ' GLY . . . . . . . . . . . . . . . -79.19 -158.2 13.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-O 121.92 0.733 . . . . 12.55 112.483 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 122' ' ' VAL . . . . . . . . . . . . . 66.4 t -116.37 -62.91 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 N-CA-C 108.314 -0.995 . . . . 29.86 108.314 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 123' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.11 -18.22 14.62 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.64 0.607 . . . . 47.61 112.64 -174.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 124' ' ' GLY . . . . . . . . . . . . . . . -86.8 154.83 27.21 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 109.221 -1.552 . . . . 24.42 109.221 161.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.97 168.85 19.16 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 119.709 -0.797 . . . . 6.84 110.335 176.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 126' ' ' VAL . . . . . 0.584 HG12 ' HA ' ' L' ' 120' ' ' ASP . 34.7 m -69.41 153.56 8.73 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 CA-C-N 115.347 -0.842 . . . . 17.3 109.556 -177.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 127' ' ' GLU . . . . . . . . . . . . . 21.9 pt-20 -143.88 133.26 23.29 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.723 -0.473 . . . . 35.39 109.723 -178.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 128' ' ' ILE . . . . . 0.508 ' HA ' ' HB3' ' L' ' 118' ' ' TYR . 86.5 mt -102.61 123.32 55.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 109.376 -0.602 . . . . 17.3 109.376 -176.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 129' ' ' SER . . . . . 0.494 ' HB2' ' O ' ' L' ' 117' ' ' GLU . 68.8 m -102.54 132.78 48.38 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.55 -0.907 . . . . 24.95 108.55 171.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 130' ' ' ILE . . . . . . . . . . . . . 85.0 mt -134.96 128.31 49.64 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 108.873 -0.788 . . . . 17.3 108.873 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 131' ' ' SER . . . . . 0.53 ' HB2' ' HB2' ' L' ' 114' ' ' GLU . 60.1 m -93.83 147.27 23.23 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.109 -0.496 . . . . 17.3 110.011 175.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 132' ' ' LEU . . . . . 0.51 ' O ' ' HA ' ' L' ' 62' ' ' SER . 7.0 mp -131.39 152.4 50.67 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 116.057 -0.519 . . . . 34.95 110.236 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 133' ' ' GLN . . . . . 0.806 ' HB3' HD11 ' K' ' 53' ' ' ILE . 20.6 mm100 -141.78 125.99 17.48 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.791 0.836 . . . . 17.3 109.454 -177.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 134' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.83 147.06 28.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 109.322 -0.622 . . . . 8.43 109.322 -177.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 135' ' ' ILE . . . . . . . . . . . . . 24.3 mm -62.46 -60.34 2.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 116.004 -0.544 . . . . 6.85 110.796 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 136' ' ' GLY . . . . . . . . . . . . . . . -158.64 137.36 5.18 Favored Glycine 0 N--CA 1.443 -0.854 0 N-CA-C 111.343 -0.703 . . . . 17.3 111.343 -178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 137' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -67.35 155.69 38.31 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 121.387 0.613 . . . . 29.67 110.22 175.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 138' ' ' LEU . . . . . . . . . . . . . 30.8 tp -140.59 128.61 22.06 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.87 -1.159 . . . . 12.51 107.87 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -83.72 76.64 9.97 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 122.391 1.091 . . . . 17.3 109.344 -170.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 140' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -94.07 83.14 4.25 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.105 -0.952 . . . . 37.97 108.558 -178.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.18 108.16 2.41 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.093 -1.051 . . . . 30.13 110.479 175.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.65 -172.66 2.42 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.23 -0.655 . . . . 18.3 109.23 -174.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 143' ' ' ILE . . . . . 0.674 HG22 ' H ' ' L' ' 103' ' ' LYS . 1.5 pp -117.82 -59.12 3.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 113.344 0.868 . . . . 28.55 113.344 -170.006 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -86.34 129.5 34.83 Favored 'General case' 0 C--N 1.33 -0.254 0 O-C-N 121.326 -0.859 . . . . 17.67 111.385 -169.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 145' ' ' THR . . . . . . . . . . . . . 71.7 p -121.91 11.94 10.41 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 112.691 0.626 . . . . 21.73 112.691 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 146' ' ' LEU . . . . . 0.481 ' HG ' ' HA ' ' L' ' 24' ' ' SER . 4.1 mm? 54.29 75.77 0.58 Allowed Pre-proline 0 C--O 1.237 0.413 0 C-N-CA 126.753 2.021 . . . . 17.3 110.135 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 147' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -68.76 74.56 0.88 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 N-CA-C 115.585 1.34 . . . . 5.55 115.585 -160.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 148' ' ' GLU . . . . . 0.461 ' OE1' ' ND2' ' L' ' 152' ' ' ASN . 80.2 mm-40 -105.3 8.69 33.91 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 116.032 -0.531 . . . . 32.81 111.632 166.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 149' ' ' GLU . . . . . 0.412 ' O ' ' NZ ' ' L' ' 12' ' ' LYS . 25.9 pm0 -140.07 4.81 2.08 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 112.883 0.697 . . . . 23.49 112.883 -176.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 150' ' ' ILE . . . . . 0.409 HG23 HG23 ' L' ' 96' ' ' THR . 43.9 mm -111.98 -47.65 5.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.88 0.763 . . . . 28.28 111.061 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 151' ' ' VAL . . . . . . . . . . . . . 45.0 t -105.87 -29.32 2.74 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.538 -1.282 . . . . 19.43 107.538 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 152' ' ' ASN . . . . . 0.461 ' ND2' ' OE1' ' L' ' 148' ' ' GLU . 37.8 t-20 -68.5 -31.5 70.8 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 116.046 -0.524 . . . . 17.3 111.719 -176.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -73.88 99.65 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.775 -1.194 . . . . 9.42 107.775 172.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 154' ' ' SER . . . . . . . . . . . . . 37.1 t -117.56 -58.73 2.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.232 -0.895 . . . . 37.02 111.747 -172.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 155' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -128.66 -29.94 2.34 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 123.887 0.875 . . . . 26.06 113.057 176.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.64 -60.72 1.48 Allowed Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.236 -1.146 . . . . 41.56 110.236 -160.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 157' ' ' GLY . . . . . . . . . . . . . . . -96.52 172.8 29.18 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-O 121.985 0.769 . . . . 17.3 112.237 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 158' ' ' TYR . . . . . 0.447 ' HB2' ' HG2' ' L' ' 171' ' ' PRO . 13.6 m-30 -113.92 -173.4 2.27 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.401 0.68 . . . . 14.35 110.311 -177.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -79.08 -67.7 0.73 Allowed 'General case' 0 C--O 1.236 0.37 0 C-N-CA 119.849 -0.741 . . . . 46.38 111.921 -167.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 160' ' ' PHE . . . . . 0.474 ' HD2' ' HG3' ' L' ' 162' ' ' GLN . 37.4 p90 -175.85 157.83 2.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 108.618 -0.882 . . . . 18.94 108.618 -175.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 161' ' ' GLN . . . . . . . . . . . . . 65.9 tt0 -153.08 98.85 2.34 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 104.802 -2.296 . . . . 27.82 104.802 154.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 162' ' ' GLN . . . . . 0.474 ' HG3' ' HD2' ' L' ' 160' ' ' PHE . 86.2 mt-30 -74.51 -46.18 5.68 Favored Pre-proline 0 C--O 1.241 0.624 0 CA-C-O 117.981 -1.009 . . . . 23.74 113.7 -159.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 163' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -77.55 -46.14 0.14 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 CA-C-N 122.092 1.783 . . . . 7.47 113.759 171.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 164' ' ' GLY . . . . . . . . . . . . . . . -113.76 39.51 2.8 Favored Glycine 0 N--CA 1.449 -0.441 0 N-CA-C 116.278 1.271 . . . . 48.82 116.278 -160.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -68.02 -63.13 1.12 Allowed 'General case' 0 C--O 1.238 0.473 0 C-N-CA 120.335 -0.546 . . . . 15.69 110.8 176.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 166' ' ' THR . . . . . . . . . . . . . 33.7 p 53.12 51.52 15.52 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.88 1.672 . . . . 15.26 111.765 176.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 1.6 m -136.22 168.45 19.39 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 107.721 -1.214 . . . . 5.64 107.721 -169.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.94 -125.49 1.19 Allowed Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.256 -1.137 . . . . 4.6 110.256 172.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -76.81 -62.11 1.75 Allowed 'General case' 0 C--O 1.235 0.317 0 C-N-CA 119.789 -0.765 . . . . 30.03 110.979 -178.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.81 106.07 1.04 Allowed Pre-proline 0 C--O 1.236 0.376 0 C-N-CA 123.834 0.854 . . . . 3.8 109.685 -176.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 171' ' ' PRO . . . . . 0.447 ' HG2' ' HB2' ' L' ' 158' ' ' TYR . 69.5 Cg_endo -83.56 -172.96 1.47 Allowed 'Trans proline' 0 C--N 1.324 -0.738 0 C-N-CA 121.392 1.395 . . . . 32.06 111.782 -159.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 172' ' ' GLY . . . . . . . . . . . . . . . 80.52 64.63 1.81 Allowed Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 114.596 -1.184 . . . . 46.27 114.905 167.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 173' ' ' THR . . . . . . . . . . . . . 9.5 t -135.67 168.84 18.53 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.707 0.765 . . . . 45.85 109.227 170.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 174' ' ' VAL . . . . . . . . . . . . . 28.8 m -70.97 154.4 94.23 Favored Pre-proline 0 C--O 1.242 0.665 0 CA-C-N 114.994 -1.003 . . . . 1.04 108.654 178.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 175' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -63.03 111.01 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 CA-C-N 119.31 0.789 . . . . 17.34 111.007 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.2 0 C-N-CA 125.483 1.513 . . . . 20.79 110.993 -163.491 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.491 ' HB2' ' H ' ' A' ' 6' ' ' ILE . 43.9 Cg_endo . . . . . 0 N--CA 1.465 -0.158 0 N-CA-C 112.428 0.126 . . . . 13.51 112.428 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.491 ' H ' ' HB2' ' A' ' 5' ' ' PRO . 96.8 mt -121.61 119.82 59.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 N-CA-C 108.013 -1.106 . . . . 9.13 108.013 178.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -85.7 169.04 13.83 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.927 0.87 . . . . 42.11 110.698 -177.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.04 -11.39 66.81 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.394 -0.821 . . . . 17.08 114.363 175.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -95.14 -15.26 23.47 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 117.644 0.722 . . . . 17.08 112.175 171.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -77.23 -2.83 36.63 Favored 'General case' 0 CA--C 1.519 -0.24 0 N-CA-C 114.095 1.146 . . . . 27.35 114.095 -171.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.0 123.19 61.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-N 119.701 1.137 . . . . 17.08 108.231 -177.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.02 163.34 29.45 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.553 0.692 . . . . 28.68 110.008 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.405 ' CE1' ' HG3' ' A' ' 93' ' ' ARG . 19.2 m-30 -114.03 97.68 6.52 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.095 -0.957 . . . . 17.08 108.511 -165.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.812 HD23 ' HB3' ' A' ' 27' ' ' LEU . 96.7 mt -73.14 123.84 24.42 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 109.843 -0.428 . . . . 37.84 109.843 175.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.1 m-30 -107.96 152.97 23.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.148 0.499 . . . . 15.37 109.917 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 67.3 tp60 -147.1 134.91 21.22 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.152 -0.684 . . . . 19.81 109.152 174.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.1 t -74.93 155.25 37.64 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.601 0.715 . . . . 17.08 110.812 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -76.61 -13.28 14.55 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 N-CA-C 113.275 0.842 . . . . 2.05 113.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -113.81 -7.16 13.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 112.736 0.643 . . . . 37.16 112.736 -169.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.34 -46.49 32.88 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 119.703 -0.799 . . . . 27.54 111.514 -176.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.77 43.28 31.6 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.91 1.284 . . . . 12.24 111.382 -170.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 70.8 p -119.91 125.13 47.72 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.41 0.684 . . . . 6.83 109.243 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.46 75.31 2.32 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 121.44 -0.409 . . . . 16.1 113.424 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.6 p -131.52 -27.18 1.97 Allowed 'General case' 0 C--O 1.235 0.338 0 C-N-CA 120.595 -0.442 . . . . 44.72 111.699 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.25 74.39 0.81 Allowed Pre-proline 0 C--O 1.236 0.382 0 C-N-CA 127.029 2.132 . . . . 31.44 112.434 -173.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -72.26 104.49 1.69 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 CA-C-N 119.637 0.906 . . . . 11.57 112.332 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.812 ' HB3' HD23 ' A' ' 14' ' ' LEU . 2.1 pt? -78.98 163.98 24.76 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.038 -0.727 . . . . 7.34 109.038 167.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 32.7 t80 -102.55 136.9 19.27 Favored Pre-proline 0 C--N 1.314 -0.966 1 C-N-CA 110.707 -4.397 . . . . 9.9 110.11 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -77.36 178.59 7.43 Favored 'Trans proline' 0 C--O 1.234 0.276 0 CA-C-N 118.655 0.555 . . . . 36.59 112.534 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.74 ' HA ' ' HB3' ' L' ' 47' ' ' GLN . . . 57.16 57.91 4.25 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.472 1.109 . . . . 21.0 112.035 178.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 1.8 m-30 -73.39 -176.71 2.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 122.901 1.334 . . . . 47.9 112.348 -179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.46 ' HG3' ' H ' ' A' ' 33' ' ' THR . 7.6 tp-100 -148.85 -159.56 1.05 Allowed 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 103.4 -2.815 . . . . 15.2 103.4 169.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.46 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 13.3 t -66.77 164.19 17.68 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 122.604 1.193 . . . . 24.62 111.673 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.485 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 84.1 m-20 -135.11 -170.51 2.59 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.12 -1.4 . . . . 37.7 108.296 -170.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.697 ' O ' ' HA2' ' A' ' 63' ' ' GLY . . . 176.79 132.73 1.69 Allowed Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.482 -0.781 . . . . 3.83 111.203 169.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 69.1 m -121.58 84.59 2.27 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 106.154 -1.795 . . . . 7.36 106.154 176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.56 HG23 ' HB2' ' A' ' 62' ' ' SER . 4.0 m -90.36 110.1 21.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 108.563 -0.902 . . . . 11.35 108.563 -172.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.7 m -98.76 94.77 6.79 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 107.912 -1.144 . . . . 19.64 107.912 -171.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -96.94 102.64 2.78 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.329 -0.938 . . . . 16.28 113.645 -177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -108.67 123.92 49.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.684 -0.858 . . . . 11.62 108.684 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.597 ' O ' ' HA3' ' A' ' 57' ' ' GLY . 88.8 mtm-85 -83.27 -173.29 4.63 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.151 -0.685 . . . . 43.29 109.151 -178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -158.62 141.56 14.62 Favored 'General case' 0 C--N 1.329 -0.322 0 O-C-N 121.756 -0.59 . . . . 29.65 110.179 -170.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.26 113.4 5.84 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 108.772 -0.825 . . . . 9.61 108.772 174.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.448 ' HD1' HG13 ' A' ' 53' ' ' ILE . 83.6 t80 -124.46 106.32 10.1 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.65 -0.5 . . . . 38.63 109.65 -171.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -132.11 -170.3 2.39 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 123.186 0.594 . . . . 31.64 110.922 175.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.662 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . 56.4 mp0 -125.28 -37.69 2.37 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 113.633 0.975 . . . . 8.59 113.633 177.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLN . . . . . . . . . . . . . 76.0 mm-40 59.4 32.93 22.15 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 125.14 1.376 . . . . 39.63 112.462 172.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.1 p 52.64 38.9 27.25 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.28 1.432 . . . . 17.08 111.705 -171.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -138.43 -165.15 1.76 Allowed 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.552 -1.277 . . . . 29.24 107.552 -176.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -67.2 -23.31 65.73 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 112.267 0.469 . . . . 28.94 112.267 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.662 ' HA2' ' HA ' ' A' ' 46' ' ' GLU . . . 143.38 164.81 10.46 Favored Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.308 -0.717 . . . . 30.47 111.308 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 18.3 tpp85 -125.09 52.07 1.62 Allowed 'General case' 0 C--O 1.235 0.296 0 N-CA-C 105.577 -2.008 . . . . 7.53 105.577 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.798 HD11 HE21 ' B' ' 133' ' ' GLN . 6.1 tt -73.08 -11.53 14.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 CA-C-N 114.939 -1.028 . . . . 40.72 111.805 -169.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.622 HD23 HE22 ' B' ' 88' ' ' GLN . 7.7 mp -71.18 -16.12 62.51 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 123.173 0.589 . . . . 41.04 112.477 -172.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.38 143.12 38.48 Favored Glycine 0 N--CA 1.443 -0.838 0 CA-C-O 121.462 0.479 . . . . 26.7 114.104 -172.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -77.67 178.91 7.03 Favored 'Trans proline' 0 C--N 1.326 -0.636 0 C-N-CA 121.25 1.3 . . . . 9.15 111.787 -176.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.597 ' HA3' ' O ' ' A' ' 41' ' ' ARG . . . -150.68 174.72 29.94 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 109.584 -1.406 . . . . 43.79 109.584 177.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 47.8 t -75.78 144.77 41.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.668 0.747 . . . . 2.52 110.333 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 2.3 p -101.84 117.55 47.32 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 108.68 -0.859 . . . . 23.56 108.68 -177.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -116.06 110.9 19.53 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 107.045 -1.465 . . . . 17.08 107.045 174.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -110.85 120.89 43.89 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.812 -0.81 . . . . 64.91 108.812 -172.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.718 ' HA ' ' O ' ' A' ' 132' ' ' LEU . 69.6 m -109.4 168.93 9.03 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 124.767 1.227 . . . . 11.55 110.411 -176.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.697 ' HA2' ' O ' ' A' ' 35' ' ' GLY . . . -147.33 125.27 2.12 Favored Glycine 0 N--CA 1.443 -0.842 0 CA-C-N 115.142 -0.935 . . . . 17.08 112.564 177.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 65.9 mm-40 -101.73 99.31 9.55 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.355 -1.35 . . . . 49.67 107.355 172.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 97.2 t -106.33 120.66 57.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 108.19 -1.041 . . . . 0.32 108.19 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 68.5 p -115.88 147.33 41.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.435 -0.58 . . . . 17.08 109.435 177.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . 0.445 ' HE1' HD12 ' A' ' 130' ' ' ILE . 53.1 p90 -156.41 -174.1 4.79 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 108.585 -0.894 . . . . 2.35 108.585 175.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.7 m-30 -116.04 140.48 49.23 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 176.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.21 116.56 4.24 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 116.097 -0.501 . . . . 17.08 114.318 -175.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.447 ' O ' ' NE2' ' A' ' 76' ' ' GLN . 38.9 ttmt -92.0 148.98 21.79 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.185 -0.672 . . . . 1.74 109.185 175.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . . . . . . . . . 21.0 ptp180 -69.11 -17.21 63.82 Favored 'General case' 0 C--O 1.234 0.275 0 N-CA-C 114.008 1.114 . . . . 30.37 114.008 -169.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.85 -143.08 5.75 Favored Glycine 0 N--CA 1.452 -0.284 0 N-CA-C 109.891 -1.284 . . . . 20.89 109.891 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.1 t0 60.0 74.23 0.45 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 124.915 1.286 . . . . 37.95 111.123 167.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.04 10.76 0.05 Allowed 'General case' 0 C--O 1.234 0.276 0 N-CA-C 117.227 2.306 . . . . 25.19 117.227 -161.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.8 -40.25 94.81 Favored Glycine 0 C--N 1.338 0.643 0 C-N-CA 120.407 -0.902 . . . . 30.35 112.776 170.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.447 ' NE2' ' O ' ' A' ' 70' ' ' LYS . 21.8 pt20 -68.7 -24.56 64.51 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 119.999 -0.68 . . . . 11.83 111.811 172.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 61.6 mttp -73.79 -23.81 59.74 Favored 'General case' 0 CA--C 1.517 -0.31 0 C-N-CA 119.758 -0.777 . . . . 12.64 111.301 172.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.12 -31.7 61.2 Favored 'General case' 0 C--O 1.239 0.542 0 C-N-CA 120.617 -0.433 . . . . 17.68 111.157 169.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 51.9 mm -62.97 -42.82 98.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 121.134 0.493 . . . . 30.14 110.282 171.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -75.66 -22.74 56.47 Favored 'General case' 0 C--O 1.234 0.263 0 O-C-N 121.875 -0.515 . . . . 17.44 112.085 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -70.52 -31.68 68.85 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 120.146 -0.621 . . . . 42.54 111.167 169.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.775 ' HA ' ' HB2' ' A' ' 87' ' ' LYS . . . -74.84 -35.55 62.39 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 119.435 -0.906 . . . . 7.59 111.572 174.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -83.51 -63.05 1.43 Allowed 'General case' 0 C--O 1.236 0.36 0 C-N-CA 120.256 -0.578 . . . . 17.08 112.111 -175.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -76.43 -42.61 43.5 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 111.93 0.344 . . . . 23.14 111.93 -166.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -72.25 -41.45 66.76 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 119.998 -0.681 . . . . 31.74 111.001 172.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.26 96.68 2.45 Favored Glycine 0 N--CA 1.449 -0.499 0 O-C-N 122.27 -0.269 . . . . 5.81 113.224 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.775 ' HB2' ' HA ' ' A' ' 82' ' ' ALA . 98.5 mttt -148.14 -161.82 1.42 Allowed 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 106.887 -1.523 . . . . 17.08 106.887 -179.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.704 HE22 HD23 ' F' ' 54' ' ' LEU . 87.3 mt-30 -129.08 176.8 7.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.392 0.615 . . . . 17.08 109.662 171.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 113' ' ' ILE . 78.9 mt -129.61 132.41 66.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.117 -0.492 . . . . 29.53 109.866 -173.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 36.4 mtmm -82.96 120.38 25.63 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 108.424 -0.954 . . . . 22.16 108.424 166.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.521 ' HB3' ' O ' ' A' ' 109' ' ' GLY . 88.7 t80 -117.69 127.58 54.06 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 124.42 1.088 . . . . 16.4 110.106 -165.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' TRP . . . . . 0.536 ' HB2' ' HB2' ' A' ' 14' ' ' LEU . 91.3 m95 -128.72 128.79 44.74 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 123.838 0.855 . . . . 13.22 108.929 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.806 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 78.4 ttt-85 -110.97 96.02 5.9 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.284 -1.006 . . . . 25.99 108.284 173.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.57 HG12 ' HB2' ' A' ' 106' ' ' ALA . 27.0 m -109.24 161.19 7.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 122.341 1.067 . . . . 35.9 109.813 -172.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -105.19 165.41 11.12 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 114.71 -1.132 . . . . 16.18 110.951 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.484 HG23 HG23 ' A' ' 150' ' ' ILE . 33.2 m -98.79 -29.68 12.85 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.024 -0.989 . . . . 17.0 112.437 -177.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 35.4 m -68.88 154.94 8.03 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 CA-C-O 121.756 0.788 . . . . 17.08 110.191 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.435 ' NZ ' ' O ' ' A' ' 99' ' ' ASN . 29.2 tptp -91.07 119.28 31.09 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.67 -0.695 . . . . 34.86 109.761 -176.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.435 ' O ' ' NZ ' ' A' ' 98' ' ' LYS . 35.1 m120 -78.83 168.56 19.54 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-O 121.844 0.83 . . . . 18.72 109.9 171.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -105.48 -11.37 16.44 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.684 0.994 . . . . 15.36 113.684 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -93.28 -49.91 5.73 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 118.221 0.464 . . . . 14.89 111.532 168.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -109.77 -176.8 3.1 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 108.642 -0.873 . . . . 22.87 108.642 173.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.67 ' H ' HG22 ' A' ' 143' ' ' ILE . 97.0 mttt -75.64 -57.09 4.09 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 120.221 -0.592 . . . . 47.87 110.112 168.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -133.47 -171.46 2.71 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 107.771 -1.196 . . . . 28.57 107.771 -178.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.519 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 21.8 p-10 -149.67 169.18 21.61 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.529 0.68 . . . . 38.21 109.498 176.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.806 ' HA ' ' O ' ' A' ' 93' ' ' ARG . . . -153.1 160.34 42.9 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.258 -0.883 . . . . 2.53 111.315 -162.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.433 ' OE1' ' OH ' ' B' ' 118' ' ' TYR . 88.0 mt-30 -119.07 122.43 42.11 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 106.994 -1.484 . . . . 12.91 106.994 159.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.418 ' HB3' ' O ' ' A' ' 138' ' ' LEU . 85.7 t80 -109.47 150.72 27.7 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.132 0.973 . . . . 23.1 110.286 -164.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . 0.521 ' O ' ' HB3' ' A' ' 91' ' ' PHE . . . -172.84 153.05 17.67 Favored Glycine 0 C--N 1.333 0.379 0 C-N-CA 119.483 -1.342 . . . . 15.91 112.73 174.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -93.41 108.97 20.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 108.967 -0.753 . . . . 2.09 108.967 170.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -112.24 162.02 15.95 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 121.52 0.676 . . . . 31.23 111.738 -167.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 69.5 t80 -137.99 140.87 40.4 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.591 -1.186 . . . . 17.94 107.842 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 89' ' ' ILE . 78.1 mt -87.15 130.32 37.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.823 -0.436 . . . . 17.08 109.823 -171.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.536 ' HB2' ' HB2' ' A' ' 131' ' ' SER . 98.0 mt-10 -73.12 -64.21 1.02 Allowed 'General case' 0 C--O 1.236 0.355 0 C-N-CA 119.816 -0.754 . . . . 25.56 110.742 164.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 74.7 m -142.05 149.61 40.17 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-O 121.7 0.762 . . . . 4.65 110.379 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 8.7 tmm_? -123.61 94.53 4.27 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 104.856 -2.276 . . . . 4.84 104.856 176.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.524 ' HB3' HG12 ' F' ' 37' ' ' VAL . 97.6 mt-10 -115.52 107.33 15.01 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.637 -1.245 . . . . 25.07 107.637 -175.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.538 ' HB3' ' HA ' ' A' ' 128' ' ' ILE . 19.7 p90 -113.05 144.58 42.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.556 0.693 . . . . 17.08 112.056 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . . . . . . . . . 35.2 t -100.25 130.98 46.44 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 114.606 -1.179 . . . . 17.08 109.885 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.642 ' HB3' ' HB2' ' F' ' 34' ' ' ASP . 59.5 t0 -106.63 98.56 8.21 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 106.278 -1.749 . . . . 44.34 106.278 169.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.56 -157.87 22.91 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 121.685 0.603 . . . . 4.06 111.828 176.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.45 -62.66 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 108.141 -1.059 . . . . 22.24 108.141 176.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -85.44 -40.08 16.81 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 113.112 0.782 . . . . 64.97 113.112 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.549 ' HA2' HD21 ' L' ' 43' ' ' LEU . . . -74.12 149.71 41.32 Favored Glycine 0 N--CA 1.452 -0.261 0 N-CA-C 109.875 -1.29 . . . . 17.06 109.875 172.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.91 168.37 19.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.752 0.787 . . . . 17.08 110.163 175.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.637 HG12 ' HA ' ' A' ' 120' ' ' ASP . 30.5 m -68.93 146.19 12.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-N 115.138 -0.937 . . . . 17.08 109.878 -176.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -136.22 125.0 23.92 Favored 'General case' 0 CA--C 1.518 -0.269 0 CA-C-N 116.302 -0.408 . . . . 21.27 110.304 -176.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.538 ' HA ' ' HB3' ' A' ' 118' ' ' TYR . 86.6 mt -95.25 120.89 45.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 N-CA-C 109.359 -0.608 . . . . 17.08 109.359 -177.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . 0.488 ' HB2' ' O ' ' A' ' 117' ' ' GLU . 67.4 m -100.84 135.6 42.04 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.422 -0.955 . . . . 31.38 108.422 170.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.445 HD12 ' HE1' ' A' ' 67' ' ' TYR . 65.2 mt -137.88 129.37 38.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.406 0 N-CA-C 108.958 -0.756 . . . . 17.08 108.958 -177.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' SER . . . . . 0.536 ' HB2' ' HB2' ' A' ' 114' ' ' GLU . 58.4 m -95.86 151.7 19.16 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 121.054 0.454 . . . . 31.17 110.255 175.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.718 ' O ' ' HA ' ' A' ' 62' ' ' SER . 6.9 mp -135.87 139.64 43.52 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.198 -0.456 . . . . 54.41 111.144 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.623 HE21 HD11 ' F' ' 53' ' ' ILE . 30.1 mm100 -120.67 137.22 54.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.546 -0.909 . . . . 17.08 108.546 170.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 11.4 p -136.69 148.57 26.81 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 N-CA-C 108.508 -0.923 . . . . 9.66 108.508 175.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 18.5 mm -59.58 -59.34 4.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-O 121.304 0.574 . . . . 16.44 110.848 176.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -165.26 141.74 7.24 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 109.649 -1.38 . . . . 8.58 109.649 -177.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -69.61 155.17 40.91 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.618 0.723 . . . . 15.49 110.531 179.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 108' ' ' PHE . 33.2 tp -140.65 125.76 18.5 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.033 -1.469 . . . . 6.31 107.033 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -85.08 67.67 10.27 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 122.289 1.042 . . . . 20.25 109.871 -169.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -88.24 74.69 8.69 Favored 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 108.312 -0.996 . . . . 11.24 108.312 175.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.69 112.12 3.71 Favored Glycine 0 C--O 1.237 0.295 0 N-CA-C 110.373 -1.091 . . . . 21.84 110.373 174.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -118.65 -172.46 2.29 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 109.414 -0.587 . . . . 31.33 109.414 -174.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.67 HG22 ' H ' ' A' ' 103' ' ' LYS . 1.2 pp -107.02 -63.3 1.88 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 113.418 0.896 . . . . 37.79 113.418 -169.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ASP . . . . . . . . . . . . . 23.7 p-10 -80.86 129.41 34.51 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 118.928 0.785 . . . . 42.09 111.052 -168.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 66.9 p -121.65 12.0 10.62 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.345 0.498 . . . . 12.06 112.345 176.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.402 ' O ' ' N ' ' A' ' 148' ' ' GLU . 4.2 mm? 54.24 75.97 0.56 Allowed Pre-proline 0 C--O 1.238 0.458 0 C-N-CA 126.881 2.073 . . . . 21.66 110.184 -177.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -68.51 70.79 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 N-CA-C 115.392 1.266 . . . . 17.08 115.392 -161.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLU . . . . . 0.525 ' OE1' ' ND2' ' A' ' 152' ' ' ASN . 79.4 mm-40 -104.5 12.95 32.62 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.955 -0.566 . . . . 43.66 111.281 167.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 25.9 pm0 -139.43 4.76 2.21 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.545 0.572 . . . . 22.95 112.545 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.484 HG23 HG23 ' A' ' 96' ' ' THR . 46.1 mm -113.28 -49.7 5.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 118.738 0.699 . . . . 42.75 111.153 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 35.2 t -106.46 -26.88 3.18 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 N-CA-C 107.691 -1.226 . . . . 36.49 107.691 -177.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.525 ' ND2' ' OE1' ' A' ' 148' ' ' GLU . 36.7 t-20 -67.3 -32.02 72.72 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.227 -0.442 . . . . 23.02 111.642 -178.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -75.51 95.82 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.52 -1.289 . . . . 17.08 107.52 170.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.9 t -117.26 -61.91 1.64 Allowed 'General case' 0 C--O 1.234 0.278 0 CA-C-N 115.605 -0.725 . . . . 5.05 112.688 -172.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 17.7 tppt? -135.67 -28.92 1.08 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 113.751 1.019 . . . . 32.54 113.751 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.45 -52.39 3.07 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 119.243 0.929 . . . . 26.85 111.356 -170.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -83.69 143.3 21.49 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-O 122.122 0.845 . . . . 17.08 112.542 178.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.446 ' CD2' ' HG2' ' A' ' 171' ' ' PRO . 18.5 m-30 -112.03 -172.5 2.05 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 124.356 1.062 . . . . 21.15 108.717 177.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -79.33 -75.24 0.25 Allowed 'General case' 0 C--O 1.234 0.274 0 C-N-CA 118.642 -1.223 . . . . 47.89 113.111 -158.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.427 ' CD2' ' HG3' ' A' ' 162' ' ' GLN . 39.5 p90 176.85 173.01 0.44 Allowed 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 127.699 2.4 . . . . 17.08 109.528 168.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -156.56 99.68 1.9 Allowed 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 105.347 -2.094 . . . . 23.47 105.347 155.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLN . . . . . 0.427 ' HG3' ' CD2' ' A' ' 160' ' ' PHE . 89.2 mt-30 -69.47 -46.26 26.93 Favored Pre-proline 0 C--O 1.244 0.811 0 N-CA-C 113.978 1.103 . . . . 6.79 113.978 -167.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -77.54 -13.7 16.38 Favored 'Trans proline' 0 C--N 1.369 1.648 0 CA-C-N 122.288 1.853 . . . . 31.9 112.789 174.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . -139.5 35.4 1.95 Allowed Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 119.527 2.571 . . . . 35.66 119.527 -169.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLN . . . . . 0.45 ' HG2' ' HD3' ' G' ' 90' ' ' LYS . 9.7 tp-100 -68.34 -60.73 2.24 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-N 119.056 1.428 . . . . 22.71 111.322 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 34.1 p 53.57 50.11 17.96 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.642 1.577 . . . . 56.03 111.709 178.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 3.0 m -139.27 147.72 42.05 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 119.872 -0.731 . . . . 6.18 109.6 -168.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -86.16 -124.8 1.63 Allowed Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.225 -0.75 . . . . 39.67 111.225 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 15.6 tm-20 -74.44 -63.32 1.26 Allowed 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.887 0.343 . . . . 24.43 111.364 -175.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.32 105.28 0.83 Allowed Pre-proline 0 C--O 1.235 0.318 0 C-N-CA 123.907 0.883 . . . . 14.12 109.426 -175.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.446 ' HG2' ' CD2' ' A' ' 158' ' ' TYR . 72.0 Cg_endo -78.64 -176.04 3.06 Favored 'Trans proline' 0 C--N 1.323 -0.774 0 C-N-CA 121.454 1.436 . . . . 13.98 113.115 -156.195 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.43 69.06 1.46 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 116.799 1.48 . . . . 21.94 116.799 165.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.6 t -130.23 166.18 20.86 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.946 0.879 . . . . 8.59 109.44 169.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.0 m -78.72 159.81 73.28 Favored Pre-proline 0 C--O 1.24 0.596 0 CA-C-N 114.601 -1.181 . . . . 18.25 107.949 177.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -68.32 106.36 1.38 Allowed 'Trans proline' 0 CA--C 1.512 -0.596 0 CA-C-N 119.787 0.96 . . . . 12.65 110.81 173.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.256 0 C-N-CA 125.149 1.38 . . . . 43.58 112.351 -168.551 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.576 ' HG3' HH11 ' H' ' 52' ' ' ARG . 52.3 Cg_endo . . . . . 0 N--CA 1.465 -0.168 0 CA-C-O 119.981 -0.091 . . . . 11.57 111.986 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.443 ' H ' ' HB2' ' B' ' 5' ' ' PRO . 96.7 mt -124.72 118.35 53.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.907 -1.145 . . . . 14.12 107.907 176.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' MET . . . . . . . . . . . . . 39.0 mmt -85.01 168.7 14.68 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-O 121.883 0.849 . . . . 36.26 110.639 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.73 -14.96 68.25 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.326 -0.852 . . . . 11.49 114.155 172.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -92.68 -14.21 28.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 117.598 0.699 . . . . 14.52 112.376 171.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -76.82 -5.27 47.58 Favored 'General case' 0 CA--C 1.519 -0.224 0 N-CA-C 114.088 1.144 . . . . 28.94 114.088 -171.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 60.1 t -127.03 124.33 64.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 119.734 1.152 . . . . 18.92 108.101 -177.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -133.56 164.96 26.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.593 0.711 . . . . 17.81 109.845 174.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' TYR . . . . . 0.414 ' CE1' ' HG3' ' B' ' 93' ' ' ARG . 19.4 m-30 -114.9 96.14 5.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.024 -0.989 . . . . 5.37 108.818 -163.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' LEU . . . . . 0.788 HD23 ' HB3' ' B' ' 27' ' ' LEU . 93.2 mt -73.54 123.24 23.57 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 120.708 -0.397 . . . . 31.94 109.949 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' PHE . . . . . . . . . . . . . 21.4 m-30 -107.45 150.89 26.26 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.763 -0.458 . . . . 20.34 109.763 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLN . . . . . . . . . . . . . 70.0 tp60 -144.99 135.57 24.38 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 109.099 -0.704 . . . . 14.51 109.099 174.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' SER . . . . . . . . . . . . . 36.8 t -74.59 157.48 35.36 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.619 -0.719 . . . . 1.99 111.077 178.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 41.9 pt -78.04 -15.49 14.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 113.229 0.826 . . . . 4.55 113.229 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -113.13 -8.59 13.57 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 112.775 0.657 . . . . 29.63 112.775 -169.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.0 -45.68 40.27 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 119.689 -0.804 . . . . 24.14 111.488 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.43 41.16 32.14 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 125.014 1.326 . . . . 4.48 111.663 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' THR . . . . . . . . . . . . . 73.3 p -123.02 129.13 51.1 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 123.387 0.675 . . . . 17.5 109.208 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.73 76.55 2.17 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 116.268 -0.423 . . . . 11.69 114.075 -176.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' SER . . . . . . . . . . . . . 87.8 p -129.17 -29.05 2.3 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 120.59 -0.444 . . . . 26.57 111.711 -178.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' ALA . . . . . 0.444 ' HB1' ' HB3' ' B' ' 14' ' ' LEU . . . 51.79 74.59 0.77 Allowed Pre-proline 0 C--O 1.237 0.405 0 C-N-CA 126.842 2.057 . . . . 14.28 112.212 -172.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -71.75 104.22 1.58 Allowed 'Trans proline' 0 CA--C 1.516 -0.408 0 CA-C-N 119.578 0.885 . . . . 9.14 111.874 176.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' LEU . . . . . 0.788 ' HB3' HD23 ' B' ' 14' ' ' LEU . 2.1 pt? -84.89 163.75 18.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 108.882 -0.784 . . . . 2.07 108.882 166.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -100.24 143.2 26.06 Favored Pre-proline 0 C--N 1.295 -1.801 0 C-N-CA 111.906 -3.918 . . . . 7.13 110.0 -174.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -77.49 167.84 23.7 Favored 'Trans proline' 0 CA--C 1.517 -0.347 0 CA-C-N 119.038 0.692 . . . . 14.37 112.195 177.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.676 ' HA ' ' HB3' ' G' ' 47' ' ' GLN . . . 57.45 61.64 2.42 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.538 1.135 . . . . 17.09 112.04 177.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-30 -76.02 -176.17 3.36 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.834 1.302 . . . . 12.49 111.298 177.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' GLN . . . . . 0.482 ' HG3' ' H ' ' B' ' 33' ' ' THR . 7.2 tp-100 -144.07 -161.21 1.23 Allowed 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 103.567 -2.753 . . . . 20.78 103.567 174.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' THR . . . . . 0.482 ' H ' ' HG3' ' B' ' 32' ' ' GLN . 12.9 t -64.39 163.04 13.88 Favored 'General case' 0 C--O 1.244 0.774 0 CA-C-O 122.749 1.261 . . . . 24.37 111.633 177.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . 0.493 ' HB2' ' HB3' ' C' ' 120' ' ' ASP . 82.5 m-20 -135.72 -169.4 2.4 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 113.977 -1.465 . . . . 38.73 108.194 -168.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . 0.673 ' O ' ' HA2' ' B' ' 63' ' ' GLY . . . 177.41 132.89 1.74 Allowed Glycine 0 N--CA 1.441 -0.978 0 CA-C-N 115.386 -0.825 . . . . 14.4 111.113 168.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' SER . . . . . . . . . . . . . 65.2 m -120.9 84.41 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 105.58 -2.008 . . . . 7.83 105.58 175.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' VAL . . . . . 0.58 HG23 ' HB2' ' B' ' 62' ' ' SER . 3.5 m -92.38 109.17 21.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 108.494 -0.928 . . . . 17.01 108.494 -172.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' SER . . . . . . . . . . . . . 44.2 m -100.13 98.74 9.42 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.719 -1.215 . . . . 18.87 107.719 -170.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . -101.17 104.29 2.71 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.283 -0.961 . . . . 0.18 113.165 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -107.36 121.22 44.15 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.52 -0.918 . . . . 9.21 108.52 -178.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.632 ' O ' ' HA3' ' B' ' 57' ' ' GLY . 89.3 mtm-85 -80.49 -176.27 5.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.731 0.776 . . . . 29.74 109.321 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -158.85 147.48 18.44 Favored 'General case' 0 C--N 1.329 -0.32 0 O-C-N 121.804 -0.56 . . . . 20.01 109.536 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' LEU . . . . . . . . . . . . . 70.1 mt -68.94 113.19 6.12 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 108.89 -0.782 . . . . 17.43 108.89 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -109.1 104.55 13.76 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 108.916 -0.772 . . . . 25.47 108.916 -173.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ASP . . . . . 0.526 ' HB2' ' HB3' ' B' ' 52' ' ' ARG . 77.1 m-20 -136.33 179.1 6.56 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.302 -0.408 . . . . 27.64 111.575 -175.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . 0.706 ' HA ' ' HA2' ' B' ' 51' ' ' GLY . 56.4 mp0 -128.35 -38.52 1.76 Allowed 'General case' 0 C--O 1.236 0.381 0 N-CA-C 113.67 0.989 . . . . 19.25 113.67 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' GLN . . . . . . . . . . . . . 79.9 mm-40 57.85 33.75 23.57 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.305 1.442 . . . . 23.02 112.448 175.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' THR . . . . . . . . . . . . . 44.3 p 52.53 39.84 28.7 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 125.305 1.442 . . . . 17.03 111.702 -172.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -138.12 -164.73 1.67 Allowed 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.497 -1.297 . . . . 4.31 107.497 -176.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -65.44 -27.71 68.71 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.252 -0.431 . . . . 23.58 112.044 173.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.706 ' HA2' ' HA ' ' B' ' 46' ' ' GLU . . . 148.06 157.71 7.62 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 111.928 -0.469 . . . . 11.19 111.928 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' ARG . . . . . 0.526 ' HB3' ' HB2' ' B' ' 45' ' ' ASP . 17.6 tpp85 -123.1 50.71 1.51 Allowed 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.328 -2.101 . . . . 5.06 105.328 176.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' ILE . . . . . . . . . . . . . 8.0 tt -81.3 -5.81 9.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 CA-C-N 115.202 -0.908 . . . . 30.68 111.083 -172.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' LEU . . . . . 0.673 HD23 HE22 ' C' ' 88' ' ' GLN . 7.2 mp -66.04 -20.5 66.2 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 112.767 0.655 . . . . 26.8 112.767 -177.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.65 145.21 43.38 Favored Glycine 0 N--CA 1.443 -0.836 0 CA-C-O 121.473 0.485 . . . . 12.91 114.08 -172.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -76.37 -179.8 5.64 Favored 'Trans proline' 0 C--N 1.327 -0.56 0 C-N-CA 121.284 1.323 . . . . 12.85 112.028 -175.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' GLY . . . . . 0.632 ' HA3' ' O ' ' B' ' 41' ' ' ARG . . . -151.89 172.92 31.22 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 109.679 -1.369 . . . . 19.44 109.679 178.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' SER . . . . . . . . . . . . . 46.7 t -75.28 146.55 40.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.604 0.716 . . . . 18.91 110.389 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 5.8 p -100.23 127.55 53.1 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.184 -1.043 . . . . 17.05 108.184 -178.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' ALA . . . . . . . . . . . . . . . -125.49 113.19 17.15 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 106.976 -1.49 . . . . 0.01 106.976 173.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -115.11 120.88 41.3 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.814 -0.81 . . . . 28.32 108.814 -171.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' SER . . . . . 0.711 ' HA ' ' O ' ' B' ' 132' ' ' LEU . 70.8 m -107.09 164.68 11.95 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.484 1.114 . . . . 20.22 110.458 -176.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' GLY . . . . . 0.673 ' HA2' ' O ' ' B' ' 35' ' ' GLY . . . -139.74 121.66 2.08 Favored Glycine 0 N--CA 1.444 -0.808 0 CA-C-N 115.173 -0.921 . . . . 6.63 112.529 175.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' GLU . . . . . . . . . . . . . 67.5 mm-40 -101.73 94.14 5.68 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 107.299 -1.371 . . . . 33.79 107.299 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' VAL . . . . . . . . . . . . . 89.5 t -106.23 120.05 56.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.053 -1.091 . . . . 17.03 108.053 -177.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' THR . . . . . . . . . . . . . 64.7 p -115.24 149.34 37.91 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.457 -0.572 . . . . 17.03 109.457 177.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -155.53 -174.12 4.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 108.976 -0.749 . . . . 12.32 108.976 174.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' TYR . . . . . . . . . . . . . 15.0 m-30 -114.16 136.26 53.13 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 109.414 -0.587 . . . . 15.04 109.414 174.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.85 113.15 3.62 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.84 -0.695 . . . . 15.65 113.936 -175.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.425 ' O ' ' NE2' ' B' ' 76' ' ' GLN . 38.5 ttmt -82.62 149.72 27.24 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.768 -0.827 . . . . 28.21 108.768 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -67.28 -16.68 64.42 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 114.002 1.112 . . . . 11.97 114.002 -170.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.22 -142.49 5.58 Favored Glycine 0 N--CA 1.451 -0.337 0 N-CA-C 110.153 -1.179 . . . . 24.43 110.153 176.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' ASP . . . . . . . . . . . . . 31.1 t0 59.86 74.86 0.43 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.048 1.339 . . . . 18.35 111.108 168.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.28 11.02 0.03 OUTLIER 'General case' 0 C--O 1.235 0.29 0 N-CA-C 117.535 2.42 . . . . 30.51 117.535 -160.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.78 -41.01 95.75 Favored Glycine 0 C--N 1.338 0.686 0 C-N-CA 120.356 -0.926 . . . . 16.26 112.797 170.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' GLN . . . . . 0.425 ' NE2' ' O ' ' B' ' 70' ' ' LYS . 21.8 pt20 -69.2 -24.36 64.02 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 119.865 -0.734 . . . . 19.69 111.819 172.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -72.58 -25.13 61.23 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 119.751 -0.78 . . . . 22.73 111.108 171.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.19 -31.42 60.93 Favored 'General case' 0 C--O 1.239 0.501 0 C-N-CA 120.67 -0.412 . . . . 17.07 111.238 170.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' ILE . . . . . . . . . . . . . 51.2 mm -63.16 -43.04 98.64 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 121.148 0.499 . . . . 4.35 110.291 171.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -75.64 -19.32 59.28 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.894 -0.504 . . . . 15.89 111.999 178.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -71.49 -31.37 67.05 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.972 -0.691 . . . . 26.41 111.027 167.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . 0.724 ' HA ' ' HB2' ' B' ' 87' ' ' LYS . . . -76.71 -29.32 56.19 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 119.668 -0.813 . . . . 15.34 111.775 175.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' TYR . . . . . . . . . . . . . 83.0 t80 -95.71 -60.39 1.66 Allowed 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.776 -0.77 . . . . 12.51 112.26 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -72.0 -42.0 66.96 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 111.701 0.259 . . . . 26.5 111.701 -170.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -75.0 -47.42 29.21 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 119.986 -0.685 . . . . 1.89 110.989 170.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.3 97.37 2.49 Favored Glycine 0 N--CA 1.449 -0.479 0 O-C-N 122.231 -0.293 . . . . 18.63 113.175 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' LYS . . . . . 0.724 ' HB2' ' HA ' ' B' ' 82' ' ' ALA . 98.3 mttt -147.41 -162.88 1.64 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 107.023 -1.473 . . . . 15.85 107.023 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' GLN . . . . . 0.622 HE22 HD23 ' A' ' 54' ' ' LEU . 86.4 mt-30 -127.68 173.36 9.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.317 0.579 . . . . 18.67 109.663 173.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . . . . . . . . . 70.5 mt -128.53 134.44 64.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.059 0.457 . . . . 27.24 109.847 -171.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -85.11 119.28 25.32 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 108.603 -0.888 . . . . 23.04 108.603 165.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' PHE . . . . . 0.42 ' HB3' ' O ' ' B' ' 109' ' ' GLY . 79.8 t80 -116.7 126.86 53.78 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 124.463 1.105 . . . . 23.66 110.195 -165.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' TRP . . . . . 0.485 ' HB2' ' HB2' ' B' ' 14' ' ' LEU . 90.0 m95 -127.29 127.43 44.33 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.949 0.9 . . . . 25.7 109.018 -177.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' ARG . . . . . 0.763 ' O ' ' HA ' ' B' ' 106' ' ' ALA . 78.1 ttt-85 -109.3 95.43 5.62 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.261 -1.015 . . . . 8.0 108.261 173.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' VAL . . . . . 0.531 HG12 ' HB2' ' B' ' 106' ' ' ALA . 24.7 m -109.52 162.27 7.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 CA-C-O 122.196 0.998 . . . . 9.85 109.652 -172.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -109.95 169.16 8.91 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.94 -1.027 . . . . 17.12 111.411 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.549 HG23 HG23 ' B' ' 150' ' ' ILE . 33.3 m -101.65 -29.85 11.69 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 114.862 -1.063 . . . . 10.7 112.594 -175.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' VAL . . . . . . . . . . . . . 35.6 m -68.9 153.17 9.06 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 CA-C-O 121.738 0.78 . . . . 3.84 110.16 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' LYS . . . . . 0.486 ' NZ ' ' O ' ' B' ' 99' ' ' ASN . 29.7 tptp -89.45 125.85 35.33 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.619 -0.719 . . . . 16.58 109.739 -176.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . 0.486 ' O ' ' NZ ' ' B' ' 98' ' ' LYS . 34.4 m120 -85.19 168.41 14.81 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 121.843 0.83 . . . . 17.28 110.031 172.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' GLU . . . . . . . . . . . . . 55.9 mp0 -103.28 -14.76 16.19 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 113.593 0.96 . . . . 25.01 113.593 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -94.48 -47.86 6.37 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.303 0.501 . . . . 7.65 111.16 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -108.5 -175.17 2.7 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 108.836 -0.801 . . . . 20.36 108.836 175.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' LYS . . . . . 0.675 ' H ' HG22 ' B' ' 143' ' ' ILE . 97.6 mttt -80.6 -57.3 3.64 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.216 0.532 . . . . 29.0 110.165 168.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -133.11 -173.34 3.17 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.897 -1.149 . . . . 23.56 107.897 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' B' ' 94' ' ' VAL . 25.8 p-10 -146.99 168.61 21.09 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.575 0.702 . . . . 13.41 109.706 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.763 ' HA ' ' O ' ' B' ' 93' ' ' ARG . . . -154.13 158.01 39.77 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.167 -0.924 . . . . 19.83 111.166 -162.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' GLN . . . . . 0.455 ' OE1' ' OH ' ' C' ' 118' ' ' TYR . 88.9 mt-30 -119.03 123.18 43.89 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 107.123 -1.436 . . . . 9.01 107.123 159.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' PHE . . . . . 0.441 ' HB3' ' O ' ' B' ' 138' ' ' LEU . 87.7 t80 -111.58 151.1 29.12 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 124.196 0.998 . . . . 7.97 110.526 -163.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . 0.42 ' O ' ' HB3' ' B' ' 91' ' ' PHE . . . -170.4 156.01 26.1 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 119.743 -1.218 . . . . 3.32 112.591 174.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -95.21 108.45 20.58 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 109.023 -0.732 . . . . 7.98 109.023 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.71 161.7 15.5 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-O 121.513 0.673 . . . . 28.03 111.769 -166.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' TYR . . . . . 0.526 ' HD1' ' HG2' ' B' ' 88' ' ' GLN . 52.8 t80 -140.24 138.21 34.88 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.659 -1.155 . . . . 19.65 107.963 -177.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' ILE . . . . . . . . . . . . . 82.9 mt -85.13 128.75 38.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 109.984 -0.376 . . . . 8.33 109.984 -171.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' GLU . . . . . 0.512 ' HB2' ' HB2' ' B' ' 131' ' ' SER . 98.1 mt-10 -71.11 -64.08 0.98 Allowed 'General case' 0 C--O 1.234 0.287 0 C-N-CA 119.779 -0.768 . . . . 32.15 110.668 163.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' SER . . . . . . . . . . . . . 73.7 m -142.32 149.45 39.49 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 121.581 0.705 . . . . 15.75 110.375 -169.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -123.13 94.75 4.36 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 105.039 -2.208 . . . . 15.68 105.039 175.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' GLU . . . . . 0.539 ' HB3' HG12 ' A' ' 37' ' ' VAL . 98.3 mt-10 -115.35 108.52 16.65 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.409 -1.33 . . . . 21.71 107.409 -176.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' TYR . . . . . 0.511 ' HB3' ' HA ' ' B' ' 128' ' ' ILE . 25.2 p90 -112.95 139.22 48.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.616 0.722 . . . . 9.23 111.854 177.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' SER . . . . . . . . . . . . . 37.4 t -95.66 131.37 41.97 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 114.6 -1.182 . . . . 17.03 109.821 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.562 ' HA ' HG12 ' B' ' 126' ' ' VAL . 59.6 t0 -111.15 100.42 9.08 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 106.5 -1.667 . . . . 12.65 106.5 172.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' GLY . . . . . . . . . . . . . . . -83.12 -158.55 25.8 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-O 121.707 0.615 . . . . 12.21 112.014 177.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.08 -62.36 2.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 107.969 -1.122 . . . . 20.2 107.969 177.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' GLU . . . . . 0.489 ' OE2' ' NH2' ' G' ' 41' ' ' ARG . 94.9 mt-10 -91.49 -36.38 13.77 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 113.204 0.816 . . . . 40.23 113.204 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' GLY . . . . . 0.566 ' HA2' HD21 ' G' ' 43' ' ' LEU . . . -70.85 142.86 35.51 Favored Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 109.939 -1.264 . . . . 13.54 109.939 172.218 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.09 165.57 23.25 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.774 0.797 . . . . 14.45 110.339 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.562 HG12 ' HA ' ' B' ' 120' ' ' ASP . 27.5 m -68.78 149.08 11.39 Favored 'Isoleucine or valine' 0 C--O 1.238 0.49 0 CA-C-N 115.111 -0.949 . . . . 17.47 109.749 -176.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -138.8 126.23 21.73 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.295 -0.411 . . . . 25.05 109.994 -179.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' ILE . . . . . 0.511 ' HA ' ' HB3' ' B' ' 118' ' ' TYR . 89.5 mt -93.65 118.58 39.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.034 -0.728 . . . . 3.81 109.034 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' SER . . . . . 0.513 ' HB2' ' O ' ' B' ' 117' ' ' GLU . 69.2 m -98.61 133.66 42.65 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.365 -0.976 . . . . 20.76 108.365 171.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . . . . . . . . . 68.9 mt -135.57 128.51 47.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 109.054 -0.721 . . . . 15.91 109.054 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' SER . . . . . 0.512 ' HB2' ' HB2' ' B' ' 114' ' ' GLU . 50.2 m -96.14 151.66 19.27 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.129 -0.487 . . . . 19.9 110.005 175.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.711 ' O ' ' HA ' ' B' ' 62' ' ' SER . 7.1 mp -136.07 142.79 44.4 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.082 -0.508 . . . . 29.36 110.906 -177.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' GLN . . . . . 0.798 HE21 HD11 ' A' ' 53' ' ' ILE . 30.0 mm100 -124.67 137.13 54.38 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.236 -1.024 . . . . 3.24 108.236 169.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -136.36 148.88 27.07 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 108.65 -0.871 . . . . 0.37 108.65 175.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 16.0 mm -60.42 -59.11 4.63 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.244 0.545 . . . . 8.07 110.826 176.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' GLY . . . . . . . . . . . . . . . -165.04 139.5 5.86 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 109.611 -1.396 . . . . 15.08 109.611 -176.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' GLU . . . . . . . . . . . . . 77.0 mm-40 -67.58 151.17 47.78 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.571 0.701 . . . . 14.21 110.547 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' LEU . . . . . 0.441 ' O ' ' HB3' ' B' ' 108' ' ' PHE . 35.2 tp -140.55 125.25 18.06 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.166 -1.42 . . . . 11.08 107.166 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.98 69.11 10.23 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 122.287 1.041 . . . . 22.24 109.796 -168.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -87.98 74.82 8.87 Favored 'General case' 0 C--N 1.333 -0.137 0 N-CA-C 108.18 -1.044 . . . . 15.48 108.18 175.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.4 113.86 4.44 Favored Glycine 0 C--O 1.237 0.32 0 N-CA-C 110.546 -1.021 . . . . 18.71 110.546 176.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -118.45 -172.84 2.35 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.344 -0.613 . . . . 30.93 109.344 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' ILE . . . . . 0.675 HG22 ' H ' ' B' ' 103' ' ' LYS . 1.3 pp -109.66 -61.93 2.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 N-CA-C 113.191 0.811 . . . . 20.34 113.191 -169.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -80.83 125.22 29.82 Favored 'General case' 0 C--N 1.332 -0.183 0 O-C-N 121.384 -0.822 . . . . 24.01 110.964 -169.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' THR . . . . . . . . . . . . . 70.8 p -117.59 13.37 14.3 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-O 119.024 -0.512 . . . . 16.28 112.357 178.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' LEU . . . . . . . . . . . . . 4.1 mm? 54.24 75.63 0.6 Allowed Pre-proline 0 C--O 1.237 0.423 0 C-N-CA 126.953 2.101 . . . . 22.38 110.478 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -68.79 71.05 1.08 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 N-CA-C 115.498 1.307 . . . . 12.25 115.498 -160.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' GLU . . . . . 0.516 ' OE1' ' ND2' ' B' ' 152' ' ' ASN . 79.8 mm-40 -105.08 13.17 31.23 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.221 -0.445 . . . . 18.96 111.387 167.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' GLU . . . . . . . . . . . . . 25.8 pm0 -139.79 3.41 2.05 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 112.776 0.658 . . . . 14.88 112.776 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' ILE . . . . . 0.549 HG23 HG23 ' B' ' 96' ' ' THR . 50.0 mm -115.03 -52.13 4.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.807 0.73 . . . . 17.32 111.228 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' VAL . . . . . . . . . . . . . 23.8 t -105.5 -24.79 3.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 107.457 -1.312 . . . . 20.57 107.457 -176.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' ASN . . . . . 0.516 ' ND2' ' OE1' ' B' ' 148' ' ' GLU . 39.0 t-20 -66.95 -33.19 75.04 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.238 -0.437 . . . . 20.95 111.565 179.382 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -75.72 96.44 1.23 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.42 1.105 . . . . 19.59 108.046 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' SER . . . . . . . . . . . . . 37.4 t -117.48 -61.1 1.74 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.494 -0.775 . . . . 13.41 112.501 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 155' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -134.93 -29.09 1.15 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 113.794 1.035 . . . . 36.82 113.794 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.71 -59.88 4.26 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 110.581 -1.008 . . . . 21.4 110.581 -167.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.85 143.84 28.2 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.535 -0.84 . . . . 4.23 112.42 177.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 158' ' ' TYR . . . . . 0.423 ' CD2' ' HG2' ' B' ' 171' ' ' PRO . 16.9 m-30 -113.59 -172.03 2.0 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.861 1.264 . . . . 22.36 108.997 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 159' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -79.16 -74.94 0.26 Allowed 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 118.771 -1.172 . . . . 26.78 113.134 -156.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 160' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' B' ' 162' ' ' GLN . 39.0 p90 177.12 172.1 0.5 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 127.413 2.285 . . . . 1.94 109.676 168.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -156.87 99.77 1.86 Allowed 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 105.426 -2.064 . . . . 12.07 105.426 155.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.412 ' HG3' ' CD2' ' B' ' 160' ' ' PHE . 90.2 mt-30 -69.64 -45.26 25.43 Favored Pre-proline 0 C--O 1.243 0.754 0 N-CA-C 114.001 1.112 . . . . 8.3 114.001 -166.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -78.01 -13.68 15.61 Favored 'Trans proline' 0 C--N 1.369 1.628 0 CA-C-N 122.22 1.829 . . . . 17.94 112.62 173.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 164' ' ' GLY . . . . . . . . . . . . . . . -140.13 34.95 1.95 Allowed Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 119.889 2.716 . . . . 22.02 119.889 -170.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 165' ' ' GLN . . . . . 0.433 ' HG2' ' HD3' ' H' ' 90' ' ' LYS . 9.7 tp-100 -68.45 -57.86 5.21 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 119.257 1.529 . . . . 21.64 111.09 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 166' ' ' THR . . . . . . . . . . . . . 31.2 p 54.18 49.54 18.47 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.745 1.618 . . . . 29.91 111.728 176.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 167' ' ' THR . . . . . 0.463 HG21 ' HA ' ' B' ' 171' ' ' PRO . 3.2 m -139.47 149.23 43.76 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 119.835 -0.746 . . . . 11.07 109.547 -167.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 168' ' ' GLY . . . . . . . . . . . . . . . -85.7 -124.37 1.46 Allowed Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.87 -0.892 . . . . 22.27 110.87 169.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 169' ' ' GLU . . . . . . . . . . . . . 15.6 tm-20 -74.37 -63.84 1.15 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 120.548 -0.461 . . . . 18.3 111.304 -176.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.41 104.5 0.66 Allowed Pre-proline 0 C--O 1.235 0.326 0 C-N-CA 124.057 0.943 . . . . 22.28 109.887 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 171' ' ' PRO . . . . . 0.463 ' HA ' HG21 ' B' ' 167' ' ' THR . 90.2 Cg_endo -80.04 -172.93 1.66 Allowed 'Trans proline' 0 C--N 1.323 -0.779 0 C-N-CA 121.475 1.45 . . . . 14.9 112.983 -156.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.43 68.65 1.56 Allowed Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 116.481 1.352 . . . . 17.93 116.481 166.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 173' ' ' THR . . . . . . . . . . . . . 11.4 t -133.28 166.14 23.19 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.909 0.861 . . . . 15.99 109.426 170.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -82.3 158.59 66.35 Favored Pre-proline 0 C--O 1.239 0.547 0 N-CA-C 107.334 -1.358 . . . . 14.16 107.334 174.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 175' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -67.27 108.94 1.65 Allowed 'Trans proline' 0 CA--C 1.514 -0.524 0 CA-C-N 119.769 0.953 . . . . 26.18 111.469 175.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.246 0 C-N-CA 125.295 1.438 . . . . 26.62 112.443 -174.113 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 5' ' ' PRO . . . . . 0.538 ' HG3' HH11 ' I' ' 52' ' ' ARG . 56.1 Cg_endo . . . . . 0 N--CA 1.464 -0.213 0 N-CA-C 112.213 0.044 . . . . 5.92 112.213 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 6' ' ' ILE . . . . . 0.466 ' H ' ' HB2' ' C' ' 5' ' ' PRO . 96.6 mt -124.53 119.32 56.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 N-CA-C 107.896 -1.15 . . . . 20.07 107.896 176.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -79.59 173.17 12.85 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-O 121.945 0.878 . . . . 39.14 110.381 178.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 8' ' ' GLY . . . . . . . . . . . . . . . -72.89 -10.88 77.98 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.546 -0.835 . . . . 17.34 113.81 167.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' GLN . . . . . . . . . . . . . 80.3 mt-30 -97.04 -15.82 20.85 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 123.788 0.835 . . . . 3.53 112.215 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' ASP . . . . . . . . . . . . . 76.3 m-20 -74.93 -5.48 44.04 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 114.192 1.182 . . . . 33.8 114.192 -171.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' VAL . . . . . . . . . . . . . 83.1 t -128.17 125.51 64.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 N-CA-C 107.983 -1.117 . . . . 6.96 107.983 -177.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' LYS . . . . . 0.431 ' NZ ' ' O ' ' C' ' 149' ' ' GLU . 51.8 mtmt -132.92 161.92 32.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.526 0.679 . . . . 27.15 110.009 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' TYR . . . . . 0.417 ' CE1' ' HG3' ' C' ' 93' ' ' ARG . 19.1 m-30 -112.14 96.52 6.08 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 108.046 -1.094 . . . . 17.34 108.046 -165.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' LEU . . . . . 0.716 HD23 ' HB3' ' C' ' 27' ' ' LEU . 89.6 mt -74.68 126.24 30.44 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.961 -0.385 . . . . 45.31 109.961 177.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' PHE . . . . . . . . . . . . . 21.5 m-30 -108.69 151.12 26.6 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.138 0.494 . . . . 30.29 109.921 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' GLN . . . . . . . . . . . . . 70.2 tp60 -145.27 135.68 24.15 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.033 -0.729 . . . . 31.67 109.033 174.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' SER . . . . . . . . . . . . . 37.8 t -76.23 153.62 35.89 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.616 0.722 . . . . 6.1 110.978 178.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -76.41 -13.5 14.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.266 0.839 . . . . 17.34 113.266 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -111.96 -8.42 14.08 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 112.678 0.621 . . . . 49.35 112.678 -171.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.63 -46.83 35.7 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 119.759 -0.776 . . . . 27.9 111.536 -176.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . 54.24 39.75 31.09 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.053 1.341 . . . . 16.85 111.677 -172.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' THR . . . . . . . . . . . . . 69.8 p -123.23 129.07 50.88 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.426 0.69 . . . . 3.25 109.431 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.6 76.01 2.29 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 114.294 0.477 . . . . 6.37 114.294 -177.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' SER . . . . . . . . . . . . . 92.1 p -129.69 -26.08 2.51 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 120.487 -0.485 . . . . 40.57 111.654 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' ALA . . . . . . . . . . . . . . . 51.16 73.6 0.95 Allowed Pre-proline 0 C--O 1.237 0.441 0 C-N-CA 126.869 2.067 . . . . 53.81 112.511 -173.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -72.27 104.36 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 CA-C-N 119.591 0.89 . . . . 15.14 111.71 176.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.716 ' HB3' HD23 ' C' ' 14' ' ' LEU . 2.1 pt? -86.36 153.6 21.81 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 108.801 -0.814 . . . . 17.34 108.801 166.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' PHE . . . . . 0.479 ' HE1' ' HB3' ' C' ' 73' ' ' ASP . 69.7 t80 -99.88 130.06 27.23 Favored Pre-proline 0 C--N 1.318 -0.791 1 C-N-CA 110.635 -4.426 . . . . 22.15 110.207 -178.118 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -73.91 -172.0 1.01 Allowed 'Trans proline' 0 C--O 1.235 0.344 0 C-N-CA 120.518 0.812 . . . . 29.33 113.708 -177.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.654 ' HA ' ' HB3' ' H' ' 47' ' ' GLN . . . 55.79 57.66 5.05 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.517 1.127 . . . . 3.88 111.339 -175.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' TYR . . . . . . . . . . . . . 1.5 m-30 -69.93 -179.02 1.72 Allowed 'General case' 0 N--CA 1.455 -0.199 0 CA-C-O 123.067 1.413 . . . . 45.02 112.403 -179.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' GLN . . . . . 0.474 ' HG3' ' H ' ' C' ' 33' ' ' THR . 6.9 tp-100 -148.82 -159.36 1.02 Allowed 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 103.305 -2.85 . . . . 21.77 103.305 168.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' THR . . . . . 0.474 ' H ' ' HG3' ' C' ' 32' ' ' GLN . 15.3 t -65.95 164.92 14.13 Favored 'General case' 0 C--O 1.242 0.707 0 CA-C-O 122.67 1.224 . . . . 21.71 111.616 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' ASP . . . . . 0.582 ' HB2' ' HB3' ' D' ' 120' ' ' ASP . 84.6 m-20 -135.4 -168.46 2.19 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 114.04 -1.437 . . . . 44.64 108.269 -167.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' GLY . . . . . 0.593 ' O ' ' HA2' ' C' ' 63' ' ' GLY . . . 172.25 135.11 1.9 Allowed Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.507 -0.769 . . . . 7.58 111.464 170.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' SER . . . . . . . . . . . . . 67.7 m -125.74 84.62 2.29 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 106.016 -1.846 . . . . 5.6 106.016 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' VAL . . . . . 0.584 HG23 ' HB2' ' C' ' 62' ' ' SER . 4.2 m -90.62 111.33 23.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 108.314 -0.995 . . . . 19.14 108.314 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' SER . . . . . . . . . . . . . 47.6 m -101.28 93.66 5.55 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.935 -1.135 . . . . 36.05 107.935 -169.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.92 102.64 2.84 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.13 -1.033 . . . . 35.7 113.475 -177.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -108.61 125.28 51.68 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 108.499 -0.926 . . . . 11.65 108.499 -178.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . 0.567 ' O ' ' HA3' ' C' ' 57' ' ' GLY . 87.8 mtm-85 -84.63 -173.04 4.51 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.615 0.722 . . . . 37.37 109.086 -178.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' GLU . . . . . . . . . . . . . 20.8 pt-20 -161.02 148.1 15.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.523 -0.547 . . . . 38.55 109.523 -170.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' LEU . . . . . . . . . . . . . 72.2 mt -69.73 124.26 23.51 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 108.926 -0.768 . . . . 27.59 108.926 177.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -124.12 101.23 7.1 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.233 -0.654 . . . . 37.44 109.233 -169.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 45' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -137.23 -177.27 4.7 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 122.733 0.413 . . . . 41.82 111.44 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 46' ' ' GLU . . . . . 0.706 ' HA ' ' HA2' ' C' ' 51' ' ' GLY . 57.5 mp0 -127.27 -37.67 2.03 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 113.398 0.888 . . . . 16.37 113.398 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 47' ' ' GLN . . . . . . . . . . . . . 85.5 mm-40 60.05 33.77 21.32 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.051 1.341 . . . . 39.23 112.622 170.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 48' ' ' THR . . . . . . . . . . . . . 49.1 p 52.61 39.32 28.01 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.137 1.375 . . . . 17.34 111.625 -171.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 49' ' ' LYS . . . . . . . . . . . . . 48.5 mmtm -138.09 -165.42 1.79 Allowed 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.534 -1.284 . . . . 17.52 107.534 -177.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 50' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -68.42 -25.7 65.16 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.27 -0.423 . . . . 24.92 112.038 173.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 51' ' ' GLY . . . . . 0.706 ' HA2' ' HA ' ' C' ' 46' ' ' GLU . . . 144.9 160.12 8.39 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 117.908 0.322 . . . . 24.58 112.597 179.006 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 52' ' ' ARG . . . . . . . . . . . . . 16.4 tpp85 -122.93 49.96 1.58 Allowed 'General case' 0 C--O 1.234 0.289 0 N-CA-C 105.425 -2.065 . . . . 19.34 105.425 176.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 53' ' ' ILE . . . . . . . . . . . . . 7.7 tt -82.31 -5.2 8.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-N 115.319 -0.855 . . . . 43.76 110.942 -173.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 54' ' ' LEU . . . . . 0.689 HD23 HE22 ' D' ' 88' ' ' GLN . 6.8 mp -64.85 -23.64 67.3 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 112.597 0.591 . . . . 34.39 112.597 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.0 143.37 41.37 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.461 0.478 . . . . 1.68 113.997 -170.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.77 177.16 8.86 Favored 'Trans proline' 0 C--N 1.327 -0.584 0 C-N-CA 121.333 1.355 . . . . 14.03 112.031 -174.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 57' ' ' GLY . . . . . 0.567 ' HA3' ' O ' ' C' ' 41' ' ' ARG . . . -148.14 173.31 28.2 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 109.619 -1.392 . . . . 28.69 109.619 177.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 58' ' ' SER . . . . . . . . . . . . . 42.8 t -75.76 148.36 38.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.582 0.706 . . . . 2.63 110.498 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -101.06 131.99 47.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 107.901 -1.148 . . . . 17.34 107.901 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 60' ' ' ALA . . . . . . . . . . . . . . . -128.72 113.23 15.1 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.714 -1.588 . . . . 21.3 106.714 171.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 61' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -114.13 120.5 40.74 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.7 -0.852 . . . . 35.31 108.7 -170.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 62' ' ' SER . . . . . 0.733 ' HA ' ' O ' ' C' ' 132' ' ' LEU . 71.1 m -106.6 163.0 13.25 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.462 1.105 . . . . 5.42 110.252 -176.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 63' ' ' GLY . . . . . 0.593 ' HA2' ' O ' ' C' ' 35' ' ' GLY . . . -138.47 121.08 2.09 Favored Glycine 0 N--CA 1.443 -0.871 0 CA-C-N 115.049 -0.978 . . . . 17.34 112.217 176.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -99.47 96.45 7.69 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 107.272 -1.381 . . . . 47.51 107.272 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 65' ' ' VAL . . . . . . . . . . . . . 95.8 t -104.84 117.84 51.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 108.148 -1.056 . . . . 17.34 108.148 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 66' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' C' ' 33' ' ' THR . 67.2 p -113.77 144.37 43.1 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.134 -0.691 . . . . 9.84 109.134 176.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 67' ' ' TYR . . . . . 0.44 ' HE1' HD12 ' C' ' 130' ' ' ILE . 52.7 p90 -155.13 -175.06 5.25 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 108.814 -0.809 . . . . 20.72 108.814 176.056 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 68' ' ' TYR . . . . . . . . . . . . . 14.9 m-30 -114.55 137.32 52.02 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 109.311 -0.626 . . . . 17.34 109.311 174.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 69' ' ' GLY . . . . . . . . . . . . . . . -85.18 111.47 3.53 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.938 -0.649 . . . . 17.34 114.122 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 70' ' ' LYS . . . . . 0.409 ' O ' ' NE2' ' C' ' 76' ' ' GLN . 38.3 ttmt -80.0 153.35 28.92 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 108.645 -0.872 . . . . 17.34 108.645 174.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -68.67 -15.61 63.57 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 114.048 1.129 . . . . 24.92 114.048 -171.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.63 -141.49 5.19 Favored Glycine 0 N--CA 1.451 -0.327 0 N-CA-C 110.217 -1.153 . . . . 51.19 110.217 177.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 73' ' ' ASP . . . . . 0.479 ' HB3' ' HE1' ' C' ' 28' ' ' PHE . 30.1 t0 60.06 72.89 0.5 Allowed 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.166 1.386 . . . . 18.34 111.169 168.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.3 10.94 0.05 Allowed 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 117.241 2.312 . . . . 52.71 117.241 -160.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.51 -40.1 93.97 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 120.172 -1.013 . . . . 16.66 112.513 169.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 76' ' ' GLN . . . . . 0.409 ' NE2' ' O ' ' C' ' 70' ' ' LYS . 22.2 pt20 -69.96 -22.37 63.17 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 119.894 -0.722 . . . . 29.16 111.938 172.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -73.78 -25.36 60.1 Favored 'General case' 0 CA--C 1.517 -0.31 0 C-N-CA 119.359 -0.936 . . . . 18.43 111.411 170.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.98 -31.85 64.81 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 120.236 -0.586 . . . . 44.7 111.102 169.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 79' ' ' ILE . . . . . . . . . . . . . 51.0 mm -62.94 -45.31 99.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 CA-C-O 121.066 0.46 . . . . 34.23 110.455 172.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -75.41 -21.08 58.5 Favored 'General case' 0 C--O 1.235 0.295 0 O-C-N 121.899 -0.5 . . . . 25.41 112.016 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 81' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -69.18 -34.33 74.77 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 120.223 -0.591 . . . . 39.48 111.178 167.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 82' ' ' ALA . . . . . 0.696 ' HA ' ' HB2' ' C' ' 87' ' ' LYS . . . -73.3 -36.7 66.32 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 119.661 -0.816 . . . . 17.34 111.667 176.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 83' ' ' TYR . . . . . . . . . . . . . 83.0 t80 -84.08 -62.23 1.62 Allowed 'General case' 0 C--O 1.236 0.363 0 C-N-CA 120.284 -0.566 . . . . 7.56 112.047 -176.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -73.81 -42.41 60.97 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.919 0.34 . . . . 25.84 111.919 -167.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 85' ' ' ASN . . . . . . . . . . . . . 35.6 m120 -76.2 -44.99 35.24 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 119.885 -0.726 . . . . 7.51 111.075 173.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.31 96.73 2.4 Favored Glycine 0 N--CA 1.449 -0.486 0 O-C-N 122.255 -0.278 . . . . 4.2 113.374 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 87' ' ' LYS . . . . . 0.696 ' HB2' ' HA ' ' C' ' 82' ' ' ALA . 98.0 mttt -148.26 -162.72 1.61 Allowed 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 107.165 -1.42 . . . . 17.34 107.165 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 88' ' ' GLN . . . . . 0.673 HE22 HD23 ' B' ' 54' ' ' LEU . 88.5 mt-30 -129.39 174.24 9.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.371 0.605 . . . . 17.34 109.718 172.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 89' ' ' ILE . . . . . 0.403 HD11 HD11 ' C' ' 113' ' ' ILE . 72.9 mt -128.67 134.99 63.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 116.108 -0.496 . . . . 28.06 109.698 -173.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 90' ' ' LYS . . . . . . . . . . . . . 36.7 mtmm -84.54 117.41 23.69 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 108.66 -0.867 . . . . 24.09 108.66 165.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 91' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -112.64 127.59 56.15 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.766 1.226 . . . . 25.04 110.179 -167.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 92' ' ' TRP . . . . . 0.478 ' HB2' ' HB2' ' C' ' 14' ' ' LEU . 90.1 m95 -126.51 130.94 51.59 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 124.131 0.972 . . . . 7.39 108.749 -178.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 93' ' ' ARG . . . . . 0.774 ' O ' ' HA ' ' C' ' 106' ' ' ALA . 78.4 ttt-85 -113.83 93.73 4.51 Favored 'General case' 0 N--CA 1.464 0.246 0 N-CA-C 108.136 -1.061 . . . . 30.73 108.136 172.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 94' ' ' VAL . . . . . 0.565 HG12 ' HB2' ' C' ' 106' ' ' ALA . 21.6 m -107.71 163.07 5.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 122.344 1.069 . . . . 28.65 109.679 -172.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 95' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -106.21 165.79 10.99 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 114.719 -1.128 . . . . 15.99 111.343 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 96' ' ' THR . . . . . 0.562 HG23 HD12 ' C' ' 150' ' ' ILE . 30.1 m -101.33 -29.87 11.81 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 114.89 -1.05 . . . . 20.04 112.338 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 97' ' ' VAL . . . . . . . . . . . . . 35.0 m -68.92 153.43 8.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.464 0 CA-C-O 121.806 0.813 . . . . 2.88 109.968 179.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 98' ' ' LYS . . . . . 0.517 ' NZ ' ' O ' ' C' ' 99' ' ' ASN . 29.8 tptp -89.58 125.79 35.36 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.67 -0.696 . . . . 21.89 109.674 -176.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 99' ' ' ASN . . . . . 0.517 ' O ' ' NZ ' ' C' ' 98' ' ' LYS . 35.8 m120 -86.43 168.37 13.84 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.77 0.795 . . . . 6.97 109.792 171.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 100' ' ' GLU . . . . . . . . . . . . . 55.1 mp0 -104.31 -13.0 16.3 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 113.824 1.046 . . . . 29.49 113.824 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 101' ' ' ASN . . . . . . . . . . . . . 16.2 p30 -91.94 -59.59 2.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 118.408 0.549 . . . . 48.44 111.48 165.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 102' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -98.27 -179.75 4.47 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 108.631 -0.877 . . . . 25.22 108.631 174.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 103' ' ' LYS . . . . . 0.724 ' H ' HG22 ' C' ' 143' ' ' ILE . 96.9 mttt -75.2 -56.95 4.22 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 120.265 -0.574 . . . . 45.03 110.073 169.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 104' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -133.96 -170.93 2.61 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 108.179 -1.045 . . . . 16.91 108.179 -178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 105' ' ' ASP . . . . . 0.51 ' O ' ' HA ' ' C' ' 94' ' ' VAL . 20.7 p-10 -151.25 171.03 18.06 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.498 0.665 . . . . 20.23 109.512 176.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 106' ' ' ALA . . . . . 0.774 ' HA ' ' O ' ' C' ' 93' ' ' ARG . . . -154.21 153.93 32.62 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.222 -0.899 . . . . 30.47 111.104 -164.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 107' ' ' GLN . . . . . 0.461 ' OE1' ' OH ' ' D' ' 118' ' ' TYR . 87.3 mt-30 -110.82 125.66 53.82 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 106.828 -1.545 . . . . 7.39 106.828 156.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 108' ' ' PHE . . . . . 0.637 ' HB3' ' O ' ' C' ' 138' ' ' LEU . 88.0 t80 -117.03 153.33 32.89 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 123.654 0.782 . . . . 14.88 110.698 -160.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 109' ' ' GLY . . . . . . . . . . . . . . . -172.78 163.01 34.78 Favored Glycine 0 C--N 1.333 0.37 0 C-N-CA 119.156 -1.497 . . . . 6.03 112.924 172.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 110' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -99.08 109.2 21.96 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 108.874 -0.787 . . . . 17.34 108.874 168.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 111' ' ' ALA . . . . . . . . . . . . . . . -112.3 161.61 16.43 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.522 0.677 . . . . 5.64 111.799 -166.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 112' ' ' TYR . . . . . 0.567 ' HD1' ' HG2' ' C' ' 88' ' ' GLN . 58.3 t80 -138.73 138.43 37.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.575 -1.193 . . . . 14.03 107.817 -176.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 113' ' ' ILE . . . . . 0.403 HD11 HD11 ' C' ' 89' ' ' ILE . 79.6 mt -84.25 130.1 36.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 N-CA-C 109.777 -0.453 . . . . 17.76 109.777 -172.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 114' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' C' ' 131' ' ' SER . 98.5 mt-10 -73.67 -64.32 1.02 Allowed 'General case' 0 C--O 1.235 0.319 0 C-N-CA 119.779 -0.768 . . . . 49.83 110.654 163.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 115' ' ' SER . . . . . . . . . . . . . 72.8 m -142.08 149.46 39.93 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.65 0.738 . . . . 32.52 110.355 -167.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 116' ' ' ARG . . . . . . . . . . . . . 8.7 tmm_? -125.66 95.43 4.43 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 105.105 -2.183 . . . . 17.34 105.105 177.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 117' ' ' GLU . . . . . 0.526 ' HB3' HG12 ' B' ' 37' ' ' VAL . 98.6 mt-10 -117.86 109.09 16.12 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 107.642 -1.244 . . . . 32.82 107.642 -175.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 118' ' ' TYR . . . . . 0.567 ' HB3' ' HA ' ' C' ' 128' ' ' ILE . 19.7 p90 -113.94 143.1 45.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.578 0.704 . . . . 1.27 112.115 177.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 119' ' ' SER . . . . . . . . . . . . . 35.2 t -98.6 133.73 42.54 Favored 'General case' 0 C--O 1.24 0.574 0 CA-C-N 114.605 -1.18 . . . . 7.79 109.981 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 120' ' ' ASP . . . . . 0.574 ' HA ' HG12 ' C' ' 126' ' ' VAL . 58.4 t0 -111.82 98.53 7.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 106.406 -1.701 . . . . 20.31 106.406 172.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.32 -163.52 32.94 Favored Glycine 0 N--CA 1.449 -0.481 0 CA-C-O 121.731 0.628 . . . . 9.67 111.963 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 122' ' ' VAL . . . . . . . . . . . . . 68.8 t -108.72 -61.68 2.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 107.795 -1.187 . . . . 10.53 107.795 177.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 123' ' ' GLU . . . . . 0.429 ' OE2' ' NH2' ' H' ' 41' ' ' ARG . 96.7 mt-10 -87.09 -38.22 16.7 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.966 0.728 . . . . 56.31 112.966 176.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 124' ' ' GLY . . . . . 0.596 ' HA2' HD21 ' H' ' 43' ' ' LEU . . . -73.13 149.14 42.14 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 110.194 -1.162 . . . . 24.31 110.194 174.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 125' ' ' ALA . . . . . 0.475 ' HB2' HD13 ' H' ' 43' ' ' LEU . . . -73.16 167.57 20.88 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.67 0.747 . . . . 5.55 110.161 173.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 126' ' ' VAL . . . . . 0.574 HG12 ' HA ' ' C' ' 120' ' ' ASP . 31.2 m -68.82 151.89 9.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.499 0 CA-C-N 115.318 -0.856 . . . . 17.34 109.61 -178.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 127' ' ' GLU . . . . . . . . . . . . . 19.3 pt-20 -142.19 124.69 15.74 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 116.423 -0.353 . . . . 31.44 110.248 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 128' ' ' ILE . . . . . 0.567 ' HA ' ' HB3' ' C' ' 118' ' ' TYR . 88.5 mt -93.65 120.72 43.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.221 -0.659 . . . . 17.34 109.221 -177.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 129' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' C' ' 117' ' ' GLU . 69.9 m -102.6 133.61 47.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.398 -0.964 . . . . 17.28 108.398 172.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 130' ' ' ILE . . . . . 0.44 HD12 ' HE1' ' C' ' 67' ' ' TYR . 71.2 mt -135.67 128.26 46.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.418 0 N-CA-C 109.177 -0.675 . . . . 17.34 109.177 -176.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 131' ' ' SER . . . . . 0.521 ' HB2' ' HB2' ' C' ' 114' ' ' GLU . 62.7 m -96.18 150.59 20.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.195 -0.457 . . . . 12.56 110.165 175.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 132' ' ' LEU . . . . . 0.733 ' O ' ' HA ' ' C' ' 62' ' ' SER . 7.3 mp -135.32 140.81 45.39 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.081 -0.509 . . . . 44.05 110.837 -177.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 133' ' ' GLN . . . . . 0.403 ' HG2' ' HG3' ' C' ' 114' ' ' GLU . 30.4 mm100 -120.04 135.64 54.86 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 108.391 -0.966 . . . . 10.2 108.391 167.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 134' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.02 149.16 30.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 N-CA-C 108.318 -0.993 . . . . 4.39 108.318 175.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 135' ' ' ILE . . . . . . . . . . . . . 25.2 mm -62.83 -60.9 2.02 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-O 121.311 0.576 . . . . 28.75 110.849 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.47 138.79 5.62 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 109.32 -1.512 . . . . 19.59 109.32 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 137' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 -68.78 150.41 47.89 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.633 0.73 . . . . 12.53 110.459 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 138' ' ' LEU . . . . . 0.637 ' O ' ' HB3' ' C' ' 108' ' ' PHE . 36.6 tp -139.23 127.51 22.71 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 106.995 -1.483 . . . . 10.09 106.995 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -89.39 67.16 7.66 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 122.244 1.021 . . . . 9.01 109.775 -168.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 140' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -85.56 76.73 9.98 Favored 'General case' 0 C--N 1.332 -0.163 0 N-CA-C 108.165 -1.05 . . . . 17.34 108.165 175.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 141' ' ' GLY . . . . . . . . . . . . . . . -74.29 114.95 4.68 Favored Glycine 0 C--O 1.237 0.289 0 N-CA-C 110.502 -1.039 . . . . 17.56 110.502 175.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.38 -173.52 2.59 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 109.369 -0.604 . . . . 9.69 109.369 -175.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 143' ' ' ILE . . . . . 0.724 HG22 ' H ' ' C' ' 103' ' ' LYS . 1.2 pp -108.3 -62.51 2.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 113.186 0.81 . . . . 34.84 113.186 -170.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 144' ' ' ASP . . . . . . . . . . . . . 20.8 p-10 -80.76 125.3 29.89 Favored 'General case' 0 C--N 1.331 -0.217 0 O-C-N 121.43 -0.794 . . . . 26.5 111.144 -168.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -117.92 16.71 14.27 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 112.33 0.492 . . . . 8.28 112.33 177.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 146' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' C' ' 146' ' ' LEU . 4.1 mm? 54.49 76.12 0.55 Allowed Pre-proline 0 C--O 1.237 0.436 0 C-N-CA 126.932 2.093 . . . . 28.36 110.522 179.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 147' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -68.19 71.8 0.86 Allowed 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 121.239 1.292 . . . . 17.34 115.346 -160.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 148' ' ' GLU . . . . . 0.509 ' OE1' ' ND2' ' C' ' 152' ' ' ASN . 80.1 mm-40 -113.25 11.43 18.7 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 115.992 -0.549 . . . . 26.92 111.598 169.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 149' ' ' GLU . . . . . 0.431 ' O ' ' NZ ' ' C' ' 12' ' ' LYS . 25.7 pm0 -136.94 4.5 2.76 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.331 0.493 . . . . 15.59 112.331 178.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 150' ' ' ILE . . . . . 0.562 HD12 HG23 ' C' ' 96' ' ' THR . 50.3 mm -115.54 -50.76 4.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 118.708 0.685 . . . . 21.56 111.228 -177.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -105.65 -25.45 3.67 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.558 -1.275 . . . . 21.99 107.558 -176.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 152' ' ' ASN . . . . . 0.509 ' ND2' ' OE1' ' C' ' 148' ' ' GLU . 37.8 t-20 -67.19 -32.48 73.59 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.343 -0.39 . . . . 25.48 111.486 179.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -74.42 97.48 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.466 0 N-CA-C 107.744 -1.206 . . . . 11.01 107.744 170.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 154' ' ' SER . . . . . . . . . . . . . 33.9 t -116.62 -61.2 1.76 Allowed 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.598 -0.728 . . . . 36.85 112.402 -173.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 155' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -135.03 -28.85 1.15 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 113.616 0.969 . . . . 40.39 113.616 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.07 -54.02 2.89 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 119.269 0.94 . . . . 30.03 111.158 -168.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 157' ' ' GLY . . . . . . . . . . . . . . . -83.45 143.49 21.79 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 120.518 -0.849 . . . . 17.34 112.485 178.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 158' ' ' TYR . . . . . 0.454 ' CD2' ' HG2' ' C' ' 171' ' ' PRO . 18.1 m-30 -112.96 -173.17 2.19 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 124.414 1.086 . . . . 17.45 108.791 178.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 159' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -77.49 -75.0 0.23 Allowed 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 118.969 -1.093 . . . . 41.15 113.281 -155.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 160' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' C' ' 162' ' ' GLN . 41.1 p90 177.05 173.02 0.47 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 127.8 2.44 . . . . 7.58 109.228 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 161' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -157.06 100.49 1.87 Allowed 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 105.466 -2.05 . . . . 21.22 105.466 154.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 162' ' ' GLN . . . . . 0.412 ' HG3' ' CD2' ' C' ' 160' ' ' PHE . 90.5 mt-30 -68.39 -45.47 37.3 Favored Pre-proline 0 C--O 1.243 0.725 0 N-CA-C 113.971 1.101 . . . . 15.32 113.971 -167.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 163' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -77.74 -17.02 14.35 Favored 'Trans proline' 0 C--N 1.369 1.618 0 CA-C-N 122.145 1.802 . . . . 38.41 112.587 173.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 164' ' ' GLY . . . . . . . . . . . . . . . -139.5 34.69 2.02 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 119.683 2.633 . . . . 33.37 119.683 -169.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 165' ' ' GLN . . . . . 0.415 ' HG2' ' HD3' ' I' ' 90' ' ' LYS . 9.8 tp-100 -67.06 -58.09 5.57 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.087 1.443 . . . . 42.19 111.062 177.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 166' ' ' THR . . . . . 0.411 HG22 ' HB2' ' I' ' 21' ' ' ALA . 34.6 p 55.17 46.4 23.95 Favored 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 125.736 1.614 . . . . 59.88 111.701 175.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 167' ' ' THR . . . . . . . . . . . . . 2.0 m -138.9 151.25 46.79 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 120.036 -0.666 . . . . 16.54 109.451 -167.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 168' ' ' GLY . . . . . . . . . . . . . . . -87.5 -126.29 2.27 Favored Glycine 0 N--CA 1.447 -0.578 0 CA-C-N 115.754 -0.657 . . . . 29.67 111.935 171.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 169' ' ' GLU . . . . . . . . . . . . . 15.3 tm-20 -74.22 -62.59 1.46 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.835 0.317 . . . . 45.16 111.312 -175.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.44 104.66 0.64 Allowed Pre-proline 0 C--O 1.236 0.347 0 N-CA-C 108.698 -0.852 . . . . 8.44 108.698 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 171' ' ' PRO . . . . . 0.454 ' HG2' ' CD2' ' C' ' 158' ' ' TYR . 85.2 Cg_endo -83.37 -173.99 1.82 Allowed 'Trans proline' 0 C--N 1.324 -0.76 0 C-N-CA 121.294 1.329 . . . . 3.15 112.816 -153.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.68 69.92 1.3 Allowed Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 117.496 1.759 . . . . 5.45 117.496 163.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 173' ' ' THR . . . . . . . . . . . . . 10.6 t -131.34 164.8 24.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 118.108 0.954 . . . . 8.36 109.69 169.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 174' ' ' VAL . . . . . . . . . . . . . 29.3 m -77.73 159.66 76.14 Favored Pre-proline 0 C--O 1.239 0.531 0 N-CA-C 107.631 -1.248 . . . . 22.82 107.631 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 175' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -69.78 105.59 1.51 Allowed 'Trans proline' 0 CA--C 1.513 -0.547 0 CA-C-N 120.05 1.053 . . . . 8.45 111.628 178.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.197 0 C-N-CA 125.636 1.575 . . . . 68.61 112.578 -173.523 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 5' ' ' PRO . . . . . 0.494 ' HB2' ' H ' ' D' ' 6' ' ' ILE . 41.5 Cg_endo . . . . . 0 N--CA 1.465 -0.177 0 N-CA-C 112.49 0.15 . . . . 17.71 112.49 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 6' ' ' ILE . . . . . 0.494 ' H ' ' HB2' ' D' ' 5' ' ' PRO . 96.6 mt -121.66 120.78 62.68 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 N-CA-C 108.057 -1.09 . . . . 10.96 108.057 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 7' ' ' MET . . . . . . . . . . . . . 39.0 mmt -86.39 170.92 11.56 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.894 0.854 . . . . 50.41 110.443 -177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.32 -12.43 69.27 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.43 -0.804 . . . . 5.14 114.23 174.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -96.07 -14.73 22.68 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 117.586 0.693 . . . . 19.3 112.151 172.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -76.37 -3.39 36.65 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 114.04 1.126 . . . . 38.59 114.04 -171.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -128.48 124.7 62.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.342 0 CA-C-N 119.665 1.12 . . . . 22.8 107.987 -177.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' LYS . . . . . 0.455 ' NZ ' ' O ' ' D' ' 149' ' ' GLU . 51.9 mtmt -133.13 162.12 32.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.597 0.713 . . . . 21.76 110.202 175.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' TYR . . . . . . . . . . . . . 19.5 m-30 -112.63 97.77 6.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.008 -0.996 . . . . 3.75 108.338 -166.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' LEU . . . . . 0.696 HD23 ' HB3' ' D' ' 27' ' ' LEU . 91.8 mt -76.69 125.16 28.78 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 110.015 -0.365 . . . . 49.03 110.015 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' PHE . . . . . . . . . . . . . 21.7 m-30 -109.18 147.94 31.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.068 0.461 . . . . 32.35 109.768 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -144.61 135.72 25.15 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.164 -0.68 . . . . 14.4 109.164 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -75.0 157.38 35.02 Favored 'General case' 0 C--O 1.233 0.23 0 CA-C-O 121.625 0.726 . . . . 11.7 111.13 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' ILE . . . . . . . . . . . . . 43.8 pt -80.49 -7.4 10.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 113.322 0.86 . . . . 7.44 113.322 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -119.44 -10.81 9.6 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 112.847 0.684 . . . . 16.13 112.847 -170.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.18 -44.09 48.51 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 119.906 -0.717 . . . . 21.91 111.701 -175.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.33 41.85 32.1 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.945 1.298 . . . . 19.34 111.537 -170.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' THR . . . . . . . . . . . . . 74.1 p -122.36 125.27 45.56 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.435 0.694 . . . . 11.94 109.242 -179.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.05 76.01 2.21 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 116.297 -0.411 . . . . 17.71 113.155 -178.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' SER . . . . . 0.416 ' HA ' ' HG ' ' D' ' 146' ' ' LEU . 89.5 p -127.98 -29.37 2.56 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 120.694 -0.403 . . . . 46.05 111.592 -178.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' ALA . . . . . 0.455 ' HB1' ' HB3' ' D' ' 14' ' ' LEU . . . 51.46 73.91 0.89 Allowed Pre-proline 0 C--O 1.236 0.356 0 C-N-CA 127.012 2.125 . . . . 15.66 112.311 -173.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_exo -71.95 104.8 1.7 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 CA-C-N 119.442 0.836 . . . . 19.19 111.92 176.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' LEU . . . . . 0.696 ' HB3' HD23 ' D' ' 14' ' ' LEU . 2.2 pt? -87.46 151.48 23.01 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.958 -0.756 . . . . 17.71 108.958 167.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' PHE . . . . . 0.469 ' HE1' ' HB3' ' D' ' 73' ' ' ASP . 65.8 t80 -98.22 131.59 26.05 Favored Pre-proline 0 C--N 1.319 -0.725 1 C-N-CA 110.713 -4.395 . . . . 24.37 110.071 -177.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -72.98 -174.06 1.43 Allowed 'Trans proline' 0 C--O 1.234 0.304 0 C-N-CA 120.492 0.795 . . . . 36.84 113.973 -176.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.65 ' HA ' ' HB3' ' I' ' 47' ' ' GLN . . . 54.61 59.76 3.93 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.646 1.178 . . . . 12.13 111.601 -175.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' TYR . . . . . . . . . . . . . 1.6 m-30 -69.88 179.7 2.15 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-O 123.06 1.409 . . . . 27.63 112.212 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' GLN . . . . . 0.485 ' HG3' ' H ' ' D' ' 33' ' ' THR . 6.4 tp-100 -148.48 -159.16 0.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 103.437 -2.801 . . . . 31.27 103.437 170.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' THR . . . . . 0.485 ' H ' ' HG3' ' D' ' 32' ' ' GLN . 14.9 t -65.3 162.57 17.19 Favored 'General case' 0 C--O 1.245 0.83 0 CA-C-O 122.723 1.249 . . . . 27.4 111.578 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' ASP . . . . . 0.581 ' HB2' ' HB3' ' E' ' 120' ' ' ASP . 84.4 m-20 -135.46 -169.52 2.41 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 113.871 -1.513 . . . . 51.24 107.962 -168.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' GLY . . . . . 0.662 ' O ' ' HA2' ' D' ' 63' ' ' GLY . . . 171.51 134.51 1.79 Allowed Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 111.177 -0.769 . . . . 16.37 111.177 168.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' SER . . . . . . . . . . . . . 69.6 m -121.57 84.84 2.31 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 105.821 -1.918 . . . . 4.07 105.821 174.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' VAL . . . . . 0.562 HG23 ' HB2' ' D' ' 62' ' ' SER . 4.0 m -89.23 108.44 19.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 108.359 -0.978 . . . . 12.88 108.359 -173.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' SER . . . . . . . . . . . . . 44.9 m -97.89 93.46 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 107.782 -1.192 . . . . 8.2 107.782 -170.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' GLY . . . . . . . . . . . . . . . -96.34 102.29 2.76 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.411 -0.9 . . . . 17.71 113.49 -177.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' GLU . . . . . 0.408 ' HA ' ' HA ' ' D' ' 59' ' ' VAL . 85.1 tt0 -108.41 123.95 49.64 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.63 -0.878 . . . . 10.85 108.63 -177.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 41' ' ' ARG . . . . . 0.523 ' O ' ' HA3' ' D' ' 57' ' ' GLY . 88.3 mtm-85 -83.77 -172.0 3.91 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.236 -0.653 . . . . 47.43 109.236 -178.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 42' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -160.61 145.15 14.15 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 121.767 -0.583 . . . . 34.93 110.03 -169.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 43' ' ' LEU . . . . . . . . . . . . . 72.0 mt -68.57 137.47 54.32 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.118 -0.697 . . . . 20.29 109.118 177.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 44' ' ' PHE . . . . . 0.45 ' HD1' HG13 ' D' ' 53' ' ' ILE . 75.6 t80 -140.68 102.59 4.34 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.106 -0.331 . . . . 18.56 110.106 -168.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 45' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -133.51 -173.16 3.14 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 122.882 0.473 . . . . 41.43 110.808 168.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 46' ' ' GLU . . . . . 0.576 ' HA ' ' HA2' ' D' ' 51' ' ' GLY . 54.0 mp0 -127.55 -34.12 2.26 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 113.747 1.018 . . . . 26.44 113.747 177.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 47' ' ' GLN . . . . . . . . . . . . . 80.1 mm-40 61.5 29.09 18.22 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.931 1.293 . . . . 19.35 112.856 169.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 48' ' ' THR . . . . . . . . . . . . . 48.1 p 51.14 41.3 27.49 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.94 1.296 . . . . 38.66 111.439 -169.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 49' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -137.88 -166.11 1.9 Allowed 'General case' 0 C--O 1.236 0.381 0 N-CA-C 107.467 -1.308 . . . . 17.71 107.467 -176.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 50' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -67.85 -24.84 65.3 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 112.183 0.438 . . . . 32.97 112.183 173.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 51' ' ' GLY . . . . . 0.576 ' HA2' ' HA ' ' D' ' 46' ' ' GLU . . . 141.23 158.6 7.6 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.99 -0.444 . . . . 33.1 111.99 178.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 52' ' ' ARG . . . . . . . . . . . . . 17.5 tpp85 -124.08 50.73 1.62 Allowed 'General case' 0 C--O 1.235 0.31 0 N-CA-C 105.83 -1.915 . . . . 6.79 105.83 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 53' ' ' ILE . . . . . 0.45 HG13 ' HD1' ' D' ' 44' ' ' PHE . 8.6 tt -79.08 -5.34 7.94 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 115.365 -0.834 . . . . 9.19 111.246 -174.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 54' ' ' LEU . . . . . 0.732 HD23 HE22 ' E' ' 88' ' ' GLN . 7.0 mp -65.78 -21.26 66.49 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 112.872 0.693 . . . . 37.27 112.872 -176.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.07 143.33 41.19 Favored Glycine 0 N--CA 1.444 -0.822 0 CA-C-O 121.417 0.454 . . . . 19.46 113.961 -171.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 56' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -74.56 176.89 9.13 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 121.351 1.367 . . . . 17.71 112.039 -175.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 57' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' D' ' 41' ' ' ARG . . . -148.45 173.35 28.46 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 109.57 -1.412 . . . . 11.14 109.57 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 58' ' ' SER . . . . . . . . . . . . . 46.8 t -75.9 146.58 39.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.685 0.755 . . . . 17.71 110.354 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 59' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' D' ' 40' ' ' GLU . 2.6 p -103.01 122.08 54.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.43 0 N-CA-C 108.555 -0.906 . . . . 3.48 108.555 -176.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 60' ' ' ALA . . . . . . . . . . . . . . . -119.5 112.17 19.03 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 106.799 -1.556 . . . . 39.46 106.799 173.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 61' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -111.77 121.66 45.68 Favored 'General case' 0 C--O 1.24 0.585 0 N-CA-C 108.59 -0.893 . . . . 24.09 108.59 -172.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 62' ' ' SER . . . . . 0.65 ' HA ' ' O ' ' D' ' 132' ' ' LEU . 70.1 m -109.14 166.37 10.9 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 124.203 1.001 . . . . 24.26 110.429 -175.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 63' ' ' GLY . . . . . 0.662 ' HA2' ' O ' ' D' ' 35' ' ' GLY . . . -141.2 123.01 2.2 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.15 -0.932 . . . . 3.56 112.297 177.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 64' ' ' GLU . . . . . 0.406 ' O ' ' HA ' ' D' ' 34' ' ' ASP . 65.3 mm-40 -101.9 99.42 9.62 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 107.292 -1.373 . . . . 25.37 107.292 172.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 65' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.26 119.39 57.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 108.143 -1.058 . . . . 20.88 108.143 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 66' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' D' ' 128' ' ' ILE . 50.6 p -115.59 146.24 41.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.484 -0.562 . . . . 11.07 109.484 176.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 67' ' ' TYR . . . . . 0.446 ' HE1' HD12 ' D' ' 130' ' ' ILE . 52.2 p90 -155.28 -173.76 4.69 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.72 -0.845 . . . . 11.51 108.72 176.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 68' ' ' TYR . . . . . . . . . . . . . 14.9 m-30 -116.13 139.17 50.59 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.844 -0.428 . . . . 4.27 109.844 176.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.69 118.75 4.69 Favored Glycine 0 N--CA 1.449 -0.485 0 N-CA-C 114.447 0.539 . . . . 18.98 114.447 -175.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 70' ' ' LYS . . . . . 0.417 ' O ' ' NE2' ' D' ' 76' ' ' GLN . 39.0 ttmt -93.04 152.15 19.47 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.868 -0.79 . . . . 28.91 108.868 174.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 71' ' ' ARG . . . . . . . . . . . . . 21.0 ptp180 -69.52 -15.58 63.27 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.042 1.127 . . . . 24.14 114.042 -171.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.85 -141.03 5.2 Favored Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 110.191 -1.164 . . . . 34.32 110.191 176.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 73' ' ' ASP . . . . . 0.469 ' HB3' ' HE1' ' D' ' 28' ' ' PHE . 32.2 t0 59.93 71.73 0.56 Allowed 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.185 1.394 . . . . 17.7 111.221 167.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.62 9.85 0.08 Allowed 'General case' 0 C--O 1.234 0.288 0 N-CA-C 117.167 2.284 . . . . 46.91 117.167 -159.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.98 -39.66 94.47 Favored Glycine 0 C--N 1.338 0.644 0 C-N-CA 120.285 -0.96 . . . . 4.26 112.572 170.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 76' ' ' GLN . . . . . 0.417 ' NE2' ' O ' ' D' ' 70' ' ' LYS . 22.3 pt20 -69.33 -24.15 63.88 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 119.859 -0.736 . . . . 12.4 111.856 172.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 77' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -72.98 -25.19 60.91 Favored 'General case' 0 CA--C 1.517 -0.314 0 C-N-CA 119.61 -0.836 . . . . 26.67 111.306 171.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.73 -32.15 63.72 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 120.41 -0.516 . . . . 19.88 111.28 169.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 79' ' ' ILE . . . . . . . . . . . . . 51.8 mm -62.99 -42.71 97.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-O 121.168 0.509 . . . . 17.52 110.324 171.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -74.74 -22.2 58.93 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 121.887 -0.508 . . . . 20.76 111.948 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 81' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -69.73 -32.49 71.08 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 120.182 -0.607 . . . . 9.87 111.183 168.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 82' ' ' ALA . . . . . 0.741 ' HA ' ' HB2' ' D' ' 87' ' ' LYS . . . -73.63 -37.08 65.47 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 119.547 -0.861 . . . . 0.03 111.677 174.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 83' ' ' TYR . . . . . . . . . . . . . 81.6 t80 -84.55 -62.5 1.54 Allowed 'General case' 0 C--O 1.235 0.333 0 C-N-CA 119.979 -0.688 . . . . 12.94 112.195 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -73.91 -39.19 64.01 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 111.86 0.319 . . . . 34.89 111.86 -167.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 85' ' ' ASN . . . . . . . . . . . . . 34.5 m120 -78.32 -45.5 22.49 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 119.942 -0.703 . . . . 17.71 111.155 173.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.03 96.63 2.4 Favored Glycine 0 N--CA 1.45 -0.403 0 O-C-N 122.23 -0.294 . . . . 4.02 113.285 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 87' ' ' LYS . . . . . 0.741 ' HB2' ' HA ' ' D' ' 82' ' ' ALA . 98.0 mttt -148.48 -161.97 1.46 Allowed 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 107.135 -1.431 . . . . 17.71 107.135 -178.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 88' ' ' GLN . . . . . 0.689 HE22 HD23 ' C' ' 54' ' ' LEU . 88.9 mt-30 -130.19 176.0 8.46 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.428 0.632 . . . . 17.71 109.802 170.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 89' ' ' ILE . . . . . 0.417 HD11 HD11 ' D' ' 113' ' ' ILE . 81.9 mt -129.96 133.04 65.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 CA-C-N 116.109 -0.496 . . . . 13.1 109.901 -173.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 90' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -82.78 120.14 25.25 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 108.514 -0.921 . . . . 26.03 108.514 165.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 91' ' ' PHE . . . . . 0.423 ' HB3' ' O ' ' D' ' 109' ' ' GLY . 85.6 t80 -116.72 128.13 55.04 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.58 1.152 . . . . 14.57 109.993 -166.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 92' ' ' TRP . . . . . 0.525 ' HB2' ' HB2' ' D' ' 14' ' ' LEU . 91.8 m95 -127.38 131.84 50.27 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 123.815 0.846 . . . . 30.93 108.928 -178.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 93' ' ' ARG . . . . . 0.796 ' O ' ' HA ' ' D' ' 106' ' ' ALA . 78.0 ttt-85 -114.16 97.12 6.16 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.343 -0.984 . . . . 17.71 108.343 172.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 94' ' ' VAL . . . . . 0.527 HG12 ' HB2' ' D' ' 106' ' ' ALA . 27.0 m -109.06 159.7 8.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 CA-C-O 122.333 1.064 . . . . 15.36 109.885 -172.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 95' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -103.3 159.15 15.81 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 114.681 -1.145 . . . . 28.34 110.653 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 96' ' ' THR . . . . . 0.478 HG23 HG23 ' D' ' 150' ' ' ILE . 28.5 m -95.67 -29.41 14.31 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.164 -0.925 . . . . 23.09 112.365 -178.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 97' ' ' VAL . . . . . . . . . . . . . 35.0 m -68.67 153.62 8.79 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-O 121.827 0.822 . . . . 4.39 109.993 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 98' ' ' LYS . . . . . 0.51 ' NZ ' ' O ' ' D' ' 99' ' ' ASN . 29.7 tptp -88.43 124.25 33.77 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.609 -0.723 . . . . 27.59 109.739 -175.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 99' ' ' ASN . . . . . 0.51 ' O ' ' NZ ' ' D' ' 98' ' ' LYS . 34.7 m120 -84.41 166.98 16.89 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.796 0.808 . . . . 7.41 109.818 170.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 100' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -103.93 -13.23 16.43 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 113.732 1.012 . . . . 30.25 113.732 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 101' ' ' ASN . . . . . . . . . . . . . 16.6 p30 -89.7 -58.69 2.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 118.323 0.511 . . . . 8.96 111.538 167.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 102' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -100.85 -177.79 3.57 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 108.52 -0.918 . . . . 31.68 108.52 173.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 103' ' ' LYS . . . . . 0.661 ' H ' HG22 ' D' ' 143' ' ' ILE . 97.2 mttt -73.23 -58.15 3.52 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.037 -0.665 . . . . 36.33 110.045 168.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 104' ' ' TYR . . . . . . . . . . . . . 46.5 m-85 -132.94 -170.95 2.55 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 107.652 -1.24 . . . . 20.57 107.652 -178.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 105' ' ' ASP . . . . . 0.473 ' O ' ' HA ' ' D' ' 94' ' ' VAL . 20.2 p-10 -149.57 169.03 21.9 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.446 0.641 . . . . 18.47 109.427 175.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 106' ' ' ALA . . . . . 0.796 ' HA ' ' O ' ' D' ' 93' ' ' ARG . . . -153.06 158.88 42.6 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.324 -0.853 . . . . 13.65 111.123 -162.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 107' ' ' GLN . . . . . 0.43 ' OE1' ' OH ' ' E' ' 118' ' ' TYR . 88.5 mt-30 -117.69 120.54 38.32 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 107.046 -1.464 . . . . 25.15 107.046 160.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 108' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -104.15 152.4 22.17 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 123.669 0.788 . . . . 16.05 110.274 -168.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 109' ' ' GLY . . . . . 0.448 ' HA3' HG21 ' D' ' 134' ' ' VAL . . . -167.35 156.05 27.52 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 119.928 -1.129 . . . . 22.86 112.403 168.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 110' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -93.87 110.37 22.03 Favored 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.812 -0.811 . . . . 14.08 108.812 168.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 111' ' ' ALA . . . . . . . . . . . . . . . -114.5 159.85 19.89 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.47 0.652 . . . . 26.73 111.799 -167.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 112' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -135.66 139.02 43.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.62 -1.173 . . . . 21.98 107.941 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 113' ' ' ILE . . . . . 0.417 HD11 HD11 ' D' ' 89' ' ' ILE . 78.4 mt -83.78 129.47 37.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 N-CA-C 109.79 -0.448 . . . . 16.61 109.79 -172.382 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 114' ' ' GLU . . . . . 0.512 ' HB2' ' HB2' ' D' ' 131' ' ' SER . 98.3 mt-10 -72.91 -64.32 0.99 Allowed 'General case' 0 C--O 1.235 0.316 0 C-N-CA 119.694 -0.802 . . . . 29.14 110.696 164.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -142.27 152.6 43.18 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 121.683 0.754 . . . . 34.36 110.362 -169.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -127.27 93.65 3.79 Favored 'General case' 0 C--N 1.332 -0.196 0 N-CA-C 104.946 -2.242 . . . . 10.27 104.946 178.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 117' ' ' GLU . . . . . 0.522 ' HB3' HG12 ' C' ' 37' ' ' VAL . 98.3 mt-10 -115.09 108.91 17.28 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.624 -1.251 . . . . 37.96 107.624 -175.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 118' ' ' TYR . . . . . 0.54 ' HB3' ' HA ' ' D' ' 128' ' ' ILE . 21.1 p90 -114.61 146.41 40.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.523 0.678 . . . . 17.71 111.964 177.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 119' ' ' SER . . . . . . . . . . . . . 35.7 t -102.5 134.94 45.02 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 114.717 -1.128 . . . . 17.71 110.012 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 120' ' ' ASP . . . . . 0.582 ' HB3' ' HB2' ' C' ' 34' ' ' ASP . 58.0 t0 -115.3 96.38 5.64 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.621 -1.622 . . . . 20.72 106.621 172.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.09 -158.2 22.28 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-O 121.694 0.608 . . . . 30.48 112.193 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 122' ' ' VAL . . . . . . . . . . . . . 72.9 t -113.04 -63.21 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 107.913 -1.143 . . . . 20.46 107.913 175.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 123' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -79.12 -44.94 21.01 Favored 'General case' 0 N--CA 1.45 -0.428 0 N-CA-C 112.725 0.639 . . . . 58.76 112.725 178.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.08 151.96 46.33 Favored Glycine 0 C--O 1.236 0.278 0 N-CA-C 110.263 -1.135 . . . . 20.52 110.263 174.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 125' ' ' ALA . . . . . 0.474 ' HB2' HD13 ' I' ' 43' ' ' LEU . . . -75.0 171.38 14.21 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 121.726 0.774 . . . . 17.58 110.207 173.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 126' ' ' VAL . . . . . 0.491 HG12 ' HA ' ' D' ' 120' ' ' ASP . 33.8 m -69.19 154.48 8.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.558 0 CA-C-N 115.252 -0.885 . . . . 8.76 109.578 -178.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 127' ' ' GLU . . . . . . . . . . . . . 19.4 pt-20 -144.81 124.92 13.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.379 -0.373 . . . . 32.62 110.086 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 128' ' ' ILE . . . . . 0.54 ' HA ' ' HB3' ' D' ' 118' ' ' TYR . 87.3 mt -95.28 119.96 44.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.335 -0.617 . . . . 17.71 109.335 -176.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 129' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' D' ' 117' ' ' GLU . 69.0 m -100.48 134.42 43.46 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.359 -0.978 . . . . 13.09 108.359 170.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 130' ' ' ILE . . . . . 0.446 HD12 ' HE1' ' D' ' 67' ' ' TYR . 66.1 mt -136.81 128.91 43.99 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.997 -0.742 . . . . 14.17 108.997 -177.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 131' ' ' SER . . . . . 0.512 ' HB2' ' HB2' ' D' ' 114' ' ' GLU . 58.7 m -97.36 150.53 20.89 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.202 -0.453 . . . . 8.77 110.142 176.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 132' ' ' LEU . . . . . 0.65 ' O ' ' HA ' ' D' ' 62' ' ' SER . 7.4 mp -134.7 140.63 46.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.118 -0.492 . . . . 35.37 110.912 -178.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 133' ' ' GLN . . . . . 0.434 ' HG2' ' HG3' ' D' ' 114' ' ' GLU . 29.9 mm100 -119.1 137.01 53.87 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.567 -0.901 . . . . 17.71 108.567 167.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 134' ' ' VAL . . . . . 0.448 HG21 ' HA3' ' D' ' 109' ' ' GLY . 11.0 p -135.62 146.9 29.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 N-CA-C 108.546 -0.909 . . . . 21.28 108.546 175.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 135' ' ' ILE . . . . . . . . . . . . . 26.5 mm -61.21 -61.14 1.71 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.331 0 CA-C-N 115.885 -0.598 . . . . 10.66 110.808 178.033 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.1 139.55 6.11 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 109.858 -1.297 . . . . 38.83 109.858 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 137' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -68.79 152.6 45.1 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.606 0.717 . . . . 10.13 110.291 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 138' ' ' LEU . . . . . . . . . . . . . 33.4 tp -138.38 124.46 20.2 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 107.265 -1.383 . . . . 14.09 107.265 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -82.9 70.04 9.83 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 122.313 1.054 . . . . 16.98 109.758 -169.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 140' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -90.34 76.07 6.79 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.243 -1.021 . . . . 26.2 108.243 177.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.53 112.07 3.71 Favored Glycine 0 C--O 1.237 0.302 0 N-CA-C 110.433 -1.067 . . . . 10.67 110.433 174.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -119.73 -174.25 2.71 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.375 -0.602 . . . . 8.34 109.375 -175.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 143' ' ' ILE . . . . . 0.661 HG22 ' H ' ' D' ' 103' ' ' LYS . 1.2 pp -105.54 -63.69 1.77 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 113.438 0.903 . . . . 32.75 113.438 -170.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 144' ' ' ASP . . . . . . . . . . . . . 24.5 p-10 -80.9 131.06 35.33 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 121.438 -0.789 . . . . 27.27 111.05 -167.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 145' ' ' THR . . . . . . . . . . . . . 74.8 p -122.18 15.15 10.61 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 112.529 0.566 . . . . 30.29 112.529 176.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 146' ' ' LEU . . . . . 0.416 ' HG ' ' HA ' ' D' ' 24' ' ' SER . 4.2 mm? 54.56 76.16 0.54 Allowed Pre-proline 0 C--O 1.237 0.434 0 C-N-CA 126.702 2.001 . . . . 9.64 110.169 -178.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 147' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -68.21 71.24 0.89 Allowed 'Trans proline' 0 C--N 1.347 0.463 0 N-CA-C 115.434 1.282 . . . . 19.87 115.434 -160.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 148' ' ' GLU . . . . . 0.53 ' OE1' ' ND2' ' D' ' 152' ' ' ASN . 79.3 mm-40 -109.89 9.25 24.55 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 123.186 0.594 . . . . 36.67 111.438 170.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 149' ' ' GLU . . . . . 0.455 ' O ' ' NZ ' ' D' ' 12' ' ' LYS . 25.8 pm0 -138.15 4.39 2.47 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 112.411 0.523 . . . . 10.02 112.411 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 150' ' ' ILE . . . . . 0.478 HG23 HG23 ' D' ' 96' ' ' THR . 45.7 mm -111.52 -47.77 6.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 118.717 0.69 . . . . 14.89 111.101 -178.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 151' ' ' VAL . . . . . . . . . . . . . 45.2 t -106.94 -29.52 2.65 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 107.879 -1.156 . . . . 22.9 107.879 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 152' ' ' ASN . . . . . 0.53 ' ND2' ' OE1' ' D' ' 148' ' ' GLU . 33.8 t-20 -67.49 -28.08 67.54 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.128 -0.487 . . . . 19.56 111.709 -176.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -75.26 96.02 1.07 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 107.35 -1.352 . . . . 21.6 107.35 168.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 154' ' ' SER . . . . . . . . . . . . . 39.3 t -117.44 -62.2 1.6 Allowed 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.633 -0.712 . . . . 12.43 112.663 -172.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 155' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -135.51 -28.81 1.1 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 113.819 1.044 . . . . 28.2 113.819 179.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 156' ' ' GLY . . . . . . . . . . . . . . . 90.37 -61.05 3.27 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 119.368 0.986 . . . . 30.81 110.881 -169.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.77 141.6 25.63 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.45 -0.881 . . . . 33.96 112.217 176.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 158' ' ' TYR . . . . . 0.463 ' CD2' ' HG2' ' D' ' 171' ' ' PRO . 19.8 m-30 -112.15 -171.27 1.82 Allowed 'General case' 0 C--O 1.236 0.343 0 C-N-CA 124.185 0.994 . . . . 7.5 108.677 179.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 159' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -76.66 -74.16 0.25 Allowed 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.351 -0.94 . . . . 29.41 113.307 -155.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 160' ' ' PHE . . . . . 0.436 ' CD2' ' HG3' ' D' ' 162' ' ' GLN . 41.1 p90 177.4 173.8 0.49 Allowed 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 127.782 2.433 . . . . 9.26 109.318 165.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 161' ' ' GLN . . . . . . . . . . . . . 65.2 tt0 -156.76 100.81 1.94 Allowed 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 105.446 -2.057 . . . . 8.03 105.446 154.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 162' ' ' GLN . . . . . 0.436 ' HG3' ' CD2' ' D' ' 160' ' ' PHE . 88.7 mt-30 -68.66 -46.3 34.52 Favored Pre-proline 0 C--O 1.242 0.672 0 N-CA-C 113.997 1.11 . . . . 17.71 113.997 -167.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 163' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -77.86 -19.17 12.72 Favored 'Trans proline' 0 C--N 1.367 1.532 0 CA-C-N 122.097 1.785 . . . . 29.74 112.467 174.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 164' ' ' GLY . . . . . . . . . . . . . . . -138.39 35.43 2.01 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 119.237 2.455 . . . . 33.79 119.237 -167.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 165' ' ' GLN . . . . . 0.45 ' HG2' ' HD3' ' J' ' 90' ' ' LYS . 9.8 tp-100 -66.29 -57.59 7.19 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 118.715 1.257 . . . . 31.23 111.032 178.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 166' ' ' THR . . . . . 0.412 HG22 ' HB2' ' J' ' 21' ' ' ALA . 33.8 p 54.74 46.86 23.73 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 125.754 1.621 . . . . 34.31 111.644 176.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 167' ' ' THR . . . . . . . . . . . . . 2.6 m -137.99 150.35 46.91 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 119.744 -0.783 . . . . 3.71 109.431 -168.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 168' ' ' GLY . . . . . . . . . . . . . . . -82.73 -129.45 1.34 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 111.272 -0.731 . . . . 40.11 111.272 168.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 169' ' ' GLU . . . . . 0.427 ' HG3' ' HG ' ' I' ' 54' ' ' LEU . 15.2 tm-20 -73.15 -62.72 1.37 Allowed 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.817 -0.353 . . . . 45.84 111.413 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.47 104.33 0.59 Allowed Pre-proline 0 C--O 1.235 0.293 0 C-N-CA 123.798 0.839 . . . . 8.16 109.098 -176.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 171' ' ' PRO . . . . . 0.463 ' HG2' ' CD2' ' D' ' 158' ' ' TYR . 98.3 Cg_endo -83.01 -174.62 2.09 Favored 'Trans proline' 0 C--N 1.323 -0.814 0 C-N-CA 121.306 1.338 . . . . 17.71 112.863 -152.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 172' ' ' GLY . . . . . . . . . . . . . . . 72.06 69.38 1.4 Allowed Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 116.69 1.436 . . . . 15.19 116.69 165.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -130.84 167.17 19.36 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.881 0.848 . . . . 3.32 109.346 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 174' ' ' VAL . . . . . . . . . . . . . 23.9 m -82.8 157.72 66.3 Favored Pre-proline 0 C--O 1.239 0.549 0 CA-C-N 114.605 -1.179 . . . . 5.84 108.445 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 175' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -66.19 110.98 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.551 0 CA-C-N 119.465 0.844 . . . . 11.61 111.887 175.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.384 0 C-N-CA 125.508 1.523 . . . . 35.92 112.762 -172.538 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 5' ' ' PRO . . . . . 0.47 ' HB2' ' H ' ' E' ' 6' ' ' ILE . 39.9 Cg_endo . . . . . 0 N--CA 1.466 -0.112 0 CA-C-O 119.86 -0.142 . . . . 5.43 112.451 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 6' ' ' ILE . . . . . 0.47 ' H ' ' HB2' ' E' ' 5' ' ' PRO . 96.4 mt -121.94 120.72 62.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 N-CA-C 107.989 -1.115 . . . . 17.43 107.989 177.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -89.12 170.74 10.36 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-O 121.934 0.873 . . . . 47.72 110.802 -177.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.0 -11.59 66.98 Favored Glycine 0 C--N 1.333 0.397 0 CA-C-N 115.308 -0.86 . . . . 17.06 114.391 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -96.1 -14.01 23.19 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 117.654 0.727 . . . . 17.43 112.277 171.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -77.02 -5.72 49.85 Favored 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 113.908 1.077 . . . . 28.45 113.908 -171.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' VAL . . . . . . . . . . . . . 71.9 t -127.03 124.92 65.53 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 119.597 1.089 . . . . 41.68 108.07 -176.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' LYS . . . . . 0.46 ' NZ ' ' O ' ' E' ' 149' ' ' GLU . 51.1 mtmt -134.5 162.61 31.77 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.639 0.733 . . . . 25.52 109.859 175.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' TYR . . . . . 0.409 ' CE1' ' HG3' ' E' ' 93' ' ' ARG . 19.9 m-30 -113.23 97.09 6.27 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.942 -1.026 . . . . 17.43 108.483 -165.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' LEU . . . . . 0.754 HD23 ' HB3' ' E' ' 27' ' ' LEU . 86.9 mt -74.98 125.67 29.4 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 120.689 -0.404 . . . . 54.21 110.056 177.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -109.27 147.8 32.04 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.773 -0.454 . . . . 24.77 109.773 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' GLN . . . . . . . . . . . . . 70.9 tp60 -144.14 135.82 25.99 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 109.173 -0.677 . . . . 30.25 109.173 176.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' SER . . . . . . . . . . . . . 36.8 t -74.64 159.42 32.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.636 0.732 . . . . 6.52 111.158 179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 pt -82.0 -12.65 12.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-N 115.414 -0.812 . . . . 8.3 113.163 178.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -115.32 -9.86 12.13 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 112.769 0.655 . . . . 24.65 112.769 -169.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.16 -45.12 42.84 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 119.7 -0.8 . . . . 24.92 111.628 -177.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.3 41.11 32.15 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.024 1.33 . . . . 25.41 111.646 -171.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' THR . . . . . . . . . . . . . 70.2 p -123.39 126.01 46.02 Favored 'General case' 0 C--O 1.236 0.344 0 C-N-CA 123.422 0.689 . . . . 17.43 109.2 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.47 77.14 2.08 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 114.33 0.492 . . . . 26.12 114.33 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' SER . . . . . 0.418 ' HA ' ' HG ' ' E' ' 146' ' ' LEU . 93.3 p -128.65 -26.63 2.69 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 120.541 -0.463 . . . . 43.19 111.672 -178.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' ALA . . . . . 0.417 ' HB1' ' HB3' ' E' ' 14' ' ' LEU . . . 51.16 73.74 0.92 Allowed Pre-proline 0 C--O 1.237 0.4 0 C-N-CA 126.961 2.104 . . . . 21.35 112.48 -173.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo -72.16 104.62 1.7 Allowed 'Trans proline' 0 C--O 1.236 0.386 0 CA-C-N 119.494 0.855 . . . . 23.52 112.067 176.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' LEU . . . . . 0.754 ' HB3' HD23 ' E' ' 14' ' ' LEU . 2.1 pt? -86.11 151.73 23.44 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.915 -0.772 . . . . 17.43 108.915 166.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' PHE . . . . . 0.496 ' HE1' ' HB3' ' E' ' 73' ' ' ASP . 70.5 t80 -99.52 132.14 23.68 Favored Pre-proline 0 C--N 1.305 -1.359 1 C-N-CA 111.674 -4.01 . . . . 27.95 110.151 -178.595 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.32 -172.74 1.1 Allowed 'Trans proline' 0 C--O 1.234 0.315 0 N-CA-C 114.15 0.788 . . . . 11.88 114.15 -176.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.68 ' HA ' ' HB3' ' J' ' 47' ' ' GLN . . . 56.47 56.93 5.23 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.705 1.202 . . . . 17.01 111.677 -175.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' TYR . . . . . 0.411 ' HD1' ' HA ' ' E' ' 31' ' ' TYR . 2.1 m-30 -70.29 178.54 2.81 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-O 123.012 1.387 . . . . 39.34 112.097 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' GLN . . . . . 0.478 ' HG3' ' H ' ' E' ' 33' ' ' THR . 6.2 tp-100 -149.34 -158.57 0.93 Allowed 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 103.473 -2.788 . . . . 48.05 103.473 172.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' THR . . . . . 0.478 ' H ' ' HG3' ' E' ' 32' ' ' GLN . 14.2 t -63.71 161.55 14.85 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 122.736 1.255 . . . . 26.33 111.719 178.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' ASP . . . . . 0.59 ' HB2' ' HB3' ' F' ' 120' ' ' ASP . 83.3 m-20 -136.12 -168.75 2.29 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 113.829 -1.532 . . . . 59.62 107.856 -167.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' GLY . . . . . 0.705 ' O ' ' HA2' ' E' ' 63' ' ' GLY . . . 172.27 135.04 1.89 Allowed Glycine 0 N--CA 1.441 -0.984 0 C-N-CA 120.37 -0.919 . . . . 17.43 111.843 167.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' SER . . . . . . . . . . . . . 66.0 m -123.3 84.98 2.35 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 105.618 -1.993 . . . . 6.96 105.618 174.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' VAL . . . . . 0.563 HG23 ' HB2' ' E' ' 62' ' ' SER . 3.9 m -92.15 109.35 21.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.41 -0.959 . . . . 4.52 108.41 -172.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' SER . . . . . . . . . . . . . 49.9 m -98.83 94.59 6.68 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.923 -1.14 . . . . 24.09 107.923 -168.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.43 102.89 2.9 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.373 -0.918 . . . . 29.57 113.669 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' E' ' 59' ' ' VAL . 84.6 tt0 -109.33 118.64 37.19 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.859 . . . . 10.27 108.682 -178.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 41' ' ' ARG . . . . . 0.608 ' O ' ' HA3' ' E' ' 57' ' ' GLY . 88.8 mtm-85 -81.69 -174.38 4.97 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.553 0.692 . . . . 46.9 109.473 -177.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 42' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -161.29 146.43 13.81 Favored 'General case' 0 C--N 1.329 -0.29 0 O-C-N 121.855 -0.528 . . . . 55.7 110.082 -170.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 43' ' ' LEU . . . . . . . . . . . . . 81.5 mt -77.94 146.77 35.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.638 -0.71 . . . . 17.56 109.526 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 44' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -147.71 125.68 12.04 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.533 0.206 . . . . 32.68 110.929 172.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 45' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -125.63 -170.96 2.27 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 108.52 -0.918 . . . . 36.52 108.52 157.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 46' ' ' GLU . . . . . . . . . . . . . 49.0 mp0 -113.67 -34.65 5.44 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 113.679 0.992 . . . . 24.79 113.679 174.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 47' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 59.17 25.58 14.15 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.355 1.462 . . . . 27.02 112.281 -179.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 48' ' ' THR . . . . . . . . . . . . . 56.2 p 48.07 45.57 19.44 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.006 1.323 . . . . 12.29 111.406 -165.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 49' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -137.32 -165.33 1.74 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.523 -1.288 . . . . 17.43 107.523 -175.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 50' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -66.84 -25.28 66.35 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.376 0.51 . . . . 30.21 112.376 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 51' ' ' GLY . . . . . . . . . . . . . . . 138.81 160.08 8.26 Favored Glycine 0 N--CA 1.448 -0.555 0 N-CA-C 111.577 -0.609 . . . . 9.65 111.577 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 52' ' ' ARG . . . . . . . . . . . . . 17.0 tpp85 -124.49 51.24 1.62 Allowed 'General case' 0 C--O 1.234 0.285 0 N-CA-C 106.228 -1.767 . . . . 7.84 106.228 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 53' ' ' ILE . . . . . . . . . . . . . 6.5 tt -79.06 -4.94 7.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.672 -0.695 . . . . 59.64 111.4 -173.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 54' ' ' LEU . . . . . 0.716 HD23 HE22 ' F' ' 88' ' ' GLN . 7.0 mp -64.66 -21.71 66.8 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 47.32 112.897 -177.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.15 145.02 43.92 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-O 121.481 0.49 . . . . 23.4 114.209 -170.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 56' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -75.7 -178.97 4.69 Favored 'Trans proline' 0 C--N 1.328 -0.542 0 C-N-CA 121.31 1.34 . . . . 17.43 112.001 -175.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 57' ' ' GLY . . . . . 0.608 ' HA3' ' O ' ' E' ' 41' ' ' ARG . . . -153.89 171.18 32.58 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.468 -1.453 . . . . 25.4 109.468 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 58' ' ' SER . . . . . . . . . . . . . 44.0 t -73.61 146.69 44.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.656 0.741 . . . . 10.01 110.409 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 59' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' E' ' 40' ' ' GLU . 2.7 p -107.57 122.49 61.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 N-CA-C 108.517 -0.92 . . . . 2.89 108.517 -177.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.28 118.07 29.46 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 106.931 -1.507 . . . . 14.7 106.931 172.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 61' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -113.08 121.11 43.59 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.425 -0.954 . . . . 61.06 108.425 -172.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 62' ' ' SER . . . . . 0.646 ' HA ' ' O ' ' E' ' 132' ' ' LEU . 66.8 m -106.33 165.13 11.48 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.727 0.811 . . . . 17.43 110.399 -176.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 63' ' ' GLY . . . . . 0.705 ' HA2' ' O ' ' E' ' 35' ' ' GLY . . . -139.76 122.02 2.15 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.191 -0.913 . . . . 17.43 112.419 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 64' ' ' GLU . . . . . 0.418 ' O ' ' HA ' ' E' ' 34' ' ' ASP . 66.8 mm-40 -103.32 95.51 6.14 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 107.359 -1.348 . . . . 56.28 107.359 174.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 65' ' ' VAL . . . . . . . . . . . . . 86.4 t -106.73 119.79 56.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.111 -1.07 . . . . 17.43 108.111 -178.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 66' ' ' THR . . . . . . . . . . . . . 72.9 p -116.68 145.24 43.58 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.522 -0.547 . . . . 24.78 109.522 177.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 67' ' ' TYR . . . . . 0.457 ' HE1' HD12 ' E' ' 130' ' ' ILE . 51.4 p90 -154.82 -174.92 5.18 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.901 -0.777 . . . . 1.29 108.901 178.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 68' ' ' TYR . . . . . . . . . . . . . 15.6 m-30 -114.68 136.57 52.91 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 109.555 -0.535 . . . . 17.43 109.555 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 69' ' ' GLY . . . . . . . . . . . . . . . -85.29 114.3 3.95 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.969 -0.634 . . . . 17.43 113.939 -176.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 70' ' ' LYS . . . . . 0.499 ' O ' ' NE2' ' E' ' 76' ' ' GLN . 38.3 ttmt -82.97 152.75 25.33 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.609 -0.886 . . . . 17.43 108.609 174.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -68.49 -15.6 63.6 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 113.935 1.087 . . . . 40.31 113.935 -171.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.51 -140.08 5.04 Favored Glycine 0 N--CA 1.452 -0.296 0 N-CA-C 110.083 -1.207 . . . . 37.12 110.083 175.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 73' ' ' ASP . . . . . 0.496 ' HB3' ' HE1' ' E' ' 28' ' ' PHE . 32.9 t0 59.88 73.01 0.5 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 125.145 1.378 . . . . 16.31 111.125 168.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.68 11.3 0.07 Allowed 'General case' 0 C--O 1.235 0.291 0 N-CA-C 117.113 2.264 . . . . 26.3 117.113 -158.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.29 96.75 Favored Glycine 0 C--N 1.338 0.661 0 C-N-CA 120.268 -0.967 . . . . 23.8 112.555 170.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 76' ' ' GLN . . . . . 0.499 ' NE2' ' O ' ' E' ' 70' ' ' LYS . 22.1 pt20 -70.47 -23.73 62.75 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 119.921 -0.712 . . . . 32.42 111.859 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 77' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -70.71 -28.08 64.47 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 119.693 -0.803 . . . . 14.13 111.191 170.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.64 -30.28 62.84 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 120.624 -0.43 . . . . 40.88 111.443 170.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 79' ' ' ILE . . . . . . . . . . . . . 50.6 mm -64.3 -43.42 97.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 CA-C-O 121.098 0.475 . . . . 17.43 110.301 172.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.55 -22.69 60.01 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 120.362 -0.535 . . . . 30.96 112.009 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 81' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -69.32 -32.67 71.93 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 120.314 -0.554 . . . . 22.7 111.24 168.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 82' ' ' ALA . . . . . 0.746 ' HA ' ' HB2' ' E' ' 87' ' ' LYS . . . -75.44 -34.95 61.01 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 119.548 -0.861 . . . . 17.43 111.642 175.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 83' ' ' TYR . . . . . . . . . . . . . 83.3 t80 -84.3 -62.1 1.64 Allowed 'General case' 0 C--O 1.235 0.336 0 C-N-CA 120.184 -0.606 . . . . 9.61 112.135 -176.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 84' ' ' GLN . . . . . . . . . . . . . 64.6 tt0 -73.56 -41.01 63.51 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 111.922 0.342 . . . . 15.78 111.922 -167.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 85' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -74.18 -43.44 57.28 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 119.836 -0.745 . . . . 19.48 111.008 171.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.86 97.03 2.48 Favored Glycine 0 N--CA 1.448 -0.544 0 O-C-N 122.253 -0.28 . . . . 17.43 112.902 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 87' ' ' LYS . . . . . 0.746 ' HB2' ' HA ' ' E' ' 82' ' ' ALA . 98.0 mttt -147.88 -162.2 1.5 Allowed 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.057 -1.46 . . . . 17.43 107.057 -178.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 88' ' ' GLN . . . . . 0.732 HE22 HD23 ' D' ' 54' ' ' LEU . 89.7 mt-30 -129.94 175.21 9.05 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.48 0.657 . . . . 17.43 109.82 170.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 89' ' ' ILE . . . . . . . . . . . . . 70.1 mt -128.88 134.26 64.63 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-N 115.903 -0.59 . . . . 18.82 109.618 -172.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -83.27 120.34 25.71 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.465 -0.939 . . . . 13.36 108.465 165.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 91' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' E' ' 109' ' ' GLY . 78.9 t80 -118.15 129.36 55.48 Favored 'General case' 0 C--O 1.237 0.422 0 C-N-CA 124.319 1.047 . . . . 5.27 110.032 -165.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 92' ' ' TRP . . . . . 0.534 ' HB2' ' HB2' ' E' ' 14' ' ' LEU . 89.9 m95 -129.11 130.87 47.02 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.87 0.868 . . . . 17.43 108.898 -177.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 93' ' ' ARG . . . . . 0.794 ' O ' ' HA ' ' E' ' 106' ' ' ALA . 78.1 ttt-85 -112.19 94.31 4.87 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.187 -1.042 . . . . 15.55 108.187 172.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 94' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' E' ' 106' ' ' ALA . 25.4 m -107.36 162.22 5.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.197 0.998 . . . . 46.02 109.636 -172.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 95' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -109.47 167.96 9.74 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.842 -1.072 . . . . 15.36 111.291 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 96' ' ' THR . . . . . 0.5 HG23 HG23 ' E' ' 150' ' ' ILE . 28.3 m -101.51 -29.68 11.84 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 114.941 -1.027 . . . . 29.59 112.527 -175.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 97' ' ' VAL . . . . . . . . . . . . . 35.1 m -69.28 152.97 9.08 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 CA-C-O 121.702 0.763 . . . . 11.14 110.153 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 98' ' ' LYS . . . . . 0.453 ' NZ ' ' O ' ' E' ' 99' ' ' ASN . 29.7 tptp -89.31 123.53 33.58 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.699 -0.682 . . . . 30.45 109.822 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 99' ' ' ASN . . . . . 0.453 ' O ' ' NZ ' ' E' ' 98' ' ' LYS . 34.7 m120 -84.06 168.25 16.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.779 0.799 . . . . 6.7 109.949 171.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 100' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 -105.83 -12.46 15.86 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 113.64 0.978 . . . . 18.17 113.64 178.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 101' ' ' ASN . . . . . . . . . . . . . 15.8 p30 -94.55 -56.25 2.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 118.296 0.498 . . . . 32.03 111.088 170.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 102' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -99.12 -174.28 2.71 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 107.965 -1.124 . . . . 20.71 107.965 168.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 103' ' ' LYS . . . . . 0.644 ' H ' HG22 ' E' ' 143' ' ' ILE . 97.2 mttt -82.07 -54.88 4.94 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 120.18 -0.608 . . . . 50.01 110.144 169.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 104' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -131.4 -171.37 2.58 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 107.723 -1.214 . . . . 17.43 107.723 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 105' ' ' ASP . . . . . 0.412 ' O ' ' HA ' ' E' ' 94' ' ' VAL . 22.6 p-10 -150.5 167.08 28.23 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.604 0.716 . . . . 27.13 109.543 176.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 106' ' ' ALA . . . . . 0.794 ' HA ' ' O ' ' E' ' 93' ' ' ARG . . . -154.78 159.79 40.86 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.087 -0.961 . . . . 10.17 110.991 -162.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 107' ' ' GLN . . . . . 0.467 ' OE1' ' OH ' ' F' ' 118' ' ' TYR . 88.7 mt-30 -121.41 121.31 37.31 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 107.187 -1.412 . . . . 8.04 107.187 161.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 108' ' ' PHE . . . . . . . . . . . . . 92.8 t80 -105.88 152.88 22.71 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.265 1.026 . . . . 14.65 110.282 -165.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 109' ' ' GLY . . . . . 0.428 ' O ' ' HB3' ' E' ' 91' ' ' PHE . . . -169.47 155.09 24.94 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.753 -1.213 . . . . 7.84 112.491 171.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 110' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -94.32 107.55 19.5 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 108.924 -0.769 . . . . 16.85 108.924 168.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.24 160.17 16.75 Favored 'General case' 0 C--O 1.237 0.395 0 CA-C-O 121.537 0.685 . . . . 32.2 111.621 -166.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 112' ' ' TYR . . . . . 0.494 ' HD1' ' HG2' ' E' ' 88' ' ' GLN . 64.4 t80 -138.31 136.45 36.44 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.615 -1.175 . . . . 13.21 108.073 -178.253 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 113' ' ' ILE . . . . . . . . . . . . . 79.8 mt -83.27 129.4 37.53 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.871 -0.418 . . . . 19.96 109.871 -171.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 114' ' ' GLU . . . . . 0.532 ' HB2' ' HB2' ' E' ' 131' ' ' SER . 98.1 mt-10 -72.67 -64.25 1.0 Allowed 'General case' 0 C--O 1.236 0.343 0 C-N-CA 119.77 -0.772 . . . . 38.93 110.645 164.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 115' ' ' SER . . . . . . . . . . . . . 73.3 m -141.67 149.25 40.35 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-O 121.634 0.731 . . . . 34.04 110.333 -169.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -123.43 94.91 4.39 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 105.119 -2.178 . . . . 13.74 105.119 176.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 117' ' ' GLU . . . . . 0.543 ' HB3' HG12 ' D' ' 37' ' ' VAL . 98.1 mt-10 -115.54 108.47 16.49 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.387 -1.338 . . . . 44.54 107.387 -175.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 118' ' ' TYR . . . . . 0.523 ' HB3' ' HA ' ' E' ' 128' ' ' ILE . 23.7 p90 -112.97 140.89 47.39 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.594 0.711 . . . . 4.42 111.896 177.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 119' ' ' SER . . . . . . . . . . . . . 36.5 t -97.64 132.86 42.9 Favored 'General case' 0 C--O 1.239 0.545 0 CA-C-N 114.641 -1.163 . . . . 17.93 109.815 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 120' ' ' ASP . . . . . 0.581 ' HB3' ' HB2' ' D' ' 34' ' ' ASP . 58.9 t0 -114.09 98.63 7.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 106.61 -1.626 . . . . 14.02 106.61 173.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 121' ' ' GLY . . . . . . . . . . . . . . . -83.6 -157.42 24.68 Favored Glycine 0 N--CA 1.449 -0.488 0 CA-C-O 121.727 0.626 . . . . 5.36 112.176 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 122' ' ' VAL . . . . . 0.45 HG13 ' H ' ' I' ' 48' ' ' THR . 59.5 t -111.85 -62.8 2.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 107.618 -1.253 . . . . 14.68 107.618 176.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 123' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -82.78 -45.15 14.71 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.891 0.7 . . . . 69.27 112.891 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 124' ' ' GLY . . . . . 0.56 ' HA2' HD21 ' J' ' 43' ' ' LEU . . . -71.06 144.78 38.48 Favored Glycine 0 C--O 1.236 0.279 0 N-CA-C 110.28 -1.128 . . . . 22.71 110.28 175.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 125' ' ' ALA . . . . . 0.424 ' HB2' HD13 ' J' ' 43' ' ' LEU . . . -71.23 168.01 18.19 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-O 121.754 0.788 . . . . 2.65 110.296 174.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 126' ' ' VAL . . . . . 0.534 HG12 ' HA ' ' E' ' 120' ' ' ASP . 35.6 m -69.16 151.01 10.3 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 CA-C-N 115.131 -0.94 . . . . 20.58 109.738 -176.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 127' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -140.67 126.72 19.54 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.312 -0.403 . . . . 33.41 109.958 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 128' ' ' ILE . . . . . 0.523 ' HA ' ' HB3' ' E' ' 118' ' ' TYR . 95.2 mt -93.88 118.77 40.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 108.991 -0.744 . . . . 17.43 108.991 -178.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 129' ' ' SER . . . . . 0.48 ' HB2' ' O ' ' E' ' 117' ' ' GLU . 70.1 m -98.87 133.41 43.2 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.344 -0.984 . . . . 7.33 108.344 171.231 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 130' ' ' ILE . . . . . 0.457 HD12 ' HE1' ' E' ' 67' ' ' TYR . 62.2 mt -135.83 128.38 46.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 109.275 -0.639 . . . . 17.43 109.275 -176.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 131' ' ' SER . . . . . 0.532 ' HB2' ' HB2' ' E' ' 114' ' ' GLU . 49.5 m -95.81 152.98 17.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.123 -0.49 . . . . 12.69 109.964 175.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 132' ' ' LEU . . . . . 0.646 ' O ' ' HA ' ' E' ' 62' ' ' SER . 7.2 mp -137.98 140.83 40.4 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.149 -0.478 . . . . 51.13 110.711 -177.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 133' ' ' GLN . . . . . 0.413 ' HG2' ' HG3' ' E' ' 114' ' ' GLU . 30.3 mm100 -120.51 137.27 54.46 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 108.45 -0.945 . . . . 17.43 108.45 167.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 134' ' ' VAL . . . . . 0.404 HG21 ' HA3' ' E' ' 109' ' ' GLY . 8.6 p -137.25 148.39 26.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.44 0 N-CA-C 108.455 -0.942 . . . . 13.1 108.455 175.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 135' ' ' ILE . . . . . . . . . . . . . 27.0 mm -62.17 -60.7 2.31 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-O 121.333 0.587 . . . . 8.86 110.928 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 136' ' ' GLY . . . . . . . . . . . . . . . -161.71 141.77 7.53 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.161 -1.575 . . . . 35.11 109.161 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 137' ' ' GLU . . . . . . . . . . . . . 76.1 mm-40 -68.73 153.58 43.53 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 121.555 0.693 . . . . 32.63 110.306 178.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 138' ' ' LEU . . . . . . . . . . . . . 36.0 tp -138.55 122.83 18.19 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.203 -1.406 . . . . 4.9 107.203 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -84.3 70.12 10.56 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 122.323 1.059 . . . . 18.69 109.698 -169.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 140' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -85.98 76.45 9.83 Favored 'General case' 0 C--N 1.334 -0.093 0 N-CA-C 108.148 -1.056 . . . . 18.62 108.148 176.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 141' ' ' GLY . . . . . . . . . . . . . . . -71.74 111.0 3.43 Favored Glycine 0 C--O 1.237 0.307 0 N-CA-C 110.51 -1.036 . . . . 22.52 110.51 175.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -119.96 -172.24 2.3 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.353 0.597 . . . . 30.98 109.398 -173.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 143' ' ' ILE . . . . . 0.644 HG22 ' H ' ' E' ' 103' ' ' LYS . 1.4 pp -112.28 -59.27 3.28 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 113.152 0.797 . . . . 11.98 113.152 -169.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 144' ' ' ASP . . . . . . . . . . . . . 18.9 p-10 -84.44 126.36 33.18 Favored 'General case' 0 C--N 1.33 -0.239 0 O-C-N 121.453 -0.78 . . . . 36.16 111.141 -169.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 145' ' ' THR . . . . . . . . . . . . . 73.2 p -117.0 12.07 14.49 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 112.527 0.566 . . . . 39.49 112.527 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 146' ' ' LEU . . . . . 0.418 ' HG ' ' HA ' ' E' ' 24' ' ' SER . 4.2 mm? 54.29 75.75 0.59 Allowed Pre-proline 0 C--O 1.237 0.4 0 C-N-CA 126.782 2.033 . . . . 8.79 110.261 -178.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 147' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -68.54 71.02 1.01 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 N-CA-C 115.393 1.266 . . . . 10.23 115.393 -160.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 148' ' ' GLU . . . . . 0.513 ' OE1' ' ND2' ' E' ' 152' ' ' ASN . 80.0 mm-40 -103.49 11.68 36.08 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 116.036 -0.529 . . . . 7.78 111.48 167.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 149' ' ' GLU . . . . . 0.46 ' O ' ' NZ ' ' E' ' 12' ' ' LYS . 26.0 pm0 -141.13 4.67 1.86 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 113.111 0.782 . . . . 11.91 113.111 -178.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 150' ' ' ILE . . . . . 0.5 HG23 HG23 ' E' ' 96' ' ' THR . 47.4 mm -113.89 -53.91 4.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 118.997 0.817 . . . . 10.56 111.28 -176.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 151' ' ' VAL . . . . . . . . . . . . . 23.8 t -106.2 -23.59 4.39 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.781 -1.563 . . . . 16.0 106.781 -177.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 152' ' ' ASN . . . . . 0.513 ' ND2' ' OE1' ' E' ' 148' ' ' GLU . 44.1 t-20 -64.68 -38.01 89.54 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.761 -0.654 . . . . 35.34 111.797 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -73.78 99.08 1.16 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.444 0 N-CA-C 108.111 -1.07 . . . . 0.22 108.111 173.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 154' ' ' SER . . . . . . . . . . . . . 36.6 t -116.31 -61.46 1.73 Allowed 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.533 -0.758 . . . . 14.7 112.477 -171.18 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 155' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -134.47 -28.74 1.26 Allowed 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 113.659 0.985 . . . . 41.95 113.659 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.97 -59.18 2.81 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 110.655 -0.978 . . . . 49.12 110.655 -168.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 157' ' ' GLY . . . . . . . . . . . . . . . -81.98 143.59 23.27 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.466 -0.873 . . . . 17.43 112.156 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 158' ' ' TYR . . . . . 0.423 ' CD2' ' HG2' ' E' ' 171' ' ' PRO . 14.6 m-30 -110.47 -172.57 2.06 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 123.373 0.669 . . . . 3.94 109.555 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 159' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -77.07 -72.37 0.35 Allowed 'General case' 0 C--O 1.235 0.291 0 N-CA-C 113.202 0.816 . . . . 58.89 113.202 -149.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 160' ' ' PHE . . . . . 0.403 ' CD2' ' HG3' ' E' ' 162' ' ' GLN . 33.3 p90 177.6 173.27 0.55 Allowed 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 127.952 2.501 . . . . 7.43 108.984 161.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -158.99 108.8 1.96 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 105.379 -2.082 . . . . 28.57 105.379 156.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 162' ' ' GLN . . . . . 0.403 ' HG3' ' CD2' ' E' ' 160' ' ' PHE . 89.4 mt-30 -73.51 -49.27 6.64 Favored Pre-proline 0 C--O 1.242 0.674 0 C-N-CA 119.006 -1.077 . . . . 24.87 113.722 -170.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 163' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -76.72 -23.71 10.83 Favored 'Trans proline' 0 C--N 1.371 1.716 0 CA-C-N 122.096 1.784 . . . . 34.81 112.814 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 164' ' ' GLY . . . . . . . . . . . . . . . -134.93 38.88 1.76 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 119.22 2.448 . . . . 45.41 119.22 -169.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 165' ' ' GLN . . . . . 0.467 ' HG2' ' HD3' ' K' ' 90' ' ' LYS . 9.8 tp-100 -67.46 -55.87 11.86 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 119.005 1.402 . . . . 11.87 111.008 178.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 166' ' ' THR . . . . . . . . . . . . . 33.3 p 53.57 53.44 11.54 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.808 1.643 . . . . 30.44 111.671 176.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 167' ' ' THR . . . . . 0.467 HG21 ' HA ' ' E' ' 171' ' ' PRO . 6.4 m -142.41 146.62 35.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.484 -0.562 . . . . 15.31 109.484 -166.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 168' ' ' GLY . . . . . . . . . . . . . . . -81.69 -129.06 1.06 Allowed Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 110.908 -0.877 . . . . 48.49 110.908 165.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 169' ' ' GLU . . . . . 0.42 ' HG3' ' HG ' ' J' ' 54' ' ' LEU . 15.1 tm-20 -73.31 -61.17 1.92 Allowed 'General case' 0 C--O 1.235 0.302 0 O-C-N 122.514 -0.403 . . . . 42.17 111.467 -176.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.01 103.32 0.44 Allowed Pre-proline 0 C--N 1.344 0.35 0 C-N-CA 124.077 0.951 . . . . 17.43 109.707 -172.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 171' ' ' PRO . . . . . 0.467 ' HA ' HG21 ' E' ' 167' ' ' THR . 98.4 Cg_endo -81.94 -179.0 4.46 Favored 'Trans proline' 0 C--N 1.323 -0.807 0 C-N-CA 121.373 1.382 . . . . 8.82 112.96 -151.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.2 68.93 1.5 Allowed Glycine 0 N--CA 1.449 -0.468 0 N-CA-C 117.008 1.563 . . . . 21.56 117.008 164.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 173' ' ' THR . . . . . . . . . . . . . 11.1 t -130.0 165.24 22.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 117.971 0.886 . . . . 19.48 109.533 171.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 174' ' ' VAL . . . . . . . . . . . . . 30.6 m -76.75 158.62 80.48 Favored Pre-proline 0 C--O 1.24 0.563 0 CA-C-N 114.666 -1.152 . . . . 21.08 107.949 176.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 175' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -63.71 112.37 1.78 Allowed 'Trans proline' 0 C--N 1.353 0.784 0 CA-C-N 119.633 0.905 . . . . 13.55 112.14 175.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.413 0 C-N-CA 125.771 1.629 . . . . 42.06 113.442 -172.846 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 5' ' ' PRO . . . . . 0.578 ' HG3' HH11 ' L' ' 52' ' ' ARG . 39.0 Cg_endo . . . . . 0 N--CA 1.466 -0.146 0 N-CA-C 112.424 0.125 . . . . 2.59 112.424 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 6' ' ' ILE . . . . . 0.467 ' H ' ' HB2' ' F' ' 5' ' ' PRO . 96.4 mt -121.48 120.73 62.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.416 0 N-CA-C 107.895 -1.15 . . . . 30.14 107.895 177.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 7' ' ' MET . . . . . . . . . . . . . 39.1 mmt -90.16 172.91 8.47 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.903 0.858 . . . . 49.38 110.908 -176.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.3 -11.29 67.5 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.291 -0.868 . . . . 8.83 114.414 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -96.6 -15.58 21.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 117.692 0.746 . . . . 16.65 112.176 172.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -76.57 -4.75 44.53 Favored 'General case' 0 CA--C 1.519 -0.223 0 N-CA-C 113.885 1.068 . . . . 26.53 113.885 -171.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' VAL . . . . . . . . . . . . . 95.1 t -126.72 123.76 63.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 N-CA-C 108.117 -1.068 . . . . 12.14 108.117 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -133.55 161.73 33.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.526 0.679 . . . . 21.97 110.084 175.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' F' ' 93' ' ' ARG . 18.8 m-30 -112.16 96.11 5.84 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 108.319 -0.993 . . . . 17.61 108.319 -166.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' LEU . . . . . 0.782 HD23 ' HB3' ' F' ' 27' ' ' LEU . 80.9 mt -73.04 125.28 27.28 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 116.445 -0.343 . . . . 59.12 110.161 176.48 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-30 -108.14 153.39 23.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.176 0.512 . . . . 11.29 109.89 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' GLN . . . . . . . . . . . . . 69.9 tp60 -147.71 135.51 21.05 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 108.967 -0.753 . . . . 11.64 108.967 174.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' SER . . . . . . . . . . . . . 38.1 t -76.59 153.57 35.22 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 121.613 0.721 . . . . 14.99 110.957 178.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' ILE . . . . . . . . . . . . . 41.7 pt -76.19 -15.33 15.15 Favored 'Isoleucine or valine' 0 C--O 1.237 0.416 0 N-CA-C 113.205 0.817 . . . . 17.61 113.205 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -108.98 -8.47 15.21 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 112.661 0.615 . . . . 18.47 112.661 -171.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.96 -46.9 32.36 Favored 'General case' 0 C--O 1.236 0.388 0 C-N-CA 119.726 -0.789 . . . . 23.24 111.555 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.36 41.03 32.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 125.061 1.344 . . . . 27.48 111.639 -171.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' THR . . . . . . . . . . . . . 69.5 p -123.0 127.62 49.06 Favored 'General case' 0 C--O 1.236 0.344 0 C-N-CA 123.394 0.678 . . . . 13.15 109.365 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' GLY . . . . . . . . . . . . . . . -82.34 76.08 2.26 Favored Glycine 0 N--CA 1.449 -0.435 0 N-CA-C 114.269 0.467 . . . . 19.12 114.269 -177.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' SER . . . . . . . . . . . . . 92.9 p -129.82 -26.01 2.49 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 120.503 -0.479 . . . . 33.96 111.59 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' ALA . . . . . . . . . . . . . . . 50.98 73.36 0.99 Allowed Pre-proline 0 C--O 1.237 0.399 0 C-N-CA 126.912 2.085 . . . . 41.47 112.568 -173.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_exo -72.94 104.65 1.8 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 CA-C-N 119.552 0.876 . . . . 5.87 111.998 176.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' LEU . . . . . 0.782 ' HB3' HD23 ' F' ' 14' ' ' LEU . 2.1 pt? -82.56 153.43 25.51 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 108.795 -0.817 . . . . 17.61 108.795 166.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' PHE . . . . . 0.462 ' HE1' ' HB3' ' F' ' 73' ' ' ASP . 71.0 t80 -97.56 127.33 38.14 Favored Pre-proline 0 C--N 1.321 -0.635 1 C-N-CA 110.516 -4.474 . . . . 35.64 110.187 179.274 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.44 -173.0 1.17 Allowed 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 120.595 0.863 . . . . 28.08 113.56 -176.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.639 ' HA ' ' HB3' ' K' ' 47' ' ' GLN . . . 55.15 61.61 2.85 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.498 1.119 . . . . 17.61 111.231 -174.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' TYR . . . . . 0.429 ' HD1' ' HA ' ' F' ' 31' ' ' TYR . 1.3 m-30 -72.96 -177.08 2.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 123.072 1.415 . . . . 15.25 112.424 -178.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' GLN . . . . . 0.473 ' HG3' ' H ' ' F' ' 33' ' ' THR . 7.0 tp-100 -149.27 -158.77 0.95 Allowed 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 103.389 -2.819 . . . . 20.79 103.389 166.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' THR . . . . . 0.473 ' H ' ' HG3' ' F' ' 32' ' ' GLN . 15.2 t -67.51 167.14 13.39 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 122.646 1.212 . . . . 7.47 111.682 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' ASP . . . . . 0.642 ' HB2' ' HB3' ' A' ' 120' ' ' ASP . 85.2 m-20 -135.7 -169.0 2.31 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.076 -1.42 . . . . 37.96 108.355 -168.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' GLY . . . . . 0.669 ' O ' ' HA2' ' F' ' 63' ' ' GLY . . . 177.07 133.63 1.85 Allowed Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.478 -0.783 . . . . 28.65 111.341 170.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' SER . . . . . . . . . . . . . 69.0 m -127.56 84.98 2.3 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.246 -1.761 . . . . 17.61 106.246 175.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' VAL . . . . . 0.553 HG23 ' HB2' ' F' ' 62' ' ' SER . 4.9 m -93.22 113.19 27.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.438 -0.949 . . . . 6.97 108.438 -172.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' SER . . . . . . . . . . . . . 48.6 m -103.72 90.09 3.54 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.207 -1.034 . . . . 14.3 108.207 -168.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' GLY . . . . . . . . . . . . . . . -91.49 103.9 3.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.488 -0.863 . . . . 1.89 113.76 -176.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -109.9 119.21 38.63 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.651 -0.87 . . . . 17.61 108.651 -178.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 41' ' ' ARG . . . . . 0.779 ' O ' ' HA3' ' F' ' 57' ' ' GLY . 87.2 mtm-85 -83.65 -173.9 4.98 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.479 0.657 . . . . 37.99 109.367 -177.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 42' ' ' GLU . . . . . . . . . . . . . 19.5 pt-20 -161.34 137.32 8.05 Favored 'General case' 0 C--N 1.33 -0.26 0 O-C-N 121.982 -0.449 . . . . 26.25 110.233 -169.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 43' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.68 127.27 32.09 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 109.05 -0.722 . . . . 16.06 109.05 175.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 44' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -132.84 119.04 19.71 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 110.091 -0.337 . . . . 24.52 110.091 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 45' ' ' ASP . . . . . . . . . . . . . 78.0 m-20 -125.72 -169.02 1.93 Allowed 'General case' 0 C--O 1.235 0.339 0 N-CA-C 109.245 -0.65 . . . . 48.29 109.245 164.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 46' ' ' GLU . . . . . 0.414 ' HA ' ' HA2' ' F' ' 51' ' ' GLY . 56.4 mp0 -121.28 -33.79 3.61 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 113.529 0.937 . . . . 12.4 113.529 176.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 47' ' ' GLN . . . . . . . . . . . . . 87.6 mm-40 60.1 28.38 17.92 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.347 1.459 . . . . 47.49 112.402 174.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 48' ' ' THR . . . . . . . . . . . . . 50.7 p 50.32 43.31 26.58 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.069 1.348 . . . . 5.14 111.43 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 49' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -137.69 -165.34 1.76 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.445 -1.317 . . . . 14.64 107.445 -176.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 50' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -67.19 -25.12 65.98 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 112.335 0.494 . . . . 32.61 112.335 174.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 51' ' ' GLY . . . . . 0.414 ' HA2' ' HA ' ' F' ' 46' ' ' GLU . . . 143.19 166.81 11.32 Favored Glycine 0 N--CA 1.448 -0.534 0 N-CA-C 111.228 -0.749 . . . . 33.78 111.228 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 52' ' ' ARG . . . . . . . . . . . . . 17.5 tpp85 -128.71 52.32 1.94 Allowed 'General case' 0 C--O 1.234 0.28 0 N-CA-C 106.606 -1.627 . . . . 15.47 106.606 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 53' ' ' ILE . . . . . 0.623 HD11 HE21 ' A' ' 133' ' ' GLN . 5.9 tt -75.98 -8.76 12.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.739 -0.664 . . . . 51.77 111.664 -171.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 54' ' ' LEU . . . . . 0.704 HD23 HE22 ' A' ' 88' ' ' GLN . 7.5 mp -67.1 -21.33 65.87 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.277 0.631 . . . . 45.17 112.687 -176.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.45 141.99 38.09 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-O 121.437 0.465 . . . . 49.64 114.001 -170.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 56' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -76.73 -179.37 5.3 Favored 'Trans proline' 0 C--N 1.327 -0.572 0 C-N-CA 121.177 1.252 . . . . 15.4 111.803 -175.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 57' ' ' GLY . . . . . 0.779 ' HA3' ' O ' ' F' ' 41' ' ' ARG . . . -153.03 173.24 31.96 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 110.091 -1.203 . . . . 46.63 110.091 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 58' ' ' SER . . . . . . . . . . . . . 40.4 t -76.13 144.65 40.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.663 0.744 . . . . 5.36 110.611 179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 59' ' ' VAL . . . . . . . . . . . . . 3.1 p -104.04 124.13 58.24 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 N-CA-C 108.562 -0.903 . . . . 8.32 108.562 -177.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 60' ' ' ALA . . . . . . . . . . . . . . . -123.04 117.75 26.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.039 -1.467 . . . . 17.61 107.039 173.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 61' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -117.12 120.91 39.77 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.817 -0.808 . . . . 70.1 108.817 -168.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 62' ' ' SER . . . . . 0.719 ' HA ' ' O ' ' F' ' 132' ' ' LEU . 69.0 m -108.58 164.1 12.65 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 124.211 1.005 . . . . 17.61 110.585 -175.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 63' ' ' GLY . . . . . 0.669 ' HA2' ' O ' ' F' ' 35' ' ' GLY . . . -140.07 122.54 2.23 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.108 -0.951 . . . . 3.87 112.733 177.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 64' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -101.18 95.41 6.52 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 107.499 -1.297 . . . . 61.56 107.499 173.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 65' ' ' VAL . . . . . . . . . . . . . 92.6 t -102.57 119.46 50.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.2 -1.037 . . . . 17.61 108.2 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 66' ' ' THR . . . . . . . . . . . . . 79.6 p -115.24 144.31 43.91 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.195 -0.669 . . . . 9.04 109.195 176.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 67' ' ' TYR . . . . . 0.413 ' HE1' HD12 ' F' ' 130' ' ' ILE . 53.9 p90 -155.09 -173.63 4.65 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 108.922 -0.77 . . . . 17.61 108.922 175.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 68' ' ' TYR . . . . . . . . . . . . . 16.8 m-30 -115.37 136.89 52.63 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 109.232 -0.655 . . . . 17.61 109.232 175.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.86 113.51 3.74 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.944 -0.646 . . . . 17.61 114.403 -175.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 70' ' ' LYS . . . . . 0.473 ' O ' ' NE2' ' F' ' 76' ' ' GLN . 38.4 ttmt -83.44 152.08 25.16 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 108.766 -0.827 . . . . 16.42 108.766 175.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -68.2 -17.21 64.26 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 113.997 1.11 . . . . 17.59 113.997 -171.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.62 -140.39 5.09 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.114 -1.194 . . . . 24.64 110.114 176.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 73' ' ' ASP . . . . . 0.462 ' HB3' ' HE1' ' F' ' 28' ' ' PHE . 31.2 t0 59.75 72.71 0.51 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 125.18 1.392 . . . . 10.75 111.082 168.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.42 10.92 0.05 Allowed 'General case' 0 C--O 1.235 0.29 0 N-CA-C 117.309 2.337 . . . . 31.35 117.309 -159.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.47 -40.75 94.78 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 120.227 -0.987 . . . . 22.48 112.598 170.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 76' ' ' GLN . . . . . 0.473 ' NE2' ' O ' ' F' ' 70' ' ' LYS . 22.1 pt20 -70.66 -22.35 62.5 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 119.972 -0.691 . . . . 12.03 111.873 172.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 77' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -72.36 -26.65 61.99 Favored 'General case' 0 CA--C 1.517 -0.293 0 C-N-CA 119.345 -0.942 . . . . 23.73 111.389 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.16 -30.72 63.78 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.222 -0.591 . . . . 9.85 111.169 169.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 79' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.61 -45.64 97.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 CA-C-O 121.05 0.453 . . . . 17.61 110.491 172.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -75.02 -22.79 58.25 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 121.827 -0.546 . . . . 22.42 111.992 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 81' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -70.07 -33.6 72.13 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.212 -0.595 . . . . 37.8 111.301 168.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 82' ' ' ALA . . . . . 0.737 ' HA ' ' HB2' ' F' ' 87' ' ' LYS . . . -74.2 -33.16 63.32 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.388 -0.925 . . . . 8.46 111.537 175.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 83' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -83.23 -62.63 1.54 Allowed 'General case' 0 C--O 1.235 0.341 0 C-N-CA 120.421 -0.512 . . . . 20.56 111.966 -176.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -76.24 -41.71 48.28 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 111.92 0.341 . . . . 10.83 111.92 -166.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 85' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -72.9 -41.5 64.55 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 119.812 -0.755 . . . . 28.11 110.905 171.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.33 96.93 2.46 Favored Glycine 0 N--CA 1.449 -0.469 0 O-C-N 122.266 -0.271 . . . . 4.59 113.205 178.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 87' ' ' LYS . . . . . 0.737 ' HB2' ' HA ' ' F' ' 82' ' ' ALA . 98.4 mttt -147.94 -163.11 1.69 Allowed 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 107.139 -1.43 . . . . 17.33 107.139 -179.306 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 88' ' ' GLN . . . . . 0.716 HE22 HD23 ' E' ' 54' ' ' LEU . 89.2 mt-30 -128.72 173.48 10.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.408 0.623 . . . . 17.52 109.705 171.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 89' ' ' ILE . . . . . 0.414 HD11 HD11 ' F' ' 113' ' ' ILE . 72.9 mt -128.33 133.67 66.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 116.059 -0.519 . . . . 11.07 109.722 -173.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 90' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -81.64 118.14 22.56 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 108.585 -0.894 . . . . 20.47 108.585 166.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 91' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -114.31 129.84 56.65 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 124.685 1.194 . . . . 12.46 109.939 -166.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 92' ' ' TRP . . . . . 0.502 ' HB2' ' O ' ' F' ' 14' ' ' LEU . 89.6 m95 -130.15 129.11 43.06 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 123.967 0.907 . . . . 21.11 108.838 -177.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 93' ' ' ARG . . . . . 0.804 ' O ' ' HA ' ' F' ' 106' ' ' ALA . 78.6 ttt-85 -111.57 92.33 3.99 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 108.101 -1.074 . . . . 11.99 108.101 173.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 94' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' F' ' 106' ' ' ALA . 22.2 m -105.68 162.82 4.78 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 CA-C-O 122.3 1.048 . . . . 14.23 109.646 -172.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 95' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -108.05 167.65 9.84 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 114.789 -1.096 . . . . 18.32 111.305 178.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 96' ' ' THR . . . . . 0.5 HG23 HG23 ' F' ' 150' ' ' ILE . 27.7 m -101.78 -29.94 11.58 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 114.87 -1.059 . . . . 25.62 112.447 -176.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 97' ' ' VAL . . . . . . . . . . . . . 35.4 m -69.0 154.13 8.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.771 0.796 . . . . 17.61 110.144 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 98' ' ' LYS . . . . . 0.512 ' NZ ' ' O ' ' F' ' 99' ' ' ASN . 29.7 tptp -91.3 122.61 34.06 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.67 -0.695 . . . . 17.61 109.803 -175.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 99' ' ' ASN . . . . . 0.512 ' O ' ' NZ ' ' F' ' 98' ' ' LYS . 34.6 m120 -81.78 169.11 17.29 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.825 0.821 . . . . 21.02 109.903 171.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 100' ' ' GLU . . . . . . . . . . . . . 56.0 mp0 -107.55 -12.12 15.34 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 113.983 1.105 . . . . 6.73 113.983 -179.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 101' ' ' ASN . . . . . . . . . . . . . 21.1 p30 -96.15 -54.45 3.29 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 118.492 0.587 . . . . 6.24 111.438 167.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 102' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -98.65 -173.36 2.52 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.249 -1.019 . . . . 23.72 108.249 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 103' ' ' LYS . . . . . 0.591 ' H ' HG22 ' F' ' 143' ' ' ILE . 97.0 mttt -85.52 -54.86 4.3 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.208 0.528 . . . . 59.25 110.306 172.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 104' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -132.01 -171.11 2.55 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 107.985 -1.117 . . . . 26.33 107.985 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 105' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' F' ' 94' ' ' VAL . 20.8 p-10 -151.24 169.11 22.73 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 121.515 0.674 . . . . 16.88 109.362 175.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 106' ' ' ALA . . . . . 0.804 ' HA ' ' O ' ' F' ' 93' ' ' ARG . . . -155.02 159.24 40.17 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.186 -0.916 . . . . 17.61 110.926 -163.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 107' ' ' GLN . . . . . 0.436 ' OE1' ' OH ' ' A' ' 118' ' ' TYR . 88.2 mt-30 -117.27 121.26 40.67 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 107.1 -1.444 . . . . 15.05 107.1 159.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 108' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' F' ' 138' ' ' LEU . 85.2 t80 -108.83 152.9 24.26 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.383 1.073 . . . . 25.92 110.249 -164.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 109' ' ' GLY . . . . . . . . . . . . . . . -174.39 155.48 21.37 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 119.367 -1.396 . . . . 17.61 112.533 172.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 110' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -92.27 108.85 20.25 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 108.867 -0.79 . . . . 12.6 108.867 169.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 111' ' ' ALA . . . . . . . . . . . . . . . -111.59 161.79 15.83 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-O 121.493 0.663 . . . . 46.93 111.606 -168.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 112' ' ' TYR . . . . . 0.534 ' HD1' ' HG2' ' F' ' 88' ' ' GLN . 61.1 t80 -138.78 136.6 35.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 114.704 -1.134 . . . . 25.94 107.955 -176.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 113' ' ' ILE . . . . . 0.414 HD11 HD11 ' F' ' 89' ' ' ILE . 72.9 mt -82.74 131.33 34.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 109.665 -0.494 . . . . 17.61 109.665 -172.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 114' ' ' GLU . . . . . 0.544 ' HB2' ' HB2' ' F' ' 131' ' ' SER . 98.8 mt-10 -75.33 -64.47 1.06 Allowed 'General case' 0 C--O 1.235 0.301 0 C-N-CA 119.74 -0.784 . . . . 24.43 110.752 164.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 115' ' ' SER . . . . . . . . . . . . . 70.1 m -141.13 149.49 41.61 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.647 0.737 . . . . 37.8 110.186 -168.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -125.44 93.74 3.95 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 105.028 -2.212 . . . . 0.93 105.028 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 117' ' ' GLU . . . . . 0.533 ' HB3' HG12 ' E' ' 37' ' ' VAL . 97.4 mt-10 -115.84 109.36 17.53 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 107.522 -1.288 . . . . 33.98 107.522 -175.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 118' ' ' TYR . . . . . 0.553 ' HB3' ' HA ' ' F' ' 128' ' ' ILE . 20.6 p90 -115.33 142.38 46.76 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.558 0.694 . . . . 25.47 112.122 178.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 119' ' ' SER . . . . . . . . . . . . . 35.1 t -98.24 131.13 44.83 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 114.611 -1.177 . . . . 17.61 109.949 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 120' ' ' ASP . . . . . 0.59 ' HB3' ' HB2' ' E' ' 34' ' ' ASP . 58.5 t0 -107.11 98.71 8.32 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 106.361 -1.718 . . . . 28.19 106.361 170.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.73 -158.15 24.01 Favored Glycine 0 N--CA 1.449 -0.489 0 CA-C-O 121.717 0.621 . . . . 25.42 112.013 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 122' ' ' VAL . . . . . . . . . . . . . 59.8 t -114.53 -62.82 2.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 N-CA-C 108.13 -1.063 . . . . 14.28 108.13 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 123' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -83.3 -43.07 16.42 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.941 0.719 . . . . 57.93 112.941 179.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 124' ' ' GLY . . . . . 0.562 ' HA2' HD21 ' K' ' 43' ' ' LEU . . . -74.41 150.02 41.28 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.083 -1.207 . . . . 23.46 110.083 173.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.78 170.33 15.52 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.697 0.761 . . . . 21.78 110.192 174.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 126' ' ' VAL . . . . . 0.589 HG12 ' HA ' ' F' ' 120' ' ' ASP . 26.8 m -69.14 149.9 10.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.522 0 CA-C-N 115.203 -0.908 . . . . 17.61 109.885 -175.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 127' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -138.28 125.92 22.17 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.34 -0.391 . . . . 53.51 110.222 -179.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 128' ' ' ILE . . . . . 0.553 ' HA ' ' HB3' ' F' ' 118' ' ' TYR . 87.6 mt -95.36 121.4 45.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.324 -0.621 . . . . 17.61 109.324 -177.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 129' ' ' SER . . . . . 0.438 ' HB2' ' O ' ' F' ' 117' ' ' GLU . 70.9 m -102.98 134.23 46.76 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.476 -0.935 . . . . 46.92 108.476 172.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 130' ' ' ILE . . . . . 0.413 HD12 ' HE1' ' F' ' 67' ' ' TYR . 71.5 mt -136.77 128.41 43.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 N-CA-C 109.157 -0.682 . . . . 10.99 109.157 -175.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 131' ' ' SER . . . . . 0.544 ' HB2' ' HB2' ' F' ' 114' ' ' GLU . 62.3 m -96.23 151.85 19.12 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-O 120.975 0.417 . . . . 40.73 110.19 175.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 132' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' F' ' 62' ' ' SER . 7.2 mp -136.26 141.21 43.87 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 116.141 -0.482 . . . . 37.61 110.873 -178.191 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 133' ' ' GLN . . . . . . . . . . . . . 30.5 mm100 -120.64 136.95 54.68 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 108.448 -0.945 . . . . 17.61 108.448 168.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 134' ' ' VAL . . . . . . . . . . . . . 11.0 p -137.87 148.04 25.66 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 N-CA-C 108.328 -0.99 . . . . 32.79 108.328 175.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 135' ' ' ILE . . . . . . . . . . . . . 27.3 mm -62.56 -61.21 1.75 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.385 0 CA-C-O 121.319 0.581 . . . . 18.82 110.915 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.51 139.3 6.0 Favored Glycine 0 N--CA 1.441 -1.011 0 N-CA-C 109.243 -1.543 . . . . 54.56 109.243 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 137' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -69.08 153.65 43.4 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.611 0.72 . . . . 15.77 110.288 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 138' ' ' LEU . . . . . 0.428 ' O ' ' HB3' ' F' ' 108' ' ' PHE . 35.7 tp -138.49 124.49 20.08 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 107.119 -1.437 . . . . 9.02 107.119 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -86.08 68.84 10.42 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 122.35 1.071 . . . . 6.84 109.816 -168.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 140' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -87.32 77.08 9.02 Favored 'General case' 0 C--N 1.334 -0.101 0 N-CA-C 108.22 -1.03 . . . . 16.59 108.22 176.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.14 111.31 3.45 Favored Glycine 0 C--O 1.237 0.333 0 N-CA-C 110.493 -1.043 . . . . 22.31 110.493 175.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.5 -172.08 2.3 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 109.278 -0.638 . . . . 25.19 109.278 -174.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 143' ' ' ILE . . . . . 0.591 HG22 ' H ' ' F' ' 103' ' ' LYS . 1.3 pp -109.82 -60.95 2.67 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 N-CA-C 113.558 0.948 . . . . 12.99 113.558 -167.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 144' ' ' ASP . . . . . . . . . . . . . 24.0 p-10 -82.26 132.9 35.23 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.34 -0.85 . . . . 27.65 110.949 -170.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 145' ' ' THR . . . . . . . . . . . . . 66.2 p -122.53 13.09 10.11 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 119.042 -0.504 . . . . 7.56 112.219 176.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 146' ' ' LEU . . . . . . . . . . . . . 4.1 mm? 54.26 76.48 0.51 Allowed Pre-proline 0 C--O 1.238 0.456 0 C-N-CA 126.827 2.051 . . . . 14.48 110.083 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 147' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -67.8 73.04 0.69 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 121.31 1.34 . . . . 10.58 115.38 -159.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 148' ' ' GLU . . . . . 0.535 ' OE1' ' ND2' ' F' ' 152' ' ' ASN . 79.6 mm-40 -108.54 9.37 27.4 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.716 -0.675 . . . . 20.19 111.65 169.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 149' ' ' GLU . . . . . . . . . . . . . 26.0 pm0 -139.49 5.21 2.22 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 112.709 0.633 . . . . 31.94 112.709 -178.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 150' ' ' ILE . . . . . 0.5 HG23 HG23 ' F' ' 96' ' ' THR . 47.5 mm -113.89 -54.86 4.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 118.8 0.727 . . . . 24.34 111.308 -176.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 151' ' ' VAL . . . . . . . . . . . . . 26.3 t -104.44 -24.57 3.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.062 -1.458 . . . . 27.28 107.062 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 152' ' ' ASN . . . . . 0.535 ' ND2' ' OE1' ' F' ' 148' ' ' GLU . 41.1 t-20 -66.66 -36.07 81.67 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.96 -0.564 . . . . 33.96 111.722 -178.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -73.99 98.2 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.427 0 N-CA-C 107.856 -1.164 . . . . 10.33 107.856 172.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 154' ' ' SER . . . . . . . . . . . . . 30.1 t -116.82 -62.29 1.6 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.471 -0.786 . . . . 12.96 112.525 -172.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 155' ' ' LYS . . . . . . . . . . . . . 16.9 tppt? -132.74 -31.78 1.31 Allowed 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 113.721 1.008 . . . . 56.67 113.721 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 156' ' ' GLY . . . . . . . . . . . . . . . 92.34 -55.77 2.79 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 119.359 0.982 . . . . 18.65 110.794 -169.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 157' ' ' GLY . . . . . . . . . . . . . . . -80.09 142.54 24.32 Favored Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.475 -0.869 . . . . 4.61 112.343 176.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 158' ' ' TYR . . . . . 0.416 ' CD2' ' HG2' ' F' ' 171' ' ' PRO . 14.4 m-30 -111.44 -173.28 2.21 Favored 'General case' 0 C--O 1.236 0.388 0 C-N-CA 123.727 0.811 . . . . 20.34 109.417 178.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 159' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -77.55 -73.84 0.28 Allowed 'General case' 0 C--O 1.234 0.281 0 C-N-CA 119.451 -0.9 . . . . 66.33 113.007 -153.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 160' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' F' ' 162' ' ' GLN . 38.5 p90 177.02 173.47 0.45 Allowed 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 128.262 2.625 . . . . 17.61 109.009 162.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 161' ' ' GLN . . . . . . . . . . . . . 65.5 tt0 -157.6 104.74 2.0 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 105.589 -2.004 . . . . 17.36 105.589 155.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 162' ' ' GLN . . . . . 0.421 ' HG3' ' CD2' ' F' ' 160' ' ' PHE . 89.7 mt-30 -71.3 -48.33 13.02 Favored Pre-proline 0 C--O 1.243 0.756 0 N-CA-C 113.806 1.039 . . . . 14.19 113.806 -169.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 163' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -77.05 -19.64 13.6 Favored 'Trans proline' 0 C--N 1.372 1.795 0 CA-C-N 122.237 1.835 . . . . 31.8 112.496 176.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 164' ' ' GLY . . . . . . . . . . . . . . . -134.4 37.52 1.95 Allowed Glycine 0 N--CA 1.448 -0.566 0 N-CA-C 119.752 2.661 . . . . 38.74 119.752 -170.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 165' ' ' GLN . . . . . 0.497 ' HG2' ' HD3' ' L' ' 90' ' ' LYS . 9.9 tp-100 -67.99 -59.25 3.41 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 119.06 1.43 . . . . 22.78 111.152 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 166' ' ' THR . . . . . . . . . . . . . 33.7 p 54.57 49.53 17.99 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.765 1.626 . . . . 30.57 111.582 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 167' ' ' THR . . . . . . . . . . . . . 3.4 m -140.69 149.79 42.65 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.369 -0.604 . . . . 10.12 109.369 -167.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 168' ' ' GLY . . . . . . . . . . . . . . . -86.44 -125.06 1.74 Allowed Glycine 0 N--CA 1.446 -0.647 0 N-CA-C 111.098 -0.801 . . . . 18.7 111.098 168.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 169' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -74.21 -63.47 1.22 Allowed 'General case' 0 C--O 1.236 0.344 0 C-N-CA 120.865 -0.334 . . . . 31.86 111.374 -176.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.6 104.59 0.63 Allowed Pre-proline 0 C--O 1.235 0.336 0 C-N-CA 123.982 0.913 . . . . 23.96 109.457 -174.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 171' ' ' PRO . . . . . 0.416 ' HG2' ' CD2' ' F' ' 158' ' ' TYR . 83.2 Cg_endo -80.17 -177.23 3.66 Favored 'Trans proline' 0 C--N 1.322 -0.83 0 C-N-CA 121.461 1.441 . . . . 17.61 112.964 -153.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 172' ' ' GLY . . . . . . . . . . . . . . . 71.67 69.35 1.41 Allowed Glycine 0 N--CA 1.448 -0.567 0 N-CA-C 116.952 1.541 . . . . 22.97 116.952 164.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 173' ' ' THR . . . . . . . . . . . . . 9.3 t -130.03 165.72 21.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.868 0.842 . . . . 17.61 109.264 168.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 174' ' ' VAL . . . . . . . . . . . . . 28.7 m -80.55 158.85 70.7 Favored Pre-proline 0 C--O 1.24 0.576 0 N-CA-C 107.816 -1.179 . . . . 10.57 107.816 176.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 175' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_exo -64.28 110.42 1.37 Allowed 'Trans proline' 0 CA--C 1.512 -0.582 0 CA-C-N 119.609 0.896 . . . . 16.46 110.14 170.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.192 0 C-N-CA 125.077 1.351 . . . . 45.89 111.255 -161.482 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 5' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' G' ' 6' ' ' ILE . 39.3 Cg_endo . . . . . 0 N--CA 1.465 -0.161 0 CA-C-O 119.643 -0.232 . . . . 15.58 112.396 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 6' ' ' ILE . . . . . 0.405 ' H ' ' HB2' ' G' ' 5' ' ' PRO . 96.6 mt -121.24 120.5 62.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 108.052 -1.092 . . . . 19.16 108.052 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.58 169.39 11.37 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-O 121.846 0.832 . . . . 39.27 110.616 -177.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.23 -12.86 63.91 Favored Glycine 0 C--N 1.334 0.437 0 CA-C-N 115.441 -0.799 . . . . 17.56 114.626 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -92.52 -14.67 28.04 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 117.76 0.78 . . . . 17.56 112.378 173.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -77.73 -5.03 49.22 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 113.812 1.041 . . . . 30.53 113.812 -170.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' VAL . . . . . . . . . . . . . 74.7 t -128.84 125.25 62.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.808 -1.182 . . . . 21.85 107.808 -177.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' LYS . . . . . 0.466 ' NZ ' ' O ' ' G' ' 149' ' ' GLU . 53.4 mtmt -134.12 160.6 37.31 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.544 0.687 . . . . 18.16 110.009 175.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' TYR . . . . . 0.541 ' HA ' ' O ' ' G' ' 92' ' ' TRP . 16.7 m-30 -110.84 96.77 6.37 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.053 -1.091 . . . . 17.56 108.053 -167.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' LEU . . . . . 0.811 ' O ' ' HB2' ' G' ' 92' ' ' TRP . 99.0 mt -74.76 133.61 41.96 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.337 -0.616 . . . . 65.62 109.337 176.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' PHE . . . . . . . . . . . . . 20.8 m-30 -115.32 150.78 35.73 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.037 0.446 . . . . 34.21 109.829 -178.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' GLN . . . . . . . . . . . . . 71.0 tp60 -145.64 137.25 25.15 Favored 'General case' 0 C--O 1.237 0.418 0 N-CA-C 109.058 -0.719 . . . . 16.2 109.058 175.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' SER . . . . . 0.451 ' O ' ' NZ ' ' G' ' 90' ' ' LYS . 39.0 t -75.54 155.69 35.82 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 121.623 0.725 . . . . 16.47 111.115 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' ILE . . . . . . . . . . . . . 44.1 pt -77.44 -10.59 13.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 CA-C-N 115.468 -0.787 . . . . 17.56 112.966 176.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -113.33 -9.19 13.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 112.764 0.653 . . . . 27.16 112.764 -169.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' ALA . . . . . . . . . . . . . . . -79.46 -47.79 15.05 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 119.622 -0.831 . . . . 27.76 112.026 -170.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . 52.55 47.09 25.45 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.711 1.204 . . . . 12.42 111.278 -166.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p -123.62 121.13 34.78 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 123.537 0.735 . . . . 37.77 109.017 179.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.17 74.56 2.31 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.075 -0.583 . . . . 17.56 113.053 -178.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' SER . . . . . 0.462 ' HA ' ' HG ' ' G' ' 146' ' ' LEU . 90.6 p -129.12 -29.81 2.24 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 120.607 -0.437 . . . . 28.47 111.585 -178.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' ALA . . . . . 0.465 ' HB1' ' HB3' ' G' ' 14' ' ' LEU . . . 51.33 74.36 0.81 Allowed Pre-proline 0 C--O 1.236 0.381 0 C-N-CA 126.932 2.093 . . . . 17.26 112.229 -173.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -71.29 105.94 1.83 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 CA-C-N 119.488 0.853 . . . . 17.56 112.524 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' LEU . . . . . 0.778 ' HB3' HD23 ' G' ' 14' ' ' LEU . 2.1 pt? -82.22 158.06 23.69 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.951 -0.759 . . . . 17.56 108.951 165.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -103.86 129.51 25.14 Favored Pre-proline 0 N--CA 1.447 -0.6 1 C-N-CA 109.793 -4.763 . . . . 19.13 110.247 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -73.6 -172.3 1.04 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 120.56 0.84 . . . . 4.27 114.083 -175.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 52.23 57.49 6.4 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 124.553 1.141 . . . . 2.06 110.843 -171.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' TYR . . . . . 0.444 ' HD1' ' HA ' ' G' ' 31' ' ' TYR . 0.6 OUTLIER -68.8 163.34 24.36 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 122.975 1.369 . . . . 34.59 112.015 179.788 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' GLN . . . . . 0.442 ' HG3' ' H ' ' G' ' 33' ' ' THR . 8.3 tp-100 -136.19 -163.27 1.38 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 103.07 -2.937 . . . . 19.1 103.07 169.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' THR . . . . . 0.442 ' H ' ' HG3' ' G' ' 32' ' ' GLN . 15.3 t -67.72 166.08 15.95 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.546 1.165 . . . . 10.87 112.027 -173.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' ASP . . . . . 0.589 ' HB2' ' HB3' ' H' ' 120' ' ' ASP . 89.6 m-20 -132.13 -170.7 2.47 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.163 -1.38 . . . . 46.86 108.408 -170.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' GLY . . . . . 0.724 ' O ' ' HA2' ' G' ' 63' ' ' GLY . . . 177.93 132.65 1.73 Allowed Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.98 -0.848 . . . . 31.7 110.98 169.459 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' SER . . . . . . . . . . . . . 67.4 m -125.52 84.56 2.29 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.035 -1.839 . . . . 17.56 106.035 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' VAL . . . . . 0.536 HG12 ' HB3' ' H' ' 117' ' ' GLU . 4.5 m -93.58 113.44 28.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 108.448 -0.945 . . . . 14.44 108.448 -171.033 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' SER . . . . . . . . . . . . . 51.1 m -102.02 88.76 3.43 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 108.411 -0.959 . . . . 15.27 108.411 -167.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' GLY . . . . . . . . . . . . . . . -90.99 98.89 2.51 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.201 -0.999 . . . . 49.31 113.231 -178.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' GLU . . . . . 0.44 ' HA ' ' HA ' ' G' ' 59' ' ' VAL . 79.4 tt0 -102.42 117.96 35.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 17.55 108.169 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 41' ' ' ARG . . . . . 0.696 ' O ' ' HA3' ' G' ' 57' ' ' GLY . 91.0 mtm-85 -76.63 177.75 7.26 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.558 0.694 . . . . 31.58 109.511 -176.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 42' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -157.76 159.45 36.81 Favored 'General case' 0 C--N 1.329 -0.304 0 O-C-N 121.622 -0.674 . . . . 33.51 109.671 -174.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 43' ' ' LEU . . . . . 0.785 ' HB2' ' HA3' ' G' ' 55' ' ' GLY . 70.6 mt -96.6 106.92 19.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.721 -0.672 . . . . 10.66 109.393 173.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 44' ' ' PHE . . . . . 0.462 ' HD1' HG13 ' G' ' 53' ' ' ILE . 67.6 t80 -106.89 119.11 38.47 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.307 -1.368 . . . . 30.36 107.307 173.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 45' ' ' ASP . . . . . 0.727 ' HB2' ' HB3' ' G' ' 52' ' ' ARG . 77.2 m-20 -130.77 174.24 10.14 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 108.468 -0.938 . . . . 29.01 108.468 -173.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 46' ' ' GLU . . . . . . . . . . . . . 59.9 mp0 -126.72 -41.14 1.86 Allowed 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.858 1.058 . . . . 19.89 113.858 -170.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 47' ' ' GLN . . . . . 0.676 ' HB3' ' HA ' ' B' ' 30' ' ' ALA . 96.3 mm-40 67.43 23.26 9.15 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 114.005 1.113 . . . . 37.15 114.005 154.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 48' ' ' THR . . . . . . . . . . . . . 53.3 p 51.23 37.74 19.33 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.618 1.167 . . . . 28.33 111.121 -167.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm -139.72 -165.91 1.97 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 106.846 -1.539 . . . . 18.5 106.846 -175.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 50' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 -69.95 -31.2 68.82 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 120.538 -0.465 . . . . 32.53 112.019 171.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.34 166.18 14.73 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 121.323 -0.465 . . . . 5.39 113.747 -178.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 52' ' ' ARG . . . . . 0.727 ' HB3' ' HB2' ' G' ' 45' ' ' ASP . 19.4 tpp85 -133.58 57.95 1.79 Allowed 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.831 -1.174 . . . . 14.66 107.831 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 53' ' ' ILE . . . . . 0.786 HD11 ' HB3' ' H' ' 133' ' ' GLN . 7.6 tt -66.08 -5.02 2.64 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 C-N-CA 125.19 1.396 . . . . 50.62 113.67 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 54' ' ' LEU . . . . . 0.656 HD13 ' HD3' ' G' ' 52' ' ' ARG . 8.9 mp -61.95 -23.41 66.36 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 124.251 1.02 . . . . 74.62 113.711 -170.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 55' ' ' GLY . . . . . 0.785 ' HA3' ' HB2' ' G' ' 43' ' ' LEU . . . -67.15 120.01 12.81 Favored Glycine 0 N--CA 1.44 -1.099 0 CA-C-O 121.626 0.57 . . . . 7.32 114.179 -169.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 56' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.37 169.29 22.64 Favored 'Trans proline' 0 C--N 1.326 -0.621 0 C-N-CA 120.873 1.049 . . . . 7.48 109.873 171.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 57' ' ' GLY . . . . . 0.696 ' HA3' ' O ' ' G' ' 41' ' ' ARG . . . -137.2 170.38 23.58 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.577 -1.409 . . . . 23.59 109.577 -178.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 58' ' ' SER . . . . . 0.421 ' HB3' ' NH2' ' G' ' 41' ' ' ARG . 45.9 t -72.81 147.11 45.8 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 119.618 -0.833 . . . . 17.34 109.595 172.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 59' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' G' ' 40' ' ' GLU . 2.2 p -103.13 112.94 38.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 108.388 -0.967 . . . . 1.78 108.388 -177.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 60' ' ' ALA . . . . . . . . . . . . . . . -108.19 110.6 22.28 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 106.681 -1.6 . . . . 13.09 106.681 174.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 61' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -115.07 118.3 32.99 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.33 -0.989 . . . . 46.86 108.33 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' G' ' 132' ' ' LEU . 56.9 m -107.07 165.89 11.02 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 124.102 0.961 . . . . 11.7 110.418 -173.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 63' ' ' GLY . . . . . 0.724 ' HA2' ' O ' ' G' ' 35' ' ' GLY . . . -139.45 121.12 2.0 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 119.992 -1.099 . . . . 17.56 113.183 174.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 64' ' ' GLU . . . . . . . . . . . . . 67.2 mm-40 -97.79 95.51 7.59 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 107.253 -1.388 . . . . 37.6 107.253 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 65' ' ' VAL . . . . . . . . . . . . . 86.1 t -105.36 116.58 49.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 108.404 -0.961 . . . . 5.82 108.404 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 66' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' G' ' 128' ' ' ILE . 64.8 p -115.1 143.08 45.76 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.978 -0.749 . . . . 17.56 108.978 177.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 67' ' ' TYR . . . . . 0.415 ' HE1' HD12 ' G' ' 130' ' ' ILE . 55.6 p90 -154.3 -170.64 3.6 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.408 0.623 . . . . 15.39 109.433 176.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 68' ' ' TYR . . . . . . . . . . . . . 14.3 m-30 -116.99 134.74 54.35 Favored 'General case' 0 C--N 1.329 -0.294 0 C-N-CA 123.868 0.867 . . . . 3.83 109.488 179.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.4 116.55 4.25 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.995 -0.621 . . . . 7.04 114.315 -175.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 70' ' ' LYS . . . . . 0.493 ' O ' ' NE2' ' G' ' 76' ' ' GLN . 38.8 ttmt -91.05 150.46 21.42 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 3.01 108.83 175.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 71' ' ' ARG . . . . . . . . . . . . . 20.6 ptp180 -69.0 -16.67 63.78 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 113.925 1.083 . . . . 16.93 113.925 -170.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.97 -138.15 4.7 Favored Glycine 0 N--CA 1.451 -0.301 0 N-CA-C 109.902 -1.279 . . . . 35.85 109.902 175.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 73' ' ' ASP . . . . . . . . . . . . . 31.4 t0 59.95 73.18 0.49 Allowed 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 125.045 1.338 . . . . 12.83 111.135 167.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.69 10.39 0.05 OUTLIER 'General case' 0 C--O 1.233 0.228 0 N-CA-C 117.438 2.385 . . . . 58.08 117.438 -157.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.3 -42.07 97.16 Favored Glycine 0 C--N 1.339 0.709 0 C-N-CA 120.31 -0.948 . . . . 6.64 112.845 171.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 76' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' G' ' 70' ' ' LYS . 22.0 pt20 -70.89 -23.38 62.28 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 119.546 -0.862 . . . . 30.28 111.714 174.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 77' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -70.27 -28.01 64.88 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 119.919 -0.712 . . . . 1.1 111.352 170.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.93 -30.89 62.8 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 120.716 -0.394 . . . . 14.89 111.352 171.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 79' ' ' ILE . . . . . . . . . . . . . 51.0 mm -64.45 -44.99 97.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 CA-C-O 121.076 0.465 . . . . 17.56 110.347 172.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 80' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.16 -24.01 60.52 Favored 'General case' 0 C--O 1.234 0.289 0 O-C-N 121.895 -0.503 . . . . 21.16 112.007 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 81' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -70.3 -35.07 73.45 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.307 -0.557 . . . . 27.62 111.533 170.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 82' ' ' ALA . . . . . 0.707 ' HA ' ' HB2' ' G' ' 87' ' ' LYS . . . -74.62 -32.36 62.29 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 119.178 -1.009 . . . . 5.97 111.561 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 83' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' L' ' 38' ' ' SER . 86.1 t80 -83.29 -62.47 1.58 Allowed 'General case' 0 C--O 1.234 0.281 0 C-N-CA 120.504 -0.478 . . . . 17.56 112.049 -176.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 84' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -76.28 -39.17 54.98 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.577 -0.283 . . . . 18.17 111.735 -165.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 85' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -75.6 -40.69 56.1 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 119.929 -0.709 . . . . 19.49 111.011 172.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.42 96.33 2.44 Favored Glycine 0 N--CA 1.45 -0.403 0 O-C-N 122.234 -0.291 . . . . 17.56 113.544 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 87' ' ' LYS . . . . . 0.707 ' HB2' ' HA ' ' G' ' 82' ' ' ALA . 98.3 mttt -148.69 -162.03 1.47 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 106.882 -1.525 . . . . 17.25 106.882 -178.191 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 88' ' ' GLN . . . . . 0.653 ' HG2' ' HD1' ' G' ' 112' ' ' TYR . 64.7 mt-30 -129.13 178.78 6.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.724 0.773 . . . . 13.52 111.035 167.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 89' ' ' ILE . . . . . . . . . . . . . 68.0 mt -128.73 135.1 63.13 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-N 115.209 -0.905 . . . . 19.69 109.618 -171.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 90' ' ' LYS . . . . . 0.451 ' NZ ' ' O ' ' G' ' 17' ' ' SER . 36.4 mtmm -84.9 116.66 23.46 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 108.559 -0.904 . . . . 24.48 108.559 165.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 91' ' ' PHE . . . . . . . . . . . . . 61.5 t80 -111.71 134.38 53.32 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 124.692 1.197 . . . . 31.77 110.577 -166.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 92' ' ' TRP . . . . . 0.811 ' HB2' ' O ' ' G' ' 14' ' ' LEU . 92.5 m95 -133.49 125.56 29.23 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 123.905 0.882 . . . . 14.67 110.168 -173.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 93' ' ' ARG . . . . . 0.612 ' O ' ' HA ' ' G' ' 106' ' ' ALA . 78.8 ttt-85 -111.87 90.85 3.45 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 108.196 -1.039 . . . . 14.24 108.196 171.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 94' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' G' ' 106' ' ' ALA . 21.4 m -105.65 163.38 4.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 122.139 0.971 . . . . 17.91 109.391 -174.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 95' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -109.8 164.71 12.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.013 -0.994 . . . . 33.23 111.136 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 96' ' ' THR . . . . . 0.418 HG23 HD12 ' G' ' 150' ' ' ILE . 28.4 m -98.82 -30.85 12.17 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 114.973 -1.012 . . . . 22.24 112.645 -175.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -68.69 155.17 7.86 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 CA-C-O 121.76 0.79 . . . . 25.4 110.137 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 98' ' ' LYS . . . . . 0.512 ' NZ ' ' O ' ' G' ' 99' ' ' ASN . 29.6 tptp -90.46 122.0 32.92 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.72 -0.673 . . . . 9.56 109.821 -176.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 99' ' ' ASN . . . . . 0.512 ' O ' ' NZ ' ' G' ' 98' ' ' LYS . 34.9 m120 -83.81 171.44 13.12 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.828 0.823 . . . . 16.05 109.99 171.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 100' ' ' GLU . . . . . . . . . . . . . 58.4 mp0 -108.45 -17.2 14.04 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 113.463 0.912 . . . . 31.57 113.463 178.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 101' ' ' ASN . . . . . . . . . . . . . 19.8 p30 -86.47 -49.69 7.41 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 118.175 0.443 . . . . 14.91 111.04 170.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 102' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -112.58 -174.74 2.52 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.321 -0.992 . . . . 23.65 108.321 172.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 103' ' ' LYS . . . . . 0.66 ' H ' HG22 ' G' ' 143' ' ' ILE . 96.3 mttt -77.06 -55.01 5.82 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.015 -0.674 . . . . 33.92 110.076 168.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 104' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -133.25 -171.0 2.58 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.548 -0.908 . . . . 7.12 108.548 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 105' ' ' ASP . . . . . . . . . . . . . 17.6 p-10 -151.68 166.52 31.02 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 109.163 -0.68 . . . . 53.27 109.163 177.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 106' ' ' ALA . . . . . 0.612 ' HA ' ' O ' ' G' ' 93' ' ' ARG . . . -156.85 156.54 33.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.419 -0.81 . . . . 17.56 111.404 -162.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 107' ' ' GLN . . . . . 0.445 ' OE1' ' OH ' ' H' ' 118' ' ' TYR . 87.4 mt-30 -114.8 123.62 49.67 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.805 -1.554 . . . . 9.69 106.805 158.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 108' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -110.61 153.81 24.66 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 123.735 0.814 . . . . 7.7 110.262 -165.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 109' ' ' GLY . . . . . 0.4 ' HA3' HG21 ' G' ' 134' ' ' VAL . . . -164.75 167.41 38.51 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 119.553 -1.308 . . . . 37.56 112.79 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 110' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -108.18 108.81 20.01 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 114.667 -0.767 . . . . 18.99 109.276 168.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 111' ' ' ALA . . . . . . . . . . . . . . . -107.03 157.04 18.12 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.618 0.723 . . . . 47.07 111.71 -166.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 112' ' ' TYR . . . . . 0.653 ' HD1' ' HG2' ' G' ' 88' ' ' GLN . 55.1 t80 -137.87 136.65 37.32 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.168 -1.419 . . . . 0.61 107.168 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 113' ' ' ILE . . . . . . . . . . . . . 83.5 mt -86.53 128.16 39.75 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 109.95 -0.389 . . . . 3.73 109.95 -169.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 114' ' ' GLU . . . . . 0.552 ' HB2' ' HB2' ' G' ' 131' ' ' SER . 99.4 mt-10 -70.93 -64.63 0.87 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 119.904 -0.718 . . . . 20.3 110.479 164.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 115' ' ' SER . . . . . . . . . . . . . 67.7 m -140.93 147.8 39.39 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-O 121.562 0.696 . . . . 11.26 110.391 -170.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 116' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -120.17 89.87 3.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 104.782 -2.303 . . . . 8.25 104.782 175.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 117' ' ' GLU . . . . . 0.529 ' HB3' HG12 ' L' ' 37' ' ' VAL . 98.3 mt-10 -112.85 108.38 17.33 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.494 -1.298 . . . . 27.88 107.494 -175.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 118' ' ' TYR . . . . . 0.469 ' HB3' ' HA ' ' G' ' 128' ' ' ILE . 19.1 p90 -114.55 142.53 46.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.536 0.684 . . . . 28.76 111.917 177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 119' ' ' SER . . . . . . . . . . . . . 37.2 t -96.4 128.37 43.26 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 114.673 -1.149 . . . . 17.56 109.938 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 120' ' ' ASP . . . . . 0.611 ' HA ' HG12 ' G' ' 126' ' ' VAL . 60.3 t0 -106.22 97.9 7.65 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 106.039 -1.838 . . . . 34.73 106.039 170.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.3 -155.07 15.64 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-O 121.814 0.674 . . . . 5.15 112.086 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 122' ' ' VAL . . . . . . . . . . . . . 79.4 t -112.72 -60.61 2.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 108.329 -0.989 . . . . 16.97 108.329 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 123' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -103.24 -30.67 10.51 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.074 0.768 . . . . 56.79 113.074 -174.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 124' ' ' GLY . . . . . . . . . . . . . . . -73.05 148.51 41.29 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 109.287 -1.525 . . . . 28.65 109.287 165.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.13 165.31 24.59 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-O 121.686 0.755 . . . . 12.09 110.265 176.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 126' ' ' VAL . . . . . 0.611 HG12 ' HA ' ' G' ' 120' ' ' ASP . 28.0 m -68.96 145.91 13.08 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-N 115.303 -0.862 . . . . 17.56 109.75 -176.001 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 127' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -135.41 132.06 37.03 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 109.521 -0.548 . . . . 47.4 109.521 -176.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 128' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' G' ' 66' ' ' THR . 84.2 mt -101.82 121.3 52.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.393 -0.595 . . . . 17.56 109.393 -176.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 129' ' ' SER . . . . . 0.519 ' HB2' ' O ' ' G' ' 117' ' ' GLU . 68.6 m -100.29 132.67 45.53 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 108.44 -0.948 . . . . 23.09 108.44 170.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 130' ' ' ILE . . . . . 0.415 HD12 ' HE1' ' G' ' 67' ' ' TYR . 81.6 mt -135.23 128.07 48.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 N-CA-C 108.652 -0.869 . . . . 17.56 108.652 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 131' ' ' SER . . . . . 0.552 ' HB2' ' HB2' ' G' ' 114' ' ' GLU . 57.1 m -93.28 146.65 23.55 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-O 121.158 0.504 . . . . 17.56 109.797 174.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 132' ' ' LEU . . . . . 0.613 ' O ' ' HA ' ' G' ' 62' ' ' SER . 7.4 mp -129.5 149.89 51.07 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.967 -0.561 . . . . 41.5 110.275 -177.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 133' ' ' GLN . . . . . 0.767 ' HB3' HD11 ' L' ' 53' ' ' ILE . 21.2 mm100 -137.64 127.69 25.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.373 -0.831 . . . . 2.83 109.382 177.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 134' ' ' VAL . . . . . 0.4 HG21 ' HA3' ' G' ' 109' ' ' GLY . 10.7 p -136.04 148.91 27.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 108.962 -0.755 . . . . 7.73 108.962 -178.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 135' ' ' ILE . . . . . 0.408 HD13 ' HA ' ' G' ' 135' ' ' ILE . 25.8 mm -64.28 -60.13 3.2 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.224 0.535 . . . . 12.81 110.878 177.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.54 136.91 4.72 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 111.008 -0.837 . . . . 0.26 111.008 -179.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 137' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -67.27 153.92 42.53 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.435 0.636 . . . . 27.0 110.347 177.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 138' ' ' LEU . . . . . 0.604 HD23 HD21 ' G' ' 140' ' ' ASN . 31.7 tp -136.06 128.82 30.94 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 107.71 -1.219 . . . . 17.56 107.71 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 139' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -81.47 76.5 8.39 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 122.46 1.124 . . . . 17.56 109.268 -171.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 140' ' ' ASN . . . . . 0.604 HD21 HD23 ' G' ' 138' ' ' LEU . 87.2 m-20 -97.8 79.46 2.67 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.12 -0.946 . . . . 16.67 108.829 -177.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.78 112.27 3.88 Favored Glycine 0 C--O 1.237 0.304 0 C-N-CA 120.0 -1.095 . . . . 39.45 110.398 173.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -123.99 -172.16 2.48 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.06 -0.718 . . . . 40.11 109.06 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 143' ' ' ILE . . . . . 0.66 HG22 ' H ' ' G' ' 103' ' ' LYS . 1.3 pp -112.13 -62.84 2.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 113.383 0.883 . . . . 35.39 113.383 -170.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 144' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -81.54 127.08 32.46 Favored 'General case' 0 C--N 1.331 -0.217 0 O-C-N 121.356 -0.84 . . . . 46.88 111.13 -169.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 145' ' ' THR . . . . . . . . . . . . . 77.2 p -121.2 14.56 11.35 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 112.454 0.539 . . . . 11.02 112.454 177.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 146' ' ' LEU . . . . . 0.462 ' HG ' ' HA ' ' G' ' 24' ' ' SER . 4.2 mm? 54.48 75.86 0.57 Allowed Pre-proline 0 C--O 1.237 0.416 0 C-N-CA 126.697 1.999 . . . . 14.06 110.596 -177.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 147' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -68.75 71.03 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 N-CA-C 115.434 1.282 . . . . 11.53 115.434 -162.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 148' ' ' GLU . . . . . 0.514 ' OE1' ' ND2' ' G' ' 152' ' ' ASN . 79.6 mm-40 -104.14 8.09 36.32 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.982 0.513 . . . . 33.72 111.334 167.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 149' ' ' GLU . . . . . 0.466 ' O ' ' NZ ' ' G' ' 12' ' ' LYS . 25.9 pm0 -139.61 8.34 2.38 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.604 0.594 . . . . 21.89 112.604 -177.254 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 150' ' ' ILE . . . . . 0.418 HD12 HG23 ' G' ' 96' ' ' THR . 43.9 mm -113.31 -46.59 5.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.71 0.687 . . . . 13.89 111.0 178.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 151' ' ' VAL . . . . . . . . . . . . . 48.9 t -108.47 -32.0 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.256 -1.016 . . . . 41.23 108.256 -178.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 152' ' ' ASN . . . . . 0.514 ' ND2' ' OE1' ' G' ' 148' ' ' GLU . 37.3 t-20 -66.62 -32.21 73.38 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.264 -0.425 . . . . 21.9 111.736 -176.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -74.17 99.3 1.29 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 107.503 -1.295 . . . . 17.56 107.503 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 154' ' ' SER . . . . . . . . . . . . . 35.2 t -117.08 -58.64 2.04 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.379 -0.828 . . . . 13.23 111.872 -171.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 155' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -127.52 -34.65 2.22 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 113.274 0.842 . . . . 8.05 113.274 177.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.22 -60.51 1.33 Allowed Glycine 0 N--CA 1.448 -0.563 0 N-CA-C 110.135 -1.186 . . . . 33.33 110.135 -157.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.42 168.52 26.86 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-O 122.128 0.849 . . . . 17.56 112.774 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 158' ' ' TYR . . . . . . . . . . . . . 15.8 m-30 -116.25 -173.91 2.45 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.866 1.267 . . . . 24.58 109.559 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 159' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -79.35 -68.89 0.62 Allowed 'General case' 0 C--O 1.235 0.331 0 C-N-CA 119.227 -0.989 . . . . 39.94 112.165 -170.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 160' ' ' PHE . . . . . 0.428 ' HD2' ' HG3' ' G' ' 162' ' ' GLN . 36.3 p90 -176.33 161.72 2.3 Favored 'General case' 0 C--O 1.235 0.317 0 N-CA-C 108.835 -0.802 . . . . 38.05 108.835 -175.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 161' ' ' GLN . . . . . . . . . . . . . 65.8 tt0 -150.88 96.4 2.33 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 105.204 -2.147 . . . . 20.84 105.204 154.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 162' ' ' GLN . . . . . 0.428 ' HG3' ' HD2' ' G' ' 160' ' ' PHE . 86.5 mt-30 -71.89 -43.59 11.01 Favored Pre-proline 0 C--O 1.243 0.726 0 N-CA-C 113.976 1.102 . . . . 11.58 113.976 -165.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 163' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -73.89 -48.57 0.23 Allowed 'Trans proline' 0 C--N 1.37 1.696 0 CA-C-N 122.144 1.801 . . . . 64.26 114.146 172.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 164' ' ' GLY . . . . . . . . . . . . . . . -123.37 40.78 1.9 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 116.886 1.515 . . . . 42.51 116.886 -162.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 165' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -63.75 -65.88 0.62 Allowed 'General case' 0 C--O 1.237 0.424 0 CA-C-N 117.477 0.638 . . . . 17.58 110.815 173.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 166' ' ' THR . . . . . . . . . . . . . 37.3 p 52.61 50.35 18.36 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.893 1.677 . . . . 52.2 111.777 176.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 167' ' ' THR . . . . . . . . . . . . . 2.0 m -132.09 168.08 18.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.581 -1.266 . . . . 10.87 107.581 -169.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.13 -125.38 1.0 Allowed Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.743 -1.343 . . . . 3.24 109.743 173.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 169' ' ' GLU . . . . . . . . . . . . . 14.0 tm-20 -79.16 -60.38 2.39 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 119.008 -1.077 . . . . 41.61 110.668 -178.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.18 105.91 0.95 Allowed Pre-proline 0 C--O 1.235 0.327 0 C-N-CA 123.729 0.812 . . . . 11.2 109.8 -176.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 171' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -83.44 -173.78 1.75 Allowed 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 121.367 1.378 . . . . 10.85 111.868 -158.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 172' ' ' GLY . . . . . . . . . . . . . . . 80.17 65.8 1.71 Allowed Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 114.665 -1.152 . . . . 35.56 114.982 167.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 173' ' ' THR . . . . . . . . . . . . . 10.5 t -138.38 164.45 29.3 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.95 0.881 . . . . 33.61 109.529 170.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 174' ' ' VAL . . . . . 0.409 ' H ' HG22 ' G' ' 174' ' ' VAL . 18.7 m -74.35 154.11 88.04 Favored Pre-proline 0 C--O 1.24 0.568 0 N-CA-C 107.883 -1.155 . . . . 27.77 107.883 174.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 175' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -67.58 107.36 1.42 Allowed 'Trans proline' 0 CA--C 1.515 -0.452 0 CA-C-N 119.43 0.832 . . . . 7.84 111.569 176.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.261 0 C-N-CA 125.728 1.611 . . . . 40.4 112.996 -171.857 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 5' ' ' PRO . . . . . 0.42 ' HB2' ' H ' ' H' ' 6' ' ' ILE . 40.0 Cg_endo . . . . . 0 N--CA 1.466 -0.137 0 CA-C-O 119.748 -0.188 . . . . 16.2 112.181 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 6' ' ' ILE . . . . . 0.42 ' H ' ' HB2' ' H' ' 5' ' ' PRO . 88.5 mt -122.9 122.72 66.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 N-CA-C 108.003 -1.11 . . . . 23.77 108.003 178.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.44 168.81 11.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-O 121.934 0.874 . . . . 38.67 110.647 -178.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.67 -12.8 64.91 Favored Glycine 0 C--N 1.333 0.396 0 CA-C-N 115.39 -0.823 . . . . 32.63 114.599 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -92.34 -13.73 29.79 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 117.906 0.853 . . . . 10.36 112.333 173.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -78.67 -5.71 53.78 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 113.708 1.003 . . . . 43.64 113.708 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -127.07 123.05 61.54 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.971 -1.122 . . . . 8.42 107.971 -176.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -133.07 162.07 32.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 34.19 109.773 177.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' H' ' 92' ' ' TRP . 16.6 m-30 -112.42 96.88 6.25 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.527 -0.916 . . . . 16.86 108.527 -166.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' LEU . . . . . 0.793 ' O ' ' HB2' ' H' ' 92' ' ' TRP . 98.7 mt -75.6 130.6 39.05 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.005 -0.678 . . . . 65.4 109.252 175.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' PHE . . . . . . . . . . . . . 21.9 m-30 -112.06 156.45 22.19 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.433 -0.58 . . . . 25.18 109.433 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -151.13 136.03 17.35 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 109.065 -0.717 . . . . 26.99 109.065 175.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' SER . . . . . . . . . . . . . 41.1 t -75.57 155.76 35.67 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 121.588 0.709 . . . . 16.86 111.02 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 pt -77.24 -12.64 14.08 Favored 'Isoleucine or valine' 0 C--O 1.237 0.411 0 CA-C-N 115.491 -0.777 . . . . 16.86 113.052 179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -115.8 -6.73 12.09 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 112.581 0.585 . . . . 65.38 112.581 -170.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.59 -47.66 25.71 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 119.907 -0.717 . . . . 14.62 111.787 -172.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.46 44.76 29.49 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 124.82 1.248 . . . . 8.31 111.45 -169.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' THR . . . . . . . . . . . . . 68.7 p -126.03 123.47 38.5 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 108.927 -0.768 . . . . 28.63 108.927 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.44 75.99 2.14 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.322 -0.466 . . . . 12.1 113.052 -178.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' SER . . . . . 0.482 ' HA ' ' HG ' ' H' ' 146' ' ' LEU . 91.7 p -127.55 -30.72 2.55 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 120.68 -0.408 . . . . 14.99 111.473 -177.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' ALA . . . . . 0.528 ' HB1' ' HB3' ' H' ' 14' ' ' LEU . . . 51.52 74.95 0.71 Allowed Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 126.679 1.991 . . . . 35.29 112.292 -174.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -70.41 105.47 1.6 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 CA-C-N 119.624 0.901 . . . . 16.86 112.83 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' LEU . . . . . 0.788 ' HB3' HD23 ' H' ' 14' ' ' LEU . 2.2 pt? -85.21 168.03 15.14 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 108.852 -0.795 . . . . 16.86 108.852 163.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -111.11 141.57 24.55 Favored Pre-proline 0 N--CA 1.448 -0.532 1 C-N-CA 110.815 -4.354 . . . . 16.81 110.46 -171.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -73.71 166.72 29.04 Favored 'Trans proline' 0 C--O 1.234 0.289 0 CA-C-N 118.79 0.604 . . . . 18.69 113.418 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . 54.45 54.5 9.28 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.708 1.203 . . . . 18.73 111.609 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' TYR . . . . . 0.443 ' HD1' ' HA ' ' H' ' 31' ' ' TYR . 1.8 m-30 -69.49 164.1 23.88 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-O 122.777 1.275 . . . . 38.69 111.562 176.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' GLN . . . . . 0.469 ' HG3' ' H ' ' H' ' 33' ' ' THR . 8.4 tp-100 -132.3 -165.02 1.53 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 103.566 -2.753 . . . . 16.64 103.566 175.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' THR . . . . . 0.469 ' H ' ' HG3' ' H' ' 32' ' ' GLN . 13.2 t -67.25 167.33 12.48 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-O 122.595 1.188 . . . . 38.6 112.161 -172.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' ASP . . . . . 0.64 ' HB2' ' HB3' ' I' ' 120' ' ' ASP . 89.8 m-20 -132.59 -170.88 2.52 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.101 -1.409 . . . . 36.95 108.521 -169.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' GLY . . . . . 0.708 ' O ' ' HA2' ' H' ' 63' ' ' GLY . . . 178.06 132.16 1.66 Allowed Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 111.05 -0.82 . . . . 21.66 111.05 168.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' SER . . . . . . . . . . . . . 66.1 m -123.44 84.69 2.31 Favored 'General case' 0 CA--C 1.516 -0.349 0 N-CA-C 105.912 -1.884 . . . . 16.86 105.912 175.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' VAL . . . . . 0.556 HG23 ' HB2' ' H' ' 62' ' ' SER . 3.5 m -91.88 109.3 21.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 108.372 -0.974 . . . . 16.86 108.372 -172.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' SER . . . . . . . . . . . . . 49.1 m -98.85 92.21 5.44 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 108.084 -1.08 . . . . 16.86 108.084 -167.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' GLY . . . . . . . . . . . . . . . -94.36 98.95 2.39 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.053 -1.07 . . . . 40.71 113.511 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' H' ' 59' ' ' VAL . 80.6 tt0 -101.45 119.08 38.22 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.095 -1.076 . . . . 13.09 108.095 178.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 41' ' ' ARG . . . . . 0.58 ' O ' ' HA3' ' H' ' 57' ' ' GLY . 93.8 mtm-85 -76.82 178.17 7.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.51 0.671 . . . . 56.06 109.429 -175.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 42' ' ' GLU . . . . . . . . . . . . . 24.4 pt-20 -156.86 155.45 31.48 Favored 'General case' 0 C--N 1.33 -0.26 0 O-C-N 121.519 -0.738 . . . . 4.93 109.836 -176.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 43' ' ' LEU . . . . . 0.751 ' HB2' ' HA3' ' H' ' 55' ' ' GLY . 55.0 mt -91.55 112.43 24.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.55 -0.75 . . . . 18.1 109.155 170.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 44' ' ' PHE . . . . . . . . . . . . . 67.4 t80 -117.19 116.66 27.71 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 107.43 -1.322 . . . . 29.99 107.43 174.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 45' ' ' ASP . . . . . 0.746 ' HB2' ' HB3' ' H' ' 52' ' ' ARG . 75.2 m-20 -132.02 177.59 7.44 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 108.138 -1.06 . . . . 16.88 108.138 -172.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 46' ' ' GLU . . . . . . . . . . . . . 57.5 mp0 -126.08 -39.34 2.09 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 114.381 1.252 . . . . 18.24 114.381 -169.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 47' ' ' GLN . . . . . 0.654 ' HB3' ' HA ' ' C' ' 30' ' ' ALA . 90.3 mm-40 66.05 23.54 11.09 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.613 1.165 . . . . 42.47 113.967 156.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 48' ' ' THR . . . . . . . . . . . . . 54.9 p 50.66 38.85 20.2 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 124.637 1.175 . . . . 17.05 111.142 -166.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 49' ' ' LYS . . . . . . . . . . . . . 47.7 mmtm -139.19 -165.38 1.84 Allowed 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 106.728 -1.582 . . . . 11.44 106.728 -176.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 50' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -75.53 -28.47 59.09 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 120.022 -0.671 . . . . 19.04 112.075 172.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 51' ' ' GLY . . . . . . . . . . . . . . . 159.64 162.92 12.63 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 115.962 1.145 . . . . 5.68 115.962 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 52' ' ' ARG . . . . . 0.746 ' HB3' ' HB2' ' H' ' 45' ' ' ASP . 19.8 tpp85 -126.93 56.82 1.48 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.096 -1.446 . . . . 16.86 107.096 179.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 53' ' ' ILE . . . . . 0.795 HD11 ' HB3' ' I' ' 133' ' ' GLN . 6.7 tt -68.84 -6.71 6.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.467 0 C-N-CA 124.147 0.979 . . . . 63.97 112.894 -176.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 54' ' ' LEU . . . . . 0.571 HD13 ' HD3' ' H' ' 52' ' ' ARG . 7.6 mp -60.28 -27.13 67.02 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.664 1.186 . . . . 49.31 113.425 -171.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 55' ' ' GLY . . . . . 0.751 ' HA3' ' HB2' ' H' ' 43' ' ' LEU . . . -67.09 119.38 11.68 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-O 121.753 0.641 . . . . 20.29 114.47 -168.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 56' ' ' PRO . . . . . 0.424 ' HD2' ' HA2' ' H' ' 55' ' ' GLY . 60.1 Cg_endo -71.95 166.91 28.14 Favored 'Trans proline' 0 C--N 1.326 -0.647 0 C-N-CA 120.763 0.975 . . . . 10.69 109.892 170.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 57' ' ' GLY . . . . . 0.58 ' HA3' ' O ' ' H' ' 41' ' ' ARG . . . -134.52 171.44 22.28 Favored Glycine 0 N--CA 1.445 -0.734 0 N-CA-C 108.849 -1.7 . . . . 37.89 108.849 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 58' ' ' SER . . . . . 0.446 ' HB3' ' NH2' ' H' ' 41' ' ' ARG . 45.7 t -72.43 146.84 46.67 Favored 'General case' 0 N--CA 1.448 -0.563 0 C-N-CA 119.474 -0.89 . . . . 16.86 109.55 173.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 59' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' H' ' 40' ' ' GLU . 2.8 p -102.38 121.17 53.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.461 0 N-CA-C 108.22 -1.03 . . . . 6.43 108.22 -178.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 60' ' ' ALA . . . . . . . . . . . . . . . -118.96 109.2 15.69 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 106.855 -1.535 . . . . 6.02 106.855 175.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 61' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -108.2 119.98 41.03 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.301 -1.0 . . . . 62.57 108.301 -174.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 62' ' ' SER . . . . . 0.622 ' HA ' ' O ' ' H' ' 132' ' ' LEU . 62.4 m -102.97 164.58 11.52 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.121 0.969 . . . . 24.25 110.043 -177.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 63' ' ' GLY . . . . . 0.708 ' HA2' ' O ' ' H' ' 35' ' ' GLY . . . -137.12 123.0 2.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 120.125 -1.036 . . . . 16.86 112.781 175.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 64' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -99.44 94.83 6.63 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.16 -1.422 . . . . 44.19 107.16 171.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 65' ' ' VAL . . . . . . . . . . . . . 95.4 t -106.05 116.33 49.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 108.095 -1.076 . . . . 9.01 108.095 -177.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 66' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' H' ' 128' ' ' ILE . 67.6 p -115.52 143.42 45.35 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.262 -0.644 . . . . 16.86 109.262 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 67' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -153.4 -170.81 3.71 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 109.336 -0.616 . . . . 15.68 109.336 174.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 68' ' ' TYR . . . . . . . . . . . . . 15.5 m-30 -116.17 134.1 55.3 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.823 0.849 . . . . 8.81 109.625 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.36 115.62 4.22 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.786 -0.721 . . . . 16.84 113.758 -176.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 70' ' ' LYS . . . . . 0.435 ' O ' ' NE2' ' H' ' 76' ' ' GLN . 38.6 ttmt -92.63 149.53 21.28 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.679 -0.86 . . . . 11.94 108.679 173.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 71' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -68.1 -16.4 64.0 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 114.128 1.158 . . . . 26.48 114.128 -168.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 72' ' ' GLY . . . . . . . . . . . . . . . -128.24 -139.48 4.81 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.286 -1.126 . . . . 8.11 110.286 176.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 73' ' ' ASP . . . . . . . . . . . . . 30.2 t0 59.9 74.38 0.45 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 125.17 1.388 . . . . 18.64 111.148 168.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.17 10.74 0.04 OUTLIER 'General case' 0 C--O 1.234 0.287 0 N-CA-C 117.48 2.4 . . . . 50.46 117.48 -159.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.16 94.26 Favored Glycine 0 C--N 1.338 0.678 0 C-N-CA 120.318 -0.944 . . . . 12.0 112.647 170.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 76' ' ' GLN . . . . . 0.435 ' NE2' ' O ' ' H' ' 70' ' ' LYS . 21.8 pt20 -68.81 -24.3 64.37 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 120.033 -0.667 . . . . 41.69 111.774 172.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 77' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -74.44 -23.82 58.98 Favored 'General case' 0 CA--C 1.517 -0.327 0 C-N-CA 119.807 -0.757 . . . . 19.67 111.279 171.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 78' ' ' ALA . . . . . . . . . . . . . . . -74.03 -32.59 63.41 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 120.47 -0.492 . . . . 8.92 111.059 169.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 79' ' ' ILE . . . . . . . . . . . . . 51.1 mm -63.21 -45.71 97.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 CA-C-O 121.116 0.484 . . . . 15.39 110.483 172.015 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -76.48 -20.18 57.26 Favored 'General case' 0 C--O 1.234 0.276 0 O-C-N 121.908 -0.495 . . . . 33.45 111.963 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 81' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -72.73 -31.58 65.07 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 120.078 -0.649 . . . . 12.14 111.27 167.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 82' ' ' ALA . . . . . 0.741 ' HA ' ' HB2' ' H' ' 87' ' ' LYS . . . -75.44 -29.59 59.74 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 119.357 -0.937 . . . . 14.37 111.63 175.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 83' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -95.48 -59.81 1.8 Allowed 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.222 -0.591 . . . . 16.86 112.186 -173.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 84' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -73.45 -34.15 65.26 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 122.314 -0.241 . . . . 30.86 111.509 -170.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 85' ' ' ASN . . . . . . . . . . . . . 34.2 m120 -83.32 -47.69 11.22 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 120.027 -0.669 . . . . 11.16 111.17 171.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.57 96.9 2.3 Favored Glycine 0 N--CA 1.45 -0.374 0 O-C-N 122.141 -0.349 . . . . 14.58 113.688 178.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 87' ' ' LYS . . . . . 0.741 ' HB2' ' HA ' ' H' ' 82' ' ' ALA . 97.9 mttt -148.85 -162.04 1.47 Allowed 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.071 -1.455 . . . . 15.51 107.071 -178.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 88' ' ' GLN . . . . . 0.678 ' HG2' ' HD1' ' H' ' 112' ' ' TYR . 62.7 mt-30 -127.7 -178.98 4.7 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.738 0.78 . . . . 26.23 110.871 166.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 89' ' ' ILE . . . . . 0.472 HD11 HD11 ' H' ' 113' ' ' ILE . 60.1 mt -129.08 135.23 62.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 115.19 -0.914 . . . . 11.22 109.457 -172.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 90' ' ' LYS . . . . . 0.433 ' HD3' ' HG2' ' B' ' 165' ' ' GLN . 36.6 mtmm -84.48 116.89 23.34 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.352 -0.981 . . . . 18.75 108.352 163.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 91' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -114.37 133.02 56.0 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.424 1.09 . . . . 12.74 110.79 -164.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 92' ' ' TRP . . . . . 0.793 ' HB2' ' O ' ' H' ' 14' ' ' LEU . 93.2 m95 -132.44 124.26 28.27 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 124.136 0.974 . . . . 29.06 110.317 -172.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 93' ' ' ARG . . . . . 0.569 ' O ' ' HA ' ' H' ' 106' ' ' ALA . 78.7 ttt-85 -109.39 92.49 4.07 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 108.107 -1.071 . . . . 16.86 108.107 170.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 94' ' ' VAL . . . . . 0.479 HG12 ' HB2' ' H' ' 106' ' ' ALA . 21.4 m -107.66 163.96 5.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 122.122 0.963 . . . . 29.43 109.445 -174.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 95' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -111.73 167.9 9.99 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.985 -1.007 . . . . 16.86 111.255 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 96' ' ' THR . . . . . 0.418 HG23 HD12 ' H' ' 150' ' ' ILE . 26.9 m -101.49 -29.44 11.99 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.008 -0.996 . . . . 15.46 112.647 -174.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -70.01 155.83 7.45 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 CA-C-O 121.71 0.767 . . . . 16.86 110.249 -177.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 98' ' ' LYS . . . . . 0.503 ' NZ ' ' O ' ' H' ' 99' ' ' ASN . 29.5 tptp -90.76 125.06 35.58 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.683 -0.69 . . . . 8.25 109.749 -177.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 99' ' ' ASN . . . . . 0.503 ' O ' ' NZ ' ' H' ' 98' ' ' LYS . 34.6 m120 -85.53 171.12 11.99 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.874 0.845 . . . . 11.54 110.074 172.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 100' ' ' GLU . . . . . . . . . . . . . 57.4 mp0 -105.28 -14.96 15.19 Favored 'General case' 0 CA--C 1.519 -0.225 0 N-CA-C 113.572 0.953 . . . . 3.22 113.572 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 101' ' ' ASN . . . . . . . . . . . . . 20.2 p30 -93.29 -47.04 7.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 118.143 0.429 . . . . 23.88 111.545 169.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 102' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -112.28 -175.08 2.6 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.954 -0.758 . . . . 55.17 108.954 174.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 103' ' ' LYS . . . . . 0.69 ' H ' HG22 ' H' ' 143' ' ' ILE . 97.3 mttt -79.92 -55.21 5.13 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 120.426 -0.509 . . . . 35.9 110.18 169.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 104' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -133.07 -172.88 3.04 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 108.22 -1.03 . . . . 23.11 108.22 -178.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 105' ' ' ASP . . . . . . . . . . . . . 21.6 p-10 -149.9 164.64 34.87 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.474 0.654 . . . . 48.44 109.266 177.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 106' ' ' ALA . . . . . 0.569 ' HA ' ' O ' ' H' ' 93' ' ' ARG . . . -155.82 158.54 38.27 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.256 -0.884 . . . . 28.36 111.309 -162.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 107' ' ' GLN . . . . . 0.479 ' OE1' ' OH ' ' I' ' 118' ' ' TYR . 87.5 mt-30 -119.23 126.26 51.11 Favored 'General case' 0 C--O 1.236 0.379 0 N-CA-C 107.015 -1.476 . . . . 21.32 107.015 159.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 108' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -112.25 155.07 24.64 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 123.585 0.754 . . . . 12.32 110.202 -164.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 109' ' ' GLY . . . . . 0.425 ' HA3' HG21 ' H' ' 134' ' ' VAL . . . -168.29 162.57 36.35 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 119.507 -1.33 . . . . 7.13 112.639 172.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 110' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -101.91 109.05 20.69 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 114.885 -0.658 . . . . 20.08 109.496 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 111' ' ' ALA . . . . . . . . . . . . . . . -107.23 156.54 18.73 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.528 0.68 . . . . 59.58 111.77 -166.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 112' ' ' TYR . . . . . 0.678 ' HD1' ' HG2' ' H' ' 88' ' ' GLN . 55.3 t80 -136.9 138.28 40.51 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 107.349 -1.352 . . . . 17.89 107.349 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 113' ' ' ILE . . . . . 0.472 HD11 HD11 ' H' ' 89' ' ' ILE . 80.4 mt -88.77 128.22 41.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 109.953 -0.388 . . . . 5.27 109.953 -169.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 114' ' ' GLU . . . . . 0.499 ' HB2' ' HB2' ' H' ' 131' ' ' SER . 99.2 mt-10 -71.28 -64.57 0.89 Allowed 'General case' 0 C--O 1.235 0.303 0 C-N-CA 119.881 -0.728 . . . . 20.33 110.533 163.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 115' ' ' SER . . . . . . . . . . . . . 74.5 m -140.38 152.12 45.51 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-O 121.639 0.733 . . . . 2.92 110.627 -170.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 116' ' ' ARG . . . . . . . . . . . . . 8.6 tmm_? -125.49 94.51 4.16 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 104.807 -2.294 . . . . 16.86 104.807 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 117' ' ' GLU . . . . . 0.536 ' HB3' HG12 ' G' ' 37' ' ' VAL . 98.1 mt-10 -117.52 107.36 14.18 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 107.689 -1.226 . . . . 34.77 107.689 -173.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 118' ' ' TYR . . . . . 0.483 ' HB3' ' HA ' ' H' ' 128' ' ' ILE . 13.6 p90 -111.53 144.0 41.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.599 0.714 . . . . 4.91 111.829 177.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 119' ' ' SER . . . . . . . . . . . . . 39.5 t -97.03 126.97 42.55 Favored 'General case' 0 C--O 1.241 0.641 0 CA-C-N 114.616 -1.175 . . . . 6.37 109.591 176.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 120' ' ' ASP . . . . . 0.673 ' HA ' HG12 ' H' ' 126' ' ' VAL . 59.3 t0 -104.99 98.13 7.89 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 106.063 -1.829 . . . . 27.99 106.063 170.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 121' ' ' GLY . . . . . . . . . . . . . . . -82.5 -153.88 13.55 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-O 121.864 0.702 . . . . 32.42 112.155 178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -116.19 -59.45 3.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 107.955 -1.128 . . . . 22.96 107.955 177.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 123' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -102.97 -32.33 9.79 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 113.005 0.743 . . . . 64.75 113.005 -175.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 124' ' ' GLY . . . . . . . . . . . . . . . -75.04 145.82 34.08 Favored Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 109.228 -1.549 . . . . 58.97 109.228 165.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.96 165.99 23.91 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 119.806 -0.758 . . . . 16.86 110.26 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 126' ' ' VAL . . . . . 0.673 HG12 ' HA ' ' H' ' 120' ' ' ASP . 27.9 m -68.78 149.1 11.38 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 CA-C-N 115.234 -0.894 . . . . 16.86 109.908 -173.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 127' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -138.19 129.71 27.83 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.841 -0.429 . . . . 30.97 109.841 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 128' ' ' ILE . . . . . 0.483 ' HA ' ' HB3' ' H' ' 118' ' ' TYR . 93.5 mt -98.63 122.55 50.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.146 -0.687 . . . . 16.86 109.146 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 129' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' H' ' 117' ' ' GLU . 69.2 m -100.67 132.79 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.309 -0.997 . . . . 6.41 108.309 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 130' ' ' ILE . . . . . . . . . . . . . 96.0 mt -132.82 127.94 56.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 108.678 -0.86 . . . . 16.86 108.678 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 131' ' ' SER . . . . . 0.499 ' HB2' ' HB2' ' H' ' 114' ' ' GLU . 57.0 m -92.59 145.46 24.42 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 116.089 -0.505 . . . . 24.39 109.729 174.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 132' ' ' LEU . . . . . 0.622 ' O ' ' HA ' ' H' ' 62' ' ' SER . 7.2 mp -129.86 151.41 50.45 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 116.03 -0.532 . . . . 22.57 110.212 -178.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 133' ' ' GLN . . . . . 0.786 ' HB3' HD11 ' G' ' 53' ' ' ILE . 18.7 mm100 -142.05 123.7 15.07 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 123.89 0.876 . . . . 3.25 109.106 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 134' ' ' VAL . . . . . 0.425 HG21 ' HA3' ' H' ' 109' ' ' GLY . 12.4 p -132.57 148.67 31.72 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 109.032 -0.729 . . . . 14.47 109.032 -178.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -62.64 -59.17 4.78 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 CA-C-O 121.212 0.53 . . . . 16.86 110.923 176.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.58 137.09 4.8 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.581 -0.819 . . . . 16.86 111.53 -178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 137' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -67.07 149.33 50.73 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.44 0.638 . . . . 21.99 110.35 175.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 138' ' ' LEU . . . . . 0.586 HD23 HD21 ' H' ' 140' ' ' ASN . 31.9 tp -133.58 127.75 33.75 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.546 -1.279 . . . . 16.86 107.546 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 139' ' ' LYS . . . . . . . . . . . . . 7.9 mtmp? -81.55 76.89 8.46 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-O 122.345 1.069 . . . . 10.83 109.402 -170.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 140' ' ' ASN . . . . . 0.586 HD21 HD23 ' H' ' 138' ' ' LEU . 87.7 m-20 -98.51 77.02 2.29 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.209 -0.905 . . . . 30.3 108.779 -177.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.53 106.85 2.04 Favored Glycine 0 C--O 1.237 0.311 0 N-CA-C 110.419 -1.072 . . . . 20.9 110.419 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -117.29 -173.15 2.35 Favored 'General case' 0 C--O 1.234 0.242 0 N-CA-C 109.112 -0.699 . . . . 16.58 109.112 -176.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 143' ' ' ILE . . . . . 0.69 HG22 ' H ' ' H' ' 103' ' ' LYS . 1.3 pp -111.79 -62.29 2.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 N-CA-C 113.217 0.821 . . . . 29.28 113.217 -169.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 144' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -81.52 125.46 30.52 Favored 'General case' 0 C--N 1.331 -0.221 0 O-C-N 121.355 -0.841 . . . . 19.39 111.106 -169.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 145' ' ' THR . . . . . . . . . . . . . 68.0 p -120.76 17.1 11.91 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 112.685 0.624 . . . . 30.43 112.685 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 146' ' ' LEU . . . . . 0.482 ' HG ' ' HA ' ' H' ' 24' ' ' SER . 4.2 mm? 54.48 76.2 0.54 Allowed Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 126.572 1.949 . . . . 8.94 110.891 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 147' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -68.46 72.98 0.88 Allowed 'Trans proline' 0 C--N 1.347 0.486 0 N-CA-C 115.411 1.274 . . . . 9.56 115.411 -162.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 148' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.97 10.67 28.32 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.022 -0.536 . . . . 26.9 111.548 167.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 149' ' ' GLU . . . . . . . . . . . . . 26.1 pm0 -139.74 7.64 2.31 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 112.829 0.678 . . . . 12.56 112.829 -177.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 150' ' ' ILE . . . . . 0.418 HD12 HG23 ' H' ' 96' ' ' THR . 43.1 mm -111.36 -47.39 6.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.816 0.734 . . . . 11.42 111.129 -178.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 151' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.84 -29.04 2.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.488 0 N-CA-C 108.228 -1.027 . . . . 29.26 108.228 -176.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 152' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -66.22 -32.48 73.93 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.252 -0.431 . . . . 16.93 111.635 -177.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 153' ' ' VAL . . . . . . . . . . . . . 2.2 p -74.91 98.74 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-O 122.211 1.005 . . . . 16.86 108.448 171.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 154' ' ' SER . . . . . . . . . . . . . 41.5 t -118.98 -61.75 1.61 Allowed 'General case' 0 C--O 1.233 0.192 0 CA-C-N 115.723 -0.672 . . . . 22.09 112.32 -178.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 155' ' ' LYS . . . . . 0.545 ' HG3' ' H ' ' H' ' 157' ' ' GLY . 5.4 tppp? -128.72 -37.7 1.74 Allowed 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 113.738 1.014 . . . . 33.48 113.738 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 156' ' ' GLY . . . . . . . . . . . . . . . 93.09 -53.91 2.52 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.583 -1.407 . . . . 16.86 109.583 -160.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 157' ' ' GLY . . . . . 0.545 ' H ' ' HG3' ' H' ' 155' ' ' LYS . . . -90.2 155.5 24.41 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-O 122.095 0.831 . . . . 16.86 112.584 179.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 158' ' ' TYR . . . . . . . . . . . . . 20.4 m-30 -118.79 -171.2 2.05 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.948 1.699 . . . . 20.89 108.481 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 159' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -78.8 -71.4 0.44 Allowed 'General case' 0 C--O 1.236 0.368 0 C-N-CA 118.54 -1.264 . . . . 23.05 112.459 -169.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 160' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -178.09 163.65 1.74 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.643 0.777 . . . . 25.31 109.165 -175.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 161' ' ' GLN . . . . . . . . . . . . . 65.7 tt0 -149.63 94.46 2.19 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 105.306 -2.109 . . . . 17.71 105.306 153.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 162' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -66.21 -42.93 53.04 Favored Pre-proline 0 C--O 1.244 0.796 0 N-CA-C 114.318 1.229 . . . . 33.51 114.318 -166.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 163' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -73.79 -42.51 0.8 Allowed 'Trans proline' 0 C--N 1.364 1.38 0 CA-C-N 122.206 1.824 . . . . 29.17 113.261 172.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 164' ' ' GLY . . . . . 0.489 ' HA3' ' HG3' ' H' ' 175' ' ' PRO . . . -129.8 40.51 1.67 Allowed Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 117.941 1.936 . . . . 30.18 117.941 -165.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -62.99 -63.48 1.19 Allowed 'General case' 0 C--O 1.238 0.471 0 CA-C-N 118.324 1.062 . . . . 16.86 110.574 171.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 166' ' ' THR . . . . . . . . . . . . . 41.3 p 53.82 51.03 15.63 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.86 1.664 . . . . 55.52 111.711 173.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 167' ' ' THR . . . . . . . . . . . . . 1.8 m -134.27 166.27 23.2 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 107.818 -1.179 . . . . 18.58 107.818 -168.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.78 -125.49 1.15 Allowed Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 109.634 -1.387 . . . . 33.57 109.634 170.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 169' ' ' GLU . . . . . . . . . . . . . 16.6 tm-20 -77.65 -60.81 2.21 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 119.362 -0.935 . . . . 30.67 110.975 -179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 170' ' ' ALA . . . . . . . . . . . . . . . -65.65 105.0 0.65 Allowed Pre-proline 0 C--O 1.236 0.348 0 C-N-CA 124.051 0.94 . . . . 5.65 109.654 -172.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 171' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -83.7 -174.26 1.87 Allowed 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 121.392 1.395 . . . . 18.19 111.912 -155.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 172' ' ' GLY . . . . . . . . . . . . . . . 73.9 66.74 1.92 Allowed Glycine 0 N--CA 1.446 -0.661 0 CA-C-N 114.49 -1.232 . . . . 29.36 114.863 167.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 173' ' ' THR . . . . . . . . . . . . . 11.3 t -133.35 166.85 21.55 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.776 0.798 . . . . 8.79 109.259 170.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 m -72.1 153.58 92.55 Favored Pre-proline 0 C--O 1.24 0.573 0 CA-C-N 114.89 -1.05 . . . . 22.5 108.231 176.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 175' ' ' PRO . . . . . 0.489 ' HG3' ' HA3' ' H' ' 164' ' ' GLY . 42.2 Cg_exo -63.89 111.92 1.69 Allowed 'Trans proline' 0 C--N 1.35 0.649 0 CA-C-N 119.347 0.802 . . . . 44.92 111.264 175.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.195 0 C-N-CA 125.609 1.564 . . . . 44.53 111.821 -171.217 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 5' ' ' PRO . . . . . 0.468 ' HB2' ' H ' ' I' ' 6' ' ' ILE . 36.6 Cg_endo . . . . . 0 N--CA 1.466 -0.092 0 CA-C-O 119.583 -0.257 . . . . 23.33 112.409 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 6' ' ' ILE . . . . . 0.468 ' H ' ' HB2' ' I' ' 5' ' ' PRO . 96.7 mt -125.27 122.0 61.91 Favored 'Isoleucine or valine' 0 C--O 1.238 0.464 0 N-CA-C 108.088 -1.078 . . . . 7.12 108.088 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -93.0 170.83 9.36 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 121.817 0.817 . . . . 40.91 110.604 -177.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.97 -14.0 67.43 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.476 -0.784 . . . . 7.69 114.581 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -90.76 -13.96 32.98 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 117.819 0.81 . . . . 7.68 112.382 172.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -77.88 -7.17 56.34 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 113.751 1.019 . . . . 33.11 113.751 -170.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' VAL . . . . . . . . . . . . . 80.9 t -128.22 124.64 62.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.908 -1.145 . . . . 11.83 107.908 -176.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -133.24 162.12 32.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.599 0.714 . . . . 4.34 110.221 176.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' TYR . . . . . 0.442 ' HA ' ' O ' ' I' ' 92' ' ' TRP . 19.0 m-30 -112.69 94.76 5.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.008 -0.996 . . . . 17.0 108.458 -165.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' LEU . . . . . 0.848 ' O ' ' HB2' ' I' ' 92' ' ' TRP . 97.6 mt -77.1 131.58 38.43 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.083 -0.647 . . . . 58.6 109.5 177.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' PHE . . . . . . . . . . . . . 22.0 m-30 -112.83 155.37 24.75 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.395 -0.595 . . . . 13.06 109.395 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' GLN . . . . . . . . . . . . . 71.0 tp60 -148.6 137.5 21.57 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 109.21 -0.663 . . . . 35.81 109.21 174.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' SER . . . . . 0.435 ' O ' ' NZ ' ' I' ' 90' ' ' LYS . 40.0 t -77.0 155.19 32.78 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.646 0.736 . . . . 12.95 111.194 -178.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' ILE . . . . . . . . . . . . . 43.7 pt -78.77 -13.13 13.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.457 -0.792 . . . . 17.0 113.031 178.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -113.42 -6.72 13.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.454 0.538 . . . . 57.91 112.454 -172.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.84 -47.97 23.42 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 119.964 -0.694 . . . . 27.52 111.853 -171.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.411 ' HB2' HG22 ' C' ' 166' ' ' THR . . . 53.09 45.32 28.96 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.811 1.245 . . . . 18.72 111.428 -168.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' THR . . . . . . . . . . . . . 72.8 p -127.59 123.96 36.95 Favored 'General case' 0 C--O 1.236 0.365 0 N-CA-C 108.985 -0.746 . . . . 10.9 108.985 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.32 76.58 2.15 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 121.528 -0.367 . . . . 9.74 113.377 -178.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' SER . . . . . 0.46 ' HA ' ' HG ' ' I' ' 146' ' ' LEU . 95.4 p -128.39 -30.61 2.36 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 120.562 -0.455 . . . . 23.98 112.181 -176.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' ALA . . . . . 0.542 ' HB1' ' HB3' ' I' ' 14' ' ' LEU . . . 51.86 74.97 0.7 Allowed Pre-proline 0 C--O 1.236 0.394 0 C-N-CA 126.812 2.045 . . . . 33.08 112.485 -173.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -70.5 106.14 1.74 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 CA-C-N 119.473 0.848 . . . . 3.49 113.032 177.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' LEU . . . . . 0.739 ' HB3' HD23 ' I' ' 14' ' ' LEU . 2.2 pt? -87.85 169.72 11.8 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.101 -0.703 . . . . 11.21 109.101 164.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -112.78 143.76 29.68 Favored Pre-proline 0 N--CA 1.449 -0.497 1 C-N-CA 111.426 -4.109 . . . . 33.39 110.475 -172.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.34 161.83 41.76 Favored 'Trans proline' 0 CA--C 1.518 -0.315 0 CA-C-N 118.946 0.659 . . . . 53.3 113.679 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . 55.61 59.83 3.65 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.781 1.232 . . . . 7.07 111.708 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' TYR . . . . . 0.435 ' HD1' ' HA ' ' I' ' 31' ' ' TYR . 3.4 m-30 -71.34 167.34 19.73 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 122.624 1.202 . . . . 40.62 111.085 173.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' GLN . . . . . 0.472 ' HG3' ' H ' ' I' ' 33' ' ' THR . 7.8 tp-100 -136.79 -162.67 1.31 Allowed 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 103.636 -2.727 . . . . 29.07 103.636 177.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' THR . . . . . 0.472 ' H ' ' HG3' ' I' ' 32' ' ' GLN . 15.3 t -64.66 162.56 15.51 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-O 122.631 1.205 . . . . 36.87 112.033 -172.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' ASP . . . . . 0.644 ' HB2' ' HB3' ' J' ' 120' ' ' ASP . 79.4 m-20 -134.79 -172.46 3.04 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.018 -1.446 . . . . 37.64 108.182 -162.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' GLY . . . . . 0.615 ' O ' ' HA2' ' I' ' 63' ' ' GLY . . . 171.02 134.46 1.77 Allowed Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.399 -0.905 . . . . 17.37 112.283 166.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' SER . . . . . . . . . . . . . 64.9 m -121.87 84.64 2.28 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 105.77 -1.937 . . . . 17.0 105.77 173.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' VAL . . . . . 0.565 HG23 ' HB2' ' I' ' 62' ' ' SER . 3.2 m -89.7 108.24 19.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 108.395 -0.965 . . . . 17.0 108.395 -173.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' SER . . . . . . . . . . . . . 48.3 m -98.01 95.99 7.85 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.923 -1.14 . . . . 17.0 107.923 -170.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' GLY . . . . . . . . . . . . . . . -99.18 102.63 2.6 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.153 -1.022 . . . . 29.57 112.964 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' I' ' 59' ' ' VAL . 81.9 tt0 -102.43 126.25 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.159 -1.052 . . . . 16.35 108.159 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 41' ' ' ARG . . . . . 0.478 ' C ' ' HA3' ' I' ' 57' ' ' GLY . 93.2 mtm-85 -80.76 -176.67 5.95 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.488 0.661 . . . . 62.13 109.368 -177.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 42' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -161.59 160.48 28.93 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.493 -0.558 . . . . 60.4 109.493 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 43' ' ' LEU . . . . . 0.722 ' HB2' ' HA3' ' I' ' 55' ' ' GLY . 47.2 mt -88.23 128.09 35.46 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.848 -0.615 . . . . 4.94 109.417 175.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 44' ' ' PHE . . . . . . . . . . . . . 67.3 t80 -120.84 107.52 12.82 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 108.307 -0.998 . . . . 75.54 108.307 -173.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 45' ' ' ASP . . . . . 0.686 ' HB2' ' HB3' ' I' ' 52' ' ' ARG . 76.3 m-20 -134.76 162.19 33.07 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-N 116.264 -0.426 . . . . 17.0 110.596 -169.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 46' ' ' GLU . . . . . . . . . . . . . 59.8 mp0 -125.91 -42.73 1.88 Allowed 'General case' 0 C--O 1.236 0.348 0 N-CA-C 113.721 1.008 . . . . 15.68 113.721 -175.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 47' ' ' GLN . . . . . 0.65 ' HB3' ' HA ' ' D' ' 30' ' ' ALA . 91.1 mm-40 67.45 24.69 8.73 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 124.401 1.08 . . . . 41.36 113.871 153.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 48' ' ' THR . . . . . 0.45 ' H ' HG13 ' E' ' 122' ' ' VAL . 65.3 p 51.29 37.35 18.48 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 124.818 1.247 . . . . 43.18 111.35 -169.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 49' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm -139.44 -164.75 1.73 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 106.936 -1.505 . . . . 8.41 106.936 -176.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 50' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -73.87 -23.55 59.61 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 120.41 -0.516 . . . . 14.0 111.807 171.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 51' ' ' GLY . . . . . . . . . . . . . . . 145.23 155.81 6.61 Favored Glycine 0 N--CA 1.446 -0.673 0 C-N-CA 121.389 -0.434 . . . . 12.97 113.398 179.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 52' ' ' ARG . . . . . 0.737 ' HD3' HD13 ' I' ' 54' ' ' LEU . 21.7 tpp85 -124.7 54.22 1.41 Allowed 'General case' 0 C--O 1.235 0.294 0 N-CA-C 105.349 -2.093 . . . . 5.17 105.349 176.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 53' ' ' ILE . . . . . 0.555 HD11 HE21 ' J' ' 133' ' ' GLN . 7.4 tt -73.58 -5.07 6.08 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.127 -0.942 . . . . 26.87 111.474 -177.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 54' ' ' LEU . . . . . 0.737 HD13 ' HD3' ' I' ' 52' ' ' ARG . 8.2 mp -51.78 -29.32 18.5 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 127.619 2.368 . . . . 61.28 114.451 -175.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 55' ' ' GLY . . . . . 0.722 ' HA3' ' HB2' ' I' ' 43' ' ' LEU . . . -64.27 123.01 26.82 Favored Glycine 0 N--CA 1.44 -1.095 0 CA-C-O 121.567 0.537 . . . . 17.24 113.98 -166.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 56' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.18 156.31 65.44 Favored 'Trans proline' 0 C--N 1.326 -0.656 0 C-N-CA 121.063 1.176 . . . . 13.15 110.376 171.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 57' ' ' GLY . . . . . 0.478 ' HA3' ' C ' ' I' ' 41' ' ' ARG . . . -126.23 172.27 17.99 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 108.477 -1.849 . . . . 17.02 108.477 178.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 58' ' ' SER . . . . . 0.43 ' HB3' ' NH2' ' I' ' 41' ' ' ARG . 42.1 t -74.88 144.32 43.42 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 119.817 -0.753 . . . . 17.62 110.063 176.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 59' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' I' ' 40' ' ' GLU . 2.6 p -95.65 121.25 46.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 108.357 -0.979 . . . . 17.0 108.357 -178.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.2 114.72 22.34 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 106.905 -1.517 . . . . 10.79 106.905 175.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 61' ' ' ASP . . . . . . . . . . . . . 51.5 t0 -117.93 120.48 37.98 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.863 -0.792 . . . . 53.38 108.863 -169.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' I' ' 132' ' ' LEU . 67.9 m -105.16 166.74 10.19 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.068 0.947 . . . . 7.55 110.532 -176.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 63' ' ' GLY . . . . . 0.615 ' HA2' ' O ' ' I' ' 35' ' ' GLY . . . -139.32 123.27 2.48 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.05 -0.977 . . . . 9.11 113.058 175.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 64' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -101.73 97.24 7.66 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 107.552 -1.277 . . . . 63.47 107.552 173.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 65' ' ' VAL . . . . . . . . . . . . . 93.7 t -107.24 116.29 50.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 108.282 -1.007 . . . . 17.0 108.282 -178.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 66' ' ' THR . . . . . 0.467 ' HA ' ' O ' ' I' ' 128' ' ' ILE . 70.1 p -115.62 143.11 45.82 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.247 -0.649 . . . . 22.76 109.247 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 67' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -153.52 -170.32 3.56 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.364 0.602 . . . . 12.71 109.405 175.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -116.01 134.15 55.26 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.676 0.79 . . . . 17.94 109.367 179.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.03 107.74 2.73 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.953 -0.641 . . . . 38.99 113.911 -175.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -83.73 147.25 27.74 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 108.812 -0.81 . . . . 5.02 108.812 173.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -67.01 -16.7 64.53 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 114.126 1.158 . . . . 21.0 114.126 -168.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.78 -141.53 5.45 Favored Glycine 0 N--CA 1.451 -0.325 0 N-CA-C 110.108 -1.197 . . . . 17.67 110.108 176.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 73' ' ' ASP . . . . . . . . . . . . . 31.4 t0 59.49 72.65 0.52 Allowed 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 125.157 1.383 . . . . 17.0 111.106 169.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.75 11.25 0.04 OUTLIER 'General case' 0 C--O 1.235 0.313 0 N-CA-C 117.285 2.328 . . . . 31.59 117.285 -159.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.21 -38.7 90.79 Favored Glycine 0 C--N 1.338 0.647 0 C-N-CA 120.355 -0.926 . . . . 22.74 112.727 169.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 76' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -69.4 -24.71 63.89 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.69 -0.804 . . . . 8.28 111.325 173.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 77' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -73.51 -24.98 60.22 Favored 'General case' 0 CA--C 1.516 -0.347 0 C-N-CA 119.597 -0.841 . . . . 25.75 111.356 171.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.71 -33.37 66.4 Favored 'General case' 0 C--O 1.239 0.551 0 C-N-CA 120.274 -0.57 . . . . 15.11 111.041 169.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 79' ' ' ILE . . . . . . . . . . . . . 51.1 mm -63.76 -43.84 98.09 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.087 0.47 . . . . 4.62 110.435 172.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 80' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -75.05 -20.78 59.4 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 121.88 -0.512 . . . . 37.77 112.01 179.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 81' ' ' ASP . . . . . . . . . . . . . 55.3 m-20 -71.35 -33.45 69.61 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 120.165 -0.614 . . . . 27.13 111.224 168.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 82' ' ' ALA . . . . . 0.742 ' HA ' ' HB2' ' I' ' 87' ' ' LYS . . . -73.6 -36.42 65.52 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 119.416 -0.913 . . . . 4.66 111.634 175.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 83' ' ' TYR . . . . . . . . . . . . . 84.2 t80 -83.79 -61.9 1.71 Allowed 'General case' 0 C--O 1.235 0.317 0 C-N-CA 120.486 -0.486 . . . . 17.0 112.139 -176.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 84' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 -74.65 -40.01 61.73 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 111.763 0.283 . . . . 18.96 111.763 -166.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 85' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -76.66 -47.11 23.13 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 119.952 -0.699 . . . . 34.93 111.015 172.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.19 96.3 2.28 Favored Glycine 0 N--CA 1.45 -0.421 0 O-C-N 122.261 -0.275 . . . . 21.67 113.34 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 87' ' ' LYS . . . . . 0.742 ' HB2' ' HA ' ' I' ' 82' ' ' ALA . 98.0 mttt -148.87 -161.8 1.42 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 107.052 -1.462 . . . . 19.94 107.052 -177.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 88' ' ' GLN . . . . . 0.7 ' HG2' ' HD1' ' I' ' 112' ' ' TYR . 63.5 mt-30 -129.64 177.64 7.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.777 0.798 . . . . 25.1 111.045 167.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 89' ' ' ILE . . . . . 0.461 HD11 HD11 ' I' ' 113' ' ' ILE . 55.8 mt -127.35 136.93 59.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 115.215 -0.902 . . . . 18.47 109.446 -173.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 90' ' ' LYS . . . . . 0.435 ' NZ ' ' O ' ' I' ' 17' ' ' SER . 36.9 mtmm -85.26 118.7 24.97 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.436 -0.95 . . . . 12.1 108.436 164.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 91' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -111.94 133.56 54.05 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.342 1.057 . . . . 9.89 110.671 -166.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 92' ' ' TRP . . . . . 0.848 ' HB2' ' O ' ' I' ' 14' ' ' LEU . 91.7 m95 -132.48 125.67 31.2 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 124.183 0.993 . . . . 25.76 109.894 -173.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 93' ' ' ARG . . . . . 0.593 ' O ' ' HA ' ' I' ' 106' ' ' ALA . 78.8 ttt-85 -112.65 90.63 3.4 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 108.142 -1.059 . . . . 17.0 108.142 171.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 94' ' ' VAL . . . . . 0.472 HG12 ' HB2' ' I' ' 106' ' ' ALA . 20.3 m -105.11 165.24 3.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 122.061 0.934 . . . . 22.42 109.385 -174.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 95' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -110.72 165.14 12.07 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.07 -0.968 . . . . 21.14 111.583 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 96' ' ' THR . . . . . 0.448 HG23 HG23 ' I' ' 150' ' ' ILE . 31.9 m -98.22 -33.07 11.25 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 114.901 -1.045 . . . . 18.2 112.751 -176.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 97' ' ' VAL . . . . . . . . . . . . . 34.1 m -70.3 155.6 7.55 Favored 'Isoleucine or valine' 0 C--O 1.237 0.431 0 CA-C-O 121.81 0.814 . . . . 2.01 110.197 -177.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 98' ' ' LYS . . . . . 0.554 ' NZ ' ' O ' ' I' ' 99' ' ' ASN . 29.6 tptp -88.28 129.39 35.38 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.626 -0.715 . . . . 17.92 109.633 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 99' ' ' ASN . . . . . 0.554 ' O ' ' NZ ' ' I' ' 98' ' ' LYS . 35.4 m120 -91.37 173.16 8.06 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.76 0.79 . . . . 24.74 110.022 172.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 100' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -108.59 -16.39 14.21 Favored 'General case' 0 C--O 1.233 0.234 0 N-CA-C 113.667 0.988 . . . . 25.49 113.667 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 101' ' ' ASN . . . . . . . . . . . . . 21.3 p30 -86.73 -47.2 9.32 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 118.188 0.449 . . . . 14.22 111.054 170.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 102' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -119.44 -174.77 2.8 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.588 -0.893 . . . . 56.62 108.588 174.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 103' ' ' LYS . . . . . 0.725 ' H ' HG22 ' I' ' 143' ' ' ILE . 96.9 mttt -74.3 -57.63 3.82 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 120.184 -0.606 . . . . 34.07 110.318 169.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 104' ' ' TYR . . . . . . . . . . . . . 65.4 m-85 -132.62 -170.77 2.5 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 108.863 -0.791 . . . . 6.62 108.863 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 105' ' ' ASP . . . . . 0.419 ' N ' ' OD1' ' I' ' 105' ' ' ASP . 17.4 p-10 -151.73 166.53 31.03 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 121.471 0.653 . . . . 44.49 109.241 177.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' I' ' 93' ' ' ARG . . . -157.96 154.75 28.29 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 115.337 -0.847 . . . . 17.0 111.159 -163.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 107' ' ' GLN . . . . . 0.464 ' OE1' ' OH ' ' J' ' 118' ' ' TYR . 88.4 mt-30 -112.86 124.82 53.49 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.915 -1.513 . . . . 17.34 106.915 159.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 108' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -111.41 154.44 24.64 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 123.543 0.737 . . . . 8.89 110.268 -165.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 109' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' I' ' 134' ' ' VAL . . . -164.79 168.78 39.2 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 119.537 -1.315 . . . . 18.72 112.714 172.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 110' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.14 110.86 22.2 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.626 -0.787 . . . . 23.19 109.058 168.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 111' ' ' ALA . . . . . . . . . . . . . . . -109.93 155.94 21.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 121.607 0.718 . . . . 38.3 111.826 -165.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 112' ' ' TYR . . . . . 0.7 ' HD1' ' HG2' ' I' ' 88' ' ' GLN . 51.7 t80 -136.02 137.75 41.5 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 107.267 -1.383 . . . . 3.85 107.267 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 113' ' ' ILE . . . . . 0.461 HD11 HD11 ' I' ' 89' ' ' ILE . 84.2 mt -86.72 128.03 39.91 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.881 -0.414 . . . . 5.61 109.881 -170.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 114' ' ' GLU . . . . . 0.493 ' HB2' ' HB2' ' I' ' 131' ' ' SER . 98.7 mt-10 -71.15 -64.36 0.93 Allowed 'General case' 0 C--O 1.235 0.29 0 C-N-CA 119.832 -0.747 . . . . 26.68 110.555 164.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 115' ' ' SER . . . . . . . . . . . . . 74.3 m -141.94 153.46 44.36 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.612 0.72 . . . . 25.88 110.375 -170.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 116' ' ' ARG . . . . . . . . . . . . . 9.0 tmm_? -127.05 89.95 3.07 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 104.725 -2.324 . . . . 12.69 104.725 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 117' ' ' GLU . . . . . 0.532 ' HB3' HG12 ' H' ' 37' ' ' VAL . 98.3 mt-10 -112.63 106.85 15.36 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.733 -1.21 . . . . 24.53 107.733 -174.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 118' ' ' TYR . . . . . 0.504 ' HB3' ' HA ' ' I' ' 128' ' ' ILE . 11.9 p90 -111.88 143.59 42.59 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.621 0.724 . . . . 17.0 111.939 176.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 119' ' ' SER . . . . . . . . . . . . . 35.7 t -99.3 128.79 45.46 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-N 114.633 -1.167 . . . . 5.54 109.869 178.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 120' ' ' ASP . . . . . 0.64 ' HB3' ' HB2' ' H' ' 34' ' ' ASP . 59.3 t0 -103.56 96.33 6.66 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.217 -1.771 . . . . 25.94 106.217 170.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 121' ' ' GLY . . . . . . . . . . . . . . . -80.09 -159.94 20.29 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-O 121.842 0.69 . . . . 22.53 112.252 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 122' ' ' VAL . . . . . . . . . . . . . 88.8 t -116.45 -63.0 2.06 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 108.614 -0.884 . . . . 21.86 108.614 178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 123' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -96.37 -22.37 17.21 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 112.718 0.636 . . . . 41.28 112.718 -176.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 124' ' ' GLY . . . . . . . . . . . . . . . -86.55 155.18 27.87 Favored Glycine 0 N--CA 1.451 -0.358 0 N-CA-C 109.526 -1.43 . . . . 17.0 109.526 165.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.04 167.97 20.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.683 0.754 . . . . 14.91 110.213 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 126' ' ' VAL . . . . . 0.597 HG12 ' HA ' ' I' ' 120' ' ' ASP . 35.9 m -69.21 153.17 9.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.492 0 CA-C-N 115.287 -0.87 . . . . 17.18 109.585 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 127' ' ' GLU . . . . . . . . . . . . . 21.9 pt-20 -143.79 133.45 23.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 N-CA-C 109.859 -0.423 . . . . 47.07 109.859 -178.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 128' ' ' ILE . . . . . 0.504 ' HA ' ' HB3' ' I' ' 118' ' ' TYR . 90.1 mt -102.05 123.23 55.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 109.371 -0.603 . . . . 17.0 109.371 -176.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 129' ' ' SER . . . . . 0.506 ' HB2' ' O ' ' I' ' 117' ' ' GLU . 66.3 m -102.3 132.71 48.1 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 108.55 -0.907 . . . . 31.15 108.55 170.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 130' ' ' ILE . . . . . . . . . . . . . 91.4 mt -133.89 128.12 53.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.793 -0.817 . . . . 17.0 108.793 -179.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 131' ' ' SER . . . . . 0.493 ' HB2' ' HB2' ' I' ' 114' ' ' GLU . 62.1 m -94.26 147.6 23.03 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 116.087 -0.506 . . . . 20.21 109.84 175.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 132' ' ' LEU . . . . . 0.589 ' O ' ' HA ' ' I' ' 62' ' ' SER . 7.1 mp -132.57 152.02 51.75 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 115.999 -0.546 . . . . 30.2 110.142 -176.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 133' ' ' GLN . . . . . 0.795 ' HB3' HD11 ' H' ' 53' ' ' ILE . 18.9 mm100 -141.24 126.83 18.93 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.794 0.837 . . . . 17.0 109.105 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 134' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' I' ' 109' ' ' GLY . 13.1 p -133.06 147.54 31.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.406 0 N-CA-C 109.185 -0.672 . . . . 17.0 109.185 -177.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 135' ' ' ILE . . . . . . . . . . . . . 22.1 mm -63.45 -60.26 3.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.343 0 CA-C-N 116.038 -0.528 . . . . 29.2 110.877 176.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 136' ' ' GLY . . . . . . . . . . . . . . . -158.33 134.43 3.85 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 120.56 -0.829 . . . . 17.0 111.59 -177.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 137' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -67.09 146.61 54.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.442 0.639 . . . . 17.0 110.278 175.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 138' ' ' LEU . . . . . 0.574 HD23 HD21 ' I' ' 140' ' ' ASN . 34.7 tp -133.12 127.91 34.96 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.74 -1.207 . . . . 17.0 107.74 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -82.13 78.42 8.81 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 122.434 1.112 . . . . 8.57 109.376 -171.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 140' ' ' ASN . . . . . 0.574 HD21 HD23 ' I' ' 138' ' ' LEU . 85.3 m-20 -97.2 81.08 2.99 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.125 -0.943 . . . . 12.82 108.594 -178.139 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.33 110.81 3.26 Favored Glycine 0 C--O 1.236 0.273 0 C-N-CA 120.053 -1.07 . . . . 45.73 110.478 175.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 142' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -122.79 -174.11 2.85 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.14 -0.689 . . . . 13.18 109.14 -176.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 143' ' ' ILE . . . . . 0.725 HG22 ' H ' ' I' ' 103' ' ' LYS . 1.3 pp -112.11 -62.1 2.31 Favored 'Isoleucine or valine' 0 C--O 1.236 0.342 0 N-CA-C 113.468 0.914 . . . . 1.91 113.468 -169.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 144' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -82.18 129.17 34.76 Favored 'General case' 0 C--N 1.331 -0.239 0 O-C-N 121.373 -0.829 . . . . 32.89 111.217 -169.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 145' ' ' THR . . . . . . . . . . . . . 77.8 p -122.24 16.51 10.66 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.678 0.622 . . . . 26.61 112.678 177.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 146' ' ' LEU . . . . . 0.46 ' HG ' ' HA ' ' I' ' 24' ' ' SER . 4.2 mm? 54.49 75.79 0.58 Allowed Pre-proline 0 C--O 1.238 0.457 0 C-N-CA 126.638 1.975 . . . . 20.07 110.505 -178.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 147' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_exo -68.53 73.63 0.87 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 N-CA-C 115.543 1.324 . . . . 17.0 115.543 -161.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 148' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -111.46 12.0 21.44 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 116.077 -0.511 . . . . 27.6 111.653 168.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 149' ' ' GLU . . . . . . . . . . . . . 25.8 pm0 -139.59 4.28 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 112.789 0.663 . . . . 17.0 112.789 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 150' ' ' ILE . . . . . 0.448 HG23 HG23 ' I' ' 96' ' ' THR . 44.3 mm -112.36 -44.67 5.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 118.708 0.685 . . . . 41.17 111.027 -178.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 151' ' ' VAL . . . . . . . . . . . . . 47.1 t -108.17 -32.98 2.5 Favored 'Isoleucine or valine' 0 C--O 1.238 0.482 0 N-CA-C 108.68 -0.859 . . . . 8.83 108.68 -174.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 152' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -67.54 -31.43 71.52 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-N 116.324 -0.398 . . . . 31.5 111.801 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -75.35 98.69 1.49 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-O 122.11 0.957 . . . . 18.4 109.156 176.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 154' ' ' SER . . . . . . . . . . . . . 39.5 t -118.89 -60.86 1.71 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.784 -0.644 . . . . 17.0 112.522 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 155' ' ' LYS . . . . . 0.57 ' HG3' ' H ' ' I' ' 157' ' ' GLY . 5.8 tppp? -129.12 -38.95 1.58 Allowed 'General case' 0 C--O 1.236 0.379 0 N-CA-C 113.652 0.982 . . . . 15.31 113.652 -179.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.97 -54.16 2.93 Favored Glycine 0 N--CA 1.447 -0.57 0 N-CA-C 109.97 -1.252 . . . . 47.27 109.97 -161.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 157' ' ' GLY . . . . . 0.57 ' H ' ' HG3' ' I' ' 155' ' ' LYS . . . -85.81 155.5 29.14 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-O 122.075 0.819 . . . . 3.31 112.727 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 158' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -120.59 -172.99 2.48 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 126.018 1.727 . . . . 1.98 108.949 -176.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 159' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -79.24 -70.84 0.48 Allowed 'General case' 0 C--O 1.236 0.359 0 C-N-CA 118.734 -1.187 . . . . 19.2 112.534 -169.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 160' ' ' PHE . . . . . 0.498 ' HD2' ' HG3' ' I' ' 162' ' ' GLN . 31.6 p90 -176.17 160.36 2.2 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 108.893 -0.78 . . . . 12.29 108.893 -175.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 161' ' ' GLN . . . . . . . . . . . . . 65.6 tt0 -151.64 95.65 2.15 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 105.111 -2.181 . . . . 22.71 105.111 156.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 162' ' ' GLN . . . . . 0.498 ' HG3' ' HD2' ' I' ' 160' ' ' PHE . 89.8 mt-30 -71.12 -44.51 13.97 Favored Pre-proline 0 C--O 1.244 0.771 0 N-CA-C 114.258 1.207 . . . . 39.71 114.258 -162.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 163' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -72.72 -48.27 0.31 Allowed 'Trans proline' 0 C--N 1.366 1.48 0 CA-C-N 122.269 1.846 . . . . 41.22 112.675 171.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 164' ' ' GLY . . . . . 0.478 ' HA3' ' HG3' ' I' ' 175' ' ' PRO . . . -123.08 41.32 1.81 Allowed Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 117.719 1.847 . . . . 24.72 117.719 -163.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 165' ' ' GLN . . . . . . . . . . . . . 9.8 tp-100 -63.54 -58.92 5.45 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 117.981 0.891 . . . . 26.67 110.572 171.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 166' ' ' THR . . . . . . . . . . . . . 35.9 p 54.88 43.78 29.42 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 125.867 1.667 . . . . 46.93 111.66 173.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -128.47 160.36 32.54 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 107.792 -1.188 . . . . 17.0 107.792 -168.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 168' ' ' GLY . . . . . . . . . . . . . . . -80.32 -129.88 0.86 Allowed Glycine 0 N--CA 1.445 -0.742 0 N-CA-C 111.015 -0.834 . . . . 38.89 111.015 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -75.07 -62.67 1.47 Allowed 'General case' 0 C--O 1.235 0.302 0 C-N-CA 119.815 -0.754 . . . . 25.13 110.978 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 170' ' ' ALA . . . . . . . . . . . . . . . -67.3 106.14 1.11 Allowed Pre-proline 0 C--O 1.236 0.344 0 C-N-CA 123.35 0.66 . . . . 26.94 109.507 -177.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 171' ' ' PRO . . . . . . . . . . . . . 83.9 Cg_endo -81.89 -171.56 1.23 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.466 1.444 . . . . 8.72 112.269 -158.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 172' ' ' GLY . . . . . . . . . . . . . . . 81.26 65.34 1.69 Allowed Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.566 -1.197 . . . . 18.01 116.028 168.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -137.7 167.14 22.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.869 0.842 . . . . 22.62 109.351 167.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 174' ' ' VAL . . . . . . . . . . . . . 27.3 m -73.82 159.44 84.3 Favored Pre-proline 0 C--O 1.24 0.585 0 CA-C-N 114.772 -1.103 . . . . 11.7 108.626 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 175' ' ' PRO . . . . . 0.478 ' HG3' ' HA3' ' I' ' 164' ' ' GLY . 51.6 Cg_exo -61.66 125.22 16.19 Favored 'Trans proline' 0 C--N 1.353 0.789 0 CA-C-N 119.591 0.89 . . . . 32.14 110.708 169.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.3 0 C-N-CA 125.355 1.462 . . . . 57.59 111.159 -166.129 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' J' J ' 5' ' ' PRO . . . . . 0.47 ' HB2' ' H ' ' J' ' 6' ' ' ILE . 38.1 Cg_endo . . . . . 0 N--CA 1.466 -0.133 0 CA-C-O 119.576 -0.26 . . . . 30.72 112.43 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 6' ' ' ILE . . . . . 0.47 ' H ' ' HB2' ' J' ' 5' ' ' PRO . 96.8 mt -122.67 119.62 58.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.103 -1.073 . . . . 15.06 108.103 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -89.75 170.62 10.28 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 121.769 0.795 . . . . 47.85 110.496 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 8' ' ' GLY . . . . . . . . . . . . . . . -68.63 -13.5 65.87 Favored Glycine 0 C--N 1.333 0.402 0 CA-C-N 115.492 -0.776 . . . . 5.01 114.548 178.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 9' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -91.96 -13.82 30.49 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 117.729 0.764 . . . . 8.72 112.25 172.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 10' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -78.16 -3.93 45.0 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.792 1.034 . . . . 25.01 113.792 -171.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 11' ' ' VAL . . . . . . . . . . . . . 91.9 t -131.3 125.88 57.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 107.722 -1.214 . . . . 36.76 107.722 -177.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 12' ' ' LYS . . . . . . . . . . . . . 53.2 mtmt -133.89 160.58 37.24 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.682 0.753 . . . . 25.21 110.318 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 13' ' ' TYR . . . . . 0.457 ' HA ' ' O ' ' J' ' 92' ' ' TRP . 17.7 m-30 -110.49 97.37 6.83 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.03 -1.1 . . . . 16.57 108.03 -166.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 14' ' ' LEU . . . . . 0.755 ' O ' ' HB2' ' J' ' 92' ' ' TRP . 97.6 mt -78.66 132.08 36.9 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 120.034 -0.666 . . . . 38.68 109.457 178.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 15' ' ' PHE . . . . . . . . . . . . . 21.2 m-30 -112.07 151.56 29.23 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.781 -0.451 . . . . 22.49 109.781 -178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 16' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -147.13 137.05 23.17 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.086 -0.709 . . . . 16.71 109.086 175.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 17' ' ' SER . . . . . 0.476 ' O ' ' NZ ' ' J' ' 90' ' ' LYS . 38.5 t -75.25 153.75 37.86 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-O 121.639 0.733 . . . . 16.57 111.153 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 18' ' ' ILE . . . . . . . . . . . . . 46.5 pt -80.04 -6.53 9.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.409 -0.814 . . . . 16.57 112.917 176.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 19' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -116.05 -9.56 11.7 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 112.667 0.617 . . . . 45.68 112.667 -173.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 20' ' ' ALA . . . . . . . . . . . . . . . -77.33 -49.01 15.89 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 119.834 -0.746 . . . . 19.74 112.01 -170.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.412 ' HB2' HG22 ' D' ' 166' ' ' THR . . . 52.52 49.19 20.96 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.667 1.187 . . . . 7.73 111.235 -166.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 22' ' ' THR . . . . . . . . . . . . . 67.7 p -127.94 120.86 28.52 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.853 -0.795 . . . . 3.38 108.853 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.4 75.45 2.21 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.262 -0.494 . . . . 16.57 112.629 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 24' ' ' SER . . . . . 0.457 ' HA ' ' HG ' ' J' ' 146' ' ' LEU . 88.6 p -127.84 -29.8 2.56 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 120.892 -0.323 . . . . 42.47 111.6 -176.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 25' ' ' ALA . . . . . 0.487 ' HB1' ' HB3' ' J' ' 14' ' ' LEU . . . 51.43 74.37 0.81 Allowed Pre-proline 0 C--O 1.236 0.388 0 C-N-CA 126.868 2.067 . . . . 14.69 112.388 -173.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 26' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -70.79 106.06 1.77 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 CA-C-N 119.54 0.871 . . . . 16.57 112.682 177.033 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 27' ' ' LEU . . . . . 0.652 ' HB3' HD23 ' J' ' 14' ' ' LEU . 2.1 pt? -83.52 162.52 20.87 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.044 -0.725 . . . . 13.06 109.044 166.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 28' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -108.21 132.23 21.22 Favored Pre-proline 0 C--N 1.349 0.557 1 C-N-CA 108.786 -5.166 . . . . 18.04 110.256 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.48 177.51 6.0 Favored 'Trans proline' 0 C--O 1.235 0.334 0 C-N-CA 120.713 0.942 . . . . 19.91 114.207 -175.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . 52.86 62.12 2.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 124.552 1.141 . . . . 3.78 111.211 -172.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 31' ' ' TYR . . . . . 0.454 ' HD1' ' HA ' ' J' ' 31' ' ' TYR . 1.0 OUTLIER -68.56 163.98 22.35 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-O 122.894 1.331 . . . . 22.35 111.693 176.397 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 32' ' ' GLN . . . . . 0.44 ' HG3' ' H ' ' J' ' 33' ' ' THR . 7.4 tp-100 -136.59 -162.9 1.33 Allowed 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 103.329 -2.841 . . . . 26.39 103.329 170.003 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 33' ' ' THR . . . . . 0.44 ' H ' ' HG3' ' J' ' 32' ' ' GLN . 15.0 t -65.71 163.51 16.38 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-O 122.611 1.196 . . . . 30.79 111.998 -173.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 34' ' ' ASP . . . . . 0.665 ' HB2' ' HB3' ' K' ' 120' ' ' ASP . 79.9 m-20 -133.35 -170.62 2.51 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 114.033 -1.439 . . . . 37.56 108.103 -165.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 35' ' ' GLY . . . . . 0.628 ' O ' ' HA2' ' J' ' 63' ' ' GLY . . . 171.8 134.85 1.85 Allowed Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.85 -0.69 . . . . 16.47 111.741 168.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 36' ' ' SER . . . . . . . . . . . . . 67.0 m -125.89 84.43 2.27 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 105.93 -1.878 . . . . 16.57 105.93 174.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 37' ' ' VAL . . . . . 0.555 HG12 ' HB3' ' K' ' 117' ' ' GLU . 4.2 m -91.24 112.92 26.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 108.404 -0.961 . . . . 16.57 108.404 -171.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 38' ' ' SER . . . . . . . . . . . . . 47.1 m -101.25 93.41 5.42 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 108.169 -1.049 . . . . 12.93 108.169 -167.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 39' ' ' GLY . . . . . . . . . . . . . . . -95.33 100.03 2.49 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 119.693 -1.241 . . . . 26.6 113.12 -177.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 40' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' J' ' 59' ' ' VAL . 78.3 tt0 -104.08 117.5 34.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.116 -1.068 . . . . 6.73 108.116 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 41' ' ' ARG . . . . . 0.57 ' O ' ' HA3' ' J' ' 57' ' ' GLY . 91.0 mtm-85 -77.34 -179.72 5.89 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.705 0.764 . . . . 44.8 109.426 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 42' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -158.9 160.82 36.54 Favored 'General case' 0 N--CA 1.451 -0.376 0 O-C-N 121.716 -0.615 . . . . 22.91 109.433 -174.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 43' ' ' LEU . . . . . 0.739 ' HB2' ' HA3' ' J' ' 55' ' ' GLY . 41.6 mt -89.33 124.35 34.35 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 115.862 -0.608 . . . . 0.98 109.476 175.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 44' ' ' PHE . . . . . 0.478 ' HD1' HG13 ' J' ' 53' ' ' ILE . 78.0 t80 -120.72 107.89 13.32 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.037 -1.098 . . . . 66.87 108.037 -174.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 45' ' ' ASP . . . . . 0.727 ' HB2' ' HB3' ' J' ' 52' ' ' ARG . 76.7 m-20 -135.74 164.47 27.81 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-N 116.147 -0.479 . . . . 22.3 109.834 -170.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 46' ' ' GLU . . . . . 0.474 ' HA ' ' HA2' ' J' ' 51' ' ' GLY . 59.6 mp0 -125.71 -41.95 1.96 Allowed 'General case' 0 C--O 1.235 0.323 0 N-CA-C 113.747 1.018 . . . . 34.25 113.747 -172.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 47' ' ' GLN . . . . . 0.68 ' HB3' ' HA ' ' E' ' 30' ' ' ALA . 93.0 mm-40 68.18 25.87 7.2 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.431 1.092 . . . . 40.68 113.703 154.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 48' ' ' THR . . . . . . . . . . . . . 66.2 p 50.91 38.05 19.04 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.718 1.207 . . . . 36.91 111.225 -168.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm -139.66 -165.06 1.8 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 106.777 -1.564 . . . . 12.44 106.777 -175.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 50' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -74.42 -20.96 59.85 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 120.39 -0.524 . . . . 12.93 111.946 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 51' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' J' ' 46' ' ' GLU . . . 145.78 158.25 7.63 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 121.158 -0.544 . . . . 7.67 113.651 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 52' ' ' ARG . . . . . 0.727 ' HB3' ' HB2' ' J' ' 45' ' ' ASP . 20.5 tpp85 -128.36 55.67 1.67 Allowed 'General case' 0 C--O 1.234 0.275 0 N-CA-C 106.695 -1.595 . . . . 20.54 106.695 175.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 53' ' ' ILE . . . . . 0.801 HD11 HE21 ' K' ' 133' ' ' GLN . 5.3 tt -70.95 -6.95 8.05 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 CA-C-N 115.333 -0.849 . . . . 31.89 112.019 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 54' ' ' LEU . . . . . 0.707 HD13 ' HD3' ' J' ' 52' ' ' ARG . 8.7 mp -55.68 -28.55 56.16 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 127.215 2.206 . . . . 57.08 114.328 -170.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 55' ' ' GLY . . . . . 0.739 ' HA3' ' HB2' ' J' ' 43' ' ' LEU . . . -64.81 125.37 30.46 Favored Glycine 0 N--CA 1.441 -0.976 0 CA-C-O 121.552 0.529 . . . . 16.57 114.206 -165.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 56' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.53 159.74 52.42 Favored 'Trans proline' 0 C--N 1.325 -0.675 0 C-N-CA 120.998 1.132 . . . . 16.57 110.225 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 57' ' ' GLY . . . . . 0.57 ' HA3' ' O ' ' J' ' 41' ' ' ARG . . . -131.45 170.86 21.35 Favored Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 109.209 -1.556 . . . . 32.98 109.209 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 58' ' ' SER . . . . . 0.424 ' HB3' ' NH2' ' J' ' 41' ' ' ARG . 44.7 t -73.36 149.68 42.39 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 119.76 -0.776 . . . . 13.43 109.903 175.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 59' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' J' ' 40' ' ' GLU . 3.0 p -104.42 121.69 56.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 108.254 -1.017 . . . . 16.57 108.254 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 60' ' ' ALA . . . . . . . . . . . . . . . -117.8 112.23 20.12 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 106.299 -1.741 . . . . 48.82 106.299 172.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 61' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -115.16 123.49 49.05 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.164 -1.05 . . . . 42.04 108.164 -171.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 62' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' J' ' 132' ' ' LEU . 68.3 m -111.13 162.29 15.07 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 10.82 110.509 -171.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 63' ' ' GLY . . . . . 0.628 ' HA2' ' O ' ' J' ' 35' ' ' GLY . . . -134.17 118.52 2.04 Favored Glycine 0 N--CA 1.443 -0.891 0 CA-C-N 115.109 -0.95 . . . . 16.57 112.296 177.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 64' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -99.14 96.72 7.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.096 -1.446 . . . . 39.72 107.096 172.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 65' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.0 116.89 52.44 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 108.333 -0.988 . . . . 16.57 108.333 -177.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 66' ' ' THR . . . . . 0.517 ' HA ' ' O ' ' J' ' 128' ' ' ILE . 52.7 p -115.07 142.32 46.8 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.871 -0.788 . . . . 17.36 108.871 176.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 67' ' ' TYR . . . . . 0.413 ' HE1' HD12 ' J' ' 130' ' ' ILE . 55.0 p90 -153.66 -171.43 3.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.398 0.618 . . . . 23.22 109.418 176.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 68' ' ' TYR . . . . . . . . . . . . . 16.3 m-30 -115.99 131.48 56.93 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 123.776 0.83 . . . . 11.2 109.271 178.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.67 113.73 3.76 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.909 -0.662 . . . . 10.64 114.5 -174.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 70' ' ' LYS . . . . . 0.476 ' O ' ' NE2' ' J' ' 76' ' ' GLN . 38.5 ttmt -85.92 151.07 24.05 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.803 -0.814 . . . . 23.57 108.803 175.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 71' ' ' ARG . . . . . . . . . . . . . 20.8 ptp180 -68.75 -15.85 63.63 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 114.02 1.119 . . . . 34.46 114.02 -169.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.79 -138.26 4.75 Favored Glycine 0 N--CA 1.45 -0.368 0 N-CA-C 110.132 -1.187 . . . . 16.57 110.132 175.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 t0 60.31 73.47 0.48 Allowed 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 125.056 1.342 . . . . 5.12 111.319 167.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.18 9.95 0.04 OUTLIER 'General case' 0 C--O 1.235 0.322 0 N-CA-C 117.574 2.435 . . . . 22.96 117.574 -158.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 75' ' ' GLY . . . . . . . . . . . . . . . -58.97 -42.93 97.1 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 120.31 -0.948 . . . . 14.79 112.711 170.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 76' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' J' ' 70' ' ' LYS . 21.4 pt20 -69.79 -23.54 63.36 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 119.791 -0.764 . . . . 46.19 111.785 173.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -70.39 -28.9 65.45 Favored 'General case' 0 CA--C 1.518 -0.271 0 C-N-CA 119.88 -0.728 . . . . 31.44 111.323 170.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.62 -32.2 65.75 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 120.461 -0.495 . . . . 22.59 111.354 171.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 79' ' ' ILE . . . . . . . . . . . . . 51.8 mm -64.21 -43.53 97.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.422 0 CA-C-O 121.14 0.495 . . . . 8.31 110.426 173.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 80' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -73.05 -22.48 60.61 Favored 'General case' 0 C--O 1.235 0.29 0 O-C-N 121.89 -0.506 . . . . 26.08 112.0 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 81' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 -69.94 -33.3 71.96 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 120.315 -0.554 . . . . 33.88 111.298 168.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 82' ' ' ALA . . . . . 0.71 ' HA ' ' HB2' ' J' ' 87' ' ' LYS . . . -74.01 -36.5 64.49 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 119.466 -0.894 . . . . 8.74 111.64 175.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 83' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -83.92 -61.17 1.89 Allowed 'General case' 0 C--O 1.236 0.352 0 C-N-CA 120.146 -0.622 . . . . 10.35 112.004 -175.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 84' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -74.95 -40.6 60.69 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 111.794 0.294 . . . . 20.52 111.794 -167.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 85' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -77.84 -43.57 29.97 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 119.932 -0.707 . . . . 10.72 111.189 173.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 86' ' ' GLY . . . . . . . . . . . . . . . 107.94 96.48 2.45 Favored Glycine 0 N--CA 1.45 -0.397 0 O-C-N 122.302 -0.249 . . . . 8.38 113.344 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 87' ' ' LYS . . . . . 0.71 ' HB2' ' HA ' ' J' ' 82' ' ' ALA . 97.5 mttt -149.22 -161.41 1.34 Allowed 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 107.05 -1.463 . . . . 7.06 107.05 -178.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 88' ' ' GLN . . . . . 0.626 ' HG2' ' HD1' ' J' ' 112' ' ' TYR . 68.9 mt-30 -131.73 179.32 6.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.827 0.822 . . . . 13.19 111.146 167.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 89' ' ' ILE . . . . . 0.462 HD11 HD11 ' J' ' 113' ' ' ILE . 69.9 mt -129.25 134.82 63.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 115.089 -0.96 . . . . 13.03 109.682 -171.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 90' ' ' LYS . . . . . 0.476 ' NZ ' ' O ' ' J' ' 17' ' ' SER . 36.7 mtmm -84.59 116.27 23.07 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 108.402 -0.962 . . . . 12.63 108.402 164.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 91' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -110.95 134.47 52.55 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 124.374 1.07 . . . . 15.58 110.719 -166.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 92' ' ' TRP . . . . . 0.755 ' HB2' ' O ' ' J' ' 14' ' ' LEU . 92.9 m95 -131.94 128.99 39.66 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.093 0.957 . . . . 16.78 110.033 -174.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 93' ' ' ARG . . . . . 0.626 ' O ' ' HA ' ' J' ' 106' ' ' ALA . 78.7 ttt-85 -115.59 93.42 4.27 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 108.453 -0.943 . . . . 16.57 108.453 170.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 94' ' ' VAL . . . . . 0.524 HG12 ' HB2' ' J' ' 106' ' ' ALA . 20.1 m -107.26 163.1 5.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-O 122.208 1.004 . . . . 23.83 109.559 -174.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 95' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -107.36 156.9 18.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 114.869 -1.059 . . . . 13.8 110.966 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 96' ' ' THR . . . . . 0.48 HG23 HG23 ' J' ' 150' ' ' ILE . 27.9 m -93.59 -31.19 14.61 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.15 -0.932 . . . . 32.66 112.616 -177.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 97' ' ' VAL . . . . . . . . . . . . . 33.9 m -70.07 153.01 8.8 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.817 0.817 . . . . 0.85 109.936 -178.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 98' ' ' LYS . . . . . 0.457 ' NZ ' ' O ' ' J' ' 99' ' ' ASN . 29.6 tptp -87.37 129.39 35.04 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.593 -0.731 . . . . 16.28 109.758 -173.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 99' ' ' ASN . . . . . 0.457 ' O ' ' NZ ' ' J' ' 98' ' ' LYS . 35.0 m120 -92.3 173.47 7.79 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.766 0.793 . . . . 20.33 109.995 171.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 100' ' ' GLU . . . . . . . . . . . . . 58.1 mp0 -110.09 -15.09 14.1 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 113.633 0.975 . . . . 20.28 113.633 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 101' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -86.38 -58.85 2.46 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 118.245 0.475 . . . . 31.02 110.979 168.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 102' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -102.55 -176.69 3.18 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.806 -1.183 . . . . 34.34 107.806 170.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 103' ' ' LYS . . . . . 0.4 ' HG2' ' HE2' ' J' ' 98' ' ' LYS . 94.7 mttt -71.84 -60.5 2.2 Favored 'General case' 0 C--O 1.235 0.31 0 C-N-CA 118.982 -1.087 . . . . 34.4 110.356 163.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 104' ' ' TYR . . . . . . . . . . . . . 35.3 m-85 -128.58 -172.02 2.61 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 108.386 -0.968 . . . . 28.22 108.386 -175.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 105' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' J' ' 105' ' ' ASP . 16.1 p-10 -151.08 168.87 23.29 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.016 -0.735 . . . . 19.84 109.016 177.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 106' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' J' ' 93' ' ' ARG . . . -154.6 155.71 35.22 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.81 0.814 . . . . 0.01 111.259 -163.028 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 107' ' ' GLN . . . . . 0.451 ' OE1' ' OH ' ' K' ' 118' ' ' TYR . 88.0 mt-30 -113.01 122.68 48.34 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.619 -1.623 . . . . 27.88 106.619 158.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 108' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -111.38 153.21 26.37 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 123.825 0.85 . . . . 6.21 110.113 -165.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 109' ' ' GLY . . . . . . . . . . . . . . . -163.87 167.83 38.13 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.591 -1.29 . . . . 16.57 112.822 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 110' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -109.23 109.47 20.42 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.646 -0.777 . . . . 16.14 108.971 168.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.63 155.77 21.91 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.572 0.701 . . . . 46.11 111.778 -165.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 112' ' ' TYR . . . . . 0.626 ' HD1' ' HG2' ' J' ' 88' ' ' GLN . 71.7 t80 -134.26 137.93 44.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 114.326 -1.306 . . . . 15.97 107.552 178.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 113' ' ' ILE . . . . . 0.462 HD11 HD11 ' J' ' 89' ' ' ILE . 81.0 mt -84.66 128.37 39.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 N-CA-C 109.96 -0.385 . . . . 16.57 109.96 -169.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 114' ' ' GLU . . . . . 0.508 ' HB2' ' HB2' ' J' ' 131' ' ' SER . 98.2 mt-10 -71.1 -64.72 0.85 Allowed 'General case' 0 C--O 1.234 0.276 0 C-N-CA 119.871 -0.732 . . . . 18.82 110.601 164.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 115' ' ' SER . . . . . . . . . . . . . 72.2 m -142.38 151.16 41.59 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.567 0.698 . . . . 29.44 110.385 -168.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 116' ' ' ARG . . . . . . . . . . . . . 9.1 tmm_? -126.45 88.53 2.85 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 104.951 -2.24 . . . . 1.68 104.951 178.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 117' ' ' GLU . . . . . 0.528 ' O ' ' HB2' ' J' ' 129' ' ' SER . 98.6 mt-10 -111.88 110.14 20.32 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 107.353 -1.351 . . . . 28.53 107.353 -175.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 118' ' ' TYR . . . . . 0.464 ' OH ' ' OE1' ' I' ' 107' ' ' GLN . 18.5 p90 -116.72 143.5 45.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.491 0.662 . . . . 16.57 111.841 178.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 119' ' ' SER . . . . . . . . . . . . . 37.9 t -99.06 131.34 45.18 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.719 -1.128 . . . . 2.36 110.122 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 120' ' ' ASP . . . . . 0.644 ' HB3' ' HB2' ' I' ' 34' ' ' ASP . 59.2 t0 -109.13 97.77 7.33 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 106.376 -1.713 . . . . 34.5 106.376 172.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 121' ' ' GLY . . . . . . . . . . . . . . . -81.05 -161.15 25.91 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-O 121.82 0.678 . . . . 23.55 112.164 177.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 122' ' ' VAL . . . . . . . . . . . . . 92.0 t -115.1 -63.19 2.02 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 N-CA-C 108.701 -0.851 . . . . 1.58 108.701 178.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 123' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -96.23 -18.13 20.27 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.976 -0.556 . . . . 51.15 112.471 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 124' ' ' GLY . . . . . . . . . . . . . . . -92.0 157.59 24.35 Favored Glycine 0 N--CA 1.451 -0.312 0 N-CA-C 109.587 -1.405 . . . . 24.72 109.587 163.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 125' ' ' ALA . . . . . . . . . . . . . . . -77.0 171.12 15.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.755 0.788 . . . . 25.97 110.35 176.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 126' ' ' VAL . . . . . 0.488 HG12 ' HA ' ' J' ' 120' ' ' ASP . 33.9 m -71.06 157.97 6.43 Favored 'Isoleucine or valine' 0 C--O 1.239 0.536 0 CA-C-N 115.37 -0.832 . . . . 18.77 109.713 -176.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 127' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -147.19 135.46 21.64 Favored 'General case' 0 CA--C 1.518 -0.268 0 N-CA-C 109.596 -0.52 . . . . 51.19 109.596 179.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 128' ' ' ILE . . . . . 0.517 ' O ' ' HA ' ' J' ' 66' ' ' THR . 87.8 mt -104.54 124.43 59.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 109.641 -0.503 . . . . 16.57 109.641 -176.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 129' ' ' SER . . . . . 0.528 ' HB2' ' O ' ' J' ' 117' ' ' GLU . 68.2 m -103.54 132.97 49.33 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 108.729 -0.841 . . . . 32.38 108.729 170.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 130' ' ' ILE . . . . . 0.413 HD12 ' HE1' ' J' ' 67' ' ' TYR . 82.1 mt -135.58 130.17 49.76 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 N-CA-C 108.681 -0.859 . . . . 16.57 108.681 -178.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 131' ' ' SER . . . . . 0.508 ' HB2' ' HB2' ' J' ' 114' ' ' GLU . 55.2 m -98.05 149.43 22.48 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-O 121.026 0.441 . . . . 22.33 110.087 175.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 132' ' ' LEU . . . . . 0.669 ' O ' ' HA ' ' J' ' 62' ' ' SER . 7.8 mp -133.84 144.27 48.85 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 116.03 -0.532 . . . . 15.49 110.544 -177.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 133' ' ' GLN . . . . . 0.555 HE21 HD11 ' I' ' 53' ' ' ILE . 29.8 mm100 -125.28 139.08 54.03 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.622 -0.881 . . . . 16.57 108.622 170.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 134' ' ' VAL . . . . . . . . . . . . . 8.8 p -135.95 149.37 27.76 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 108.91 -0.774 . . . . 18.73 108.91 177.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 135' ' ' ILE . . . . . . . . . . . . . 23.5 mm -62.46 -61.38 1.66 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.326 0 CA-C-O 121.299 0.571 . . . . 25.65 110.587 176.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 136' ' ' GLY . . . . . . . . . . . . . . . -160.88 133.44 3.21 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 111.33 -0.708 . . . . 11.8 111.33 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 137' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -66.49 147.3 53.49 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 121.44 0.638 . . . . 27.02 110.675 177.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 138' ' ' LEU . . . . . 0.574 HD23 HD21 ' J' ' 140' ' ' ASN . 35.1 tp -133.9 130.95 38.52 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.099 -1.074 . . . . 11.71 108.099 -179.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 139' ' ' LYS . . . . . . . . . . . . . 8.0 mtmp? -83.03 81.02 8.86 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-O 122.398 1.094 . . . . 10.87 109.359 -171.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 140' ' ' ASN . . . . . 0.574 HD21 HD23 ' J' ' 138' ' ' LEU . 86.0 m-20 -102.74 83.02 2.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.195 -0.912 . . . . 9.06 108.984 -177.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.96 122.6 6.65 Favored Glycine 0 C--O 1.237 0.289 0 C-N-CA 119.984 -1.103 . . . . 23.97 110.439 173.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 142' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -132.1 -171.71 2.7 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 109.342 -0.614 . . . . 14.99 109.342 -178.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 143' ' ' ILE . . . . . 0.432 ' H ' HG13 ' J' ' 143' ' ' ILE . 1.5 pp -112.78 -56.86 4.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.307 0 N-CA-C 113.575 0.954 . . . . 10.0 113.575 -167.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -87.48 124.97 34.01 Favored 'General case' 0 C--O 1.234 0.237 0 O-C-N 121.285 -0.884 . . . . 3.21 111.19 -172.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 145' ' ' THR . . . . . . . . . . . . . 70.6 p -119.91 18.5 12.51 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 112.553 0.575 . . . . 34.62 112.553 176.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 146' ' ' LEU . . . . . 0.457 ' HG ' ' HA ' ' J' ' 24' ' ' SER . 4.3 mm? 54.94 75.92 0.56 Allowed Pre-proline 0 C--O 1.237 0.411 0 C-N-CA 126.669 1.987 . . . . 11.85 110.782 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 147' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -68.81 69.69 1.15 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 N-CA-C 115.586 1.341 . . . . 7.26 115.586 -163.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 148' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -107.79 7.03 28.07 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 122.952 0.501 . . . . 8.3 111.614 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 149' ' ' GLU . . . . . . . . . . . . . 26.0 pm0 -138.19 7.19 2.63 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.515 0.561 . . . . 11.79 112.515 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 150' ' ' ILE . . . . . 0.48 HG23 HG23 ' J' ' 96' ' ' THR . 44.8 mm -113.87 -44.79 4.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 118.693 0.679 . . . . 9.62 111.061 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 151' ' ' VAL . . . . . . . . . . . . . 48.1 t -108.16 -32.19 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 108.275 -1.009 . . . . 13.45 108.275 -176.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 152' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -67.72 -30.63 70.17 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.35 -0.386 . . . . 18.54 111.821 -176.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 p -73.82 100.25 1.36 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.403 0 CA-C-O 122.165 0.983 . . . . 30.18 108.464 173.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 154' ' ' SER . . . . . . . . . . . . . 38.8 t -117.51 -59.13 1.97 Allowed 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.603 -0.726 . . . . 15.74 112.176 -174.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 155' ' ' LYS . . . . . 0.473 ' HG3' ' H ' ' J' ' 157' ' ' GLY . 5.5 tppp? -128.37 -36.93 1.86 Allowed 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 113.675 0.991 . . . . 22.03 113.675 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.57 -58.09 1.61 Allowed Glycine 0 N--CA 1.447 -0.59 0 N-CA-C 110.118 -1.193 . . . . 33.79 110.118 -156.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 157' ' ' GLY . . . . . 0.473 ' H ' ' HG3' ' J' ' 155' ' ' LYS . . . -92.7 162.32 26.49 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.615 -0.802 . . . . 16.57 112.666 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 158' ' ' TYR . . . . . . . . . . . . . 20.2 m-30 -117.6 -172.84 2.31 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.085 1.354 . . . . 25.68 108.807 -178.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 159' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -79.2 -70.74 0.48 Allowed 'General case' 0 C--O 1.236 0.365 0 C-N-CA 118.827 -1.149 . . . . 14.21 112.436 -167.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 160' ' ' PHE . . . . . 0.535 ' HD2' ' HG3' ' J' ' 162' ' ' GLN . 30.2 p90 -176.72 160.49 1.94 Allowed 'General case' 0 C--O 1.235 0.296 0 CA-C-O 121.699 0.761 . . . . 11.17 109.0 -175.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 161' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.51 100.44 2.26 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 104.747 -2.316 . . . . 26.64 104.747 155.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 162' ' ' GLN . . . . . 0.535 ' HG3' ' HD2' ' J' ' 160' ' ' PHE . 88.6 mt-30 -72.82 -46.95 8.95 Favored Pre-proline 0 C--O 1.243 0.746 0 N-CA-C 113.985 1.105 . . . . 38.06 113.985 -161.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 163' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -75.72 -47.01 0.18 Allowed 'Trans proline' 0 C--N 1.365 1.396 0 CA-C-N 122.262 1.843 . . . . 18.11 112.936 174.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 164' ' ' GLY . . . . . 0.404 ' HA3' ' HG3' ' J' ' 175' ' ' PRO . . . -119.18 41.14 2.06 Favored Glycine 0 N--CA 1.448 -0.529 0 N-CA-C 116.323 1.289 . . . . 27.04 116.323 -161.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -64.62 -59.63 4.05 Favored 'General case' 0 C--O 1.238 0.481 0 C-N-CA 120.059 -0.656 . . . . 16.57 110.593 172.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 166' ' ' THR . . . . . . . . . . . . . 42.9 p 54.01 48.56 20.84 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.916 1.687 . . . . 35.56 111.697 174.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 167' ' ' THR . . . . . . . . . . . . . 2.5 m -133.85 160.53 37.37 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 108.069 -1.086 . . . . 11.29 108.069 -168.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 168' ' ' GLY . . . . . . . . . . . . . . . -80.66 -130.07 0.93 Allowed Glycine 0 N--CA 1.447 -0.632 0 N-CA-C 111.165 -0.774 . . . . 24.38 111.165 172.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 169' ' ' GLU . . . . . . . . . . . . . 15.5 tm-20 -73.29 -62.25 1.54 Allowed 'General case' 0 C--O 1.235 0.313 0 C-N-CA 119.939 -0.705 . . . . 44.07 111.037 -178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 170' ' ' ALA . . . . . . . . . . . . . . . -68.97 105.67 1.12 Allowed Pre-proline 0 C--O 1.235 0.333 0 C-N-CA 123.271 0.629 . . . . 6.94 109.592 -176.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 171' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -81.4 -172.39 1.48 Allowed 'Trans proline' 0 C--N 1.325 -0.694 0 C-N-CA 121.484 1.456 . . . . 20.44 112.04 -159.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 172' ' ' GLY . . . . . . . . . . . . . . . 81.83 64.82 1.7 Allowed Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 114.636 -1.165 . . . . 34.55 115.84 167.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 173' ' ' THR . . . . . . . . . . . . . 11.4 t -134.89 170.19 16.25 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.712 0.768 . . . . 6.52 109.192 168.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 174' ' ' VAL . . . . . . . . . . . . . 34.0 m -73.32 158.78 86.24 Favored Pre-proline 0 C--O 1.241 0.647 0 CA-C-N 115.024 -0.989 . . . . 16.57 108.76 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 175' ' ' PRO . . . . . 0.404 ' HG3' ' HA3' ' J' ' 164' ' ' GLY . 56.9 Cg_exo -59.84 124.54 15.57 Favored 'Trans proline' 0 CA--C 1.516 -0.416 0 N-CA-C 109.754 -0.902 . . . . 11.96 109.754 164.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.312 0 C-N-CA 125.231 1.413 . . . . 26.47 110.506 -161.281 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 5' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' K' ' 6' ' ' ILE . 38.2 Cg_endo . . . . . 0 N--CA 1.466 -0.145 0 CA-C-O 119.791 -0.17 . . . . 1.86 112.304 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 6' ' ' ILE . . . . . 0.405 ' H ' ' HB2' ' K' ' 5' ' ' PRO . 93.9 mt -121.53 122.15 66.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 N-CA-C 107.99 -1.115 . . . . 6.36 107.99 178.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 7' ' ' MET . . . . . . . . . . . . . 39.2 mmt -90.57 170.17 10.41 Favored 'General case' 0 N--CA 1.451 -0.383 0 CA-C-O 121.866 0.841 . . . . 36.21 110.636 -177.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.15 -11.44 63.94 Favored Glycine 0 C--N 1.333 0.412 0 CA-C-N 115.375 -0.829 . . . . 17.79 114.688 179.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 9' ' ' GLN . . . . . . . . . . . . . 85.1 mt-30 -94.62 -14.16 25.21 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 117.833 0.817 . . . . 18.92 112.256 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 10' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -77.18 -4.71 46.0 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 113.711 1.004 . . . . 27.43 113.711 -171.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 11' ' ' VAL . . . . . . . . . . . . . 69.9 t -129.04 125.32 62.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 N-CA-C 107.829 -1.174 . . . . 27.14 107.829 -176.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 12' ' ' LYS . . . . . 0.466 ' NZ ' ' O ' ' K' ' 149' ' ' GLU . 53.6 mtmt -134.1 160.66 37.1 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.487 0.661 . . . . 4.73 110.077 176.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 13' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' K' ' 92' ' ' TRP . 18.8 m-30 -110.71 98.79 7.86 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 108.21 -1.033 . . . . 17.79 108.21 -167.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 14' ' ' LEU . . . . . 0.8 ' O ' ' HB2' ' K' ' 92' ' ' TRP . 95.7 mt -79.08 129.27 34.27 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 120.002 -0.679 . . . . 40.78 109.652 178.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 15' ' ' PHE . . . . . . . . . . . . . 21.9 m-30 -109.89 150.05 29.0 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.602 -0.518 . . . . 38.49 109.602 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 16' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -145.34 135.53 23.92 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 109.148 -0.686 . . . . 15.72 109.148 175.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 17' ' ' SER . . . . . . . . . . . . . 40.8 t -75.44 153.55 37.57 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.644 0.735 . . . . 10.6 111.013 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 18' ' ' ILE . . . . . . . . . . . . . 45.0 pt -78.63 -11.58 13.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.466 -0.788 . . . . 17.84 113.03 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 19' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -113.67 -12.22 12.85 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 112.638 0.607 . . . . 18.77 112.638 -173.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.15 -49.54 27.66 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 120.269 -0.573 . . . . 22.23 111.754 -172.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.63 48.03 22.52 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.91 1.284 . . . . 2.4 111.557 -171.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 22' ' ' THR . . . . . . . . . . . . . 69.7 p -127.19 123.83 37.57 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 108.656 -0.868 . . . . 29.53 108.656 177.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.37 75.42 2.21 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 121.25 -0.5 . . . . 0.36 113.254 -176.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 24' ' ' SER . . . . . 0.517 ' HA ' ' HG ' ' K' ' 146' ' ' LEU . 89.4 p -126.58 -29.13 2.94 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 120.868 -0.333 . . . . 21.79 111.332 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 25' ' ' ALA . . . . . 0.427 ' HB1' ' HB3' ' K' ' 14' ' ' LEU . . . 51.21 73.83 0.91 Allowed Pre-proline 0 C--O 1.237 0.411 0 C-N-CA 126.952 2.101 . . . . 16.71 112.281 -173.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 26' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -71.68 106.07 1.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 CA-C-N 119.498 0.856 . . . . 12.73 112.823 177.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 27' ' ' LEU . . . . . 0.765 ' HB3' HD23 ' K' ' 14' ' ' LEU . 2.0 pt? -79.98 161.45 25.46 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 119.731 -0.788 . . . . 8.0 108.987 163.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 28' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -107.58 132.0 21.31 Favored Pre-proline 0 N--CA 1.447 -0.617 1 C-N-CA 109.352 -4.939 . . . . 9.49 110.28 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.7 -174.64 1.55 Allowed 'Trans proline' 0 C--O 1.234 0.305 0 C-N-CA 120.627 0.885 . . . . 18.54 114.309 -175.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 51.56 60.71 3.66 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.591 1.156 . . . . 22.45 111.091 -169.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 31' ' ' TYR . . . . . 0.479 ' HD1' ' HA ' ' K' ' 31' ' ' TYR . 0.7 OUTLIER -69.24 160.83 30.46 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 122.846 1.307 . . . . 25.48 111.884 178.228 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' K' K ' 32' ' ' GLN . . . . . 0.459 ' HG3' ' H ' ' K' ' 33' ' ' THR . 7.7 tp-100 -136.94 -162.69 1.31 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 103.193 -2.891 . . . . 3.8 103.193 170.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 33' ' ' THR . . . . . 0.459 ' H ' ' HG3' ' K' ' 32' ' ' GLN . 15.3 t -65.25 162.05 18.12 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.68 1.228 . . . . 31.24 111.939 -172.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 34' ' ' ASP . . . . . 0.674 ' HB2' ' HB3' ' L' ' 120' ' ' ASP . 76.4 m-20 -132.18 -170.88 2.5 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.129 -1.396 . . . . 35.11 107.871 -166.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 35' ' ' GLY . . . . . 0.639 ' O ' ' HA2' ' K' ' 63' ' ' GLY . . . 171.59 134.79 1.83 Allowed Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.141 -1.028 . . . . 16.59 112.512 170.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 36' ' ' SER . . . . . . . . . . . . . 66.6 m -128.03 84.71 2.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.107 -1.812 . . . . 15.91 106.107 175.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 37' ' ' VAL . . . . . 0.556 HG23 ' HB2' ' K' ' 62' ' ' SER . 3.5 m -91.79 110.52 22.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 108.46 -0.941 . . . . 12.48 108.46 -172.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 38' ' ' SER . . . . . . . . . . . . . 50.3 m -99.3 92.75 5.58 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.278 -1.008 . . . . 2.58 108.278 -166.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 39' ' ' GLY . . . . . . . . . . . . . . . -93.28 100.31 2.62 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.128 -1.034 . . . . 12.96 113.757 -176.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 40' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' K' ' 59' ' ' VAL . 80.9 tt0 -106.26 117.99 35.47 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 108.233 -1.025 . . . . 17.79 108.233 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 41' ' ' ARG . . . . . 0.628 ' O ' ' HA3' ' K' ' 57' ' ' GLY . 92.4 mtm-85 -77.37 -178.65 5.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.551 0.691 . . . . 43.35 109.746 -174.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 42' ' ' GLU . . . . . . . . . . . . . 24.3 pt-20 -160.27 164.13 32.9 Favored 'General case' 0 C--N 1.33 -0.263 0 O-C-N 121.631 -0.668 . . . . 43.49 109.623 -174.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 43' ' ' LEU . . . . . 0.753 ' HB2' ' HA3' ' K' ' 55' ' ' GLY . 81.6 mt -106.81 111.93 24.67 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.161 -0.681 . . . . 10.89 109.161 172.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 44' ' ' PHE . . . . . . . . . . . . . 75.4 t80 -110.89 113.4 25.94 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.104 -1.443 . . . . 14.63 107.104 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 45' ' ' ASP . . . . . 0.705 ' HB2' ' HB3' ' K' ' 52' ' ' ARG . 78.1 m-20 -127.0 175.91 7.74 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.299 -1.0 . . . . 12.5 108.299 -173.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 46' ' ' GLU . . . . . . . . . . . . . 58.7 mp0 -126.1 -40.29 2.01 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 114.323 1.231 . . . . 5.81 114.323 -166.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 47' ' ' GLN . . . . . 0.639 ' HB3' ' HA ' ' F' ' 30' ' ' ALA . 89.8 mm-40 66.65 20.17 10.76 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.532 1.133 . . . . 45.08 113.987 155.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 48' ' ' THR . . . . . . . . . . . . . 49.8 p 50.13 41.02 23.12 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.466 1.106 . . . . 37.36 110.945 -165.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 49' ' ' LYS . . . . . . . . . . . . . 46.2 mmtm -139.46 -166.3 2.03 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.165 -1.42 . . . . 21.75 107.165 -175.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 50' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 -72.91 -27.43 61.87 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 120.605 -0.438 . . . . 26.9 111.989 172.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.29 163.19 11.56 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 121.301 -0.476 . . . . 28.58 114.068 -177.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 52' ' ' ARG . . . . . 0.705 ' HB3' ' HB2' ' K' ' 45' ' ' ASP . 19.0 tpp85 -133.33 57.26 1.81 Allowed 'General case' 0 C--O 1.233 0.236 0 N-CA-C 107.928 -1.138 . . . . 16.54 107.928 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 53' ' ' ILE . . . . . 0.806 HD11 ' HB3' ' L' ' 133' ' ' GLN . 6.5 tt -66.44 -5.47 3.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 C-N-CA 124.937 1.295 . . . . 32.67 113.304 -177.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 54' ' ' LEU . . . . . 0.7 HD13 ' HD3' ' K' ' 52' ' ' ARG . 9.1 mp -61.33 -23.21 65.58 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 124.973 1.309 . . . . 55.76 113.604 -170.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 55' ' ' GLY . . . . . 0.753 ' HA3' ' HB2' ' K' ' 43' ' ' LEU . . . -67.07 119.69 12.32 Favored Glycine 0 N--CA 1.44 -1.037 0 CA-C-O 121.645 0.581 . . . . 15.39 114.097 -170.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 56' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.0 164.98 34.06 Favored 'Trans proline' 0 C--N 1.325 -0.67 0 C-N-CA 120.872 1.048 . . . . 17.79 109.753 171.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 57' ' ' GLY . . . . . 0.628 ' HA3' ' O ' ' K' ' 41' ' ' ARG . . . -132.04 168.14 22.59 Favored Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.11 -1.596 . . . . 41.74 109.11 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 58' ' ' SER . . . . . 0.437 ' HB3' ' NH2' ' K' ' 41' ' ' ARG . 44.0 t -72.8 148.34 44.64 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 119.672 -0.811 . . . . 25.75 109.591 173.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 59' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' K' ' 40' ' ' GLU . 2.9 p -105.46 122.5 58.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 N-CA-C 108.228 -1.027 . . . . 20.06 108.228 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.41 110.58 15.8 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 106.745 -1.576 . . . . 6.85 106.745 174.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 61' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -106.11 124.94 50.36 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.202 -1.036 . . . . 32.68 108.202 -175.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' K' ' 132' ' ' LEU . 69.8 m -107.08 163.19 13.2 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 124.19 0.996 . . . . 8.48 110.223 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 63' ' ' GLY . . . . . 0.639 ' HA2' ' O ' ' K' ' 35' ' ' GLY . . . -133.43 123.27 3.34 Favored Glycine 0 N--CA 1.443 -0.852 0 CA-C-N 115.029 -0.987 . . . . 24.45 112.261 178.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 64' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -102.84 94.55 5.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.127 -1.434 . . . . 33.44 107.127 171.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 65' ' ' VAL . . . . . . . . . . . . . 91.1 t -107.39 115.63 49.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.123 -1.066 . . . . 17.79 108.123 -177.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 66' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' K' ' 128' ' ' ILE . 72.5 p -116.81 142.31 47.09 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.589 -0.523 . . . . 20.12 109.589 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 67' ' ' TYR . . . . . . . . . . . . . 55.2 p90 -152.98 -170.81 3.74 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.16 -0.616 . . . . 16.83 109.469 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 68' ' ' TYR . . . . . . . . . . . . . 17.7 m-30 -115.59 131.99 56.76 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 123.787 0.835 . . . . 13.28 109.219 177.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.16 113.26 3.61 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.552 -0.833 . . . . 10.35 113.733 -176.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 70' ' ' LYS . . . . . 0.497 ' O ' ' NE2' ' K' ' 76' ' ' GLN . 38.5 ttmt -86.9 151.5 23.26 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 108.683 -0.858 . . . . 10.83 108.683 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 71' ' ' ARG . . . . . . . . . . . . . 20.6 ptp180 -68.45 -14.93 63.34 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 114.141 1.163 . . . . 20.78 114.141 -169.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 72' ' ' GLY . . . . . . . . . . . . . . . -129.11 -136.79 4.18 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 110.062 -1.215 . . . . 35.33 110.062 176.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 73' ' ' ASP . . . . . . . . . . . . . 33.5 t0 60.0 72.93 0.5 Allowed 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 125.103 1.361 . . . . 2.85 111.12 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.64 9.63 0.06 Allowed 'General case' 0 C--O 1.234 0.275 0 N-CA-C 117.433 2.383 . . . . 36.88 117.433 -158.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.47 -41.09 96.95 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.303 -0.951 . . . . 23.98 112.62 170.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 76' ' ' GLN . . . . . 0.497 ' NE2' ' O ' ' K' ' 70' ' ' LYS . 22.0 pt20 -70.74 -23.21 62.39 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 119.81 -0.756 . . . . 17.8 111.847 173.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 77' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -70.95 -28.01 64.16 Favored 'General case' 0 CA--C 1.517 -0.306 0 C-N-CA 119.742 -0.783 . . . . 3.05 111.237 170.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.01 -30.93 64.14 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 120.571 -0.452 . . . . 14.34 111.346 170.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 79' ' ' ILE . . . . . . . . . . . . . 49.7 mm -64.52 -45.55 95.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-O 121.057 0.456 . . . . 9.04 110.425 172.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 80' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -73.93 -21.25 60.11 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 120.551 -0.459 . . . . 20.01 111.991 179.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 81' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -71.53 -31.54 67.15 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 120.088 -0.645 . . . . 22.01 111.331 168.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 82' ' ' ALA . . . . . 0.741 ' HA ' ' HB2' ' K' ' 87' ' ' LYS . . . -75.0 -32.56 61.68 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 119.554 -0.858 . . . . 11.58 111.565 175.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 83' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -91.39 -59.54 2.12 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 120.207 -0.597 . . . . 9.9 112.171 -174.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 84' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -74.28 -35.79 63.76 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.641 0.237 . . . . 19.13 111.641 -169.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 85' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -80.95 -44.29 18.45 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 119.984 -0.686 . . . . 18.79 111.207 171.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.12 97.07 2.48 Favored Glycine 0 N--CA 1.45 -0.413 0 O-C-N 122.266 -0.271 . . . . 8.25 113.414 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 87' ' ' LYS . . . . . 0.741 ' HB2' ' HA ' ' K' ' 82' ' ' ALA . 97.5 mttt -149.13 -161.57 1.37 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 107.122 -1.436 . . . . 5.98 107.122 -178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 88' ' ' GLN . . . . . 0.695 ' HG2' ' HD1' ' K' ' 112' ' ' TYR . 65.0 mt-30 -129.11 -179.04 4.9 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.78 0.8 . . . . 23.34 110.98 167.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 89' ' ' ILE . . . . . 0.48 HD11 HD11 ' K' ' 113' ' ' ILE . 58.3 mt -129.51 136.18 59.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.342 0 CA-C-N 115.104 -0.953 . . . . 9.37 109.379 -173.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 90' ' ' LYS . . . . . 0.467 ' HD3' ' HG2' ' E' ' 165' ' ' GLN . 37.0 mtmm -84.8 117.77 24.05 Favored 'General case' 0 C--O 1.237 0.408 0 N-CA-C 108.213 -1.032 . . . . 22.17 108.213 163.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 91' ' ' PHE . . . . . . . . . . . . . 65.8 t80 -112.98 134.96 54.26 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.934 0.894 . . . . 13.71 110.706 -165.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 92' ' ' TRP . . . . . 0.8 ' HB2' ' O ' ' K' ' 14' ' ' LEU . 91.7 m95 -132.54 130.39 40.31 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 124.06 0.944 . . . . 17.79 110.111 -174.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 93' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' K' ' 106' ' ' ALA . 78.5 ttt-85 -116.64 94.13 4.49 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 108.121 -1.066 . . . . 12.04 108.121 170.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 94' ' ' VAL . . . . . 0.484 HG12 ' HB2' ' K' ' 106' ' ' ALA . 22.5 m -106.94 163.48 5.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 122.183 0.992 . . . . 19.98 109.411 -174.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 95' ' ' ASP . . . . . . . . . . . . . 82.7 m-20 -107.99 162.85 13.66 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.961 -1.018 . . . . 20.83 110.92 177.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 96' ' ' THR . . . . . . . . . . . . . 28.9 m -97.72 -31.43 12.26 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 115.007 -0.997 . . . . 24.08 112.709 -175.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 97' ' ' VAL . . . . . . . . . . . . . 34.0 m -70.66 155.2 7.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 CA-C-O 121.732 0.777 . . . . 21.68 110.15 -177.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 98' ' ' LYS . . . . . 0.566 ' NZ ' ' O ' ' K' ' 99' ' ' ASN . 29.5 tptp -87.16 127.21 35.14 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.696 -0.683 . . . . 25.88 109.551 -177.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 99' ' ' ASN . . . . . 0.566 ' O ' ' NZ ' ' K' ' 98' ' ' LYS . 34.6 m120 -89.95 171.79 9.33 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 121.795 0.807 . . . . 21.31 110.048 172.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 100' ' ' GLU . . . . . . . . . . . . . 57.3 mp0 -108.91 -17.57 13.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 113.681 0.993 . . . . 48.42 113.681 178.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 101' ' ' ASN . . . . . . . . . . . . . 17.2 p30 -84.94 -51.31 6.8 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 122.991 0.517 . . . . 25.09 111.59 170.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 102' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -113.03 -173.51 2.27 Favored 'General case' 0 N--CA 1.45 -0.471 0 N-CA-C 108.298 -1.001 . . . . 38.34 108.298 169.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 103' ' ' LYS . . . . . 0.722 ' H ' HG22 ' K' ' 143' ' ' ILE . 97.6 mttt -75.81 -56.49 4.63 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 120.085 -0.646 . . . . 31.21 110.348 168.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 104' ' ' TYR . . . . . . . . . . . . . 69.0 m-85 -131.77 -171.15 2.54 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.403 -0.962 . . . . 26.81 108.403 -178.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 105' ' ' ASP . . . . . 0.407 ' N ' ' OD1' ' K' ' 105' ' ' ASP . 18.3 p-10 -151.9 163.85 38.35 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.497 0.665 . . . . 41.97 109.268 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 106' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' K' ' 93' ' ' ARG . . . -155.66 157.41 36.63 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.315 -0.857 . . . . 2.09 111.142 -162.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 107' ' ' GLN . . . . . 0.475 ' OE1' ' OH ' ' L' ' 118' ' ' TYR . 86.7 mt-30 -117.49 125.97 51.8 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.085 -1.45 . . . . 12.69 107.085 160.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 108' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -113.83 153.76 28.59 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.766 0.826 . . . . 17.09 110.319 -163.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 109' ' ' GLY . . . . . . . . . . . . . . . -164.01 168.79 38.65 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 119.615 -1.279 . . . . 5.68 112.685 174.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 110' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -110.79 110.71 21.46 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 108.807 -0.812 . . . . 13.37 108.807 168.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 111' ' ' ALA . . . . . . . . . . . . . . . -110.75 157.58 19.62 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-O 121.625 0.726 . . . . 30.61 111.906 -165.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 112' ' ' TYR . . . . . 0.695 ' HD1' ' HG2' ' K' ' 88' ' ' GLN . 63.6 t80 -138.17 134.75 34.93 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.363 -1.289 . . . . 16.17 107.603 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 113' ' ' ILE . . . . . 0.48 HD11 HD11 ' K' ' 89' ' ' ILE . 77.9 mt -84.96 129.03 38.41 Favored 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 109.99 -0.374 . . . . 11.93 109.99 -169.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 114' ' ' GLU . . . . . 0.512 ' HB2' ' HB2' ' K' ' 131' ' ' SER . 98.2 mt-10 -72.39 -64.22 0.99 Allowed 'General case' 0 C--O 1.235 0.328 0 C-N-CA 120.029 -0.669 . . . . 49.87 110.598 164.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 115' ' ' SER . . . . . . . . . . . . . 75.6 m -141.2 151.35 43.72 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.72 0.772 . . . . 25.92 110.435 -169.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 116' ' ' ARG . . . . . . . . . . . . . 8.6 tmm_? -126.52 92.96 3.66 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 104.653 -2.351 . . . . 27.8 104.653 177.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 117' ' ' GLU . . . . . 0.555 ' HB3' HG12 ' J' ' 37' ' ' VAL . 98.1 mt-10 -116.8 110.23 18.13 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 107.61 -1.255 . . . . 39.69 107.61 -173.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 118' ' ' TYR . . . . . 0.47 ' HB3' ' HA ' ' K' ' 128' ' ' ILE . 13.9 p90 -115.29 145.09 42.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.634 0.731 . . . . 11.08 111.992 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 119' ' ' SER . . . . . . . . . . . . . 39.3 t -98.99 129.68 45.3 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 114.565 -1.198 . . . . 17.79 109.706 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 120' ' ' ASP . . . . . 0.665 ' HB3' ' HB2' ' J' ' 34' ' ' ASP . 59.1 t0 -108.6 97.21 6.9 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 106.234 -1.765 . . . . 41.37 106.234 172.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 121' ' ' GLY . . . . . . . . . . . . . . . -81.71 -156.88 17.8 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-O 121.823 0.679 . . . . 19.83 112.281 178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 122' ' ' VAL . . . . . . . . . . . . . 96.8 t -118.22 -63.2 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.365 0 N-CA-C 108.177 -1.046 . . . . 11.45 108.177 176.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 123' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -95.54 -17.03 21.74 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 112.677 0.621 . . . . 37.48 112.677 -174.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 124' ' ' GLY . . . . . . . . . . . . . . . -95.58 154.69 21.06 Favored Glycine 0 N--CA 1.452 -0.276 0 N-CA-C 109.532 -1.427 . . . . 3.5 109.532 164.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 125' ' ' ALA . . . . . . . . . . . . . . . -75.35 169.33 18.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.721 0.772 . . . . 7.9 110.325 176.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 126' ' ' VAL . . . . . 0.591 HG12 ' HA ' ' K' ' 120' ' ' ASP . 34.7 m -70.44 155.08 7.78 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 CA-C-N 115.338 -0.846 . . . . 14.3 109.678 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 127' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -144.03 132.07 21.66 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 109.677 -0.49 . . . . 26.88 109.677 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 128' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' K' ' 66' ' ' THR . 88.4 mt -102.13 123.7 55.54 Favored 'Isoleucine or valine' 0 C--O 1.238 0.463 0 N-CA-C 109.291 -0.633 . . . . 17.79 109.291 -176.306 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 129' ' ' SER . . . . . 0.417 ' HB2' ' O ' ' K' ' 117' ' ' GLU . 69.8 m -102.03 133.57 46.64 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.496 -0.927 . . . . 24.52 108.496 170.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 130' ' ' ILE . . . . . . . . . . . . . 87.7 mt -134.68 128.54 50.92 Favored 'Isoleucine or valine' 0 C--O 1.237 0.443 0 N-CA-C 108.888 -0.782 . . . . 3.46 108.888 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 131' ' ' SER . . . . . 0.512 ' HB2' ' HB2' ' K' ' 114' ' ' GLU . 56.5 m -94.03 149.06 21.57 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.085 0.469 . . . . 23.2 109.974 175.015 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 132' ' ' LEU . . . . . 0.62 ' O ' ' HA ' ' K' ' 62' ' ' SER . 7.4 mp -133.96 147.07 50.99 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.162 -0.472 . . . . 11.15 110.352 -178.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 133' ' ' GLN . . . . . 0.801 HE21 HD11 ' J' ' 53' ' ' ILE . 30.4 mm100 -131.04 133.11 45.41 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.882 -0.784 . . . . 17.79 108.882 174.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 134' ' ' VAL . . . . . . . . . . . . . 14.2 p -134.16 145.0 33.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 N-CA-C 109.039 -0.726 . . . . 3.93 109.039 177.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 135' ' ' ILE . . . . . . . . . . . . . 19.8 mm -61.65 -58.16 8.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.91 -0.586 . . . . 34.35 110.763 175.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 136' ' ' GLY . . . . . . . . . . . . . . . -156.05 132.45 3.35 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.014 -1.088 . . . . 0.12 112.314 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 137' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -66.64 150.13 49.49 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.435 0.636 . . . . 30.04 110.337 173.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 138' ' ' LEU . . . . . 0.411 HD23 HD21 ' K' ' 140' ' ' ASN . 31.4 tp -138.39 130.24 28.14 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.057 -1.09 . . . . 8.19 108.057 -178.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -83.42 80.24 9.16 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-O 122.357 1.075 . . . . 11.43 109.353 -171.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 140' ' ' ASN . . . . . 0.411 HD21 HD23 ' K' ' 138' ' ' LEU . 84.1 m-20 -99.95 81.14 2.39 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 122.009 0.909 . . . . 20.28 108.673 -178.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.22 112.69 3.99 Favored Glycine 0 C--O 1.237 0.333 0 N-CA-C 110.329 -1.108 . . . . 21.45 110.329 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 142' ' ' GLU . . . . . . . . . . . . . 2.6 pp20? -123.42 -171.64 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.224 -0.658 . . . . 26.87 109.224 -175.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 143' ' ' ILE . . . . . 0.722 HG22 ' H ' ' K' ' 103' ' ' LYS . 1.4 pp -116.99 -60.08 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 113.345 0.868 . . . . 19.36 113.345 -169.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 144' ' ' ASP . . . . . . . . . . . . . 19.1 p-10 -82.95 125.6 31.57 Favored 'General case' 0 C--O 1.233 0.22 0 O-C-N 121.411 -0.806 . . . . 14.69 111.159 -171.033 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 145' ' ' THR . . . . . . . . . . . . . 75.5 p -120.53 15.49 12.01 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 112.642 0.608 . . . . 27.11 112.642 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 146' ' ' LEU . . . . . 0.517 ' HG ' ' HA ' ' K' ' 24' ' ' SER . 4.2 mm? 54.55 76.42 0.52 Allowed Pre-proline 0 C--N 1.345 0.406 0 C-N-CA 126.54 1.936 . . . . 26.22 110.88 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 147' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_exo -68.38 72.72 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 N-CA-C 115.435 1.283 . . . . 17.79 115.435 -162.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 148' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -107.09 5.32 27.83 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 123.092 0.557 . . . . 32.62 111.569 167.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 149' ' ' GLU . . . . . 0.466 ' O ' ' NZ ' ' K' ' 12' ' ' LYS . 25.9 pm0 -139.98 5.8 2.16 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 112.885 0.698 . . . . 8.29 112.885 -176.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 150' ' ' ILE . . . . . . . . . . . . . 44.1 mm -111.56 -48.93 6.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 118.857 0.753 . . . . 15.81 111.093 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 151' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.93 -28.36 2.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 107.483 -1.303 . . . . 6.41 107.483 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 152' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -67.82 -30.07 69.39 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 116.08 -0.509 . . . . 28.39 111.72 -177.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -73.59 100.4 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.378 0 N-CA-C 108.107 -1.072 . . . . 17.79 108.107 172.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 154' ' ' SER . . . . . . . . . . . . . 39.0 t -117.9 -58.38 2.02 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.395 -0.82 . . . . 20.41 111.88 -173.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 155' ' ' LYS . . . . . 0.404 ' HG3' ' H ' ' K' ' 157' ' ' GLY . 16.4 tppt? -127.85 -34.68 2.15 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 124.047 0.939 . . . . 23.96 113.408 178.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.25 -57.99 1.43 Allowed Glycine 0 N--CA 1.447 -0.575 0 N-CA-C 109.9 -1.28 . . . . 33.75 109.9 -157.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 157' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' K' ' 155' ' ' LYS . . . -97.31 177.46 32.29 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-O 122.037 0.798 . . . . 17.79 112.475 177.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 158' ' ' TYR . . . . . . . . . . . . . 20.2 m-30 -115.8 -172.22 2.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.336 1.055 . . . . 8.06 109.463 -178.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 159' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -79.19 -68.45 0.66 Allowed 'General case' 0 C--O 1.236 0.355 0 C-N-CA 119.55 -0.86 . . . . 22.64 111.85 -172.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 160' ' ' PHE . . . . . 0.476 ' HD2' ' HG3' ' K' ' 162' ' ' GLN . 34.5 p90 -175.85 159.31 2.22 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 108.72 -0.845 . . . . 15.75 108.72 -176.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 161' ' ' GLN . . . . . . . . . . . . . 65.9 tt0 -153.32 100.14 2.42 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 105.29 -2.115 . . . . 32.7 105.29 154.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 162' ' ' GLN . . . . . 0.476 ' HG3' ' HD2' ' K' ' 160' ' ' PHE . 85.6 mt-30 -74.33 -45.4 6.03 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 117.927 -1.035 . . . . 25.37 113.705 -163.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 163' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -76.18 -46.09 0.19 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 CA-C-N 122.204 1.823 . . . . 28.41 113.704 173.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 164' ' ' GLY . . . . . . . . . . . . . . . -120.35 39.41 2.45 Favored Glycine 0 N--CA 1.449 -0.451 0 N-CA-C 116.666 1.426 . . . . 17.56 116.666 -160.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 165' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -66.47 -62.31 1.53 Allowed 'General case' 0 C--O 1.238 0.468 0 C-N-CA 120.025 -0.67 . . . . 25.1 110.799 173.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 166' ' ' THR . . . . . . . . . . . . . 42.0 p 53.1 50.46 17.78 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 125.901 1.68 . . . . 29.05 111.7 177.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 167' ' ' THR . . . . . . . . . . . . . 1.7 m -138.0 164.54 28.8 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.046 -1.094 . . . . 1.89 108.046 -169.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.98 -126.53 1.32 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.1 -0.8 . . . . 15.93 111.1 173.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -72.69 -61.91 1.64 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 120.404 -0.519 . . . . 40.51 111.036 -178.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.68 105.21 0.76 Allowed Pre-proline 0 C--O 1.235 0.335 0 C-N-CA 124.026 0.93 . . . . 19.75 109.605 -175.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 171' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -84.52 -173.85 1.63 Allowed 'Trans proline' 0 C--N 1.322 -0.834 0 C-N-CA 121.262 1.308 . . . . 0.27 111.791 -159.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 172' ' ' GLY . . . . . . . . . . . . . . . 76.55 66.71 1.79 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 114.544 -1.207 . . . . 37.09 115.429 166.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 173' ' ' THR . . . . . . . . . . . . . 7.2 t -139.36 166.77 23.67 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-O 121.74 0.781 . . . . 40.25 109.363 169.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 174' ' ' VAL . . . . . . . . . . . . . 28.5 m -71.64 156.67 91.01 Favored Pre-proline 0 C--O 1.241 0.617 0 CA-C-N 114.964 -1.017 . . . . 0.0 109.103 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 175' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -62.21 122.04 10.32 Favored 'Trans proline' 0 C--N 1.349 0.597 0 CA-C-N 119.245 0.766 . . . . 25.62 110.692 169.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.303 0 C-N-CA 125.514 1.526 . . . . 20.35 110.384 -165.253 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 5' ' ' PRO . . . . . 0.415 ' HB2' ' H ' ' L' ' 6' ' ' ILE . 37.3 Cg_endo . . . . . 0 N--CA 1.465 -0.157 0 CA-C-O 119.607 -0.247 . . . . 20.92 112.408 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 6' ' ' ILE . . . . . 0.415 ' H ' ' HB2' ' L' ' 5' ' ' PRO . 96.5 mt -123.55 121.82 63.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.99 -1.115 . . . . 41.64 107.99 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 7' ' ' MET . . . . . . . . . . . . . 39.3 mmt -91.47 170.55 9.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.935 0.874 . . . . 39.84 110.799 -176.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.19 -9.88 64.63 Favored Glycine 0 C--N 1.334 0.42 0 CA-C-N 115.403 -0.817 . . . . 17.3 114.719 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -94.87 -14.95 24.09 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 117.883 0.842 . . . . 17.3 112.291 172.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -76.12 -7.03 53.84 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 113.739 1.014 . . . . 23.45 113.739 -170.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' VAL . . . . . . . . . . . . . 66.3 t -127.11 125.33 66.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.372 0 N-CA-C 107.917 -1.142 . . . . 11.79 107.917 -176.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' LYS . . . . . 0.412 ' NZ ' ' O ' ' L' ' 149' ' ' GLU . 53.6 mtmt -134.93 161.19 35.96 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.502 0.668 . . . . 14.38 110.011 176.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' TYR . . . . . 0.522 ' HA ' ' O ' ' L' ' 92' ' ' TRP . 18.6 m-30 -112.15 95.47 5.48 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.215 -1.031 . . . . 17.3 108.215 -166.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' LEU . . . . . 0.86 ' O ' ' HB2' ' L' ' 92' ' ' TRP . 98.0 mt -74.78 131.2 40.61 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 120.246 -0.582 . . . . 57.33 109.56 176.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' PHE . . . . . . . . . . . . . 22.0 m-30 -112.41 151.61 29.63 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.64 -0.504 . . . . 23.7 109.64 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' GLN . . . . . . . . . . . . . 71.6 tp60 -145.14 136.24 24.85 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 109.291 -0.633 . . . . 17.64 109.291 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 40.1 t -75.61 155.53 35.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 121.614 0.721 . . . . 7.08 111.175 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' ILE . . . . . . . . . . . . . 44.5 pt -79.27 -11.9 13.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.4 0 CA-C-N 115.425 -0.807 . . . . 16.92 113.102 178.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -112.33 -11.75 13.65 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 112.661 0.615 . . . . 23.23 112.661 -170.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' ALA . . . . . . . . . . . . . . . -76.45 -47.0 24.5 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 119.965 -0.694 . . . . 21.18 111.87 -170.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . 53.18 45.12 29.28 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.887 1.275 . . . . 17.3 111.399 -168.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' THR . . . . . . . . . . . . . 69.3 p -123.95 121.3 34.93 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 108.979 -0.748 . . . . 38.78 108.979 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -81.16 76.59 2.14 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 116.264 -0.425 . . . . 17.3 113.758 -176.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' SER . . . . . 0.481 ' HA ' ' HG ' ' L' ' 146' ' ' LEU . 92.4 p -128.84 -26.64 2.64 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 120.373 -0.531 . . . . 14.69 111.469 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' L' ' 14' ' ' LEU . . . 51.31 74.38 0.81 Allowed Pre-proline 0 C--O 1.237 0.395 0 C-N-CA 127.01 2.124 . . . . 61.95 112.099 -172.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_exo -71.68 105.74 1.84 Allowed 'Trans proline' 0 C--N 1.345 0.381 0 CA-C-N 119.4 0.821 . . . . 17.3 112.633 177.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' LEU . . . . . 0.792 ' HB3' HD23 ' L' ' 14' ' ' LEU . 2.2 pt? -81.55 155.86 25.52 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.13 -0.693 . . . . 5.96 109.13 165.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.1 t80 -101.61 130.06 25.43 Favored Pre-proline 0 N--CA 1.446 -0.64 1 C-N-CA 109.56 -4.856 . . . . 6.24 110.173 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.9 -173.58 1.27 Allowed 'Trans proline' 0 C--O 1.235 0.347 0 C-N-CA 120.638 0.892 . . . . 11.84 114.248 -175.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . 53.42 60.23 3.85 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 124.769 1.228 . . . . 9.15 111.048 -172.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' TYR . . . . . 0.423 ' HD1' ' HA ' ' L' ' 31' ' ' TYR . 1.0 OUTLIER -70.44 163.22 27.19 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-O 122.934 1.349 . . . . 22.48 111.948 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' GLN . . . . . 0.461 ' HG3' ' H ' ' L' ' 33' ' ' THR . 7.8 tp-100 -136.43 -161.85 1.21 Allowed 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 103.146 -2.909 . . . . 4.98 103.146 169.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' THR . . . . . 0.461 ' H ' ' HG3' ' L' ' 32' ' ' GLN . 15.1 t -65.9 164.73 14.39 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 122.557 1.17 . . . . 29.35 112.066 -174.12 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' G' ' 120' ' ' ASP . 84.0 m-20 -135.28 -169.24 2.34 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.061 -1.427 . . . . 48.33 108.26 -167.218 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' GLY . . . . . 0.628 ' O ' ' HA2' ' L' ' 63' ' ' GLY . . . 171.25 135.35 1.91 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.896 -0.669 . . . . 4.76 111.745 170.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' SER . . . . . . . . . . . . . 66.1 m -127.32 84.63 2.28 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.015 -1.846 . . . . 17.3 106.015 175.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' VAL . . . . . 0.54 HG23 ' HB2' ' L' ' 62' ' ' SER . 3.6 m -91.9 110.73 23.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.513 -0.921 . . . . 4.17 108.513 -171.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' G' ' 83' ' ' TYR . 51.0 m -100.47 84.09 2.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.335 -0.987 . . . . 22.2 108.335 -167.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' GLY . . . . . . . . . . . . . . . -88.09 99.63 2.53 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.769 -0.729 . . . . 32.58 113.177 -177.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' GLU . . . . . 0.43 ' HA ' ' HA ' ' L' ' 59' ' ' VAL . 80.8 tt0 -101.95 124.65 47.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.067 -1.086 . . . . 2.66 108.067 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 41' ' ' ARG . . . . . 0.801 ' O ' ' HA3' ' L' ' 57' ' ' GLY . 93.0 mtm-85 -79.01 -178.49 6.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.449 0.642 . . . . 27.56 109.581 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 42' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -162.52 163.85 27.23 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.425 -0.583 . . . . 24.15 109.425 -175.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 43' ' ' LEU . . . . . 0.768 ' HB2' ' HA3' ' L' ' 55' ' ' GLY . 77.8 mt -106.99 112.53 25.53 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.069 -0.715 . . . . 11.23 109.069 171.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 44' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -117.07 112.09 20.43 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 107.569 -1.271 . . . . 17.12 107.569 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 45' ' ' ASP . . . . . 0.53 ' HB2' ' HB3' ' L' ' 52' ' ' ARG . 79.0 m-20 -127.51 -173.83 3.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.971 -0.751 . . . . 23.32 108.971 -172.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 46' ' ' GLU . . . . . . . . . . . . . 58.5 mp0 -127.3 -40.95 1.78 Allowed 'General case' 0 C--O 1.233 0.233 0 N-CA-C 114.68 1.363 . . . . 7.0 114.68 -169.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 47' ' ' GLN . . . . . 0.74 ' HB3' ' HA ' ' A' ' 30' ' ' ALA . 92.0 mm-40 65.29 21.69 12.03 Favored 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 124.788 1.235 . . . . 50.57 114.046 161.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 50.6 p 50.8 39.58 22.52 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.487 1.115 . . . . 9.03 110.941 -165.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 49' ' ' LYS . . . . . . . . . . . . . 45.4 mmtm -139.83 -165.43 1.88 Allowed 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 106.957 -1.497 . . . . 16.79 106.957 -174.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 50' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 -72.38 -30.38 64.63 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 120.594 -0.442 . . . . 44.69 112.066 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 157.03 166.68 16.99 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 121.058 -0.591 . . . . 16.23 114.553 -178.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 52' ' ' ARG . . . . . 0.598 ' HD3' HD13 ' L' ' 54' ' ' LEU . 17.7 tpp85 -133.74 57.06 1.82 Allowed 'General case' 0 C--O 1.234 0.24 0 N-CA-C 108.243 -1.021 . . . . 17.3 108.243 -178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 53' ' ' ILE . . . . . 0.767 HD11 ' HB3' ' G' ' 133' ' ' GLN . 7.8 tt -69.4 -3.9 3.32 Favored 'Isoleucine or valine' 0 C--O 1.238 0.459 0 C-N-CA 124.442 1.097 . . . . 32.26 113.084 -177.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 54' ' ' LEU . . . . . 0.598 HD13 ' HD3' ' L' ' 52' ' ' ARG . 7.9 mp -59.43 -24.91 63.9 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.295 1.038 . . . . 60.18 113.339 -176.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 55' ' ' GLY . . . . . 0.768 ' HA3' ' HB2' ' L' ' 43' ' ' LEU . . . -66.7 118.74 11.03 Favored Glycine 0 N--CA 1.44 -1.094 0 CA-C-O 121.64 0.578 . . . . 17.3 113.905 -172.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 56' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.36 173.8 13.61 Favored 'Trans proline' 0 C--N 1.326 -0.624 0 C-N-CA 120.773 0.982 . . . . 17.3 109.844 172.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 57' ' ' GLY . . . . . 0.801 ' HA3' ' O ' ' L' ' 41' ' ' ARG . . . -136.18 166.14 24.76 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 109.466 -1.454 . . . . 34.45 109.466 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 58' ' ' SER . . . . . 0.419 ' HB3' ' NH2' ' L' ' 41' ' ' ARG . 42.5 t -74.76 143.67 43.97 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 119.711 -0.796 . . . . 12.73 109.658 172.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 59' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' L' ' 40' ' ' GLU . 2.2 p -96.29 111.55 26.71 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 108.482 -0.932 . . . . 33.1 108.482 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 60' ' ' ALA . . . . . . . . . . . . . . . -109.34 112.74 25.04 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.82 -1.548 . . . . 49.86 106.82 174.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 61' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -118.1 120.64 38.38 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.692 -0.855 . . . . 40.56 108.692 -169.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 62' ' ' SER . . . . . 0.54 ' HB2' HG23 ' L' ' 37' ' ' VAL . 65.3 m -108.8 168.47 9.32 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 124.025 0.93 . . . . 17.3 110.604 -174.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 63' ' ' GLY . . . . . 0.628 ' HA2' ' O ' ' L' ' 35' ' ' GLY . . . -140.07 128.29 3.83 Favored Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 114.983 -1.008 . . . . 17.3 113.041 177.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 64' ' ' GLU . . . . . 0.467 ' O ' ' HA ' ' L' ' 34' ' ' ASP . 66.0 mm-40 -106.04 97.06 6.92 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 107.524 -1.287 . . . . 31.63 107.524 172.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.18 115.93 49.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 N-CA-C 108.303 -0.999 . . . . 17.3 108.303 -178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 66' ' ' THR . . . . . 0.46 ' HA ' ' O ' ' L' ' 128' ' ' ILE . 63.6 p -116.91 142.47 46.89 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.354 -0.61 . . . . 3.14 109.354 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 67' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -152.92 -170.47 3.64 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.41 0.624 . . . . 12.33 109.392 177.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 68' ' ' TYR . . . . . . . . . . . . . 15.5 m-30 -115.7 134.29 55.18 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.734 0.814 . . . . 20.66 109.518 178.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.73 113.51 3.65 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.788 -0.72 . . . . 17.3 113.771 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 70' ' ' LYS . . . . . 0.494 ' O ' ' NE2' ' L' ' 76' ' ' GLN . 38.4 ttmt -89.29 147.76 23.93 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.824 -0.806 . . . . 19.57 108.824 174.195 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 71' ' ' ARG . . . . . . . . . . . . . 20.9 ptp180 -66.92 -16.38 64.29 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 114.099 1.148 . . . . 38.0 114.099 -169.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.33 -138.52 4.86 Favored Glycine 0 N--CA 1.451 -0.327 0 N-CA-C 109.927 -1.269 . . . . 17.3 109.927 175.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 73' ' ' ASP . . . . . . . . . . . . . 32.8 t0 59.74 72.83 0.51 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 125.089 1.356 . . . . 18.16 111.16 168.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.97 9.58 0.07 Allowed 'General case' 0 C--O 1.235 0.31 0 N-CA-C 117.28 2.326 . . . . 58.55 117.28 -158.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.36 97.04 Favored Glycine 0 C--N 1.337 0.612 0 C-N-CA 120.302 -0.951 . . . . 17.3 112.663 170.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 76' ' ' GLN . . . . . 0.494 ' NE2' ' O ' ' L' ' 70' ' ' LYS . 21.9 pt20 -71.15 -23.53 62.09 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 119.578 -0.849 . . . . 44.87 111.291 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 77' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -70.38 -28.7 65.3 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 119.865 -0.734 . . . . 17.3 111.299 170.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 78' ' ' ALA . . . . . . . . . . . . . . . -72.91 -31.11 64.43 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 120.417 -0.513 . . . . 31.28 111.34 171.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 79' ' ' ILE . . . . . . . . . . . . . 49.5 mm -64.78 -44.77 96.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 CA-C-O 121.052 0.453 . . . . 34.0 110.421 173.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 80' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -72.76 -22.65 60.81 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 121.915 -0.491 . . . . 27.04 111.947 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 81' ' ' ASP . . . . . . . . . . . . . 54.8 m-20 -69.34 -34.96 75.41 Favored 'General case' 0 C--O 1.236 0.38 0 C-N-CA 120.258 -0.577 . . . . 21.24 111.415 168.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 82' ' ' ALA . . . . . 0.705 ' HA ' ' HB2' ' L' ' 87' ' ' LYS . . . -74.07 -33.68 63.76 Favored 'General case' 0 C--O 1.236 0.374 0 C-N-CA 119.417 -0.913 . . . . 15.07 111.629 176.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 83' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -83.25 -62.21 1.65 Allowed 'General case' 0 C--O 1.235 0.318 0 C-N-CA 120.404 -0.518 . . . . 7.64 112.053 -176.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 84' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -75.39 -38.03 60.19 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 111.722 0.268 . . . . 25.28 111.722 -165.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 85' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -77.18 -43.11 35.02 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 119.886 -0.726 . . . . 7.3 111.045 171.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 86' ' ' GLY . . . . . . . . . . . . . . . 107.8 96.33 2.44 Favored Glycine 0 N--CA 1.45 -0.404 0 O-C-N 122.256 -0.277 . . . . 23.56 113.361 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 87' ' ' LYS . . . . . 0.705 ' HB2' ' HA ' ' L' ' 82' ' ' ALA . 98.0 mttt -148.88 -162.26 1.52 Allowed 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 107.067 -1.457 . . . . 6.04 107.067 -177.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 88' ' ' GLN . . . . . 0.719 ' HG2' ' HD1' ' L' ' 112' ' ' TYR . 65.4 mt-30 -128.64 178.0 6.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.721 0.772 . . . . 10.54 110.875 167.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 89' ' ' ILE . . . . . 0.484 HD11 HD11 ' L' ' 113' ' ' ILE . 57.4 mt -128.46 137.05 58.44 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.244 -0.889 . . . . 17.3 109.282 -173.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 90' ' ' LYS . . . . . 0.497 ' HD3' ' HG2' ' F' ' 165' ' ' GLN . 36.6 mtmm -84.99 118.34 24.51 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.498 -0.927 . . . . 18.93 108.498 164.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 91' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -111.96 133.76 53.94 Favored 'General case' 0 C--O 1.238 0.47 0 C-N-CA 124.434 1.094 . . . . 28.15 110.718 -166.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 92' ' ' TRP . . . . . 0.86 ' HB2' ' O ' ' L' ' 14' ' ' LEU . 89.8 m95 -132.63 125.5 30.52 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 10.58 109.971 -173.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 93' ' ' ARG . . . . . 0.61 ' O ' ' HA ' ' L' ' 106' ' ' ALA . 78.7 ttt-85 -111.91 90.35 3.31 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.067 -1.086 . . . . 11.86 108.067 171.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 94' ' ' VAL . . . . . 0.473 HG12 ' HB2' ' L' ' 106' ' ' ALA . 20.2 m -104.89 165.03 3.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 CA-C-O 122.07 0.938 . . . . 14.71 109.295 -174.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 95' ' ' ASP . . . . . . . . . . . . . 85.9 m-20 -110.5 168.97 9.06 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.132 -0.94 . . . . 25.49 111.501 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 96' ' ' THR . . . . . 0.409 HG23 HG23 ' L' ' 150' ' ' ILE . 29.8 m -102.03 -32.58 10.09 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.877 -1.056 . . . . 34.22 112.803 -175.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 97' ' ' VAL . . . . . . . . . . . . . 34.4 m -70.42 155.69 7.5 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.767 0.794 . . . . 17.33 110.244 -177.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 98' ' ' LYS . . . . . 0.524 ' NZ ' ' O ' ' L' ' 99' ' ' ASN . 29.6 tptp -89.19 125.43 35.06 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.696 -0.684 . . . . 14.09 109.683 -178.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 99' ' ' ASN . . . . . 0.524 ' O ' ' NZ ' ' L' ' 98' ' ' LYS . 35.3 m120 -86.52 171.22 11.23 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.749 0.785 . . . . 22.14 109.994 171.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 100' ' ' GLU . . . . . . . . . . . . . 57.1 mp0 -107.3 -14.38 14.9 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 113.762 1.023 . . . . 21.13 113.762 178.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 101' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -89.84 -52.18 5.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 118.186 0.448 . . . . 14.65 111.488 170.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 102' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -110.79 -173.55 2.27 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.355 -0.98 . . . . 44.12 108.355 170.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 103' ' ' LYS . . . . . 0.674 ' H ' HG22 ' L' ' 143' ' ' ILE . 96.7 mttt -79.04 -54.8 5.65 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 120.095 -0.642 . . . . 39.88 110.395 170.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 104' ' ' TYR . . . . . . . . . . . . . 71.2 m-85 -132.0 -170.35 2.39 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 108.774 -0.824 . . . . 27.29 108.774 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 105' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' L' ' 105' ' ' ASP . 15.8 p-10 -152.95 165.22 36.19 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 109.139 -0.689 . . . . 43.34 109.139 177.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 106' ' ' ALA . . . . . 0.61 ' HA ' ' O ' ' L' ' 93' ' ' ARG . . . -157.69 154.81 28.89 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.274 -0.875 . . . . 5.32 111.095 -163.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 107' ' ' GLN . . . . . 0.441 ' OE1' ' OH ' ' G' ' 118' ' ' TYR . 87.9 mt-30 -114.08 125.07 53.57 Favored 'General case' 0 C--O 1.235 0.33 0 N-CA-C 106.896 -1.52 . . . . 20.11 106.896 159.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 108' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -112.68 154.66 25.76 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 123.657 0.783 . . . . 17.3 110.197 -164.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 109' ' ' GLY . . . . . . . . . . . . . . . -166.17 167.64 39.43 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 119.405 -1.378 . . . . 17.3 112.684 174.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 110' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -108.53 110.82 22.4 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.626 -0.787 . . . . 40.16 108.957 168.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 111' ' ' ALA . . . . . . . . . . . . . . . -109.06 156.56 19.64 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 121.598 0.713 . . . . 33.53 111.76 -165.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 112' ' ' TYR . . . . . 0.719 ' HD1' ' HG2' ' L' ' 88' ' ' GLN . 52.8 t80 -137.6 136.92 37.98 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.135 -1.432 . . . . 14.99 107.135 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 113' ' ' ILE . . . . . 0.484 HD11 HD11 ' L' ' 89' ' ' ILE . 75.6 mt -87.18 129.46 38.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 109.869 -0.419 . . . . 7.44 109.869 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 114' ' ' GLU . . . . . 0.53 ' HB2' ' HB2' ' L' ' 131' ' ' SER . 98.7 mt-10 -73.1 -64.77 0.9 Allowed 'General case' 0 C--O 1.235 0.328 0 C-N-CA 119.906 -0.718 . . . . 49.45 110.584 164.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 115' ' ' SER . . . . . . . . . . . . . 74.4 m -140.56 149.33 42.26 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.676 0.751 . . . . 8.08 110.365 -170.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 116' ' ' ARG . . . . . . . . . . . . . 8.8 tmm_? -122.59 89.71 3.16 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 104.425 -2.435 . . . . 16.25 104.425 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 117' ' ' GLU . . . . . 0.539 ' HB3' HG12 ' K' ' 37' ' ' VAL . 98.3 mt-10 -112.75 108.38 17.36 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 107.639 -1.245 . . . . 30.17 107.639 -174.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 118' ' ' TYR . . . . . 0.508 ' HB3' ' HA ' ' L' ' 128' ' ' ILE . 12.4 p90 -113.74 144.56 42.75 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.534 0.683 . . . . 22.45 112.056 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 36.9 t -99.8 126.94 45.96 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.67 -1.15 . . . . 17.3 109.877 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 120' ' ' ASP . . . . . 0.674 ' HB3' ' HB2' ' K' ' 34' ' ' ASP . 59.7 t0 -100.4 97.93 8.62 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 106.115 -1.809 . . . . 15.87 106.115 168.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 121' ' ' GLY . . . . . . . . . . . . . . . -79.19 -158.2 13.09 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-O 121.92 0.733 . . . . 12.55 112.483 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 122' ' ' VAL . . . . . . . . . . . . . 66.4 t -116.37 -62.91 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 N-CA-C 108.314 -0.995 . . . . 29.86 108.314 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 123' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.11 -18.22 14.62 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.64 0.607 . . . . 47.61 112.64 -174.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 124' ' ' GLY . . . . . . . . . . . . . . . -86.8 154.83 27.21 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 109.221 -1.552 . . . . 24.42 109.221 161.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.97 168.85 19.16 Favored 'General case' 0 C--O 1.235 0.338 0 C-N-CA 119.709 -0.797 . . . . 6.84 110.335 176.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 126' ' ' VAL . . . . . 0.584 HG12 ' HA ' ' L' ' 120' ' ' ASP . 34.7 m -69.41 153.56 8.73 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 CA-C-N 115.347 -0.842 . . . . 17.3 109.556 -177.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 127' ' ' GLU . . . . . . . . . . . . . 21.9 pt-20 -143.88 133.26 23.29 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.723 -0.473 . . . . 35.39 109.723 -178.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 128' ' ' ILE . . . . . 0.508 ' HA ' ' HB3' ' L' ' 118' ' ' TYR . 86.5 mt -102.61 123.32 55.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 109.376 -0.602 . . . . 17.3 109.376 -176.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 129' ' ' SER . . . . . 0.494 ' HB2' ' O ' ' L' ' 117' ' ' GLU . 68.8 m -102.54 132.78 48.38 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.55 -0.907 . . . . 24.95 108.55 171.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 130' ' ' ILE . . . . . . . . . . . . . 85.0 mt -134.96 128.31 49.64 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 108.873 -0.788 . . . . 17.3 108.873 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 131' ' ' SER . . . . . 0.53 ' HB2' ' HB2' ' L' ' 114' ' ' GLU . 60.1 m -93.83 147.27 23.23 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.109 -0.496 . . . . 17.3 110.011 175.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 132' ' ' LEU . . . . . 0.51 ' O ' ' HA ' ' L' ' 62' ' ' SER . 7.0 mp -131.39 152.4 50.67 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 116.057 -0.519 . . . . 34.95 110.236 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 133' ' ' GLN . . . . . 0.806 ' HB3' HD11 ' K' ' 53' ' ' ILE . 20.6 mm100 -141.78 125.99 17.48 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.791 0.836 . . . . 17.3 109.454 -177.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 134' ' ' VAL . . . . . . . . . . . . . 12.4 p -135.83 147.06 28.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 109.322 -0.622 . . . . 8.43 109.322 -177.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 135' ' ' ILE . . . . . . . . . . . . . 24.3 mm -62.46 -60.34 2.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 116.004 -0.544 . . . . 6.85 110.796 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 136' ' ' GLY . . . . . . . . . . . . . . . -158.64 137.36 5.18 Favored Glycine 0 N--CA 1.443 -0.854 0 N-CA-C 111.343 -0.703 . . . . 17.3 111.343 -178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 137' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -67.35 155.69 38.31 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 121.387 0.613 . . . . 29.67 110.22 175.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 138' ' ' LEU . . . . . . . . . . . . . 30.8 tp -140.59 128.61 22.06 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 107.87 -1.159 . . . . 12.51 107.87 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 139' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -83.72 76.64 9.97 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 122.391 1.091 . . . . 17.3 109.344 -170.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 140' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -94.07 83.14 4.25 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.105 -0.952 . . . . 37.97 108.558 -178.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . -72.18 108.16 2.41 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.093 -1.051 . . . . 30.13 110.479 175.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 142' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -120.65 -172.66 2.42 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.23 -0.655 . . . . 18.3 109.23 -174.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 143' ' ' ILE . . . . . 0.674 HG22 ' H ' ' L' ' 103' ' ' LYS . 1.5 pp -117.82 -59.12 3.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 113.344 0.868 . . . . 28.55 113.344 -170.006 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 144' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -86.34 129.5 34.83 Favored 'General case' 0 C--N 1.33 -0.254 0 O-C-N 121.326 -0.859 . . . . 17.67 111.385 -169.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 145' ' ' THR . . . . . . . . . . . . . 71.7 p -121.91 11.94 10.41 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 112.691 0.626 . . . . 21.73 112.691 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 146' ' ' LEU . . . . . 0.481 ' HG ' ' HA ' ' L' ' 24' ' ' SER . 4.1 mm? 54.29 75.77 0.58 Allowed Pre-proline 0 C--O 1.237 0.413 0 C-N-CA 126.753 2.021 . . . . 17.3 110.135 -176.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 147' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -68.76 74.56 0.88 Allowed 'Trans proline' 0 C--N 1.347 0.451 0 N-CA-C 115.585 1.34 . . . . 5.55 115.585 -160.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 148' ' ' GLU . . . . . 0.461 ' OE1' ' ND2' ' L' ' 152' ' ' ASN . 80.2 mm-40 -105.3 8.69 33.91 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 116.032 -0.531 . . . . 32.81 111.632 166.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 149' ' ' GLU . . . . . 0.412 ' O ' ' NZ ' ' L' ' 12' ' ' LYS . 25.9 pm0 -140.07 4.81 2.08 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 112.883 0.697 . . . . 23.49 112.883 -176.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 150' ' ' ILE . . . . . 0.409 HG23 HG23 ' L' ' 96' ' ' THR . 43.9 mm -111.98 -47.65 5.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.88 0.763 . . . . 28.28 111.061 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 151' ' ' VAL . . . . . . . . . . . . . 45.0 t -105.87 -29.32 2.74 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.538 -1.282 . . . . 19.43 107.538 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 152' ' ' ASN . . . . . 0.461 ' ND2' ' OE1' ' L' ' 148' ' ' GLU . 37.8 t-20 -68.5 -31.5 70.8 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 116.046 -0.524 . . . . 17.3 111.719 -176.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 153' ' ' VAL . . . . . . . . . . . . . 2.4 p -73.88 99.65 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 107.775 -1.194 . . . . 9.42 107.775 172.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 154' ' ' SER . . . . . . . . . . . . . 37.1 t -117.56 -58.73 2.0 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.232 -0.895 . . . . 37.02 111.747 -172.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 155' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -128.66 -29.94 2.34 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 123.887 0.875 . . . . 26.06 113.057 176.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.64 -60.72 1.48 Allowed Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.236 -1.146 . . . . 41.56 110.236 -160.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 157' ' ' GLY . . . . . . . . . . . . . . . -96.52 172.8 29.18 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-O 121.985 0.769 . . . . 17.3 112.237 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 158' ' ' TYR . . . . . 0.447 ' HB2' ' HG2' ' L' ' 171' ' ' PRO . 13.6 m-30 -113.92 -173.4 2.27 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.401 0.68 . . . . 14.35 110.311 -177.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -79.08 -67.7 0.73 Allowed 'General case' 0 C--O 1.236 0.37 0 C-N-CA 119.849 -0.741 . . . . 46.38 111.921 -167.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 160' ' ' PHE . . . . . 0.474 ' HD2' ' HG3' ' L' ' 162' ' ' GLN . 37.4 p90 -175.85 157.83 2.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 108.618 -0.882 . . . . 18.94 108.618 -175.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 161' ' ' GLN . . . . . . . . . . . . . 65.9 tt0 -153.08 98.85 2.34 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 104.802 -2.296 . . . . 27.82 104.802 154.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 162' ' ' GLN . . . . . 0.474 ' HG3' ' HD2' ' L' ' 160' ' ' PHE . 86.2 mt-30 -74.51 -46.18 5.68 Favored Pre-proline 0 C--O 1.241 0.624 0 CA-C-O 117.981 -1.009 . . . . 23.74 113.7 -159.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 163' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -77.55 -46.14 0.14 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 CA-C-N 122.092 1.783 . . . . 7.47 113.759 171.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 164' ' ' GLY . . . . . . . . . . . . . . . -113.76 39.51 2.8 Favored Glycine 0 N--CA 1.449 -0.441 0 N-CA-C 116.278 1.271 . . . . 48.82 116.278 -160.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 165' ' ' GLN . . . . . . . . . . . . . 9.9 tp-100 -68.02 -63.13 1.12 Allowed 'General case' 0 C--O 1.238 0.473 0 C-N-CA 120.335 -0.546 . . . . 15.69 110.8 176.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 166' ' ' THR . . . . . . . . . . . . . 33.7 p 53.12 51.52 15.52 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.88 1.672 . . . . 15.26 111.765 176.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 1.6 m -136.22 168.45 19.39 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 107.721 -1.214 . . . . 5.64 107.721 -169.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 168' ' ' GLY . . . . . . . . . . . . . . . -83.94 -125.49 1.19 Allowed Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.256 -1.137 . . . . 4.6 110.256 172.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 169' ' ' GLU . . . . . . . . . . . . . 16.1 tm-20 -76.81 -62.11 1.75 Allowed 'General case' 0 C--O 1.235 0.317 0 C-N-CA 119.789 -0.765 . . . . 30.03 110.979 -178.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -66.81 106.07 1.04 Allowed Pre-proline 0 C--O 1.236 0.376 0 C-N-CA 123.834 0.854 . . . . 3.8 109.685 -176.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 171' ' ' PRO . . . . . 0.447 ' HG2' ' HB2' ' L' ' 158' ' ' TYR . 69.5 Cg_endo -83.56 -172.96 1.47 Allowed 'Trans proline' 0 C--N 1.324 -0.738 0 C-N-CA 121.392 1.395 . . . . 32.06 111.782 -159.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 172' ' ' GLY . . . . . . . . . . . . . . . 80.52 64.63 1.81 Allowed Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 114.596 -1.184 . . . . 46.27 114.905 167.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 173' ' ' THR . . . . . . . . . . . . . 9.5 t -135.67 168.84 18.53 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.707 0.765 . . . . 45.85 109.227 170.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 174' ' ' VAL . . . . . . . . . . . . . 28.8 m -70.97 154.4 94.23 Favored Pre-proline 0 C--O 1.242 0.665 0 CA-C-N 114.994 -1.003 . . . . 1.04 108.654 178.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 175' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -63.03 111.01 1.28 Allowed 'Trans proline' 0 C--N 1.347 0.466 0 CA-C-N 119.31 0.789 . . . . 17.34 111.007 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.2 0 C-N-CA 125.483 1.513 . . . . 20.79 110.993 -163.491 . . . . . . . . 0 0 . 1 stop_ save_